2015 Scientific Report IIB Sant Pau

2015
Scientific Report
Sant Pau Biomedical Research Institute

HSCSP Research IIB Sant Pau
Institute Board of Steering
Trustees Committee
President Chair
Enric Argelagués Vidal Alberto Salazar Soler
Managing Director,
Secretary Hospital de la Santa Creu i Sant Pau Healthcare
Joaquim Jornet Porta Management Foundation
Members Members
Managing Director, Jordi Bachs i Ferrer

Hospital de la Santa Creu i Sant Pau Hospital de la Santa Creu i Sant Pau
Alberto Salazar Soler Private Foundation
Designated by the Hospital de la Santa Creu Lluís Tort i Bardolet

i Sant Pau Foundation Autonomous University of Barcelona
Jordi Sierra Gil
Francisco Blanco Vaca Lina Badimon Maestro
Josep M. Foracada i Casanovas Catalan Institute of Cardiovascular Sciences
Designated by the Generalitat de Catalunya Helena Isábal Roca

Carles Constante Beitia Puigvert Foundation
Andreu Mas-Collell
[Pending to nominate]
Designated by the Autonomous University Blood and Tissue Bank
of Barcelona
Antonio Escartín Siquier Xavier Bonfill i Cosp
Manuel Armengol Carrasco Iberoamerican Cochrane Centre
Designated by the Board of the Research Institute Jaume Sellarès Sallas

of Sant Pau Hospital Barcelona-Sardenya Primary Care Centre
Josep M. Ventura Ferrero
Antoni Esteve Cruella Carme Borrell Thió
Public Health Agency of Barcelona
Jaume Kulisevsky Bojarski

Hospital de la Santa Creu i Sant Pau
Research Institute

Summary
IIB Sant Pau · 2015 Scientific Report
04 Presentation
07 IIB Sant Pau Scientific Structure
08 Who We Are
09 Strategic Objectives
10 IIB Sant Pau Entities
12 Vertical Areas of Research
13 Transversal Areas of Research
13 Associated Groups
14 Organization Chart
16 Financial Data
18 Scientific Outcomes
20 Publications with an Impact Factor
21 Publications by Thematic Area and Quartile
22 Research Resources
23 Research Training
24 Doctoral Theses
27 Patents
28 Technology Transfer Agreements
29 Clinical Guidelines
32 Research Support Services
42 Scientific and Technical Service Platforms
46 Areas of Research
48 Area 1. Cardiovascular Diseases
78 Area 2. Genetic, Metabolic and Inflammatory Diseases
116 Area 3. Haematological and Oncological Diseases
138 Area 4. Neurological, Mental Disorders and Ageing
176 Area 5. Uronephrology and Experimental Surgery
186 Area T1. Epidemiology, Public Health and Healthcare Services
208 Area T2. Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment
218 Associated Groups
Scientific Report 2015

4
Presentation
Dear colleagues and friends
Once again I am pleased to present the Annual Scientific Report of the Sant Pau
Biomedical Research Institute (IIB Sant Pau) for the year 2015. This annual event gives
us the opportunity to share and acknowledge the efforts and achievements of all those
who collaborate to make our Institute a dynamic and solid entity, committed to the
advancement of medical knowledge and its applicability to clinical practice.
In the pages of this Report the reader will find evidence of the sustained improvement
in the amount and the quality of the scientific output of our research groups. Moreover,
this report completes the first life-cycle of the IIB Sant Pau as Sanitary Research Institute
credited by the Ministry of Health (2011-2015). Remarkably, the great work done
during this period by the researchers, managers, administrative staff, support staff, and
technicians, has led to the recent renewal of this important recognition.
The activity of the seven areas of scientific research that integrate the structure of the
IIB Sant Pau, composed of 52 consolidated and 22 associated groups, has achieved
significant indicators. For instance, in 2015, our researchers published 804 scientific
papers, most (or many) of them (58%) in journals of the first quartile and many in the
first decile of the correspondent research area. The total impact factor of the published
articles was 3.927,427 with a mean impact factor of 4.096. The sustained growth
of the activities of clinical research allowed us to maintain our leading position for
performing clinical trials. Importantly, there was a growth in studies of early clinical
development (phase I and II) of the Drug Research Area (CIM Sant Pau). The Scientific
Management Area gave support to the presentation and management of more than
300 projects during 2015, which included technical assessment to young researchers
for the presentation of investigator initiated research. The Innovation Area succeeded
in provide technical support for the presentation of 24 International and European
Projects, one of them eventually granted. Moreover, in 2015 six inventions were
protected, some of them transferred to the industry thereby providing royalties to our
institute. Regarding training and education, the implication of the researchers with the
University gave rise to the lecture of XXX doctoral thesis.
Among other important aspects of the activity of the IIB during 2015, it is worth
mentioning the operative implementation of the 2014-2017 Strategic Plan and its
corresponding indicators for evaluation, which was previously discussed and agreed
with the effective participation of the organization. In 2015 the European Commission
awarded our institute with the recognition “HR Excellence in Research”, owing to our
commitment to deploy a 4-year action plan intended to develop a favorable working
environment for our research staff. A third milestone in 2015 has been the launch of
our intranet, a tool that will improve internal communication and allow investigators to
speed up a number of ancillary processes related with their research.

5
As for the obtained financial resources needed to sustain the research activities, our institute, with an annual budget of around
14 million euros, displays very high efficiency rates. The dynamic activity of our researchers for obtaining competitive resources
(including scientific grants, donations, and contracts with the pharmaceutical industry and other promoters), allowed us to
continue our activities with a minimal index of public subsidy. Among the challenges for coming years, is securing funding to
allow an adequate policy for capture research talent and development of new infrastructures of research.
Other areas for improvement that face our Institute for the next future are the growth in human capital and scientific quality,
properly distributed among the different areas and research programs of the IIB. Specifically, we need to secure the funding
and prepare the organization for the future moving of the bulk of the experimental activity to the New Research Building of the
Institute that will represent a quantum leap in the life of the Institute. It should be preceded by a further strengthening within
the organization of the particularities of the research culture, and the crucial role of competitiveness and merits in the policy for
distributing space and resources. According to the Strategic Plan, we will continue conducting external evaluations to analyze the
scientific outputs of the researchers funded by the IIB and the activity of the research groups, persuaded that these assessments
help to learn and improve the performance of the groups and to ensure their alignment to the strategic positioning of the
organization.
Research and education activities are essential to advancing patient care. The multidisciplinary research teams of the different
biomedical and healthcare entities integrated in the IIB Sant Pau strive to generate and rapidly translate new discoveries to
improve the prevention and treatment of disease and injury. They are in close contact with the needs of the patients and work
across disciplines to expand the frontiers of scientific understanding while moving the most promising breakthroughs into
tangible health benefits through clinical trials. However, we firmly believe that a passive role of patients in health investigation is
no longer satisfactory and see our patients as partners in health research collaborating to prioritize a patient-centered research
agenda that captures issues that patients, their relatives, clinical specialists and researchers consider important. Many of these
activities that our members bring to the patients and the community promoting the dissemination of science, the importance
of translational medicine and the crucial role of patient involvement in research priorities, were conducted in 2015 and will be
stimulated in the next future.
I take this opportunity to once again congratulate all who in one way or another was involved in the activities of the IIB Sant Pau
for the results summarized at this 2015 Report, and to encourage our patients and investigators to continue to work together with
renewed enthusiasm to face the many challenges of medical research.
Jaume Kulisevsky
Scientific Director

6

7
IIB Sant Pau Scientific

Structure
IIB Sant Pau has seven research areas that can be divided into two
research lines: vertical, transversal and associated groups.
The vertical line has five main areas:

JJ Cardiovascular Diseases
JJ Genetic, Metabolic and Inflammatory Diseases
JJ Haematological and Oncological Diseases
JJ Neurological and Mental Disorders
JJ Uronephrology and Experimental Surgery
The transversal line consists of two areas:

JJ Epidemiology, Public Health and Healthcare Services
JJ Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Di-
seases and their Treatment
Activities in the transversal line complement and support research in

the vertical line.

8
Who We Are
The Sant Pau Biomedical Research Institute (IIB Sant Pau) IIB Sant Pau was founded in 2009 as an association of healthcare
conducts research into basic, clinical and epidemiological entities carrying out their own research. Throughout 2010,
medicine and healthcare services. Ten entities cooperate IIB Sant Pau became consolidated as a research centre,
to perform high-level research into new techniques and while continuing to implement an accreditation process as
processes aimed at improving the quality of life of patients. a Healthcare Research Institute with the Spanish Ministry
Stakeholders include the following: of Science and Innovation. This accreditation was finally
obtained in early 2011. The institutions participating in IIB
JJ Hospital de la Santa Creu i Sant Pau Healthcare Manage-
Sant Pau, which together form a natural alliance for historical
ment Foundation
and geographical proximity reasons, jointly implement
JJ Hospital de la Santa Creu i Sant Pau Private Foundation research activities and cooperate in other scientific areas. The
JJ Hospital de la Santa Creu i Sant Pau Research Institute cooperation between these institutes represents a qualitative
leap in terms of fostering translational research projects that
JJ Autonomous University of Barcelona - Ageing Institute bridge the gap between basic and clinical research.
JJ Catalan Institute of Cardiovascular Sciences The knowledge developed in this kind of research is
channelled to society by the application of discoveries to
JJ Puigvert Foundation
clinical practice and to healing patients. The most tangible
JJ Blood and Tissue Bank benefits are the application of technology to health and the
JJ Iberoamerican Cochrane Centre scientific communication of new knowledge. This research
infrastructure also generates employment and spotlights
JJ Barcelona-Sardenya Primary Health Care Centre Catalonia’s contributions to biomedical research. The success
JJ Public Health Agency of Barcelona as a research centre ultimately translates to patient health.

9
Strategic Objectives
IIB Sant Pau’s mission is to manage, promote, develop and JJ Participate in developing policies aimed at coordinating
communicate research into the health sciences. biomedical research in Catalonia, while ensuring a strong
To fulfil its mission, IIB Sant Pau has set itself a number of presence in national and international research projects
strategic objectives that guide its activities: and networks of excellence.
JJ Promote and consolidate relationships and knowledge ex- JJ Acquire, maintain and optimize use of scientific and techno-
changes between IIB Sant Pau researchers and with other logical infrastructures and equipment.
public and private organizations, prioritizing the imple-
mentation of joint projects and the creation of multidisci-
plinary teams so as to strengthen alliances and implement
translational research with a bearing on clinical activities.
JJ Organize courses, conferences, open days, seminars and
workshops aimed at communicating scientific advances to
society and at facilitating innovation and technology trans-
fers to the productive sector.
JJ Organize and participate in continuous professional de-
velopment, whether by developing teaching activities or
arranging grant-aided stays abroad for researchers.

10
IIB Sant Pau Entities

Hospital de la Santa Creu i Sant Pau Healthcare
Management Foundation
The Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation (HSCSP
Healthcare Management Foundation) is a high-technology specialist care hospital
performing patient care, teaching and research activities in the clinical, epidemiological
and healthcare services fields. It offers accredited specialist and undergraduate health
science training courses.
Hospital de la Santa Creu i Sant Pau Research Institute

The Hospital de la Santa Creu i Sant Pau Research Institute (HSCSP RI) promotes,
manages and communicates biomedical research conducted in the HSCSP. It raises and
manages funds and other resources for health science research in the basic, clinical,
Institut de Recerca
epidemiological and healthcare service fields.
Hospital de la Santa Creu i Sant Pau Private Foundation

The Hospital de la Santa Creu i Sant Pau Private Foundation (HSCSP Private
Foundation), which owns the HSCSP, is responsible for building, improving and
maintaining buildings and premises used for medical care and associated and
complementary activities.
Autonomous University of Barcelona (UAB) - Ageing Institute

The UAB, a leading university renowned for quality and innovation in research,
coordinates an influential scientific and technological centre, called Esfera UAB,
responsible for promoting new business projects. The UAB also projects its productive
activity in such a way as to disseminate new knowledge in society.
The Ageing Institute, attached to this university, is a non-profit foundation governed by

a board of trustees formed by the UAB, the UAB Foundation and the Agrupació Mútua
del Comerç i de la Indústria. Its mission is to improve knowledge of different aspects
related to ageing with the aim of enhancing the quality of life of older people and
promoting actions that contribute to adapting society and people to the challenges of
demographic change.

11
Catalan Institute of Cardiovascular Sciences (ICCC)

The ICCC performs basic and clinical research into cardiovascular and heart diseases.
The fact that it competes successfully at the international level enables it to avail
of the infrastructure necessary to transfer basic research to the development of
therapies and diagnostic methods, ultimately improving medical care for patients.
Puigvert Foundation
The Puigvert Foundation has the aim of deepening medical knowledge and perfecting
medical techniques in the field of research and treatment of urinary and male
reproductive system disorders and diseases. More specifically, it performs urology,
nephrology and andrology research, focusing particularly on medical care, teaching,
training and studies.
Iberoamerican Cochrane Centre

This independent, not-for-profit organization has as its main aim the promotion of
medical practice based on the best available scientific evidence. To this end, it ensures
that valid, useful, up-to-date and thoroughly reviewed information is made available
for clinical and healthcare decision making.
Barcelona-Sardenya Primary Care Centre

Part of the public healthcare system, this teaching and care centre provides primary
care services in its catchment area of Barcelona and has a research unit which
performs clinical trials and epidemiology studies.
Public Health Agency of Barcelona

This autonomous body, created by the Barcelona Health Consortium, has as its
main mission to analyse and monitor the health of the population of Barcelona
with a view to improving health and preventing risk. It is also responsible for
epidemiological surveillance and the provision of medical care to substance abusers.
It has an excellent track record in the public health and applied research fields.
Blood and Tissue Bank

The Blood and Tissue Bank is a public healthcare body which carries out patient care,
teaching and research activities in the blood transfusion and tissue bank fields.

12
Vertical
Areas of Research
Cardiovascular Diseases
The incorporation of new technologies that facilitate molecular profiling and gene
regulation has led to innovative research into heart disease. The great diversity of the
groups in this area gives research varied perspectives, whether in developing or testing
the effectiveness of new biomarkers (as in the investigation of the metabolic and genetic
bases of diseases) or improving the range of results and possible applications in short-
term therapies.
Genetic, Metabolic and Inflammatory Diseases

Identifying the genes and mutations responsible for genetic diseases is an essential
component of knowledge and understanding of the physiological bases of metabolic
pathways and also in the development of new forms of treatment for common diseases
affecting large proportions of the population, such as diabetes and obesity, known but
with a hereditary diseases, infectious diseases (AIDS, tuberculosis, etc) and rare diseases
(not well know but with a devastating impact on those affected).
Haematological and Oncological Diseases

A broad range of research is conducted in this area, particularly in head-and-neck, breast, ovary,
colorectal and haematological cancers, among others. Research in covers a wide range of fields,
with disciplines that include nanomedicine, new anticancer agents and predictive molecular
markers. Initiatives of specific relevance include the GAIT (Genetic Analysis of Idiopathic
Thrombophilia) project, a world pioneer in the identification of genes influencing the risk of
thromboembolic disease, and research into antitumour immunotherapy in animals and humans.
Neurological, Mental Disorders and Ageing

This area covers research in a broad range of disciplines. Besides the study of ageing and the most
common neurodegenerative disorders such as Alzheimer and Parkinson, neurological research is also
focused on stroke, neuroimmunology and neuromuscular diseases. Research into cognitive, affective,
psychotic and personality disorders ranges from identification and evaluation of new therapeutic
targets to neurogenesis and the effects of deep-brain stimulation. Research in this field has the support
of the Drug Research Centre, which assesses the effectiveness of new drugs and therapies in humans.
Uronephrology and Experimental Surgery

IIB Sant Pau promotes experimental surgery in the knowledge that this area has a promising
future both as an independent research line and as a complement to general surgery. This
interdisciplinary approach provides valuable new insights and ensures techniques and procedures
of great clinical relevance. Current areas of interest include the development of minimally invasive
techniques and the application of deep-brain stimulation in different pathologies. In the fields of
andrology, urology and nephrology research, the Puigvert Foundation is a leading centre in Spain.

13
Transversal
Areas of Research
Epidemiology, Public Health and Healthcare Services
Research in these fields aims to determine the magnitude and distribution and identify
the determinants of public health problems in order to evaluate the effectiveness and
efficiency of public interventions and prevention practices. This area also aims to reduce
patient risk and make healthcare safer by promoting evidence-based medical practice and
ensuring the use of conscious, explicit and rational decision making concerning patient
care.
Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and

their Treatment
This area focuses on the structure of proteins associated with neurodegenerative diseases and
inflammatory processes and on factors linked to the innate immune system. Research is also
conducted in the area of osteoporosis, ageing-related macular degeneration and coagulation-
cascade factors closely linked to cardiovascular disease and haemophilia. Such studies are vital
to the understanding of diseases of the heart, blood and nervous systems and to advances in
the fields of cancer and epidemiology.
Associated Groups
This area includes HSCSP Research Institute groups that do not form part of IIB Sant Pau
because they have not, as yet, been accredited by the External Scientific Committee.

14
Organization Chart
Steering Committee
Executive Committee
Clinical Research
Ethics Committee
Internal Scientific
Committee
Animal Experimentation
Ethics Committee
External Scientific
Committee
IIB Sant Pau Management
HSCSP Research Institute Management Director Research Areas
Steering Committee Executive Committee

Chair Chair
Dr. Alberto Salazar Dr. Jaume Kulisevsky
Hospital de la Santa Creu i Sant Pau Healthcare Management IIB Sant Pau Manager
Foundation
Representatives of Associated Entities
Members
Dr. Manel Trias
Dr. Jordi Bachs Autonomous University of Barcelona
Hospital de la Santa Creu i Sant Pau Private Foundation
Dr. Ramon Mangues
Dr. Lluís Tort Hospital de la Santa Creu i Sant Pau Research Institute
Autonomous University of Barcelona
Dr. Xavier Bonfill
Dr. Lina Badimon Iberoamerican Cochrane Centre
Catalan Institute of Cardiovascular Sciences
Dr. Juan Cinca
Dr. Helena Isábal Hospital de la Santa Creu i Sant Pau Healthcare Management
Puigvert Foundation Foundation
[Pending to nominate] Dr. Alessandro Sionis
Blood and Tissue Bank Hospital de la Santa Creu i Sant Pau Private Foundation
Dr. Xavier Bonfill Dr. Lina Badimon
Iberoamerican Cochrane Centre Catalan Institute of Cardiovascular Sciences
Dr. Carme Borrell Dr. Helena Isabal
Public Health Agency of Barcelona Puigvert Foundation
Mr. Jaume Sellarès [Pending to nominate]
Barcelona-Sardenya Primary Care Centre Blood and Tissue Bank
Dr. Jaume Kulisevsky Dr. Carme Borrell
Hospital de la Santa Creu i Sant Pau Research Institute Public Health Agency of Barcelona
Dr. Carlos Brotons
Barcelona-Sardenya Primary Care Centre

15
Internal Scientific External Scientific

Committee Committee
Chair Haematological and Dr. José López-Barneo
Oncological Diseases Physiology professor
Dr. Jaume Kulisevsky Institute of Biomedicine of Seville (Spain)
IIB Sant Pau Manager Dr. Josep Nomdedéu
Hospital de la Santa Creu i Sant Pau: Dr. Ángel María Carracedo
Vice-Chair Haematological diagnosis Genomic medicine group researcher
Institute of Legal Medicine
Dr. Antonio López Pousa Dr. Jaime Prat
Faculty of Medicine and Dentistry
Chair, Clinical Research Ethics Committee Hospital de la Santa Creu i Sant Pau:
Santiago de Compostela University
Molecular cancer pathology
4 members designated by the IIB Sant Pau (Spain)
Manager Neurological, Mental Disorders and Ageing
Dr. Vicente Vicente
Dr. Antoni Salvà Dr. Víctor Pérez Haematology group researcher
Autonomous University of Barcelona - Hospital de la Santa Creu i Sant Pau: Clinical Faculty of Internal Medicine
Ageing Institute psychiatry Murcia General University Hospital (Spain)
Dr. Carlos Brotons Dr. Alberto Lleó Dr. José Palacios

Barcelona-Sardenya Primary Care Centre Hospital de la Santa Creu i Sant Pau Research Head of the pathology/anatomy
Institute: Neurobiology of dementia Department
Dr. Lina Badimon Ramón y Cajal Hospital (Madrid, Spain)
Uronephrology and Experimental Surgery
Catalan Institute of Cardiovascular Sciences
Dr. Agustín Gómez de la Cámara
Dr. José Ballarín
Dr. Sílvia Mateu Clinical epidemiology group researcher
Puigvert Foundation: Nephrology research
Puigvert Foundation Doce de Octubre Teaching Hospital
Dr. Manel Trias (Madrid, Spain)
2 members each representing Hospital de la Santa Creu i Sant Pau:
IIB Sant Pau thematic areas General and digestive surgery Dr. John Louis McGregor
Director of Research-INSERM Unit 689
Cardiovascular Diseases Epidemiology, Public Health Cardiovascular Research Centre–
and Healthcare Services Lariboisière Hospital (Paris, France)
Dr. Jordi Ordóñez
Hospital de la Santa Creu i Sant Pau: Dr. Gerard Urrútia Dr. Jordi Alonso
Cardiovascular biochemistry Hospital de la Santa Creu i Sant Pau: Health Services Research Unit
Clinical epidemiology and healthcare Hospital del Mar Municipal
Dr. Luis Vila services Institute for Medical Research (Barcelona,
Hospital de la Santa Creu i Sant Pau Spain)
Research Institute: Vascular biology and Dr. Carles Ariza
inflammation Public Health Agency of Barcelona: Mr. Guillem López Casasnovas
Evaluation of public health policies and Professor
Genetic, Metabolic, Inflammatory and programmes Faculty of Economics and Business
Infectious Diseases Sciences
Molecular, Genomic, Cellular and
Kinetic-Dynamic Bases for Diseases and Pompeu Fabra University (Barcelona,
Dr. Cándido Juárez
Treatments Spain)
Hospital de la Santa Creu i Sant Pau:
Inflammatory diseases
Dr. Jordi Sierra
Dr. Carlos Guarner Blood and Tissue Bank: Generation of
Hospital de la Santa Creu i Sant Pau: advanced treatments
Cirrhosis complications
Dr. José Manuel Soria
Hospital de la Santa Creu i Sant Pau Research
Institute: Genomics and bioinformatics for
genetically complex disease

16
Financial Data
Public/Private Income Summary 2005-2015
100 %
90 %
80 %
70 %
60 %
50 %
40 %
30 %
20 %
10 %
0%
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Public 3.57 3.61 4.27 4.81 7.02 7.73 6.31 6.02 4.99 5.92 7.42
Private 5.67 4.42 4.85 8.02 7.28 6.33 6.81 5.99 7.59 7.42 7.94
In millions of euros

17
Income Statement year ending 31 December 2015
Income from activities 14,030,821

Services 4,408,892
Collaborations with partners and sponsors 2,281,391
Government grants 6,071,938
Other grants, donations and legacies 1,364,529
Repayment of grants, donations, etc -95,929
Stocks and supplies -1,153,789
Material and equipment for activities -1,153,789
Other income 157,738
Additional and management income 157,738
Personnel expenditure -8,357,984
Salaries -6,426,977
Social security -1,931,007
Other operating expenses -4,432,967
External services -3,933,605
Leases and Royalties -227
Repairs and maintenance -106,418
Freelance services -460,949
Insurance -49,215
Banking -17,034
Sundry -1,750
Other services -3,298,011
Taxes -21,082
Loss, deterioration and variation in provisions for operations 64,314
Other operating expenses -542,595
Depreciation of fixed assets -1,247,901
Grants, donations and bequests transferred to results 888,382
Deterioration and gains/losses on disposal of fixed assets 0
Gains/losses from disposal and other 0
Other gains/losses 10,914
Incidental expenses -41,315
Incidental income 52,229
OPERATIONAL PROFIT/LOSS -104,787
Financial income 245,811

From investments in equity instruments 245,811
Negotiable costs 245,811
Financial expenditure -179,032
Debts with third parties -179,032
Exchange differences -1,177
FINANCIAL PROFIT/LOSS 65,602
OVERALL PROFIT/LOSS -39,185
In euros

18
Scientific Outcomes
Outcomes for IIB Sant Pau’s scientific activities are summarized in the following pages as follows:
JJ Publications with an Impact Factor (IF): This figure shows IIB Sant Pau publications over the years with an impact factor, one of
the most important indicators used to identify the relevance of a science journal in its field and to give an approximate idea of
the quality of the publications of researchers.
JJ Publications by Thematic Area: This figure reflects the relative importance of each of the thematic areas covered by IIB Sant Pau.
JJ Publications by Quartile: This figure depicts IIB Sant Pau publications by quartiles that reflect the importance of the scientific
journal. The journals in a specific category are listed in descending order according to their impact factor and the list is divided
into four equal quartiles. Thus, journals in the top quartile (Q1) are the most important journals in their category.
JJ Research Resources and Training: These tables show the list of institutions providing support to IIB Sant Pau and sharing its
vision of research.
JJ Doctoral Theses: This table reflects the potential of up-and-coming IIB Sant Pau staff members and their ability to generate new
ideas and drive new projects.
JJ Patents: This table shows the patents requested by IIB Sant Pau researchers between 2009 (foundation year) and 2014.
JJ Technology Transfer Agreements: This table reflects agreements signed between 2009 (foundation year) and 2014.
JJ Clinical Guidelines.

19

20
Publications with
an Impact Factor
Production status
4,000 6
5
3,200
4
2,400
1,600
2
800
1
0 0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Publications 275 250 367 461 514 534 664 654 933 804
Total IF 1,001.03 975.36 1,722.76 2,158.53 2,448.88 2,298.44 3,269.47 2,848.27 4,074.22 3,927.43
Mean IF 3.64 3.9 4.69 4.68 4.78 4.30 4.92 4.35 4.37 3.98

21
Publications by Thematic
Area and Quartile
Indexed publications
240
240
200
200
160
160
120
120
80
80
40
40
00
A1
A1 A2A2 A3 A3 A4 A4 A5 A5 T1 T1 T2 T2AG AG
Indexed
publications
150 172 106 127 33 153 16 193
Mean IF 5.062 5.389 6.346 4.806 3.916 3.444 6.382 4.096

A1 Cardiovascular Diseases A5 Urology, Nephrology and Experimental Surgery
A2 Genetic, Metabolic and Inflammatory Diseases T1 Epidemiology, Public Health and Healthcare Services
A3 Haematological and Oncological Diseases T2 Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment
A4 Neurological, Mental Disorders and Ageing AG Associated Groups
55
Q1
126
Q2 Q1
469 Q3 Q2
154
Q4 Q3
Q4

22
Research Resources
Centre Active Granted
2014 2015 2014 2015
AGAUR (Agència de Gestió d'Ajuts Universitats i Recerca) 19 23 23 2
European Comission 5 5 1 1
American Grants 1 1
EAES (European Association for Endoscopic Surgery) 1 1 - -
COIB (Col·legi Oficial d'Infermeria de Barcelona) 2 1 - 1
Fundació Marató TV3 9 10 5 5
Fundació Mútua Madrileña (FMM) 2 2 - 1
Fundación Mapfre 1 - - -
ISCIII (Instituto de Salud Carlos III) 113 101 21 21
MINECO (Ministerio de Economía y Competitividad) 6 8 6 2
Ministerio de Sanidad, Servicios Sociales e Igualdad 11 10 - 1
SEPAR (Sociedad Española de Neumología y Cirugía Torácica) 9 8 4 -
AECC (Asociación Española Contra el Cáncer) 3 3 - 3
Merk Serono 1 1 - -
Fundació Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears 1 - - -
SOCAP (Societat Catalana de Pneumologia) 1 2 - -
Sociedad Española de Diabetes 1 - - 1
Fundació Catalana de Pneumologia 2 2 1 1
Sociedad Española de Cardiología - - - 1
Asociación Española de Artroscopia 1 - - -
AFM Telethon 1 1 1 1
Societat Catalana de Psiquiatria i Salut Mental 1 1 - -
Fundació Alfonso Martín Escudero 1 1 - -
CIBERER 1 - - -
GILEAD 1 2 1 -
Grup Espanyol d’Investigació en Sarcomes - 1 1 -
Mutual Médica - - 1 -
Federación Española de Enfermedades Raras / Fundación Isabel Gemio /
- 1 1 -
Federación Española de Enfermedades Neuromusculares
Fundació Privada de l’Hospital de la Santa Creu i Sant Pau - - - 6
Col·legi de Farmacèutics de Barcelona - - - 1
Fundación y Sociedad Española de Arteriosclerosis - - - 1
European Society of Cardiology - - - 1
Fundació Víctor Grífols i Lucas - - - 1
Fundació Ramón Pla Armengol - - - 1
Institució CERCA - - - 1
Fundació Privada Daniel Bravo-Andreu - - - 1
Foundation International Guillain-Barré - 1 - -
194 186 66 54

23
Research Training
Centre Active Granted
2014 2015 2014 2015
AGAUR (Agència de Gestió d'Ajuts Universitats i Recerca) 3 5 2 2

Departament de Salut (Generalitat de Catalunya) 3 3 - -
MINECO (Ministerio de Economía y Competitividad) 6 3 - 1
ISCIII (Instituto de Salud Carlos III) 27 30 12 12
Fundació Gestió Sanitària 5 - - -
Fundación Casa del Corazón - 1 1 1
American Grants - 1 1 -
Fundación J. L. Castaño - 1 1 -
Fundació Privada de l’Hospital de la Santa Creu i Sant Pau - - - 4
44 44 17 20
Source: Hospital de la Santa Creu i Sant Pau Research Institute

24
Doctoral Theses
IIB Sant Pau Accredited Groups Candidate Thesis title Director(s)
Anaesthesiology Mercedes García Álvarez NGAL como biomarcador de disfunción renal aguda en Antoni Betbesé
pacientes postoperados de cirugía cardíaca Roig, Alfonso
Martínez López,
Jorge Ordóñez
Llanos
Anaesthesiology Pilar Paniagua Lesión miocárdica tras la cirugía no cardíaca: Análisis de Xavier León Vintró,
la cohorte española del estudio VISION Pablo Alonso Coello
Anaesthesiology M. L. Maestre Hittinger Valoración de los factores de riesgo asociados a la Xavier Ruis
transfusión en pacientes de criugía cardíaca mediante Cornadó, Xavier
análisis de partición recursiva Borràs Pérez, Josep
M. Padró Fernández
Andrology Chiara Chianese Genetic and Epigenetic Aspects of Male Infertility C. Krausz
Angiology, Vascular Biology and Zenaida Piñeiro Aguin Expresión de la prostaciclina sintetasa en los Mercedes Camacho,
Inflammation carcinomas de cabeza y cuello y valor pronóstico en la Xavier León, Luis
respuesta a radioterapia Vila
Chronic Respiratory Diseases Diego M. Castillo Villegas Rendimiento de un programa de estudio de casos Pere Casan Clara,
de EPOC en usuarios de alto riesgo de la farmacia Mercedes Mayos
comunitaria
Chronic Respiratory Diseases Jordi Giner Donaire Estàndards i qualitat en la determinació de la funció Joaquín Sanchis
pulmonar (l'espirometria) a l'Atenció Primària Aldas, Vicente Plaza
Moral
Chronic Respiratory Diseases Virginia Pajares Ruiz Utilización de criosondas para la realización de la Joaquín Sanchis
biopsia pulmonar transbronquial Aldás, Vicente Plaza
Moral
Clinical and Translational Francisco Javier Noriega Caracterización clínica y electrofisiológica de las Joan M. Cinca
Cardiology Sanz alteraciones recíprocas del electrocardiograma en el Cuscullola
infarto agudo de miocardio
Clinical and Translational Jesús Álvarez García Consecuencias clínicas, bioquímicas y Joan M. Cinca
Cardiology electrofisiológicas de la oclusión aguda de las arterias Cuscullola
coronarias auriculares durante la angioplastia en el ser
humano
Clinical Oncology Bárbara Garcia-Valdecasas Cáncer de mama: estudio de focos neoplásicos Agustí Barnadas
Vilanova invasores y no invasores de la expresión de Ki67 y su
relación con la supervivencia
Digestive Diseases Elisabet Sánchez Ardid Modelos experimentales de peritonitis bacteriana Carlos Guarner
inducida en ratas con cirrosis y nuevas estrategias
terapéuticas
Digestive Diseases Juan Camilo Nieta Sachica Caracterización de la respuesta inmune innata a Carlos Guarner
ligandos de tlr, infecciones bacterianas y tratamiento
con probióticos en la cirrosis
Endocrinology, Diabetes and Gemma Carreras González Terapia intensiva en la diabetes mellitus tipo 1 desde Antonio Pérez,
Nutrition el debut. Efecto sobre el control glucémico y las Isabel Badell
complicaciones tardías a los 20 años de evolución

25
Evaluation of Public Health Núria Obradors Factors individuals i contextuals associats al consum de Carles Ariza
Policies and Programmes risc d'alcohol en joves de la Catalunya Central
Evaluation of Public Health Olga Juárez Programas de prevención del embarazo, las infecciones Carles Ariza
Policies and Programmes de transmisión sexual, incluida la infección por el VIH/
SIDA, entre jóvenes escolarizados de Barcelona ciudad
(1992-2014)
Inflammation and Vascular Judith Alonso Nieto Papel de NOR-1 en la apoptosis y el estrés oxidativo: Antonio Rodríguez
Remodelling regulación de cIAP2 y la familia SOD en células Sinovas, José
musculares lisas humanas Martínez González
Inflammation and Vascular Mar Orriols Martins Mecanismes de regulació de la Lisil Oxidasa i la Antonio Rodríguez
Remodelling Fibulina-5 a nivell vascular: Implicació en la reestenosi i Sinovas, José
l'aneurisma d'aorta abdominal Martínez González
Inflammatory Diseases Eder Fredy Mateus Medina Papel de STAT1 y STAT3 en la tolerancia inducida por Cándido Juárez
Staphylococcal enterotoxin B.Entity
Inflammatory Diseases Juan C. Nieto Sachica Caracterización de la respuesta inmune innata a Silvia Vidal Alcorisa
ligandos de TLR, infecciones bacterianas y tratamiento
con probióticos en la cirrosis
Intensive Medicine Mercedes García Neutrophil gelatinase-associated lipocalin (NGAL) Antoni-Jordi

como marcador predictivo de fracaso renal agudo en Betbesé Roig, Jorge
pacientes postoperados de cirugía cardíaca Ordóñez Llanos,
Alfonso Martínez
López
Lipids and Cardiovascular Elena Revuelta-López Implicación del receptor LRP1 en el remodelado Vicenta Llorente
Pathology vascular y cardiaco Cortés
Locomotor System Research Francisco Javier Aguilera Ácido tranexámico en cirugía protésica de rodilla Claudia Mariana
Roig Lamas Gómez
Locomotor System Research Jordi Álvarez San Nicolás Cirugía de salvamento de extremidad en sarcoma de Claudia Mariana
Ewing: supervivencia, complicaciones y factores de Lamas Gómez
riesgo
Locomotor System Research / Mireia Rodríguez Prieto Eficacia del bloqueo ecoguiado de nervios periféricos Xavier Rius
Anaesthesiology en el control del dolor postoperatorio en cirugía Cornadó, Claudia
ambulatoria de rizartrosis Mariana Lamas
Gómez, Albert
Garcia Muret
Microbiology and Infectious Laura García Arroyo Epidemiologia de les infeccions respiratòries víriques Núria Rabella,
Diseases a l’Hospital de la Santa Creu i Sant Pau: Estudi Ferran Navarro
retrospectiu de 17 anys i avaluació de dos mètodes
moleculars pel diagnòstic virològic
Microbiology and Infectious Mar Martí Carrizosa Cándida Parapsilosis, C. Orthopsilosis y C. Metapsilosis: Fernando Sánchez
Diseases Epidemiología de las candidemias, patrones de
sensibilidad y mecanismos de resistencia a las
equinocandidas
Molecular Pathology and Ilaria Ramaiola Thombus composition in acute coronary syndrome Lina Badimon,
Therapeutic of Ischaemic and Teresa Padró
Atherothrombotic Diseases /
Biomarkers for Cardiovascular
Disease
Molecular Pathology and Sonia Espinosa Ferrer Neovascularización mediada por factor tisular en la Lina Badimon,
Therapeutic of Ischaemic and placa aterosclerótica Gemma Arderiu
Atherothrombotic Diseases

26
Molecular Pathology and Raquel de la Torre Tovar Mecanismos de inflamación y trombosis: papel de la Lina Badimon
Therapeutic of Ischaemic and proteina C-reactiva y de la proteina 78 regulada por
Atherothrombotic Diseases glucosa
Nephrology Laia Sans Atxer Estudio del perfil cardiovascular, sistema renina- Patricia Fernández-
angiotensina-aldosterona, inflamación y disfunción Llama, Julio
endotelial en pacientes normotensos con poliquistosis Pascual
renal autosómica dominante y sin insuficiencia renal
Neurobiology of Dementia Daniel Andrés Alcolea Cerebrospinal fluid biomarkers for the study of the Alberto Lleó
Rodríguez pathophysiological pathways in Alzheimer's disease Bisa, Rafael Blesa
González
Neuromuscular Diseases Xavier Suárez Nous aspectes fisiopatogènics en la dermatomiositis Isabel Illa
Nursing Care Research M. Teresa Ricart Basagaña Proceso de alta de una unidad de cuidados intensivos: Mar Lleixà Fortuño
medición de la ansiedad y factores relacionados
Nursing Care Research / Intensive Gemma Robleda Font Relevancia clínica del dolor asociado con los Josep Eladi
Medicine procedimientos del paciente crítico Baños Díez, Jordi
Mancebo Cortés
Oncogenesis and Antitumoral Laia Estalella Mercadé Estudio de factores clínico-patológicos y valor Maria Virtudes
Drugs pronóstico de la expresión subcelular de E-cadherina en Céspedes, Vicenç
metástasis hepáticas de cáncer colorectal Artigas, Manuel
Trias
Ophthalmology Jaume Crespi Vilimelis New gens envolved in rare diseases in Ophthalmology José Antonio Buil
Calvo, José García-
Arumí
Ophthalmology José Ignacio Vela Segarra Estudio de las lesiones paravasculares en el paciente José Antonio Buil
alto miope mediante OCT de dominio espectral Calvo, José García-
Arumí
Pain and Neurosciences Miren Revuelta Rizo Efectividad de la respuesta al tratamiento Xavier León Vintró,
intervencionista en la Unidad del Dolor sobre la Elena Català
radiculalgia secundaria a hernia discal Puigbò
Pain and Neurosciences M. Mercè Genové Impacte de les alteracions cerebrals en la percepció del Xavier Rius
dolor per herpes zòster i neuràlgia postherpètica Cornadó, Elena
Català Puigbó,
Maria J. Portella
Moll
Parkinson Disease and Eva Ruzafa Valiente Comportamiento de la escala Parkinson’s Disease Jaime Kulisevsky,
Movement Disorders – Cognitive Rating Scale (PD-CRS) en patologías Carmen García
diferentes a la enfermedad de Parkinson Sánchez
Pharmacological Research in Savion Gropper Achitoov Absorption, safety and tolerability of a Topical Rosa Antonijoan
Humans Quinolone
Pharmacy Noé Garin Escrivà Distribution of multiple chronic conditions and their M. Antònia
impact on the Spanish population* Mangues
Pituitary and Gland Disorders Anna Aulinas Investigation of the telomere maintenance system in Susan Webb
Cushing's syndrome: A contribution to the phenomena
of early ageing and specific morbidity
Pituitary and Gland Disorders Alícia Santos Estudio neuropsicológico, neuroradiológico y clínico en Susan Webb
el hipercortisolismo endógeno
Plastic Surgery Gemma Pons Playá Planificación preoperatoria de anastomosis linfático- Jaume Masià,
venosas mediante ICG y linfoRMN Xavier Rius, Xavier
León
Urology Carlos Errando Valoración funcional y de la calidad de vida tras A. Gelabert, F.

implante de cabestrillo reajustable tipo remeex® Millán, J. Palou
en incontinencia de orina femenina recidivada o
insuficiencia esfinteriana intrínseca
* European theses

27
Patents
IIB Sant Pau Group Researchers Organizations Title Application Number
Molecular Pathology of Jaime Prat HSCSP RI Method to predict risk of PCT/EP2015/053387
Gynaecologic Cancer recurrence in endometrial
carcinoma
Reproductive Health Ramon Rovira HSCSP RI Dispositivo para simular una P201531796
operación endoscópica vía
orificio natural

28
Technology
Transfer Agreements
Organitzations Partners Intellectual property / Technology
HSCSP; HSCSP RI Sociedad de Gestión de Proyectos Tecnológicos SL mHealth Platform
HSCSP RI Eli Lilly and Company Clinical scales
HSCSP RI Bracket Global LLC Clinical scales

29
Clinical
Guidelines
PUBMED
Baselga Torres E., Bernabéu Wittel J., van Esso Arbolave D.L., Febrer Bosch M.I., Carrasco Sanz A., de Lucas Laguna R., Del Pozo
Losada J., Hernández Martín Á., Jiménez Montañés L., López Gutiérrez J.C., Martín-Santiago A., Redondo Bellón P., Ruíz-Canela
Cáceres J., Torrelo Fernández A., Vera Casaño A., Vicente Villa M.A. [Spanish consensus on infantile haemangioma]. An Pediatr
(Barc). 2015 Nov 19. pii: S1695-4033(15)00398-7. doi: 10.1016/j.anpedi.2015.10.004. [Epub ahead of print]
Puente J., García del Muro X., Pinto Á., Láinez N., Esteban E., Arranz J.Á., Gallardo E., Méndez M.J., Maroto P., Grande E., Suárez C.
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. Target Oncol.
2015 Dec 26. [Epub ahead of print]
Martin-Richard M., Custodio A., García-Girón C., Grávalos C., Gomez C., Jimenez-Fonseca P., Manzano J.L., Pericay C., Rivera F.,
Carrato A. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol. 2015 Dec;17(12):996-1004. doi: 10.1007/
s12094-015-1456-y. Epub 2015 Dec 21.
Grande E., Santamaría Sandi J., Capdevila J., Navarro González E., Zafón Llopis C., Ramón y Cajal Asensio T., Gómez Sáez J.M.,
Jiménez-Fonseca P., Riesco-Eizaguirre G., Galofré J.C. Consensus on management of advanced medullary thyroid carcinoma on
behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group
for Orphan and Infrequent Tumors (GETHI). Clin Transl Oncol. 2015 Dec 21. [Epub ahead of print]
Carrascosa J.M., de la Cueva P., Ara M., Puig L., Bordas X., Carretero G., Ferrándiz L., Sánchez-Carazo J.L., Daudén E., López-
Estebaranz J.L., Vidal D., Herranz P., Jorquera E., Coto-Segura P., Ribera M. Methotrexate in Moderate to Severe Psoriasis: Review
of the Literature and Expert Recommendations. Actas Dermosifiliogr. 2015 Nov 21. pii: S0001-7310(15)00456-1. doi: 10.1016/j.
ad.2015.10.005. [Epub ahead of print]
Riesco-Eizaguirre G., Galofré J.C., Grande E., Zafón Llopis C., Ramón y Cajal Asensio T., Navarro González E., Jiménez-Fonseca P.,
Santamaría Sandi J., Gómez Sáez J.M., Capdevila J. Spanish consensus for the management of patients with advanced radioactive
iodine refractory differentiated thyroid cancer. Endocrinol Nutr. 2015 Nov 18. pii: S1575-0922(15)00228-4. doi: 10.1016/j.
endonu.2015.08.007. [Epub ahead of print]
Fernández-Bañares F., Casanova M.J., Arguedas Y., Beltrán B., Busquets D., Fernández J.M., Fernández-Salazar L., García-Planella
E., Guagnozzi D., Lucendo A.J., Manceñido N., Marín-Jiménez I., Montoro M., Piqueras M., Robles V., Ruiz-Cerulla A., Gisbert
J.P.; Spanish Microscopic Colitis Group (SMCG). Current concepts on microscopic colitis: evidence-based statements and
recommendations of the Spanish Microscopic Colitis Group. Aliment Pharmacol Ther. 2016 Feb;43(3):400-26. doi: 10.1111/
apt.13477. Epub 2015 Nov 24.
Garcia del Muro X., de Alava E., Artigas V., Bague S., Braña A., Cubedo R., Cruz J., Mulet-Margalef N., Narvaez J.A., Martinez Tirado
O., Valverde C., Verges R., Viñals J., Martin-Broto J. Clinical practice guidelines for the diagnosis and treatment of patients with soft
tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemother Pharmacol. 2016 Jan;77(1):133-46. doi:
10.1007/s00280-015-2809-5. Epub 2015 Nov 12.
Bravo García-Morato M., Padilla-Merlano B., Nozal P., Espiño M., Juárez C., Villar L.M., López-Trascasa M.; On behalf of the Grupo de
Inmunoquímica de la Sociedad Española de Inmunología. Laboratory guidelines for the diagnosis and follow-up of patients with
monoclonal gammopathies. Rev Clin Esp. 2015 Oct 16. pii: S0014-2565(15)00227-1. doi: 10.1016/j.rce.2015.09.002. [Epub ahead of
print]
López-Sendón J., González-Juanatey J.R., Pinto F., Cuenca Castillo J., Badimón L., Dalmau R., González Torrecilla E., López-Mínguez
J.R., Maceira A.M., Pascual-Figal D., Pomar Moya-Prats J.L., Sionis A., Zamorano J.L.; INCARDIO Task Force (Indicadores de Calidad en

30
Unidades Asistenciales del Área del Corazón) joint Sociedad Española de Cardiología and Sociedad Española de Cirugía Torácica
Cardiovascular task force. Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality
Measures Related to Better Results in Clinical Practice (Performance Metrics). INCARDIO (Indicadores de Calidad en Unidades
Asistenciales del Área del Corazón): A SEC/SECTCV Consensus Position Paper. Rev Esp Cardiol (Engl Ed). 2015 Nov;68(11):976-995.
e10. doi: 10.1016/j.rec.2015.07.003. Epub 2015 Aug 25.
Verberne H.J., Acampa W., Anagnostopoulos C., Ballinger J., Bengel F., de Bondt P., Buechel R.R., Cuocolo A., van Eck-Smit B.L.,
Flotats A., Hacker M., Hindorf C., Kaufmann P.A., Lindner O., Ljungberg M., Lonsdale M., Manrique A., Minarik D., Scholte A.J.,
Slart R.H., Trägårdh E., de Wit T.C., Hesse B.; European Association of Nuclear Medicine (EANM). EANM procedural guidelines
for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging. 2015
Nov;42(12):1929-40. doi: 10.1007/s00259-015-3139-x. Epub 2015 Aug 21.
Llau J.V., Acosta F.J., Escolar G., Fernández-Mondéjar E., Guasch E., Marco P., Paniagua P., Páramo J.A., Quintana M., Torrabadella P.
Multidisciplinary consensus document on the management of massive haemorrhage (HEMOMAS document). Med Intensiva. 2015
Nov;39(8):483-504. doi: 10.1016/j.medin.2015.05.002. Epub 2015 Jul 29.
Arbizu J., García-Ribas G., Carrió I., Garrastachu P., Martínez-Lage P., Molinuevo J.L. Recommendations for the use of PET imaging
biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. Rev Esp
Med Nucl Imagen Mol. 2015 Sep-Oct;34(5):303-13. doi: 10.1016/j.remn.2015.03.002. Epub 2015 Jun 20.
Wassef M., Blei F., Adams D., Alomari A., Baselga E., Berenstein A., Burrows P., Frieden I.J., Garzon M.C., Lopez-Gutierrez J.C., Lord
D.J., Mitchel S., Powell J., Prendiville J., Vikkula M.; ISSVA Board and Scientific Committee. Vascular Anomalies Classification:
Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics. 2015 Jul;136(1):e203-14. doi:
10.1542/peds.2014-3673. Epub 2015 Jun 8.
Digby G.C., Kukla P., Zhan Z.Q., Pastore C.A., Piotrowicz R., Schapachnik E., Zareba W., Bayés de Luna A., Pruszczyk P., Baranchuk
A.M. The value of electrocardiographic abnormalities in the prognosis of pulmonary embolism: a consensus paper. Ann
Noninvasive Electrocardiol. 2015 May;20(3):207-23. doi: 10.1111/anec.12278.
Lahoz C., Esteban Gracia C., Reinares García L., Bellmunt Montoya S., Brea Hernando Á., Fernández Heredero Á., Suarez Tembra M.,
Botas Velasco M., Guijarro C., Bravo Ruiz E., Pintó X., Vega de Ceniga M., Moñux Ducajú G.; on behalf of the Grupo de Prevención
Secundaria de la Sociedad Española de Arteriosclerosis and of the Sección de Medicina Vascular de la Sociedad Española de
Angiología y Cirugía Vascular. [Guide recommendations for diagnosis and treatment of abdominal aortic aneurysm]. Clin Investig
Arterioscler. 2015 May-Jun;27(3):159-65. doi: 10.1016/j.arteri.2015.01.004. Epub 2015 Mar 30.
Gómez Sáez J.M., Jiménez-Fonseca P., Santamaría Sandi J., Capdevila Castillón J., Navarro González E., Zafón Llopis C., Ramón y
Cajal Asensio T., Riesco Eizaguirre G., Grande Pulido E., Galofré Ferrater J.C. Spanish consensus for the management of patients
with anaplastic cell thyroid carcinoma. Endocrinol Nutr. 2015 Mar;62(3):e15-22. doi: 10.1016/j.endonu.2014.11.006. Epub 2015 Jan
9.
Luger T., Boguniewicz M., Carr W., Cork M., Deleuran M., Eichenfield L., Eigenmann P., Fölster-Holst R., Gelmetti C., Gollnick H.,
Hamelmann E., Hebert A.A., Muraro A., Oranje A.P., Paller A.S., Paul C., Puig L., Ring J., Siegfried E., Spergel J.M., Stingl G., Taieb A.,
Torrelo A., Werfel T., Wahn U. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr
Allergy Immunol. 2015 Jun;26(4):306-15. doi: 10.1111/pai.12331. Epub 2015 Apr 13.
Mata P., Alonso R., Ruiz A., Gonzalez-Juanatey J.R., Badimón L., Díaz-Díaz J.L., Muñoz M.T., Muñiz O., Galve E., Irigoyen L., Fuentes-
Jiménez F., Dalmau J., Pérez-Jiménez F. [Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document].
Semergen. 2015 Jan-Feb;41(1):24-33. doi: 10.1016/j.semerg.2014.05.001. Epub 2014 Jul 17.

31
ISI Web of Knowledge

Berenguer J., Polo R., Lopez Aldeguer J., Lozano F., Aguirrebengoa K., Ramon Arribas J., Ramon Blanco J., Boix V., Luis Casado J.,
Clotet B., Crespo M., Domingo P., Estrada V., Garcia F., Gatell J.M., Gonzalez-Garcia J., Gutierrez F., Antonio Iribarren J., Knobel H.,
Llibre J.M., Locutura J., Carlos Lopez J., Miro J.M., Moreno S., Podzamczer D., Portilla J., Pulido F., Ribera E., Riera M., Rubio R., Santos
J., Sanz-Moreno J., Sanz J., Jesus Tellez M., Tuset M.,
Rivero A., GESIDA, National AIDS Plan. Executive summary of the GESIDA/National AIDS Plan Consensus Document on
antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enfermedades Infecciosas
y Microbiologia Clínica, 33 (8), 544-556. doi: 10.1016/j.eimc.2015.03.017.
Barbato E., Carrie D., Dardas P., Fajadet J., Gaul G., Haude M., Khashaba A., Koch K., Meyer-Gessner M., Palazuelos J., Reczuch K.,
Ribichini F.L., Sharma S., Sipotz J., Sjogren I., Suetsch G., Szabo G., Valdes-Chavarri M., Vaquerizo B., Wijns W., Windecker S., de
Belder A., Valgimigli M., Byrne R.A., Colombo A., di Mario C., Latib A., Hamm C. EAPCI Sci Documents Comm. European expert
consensus on rotational atherectomy. Eurointervention, 11 (1), 30-36.
Gutierrez-Rivas E., Illa I., Pascual-Pascual S.I., Perez-Lopez J., Vilchez-Padilla, J.J., Bautista-Lorite J., Barrot E., López de Munain A.
Guidelines for monitoring late-onset Pompe disease. Revista de Neurologia, 60 (7), 321-328.
Aguilar G., Albiol S., Alcaide J., Alonso M., Alonso V., Andreu M., Aparicio J., Arias de la Vega F., Arrivi A., Ayuso J.R., Bohn U., Bouzas
R., Cano J.M., Castanon C., Castells A., Cerda P., Cerezo L., Conill C., Cuatrecasas M., del Pozo M.N., Ignacio Delgado J., Enriquez-
Navascues J.M., Escudero P., Espin E., Estevan R.I., Falco E., Farre J., Feliu J., Fernandez-Martos C., Ferrer A.I., Gallego R., Galvez
E., Garcia de Albeniz X., Garcia Olmo D., Garcia-Carbonero R., Gomez Dorronsoro M., Gomez Martin C., Gonzalez Moreno S.,
Hernandez A., Iraola A., Jimenez E., Jimenez M.C., Jurado I., Leno R., Leon A., Martin E., Martin M., Maurel J., Mendez J.C., Mendez
R., Palma P., Pardo F., Pereira F., Perez-Altozano J., Perez E., Rodriguez J., Ruiz-Casado A.I., Sabater L., Sarria L., Segura A., Sevilla I.,
Tobena M., Torres E., Viudez A., Zanui M., Zorrilla M. Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer
by Grupo Espanol Multidisciplinar en Cancer Digestivo (GEMCAD). Colorectal Cancer, 4 (2), 97-112. doi: 10.2217/CRC.15.9.
Other
Alba E., Antón A., Barnadas A., Barrajón E., Blancas I., Carrasco E., Casas A., González A., Lao J., Lluch A., López-Tarruella S., Martín M.,
Muñoz M., Sánchez Escribano R., Solà I. Fundación GEICAM (Grupo Español de Investigación en Cáncer de Mama) en colaboración
con el Centro Cochrane Iberoamericano. Guía GEICAM de práctica clínica para el diagnóstico y tratamiento del cáncer de mama
metastásico. 28/02/2015.

32
Research
Support Services
The main objective of the research support services, which are Scientific and Technical Service Platforms
divided into two blocks, is the sharing and pooling of resources
as an effective way to optimize funds and boost research. The main aim of these support services is to manage, allocate
and optimize the top-level research resources available to IIB
Sant Pau. They provide researchers with support and scientific
Research Support Services and technical assessment and advise on the most appropriate
These provide facilities and equipment that are exclusively methods to prepare samples and to plan optimal work flows
available to any specific research group but are shared among for each objective.
groups at all institutions within IIB Sant Pau.
IIB Sant Pau has 5 platforms:
IIB Sant Pau has 14 services: JJ Genomics and Transcriptomics Platform
JJ Clinical Trial Documentation Management JJ Functional and Cellular Analysis Platform
JJ Research Institute Management JJ Microscopy and Immunohistochemistry Platform
JJ Research Institute Projects Unit JJ Innovation Platform i2Health Sant Pau
JJ Tumour Bank JJ Biobank
JJ Quality and Information Systems Unit
JJ Radioactivity Unit The platforms also have access to equipment available for
general use to complement their functioning.
JJ Centre for Drug Research (CIM Sant Pau)
JJ Central Clinical Research and Clinical Trials Unit (UCICEC
Sant Pau)
JJ Animal Housing
JJ Transfer and Innovation Unit
JJ Author Editing
JJ Communications Coordination Team
JJ Clinical Research Ethics Committee
JJ Clinical Research Ethics Committee Secretariat

33
Clinical Trial Documentation Management

Functions:
>> Manage and supervise all documentation >> Manage restricted access by clinical trial moni-
associated with active clinical trials in the expe- tors to the clinical workstation.
rimental phase and destruction of documenta-
>> Supervise data processing and management.
tion for terminated clinical trials located in the
external archive. >> Coordinate researchers and monitors; draw up
Manager: >> Store the supplies until the end of the studies,
agendas for meetings and study monitoring.
Rosa M. Antonijoan when they are destroyed or recycled. >> Provide logistical support to the cold area and
rantonijoana@santpau.cat
>> Oversee and manage documentation of com-
the clinical materials store associated with
Coordinator: clinical trials in the experimental phase.
pleted trials for the Centre for Drug Research
M. Teresa Mas (CIM) >> Ship biological samples to central laboratory
mmas@santpau.cat
>> Maintain and update the clinical workstation
services.
Staff: database and manage clinical studies.
Susana Daniel
Pilar Matamoros Facilities:
M. Àngels Piera Several areas have been designated to imple- >> Clinical trial monitoring meeting rooms
Montserrat Ruiz ment these functions: >> Documentation filing area
>> Head office and administration area >> Cold room.
>> Data processing and management area >> Archive.

34
Research
Support Services
Research Institute Management
Functions:
>> Management of HSCSP Research Institute management, human resources, procure-
and IIB Sant Pau finances: manage accounts ment, invoicing, control and monitoring of
and fiscal matters; design, administer and projects, general administration, manage-
control budget-related issues; manage and ment of services (courses, travel and conti-
monitor financial and material resources. nuing professional development).
Coordinator:
Hilda Herrero >> Management of public body funding >> Design, elaboration, development and
hherrero@santpau.cat requirements: fulfil obligations imposed by maintenance of information systems for
government and official regional and state management area units, both for HSCSP
Staff:
entities; ensure compliance with current Research Institute–IIB Sant Pau and research
Management Control Unit
fiscal, financial, labour and legal regulations groups.
Soraya González, Sandra Parera,
and with HSCSP Research Institute–IIB Sant
Laura San Martín
Pau management policies.
Administrative-Financial Unit
>> Administration and management of acti-
Ana Espallargas, Cristina Requena,
vities, providing management support for
Núria García, Declan de la Fuente
research groups in different areas; project
Human Resources Unit
Rafael Fernández
General Secretariat
Rosa M. García
Amanda García
Marta Lorente
Magda Sanz
Research Institute Projects Unit

Functions:
>> Search of public and private funding, broad- >> Internal and external audits from different
cast, assessment and review for the success of financial entities.
the application submission, send applications,
register and monitoring until its resolution. >> Researchers: meetings for starting and mana-
ging projects.
>> Registration of granted projects, economic
Coordinator: monitoring of both national and international >> Interaction with different transversal areas to
Fabiola Fernández projects and agreements, costs validation implement the regulations of the calls.
(concept/balance), preparing annual and final
Staff:
reports, manage incidences, interlocutor with
Eva José
official entities.
Eva Rodríguez
Amanda García >> Activity reports: scientific report, Board, Direc-
Marta L orente tion and others.

35
Quality and Information Systems Unit

Functions:
>> General: • Lead the quality assurance programme at
• Support management with strategic CIM Sant Pau and in clinical trials where
projects (accreditation, CERCA evaluation, the HSCSP Research Institute acts as
biobank legalization, evaluation of resear- sponsor.
ch groups, etc).
• Oversee auditing for protocols, databases,
Coordinator: • Manage IIB Sant Pau research groups: experimental phases, facilities, processes
Jordi Virgili creation, dissolution and changes in and final reports for clinical trials.
jvirgili@santpau.cat composition.
• Oversee supplier audits.
Staff:
• Manage new laboratory works performed
Cati Pérez • Monitor non-conformity in internal and
under the contingency plan.
Montserrat Campmany external audits.
• Implement the functional plan for the
• Draw up own SOPs and provide support
new research building.
for SOPs preparation by other units.
• Support management of the IIB Sant Pau
• Establish mechanisms to assess quality
Internal Scientific Committee, External
and good scientific practices in IIB Sant
Scientific Committee, Executive Commit-
Pau.
tee and Delegate Committee.
>> Information systems:
• Implement policies for the dissemination
of research among the general public and • Design mechanisms and implement
especially among secondary pupils and tools for the collection and organization
health science university students. of data and information to feed decision
making.
• Manage the HSCSP Research Institute • Manage and transform information and
Biosafety Committee. data to contribute to the fulfillment of
objectives and strategies.
• Participate in the Animal Experimentation
Ethics Committee. • Respond to external requests for data
and information (statistical surveys,
• Participate in the UCICEC Sant Pau Techni- SIRECS, etc).
cal Committee. • Implement policies to improve informa-
tion systems.
• Represent the HSCSP Research Institute
• Develop new indicators of use for the
before external organizations.
institution.
>> Quality: • Update research group staff details on
• Implement policies to improve quality the intranet.
under GLP, GCP, GMP and ISO 9001 stan-
dards.

36
Research
Support Services
Radioactivity Unit
Functions:
>> The Radioactivity Unit provides groups with >> Services include support for:
specific research laboratories in which to
• In vitro labelling of proteins, lipopro-
work with radioactive isotopes in liquid form.
teins and liposomes.
These areas are fully equipped and adapted
for the handling of radioactive material and • Cellular proliferation and toxicity.
Coordinator: apply optimum measures for the safety and • Nucleic acid labelling.
Montserrat Ribas radioprotection of staff and the environment. • Immunoassay techniques.
mribas@santpau.cat >> This area has been authorized by the nuclear • Determination of enzymatic activities
Supervisor in charge: safety authority and its staff supervise using radiolabelled substrates.
Josep Julve compliance with the corresponding laws, • Analysis and separation of labelled molecules.
jjulve@santpau.cat guidelines and regulations.
• Cellular cholesterol efflux.
• Metabolism in vivo.
Facilities:
The Radioactivity Unit has the following >> Shielding accessories for radiation safety
facilities: (table top shields, shielded containers,
protective equipment, etc)
>> 1 room for radioactive material storage.
>> Portable radiation and environmental con-
>> 7 equipped laboratories, one of them refri-
tamination detectors.
gerated.
>> 1 ventilated rack for in vivo studies.
>> 1 room for gamma- and beta- counters.
>> 2 chemical safety cabinets for gas extrac-
>> 1 room for radioactive waste storage.
tion.
>> 1 room for controlled disposal of radioacti- >> 1 vertical laminar air flow cabinet for cell
ve waste. cultures.
>> Radioactive liquid waste containers for >> 1 CO2 incubator for cell cultures.
controlled radioactive waste disposal.
Tumour Bank
Functions:
>> Create and maintain a collection of healthy and assuring anatomical and pathological correla-
diseased tissue samples in optimal conditions tion with definitive diagnoses for tissues.
for use in research projects that may include
>> Supply material to research groups on a
morphology, phenotype and molecular analy-
non-profit basis (investigators may apply for
ses and which may also be used in diagnosis.
samples as long as their project complies
Manager: >> Guarantee the quality of stored material by with current regulations and is scientifically,
Jaime Prat means of morphology analyses of samples, technically and ethically viable).
jprat@santpau.cat
Equipment:
Coordinators: Staff:
Lluís Catasús María Jesús Nagel >> 4 fast-freeze apparatus (isopentane bath, stored at -50°C).
lcatasus@santpau.cat Jorge Pena >> Storage and cryopreservation systems: 2 freezers -80°C and 1 deposit for liquid nitrogen.
Íñigo Espinosa >> 1 cryostat.
iespinosa@santpau.cat >> 1 manual tissue arrayer.

37
Centre for Drug Research (CIM Sant Pau)
Functions:
Perform clinical drug trials and/or clinical >> Clinical trials that are not of therapeutic
research in compliance with methodological, interest for participants (phase I, special
ethical and legal requirements in the context populations, psychopathological research,
of international GCP guidelines concerning: biomarkers, proof of concept).
Coordinator: >> Clinical trials in neuropsychopharmacology.

Rosa M. Antonijoan >> Clinical trials in initial developmental phases.
Facilities:
Staff:
Three separate work areas have been Logistical support:
M. Rosa Ballester
designated for the trials: >> Rest area for clinical trial participants with
Judit Claramunt
Susana Clos bathrooms and kitchen.
Healthcare:
Sonia Coma >> Areas for the preparation, centrifugation
M. Ángeles Funes >> Admission zone.
and separation of biological samples.
Consuelo García >> 24 beds distributed in 4 units: trials in heal-
Ignasi Gich >> Cold room.
thy volunteers and patients.
Sandra Giménez >> Archives.
Ana Gomis >> 2 individual rooms for CNS studies.
Mireia González Management, administration and data
>> Ambulatory zone.
David Martínez processing:
Joan Martínez >> 4 consulting rooms for complementary >> Offices.
Maribel Martínez testing, mainly related to CNS.
>> Area for monitors.
Pura Martínez >> 3 cubicles to evaluate psychomotor perfor-
Esteve Mercader mance. >> IT equipment for clinical trial activities of a
Sara Mora non-experimental nature.
Montserrat Puntes
Communications Coordination Team

Functions:
>> Coordinate IIB Sant Pau communications. >> Establish standards concerning graphics and
linguistic style to ensure visual uniformity in
>> Prepare IIB Sant Pau annual reports and
all IIB Sant Pau communications.
other communication materials.
>> Provide an effective news distribution servi-
ce and generate positive media coverage.
>> Respond to media enquiries.
>> Update website content.

38
Research
Support Services
Central Clinical Research and Clinical Trials Unit
(UCICEC Sant Pau)
Functions:
It provides comprehensive support to researchers in the development of independent research
projects (not sponsored by the pharmaceutical industry) on the methodological, regulatory,
administrative, economic and practical aspects, subject to compliance with the ethical, good
clinical practice and legislation.
UCICEC Sant Pau is part of the Spanish Clinical Research Network (SCReN), a functional
Coordinator: organization network to support the conduction of multi-center clinical trials.
Rosa M. Antonijoan
rantonijoana@santpau.cat .
Knowledge management: Documentation, archiving, monitoring and
follow-up unit:
Staff: >> One-stop information for independent
Claudia E. Delgado research group projects. >> Support in document creation: EudraCT
Nadia Llavero >> Comprehensive assessment and project form and annexes / application forms /
Pablo Bros coordination. evaluation forms follow form.
Enrique Peña >> Support in the processing of initial appli-
>> Point of communication between resear-
chers and technical units. cations, clarifications and amendments:
AEMPS, CEIC, other health authorities
>> Pharmacovigilance activities for trials inclu-
regarding clinical trials, and other post-au-
ding drugs or medical devices.
thorization studies.
>> Knowledge management:
>> Comprehensive monitoring of clinical trials
• Study of dimensionality and feasibility of and observational studies.
projects. >> Management of initial, follow-up and final
• Identification of each project needs. reports.
• Advice on the preparation of documen- >> Development and file custody promoter
tation: protocol, annexes, monitoring (Master File), file preparation investigator.
report, final report. >> Other communications to CEIC, auto-
• Advice on the submission of documen- nomous communities and competent
tation to Spanish Agency for Medicines authorities.
and Medical Devices (AEMPS), Clinical
Research Ethics Committee (CEIC), Auto- Unit of management and financial
nomous Communities (CCAA) and other management:
relevant authorities. >> Management of clinical trials contracts with
• Advice on project registration in public participating centers.
databases. >> Management of collaboration agreements
• Identification of spinoff projects. with laboratories / companies for funding.
• Advice on the presentation of research >> Management of clinical trial-related contracts
results. (CRO’s, E-CRDs, statistics, etc.).
Methodological and statistical support unit: >> Management of clinical trial-related client
and supplier invoices.
>> Advice on study design.
>> Management of clinical trial insurance
>> Data entry. policies.
>> Data processing. >> Preparation of financial reports for the sub-
>> Development of statistical reports. mission of studies to ethics committees.
>> Electronic CRFs validation and management. >> Management of payment of fees to the com-
>> Documentation and reports. petent authorities.

39
Animal Housing
Functions:
>> Produce different small rodent strains >> Monitor mating, mating plugs, pregnant
in-house for research and teaching females and weaning.
purposes.
>> Provide healthcare.
>> Manage the purchase and transportation
>> Advise the animal welfare expert.
of animals from domestic and internatio-
Coordinator: nal breeding and supply centres. >> Perform periodic health checks with
M. Antònia Rubio
>> Receive and house incoming animals
sentinel screening in all rooms.
arubioc@santpau.cat
and deliver them to users once quaranti- >> Maintain monitoring protocols.
Staff: ne and health requirements are met.
>> Ensure the hygiene and safety of facili-
Animal welfare advisor: >> House and maintain experimental ani- ties and equipment.
M. Antonia Rubio mals while ensuring their welfare.
>> Manage waste disposal.
Veterinary surgeon: >> Regularly check rodent health status.
>> Attend training in relation to all proto-
Eder Fredy Mateus >> Perform twice-yearly health checks. cols developed in the animal house.
Animal care workers: >> Clean and sterilize of materials and main- >> Advise on the drafting of research pro-
Margarita Domingo tain the pathogen-free area. jects involving the use of animals.
Luis Garcia >> Feed animals according to experimental >> Attend training in relation to all proto-
protocols. cols developed in the animal house.
>> Provide support for animal surgery, >> Advise on the drafting of research pro-
anaesthesia and euthanasia. jects involving the use of animals.
>> Supply laboratory materials and collect
samples.
Facilities:
Conventional Animal Facility: Pathogen-free area:
>> Mice rooms (2), total capacity 2400. >> Pre-changing room.
>> Rat room, capacity 200. >> Changing room.
>> Quarantine room. >> Air shower.
>> Washroom. >> Work room.
>> Clean-storage room. >> Mice room and changing area.
>> Standard storeroom. >> S.A.S.
>> Surgery room. >> Autoclave and washing area.
>> CO2 euthanasia equipment. >> storage room.
>> Treatment room.
>> Office.
>> Shower.
>> WC.

40
Research
Support Services
Transfer and Innovation Unit
Functions:
>> Facilitate collaboration between institute’s >> Intellectual Property protection.

research groups and industry.
>> Technology Transfer.
>> Support to public and private funding of
>> Support the creation of spin-offs and
technology development projects.
start-ups.
innovacio@iibsantpau.cat >> Support the submission of European pro-
>> Legal support to agreements with third
jects.
Coordinator: parties.
Alfons Hervàs >> Analysis of the business viability of techno-
ahervas@santpau.cat logical projects.
Staff:
Marina Passarell
Miquel Arrieta
Clinical Research Ethics Committee
The Ethics Committee for Clinical protection, protection by reviewing the

Research (CEIC) of the HSCSP Healthcare protocol, the suitability of the researchers,
Management Foundation is an facilities, equipment and methods to be
independent body that, according to the used in obtaining and documenting the
laws that accredit it, has the mission to informed consent of the subjects.
ensure the protection of rights, safety
and welfare of the subjects involved in a
President: trial and provide public assurance of that
Antonio López Pousa
alopezp@santpau.cat Its specific functions are:
Vice-president: >> Evaluate the methodological, ethical and >> Evaluate the relevant amendments in projects
Gerard Urrutia
legal aspects of: approved by the CEIC.
GUrrutia@santpau.cat
• Clinical trials with drugs and health >> Monitor of clinical drug trials and clinical
Secretary:
products. research with medical devices.
Milagros Alonso
• Observational studies.
MAlonsoMa@santpau.cat
• Pharmacogenetic and pharmacogeno-
Members:
mic studies.
Ester Amado
• Studies evaluating surgical or psycholo-
Josep Corbella
Francesc Jané gical treatments.
Xavier León • Studies involving invasive procedures
Jordi Mancebo or the use of health data or biological
Margarita Meseguer samples.
Estela Moreno
M. Virtudes Pacheco
Javier Pagonabarraga
Maria Teresa Ricart Basagaña

41
Clinical Research Ethics Committee Secretariat
The Clinical Research Ethics Committee is legal aspects as well as any other relevant
an independent agency whose mission is information regarding all research projects
to protect the rights, safety and wellbeing listed in the minutes of the Committee’s
of persons participating in HSCSP research meetings. It also advises researchers
projects which may entail physical or in the HSCSP and the HSCSP Research
psychological harm. The Secretariat of Institute regarding the preparation and
the Clinical Research Ethics Committee presentation of clinical research projects.
Coordinator: evaluates the methodological, ethical and
Milagros Alonso
malonsoma@santpau.cat Functions:
Administrative Staff: >> Receive, log and validate documentation for >> Prepare and sign the reports of the Committee
Marisol Mogollón clinical research projects submitted to the and communicate its decisions to the corres-
Albert Querol Committee for evaluation. ponding sponsors and researchers.
Romy Rodríguez
>> Arrange and call Committee meetings, inform >> Prepare the minutes of meetings and distri-
members of the agenda and provide them bute them to Committee members within the
with copies of protocol summaries and patient established period.
informed consent and information sheets.
>> Manage all documentation associated with
>> Prepare and submit reports to the Committee the operations and activities of the Committee
containing a methodological, ethical and and with the research projects evaluated by
legal description and analysis (and any other the Committee.
relevant information) of the research projects
>> Administer contracts for all clinical trials to be
listed in agendas.
performed at the HSCSP.
>> Act as a reference point in communications
>> Certify the actions of the Committee.
with and between researchers, sponsors,
medical administrators and managers and >> Prepare the annual report of the Committee.
healthcare authorities regarding all aspects of
>> Ensure compliance with the SOPs of the
the activities of the Committee and of the re-
Committee.
search projects evaluated by the Committee.
Author Editing
Functions:
>> Review and edit research papers, abstracts, >> Assist in the preparation and delivery of
posters, presentations and other scientific presentations, lectures, speeches, etc in En-
documents written in English. glish for meetings, conferences and similar
events.
Coordinator:
Carolyn Newey
cnewey@santpau.cat

42
Scientific and Technical

Service Platforms
Genomics and Transcriptomics Platform
> GENOMICS LABORATORY

Functions:
>> Next-generation sequencing: full transcripto- >> Analysis of fragments: microsatellite
me genotyping, RNA-Seq, Ampli-Seq, ChIP- instability, loss of heterozygosity studies in
Seq, amplicon sequencing and sequencing pathological conditions, mutation detection
sequenciacio_ir@santpau.cat and identification of microorganisms. and genotyping, quantification of gene copy
transcriptomica@santpau.cat numbers, methylation studies and studies
>> Sanger sequencing: mutational analysis,
of polymorphisms associated with disease
microorganism identification and validation
Coordinator: states.
of cell lines.
Elena Serrano
eserrano@santpau.cat
Equipment:
Technical Staff: >> Ion Torrent Personal Genome Machine.
Genomics Laboratory:
Eva Companys >> Ion OneTouch (TM) System.
ecompanysa@santpau.cat >> 3130xl Genetic Analyzer capillary electrophoresis sequencer.
Transcriptomics Laboratory:
Elena Serrano
eserrano@santpau.cat > TRANSCRIPTOMICS LABORATORY
Functions:
>> Hybridization and analysis of Affymetrix >> Real time quantitative PCR (gene expression,
microarrays: allelic discrimination).
• RNA and micro-RNA expression profiles >> Nucleic acid quality assessment.
in normal conditions and in diseases and
>> Quantification of nucleic acids (Bioanalyzer,
treatment.
Nanodrop).
• Loss of heterozygosity, copy number
analysis and genome-wide mutation
detection.
• Genome-wide linkage and association
studies.
Equipment:
>> Affymetrix array platform (upgrade 7G). >> Bioanalyzer 2100
>> Real time quantitative PCR ABI 7900HT (384- >> Nanodrop 2000.
well plates and TLDA).

43
Functional and Cellular Analysis Platform
> FLOW CYTOMETRY LABORATORY

Functions:
>> Conventional cytometry in homogenous • Phenotype changes and relative and
(cell line) or heterogeneous (biological fluid) absolute presence.
samples: • Production of mediators.
• Detection of the presence of proteins • Detection of minority populations.
citometria@santpau.cat and determination of cell populations
>> Cell sorter:
Coordinator: (cell markers).
• Separation of cell populations in sterile
Elena Serrano • Studies of signalling cascades (cell cycle,
conditions.
eserrano@santpau.cat cell proliferation, apoptosis, intracellular
calcium determination).
Technical Staff:
Flow Cytometry Laboratory: • Quantification of transfection efficiency.
Marta Soler
msolerC@santpau.cat
Equipment:
Cell Culture Laboratory:
Rosa Antón >> FACSCalibur (BD) conventional flow cytometry.
RAnton@santpau.cat
>> MACSQuant (Milteny Biotech) conventional flow cytometry.
>> FACSAria (BD) flow cytometry cell sorter.
> CELL CULTURE LABORATORY

Functions:
>> To make adequate facilities and equipment available to researchers working with cell cultures in a
BSL2 laboratory.
Equipment:
>> 3 CO2 incubators.
>> 2 hypoxia incubators (2-21% O2).
>> 2 IIA biosafety cabinets (BSL2).
>> 2 hypoxia cabinets (BSL1).
>> Culture baths.
>> Olympus inverted microscope with high-resolution colour camera.
>> Refrigerated centrifuge.
>> Fridge 4ºC and freezer -20ºC.
>> Thermo-desinfector and autoclave.

44
Scientific and Technical

Service Platforms
Microscopy and Immunohistochemistry Platform
> IMMUNOHISTOCHEMISTRY LABORATORY
Functions:
>> Tissue processing. trichromic, PAS, Oil Red, etc).
>> Paraffin and OCT-block preparation. >> Preparation of tissue arrays.
>> Block cutting with microtome/cryostat. >> Image acquisition and analysis using high-re-
ihq@santpau.cat
>> Automatic immunostaining (simple and dual). solution colour microscopy and specialist
microscopia@santpau.cat
software.
>> Staining (Giemsa, haematoxylin-eosin,
Coordinator:
Elena Serrano Equipment:
eserrano@santpau.cat >> Tissue processor (Sakura). >> Immune autostainer AS48 (Dako).
>> Paraffin bath (Sakura). >> Autostainer (Sakura).
Technical Staff:
Immunohistochemistry Laboratory: >> Microtome (Microm). >> Semiautomatic tissue arrayer.
Montserrat Gómez >> Cryostat (Leica).
mgomezy@santpau.cat
> MICROSCOPY LABORATORY
Microscopy Laboratory:
Eva Companys Functions:
eCompanysa@santpau.cat >> Confocal microscopy in live and fixed cells: • Inter- and intra-interactions (FRET and
FLIM).
• Immunofluorescence of 2 to 5 fluoro-
chromes. • Molecular diffusion times (FCS).
• Reconstruction of 3D and 4D images. >> Conventional fluorescence microscopy

(immunofluorescence with 1 or 2 fluorochro-
• Colocalization studies.
mes, FISH) in live and fixed cells.
Equipment:
>> Confocal multispectral Leica SP5 AOBS with high-resolution scanning system and high-speed
tandem scanning, FLIM/FCS modules and time-lapse incubation system.
>> Zeiss digital time-lapse microscope.
Innovation Platform i2Health Sant Pau
Functions:
>> Promote the development of the informa- >> Provide a dedicated space within the hospi-
tion and communication technologies in the tal to create a living lab by bringing together
health sector. medical staff, engineers, technologists,
industry and health administration.
>> Support researchers and healthcare staff
undertaking e-health projects.
info@i2healthsantpau.eu
Coordinators:
Alfons Hervàs
ahervas@santpau.cat i2 HEALTH
Sant Pau
Josep M. Colomé (i2Cat Foundation)
josep.colome@i2cat.net

45
Biobank
Functions:
>> Create and maintain a collection of healthy >> Obtain, process and store human biological
and diseased biological human samples samples in accordance with international
in optimal conditions for use in research standards, maintaining sample traceabi-
projects. lity and security in accordance with legal
requirements.
>> Facilitate collaboration projects by putting
biobanc@santpau.cat >> Provide training in legal and ethical regula-
investigators in touch and making biologi-
Coordinator: cal human sample cession possible. tions governing biological human sample
Elena Serrano management.
>> Supply (non-profit) human biological sam-
ples to research groups, in accordance with
legal regulations.
Technical Staff:
Iris Rodriguez Grants:
irodriguezR@santpau.cat
>> HSCSP Research Institute. Biobank Network 2009. Amount: €138,000.
Equipment for General Use

> IMAGE ANALYSIS LABORATORY:
Equipment:
>> Revolution 4200 microarray scanner (Vidar).
>> Image Station 4000MM Pro (Kodak) gel documentation: luminescence, fluorescence, absorption.
Coordinator:
> OTHER EQUIPMENT
Elena Serrano
Equipment:
>> Precision weighing balances (Sartorius).
Technical Staff: >> Bioanalyzer 2100 (Agilent).
Image Analysis Laboratory: >> Nanodrop 2000 (Thermo).
Rosa Anton
>> Infinite 200 (Tecan) microplate reader: spectrophotometer, fluorometer, luminometer.
ranton@santpau.cat
Other Equipment:
Grants:
Elena Serrano
eserrano@santpau.cat >> HSCSP Research Institute. Innovation Network 2009. Amount: €123,414.
>> Kulisevsky, J. Expert system integrating teleassistance and medicine to prevent dependence
and promote autonomy of the elderly in the home environment. E-HEALTH Platform for Healthy
Ageing. Plan Avanza. Amount: €60,848.55.

Areas of Research
Area 1
48 Cardiovascular Diseases
Area 2
78 Genetic, Metabolic and

Inflammatory Diseases
Area 3
116 Haematological and

Oncological Diseases
Area 4
138 Neurological,
Mental Disorders and Ageing
Area 5
176 Uronephrology
and Experimental Surgery

Area T1
186 Epidemiology, Public Health

and Healthcare Services
Area T2
Molecular, Genomic, Cellular
208 and Kinetic-Dynamic Bases for
Diseases and their Treatment
Associated Groups
218

AREA 1
Cardiovascular Dise
50 Clinical and Translational Cardiology
56 Thrombosis and Haemostasis
58 Cardiovascular Biochemistry
62 Angiology, Vascular Biology and Inflammation
Molecular Pathology and Therapeutic

64 of Ischaemic and Atherothrombotic Diseases
68 Inflammation and Vascular Remodelling
70 Biomarkers for Cardiovascular Disease
72 Atherosclerosis and Vascular Biology
74 Regulation of Cardiac Rhythm and Contraction
76 Lipids and Cardiovascular Pathology

eases

50 AREA 1 · Cardiovascular Diseases
Clinical and Translational Cardiology
Coordinator
Cinca Cuscullola, Juan FGS
jcinca@santpau.cat
Members
Álvarez García, Jesús IR
Amorós Figueras, Gerard IR
Anglí Ferràndiz, Laia IR
Carreras Costa, Francesc FGS
Fernández Martínez, Ana IR
Ferrero Gregori, Andreu IR
García-Moll Marimon,
Xavier FGS
Guerra Ramos, José M. FGS
Jorge Vizuete, Esther IR
ff Electrophysiology and arrhythmias, clinical and experimental.
of Research
Martí Claramunt, Vicenç FGS

Main Lines
ff Heart failure.
Mateo Aguilar, Ester IR ff Ischemic heart disease.
Pons Lladó, Guillem FGS
Roig Minguell, Eulàlia FGS ff Valvular heart disease.
Serra Peñaranda, Antoni FGS ff Cardiac imaging.
Sionis, Alessandro FGS
ff Percutaneous valve repair.
Solé González, Eduard IR
Subirana Doménech,
M. Teresa FGS
Viñolas Prat, Xavier FGS Electrophysiology Ischaemic heart disease
Vives Borrás, Miquel IR
ff Describe the mechanisms and clinical sig- ff Settle a Program for patients with refrac-
nificance of the electrocardiographic al- tory angina.
terations in patients with acute myocardial
infarction, using translational research in
ff Treat complex atherosclerotic coronary ar-
pig heart models. tery lesions using international techniques.
ff Characterize the ECG patterns and progno-

Valvular heart disease
sis in patients with left circumflex coronary
occlusion. ff Implement new percutaneous techniques
ff Describe the behaviour of myocardial for the treatment of mitral valve regenera-
electrical impedance in normal and acute tion and degenerative aortic stenosis.
ischemic models using new bioimpedance
Challenges
ff Implement devices for the treatment of

methods developed in our laboratory. prosthetic valve leak.
Heart failure Cardiac imaging

ff Develop new risk scores for ambulatory ff Implement new imaging software analysis
heart failure patients predicting death and to detect structural abnormalities of the
re-hospitalizations. myocardium (fibrosis, necrosis).
ff Research on new biomarkers in patients ff Implement new software analysis for fu-
with heart failure included in the Spanish sion imaging in patients submitted to cor-
registry Redinscor II (RIC) (1500 patients). onary interventions.
Our group is the national coordinator.
ff Implement new percutaneous techniques
ff Develop new markers for early detection for the treatment of mitral regurgitation
of cardiac graft rejection in transplanted in patients with heart failure or myocardial
patients. infarction.
ff Develop palliative care programs for pa-
tients with advanced heart failure.

AREA 1 · Cardiovascular Diseases 51
Collaborations with other IIB Sant Pau Groups ff Mariano Valdés Chavarri. Hospital Universitario Virgen de la Ar-
rixaca (Murcia)
ff Vicenta Llorente-Cortés, ICCC - CSIC. ff José Ramón González. Hospital Clínico Universitario (Santiago
ff Leif Hove Madsen, ICCC - CSIC. de Compostela)
ff Jordi Ordóñez Llanos, HSCSP - Biochemistry Laboratory. ff Luis Alonso-Pulpón Rivera. Hospital Puerta del Hierro (Madrid)
ff Antoni Capdevila, HSCSP - Radiodiagnostics. ff Covadonga García González. Hospital Guadarrama (Madrid)
ff María Poca Sans, HSCSP - Digestive Disorders. ff José Miguel Rivera. Hospital La Fe (Valencia)
ff Rafael Serra, HSCSP - Anaesthesiology. ff Alfonso Castro Beiras. Complejo Hospitalario Universitario A
ff Enric Álvarez, HSCSP - Psychiatry. Coruña
ff Francisco Fernández Avilés. Hospital Gregorio Marañón (Madrid)
External Collaborations ff Ignacio Flores Hernández. Centro Nacional de Investigaciones
Cardiovasculares - CNIC (Madrid)
Juan Cinca Cuscullola (HSCSP), Programme 6: Clinical and
Translational Cardiology, RD12/0042-RIC (Cardiovascular Antoni Serra Peñaranda TEAM:
Collaborations
Research Network): ff Eulogio García. Hospital Clínico San Carlos (Madrid)

ff Alfredo Bardají Ruiz. Hospital Universitari Joan XXIII (Tarragona) ff Carlos Macaya Miguel. Hospital Clínico San Carlos (Madrid)
ff Fernando Worner Diz. Hospital Universitari Arnau de Vilanova ff Andrés Iñíguez Romo. Complejo Hospitalario de Vigo
(Lleida)
Xavier Viñolas Prat, RETAC Group - European Network for the
ff Andrés Grau Sepúlveda. Hospital Son Dureta (Palma de Mallorca)
Treatment of Arrhytmias in Cardiology:
ff Xavier Rosell Ferrer. Universitat Politècnica Catalunya – UPC (Bar-
celona)
ff Philippe Lagrange. Clinique Saint Pierre (Perpignan)
ff Rafael Vázquez García. Hospital Universitario Virgen de Valme
ff Benoît Guy-Moyat. Hospital Universitaire de Limoges (France)
(Sevilla) / Hospital Puerta del Mar (Cádiz) ff Franck Halimi. C.M.C. Parly II (Le Chesnay)
ff Joaquín Lucena Romero. Instituto de Medicina Legal ff Luc de Roy. Clinique Universitaire de Saint Godinne (Yvoir-Bel-
(Sevilla) gium)
ff José M. Cubero Gómez. Hospital Virgen del Rocío (Sevilla) ff Serge Boveda. Clinique Pasteur (Toulouse)
ff Antonio Fernández Romero. CHARE Utrera SAS (Sevilla) ff Julio Martí. Hospital del Mar (Barcelona)
ff Josep Brugada Terradellas. Hospital Clínic (Barcelona) ff Pascal Defaye. Hospital Universitaire de Grenoble
ff Julián Pérez-Villacastín. Hospital Clínico San Carlos (Madrid) ff Antonio Curnis. Spedali Civili (Brescia-Italy)
ff Juan Francisco Delgado Jiménez. Hospital 12 de Octubre (Ma- ff Marc Zimmermann. Hôpital de la Tour (Geneve-Switzerland)
drid) ff Thomas Arentz. Herzzentrum Brad Krozingen (Germany)
ff Jose Luis Zamorano. Hospital Ramón y Cajal (Madrid)
ff Juan Cinca Cuscullola. Red Cardiovascular. RD12/0042/0002. Insti- ff Juan Cinca Cuscullola. Desarrollo preclínico de una nueva
tuto de Salud Carlos III. Duration: 2013-2016. €594,532.28. técnica para guiar la ablación eléctrica de las arritmias ventricu-
lares en pacientes con infarto crónico mediante bioimpedancia.
ff Eulàlia Roig Minguell. Detección de rechazo agudo postrasplante PI13/00765. Instituto de Salud Carlos III. Duration: 2014-2016.
Active Grants
cardiaco mediante la determinación de troponina T cardiaca €140,250.

de alta sensibilidad (cTnT-HS). Estudio piloto multicéntrico. SEC
2010-1. Sociedad Española de Cardiología. Duration: 2010-2016. ff Juan Cinca Cuscullola. Grup de Recerca Clínica i Translacional en
€4,999.99. Cardiologia - RCTCAR. 2014 SGR 620. Agència de Gestió d’Ajuts
Universitaris i de Recerca. Duration: 2014-2016.
ff Ana Belén Méndez Fernández. Ultrafiltración periférica frente a
tratamiento convencional para el tratamiento de las descom- Note: Total amount granted to PI. It does not include indirect costs.
pensaciones hipervolémicas en pacientes con insuficiencia cardi-
aca crónica y resistencia a diuréticos. SEC 2011. Sociedad Española
de Cardiología. Duration: 2011-2015. €5,925.98.
ff Francisco Javier Noriega Sanz. Caracterización clínica y electro- ff Jesús Álvarez García. Consecuencias clínicas, bioquímicas y elec-
fisiológica de las alteraciones recíprocas del electrocardiograma trofisiológicas de la oclusión aguda de las arterias coronarias au-
Theses
en el infarto agudo de miocardio. Universitat Autònoma de Bar- riculares durante la angioplastia en el ser humano. Universitat
celona. Director: Joan M. Cinca Cuscullola. Date of defense: 30 Autònoma de Barcelona. Director: Juan Cinca Cuscullola. Date
September de 2015. of defense: 13 de novembre de 2015.


*TIF: 312.5140 **MIF: 5.0405
Alegret J.M., Vinolas X., Martinez-Rubio A., ment of chronic total coronary occlusions: atrial fibrillation in non-cardiac and cardiac
Pedrote A., Beiras X., Garcia-Sacristan J.F., Incidence, presentation and related factors. surgery: An overview. (2015) J THROMB
Crespo-Mancebo F., Ruiz-Mateas F., Gender Data from the CIBELES trial. (2015) REV PORT HAEMOST, 13 (S1), S304-S312.
differences in patients with atrial fibrillation CARDIOL, 34 (3), 193-199. IF: 5.5650
undergoing electrical cardioversion. (2015) J IF: 0.8730 Bos L., Mirabet S., Brossa V., Lopez L., Sionis
WOMENS HEALTH, 24 (6), 466-470. Arzamendi D., Li C.H., Serra A., Cardiac Com- A., Capellades H., Cinca J., Roig E., Role of
IF: 2.0320 puted Tomography-guided Closure of Ven- Vascular Disease in the Evolution of Heart
Alonso J.J., Muniz J., Gomez-Doblas J.J., Ro- tricular Septal Defect Secondary to Myocar- Transplant Patients. (2015) TRANSPL P, 47 (8),
driguez-Roca G., Lobos J.M., Permanyer-Mi- dial Infarction. (2015) REV ESP CARDIOL, 2393-2394.
ralda G., Anguita M., Chorro F.J., Roig E., Prev- IF: 4.5960 IF: 0.8670
alence of Stable Angina in Spain. Results of Azzalini L., Sole E., Sans J., Vila M., Duran A., Chevalier B., Wijns W., Silber S., Garcia E.,
the OFRECE Study. (2015) REV ESP CARDIOL, Gil-Alonso D., Santalo M., Garcia-Moll X., Serra A., Paunovic D., Serruys P., Five-year
68 (8), 691-699. Sionis A., Feasibility and safety of an early clinical outcome of the Nobori drug-eluting
IF: 4.5960 discharge strategy after low-risk acute myo- coronary stent system in the treatment of
Alonso-Gonzalez R., Lopez-Guarch C.J., Sub- cardial infarction treated with primary per- patients with coronary artery disease: Final
irana-Domenech M.T., Oliver Ruiz J.M., Gon- cutaneous coronary intervention: The ED- results of the NOBORI 1 trial. (2015) EUROIN-
zalez I.O., Cubero J.S., Del Cerro M.J., Salva- AMI pilot trial. (2015) CARDIOLOGY, 130 (2), TERVENTION, 11 (5), 549-554.
dor M.L., Dos Subira L., Gallego P., 120-129. IF: 3.8630
Escribano-Subias P., Pulmonary hyperten- IF: 1.9940 Cortes-Vicente E., Delgado-Mederos R., Bell-
sion and congenital heart disease: An in- Ballester M.R., Roig E., Gich I., Puntes M., munt S., Borras X.F., Gomez-Anson B., Bague
sight from the REHAP national registry. Delgadillo J., Santos B., Antonijoan R.M., S., Camps-Renom P., Marti-Fabregas J.,
(2015) INT J CARDIOL, 184 (1), 717-723. Randomized, open-label, blinded-endpoint, Stroke caused by a myxoma stenosing the
IF: 4.6380 crossover, single-dose study to compare the common carotid artery. (2015) J STROKE
Alquezar Arbe A., Santalo Bel M., Sionis A., pharmacodynamics of torasemide-PR 10 CEREBROVASC, 24 (4), e87-e89.
Clinical interpretation of high sensitivity mg, torasemide-IR 10 mg, and furosemi- IF: 1.5990
troponin T. (2015) MED CLIN-BARCELONA, de-IR 40 mg, in patients with chronic heart
Scientific Production
Crespo-Leiro M.G., Segovia-Cubero J., Gon-

145 (6), 258-263. failure. (2015) DRUG DES DEV THER, 9, 4291- zalez-Costello J., Bayes-Genis A., Lopez-Fer-
IF: 1.2670 4302. nandez S., Roig E., Sanz-Julve M., Fernandez-
Alvarez-Garcia J., Ferrero-Gregori A., Puig T., IF: 2.8810 Vivancos C., De Mora-Martin M., Garcia-Pinilla
Vazquez R., Delgado J., Pascual-Figal D., Barahona M.-J., Resmini E., Vilades D., Fer- J.M., Varela-Roman A., Almenar-Bonet L., La-
Alonso-Pulpon L., Gonzalez-Juanatey J.R., nandez-Real J.-M., Ricart W., Moreno-Navar- ra-Padron A., De La Fuente-Galan L., Del-
Rivera M., Worner F., Bardaji A., Cinca J., Hov- rete J.-M., Pons-Llado G., Leta R., Webb S.M., gado-Jimenez J., Adherence to the ESC
e-Madsen L., A simple validated method for Soluble TNFα-receptor 1 as a predictor of Heart Failure Treatment Guidelines in Spain:
predicting the risk of hospitalization for coronary calcifications in patients after long- ESC Heart Failure Long-term Registry. (2015)
worsening of heart failure in ambulatory term cure of Cushing’s syndrome. (2015) PI- REV ESP CARDIOL, 68 (9), 785-793.
patients: The Redin-SCORE. (2015) EUR J TUITARY, 18 (1), 135-141. IF: 4.5960
HEART FAIL, 17 (8), 818-827. IF: 3.4070 Cruz-Gonzalez I., Arzamendi D., Rama-Mer-
IF: 5.1350 Barbato E., Carrie D., Dardas P., Fajadet J., chan J.C., Pina-Gonzalez P., Sanchez P.L.,
Alvarez-Garcia J., Ferrero-Gregori A., Puig T., Gaul G., Haude M., Khashaba A., Koch K., Serra A., Left Atrial Appendage Occlusion
Cinca J., The Redin SCORE: useful, but not for Meyer-Gessner M., Palazuelos J., Reczuch K., With the New AmuletTM Device: Feasibility,
all: Reply. (2015) EUR J HEART FAIL, Ribichini F.L., Sharma S., Sipotz J., Sjogren I., Safety and Short-term Efficacy. (2015) REV
IF: 5.1350 Suetsch G., Szabo G., Valdes-Chavarri M., ESP CARDIOL,
Anguera I., Dallaglio P., Martinez-Ferrer J., Vaquerizo B., Wijns W., Windecker S., De IF: 4.5960
Rodriguez A., Alzueta J., Perez-Villacastin J., Belder A., Valgimigli M., Byrne R.A., Colombo De Luna A.B., Rovai D., Llado G.P., Gorgels A.,
Porres J.M., Vinolas X., Fontenla A., Fernan- A., Di Mario C., Latib A., Hamm C., European Carreras F., Goldwasser D., Kim R.J., The end
dez-Lozano I., Garcia-Alberola A., Sabate X., expert consensus on rotational atherec- of an electrocardiographic dogma: A promi-
Shock Reduction with Multiple Bursts of tomy. (2015) EUROINTERVENTION, 11 (1), nent R wave in V1 is caused by a lateral not
Antitachycardia Pacing Therapies to Treat 30-36. posterior myocardial infarction - New evi-
Fast Ventricular Tachyarrhythmias in Patients IF: 3.8630 dence based on contrast-enhanced cardiac
with Implantable Cardioverter Defibrillators: Benito N., Garcia-Vazquez E., Horcajada J.P., magnetic resonance - Electrocardiogram
*Total Impact Factor **Mean Impact Factor
A Multicenter Study. (2015) J CARDIOVASC Gonzalez J., Oppenheimer F., Cofan F., Ricart correlations. (2015) EUR HEART J, 36 (16),
ELECTR, 26 (7), 774-782. M.J., Rimola A., Navasa M., Rovira M., Roig E., 959-964.
IF: 3.0970 Perez-Villa F., Cervera C., Moreno A., Clinical IF: 15.0640
Arroyo-Ucar E., Moreno R., Garcia E., Teles R., features and outcomes of tuberculosis in Duran-Cambra A., Sutil-Vega M., Fiol M.,
Rumoroso J.-R., Carvalho H.C., Goicolea F.J., transplant recipients as compared with the Nunez-Gil I.J., Vila M., Sans-Rosello J., Cinca J.,
Moreu J., Mauri J., Sabate M., Mainar V., Patri- general population: A retrospective Sionis A., Systematic review of the electro-
cio L., Valdes M., Fernandez-Vazquez F., San- matched cohort study. (2015) CLIN MICRO- cardiographic changes in the Takotsubo
chez-Recalde A., Galeote G., Jimenez-Valero BIOL INFEC, 21 (7), 651-658. syndrome. (2015) ANN NONINVAS ELECTRO,
S., Almeida M., Lopez De Sa E., Calvo L., Plaza IF: 4.5750 20 (1), 1-6.
I., Lopez-Sendon J.-L., Martin J.-L.R., Bessissow A., Khan J., Devereaux P.J., Alva- IF: 1.5690
Drug-eluting stent thrombosis in the treat- rez-Garcia J., Alonso-Coello P., Postoperative

ISI Web of Knowledge Indexed Publications without IF

*TIF: 312.5140 **MIF: 5.0405
Galassi
1. MartiA.R., SianosF.,G.,
V., Seixo Werner
Leta G.S., A.
R., Serra Escaned
Mycotic Goldwasser
aortic aneurysm D., Senthilkumar
secondary toA.,repeated
Bayes Deendocarditis.
tients with ST-elevation
Revista Portuguesamyocardial infarc-
De Cardiolo-
J., Tomasello
gia;30(11):863-4. S.D., Boukhris M., Castaing M., Luna A., Elosua R., Carreras F., Pons-Llado G., tion undergoing primary percutaneous cor-
Buttner J.H., Bufe A., Kalnins A., Spratt J.C., Kim R.J., Lateral MI Explains the Presence of onary intervention: Insights from the
2. MartíR.,
Garbo V., Hildick-Smith
García-Picart J.,D.,Carballeira
Elhadad S., L. Acute
Gag- coronary
Prominent syndrome
R Wavedue (R ≥toS)distal
in V1.embolization
(2015) ANN of aexamination
thrombus located in theINT
trial. (2015) leftJ CARDIOL,
main coronary
179,
artery.
nor A.,Revista
Lauer B.,Española De Cardiología;64(7):614.
Bryniarski L., Christiansen NONINVAS ELECTRO, 20 (6), 570-577. 73-78.
3. Brugaletta
E.H., Thuesen S., Martin-Yuste V.,M.,
L., Meyer-Gessner Goktekin IF: 1.5690
Ferreira-Gonzalez I., Cola C., Alvarez-Contreras L., De AntonioIF: M.,4.6380
Garcia-Moll X., Garcia-Picart J., Marti V.,
Balcells-Iranzo J., Sabate
O., Carlino M., Louvard Y.,M. Adequate
Lefevre antiplatelet
T., Lismanis Gomez-Hospital J.A., Mauri J., Pinar E., Goi- Jackson C.E.,undergoing
regimen in patients on chronic anti-vitamin K treatment et al. Differingpercutaneous coro-
prognostic value
nary intervention.
A., Gelev V.L., SerraWorld journal
A., Marza of cardiology;3(11):367-73.
F., Di Mario C., colea J., Garcia Del Blanco B., Serra A., Tizon- of pulse pressure in patients with heart fail-
Reifart
4. In-cycleN.,myocardium
Retrogradetissue recanalization of Marcos
electrical impedance monitoring using
H., Molina E., broadband
Sanchez E., impedance
Aragon V., spectroscopy.
ure with reducedProceedings of theejection
or preserved annual inter-
frac-
chronic conference
national total occlusions
of theinIEEEEurope: Proce- in medicine
engineering Masotti M., and biology society,
Rodriguez J., JimenezEMBS;2518
J., Ortas p.
R., tion: results from the MAGGIC individual
dural, in-hospital, and long-term outcomes Martinez P., Serra B., Moreu J., Diego Nieto G., patient meta-analysis. (2015) EUR HEART J,
5.
from Marti
theV., Seixo F., Leta
multicenter ERCTO R., registry.
Serra A. (2015)
Mycotic aortic aneurysm secondary to repeated endocarditis. Revista Portuguesa De Cardiolo-
gia;30(11):863-4. Bossa F., Nogales J.M., Bassaganyas J., Diaz J., 36 (18), 1106-1114.
J AM COLL CARDIOL, 65 (22), 2388-2400. Cascon J.D., The titan-ami multicenter regis- IF: 15.0640
IF: 17.7590 try evaluating the usage of titan2 stent in Lopez-Sendon J., Gonzalez-Juanatey J.R.,
Scopus Indexed Publications
Garcia-Moll X., Lights and (some) shadows in patients with ST segment elevation myocar- Pinto F., Cuenca Castillo J., Badimon L., Dal-
the management
Martí V., García-Picart of J.,
acute coronary
Balcells J., Colasyn- dial infarction.
C., Kastanis P., Sabaté Final resultmaneuver
M. Rescue at 12-month for fol-
entrapped
mau stent in the coronary
R., Gonzalez Torrecillatree.
E., Archivos De
Lopez-Min-
drome in Spain:
Cardiologia The DIOCLES study. (2015) low-up. (2015) MINERVA CARDIOANGIOL, 63 guez J.R., Maceira A.M., Pascual-Figal D., Po-
De Mexico;81(1):29-32.
REV ESP CARDIOL, 68 (2), 85-86. (1), 11-20. mar Moya-Prats J.L.,Clinica
SioniseA., Zamorano J.L.,
Cubedo
IF: 4.5960 J., Padró T., García-Moll X., Pintó X., Cinca IF:J., Badimon L. Serum proteome in acute myocardial
0.7520 infarction. Investigacion En
Arteriosclerosis;23(4):147-54. Quality Markers in Cardiology. Main Markers
Gil-Ortega I., Pedrote-Martinez A., Fonten- Gonzalez-Vilchez F., Segovia Cubero J., Al- to Measure Quality of Results (Outcomes)
la-Cerezuela A., Arias M.A., Pindado J., Marti menar L., Crespo-Leiro M.G., Arizon J.M., Villa and Quality Measures Related to Better Re-
J., Bodegas A., Exposito-Pineda M.C., A., Delgado J., Roig E., Lage E., Gonzalez-Cos- sults in Clinical Practice (Performance Met-
Moreno-Arribas J., Dominguez-Mafe E., Ma- tello J., Spanish Heart Transplantation Regis- rics). INCARDIO (Indicadores de Calidad en
nuel Rubio-Campal J., Sabate X., Brouzet T., try. 26th Official Report of the Spanish Soci- Unidades Asistenciales del Área del Co-
Jimenez-Diaz J., Fontenla A., Segura F., Cas- ety of Cardiology Working Group on Heart razón): A SEC/SECTCV Consensus Position
tro V., Gonzalez-Vasserot M., Campos B., Tral- Failure and Heart Transplantation (1984- Paper. (2015) REV ESP CARDIOL, 68 (11),
Production
ScientificPublications
Book
lero R.,Chapter
Perez- Castellano N., Alcalde-Rodri- 2014). (2015) REV ESP CARDIOL, 68 (11), 976-995e10.
guez O., Cabanas-Grandio P., Rivas-Gandara 1008-1021. IF: 4.5960
Other
ff Cinca J. XVII Edition “Treaty on Internal Medicine Far-

N., Rodriguez-Perez J.C., Martinez-Basterra IF: 4.5960 Marti V., Brugaletta S., Garcia-Picart J., Del-
reras-Rozman”. Chapter No 54, subsection “Electrocar-
J., Magnani S., Asso A., Ibanez-Criado J.L., Harjola V.-P., Lassus J., Sionis A., Kober L., gado G., Cequier A., Iniguez A., Hernandez-
diography”.
Jimenez-Bello J., Punti-Sala J., Romero-Gar- Tarvasmaki T., Spinar J., Parissis J., Banaszew- -Antolin R., Serruys P., Serra A., Sabate M.,
rido R., Moreno J., Matia R., Macias A., Grande ski M., Silva-Cardoso J., Carubelli V., Di Radial versus femoral access for angioplasty
A., Jimenez Candil J., Doblado-Calatrava M., Somma S., Tolppanen H., Zeymer U., Thiele of st-segment elevation acute myocardial
Arana-Rueda E., Alvarez-Lopez M., Iba- H., Nieminen M.S., Mebazaa A., Clinical pic- infarction with second-generation
nez-Criado A., Arcocha-Torres M.F., Sarrias A., ture and risk prediction of short-term mor- drug-eluting stents. (2015) REV ESP CAR-
Rubio J., Pelaez A., Pastor A., Sarquella-Bru- tality in cardiogenic shock. (2015) EUR J DIOL, 68 (1), 47-53.
gada G., Cano-Calabria L., Osca J., Fosch J., HEART FAIL, 17 (5), 501-509. IF: 4.5960
Rubin J.M., Guerra J.M., Garcia-Alberola A., IF: 5.1350
Caballero-Dorta E., Roca-Luque I., Linde A., Martinez-Selles M., Diez-Villanueva P., San-
Diaz-Infante E., Peinado R., Garcia-Medina Healey J.S., Viñolas X., Cardioverter defibrilla- chez-Sendin D., Hevia A.C., Doblas J.J.G., De
D., Perez-Rodon J., Barrera A., Alonso C., Ibars tor implantation without induction of ven- La Villa B.G., Cornide L., Tello A.A., Ogando
S., Vinolas X., Rodriguez-Font E., Ortega-Mo- tricular fibrillation: A single-blind, non-inferi- R.A., Vera T.R., Jimenez A.A., Carrillo P., Pas-
lina M., Moya-i-Mitjans A., Mont L., Romero ority, randomised controlled trial (SIMPLE). cual C.R., Romeva M.C.I., Borras X., Vazquez
R., Rodriguez-Entem F., Garcia-Fernandez J., (2015) LANCET, 385 (9970), 785-791. S., Lopez-Palop R., Comorbidity and inter-
Perez-Alvarez L., Herreros B., Arenal A., Mo- IF: 44.0020 vention in octogenarians with severe symp-
rina P., Rubio-Caballero A., Martinez-Sande Herraiz-Martinez A., Alvarez-Garcia J., Llach tomatic aortic stenosis. (2015) INT J CAR-
J.L., Mazuelos F., Almendral J., Martinez-Bro- A., Molina C.E., Fernandes J., Ferrero-Gregori DIOL, 189 (1), 61-66.
tons A., Ferrero-de-Loma A., Fidalgo M.L., A., Rodriguez C., Vallmitjana A., Benitez R., IF: 4.6380
Spanish Catheter Ablation Registry. 14th Padro J.M., Martinez-Gonzalez J., Cinca J., Martin-Yuste V., Alvarez-Contreras L., Sabate
Official Report of the Spanish Society of Hove-Madsen L., Ageing is associated with M., How should i treat subacute stent throm-
Cardiology Working Group on Electrophysi- deterioration of calcium homeostasis in iso- bosis in the context of brain haemorrhage
ology and Arrhythmias (2014). (2015) REV lated human right atrial myocytes. (2015) with abciximab? (2015) EUROINTERVEN-
ESP CARDIOL, 68 (12), 1127-1137. CARDIOVASC RES, 106 (1), 76-86. TION, 10 (10), e1-e2.
IF: 4.5960 IF: 5.4650 IF: 3.8630
Goldwasser D., Senthilkumar A., Bayes de Ielasi A., Brugaletta S., Silvestro A., Cequier Masia J., Bordoni D., Pons G., Liuzza C., Cast-
Luna A., Elosua R., Carreras F., Pons-Llado G., A., Iniguez A., Serra A., Hernandez-Antolin R., agnetti F., Falco G., Oncological safety of
Kim R.J., Lateral MI Explains the Presence of Mainar V., Valgimigli M., Den Heijer P., breast cancer patients undergoing free-flap
Prominent R Wave (R ≥ S) in V1. (2015) ANN Bethencourt A., Vazquez N., Serruys P., Sa- reconstruction and lipofilling. (2015) EJ-
NONINVAS ELECTRO, bate M., Tespili M., Everolimus-eluting stent SO-EUR J SURG ONC, 41 (5), 612-616.
IF: 1.5690 versus bare-metal stent in elderly (≥ 75 IF: 2.9400
years) versus non-elderly (< 75 years) pa-


*TIF: 312.5140 **MIF: 5.0405
Masia J., Pons G., Loschi P., Sanchez Porro-Gil diac complications during pregnancy are microparticles. Validation in ST-elevation
L., Nardulli M.L., Olivares L., Autologous Re- better predicted with the modified WHO risk myocardial infarction patients. (2015) J
construction of a Complex Form of Poland score. (2015) INT J CARDIOL, 195, 149-154. THROMB HAEMOST, 13 (10), 1776-1786.
Syndrome Using 2 Abdominal Perforator IF: 4.6380 IF: 5.5650
Free Flaps. (2015) ANN PLAS SURG, 74 (5), Ramaiola I., Padro T., Pena E., Juan-Babot O., Taniwaki M., Stefanini G.G., Raber L., Brugal-
580-583. Cubedo J., Martin-Yuste V., Sabate M., Badi- etta S., Cequier A., Heg D., Iniguez A., Kel-
IF: 1.5350 mon L., Changes in thrombus composition baek H., Serra A., Ostoijic M., Hernandez-An-
Masia J., Pons G., Nardulli M.L., Combined and profilin-1 release in acute myocardial tolin R., Baumbach A., Blochlinger S., Juni P.,
Surgical Treatment in Breast Cancer-Related infarction. (2015) EUR HEART J, 36 (16), 965- Mainar V., Sabate M., Windecker S., Predic-
Lymphedema. (2015) J RECONSTR MICRO- 975. tors of adverse events among patients un-
SURG, 32 (1), 16-27. IF: 15.0640 dergoing primary percutaneous coronary
IF: 1.7340 Roig E., Almenar L., Crespo-Leiro M., Segovia intervention: Insights from a pooled analysis
Mendez A.B., Ordonez-Llanos J., Farrero M., J., Mirabet S., Delgado J., Perez-Villa F., Luis of the COMFORTABLE AMI and EXAMINA-
Mirabet S., Brossa V., Lopez L., Bonet R., Sio- Lambert J., Teresa Blasco M., Muniz J., Heart TION trials. (2015) EUROINTERVENTION, 11
nis A., Perez-Villa F., Roig Minguell E., Cost-Ef- transplantation using allografts from older (4), 391-398.
fectiveness of Highly Sensitive Cardiac Tro- donors: Multicenter study results. (2015) J IF: 3.8630
ponin T to Rule Out Acute Rejection after HEART LUNG TRANSPL, 34 (6), 790-796. Vaquerizo B., Barros A., Pujadas S., Bajo E.,
Heart Transplantation. (2015) TRANSPL P, 47 IF: 7.5090 Estrada D., Miranda-Guardiola F., Rigla J.,
(8), 2395-2396. Roldan C., Mirabet S., Cecilia C., Brossa V., Jimenez M., Cinca J., Serra A., Bioresorbable
IF: 0.8670 Roig E., Martin C., Gelpi C., CD4+C- everolimus-eluting vascular scaffold for the
Millan X., Skaf S., Joseph L., Ruiz C., Garcia E., D45RO+CD25-/lowCD127+: CD4+CD45RO+C- treatment of chronic total occlusions:
Smolka G., Noble S., Cruz-Gonzalez I., D25hiCD127-/low Ratio in Peripheral Blood: A CTO-ABSORB pilot study. (2015) EUROIN-
Arzamendi D., Serra A., Kliger C., Sia Y.T., As- Useful Biomarker to Detect Cardiac Allograft TERVENTION, 11 (5), 555-563.
gar A., Ibrahim R., Jolicoeur E.M., Transcathe- Vasculopathy in Heart Transplanted Patients. IF: 3.8630
ter Reduction of Paravalvular Leaks: ASys- (2015) TRANSPLANTATION, 99 (7), 1521- Vaquerizo B., Miranda-Guardiola F., Fernan-
tematic Review and Meta-analysis. (2015) 1528. dez E., Rumoroso J.R., Gomez-Hospital J.A.,
CAN J CARDIOL, 31 (3), 260-269. IF: 3.6900 Bossa F., Iniguez A., Oategui I., Serra A., Treat-
IF: 3.1120 Ruiz-Morales J., et al, Left-sided infective en- ment of Small Vessel Disease with the Pacli-
Mirabet S., Roig E., Amyloidosis: Is there docarditis in patients with liver cirrhosis. taxel Drug-Eluting Balloon: 6-Month Angio-
hope? (2015) REV CLIN ESP, 215 (1), 27-28. (2015) J INFECTION, 71 (6), 627-641. graphic and 1-Year Clinical Outcomes of the
IF: 0.7600 IF: 4.3820 Spanish Multicenter Registry. (2015) J IN-
TERV CARDIOL, 28 (5), 430-438.
Munoz P., et al, Current epidemiology and Serra-Grima R., Donate M., Alvarez-Garcia J., IF: 1.3270
outcome of infective endocarditis: A multi- Barradas-Pires A., Ferrero A., Carballeira L.,
center, prospective, cohort study. (2015) Puig T., Rodriguez E., Cinca J., Long-term fol- Vaquerizo B., Theriault-Lauzier P., Piazza N.,
MEDICINE, 94 (43), low-up of early repolarization pattern in elite Percutaneous Transcatheter Mitral Valve Re-
IF: 1.2060 athletes. (2015) AM J MED, 128 (2), 192.e1- placement: Patient-specific Three-dimen-
192.e9. sional Computer-based Heart Model and
Nunez Gil I.J., Andres M., Almendro Delia M., Prototyping. (2015) REV ESP CARDIOL, 68
Sionis A., Martin A., Bastante T., Cordoba So- IF: 5.6100
(12), 1165-1173.
riano J.G., Linares Vicente J.A., Gonzalez Su- Simpson J., Castagno D., Doughty R.N., IF: 4.5960
carrats S., Sanchez-Grande Flecha A., Char- Poppe K.K., Earle N., Squire I., Richards M.,
acterization of tako-tsubo cardiomyopathy Andersson B., Ezekowitz J.A., Komajda M., Vilades Medel D., Munoz Guijosa C., Carreras
in Spain: Results from the RETAKO national Petrie M.C., McAlister F.A., Gamble G.D., Costa F., Padro Fernandez J.M., Pons Llado G.,
registry. (2015) REV ESP CARDIOL, 68 (6), Whalley G.A., McMurray J.J., Meta-Analysis Leta Petracca R., Assessment of Radial Artery
505-512. Global Group in Chronic Heart Failure (MAG- Graft Patency Through 256-slice Cardiac
IF: 4.5960 GIC). Is heart rate a risk marker in patients Computed Tomography, and the Mid-term
with chronic heart failure and concomitant Prognostic Impact of Graft Occlusion. (2015)
Ortega A., Tarazon E., Rosello-Lleti E., Gil- REV ESP CARDIOL.
Cayuela C., Lago F., Gonzolez-Juanatey J.-R., atrial fibrillation? Results from the MAGGIC
meta-analysis. (2015) EUR J HEART FAIL, IF: 4.5960
Cinca J., Jorge E., Martinez-Dolz L., Portoles
M., Rivera M., Patients with dilated cardiomy- 17(11), 1182-91. Vilades Medel D., Leta R., Alomar Serralach
opathy and sustained monomorphic ven- IF: 6.5260 X., Carreras Costa F., Pons-Llado G., Reliability
tricular tachycardia show up-regulation of Sionis A., Ruiz-Nodar J.M., Fernandez-Ortiz of a new method for coronary artery calcium
KCNN3 and KCNJ2 genes and CACNG8- A., Marin F., Abu-Assi E., Diaz-Castro O., or metal subtraction by 320-row cardiac CT.
linked left ventricular dysfunction. (2015) Nunez-Gil I.J., Lidon R.-M., Update on ische- (2015) EUR RADIOL, 1-7.
PLOS ONE, 10 (12), mic heart disease and intensive cardiac care. IF: 3.6400
IF: 3.0570 (2015) REV ESP CARDIOL, 68 (3), 234-241.
Pijuan-Domenech A., Galian L., Goya M., IF: 4.5960
Casellas M., Merced C., Ferreira-Gonzalez I., Suades R., Padro T., Vilahur G., Martin-Yuste
Marsal-Mora J.R., Dos-Subira L., Subi- V., Sabate M., Sans-Rosello J., Sionis A., Badi-
rana-Domenech M.T., Pedrosa V., Baro-Ma- mon L., Growing thrombi release increased
rine F., Manrique S., Casaldaliga-Ferrer J., levels of CD235a+ microparticles and de-
Tornos P., Cabero L., Garcia-Dorado D., Car- creased levels of activated platelet-derived

ff Hidalgo A., Pons-Lladó G. Usefulness of cardiac MRI in the prog- and Management of Acute Pulmonary Embolism; SEC Clinical
nosis and follow-up of ischemic heart disease. (2015) RADIOLO- Practice Guidelines Committee: Evangelista Masip A., Gómez
GIA, 57 (3), 201-212. de Diego J.J., Calvo Iglesias F., Forteza Gil A., García de Vinuesa
P.G., Martín M., Nistal J.F., Sánchez Sánchez V., Teixido i Tura G.,
Other Publications
ff Rovai D., Bayes de Luna A., Goldwasser D., Pons-Llado G., Carre- Vilacosta I., Azqueta Molluna M., Barros A., Fernández Tarrío R.,
ras F., di Bella G., Pingitore A., van der Weg K., Gorgels A., Kim R. García Fernández M.A., Lidón Corbi R.M., López de Sa y Areses
Q wave myocardial infarction of anteroseptal zone: a new clas- E., López Fernández T., Mesa Rubio D., Mosquera V., Pérez de la
sification. (2015) INT J CARDIOL, 180, 44-5. Sota E., Tornos Mas P., San Roman Calvar J.A., Sionis Green A.,
ff Ruiz-Salas A., Barrera-Cordero A., Viñolas X., Sola N.B., Álvarez Di Stefano S., Viana Tejedor A., Vivancos Delgado R., Zamorano
L.P., Olalla J.J., Brugada J., Alzueta J. Usefulnessof antitachycar- Gómez J.L., Anguita Sánchez M.P., Cequier Fillat A.R., Badimón
dia pacing in arrhythmogenic right ventricular dysplasia/car- Maestro L., Barrabés Rui J.A., Comin Colet J., Fernández Lozano
diomyopathy. (2015) INT J CARDIOL, 181, 172-3. I, Gómez de Diego J.J., Álvarez Osorio M.P., Rodríguez Padial L.,
San Román Calvar J.A., Sánchez Fernández P.L. Comments on
ff SEC Working Group for the ESC 2014 Guidelines on the Diag- the 2014 ESC Guidelines on the diagnosis and management of
nosis and Management of Acute Pulmonary Embolism; Ex- acute pulmonary embolism. (2015) REV ESP CARDIOL, 68(1),
pert Reviewers for the ESC 2014 Guidelines on the Diagnosis 10-6.

Thrombosis and Haemostasis
Coordinators
Souto Andres, Joan Carles FGS
jsouto@santpau.cat
Members
Cárdenas Yebra, Antonio IR
Carrasco Expósito, Marina FGS
Cerdà Urbano, Elia FGS
Coll Torrens, Inmaculada FGS
Cuevas Eduardo, Biel IR
Fontcuberta Boj, Jorge FGS
Llobet Lorente,
Maria Dolors FGS
Macho López, Raquel IR
Mateo Arranz, Jose FGS
ff Investigation of the genetic basis of ve- ff Applied clinical development of the
nous and arterial thrombosis. GAIT-1 and self-management model of oral anticoag-
Millon Caño, Juan Antonio IR
GAIT-2 projects. ulant treatment.
Morte Piferrer, Alan IR
Murillo Escoda, Joaquín IR ff Investigation of new antithrombotic ff Mathematical models of prediction of the
Pérez Calleja, Raquel IR drugs: thrombin inhibitors, molecules individual risk of thromboembolic disease
against activated factor X, low molecular in general population (RETROVE Project)
of Research
Main Lines
Tirado Garcia, Isabel FGS weight heparin with oral activity, among and in cancer patients (MIRTO Project).
Vallvé Fornieles, Cristina FGS others.
Vázquez Santiago, Miguel IR ff CITA project. Centre for Antithrombotic
ff Biomarkers of prothrombotic states in Therapy Management. Research into a new
Vilalta Seto, Noelia FGS
patients under 55 years with venous ambulatory management model for pa-
thromboembolic disease, acute ischaemic tients receiving any kind of antithrombotic
stroke, or acute myocardial infarction. therapy (anti vitamin-K, new oral antico-
VEREMA project. agulants, low molecular weight heparins,
antiplatelets) by incorporating new edu-
cational programmes, specialized nursing
and new communication technologies.
ff Study QTL detected in GAIT-1 families in ff Research plasma proteins associated with
relation to phenotypes of haemostasis the risk of venous thromboembolism by
with thrombosis risk (resistance to acti- using high affinity proteomics developed
vated protein C, factor VIII, homocysteine, at Karolinska Institutet. VEREMA project,
factor XII, body mass index and others). joint collaboration between the European
case-control studies VEBIOS (Sweden),
ff Replicate QTL related to thrombosis in RETROVE (from our unit) and MARTHA
GAIT-1 families by means of the linkage (France).
analysis using new GAIT-2 families.
ff Investigation on laboratory management
ff Conduct genome-wide association study of DOACs.
(GWAS) of phenotypes involved in GAIT-1.
ff Search for new universal laboratory meth-
ff GWAS of phenotypes included in GAIT-2.
Challenges
ods for the assessment of any kind of oral

ff Analyse RNA expression in the GAIT-2 fam- anticoagulant (AVK and DOACs).
ilies. ff Incorporation to the new CIBER cardiovas-
ff Investigate miRNA associated with throm- cular research network.
boembolic disease in GAIT-2.
ff To complete the recruitment of the co-
horts included in MIRTO Project (Model-
ling the Individual Risk of Thrombosis in
Oncology), with the goal of establishing
an individual risk score for venous throm-
boembolism (RETROVO sub-project) and
for ischaemic stroke (SINO subproject) in
patients with cancer.

Collaborations with other IIB Sant Pau Groups ff Karolinska Institutet, Stockholm, Sweden: GAIT2 and VEREMA.
ff Genomics of Complex Diseases (GAIT1, GAIT2, RETROVE, ff La Timone Hospital, Marseilles, France: GAIT2 and VEREMA.
VEREMA and MIRTO Project). ff Pierre and Marie Curie University, INSERM, UMR-S 1166, Paris,
ff Stroke Unit (HERO, EDUCANT and MIRTO Project). France: GAIT2 and VEREMA.
Collaborations
ff Vascular Surgery (GAIT2, genetics of venous insufficiency). ff Université de Genève, Switzerland: GAIT2.
ff Medical Oncology (MIRTO Project). ff Texas Research Institute (formerly Southwest Foundation for
Biomedical Research), San Antonio, USA: GAIT1 and GAIT2.
ff Clinical Haematology (MIRTO Project).
ff Universitat Politècnica de Catalunya, Barcelona, Spain. Centre for
ff Digestive Diseases (HEPACO). Biomedical Engineering Research: RETROVE and MIRTO design.
ff Thrombosis Group of the Spanish Medical Oncology Society
External Collaborations (SEOM): ONCOTHROMB and MIRTO.
ff Cardiovascular Research Network (RIC). ff Institut of Biological Psychiatry, Mental Health Snc. Hans. Roskil-
de (Denmark).
ff Joan Carles Souto Andrés. Red Cardiovascular. RD12/0042/0032. de la vitamina K versus heparina de bajo peso molecular (bemi-
Grants
Active
Instituto de Salud Carlos III. Duration: 2013-2016. €181,000. parina) en pacientes con criterios de anticoagulación. Labora-
toris Farmacèutics Rovi. Duration: 2012-2016. €6,507.11.
ff Jose Mateo Arranz. Estudio randomizado y controlado para com-
parar el tratamiento con anticoagulación oral con antagonistas Note: Total amount granted to PI. It does not include indirect costs.
Awarded
ff Joan Carles Souto Andrés. Continuación de la búsqueda de algoritmos aplicables en la clínica para definir el perfil individual de Riesgo
in 2015
Grants
de Enfermedad TROmboembólica VEnosa (RETROVE). PI15/00269. Duration: 2016-2018. €104,665.

Note: Total amount granted to PI. It does not include indirect costs.
*TIF: 25.5710 **MIF: 3.1964

Alonso-Coello P., Montori V.M., Diaz M.G., (2015) BMC HEALTH SERV RES, 15 (1). ate clinical management of direct oral antico-
Devereaux P.J., Mas G., Diez A.I., Sola I., Roura IF: 1.6060 agulants. (2015) MED CLIN-BARCELONA.
M., Souto J.C., Oliver S., Ruiz R., Coll-Vinent B., Franberg M., Gertow K., Hamsten A., PRO- IF: 1.2670
Gich I., Schunemann H.J., Guyatt G., Values CARDIS consortium, Lagergren J., Sennblad Olson N.C., Butenas S., Lange L.A., Lange
and preferences for oral antithrombotic B., Souto J., Soria J.M., Discovering Genetic E.M., Cushman M., Jenny N.S., Walston J.,
therapy in patients with atrial fibrillation: Interactions in Large-Scale Association Stud- Souto J.C., Soria J.M., Chauhan G., Debette S.,
Physician and patient perspectives. (2015) ies by Stage-wise Likelihood Ratio Tests. Longstreth W.T., Seshadri S., Reiner A.P., Tracy
HEALTH EXPECT, 18 (6), 2318-2327. (2015) PLOS GENET, 11 (9). R.P., Coagulation factor XII genetic variation,
Production
IF: 3.2070 IF: 7.5280 ex vivo thrombin generation, and stroke risk
Scientific
Carles M., Brosa M., Souto J.C., Garcia-Alamino Herrero R., Real L.M., Rivero-Juarez A., Pineda in the elderly: Results from the Cardiovascu-
J.M., Guyatt G., Alonso-Coello P., Cost-effec- J.A., Camacho A., Macias J., Laplana M., Ko- lar Health Study. (2015) J THROMB HAE-
tiveness analysis of dabigatran and anticoag- nieczny P., Marquez F.J., Souto J.C., Soria J.M., MOST, 13 (10), 1867-1877.
ulation monitoring strategies of vitamin K Saulle I., Lo Caputo S., Biasin M., Rivero A., IF: 5.5650
antagonist. (2015) BMC HEALTH SERV RES. Fibla J., Caruz A., Association of complement Pujol-Moix N., Vazquez-Santiago M., Morera
IF: 1.6060 receptor 2 polymorphisms with innate resis- A., Ziyatdinov A., Remacha A., Nomdedeu
Carles M., Brosa M., Souto J.C., Garcia-Ala- tance to HIV-1 infection. (2015) GENES IM- J.F., Fontcuberta J., Soria J.M., Souto J.C., Ge-
mino J.M., Guyatt G., Alonso-Coello P., MUN, 16 (2), 134-141. netic determinants of Platelet Large-Cell
Cost-effectiveness analysis of dabigatran IF: 2.4720 Ratio, Immature Platelet Fraction, and other
and anticoagulation monitoring strategies Millon Cano J.A., Vilalta Seto N., Mateo Arranz platelet-related phenotypes. (2015)
of Vitamin K antagonist Utilization, expendi- J., Souto Andres J.C., Importance of appropi- THROMB RES, 136 (2), 361-366.
ture, economics and financing systems. IF: 2.3200
Publications
ff Rubio-Terrés C., Soria J.M., Morange P.E., Souto J.C., Suchon P., ff Drobnic F., Pineda A., Escudero J.R., Soria J.M., Souto J.C. Guía
Mateo J., Saut N., Rubio-Rodriguez D., Sala J., Gracia A., Pich S., de práctica clínica para la prevención, diagnóstico y tratam-
Other
Salas E. Economic Analysis of Thrombo inCode, a Clinical-Ge- iento de la enfermedad tromboembólica venosa en el deporte.
netic Function for Assessing the Risk of Venous Thromboem- (2015) APUNTS MED ESPORT, 50,147-159.
bolism. (2015) APPL HEALTH ECON HEALTH POLICY, 13, 233-42.

Cardiovascular Biochemistry
Coordinator
Ordóñez Llanos, Jorge FGS
jordonez@santpau.cat
Members
Benítez González, Sonia IR
Bonet Marqués, Rosa FGS
Castellví Griso, Agustina FGS
Estruch Alrich, Montserrat IR
Freixa Martín, Julia FGS
Mercé Muntañola, Javier FGS
Porcel Jabalera,
Inmaculada FGS
Renteria Obregon,
Ivy Mariel IR Atherosclerosis mechanisms ff Development of algorithms for ruling-out
acute coronary disease.
Rivas Urbina, ff Analysis of apolipoprotein J (apoJ) as a
Andrea Patricia IR marker of CVR. ff Assessment of new biomarkers of acute
Rull Aixa, Anna IR cardiovascular disease: cardiac troponins,
ff Use of mimetic peptides derived from natriuretic peptides, ST-2.
Sánchez Quesada, José Luis IR
apoJ as therapeutic tools.
of Research
Main Lines
ff Development of methods for point-of-

ff Involvement of LDL(-) on lipid accumula- care biomarker measurement.
tion in cardiomyocytes and heart failure.
ff Vulnerability markers in atheromatous
plaque: electronegative LDL, LDL size,
Inflammatory mechanisms induced by HDL function, myeloperoxidase, phos-
LDL(-) on monocytes from patients with pholipase.
diabetes
ff Diagnosis of chronic or acute cardiovascu-
lar diseases.
ff Determine the intracellular mechanisms ff Demonstrate that electronegative LDL

involved in the inflammatory response is a marker of vulnerable atheromatous
Challenges
induced by LDL(-) and the components plaque.

of the particle that entail atherogenicity.
ff Find new markers of cardiovascular risk in
ff Analyse the therapeutic potential of mi- diseases such as diabetes, HIV or cardiac
metic peptides derived from apoJ to de- failure.
lay the development of atherosclerosis in
animal models.
ff Jorge Ordóñez Llanos. Red Cardiovascu- la arteriosclerosis. Utilización terapéu-

lar. RD12/0042/0043. Instituto de Salud tica de péptidos miméticos con activi-
Carlos III. Duration: 2013-2016. €94,000. dad chaperona. PI13/00364. Instituto
de Salud Carlos III. Duration: 2014-2016.
ff Anna Rull Aixa. Ayudas para Contratos
Active Grants
€85,500.
de Perfeccionamiento “Sara Borrell 2012”.
CD12/00439. Instituto de Salud Carlos III. ff Jorge Ordóñez Llanos. Grup de Re-
Duration: 2013-2016. €75,600. cerca d’Estructura de Lipoproteïnes,
Dislipèmies i altres factors de risc de l’Ar-
ff José Luis Sánchez Quesada. Contracte teriosclerosi. 2014 SGR 246. Agència de
Programa d’Estabilització i Intensificació. Gestió d’Ajuts Universitaris i de Recerca.
CES12/023. Departament de Salut. Dura- Duration: 2014-2016.
tion: 2013-2017. €120,000
Note: Total amount granted to PI. It does not include
ff José Luis Sánchez Quesada. Implicación indirect costs.
de la apolipoproteína J (clusterina) en

Collaborations with other IIB Sant Pau Groups ff Dr Mariano Valdés, Virgen de Arrixaca University Hospital, Mur-
cia (Spain), 3-week stay by Dr Carmen Puche in our collaborative
ff Metabolic Bases of Cardiovascular Risk (Dr F. Blanco Vaca). studies laboratory.
ff Endocrinology, Diabetes and Nutrition (Dr A. Pérez). ff Dr Laura Dos (D. Garcia-Dorado), Integrated Adult Congenital
ff Angiology, Vascular Biology and Inflammation (Dr L. Vila). Heart Disease Unit of Vall d’Hebron University Hospital, Barce-
lona, Spain (Evedes study).
ff Clinical and Translational Cardiology (Dr J. Cinca).
ff Dr Domingo Pascual-Figal, Cardiology Department, Virgen de la
ff Lipids and Cardiovascular Pathology (Dr C. Llorente). Arrixaca University Hospital, Murcia (Spain).
ff Dr Rafael Vázquez, Cardiology Service, Puerta del Mar University
External Collaborations Hospital, Cadiz, Spain.
Research into atherosclerosis mechanisms ff Dr Antoni Bayes-Genís, Cardiology Department, Germans Trias i
Pujol University Hospital, Barcelona, Spain.
ff Dr Petri Kovanen, Wihuri Research Institute, Helsinki, Finland.
IFCC Task Force on Clinical Applications of Cardiac Biomarkers (Dr
Collaborations
ff Dr Kati Öörni, Wihuri Research Institute, Helsinki, Finland. Pre- Jordi Ordóñez-Llanos, member)
doctoral stay by Montserrat Estruch (4 months).
ff Dr Fred S. Apple, Department of Laboratory Medicine and Pa-
ff Dr Olga Gursky, Boston University School of Medicine, Boston,
thology, University of Minnesota, USA.
USA. Post-doctoral stay by Anna Rull (6 months).
ff Dr Paul O. Collinson, Cardiovascular and Laboratory Depart-
ff Dr Sandra Villegas, Biochemistry and Molecular Biology Depart-
ments, St. George’s Hospital, London, UK.
ment, UAB, Barcelona, Spain (ISCIII/FIS coordinated project un-
der PI10/00265). ff Dr Alan S. Jaffe, Mayo Clinic, Cardiovascular Division, Rochester,
New York, USA.
Research into diagnosis
ff Dr James L. Januzzi, Cardiology Division, Massachusetts General
ff Dr Daniel Podzamczer, HIV Unit, Infectious Disease Service, Bell- Hospital, Boston, USA.
vitge University Hospital, Barcelona, Spain (ATADAR, SPIRAL and
BICOMBO clinical trials). Participation in multicentre studies
ff Formation and maintenance of a bank of samples within the Car- ff MUSIC (sudden death in heart failure) Risk Score, Spanish Soci-
diovascular Research Network (RIC), Programme 6 (Clinical and ety of Cardiology.
Translational Heart Failure). ff MAGGIC (meta-analysis global group in chronic heart failure),
ff Cardiovascular Research Network (RIC): Dr Francisco Marín, Car- European Society of Cardiology.
diology, Hospital Virgen de Arrixaca, Murcia, Spain, 3-month stay
by Dr Juan Antonio Vilchez (during a Rio Hortega contract) in our
collaborative studies laboratory.
*TIF: 58.5230 **MIF: 3.9015

Alquezar-Arbe A., Ordonez-Llanos J., Quo dant potential. (2015) MOL NUTR FOOD RES, ure with reduced or preserved ejection frac-
vadis, troponin? (2015) REV ESP CARDIOL, 68 59 (10), 1987-1996. tion: results from the MAGGIC individual
(6), 457-459. IF: 4.5510 patient meta-analysis. (2015) EUR HEART J,
IF: 4.5960 De Gonzalo-Calvo D., Cenarro A., Mar- 36 (18), 1106-1114.
Apple F.S., Jaffe A.S., Collinson P., Mockel M., tinez-Bujidos M., Badimon L., Bayes-Genis A., IF: 15.0640
Ordonez-Llanos J., Lindahl B., Hollander J., Ordonez-Llanos J., Civeira F., Llorente-Cortes Martinez-Bujidos M., Rull A., Gonzalez-Cura
Plebani M., Than M., Chan M.H.M. IFCC edu- V., Circulating soluble low-density lipopro- B., Perez-Cuellar M., Montoliu-Gaya L., Ville-
cational materials on selected analytical and tein receptor-related protein 1 (sLRP1) con- gas S., Ordonez-Llanos J., Sanchez-Quesada
clinical applications of high sensitivity car- centration is associated with hypercholes- J.L., Clusterin/apolipoprotein J binds to ag-
diac troponin assays. (2015) CLIN BIOCHEM, terolemia: A new potential biomarker for gregated LDL in human plasma and plays a
48 (4-5), 201-203. atherosclerosis. (2015) INT J CARDIOL, 201, protective role against LDL aggregation.
IF: 2.3820 20-29. (2015) FASEB J, 29 (5), 1688-1700.
Bayes-Genis A., Ordonez-Llanos J., Multiple IF: 4.6380 IF: 5.2990

biomarker strategies for risk stratification in Estruch M., Rajamaki K., Sanchez-Quesada Mendez A.B., Ordonez-Llanos J., Farrero M.,
heart failure. (2015) CLIN CHIM ACTA, 443, J.L., Kovanen P.T., Oorni K., Benitez S., Or- Mirabet S., Brossa V., Lopez L., Bonet R., Sio-
120-125. donez-Llanos J., Electronegative LDL in- nis A., Perez-Villa F., Roig Minguell E., Cost-Ef-
IF: 2.7990 duces priming and inflammasome activa- fectiveness of Highly Sensitive Cardiac Tro-
Cedo L., Cedo L., Escola-Gil J.C., Metso J., tion leading to IL-1β release in human ponin T to Rule Out Acute Rejection after
Santos D., Sanchez-Quesada J.L., Julve J., monocytes and macrophages. (2015) BBA- Heart Transplantation. (2015) TRANSPL P, 47
Garcia-Leon A., Mora-Brugues J., Jauhiainen MOL CELL BIOL L, 1851 (11), 1442-1449. (8), 2395-2396.
M., Blanco-Vaca F., Consumption of polyun- IF: 4.7790 IF: 0.8670
saturated fat improves the saturated fatty Jackson C.E., et al., Differing prognostic value Minambres I., Sanchez-Quesada J.L., Vinagre
acid-mediated impairment of HDL antioxi- of pulse pressure in patients with heart fail- I., Sanchez-Hernandez J., Urgell E., De Leiva

Cardiovascular Biochemistry
*TIF: 58.5230 **MIF: 3.9015
A., Perez A., Hypovitaminosis D in type 2 di- accumulation promoted by electronegative Rull A., Ordonez-Llanos J., Sanchez-Quesada
abetes: Relation with features of the meta- low-density lipoprotein in cardiomyocytes J.L., The role of LDL-bound apoJ in the devel-
bolic syndrome and glycemic control. (2015) by impairing perilipin 5 upregulation. (2015) opment of atherosclerosis. (2015) CLIN LIPI-
ENDOCR RES, 40 (3), 160-165. INT J BIOCHEM CELL B, 65, 257-267. DOL, 10 (4), 321-328.
IF: 1.4760 IF: 3.9050 IF: 0.7690

Minambres I., Sanchez-Quesada J.L., Perez Rull A., Martinez-Bujidos M., Perez-Cuellar Vilchez J.A., Perez-Cuellar M., Marin F., Gal-
A., The association between hypovitamin- M., Perez A., Ordonez-Llanos J., San- lego P., Manzano-Fernandez S., Valdes M.,
osis D and metabolic syndrome: Current chez-Quesada J.L., Increased concentration Vicente V., Noguera-Velasco J.A., Lip G.Y.H.,
understanding. (2015) CLIN LIPIDOL, 10 (6), of clusterin/apolipoprotein J (apoJ) in hy- Ordonez-Llanos J., Roldan V., sST2 levels are
513-524. perlipemic serum is paradoxically associated associated with all-cause mortality in antico-
IF: 0.7690 with decreased apoJ content in lipoproteins. agulated patients with atrial fibrillation.
Revuelta-Lopez E., Cal R., Julve J., Rull A., (2015) ATHEROSCLEROSIS, 241 (2), 463-470. (2015) EUR J CLIN INVEST, 45 (9), 899-905.
Martinez-Bujidos M., Perez-Cuellar M., Or- IF: 3.9420 IF: 2.6870
donez-Llanos J., Badimon L., Sanchez-Que-
sada J.L., Llorente-Cortes V., Hypoxia wors-
ens the impact of intracellular triglyceride

ISI Web of Knowledge Indexed Publications without IF
1. Marti V., Seixo F., Leta R., Serra A. Mycotic aortic aneurysm secondary to repeated endocarditis. Revista Portuguesa De Cardiolo-
gia;30(11):863-4.
2. Martí V., García-Picart J., Carballeira L. Acute coronary syndrome due to distal embolization of a thrombus located in the left main coronary
artery. Revista Española De Cardiología;64(7):614.
3. Brugaletta S., Martin-Yuste V., Ferreira-Gonzalez I., Cola C., Alvarez-Contreras L., De Antonio M., Garcia-Moll X., Garcia-Picart J., Marti V.,
Balcells-Iranzo J., Sabate M. Adequate antiplatelet regimen in patients on chronic anti-vitamin K treatment undergoing percutaneous coro-
nary intervention. World journal of cardiology;3(11):367-73.
4. In-cycle myocardium tissue electrical impedance monitoring using broadband impedance spectroscopy. Proceedings of the annual inter-
national conference of the IEEE engineering in medicine and biology society, EMBS;2518 p.
5. Marti V., Seixo F., Leta R., Serra A. Mycotic aortic aneurysm secondary to repeated endocarditis. Revista Portuguesa De Cardiolo-
gia;30(11):863-4.
Scopus Indexed Publications
Martí V., García-Picart J., Balcells J., Cola C., Kastanis P., Sabaté M. Rescue maneuver for entrapped stent in the coronary tree. Archivos De
Cardiologia De Mexico;81(1):29-32.
Cubedo J., Padró T., García-Moll X., Pintó X., Cinca J., Badimon L. Serum proteome in acute myocardial infarction. Clinica e Investigacion En
Arteriosclerosis;23(4):147-54.
Publications
Book Chapter
Other
ff Cinca J. XVII Edition “Treaty on Internal Medicine Far-

reras-Rozman”. Chapter No 54, subsection “Electrocar-
diography”.

Angiology, Vascular Biology and Inflammation
Coordinator
Vila Navarro, Luis IR
lvila@santpau.cat
Members
Alcolea Ruiz, Sonia IR
Alonso Nieto, Judith IR
Bellmunt Montoya, Sergio FGS
Camacho Pérez de Madrid,
María Mercedes IR
Dilmé Muñoz, Jaume Fèlix FGS
Escudero Rodríguez,
José Román FGS
Gómez Jabalera, Efren FGS
Romero Carro, Josep Maria Cardiovascular Research Cancer Research
Siguero Martin, Laura IR ff Inflammatory mechanisms involved in ff Role of inflammatory mediators in head
Solá Font, Olga IR
of Research
vascular disorders. and neck squamous carcinoma and in

Main Lines
regulating gene expression in tumour re-

ff Genetic basis of vascular pathologies: lapse.
atherothrombosis, aortic aneurism and
chronic venous insufficiency.
ff New, more effective targets. Research into
pharmacologic targets for NSAIDs of car-
diovascular interest.
ff Increase cooperation between clinicians ff Improve research quality in terms of stan-

and experimental researchers to enhance dard evaluation indexes.
Challenges
the translation level of our research by set-

ting up training programmes for clinical
physicians.
ff Increase funding sources by establishing
collaborations with the industrial sector.
Collaborations with other IIB Sant Pau ff General and Digestive Surgery (Eduard
Groups Targarona and Carmen Balagué).
ff Ear, Nose and Throat Cancers (Xavier León, External Collaborations

Jacinto Gracía and Miquel Quer).
Collaborations
ff Genomics of Complex Diseases (José Ma-

ff Dr Mercedes Salaices. Pharmacology Group,
nuel Soria, PI). Universidad Autónoma de Madrid, Spain.
ff Thrombosis and Haemostasis (Juan Carlos

ff Dr Juan Miguel Redondo. CNIC, Madrid,
Souto, PI). Spain.
ff Atherosclerosis and Vascular Biology (José

ff Dr Alicia García Arroyo. CNIC, Madrid, Spain.
Martínez, PI). ff Dr Francesc-Xavier Avilés-Jurado. Otorhi-
ff Inflammation and Vascular Remodelling nolaryngology Department, Hospital Uni-
(Cristina Rodríguez, PI). versitari de Tarragona Joan XXIII, ISPV, Uni-
versitat Rovira i Virgili, Tarragona, Spain.
ff Zenaida Piñeiro Aguin. Expresión de la prostaciclina sintetasa en los carcinomas de cabeza

Theses
y cuello y valor pronóstico en la respuesta a radioterapia. Universitat Autònoma de Barce-

lona. Directors: Mercedes Camacho, Xavier León, Luis Vila. Date of defense: 12 June 2015.

ff Luis Vila Navarro. Red Cardiovascular. RD12/0042/0051. Instituto ff Luis Vila Navarro. Laboratorio de Angiología, Biología Vascular
Active Grants
de Salud Carlos III. Duration: 2013-2016. €201,869.56. e Inflamación (LABVI). 2014 SGR 402. Agència de Gestió d’Ajuts
Universitaris i de Recerca. Duration: 2014-2016.
ff Luis Vila Navarro, Mercedes Camacho Pérez de Madrid. Papel
de las vías de la PGE2 y glutatión reducido/Nfr2-ARE en la hi- Note: Total amount granted to PI. It does not include indirect costs.
pervascularización asociada al aneurisma de aorta abdominal.
SAF2013-46707-R. Ministerio de Economía y Competitividad.
Duration: 2014-2016. €110.000.
*TIF: 42.2190 **MIF: 4.6910

Bellmunt-Montoya S., Escribano J.M., Dilme S., Camps-Renom P., Marti-Fabregas J., sis in patients with head and neck squamous
J., Martinez-Zapata M.J., CHIVA method for Stroke caused by a myxoma stenosing the cell carcinoma. (2015) ONCOTARGET, 6 (35),
the treatment of chronic venous insuffi- common carotid artery. (2015) J STROKE 37398-37409.
ciency. (2015) COCHRANE DB SYST REV, 6, CEREBROVASC, 24 (4), e87-e89. IF: 5.0080
CD009648-. IF: 1.5990 Rodriguez-Calvo R., Ferran B., Alonso J., Mar-
IF: 6.0350 Garcia-Redondo A.B., Briones A.M., Mar- ti-Pamies I., Aguil S., Calvayrac O., Rodriguez
Calvayrac O., Rodriguez-Calvo R., Mar- tinez-Revelles S., Palao T., Vila L., Alonso M.J., C., Martinez-Gonzalez J., NR4A receptors up-
ti-Pamies I., Alonso J., Ferran B., Aguilo S., Salaices M., C-Src, ERK1/2 and Rho kinase- -regulate the antiproteinase alpha-2 macro-
Crespo J., Rodriguez-Sinovas A., Rodriguez mediate hydrogen peroxide-induced vascu- globulin (A2m) and modulate MMP-2 and
C., Martinez-Gonzalez J., NOR-1 modulates lar contraction in hypertension: Role ofTXA2, MMP-9 in vascular smooth muscle cells.
the inflammatory response of vascular NAD(P)H oxidase andmitochondria. (2015) J (2015) THROMB HAEMOSTASIS, 113 (6),
smooth muscle cells by preventing NFκB HYPERTENS, 33 (1), 77-87. 1323-1334.
activation. (2015) J MOL CELL CARDIOL, 80, IF: 5.0620 IF: 5.2550
34-44. Guerrero N.A., Camacho M., Vila L., Iniguez Sola-Villa D., Dilme J.-F., Rodriguez C., Soto B.,
IF: 4.8740 M.A., Chillon-Marinas C., Cuervo H., Poveda Vila L., Escudero J.-R., Martinez-Gonzalez J.,
Camacho M., Pineiro Z., Alcolea S., Garcia J., C., Fresno M., Girones N., Cyclooxygenase-2 Camacho M., Expression and cellular local-
Balart J., Terra X., Aviles-Jurado F.-X., Soler M., and prostaglandin E<inf>2</inf> signaling ization of 15-hydroxy-prostaglandin-dehy-
Quer M., Leon X., Vila L., Prostacyclin-syn- through prostaglandin receptor EP- 2 favor drogenase in abdominal aortic aneurysm.
thase expression in head and neck carci- the development of myocarditis during (2015) PLOS ONE, 10 (8).
noma patients and its prognostic value in acute trypanosoma cruzi infection. (2015) IF: 3.0570
the response to radiotherapy. (2015) J PLOS NEGLECT TROP D, 9 (8).
PATHOL, 235 (1), 125-135. IF: 3.9480
IF: 7.3810 Leon X., Bothe C., Garcia J., Parreno M., Al-
Cortes-Vicente E., Delgado-Mederos R., Bell- colea S., Quer M., Vila L., Camacho M., Expres-
munt S., Borras X.F., Gomez-Anson B., Bague sion of IL-1α correlates with distant metasta-

Molecular Pathology and Therapeutic of

Ischaemic and Atherothrombotic Diseases
Coordinator
Badimon Maestro, Lina ICCC
lbadimon@csic-iccc.org
Members
Aledo Zamora, Rosa ICCC
Arderiu Marqués, Gemma ICCC
Azorín Ortuño, Maria ICCC
Bejar Serrano, Maria Teresa ICCC
Borrell Pagès, Maria ICCC
Camino López, Sandra ICCC
Casani Arazo, Laura ICCC
Chiva Blanch, Gemma ICCC
Crespo Asensio, Javier ICCC
Cubedo Rafols, Judit ICCC
ff Physiopathological role of LRP family pro- ff Vascular impact of ischaemia and angio-
of Research
Main Lines
teins in chronic diseases. genesis in heart disease. Cell therapy.

De la Torre Tovar, Raquel ICCC
Deya Vidal, Alba ICCC ff Identification and characterization of tran- ff Research into new targets to inhibit the
Escate Chávez, Rafael ICCC scription factors and genetic targets. Role transformation of silent atherosclerosis
Espinosa Ferrer, Sonia ICCC of lipids and inflammation. into ischaemic syndromes: tissue-factor-
mediated angiogenic switch.
Ferrer Lorente, Raquel ICCC
Florit Carbonell, Sergi ICCC
Juan Babot, Josep Oriol ICCC
Lambert Goitia, Carmen ICCC
López Bernal, Sergio ICCC
ff Broaden the experimental focus to include ff Maintain present scientific networks and
Challenges
transgenic animal models with/without establish new multidisciplinary collabo-

Serra Pascual, Selma ICCC
cardiovascular risk factors in order to pro- rations.
Vilahur Garcia, Gemma ICCC ceed to in-depth analysis of molecules in-
volved in the modulation of new proteins
ff Increase international funding for the ex-
identified by post-genomic technologies tension of new and established platforms
and systems biology approaches. in order to implement proposed activities.
ff Lina Badimon. Doctor Honoris Causa. ff Lina Badimon, Gemma Vilahur. Car-
Carol Davila University of Medicine and dioshield: Prevenció de la lesió per reper-
Pharmacy. fusió. Second Award. VALORTEC (concurs
de plans de negoci de patents i empreses
ff Lina Badimon, Judit Cubedo. Finalista. Se-
Awards
de base tecnològica). Projecte ACCIÓ.

gundo Concurso de Innovación en Salud Generalitat de Catalunya.
de Vall d’Hebron Institut de Recerca (VHIR).
ff Lina Badimon, Judit Cubedo. Apo J-Glyc
POC device in myocardial ischemia. 1a
Convocatoria CaixaImpulse Innovation for
Society. Fundació ”la Caixa”.
ff Ilaria Ramaiola. Thombus composition Directors: Lina Badimon, Gemma Arderiu.

in acute coronary syndrome. Universitat Date of defense: 20 July 2015.
Pompeu Fabra. Directors: Lina Badimon,
Raquel de la Torre Tovar. Mecanismos de
Theses
ff
Teresa Padró. Date of defense: 24 March
2015. inflamación y trombosis: papel de la pro-
teina C-reactiva y de la proteina 78 regu-
ff Sonia Espinosa Ferrer. Neovascularización lada por glucosa. Universitat de Barcelona.
mediada por factor tisular en la placa at- Director: Lina Badimon.
erosclerótica. Universidad de Barcelona.

Collaborations with other IIB Sant Pau Groups ff Centro Laparoscópico Doctor Ballesta SLU, Barcelona (Carlos Ba-
llesta-López).
ff Clinical and Translational Cardiology (PI: Juan Cinca).
ff Fundación Jiménez Díaz, Madrid (Rodrigo Alonso, Pedro Mata).
ff Biomarkers for Cardiovascular Disease (PI: Teresa Padró).
ff Cell Therapy Network (TerCel), RD12/0019.
ff Cerebrovascular Diseases (PI: Joan Martí Fábregas).
ff Cardiovascular Research Network (RIC), RD12/0042.
ff Endocrinology, Diabetes and Nutrition (PI: Alberto de Leiva).
ff Programa Emprenedoria Corporativa de ACCIÓ (MEDIGENIUM
Collaborations
ff Pharmacological Research in Humans (PI: Rosa M. Antonijoan). SL, february 2015).
National Collaborations International Collaborations

ff Department of Internal Medicine, Hospital Clínic, Barcelona (R. ff Experimental, Diagnostic and Speciality Medicine, University of
Estruch). Bologna, Bologna, Italy (Raffaele Bugiardini).
ff Department of Cardiology, Thorax Institute, Hospital Clínic, Uni- ff School of Healthcare Science, John Dalton Building, Manchester
versity of Barcelona (Salvatore Brugaletta, Victoria Martín-Yuste, Metropolitan University, UK (Mark Slevin).
Clarissa Cola, Manel Sabaté).
ff Atherothrombosis Research Unit, Zena and Michael A. Wiener Car-
ff Quirúrgica Cirujanos Asociados (Alberto Díez-Caballero). diovascular Institute, Mount Sinai School of Medicine, New York,
ff Department of Plastic Surgery, Centro Médico Teknon, Barcelona USA (Juan José Badimon).
(Fabrizio Moscatiello, Javier Herrero). ff Department of Clinical Biochemistry and Immunohematology, Fac-
ulty of Health Sciences, University of Talca, Chile (Ivan Palomo).
ff Lina Badimon Maestro. Safer and faster evidence-based trans- Health Research Projects. ISCIII-FIS PI12/02332. Duration: Jan
lation (SAFE-T). European Commission IMI_Call_2008_1_05. 2013-Dec 2015.
115003, IMI-JU. Duration: Sept 2009-June 2015.
ff Lina Badimon Maestro. Cell Therapy Network (TerCel). Carlos III
ff Lina Badimon Maestro, Gemma Vilahur Garcia. Biomarker for Health Institute. RD12/0019/0026. Duration: Jan 2013-Dec 2016.
cardiovascular risk assessment in Europe (BiomarCaRe). FP7–
European Commission HEALTH-2011. GA 278913. Duration: Oct
ff Lina Badimon Maestro. Cardiovascular Research Network (RIC).
2011-Oct 2015. Carlos III Health Institute. RD12/0042/0027. Duration: Jan 2013-
Dec 2016.
Active Grants
ff Lina Badimon Maestro. Search of new targets to inhibit the trans-

formation of silent atherosclerosis into ischemic syndromes: tis-
ff Lina Badimon Maestro. Ajuts de suport als Grups de Recerca de
sue factor mediated angiogenic switch. National Plan for Scien- Catalunya. AGAUR 2014. SGR 1303. Duration: Jan 2014-Dec 2016.
tific and Technical Research and Innovation. SAF2013-42962-R. ff Lina Badimon Maestro. Exploring the mechanisms involved in
Duration: Jan 13-Dec 2016. ticagrelor®-related acute cardioprotection. Do they translate into
ff Gemma Vilahur Garcia. Functional and molecular effects of dif- a better remodeling process and improved cardiac performance
ferent HDL forms in myocardial remodelling post-infarction: at long-term? Astra Zeneca AB. Duration: Jan 2015-June 2016.
application of a systems biology approach to identify regulated ff Lina Badimon Maestro. Transcriptomic profile of cardiac markers
genes and gene products. National Plan for Scientific and Tech- and endothelial function in humans: effect from the moderate
nical Research and Innovation. SAF2012-40208. Duration: Jan consumption of beer. Beer and Health Information Centre (CICS).
2013-Dec 2015. Duration: Nov 2013-Mar 2016.
ff Gemma Arderiu Marqués. Peripheral vascular disease and an-
giogenesis: role of tissue factor in the stabilization of neovessels.
*TIF: 216.5510 **MIF: 5.8527

Adler Y., Charron P., Imazio M., Badano L., Zamorano J.L., Aboyans V., Badimon L., erides and an increase of HDL in familial
Baron-Esquivias G., Bogaert J., Brucato A., Baumgartner H., Bax J.J., Dean V., Erol C., Fit- hypercholesterolemia patients. (2015) REV
Gueret P., Klingel K., Lionis C., Maisch B., zimons D., Gaemperli O., Kirchhof P., Lip ESP CARDIOL, 68 (4), 305-309.
Mayosi B., Pavie A., Ristic A.D., Tenas M.S., G.Y.H., Nihoyannopoulos P., Ponikowski P., IF: 4.5960
Seferovic P., Swedberg K., Tomkowski W., Roffi M., Torbicki A., Carneiro A.V., Windecker Arderiu G., Peña E., Badimon L. Angiogenic
Achenbach S., Agewall S., Al-Attar N., Ferrer S., 2015 ESC Guidelines for the diagnosis and microvascular endothelial cells release mi-
J.A., Arad M., Asteggiano R., Bueno H., Cafo- management of pericardial diseases. (2015) croparticles rich in tissue factor that pro-
rio A.L.P., Carerj S., Ceconi C., Evangelista A., EUR HEART J, 36 (42), 2921-2964. motes postischemic collateral vessel forma-
Flachskampf F., Giannakoulas G., Gielen S., IF: 15.0640 tion. (2015) ARTERIOSCLEROSIS,
Habib G., Kolh P., Lambrinou E., Lancellotti P., Aledo R., Padro T., Mata P., Alonso R., Badi- THROMBOSIS AND VASCULAR BIOLOGY,
Lazaros G., Linhart A., Meurin P., Nieman K., mon L., Rs11613352 polymorphism (TT Ge- 35(2), 348-357.
Piepoli M.F., Price S., Roos-Hesselink J., notype) associates with a decrease of triglyc- IF: 6.0100

Molecular Pathology and Therapeutic of

Ischaemic and Atherothrombotic Diseases
*TIF: 216.5510 **MIF: 5.8527
Badimon L., Vilahur G., Neutrophil extracel- Fernandez-Lozano I., Pan M., Padial L.R., San- San Roman JÁ, Sanchez PL, Sanchis J; Sionis
lular traps: A new source of tissue factor in chez P.L., Roman A.S., de Diego J.J.G. Group A. Comments on the 2015 ESC Guidelines for
atherothrombosis. (2015) EUR HEART J, 36 Author(s): SEC SECTCV Working Grp ESC the Diagnosis and Management of Pericar-
(22), 1364-1366. EACTS 2; Expert Reviewers ESC EACTS 2014 dial Diseases. A Report by the Spanish Soci-
IF: 15.0640 Gu; SEC Clinical Practice Guidelines C, Com- ety of Cardiology Guidelines Committee
Badimon L., Onate B., Vilahur G., Adipose-de- ments on the 2014 ESC/EACTS Guidelines Working Group, (2015) REVISTA ESPAÑOLA
rived mesenchymal stem cells and their re- on Myocardial Revascularization. (2015) RE- DE CARDIOLOGIA 68 (12): 1068-1074.
parative potential in ischemic heart disease. VISTA ESPAÑOLA DE CARDIOLOGIA, 68 (2), IF: 4.5960
(2015) REV ESP CARDIOL, 68 (7), 599-611. 92-97. Hoefer I.E., Steffens S., Ala-Korpela M., Back
IF: 4.5960 IF: 4.5960 M., Badimon L., Bochaton-Piallat M.-L., Bou-
Barrabes J.A., Cequier A., Bueno H., Gonzalez Costales P., Fuentes-Prior P., Castellano J., langer C.M., Caligiuri G., Dimmeler S., Egido
A., Fernandez-Ortiz A., Lidon R.M., Marin F., Revuelta-Lopez E., Corral-Rodriguez M.A., J., Evans P.C., Guzik T., Kwak B.R., Landmesser
Sanchis J., Sionis A., Hernandez J.M.D., Vinas Nasarre L., Badimon L., Llorente-Cortes V., K U., Mayr M., Monaco C., Pasterkamp G.,
J.A., Abu-Assi E., Sole, A.A., Castro O.D., domain CR9 of low density lipoprotein (LDL) Tunon J., Weber C., Novel methodologies for
Gutierrez J.L.F., Lledo A.G., Gil I.N., Roubin receptor-related protein 1 (LRP1) is critical biomarker discovery in atherosclerosis.
S.R., Rodriguez-Palomares J.F., Tejedor A.V., for aggregated LDL-induced foam cell for- (2015) EUR HEART J, 36 (39), 2635-2642.
Balcones D.V., Anguita M., Cequier A., Al- mation from human vascular smooth mus- IF: 15.0640
fonso F., Badimon L., Lozano I.F., de Diego cle cells. (2015) J BIOL CHEM, 290 (24), Lara-Pezzi E., Menasche P., Trouvin J.-H., Badi-
J.J.G., Padial L.R., Romn J.A., Sanchez P.L. 14852-14865. mon L., Ioannidis J.P.A., Wu J.C., Hill J.A., Koch
Comments on the 2015 ESC Guidelines for IF: 4.2580 W.J., De Felice A.F., de Waele P., Steenwinckel
the management of acute coronary syn- Cubedo J., Padro T., Pena E., Aledo R., For- V., Hajjar R.J., Zeiher A.M., Guidelines for
dromesin patients presenting without per- miga F., Ferrer A., Padros G., Badimon L., High Translational Research in Heart Failure.
sistent ST-segment elevation, (2015) RE- Levels of Antifibrinolytic Proteins Are Found (2015) ADV DATA ANAL CLASSI, 9 (1), 3-22.
VISTA ESPAÑOLA DE CARDIOLOGIA 68 (12): in Plasma of Older Octogenarians With Car- IF: 1.7070
1061-1067. diovascular Disease and Cognitive Decline. Lopez-Sendon J., Gonzalez-Juanatey J.R.,
IF: 4.5960 (2015) J AM COLL CARDIOL, 65 (24), 2667- Pinto F., Cuenca Castillo J., Badimon L., Dal-
Borrell-Pages M., Romero J.C., Badimon L., 2669. mau R., Gonzalez Torrecilla E., Lopez-Min-
Cholesterol modulates LRP5 expression in IF: 17.7590 guez J.R., Maceira A.M., Pascual-Figal D., Po-
the vessel wall. (2015) ATHEROSCLEROSIS, Cubedo J., Padro T., Garcia-Arguinzonis M., mar Moya-Prats J.L., Sionis A., Zamorano J.L.,
235 (2), 363-370. Vilahur G., Minambres I., Pou J.M., Ybarra J., Quality Markers in Cardiology. Main Markers
IF: 3.9420 Badimon L., A novel truncated form of apoli- to Measure Quality of Results (Outcomes)
Borrell-Pages M., Carolina Romero J., Badi- poprotein A-I transported by dense LDL is and Quality Measures Related to Better Re-
mon L., LRP5 and plasma cholesterol levels increased in diabetic patients. (2015) J LIPID sults in Clinical Practice (Performance Met-
modulate the canonical Wnt pathway in pe- RES, 56 (9), 1762-1773. rics). INCARDIO (Indicadores de Calidad en
ripheral blood leukocytes. (2015) IMMUNOL IF: 4.3680 Unidades Asistenciales del Área del Co-
CELL BIOL, 93 (7), 653-661. De Gonzalo-Calvo D., Lopez-Vilaro L., Na- razón): A SEC/SECTCV Consensus Position
IF: 4.4730 sarre L., Perez-Olabarria M., Vazquez T., Es- Paper. (2015) REV ESP CARDIOL, 68 (11),
cuin D., Badimon L., Barnadas A., Lerma E., 976-995e10.
Bugiardini R., Dorobantu M., Vasiljevic Z., IF: 4.5960
Kedev S., Knezevic B., Milicic D., Calmac L., Llorente-Cortes V., Intratumor cholesteryl
Trninic D., Daullxhiu I., Cenko E., Ricci B., ester accumulation is associated with hu- Marín F, Sánchez PL, Cortina JM, Robles JA,
Puddu P.E., Manfrini O., Koller A., Badimon L., man breast cancer proliferation and aggres- Jiménez D, Lecumberri R, Recalde ÁS, Sionis
Unfractionated heparin-clopidogrel combi- sive potential: A molecular and clinicopatho- A, Abu-Assi E, Freire RB, Iglesias FC, Doblas JJ,
nation in ST-elevation myocardial infarction logical study. (2015) BMC CANCER, 15 (1), de Sa y Areses EL, Moreiras JM, Marzal D, de
not receiving reperfusion therapy. (2015) IF: 3.2650 Isla LP, Schilling VR, Anguita M, Badimon L,
ATHEROSCLEROSIS, 241 (1), 151-156. De Gonzalo-Calvo D., Cenarro A., Mar- Barrabés JA, Cequier Á, Comín J, Lozano IF,-
IF: 3.9420 tinez-Bujidos M., Badimon L., Bayes-Genis A., deDiego JJ, Pan M, Román JA, Sánchez PL.
Ordonez-Llanos J., Civeira F., Llorente-Cortes SEC Working Group for the ESC 2014 Guide-
Calvayrac O., Rodriguez-Calvo R., Mar- lines on the Diagnosis and Management of
ti-Pamies I., Alonso J., Ferran B., Aguilo S., V., Circulating soluble low-density lipopro-
tein receptor-related protein 1 (sLRP1) con- Acute Pulmonary Embolism; Expert Review-
Crespo J., Rodriguez-Sinovas A., Rodriguez ers for theESC 2014 Guidelines on the Diag-
C., Martinez-Gonzalez J., NOR-1 modulates centration is associated with hypercholes-
terolemia: A new potential biomarker for nosis and Management of Acute Pulmonary
the inflammatory response of vascular Embolism; SEC Clinical Practice Guidelines

smooth muscle cells by preventing NFκB atherosclerosis. (2015) INT J CARDIOL, 201,
20-29. Committee. Comments on the 2014 ESC
activation. (2015) J MOL CELL CARDIOL, 80, Guidelines on the diagnosis and manage-
34-44. IF: 4.6380
ment of acute pulmonary embolism, (2015)
IF: 4.8740 Guindo J, Anguita M, Alonso J, Aznar J, Pas- REVISTA ESPAÑOLA DE CARDIOLOGIA (En-
Cequier A., Maroto J.L., Alfonso F., Barrabes J., cual JF, Ruiz MDM, Ordonez B, Quiles J, Vaz- glish ed.) 68(1):10-16.
Canovas S., Carnero M., Fernandez-Ortiz A., quez G, EsquiviasGB, Alonso VB, Sales JC, IF: 4.5960
Sabate M., Sanchis J., Reyes G., Alegria E., Loban CFG, Martinez JMG, Marimon XGM,
Borreguero LJ, Gorostiza EL, Romero FL, Marti-Fabregas J., Delgado-Mederos R., Cre-
Aros F., Cuenca J., Diaz J., Lidon R.M., Gude spo J., Pena E., Marin R., Jimenez-Xarrie E.,
M.J.L., Lozano I., Ruiz-Noda J.M., de la Torre Cubero AP, Vera TR, Fernandez JAR, Anguita
M, Cequier A, Alfonso F, Badimon L, Bar- Fernandez-Arcos A., Perez-Perez J., Mar-
J.M., Pan M., Sanchez-Recalde A., Anguita M., tinez-Domeno A., Camps-Renom P., Prats-
Badimon L., Barrabes J., Cequier A., Comin J., rabesJA, Lozano IF, de Diego JJG, Padial LR,

*TIF: 216.5510 **MIF: 5.8527

Sanchez L., Casoni F., Badimon L., Circulating low-density lipoprotein in cardiomyocytes mon L., Growing thrombi release increased
endothelial progenitor cells and the risk of by impairing perilipin 5 upregulation. (2015) levels of CD235a+ microparticles and de-
vascular events after ischemic stroke. (2015) INT J BIOCHEM CELL B, 65, 257-267. creased levels of activated platelet-derived
PLOS ONE, 10 (4), IF: 3.9050 microparticles. Validation in ST-elevation
IF: 3.0570 Roffi M., Patrono C., Collet J.-P., Mueller C., myocardial infarction patients. (2015) J
Padro T., Vilahur G., Sanchez-Hernandez J., Valgimigli M., Andreotti F., Bax J.J., Borger THROMB HAEMOST, 13 (10), 1776-1786.
Hernandez M., Antonijoan R.M., Perez A., M.A., Brotons C., Chew D.P., Gencer B., Hasen- IF: 5.5650
Badimon L., Lipidomic changes of LDL in fuss G., Kjeldsen K., Lancellotti P., Land- Vilahur G., Padro T., Casani L., Mendieta G.,
overweight and moderately hypercholester- messer U., Mehilli J., Mukherjee D., Storey Lopez J.A., Streitenberger S., Badimon L.,
olemic subjects taking phytosterol- and R.F., Windecker S., Baumgartner H., Gaem- Polyphenol-enriched diet prevents coronary
omega-3-supplemented milk. (2015) J LIPID perli O., Achenbach S., Agewall S., Badimon endothelial dysfunction by activating the
RES, 56 (5), 1043-1056. L., Baigent C., Bueno H., Bugiardini R., Carerj Akt/eNOS pathway. (2015) REV ESP CAR-
IF: 4.3680 S., Casselman F., Cuisset T., Erol C., Fitzsimons DIOL, 68 (3), 216-225.
Pallares J., Senan O., Guimera R., Vernet A., D., Halle M., Hamm C., Hildick-Smith D., IF: 4.5960
Aguilar-Mogas A., Vilahur G., Badimon L., Huber K., Iliodromitis E., James S., Lewis B.S., Vilahur G., Cubedo J., Padro T., Casani L.,
Sales-Pardo M., Cito S., A comprehensive Lip G.Y.H., Piepoli M.F., Richter D., Rosemann Mendieta G., Gonzalez A., Badimon L., Intake
study on different modelling approaches to T., Sechtem U., Steg P.G., Vrints C., Zamorano of cooked tomato sauce preserves coronary
predict platelet deposition rates in a perfu- J.L., Guía ESC 2015 sobre el tratamiento de endothelial function and improves apolipo-
sion chamber. (2015) SCI REP-UK, 5, los síndromes coronarios agudos en protein A-I and apolipoprotein J protein
IF: 5.2280 pacientes sin elevación persistente del seg- profile in high-density lipoproteins. (2015)
mento ST: Grupo de Trabajo de la Sociedad TRANSL RES, 166 (1), 44-56.
Pena E., Arderiu G., Badimon L., Protein disul- Europea de Cardiología (ESC) para el tratam-
phide-isomerase A2 regulated intracellular IF: 4.5570
iento de los síndromes coronarios agudos
tissue factor mobilisation in migrating hu- en pacientes sin elevación persistente del Vilahur G., Badimon L., Biological actions of
man vascular smooth muscle cells. (2015) segmento ST. (2015) REV ESP CARDIOL, 68 pentraxins. (2015) VASC PHARMACOL, 73,
THROMB HAEMOSTASIS, 113 (4), 891-902. (12), 1125e1-1125e64. 38-44.
IF: 5.2550 IF: 4.5960 IF: 2.5000
Ramaiola I., Padro T., Pena E., Juan-Babot O., Sambri I., Crespo J., Aguilo S., Ingrosso D., Windecker S., Kolh P., Alfonso F., Collet J.-P.,
Cubedo J., Martin-Yuste V., Sabate M., Badi- Rodriguez C., Gonzalez J.M., MiR-17 and -20a Cremer J., Falk V., Filippatos G., Hamm C.,
mon L., Changes in thrombus composition target the neuron-derived orphan recep- Head S.J., Juni P., Kappetein A.P., Kastrati A.,
and profilin-1 release in acute myocardial tor-1 (NOR-1) in vascular endothelial cells. Knuuti J., Landmesser U., Laufer G., Neu-
infarction. (2015) EUR HEART J, 36 (16), 965- (2015) PLOS ONE, 10 (11), mann F.-J., Richter D.J., Schauerte P., Uva
975. IF: 3.0570 M.S., Stefanini G.G., Taggart D.P., Torracca L.,
IF: 15.0640 Valgimigli M., Wijns W., Witkowski A., Zamo-
Slevin M., Matou S., Zeinolabediny Y., Corpas rano J.L., Achenbach S., Baumgartner H., Bax
Revuelta-Lopez E., Cal R., Herraiz-Martinez R., Weston R., Liu D., Boras E., Di Napoli M.,
A., de Gonzalo-Calvo D., Nasarre L., Roura S., J.J., Bueno H., Dean V., Deaton C., Erol C.,
Petcu E., Sarroca S., Popa-Wagner A., Love S., Fagard R., Ferrari R., Hasdai D., Hoes A.W.,
Galvez-Monton C., Bayes-Genis A., Badimon Font M.A., Potempa L.A., Al-Baradie R., Sanfe-
L., Hove-Madsen L., Llorente-Cortes V., Hy- Kirchhof P., Lancellotti P., Linhart A., Nihoyan-
liu C., Revilla S., Badimon L., Krupinski J., nopoulos P., Piepoli M.F., Ponikowski P.,
poxia-driven sarcoplasmic/endoplasmic re- Monomeric C-reactive protein - A key mole-
ticulum calcium ATPase 2 (SERCA2) down- Sirnes P.A., Tamargo J.L., Tendera M., Torbicki
cule driving development of Alzheimer’s A., Pepper J., Anyanwu A., Badimon L., Bau-
regulation depends on low-density disease associated with brain ischaemia?
lipoprotein receptor-related protein 1 ersachs J., Baumbach A., Beygui F., Bonaros
(2015) SCI REP-UK, 5, N., De Carlo M., Dobrev D., Dunning J., Eeck-
(LRP1)-signalling in cardiomyocytes. (2015) J IF: 5.2280
MOL CELL CARDIOL, 85, 25-36. hout E., Gielen S., Luckraz H., Mahrholdt H.,
IF: 4.8740 Suades R., Padro T., Badimon L., The Role of Montalescot G., Paparella D., Rastan A.J.,
Blood-Borne Microparticles in Inflammation Sanmartin M., Sergeant P., Silber S., Ten Berg
Revuelta-Lopez E., Cal R., Julve J., Rull A., and Hemostasis. (2015) SEMIN THROMB HE- J., Thiele H., Van Geuns R.J., Wagner H.-O.,
Martinez-Bujidos M., Perez-Cuellar M., Or- MOST, 41 (6), 590-606. Wassmann S., Wendler O., Clinical practice
donez-Llanos J., Badimon L., Sanchez-Que- IF: 3.5050 guidelines of the ESC on myocardial revas-
sada J.L., Llorente-Cortes V., Hypoxia wors- cularization, 2014. (2015) REV ESP CARDIOL,
ens the impact of intracellular triglyceride Suades R., Padro T., Vilahur G., Martin-Yuste
V., Sabate M., Sans-Rosello J., Sionis A., Badi- 68 (2), 144.e-144.e.
accumulation promoted by electronegative IF: 4.5960
ff Cubedo J, Padró T, Badimon L. Author reply. (2015) TRANSLA- ff Vilahur G, Gutierrez M, Casani L, Cubedo J, Capdevila A, Pons-L-
TIONAL RESEARCH, 165(2), 363-364. ladó G, Carreras F, Hidalgo A, Badimon L. Hypercholesterolemia
Publications
abolishes high-density lipoproteins-related cardioprotective ef-

ff De Gonzalo-Calvo D, Llorente-Cortés V, Orbe J, Páramo JA, Badi-
Other
fects in myocardial infarction. (2015) JOURNAL OF THE AMERI-

mon L. High triglyceride-low HDL cholesterol lipid profile is as- CAN COLLEGE OF CARDIOLOGY, Dec 1, 66(21), 2469-2470.
sociated with a dysregulated gene expression in mononuclear
leukocyte from hypercholesterolemic patients. (2015) INTERNA-
TIONAL JOURNAL OF CARDIOLOGY, 178, 02-104.

Inflammation and Vascular Remodelling
Coordinator
Rodríguez Sinovas, Cristina ICCC
crodriguezs@csic-iccc.org
Members
Aguiló Núñez, Silvia
Galán Arroyo, María IR
Segalés Aguilar, Estefanía ICCC
ff Inflammation and vascular remodelling: regulation of vascular homeostasis by extracellu-

lar matrix components and modifying enzymes.
of Research
Main Lines
ff Molecular and cellular mechanisms in atherosclerosis: identification of new therapeutic

targets.
ff Molecular basis of abdominal aortic aneurysm (AAA): new pharmacological strategies.
ff Epigenetics in cardiovascular diseases.
ff Identify new therapeutic targets, progres- ff Expand and consolidate the scientific staff.
sion markers and biomarkers in athero-
Challenges
sclerosis and AAA.

ff Increase regular funding through national
and international calls.
ff Establish genetically modified animal
models that could become useful disease
ff Set up new stable collaborations within
models in atherosclerosis and AAA. IIB Sant Pau and with national and inter-
national groups and consolidate those al-
ready established.
Collaborations with other IIB Sant Pau ff José Manuel Redondo. Centro Nacional de
Groups Investigaciones Cardiovasculares (Spain).
ff Jesús Egido. Fundación Jiménez Díaz (Ma-
ff Angiology, Vascular Biology and Inflam- drid, Spain).
mation (PI: Luis Vila).
ff Jesús Osada. CIBEROBN, Universidad de
ff Regulation of Cardiac Rhythm and Con- Zaragoza (Spain).
traction (PI: Leif Hove-Madsen).
ff Manel Vázquez Carrera. CIBERDEM, Uni-
ff Atherosclerosis and Vascular Biology (PI:
Collaborations
versitat de Barcelona (Spain)

José Martínez González).
ff Mercedes Salaices. Universidad Autóno-
ma de Madrid (Spain).
External Collaborations
ff Victoria Cachofeiro. Universidad Com-
ff Jain K. Mukesh. Case Western Reserve plutense de Madrid (Spain).
University School of Medicine (Cleveland,
Ohio, USA). ff Francisco Marín. Department of Cardiol-
ogy, Hospital Clínico Universitario Virgen
ff Mark Slevin. Manchester Metropolitan de la Arrixaca, Murcia (Spain).
University (United Kingdom).
ff Jerzy Krupinski. Hospital Mútua Univer-
ff Nadia Mercader. Universidad de Berna sitària de Terrassa (Barcelona, Spain).
(Switzerland).
ff Francisco Sánchez. Hospital de la Princesa
ff Vicente Andrés. Centro Nacional de Inves- (Madrid, Spain).
tigaciones Cardiovasculares (Spain).

Cristina Rodríguez Sinovas. Mecanismos epigenéticos implica- José Martínez González. Red de Investigación Cardiovascular
Active Grants
ff ff
dos en el remodelado de la matriz extracelular asociado al an- (RIC). MINECO-ISCIII. RD12/0042/0053. Duration: 2013-2016.
eurisma de aorta abdominal: nuevas estrategias terapéuticas. €205,000.
Instituto de Salud Carlos III. PI12/01952. Duration: 2013-2015.
€153,065.
ff Mar Orriols Martins. Mecanismes de regulació de la Lisil Oxidasa ff Judith Alonso Nieto. Papel de NOR-1 en la apoptosis y el estrés
i la Fibulina-5 a nivell vascular: Implicació en la reestenosi i l’an- oxidativo: regulación de cIAP2 y la familia SOD en células muscu-
Theses
eurisma d’aorta abdominal. Universitat de Barcelona. Directors: lares lisas humanas. Universitat de Barcelona. Directors: Antonio
Antonio Rodríguez Sinovas, José Martínez González. Date of de- Rodríguez Sinovas, José Martínez González. Date of defense: 22
fense: 30 April 2015. May 2015.
ff Galan M, Varona S, Orriols M, Aguiló S, De Diego A, Navarro MA, Fibulina-5 por estímulos inflamatorios: implicación en el aneu-
Osada J, Martínez-González J, Rodríguez C. Lysyl oxidase over- risma de aorta abdominal. 3er Premio a la mejor Comunicación.
expression impacts cardiovascular remodelling. Young investi- XXVIII Congreso Nacional de la Sociedad Española de Arterio-
Awards
gator award- Basic science. 2nd World Congress on Acute Heart sclerosis. Logroño, May 2015.
Failure. Sevilla, May 2015.
ff Orriols M, Martí-Pàmies I, Guadall A, Varona S, Galán M, Escudero
JR, Camacho M, Martínez-González J, Rodríguez C. Contribución
de SOX-9 y de mecanismos epigenéticos en la inhibición de la
*TIF: 40.9480 **MIF: 5.1185

Aguado A., Rodriguez C., Martinez-Revelles Herraiz A., Álvarez-García J., Llach A., Molina Rodriguez-Calvo R., Ferran B., Alonso J., Mar-
S., Avendano M.S., Zhenyukh O., Orriols M., C.E., Fernandes J., Ferrero A., Rodríguez C., ti-Pamies I., Aguil S., Calvayrac O., Rodriguez
Martinez-Gonzalez J., Alonso M.J., Briones Vallmitjana A., Benítez R., Padró J., Martínez- C., Martinez-Gonzalez J., NR4A receptors up-
A.M., Dixon D.A., Salaices M., HuR mediates González J., Cinca J., Hove-Madsen L. Ageing -regulate the antiproteinase alpha-2 macro-
the synergistic effects of angiotensin II and is associated with deterioration of the cal- globulin (A2m) and modulate MMP-2 and
IL-1β on vascular COX-2 expression and cell cium homeostasisin isolated human right MMP-9 in vascular smooth muscle cells.
migration. (2015) BRIT J PHARMACOL, 172 atrial myocytes. (2015) CARDIOVASC RES, (2015) THROMB HAEMOSTASIS, 113 (6),
(12), 3028-3042. 106, 76-86. 1323-1334.
IF: 5.2590 IF: 5.9400 IF: 5.2550
Calvayrac O., Rodriguez-Calvo R., Mar- Miana M., Galan M., Martinez-Martinez E., Sambri I., Crespo J., Aguilo S., Ingrosso D.,
ti-Pamies I., Alonso J., Ferran B., Aguilo S., Varona S., Jurado-Lopez R., Bausa-Miranda Rodriguez C., Gonzalez J.M., MiR-17 and -20a
Crespo J., Rodriguez-Sinovas A., Rodriguez B., Antequera A., Luaces M., Martinez-Gonza- target the neuron-derived orphan recep-
C., Martinez-Gonzalez J., NOR-1 modulates lez J., Rodriguez C., Cachofeiro V., The lysyl tor-1 (NOR-1) in vascular endothelial cells.
the inflammatory response of vascular oxidase inhibitor β-aminopropionitrile re- (2015) PLOS ONE, 10 (11).
smooth muscle cells by preventing NFκB duces body weight gain and improves the IF: 3.0570
activation. (2015) J MOL CELL CARDIOL, 80, metabolic profile in diet-induced obesity in Sola-Villa D., Dilme J.-F., Rodriguez C., Soto B.,
34-44. rats. (2015) DIS MODEL MECH, 8 (6), 543-551. Vila L., Escudero J.-R., Martinez-Gonzalez J.,
IF: 4.8740 IF: 4.3160 Camacho M., Expression and cellular local-
Jover E., Marin F., Quintana M., Perez-Andreu Palomer X., Capdevila-Busquets E., Botteri ization of 15-hydroxy-prostaglandin-dehy-
J., Hurtado J.A., Rodriguez C., Martinez-Gon- G., Davidson M.M., Rodriguez C., Mar- drogenase in abdominal aortic aneurysm.
zalez J., Gonzalez-Conejero R., Valdes M., tinez-Gonzalez J., Vidal F., Barroso E., Chan (2015) PLOS ONE, 10 (8).
Hernandez-Romero D., CALU polymorphism T.O., Feldman A.M., Vazquez-Carrera M., MiR- IF: 3.0570
A29809G affects calumenin availability in- 146a targets Fos expression in human car-
volving vascular calcification. (2015) J MOL diac cells. (2015) DIS MODEL MECH, 8 (9),
CELL CARDIOL, 82, 218-227. 1081-1091.
IF: 4.8740 IF: 4.3160

Biomarkers for Cardiovascular Disease
Coordinator
Padró Campmany, Teresa ICCC
tpadro@csic-iccc.org
Members
García Arquinzonis,
Maisa Inés ICCC
Peña Sendra, Esther ICCC
Ramaiola, Ilaria ICCC
Suades Soler, Rosa ICCC
of Research
Identification of new biomarkers of atherothrombosis and ischaemic heart disease with

Main Lines
ff
potential use in diagnosis and prognosis research is based on cell culture studies, animal
models of cardiovascular disease and human samples of patients with coronary heart dis-
ease risk factors.
ff Advance research aiming to identify and ff Validate biomarkers identified in the di-
characterize new biomarkers of vascular agnosis and prognosis of cardiovascular
injury, atherothrombotic disease and/or and/or cerebrovascular disease using
ischaemic, coronary and cerebrovascu- specific quantitative techniques (confocal
lar syndromes using postgenomic tech- microscope, ELISA, multiplex assays, etc).
niques.
Challenges
ff Characterize molecular and functional

ff Generate new information on potential mechanisms for selected biomarkers in
soluble biomarkers (in serum, plasma) cardiovascular pathology (biology of sys-
and in microparticles circulating in blood, tems).
as well as in blood and/or vascular cells
studies include proteomic and lipidomic
ff Consolidate the lipidomic platform.
techniques based on liquid chromatog- ff Lead the Biobank in the SAFE-T European
raphy and bidimensional electrophoresis, project.
antibody array systems and mass spec-
trometry (MALDIToF/ToF; linear ion trap).
External Collaborations ff Member of the Local Organizing Commit-

tee of the Congress of the MLTD (Valencia,
ff Department of Cardiology, Thorax Insti- 2014).
tute, Hospital Clínic, University of Barce-
Member of the Councilor Board of the Eu-
Collaborations
ff
lona, Spain (Salvatore Brugaletta, Victoria
Martin-Yuste, Clarissa Cola, Manel Sabaté). ropean and Mediterranean League Against
Thrombotic Diseases (EMLTD) since June
ff Fundación Jiménez Díaz, Madrid (Rodrigo 2015.
Alonso, Pedro Mata).
ff Member of the Scientific Organizing Com-
ff Red TERCEL. mittee for the Annual Congress of the
Spanish Society of Thrombosis and Hae-
ff Member of IIB Sant Pau Biobank External
mostasis, Santiago de Compostela, Spain;
Committee.
2016.
ff Member of IIB Sant Pau Training Commit-
tee.
ff Ilaria Ramaiola. Thombus composition in

Theses
acute coronary syndrome. Universitat Pom-

peu Fabra. Directors: Lina Badimon, Teresa
Padró. Date of defense: 24 March 2015.

ff Teresa Padró. Qualification of Translational Safety Biomarkers ff Teresa Padró. Identificación de nuevas dianas para inhibir el de-
from Non Clinical to Early Clinical Studies: SAFE-T Project. IMI_ sarrollo de placa arteriosclerótica: abordaje traslacional en el es-
Active Grants
Call_2008_1_05 – FP7 EU. Duration: 2009-2015. tudio de la perilipina TIP47. Sociedad Española de Cardiología
(SEC). Duration: 2014-2016.
ff Teresa Padró. Biomarker For Cardiovascular Assessment in Eu-
rope (BiomarCaRE) FP7-Health-2011/ GA 278913. European ff T eresa Padró. Cell Therapy Network (TerCel). RD12/0019/0026.
Community FP7. Duration: 2011-2016. Carlos III Health Institute. Duration: Jan 2013-Dec 2016.
ff Teresa Padró. Molecular and Cellular pathology in atherosclero- ff Teresa Padró. Consolidated Research Group. AGAUR 2014 SGR
sis. Regulating role of the extracellular matrix. ISCIII. PI13/02850. 1303. Duration: Jan 2014-Dec 2016.
Duration: 2014-2016.
ff L. Badimon; J. Cubedo; T. Padró. Title: Apolipoprotein J isoforms as

patents
Active
biomarkers of organ damage. Patent Number: P201030168. Ap-

plicant: CSIC-ICCC. Country of Priority: Spain.
ff Ramaiola I, Padro T, Peña E, Juan-Babot O, Cubedo J, Martin-Yuste V, Sabaté M, Badimon L. Changes in thrombus composition and pro-
Awards
filin-1 release in acute myocardial infraction. Best published article about thrombosis and haemostasia. XXXI Congreso Nacional de la
SETH. Valencia, 22-24 October 2015.
*TIF: 80.8370 **MIF: 6.2182

Aledo R., Padro T., Mata P., Alonso R., Badi- tinez-Domeno A., Camps-Renom P., Prats- Suades R., Padro T., Vilahur G., Martin-Yuste
mon L., Rs11613352 polymorphism (TT Ge- Sanchez L., Casoni F., Badimon L., Circulating V., Sabate M., Sans-Rosello J., Sionis A., Badi-
notype) associates with a decrease of triglyc- endothelial progenitor cells and the risk of mon L., Growing thrombi release increased
erides and an increase of HDL in familial vascular events after ischemic stroke. (2015) levels of CD235a+ microparticles and de-
hypercholesterolemia patients. (2015) REV PLOS ONE, 10 (4). creased levels of activated platelet-derived
ESP CARDIOL, 68 (4), 305-309. IF: 3.0570 microparticles. Validation in ST-elevation
IF: 4.5960 Padro T., Vilahur G., Sanchez-Hernandez J., myocardial infarction patients. (2015) J
Arderiu G., Peña E., Badimon L. Angiogenic Hernandez M., Antonijoan R.M., Perez A., THROMB HAEMOST, 13 (10), 1776-1786.
microvascular endothelial cells release mi- Badimon L., Lipidomic changes of LDL in IF: 5.5650
croparticles rich in tissue factor that pro- overweight and moderately hypercholester- Vilahur G., Padro T., Casani L., Mendieta G.,
motes postischemic collateral vesselforma- olemic subjects taking phytosterol- and Lopez J.A., Streitenberger S., Badimon L.,
tion. (2015) ARTERIOSCLER THROMB VASC omega-3-supplemented milk. (2015) J LIPID Polyphenol-enriched diet prevents coronary
BIOL, 35(2), 348-57. RES, 56 (5), 1043-1056. endothelial dysfunction by activating the
IF: 6.0100 IF: 4.3680 Akt/eNOS pathway. (2015) REV ESP CAR-
Cubedo J., Padro T., Pena E., Aledo R., For- Pena E., Arderiu G., Badimon L., Protein disul- DIOL, 68 (3), 216-225.
miga F., Ferrer A., Padros G., Badimon L., High phide-isomerase A2 regulated intracellular IF: 4.5960
Levels of Antifibrinolytic Proteins Are Found tissue factor mobilisation in migrating hu- Vilahur G., Cubedo J., Padro T., Casani L.,
in Plasma of Older Octogenarians With Car- man vascular smooth muscle cells (2015) Juan-Babot O., Crespo J., Bendjama K., Law-
diovascular Disease and Cognitive Decline. THROMB HAEMOSTASIS, 113 (4), 891-902. ton M., Badimon L. Roflumilast-induced Lo-
(2015) J AM COLL CARDIOL, 65 (24), 2667- IF: 5.2550 cal Vascular Injury Is Associated with a Coor-
2669. Ramaiola I., Padro T., Pena E., Juan-Babot O., dinated Proteome and Microparticle Change
IF: 17.7590 Cubedo J., Martin-Yuste V., Sabate M., Badi- in the Systemic Circulation in Pigs. (2015)
Cubedo J., Padro T., Garcia-Arguinzonis M., mon L., Changes in thrombus composition TOXICOL PATHOL, 43-4, 569-580.
Vilahur G., Minambres I., Pou J.M., Ybarra J., and profilin-1 release in acute myocardial IF: 2.1370
Badimon L., A novel truncated form of apoli- infarction. (2015) EUR HEART J, 36 (16), 965- Vilahur G., Cubedo J., Padro T., Casani L.,
poprotein A-I transported by dense LDL is 975. Mendieta G., Gonzalez A., Badimon L., Intake
increased in diabetic patients. (2015) J LIPID IF: 15.0640 of cooked tomato sauce preserves coronary
RES, 56 (9), 1762-1773. Suades R., Padro T., Badimon L., The Role of endothelial function and improves apolipo-
IF: 4.3680 Blood-Borne Microparticles in Inflammation protein A-I and apolipoprotein J protein
Marti-Fabregas J., Delgado-Mederos R., Cre- and Hemostasis. (2015) SEMIN THROMB HE- profile in high-density lipoproteins. (2015)
spo J., Pena E., Marin R., Jimenez-Xarrie E., MOST, 41 (6), 590-606. TRANSL RES, 166 (1), 44-56.
Fernandez-Arcos A., Perez-Perez J., Mar- IF: 3.5050 IF: 4.5570

Atherosclerosis and Vascular Biology
Coordinator
Martínez González, José CSIC
jmartinez@csic-iccc.org
Members
Ferran Pérez, Beatriz ICCC
Martí Pàmies, Ingrid ICCC
Varona Álvarez, Saray ICCC
ff Identification and characterization of mas- ff Identification and validation of new tar-

ter genes involved in the onset, develop- gets for diagnosis, prognosis and treat-
of Research
Main Lines
ment and complication of ischaemic heart ment of cardiovascular diseases.

disease (IHD), abdominal aortic aneurysm
(AAA) and cardiac hypertrophy.
ff Development of new (genetically modi-
fied) animal models for IHD, AAA and car-
ff Mechanisms involving nuclear receptors diac hypertrophy.
in IHD, AAA and cardiac hypertrophy.
ff Incorporate new PhD and postdoctoral ment joint strategies to optimize resources
Challenges
students as well as staff investigators to and access to alternative funding sources.

preserve the core group and implement
new technical expertise and experimental
ff Consolidate present relationships with na-
approaches. tional collaborators and expand our interna-
tional collaborations.
ff Find affinities with other IIB Sant Pau groups
in order to increase critical mass and imple-
Collaborations with other IIB Sant Pau ff Mercedes Salaices. Universidad Autónoma
Groups de Madrid, UAM.
ff Vicente Andrés García. Centro Nacional de
ff Inflammation and Vascular Remodelling Investigaciones Cardiovasculares, CNIC.
(PI: Cristina Rodríguez).
ff Juan Miguel Redondo. Centro Nacional de
ff Angiology, Vascular Biology and Inflamma- Investigaciones Cardiovasculares, CNIC.
tion (PI: Luis Vila).
ff Victoria Cachofeiro. Universidad Com-
ff Regulation of Cardiac Rhythm and Contrac- plutense de Madrid, UCM.
tion (PI: Leif Hove-Madsen).
Collaborations
ff José Luis Martín Ventura. Fundación Jimé-

nez Díaz-UAM.
ff Francisco Sánchez Madrid. Hospital de la
ff José Luis de la Pompa. Centro Nacional de Princesa-UAM.
Investigaciones Cardiovasculares, CNIC.
ff Manuel Vázquez Carrera. Universitat de
ff Jain K. Mukesh. Case Western Reserve Uni- Barcelona.
versity School of Medicine, Cleveland.
ff Mark Slevin. Manchester Metropolitan Uni-
versity.
ff Jerzy Krupinski. Hospital Mútua Univer-
sitària de Terrassa.
ff Francisco Marín. Hospital Clínico Universi-
tario Virgen de la Arrixaca, Murcia.
ff Jesús Osada. Universidad de Zaragoza.

ff José Martínez González. Mecanismos celulares y moleculares ff José Martínez González. Red de Investigación cardiovascular
que involucran al receptor nuclear NOR-1 en enfermedades car- (RIC). MINECO-ISCIII. Grupo referencia RD12/0042/0053. Dura-
Grants
Active
diovasculares. MINECO SAF2012-40127. Duration: Jan 2013-Dec tion: Jan 2013-Dec 2016. €170,975.
2015. €169,400.
ff José Martínez González. Immunoregulatory molecules and miR- mica: papel de cIAP2. Fundación Española del Corazón (FEC) -
Awarded in
NAs as targets in coronary heart disease and acute coronary syn- Sociedad Española de Cardiología (SEC). Duration: Oct 2015-Dec
Grants
drome. Fundació La Marató de TV3. 201523 30 31. Duration: Jan 2016. €18,000.
2015
2016-Dec 2018. €300,000.

ff José Martínez González. Análisis de las propiedades anti-ap-
optóticas del receptor nuclear NOR-1 en la cardiopatía isqué-
ff Mar Orriols Martins. Mecanismes de regulació de la Lisil Oxidasa ff Judith Alonso Nieto. Papel de NOR-1 en la apoptosis y el estrés
Theses
i la Fibulina-5 a nivell vascular: Implicació en la reestenosi i l’an- oxidativo: regulación de cIAP2 y la familia SOD en células mus-
eurisma d’aorta abdominal. Universitat de Barcelona. Date of culares lisas humanas. Universitat de Barcelona. Date of defense:
defense: 30 April 2015. 22 May 2015.
ff Galan M, Varona S, Orriols M, Aguiló S, De Diego A, Navarro MA, de SOX-9 y de mecanismos epigenéticos en la inhibición de la
Osada J, Martínez-González J, Rodríguez C. Lysyl oxidase over- Fibulina-5 por estímulos inflamatorios: implicación en el aneu-
Awards
expression impacts cardiovascular remodelling. Young investi- risma de aorta abdominal. 3er Premio a la mejor Comunicación.
gator award- Basic science. 2nd World Congress on Acute Heart XXVIII Congreso Nacional de la Sociedad Española de Arterio-
Failure. Sevilla, May 2015. sclerosis. Logroño, May 2015.
ff Orriols M, Martí-Pàmies I, Guadall A, Varona S, Galán M, Escudero
JR, Camacho M, Martínez-González J, Rodríguez C. Contribución
*TIF: 40.4730 **MIF: 4.4970

Aguado A., Rodriguez C., Martinez-Revelles Jover E., Marin F., Quintana M., Perez-Andreu Rodriguez-Calvo R., Ferran B., Alonso J., Mar-
S., Avendano M.S., Zhenyukh O., Orriols M., J., Hurtado J.A., Rodriguez C., Martinez-Gon- ti-Pamies I., Aguil S., Calvayrac O., Rodriguez
Martinez-Gonzalez J., Alonso M.J., Briones zalez J., Gonzalez-Conejero R., Valdes M., C., Martinez-Gonzalez J., NR4A receptors up-
A.M., Dixon D.A., Salaices M., HuR mediates Hernandez-Romero D., CALU polymorphism -regulate the antiproteinase alpha-2 macro-
the synergistic effects of angiotensin II and A29809G affects calumenin availability in- globulin (A2m) and modulate MMP-2 and
IL-1β on vascular COX-2 expression and cell volving vascular calcification. (2015) J MOL MMP-9 in vascular smooth muscle cells.
migration. (2015) BRIT J PHARMACOL, 172 CELL CARDIOL, 82, 218-227. (2015) THROMB HAEMOSTASIS, 113 (6),
(12), 3028-3042. IF: 4.8740 1323-1334.
IF: 5.2590 Miana M., Galan M., Martinez-Martinez E., IF: 5.2550
Calvayrac O., Rodriguez-Calvo R., Mar- Varona S., Jurado-Lopez R., Bausa-Miranda Sambri I., Crespo J., Aguilo S., Ingrosso D.,
ti-Pamies I., Alonso J., Ferran B., Aguilo S., B., Antequera A., Luaces M., Martinez-Gonza- Rodriguez C., Gonzalez J.M., MiR-17 and -20a
Crespo J., Rodriguez-Sinovas A., Rodriguez lez J., Rodriguez C., Cachofeiro V., The lysyl target the neuron-derived orphan recep-
C., Martinez-Gonzalez J., NOR-1 modulates oxidase inhibitor β-aminopropionitrile re- tor-1 (NOR-1) in vascular endothelial cells.
the inflammatory response of vascular duces body weight gain and improves the (2015) PLOS ONE, 10 (11).
smooth muscle cells by preventing NFκB metabolic profile in diet-induced obesity in IF: 3.0570
activation. (2015) J MOL CELL CARDIOL, 80, rats. (2015) DIS MODEL MECH, 8 (6), 543-551.
Sola-Villa D., Dilme J.-F., Rodriguez C., Soto B.,

34-44. IF: 4.3160 Vila L., Escudero J.-R., Martinez-Gonzalez J.,
IF: 4.8740 Palomer X., Capdevila-Busquets E., Botteri Camacho M., Expression and cellular local-
Herraiz-Martinez A., Alvarez-Garcia J., Llach G., Davidson M.M., Rodriguez C., Mar- ization of 15-hydroxy-prostaglandin-dehy-
A., Molina C.E., Fernandes J., Ferrero-Gregori tinez-Gonzalez J., Vidal F., Barroso E., Chan drogenase in abdominal aortic aneurysm.
A., Rodriguez C., Vallmitjana A., Benitez R., T.O., Feldman A.M., Vazquez-Carrera M., MiR- (2015) PLOS ONE, 10 (8).
Padro J.M., Martinez-Gonzalez J., Cinca J., 146a targets Fos expression in human car- IF: 3.0570
Hove-Madsen L., Ageing is associated with diac cells. (2015) DIS MODEL MECH, 8 (9),
deterioration of calcium homeostasis in iso- 1081-1091.
lated human right atrial myocytes. (2015) IF: 4.3160
CARDIOVASC RES, 106 (1), 76-86.
IF: 5.4650

Regulation of Cardiac Rhythm and Contraction
Coordinator
Hove-Madsen, Leif CSIC
lhove@csic-iccc.org
Members
Espinosa Molina, Cristina ICCC
Gandia Sánchez, Jordi ICCC
Tarifa Lora, Carmen ICCC of Research
Receptor-mediated changes in intracellu- Effects of development and ageing on cal-

Main Lines
ff ff
lar calcium homeostasis in atrial fibrilla- cium handling in cardiac myocytes.
tion.
ff Functional effects of lipid accumulation in
ff Contribution of genetic variants to elec- cardiomyocytes.
trical remodelling and arrhythmogenesis.
The goal is to consolidate the group as a ref- ff Consolidate current national and interna-
erence in research on calcium handling in tional collaborations and establish new
atrial fibrillation and to establish it within strategic collaborations within emerg-
other lines of research by including emerging ing fields of research such as the use of
technology and fields of research. Specifically super-resolution fluorescence imaging
Challenges
we aim to: (STORM, STED-techniques), the detec-

ff Develop computational tools and models tion and role of Reactive Oxygen Species
to improve the analysis and understand- in diseased cardiomyocytes, and the role
ing of intracellular calcium handling in of telomere length in cardiac senescence
cardiac myocytes. and regeneration.
ff Incorporate emerging technology such as

ff Achieve international funding for incor-
stretching and measurements of force de- poration of scientific expertise and partic-
velopment in single cardiomyocytes. ipation in multidisciplinary international
research projects.
Collaborations with other IIB Sant Pau ff Vicente Andrés. Fisiopatología Cardiovas-
Groups cular Molecular y Genética, CNIC.
ff Ignacio Flores. Regeneración y envejeci-
ff Clinical and Translational Cardiology (PI: miento, CNIC.
Juan Cinca)
ff Leif Hove-Madsen, Researcher Collabora-
ff Lipids and Cardiovascular Pathology (PI: tor at the Red de Investigación Cardiovas-
Vicenta Lorente) cular (RIC).
Collaborations
ff Atherosclerosis and Vascular Biology (PI:

José Martínez) International Collaborations
National Collaborations ff SR Wayne Chen. Department of Physiol-

ogy and Pharmacology, University of Cal-
ff Diego Franco, Amelia Aranega. Departa- gary, Canada.
mento de Biologia Experimental, Univer- ff Glen F Tibbits. Department of Biomedical
sidad de Jaén. Physiology and Kinesiology, Simon Fraser
ff Blas Echebarria. Departament de Física University, Burnaby & Child and Family Re-
Aplicada, Universitat Politècnica de Cata- search Institute, Vancouver, Canada.
lunya. ff Edwin Moore. Cardiovascular Research
ff Raul Benitez. Enginyeria de Sistemes, Au- Group, University of British Columbia, Van-
tomàtica i Informàtica Industrial, Universi- couver, Canada.
tat Politècnica de Catalunya.

ff Leif Hove-Madsen. Identificación de factores de riesgo molecu- ff Leif Hove-Madsen. Grup de Recerca Emergent: Anàlisi i Control
Grants
Active
lares y electrofisiologicos, que conllevan un mayor riesgo de pa- del Ritme Cardíac. AGAUR 2014. SGR 1465. Duration: 2014-2017.
decer fibrilación auricular. SAF2014-58286-C2-1-R. €22,000.
*TIF: 19.7320 **MIF: 4.9330

Álvarez-García J., Ferrero-Gregori A., Puig T., Hove-Madsen L., Ageing is associated with L., Hove-Madsen L., Llorente-Cortes V., Hy-
Vázquez R., Delgado J., Pascual-Figal D., deterioration of calcium homeostasis in iso- poxia-driven sarcoplasmic/endoplasmic re-
Alonso-Pulpón L., González-Juanatey J.R., lated human right atrial myocytes. (2015) ticulum calcium ATPase 2 (SERCA2) down-
Rivera M., Worner F., Bardají A., Cinca J. A CARDIOVASC RES, 106 (1), 76-86. regulation depends on low-density
simple validated method for predicting the IF: 5.4650 lipoprotein receptor-related protein 1
risk of hospitalization for worsening of heart Hiess F., Vallmitjana A., Wang R., Cheng H., (LRP1)-signalling in cardiomyocytes. (2015) J
failure in ambulatory patients: the Redin- Ter Keurs H.E.D.J., Chen J., Hove-Madsen L., MOL CELL CARDIOL, 85, 25-36.
SCORE.; investigators of the Spanish Heart Benitez R., Chen S.R.W., Distribution and IF: 4.8740
Failure Network (REDINSCOR). (2015) EUR J function of cardiac ryanodine receptor clus-
HEART FAIL, 17(8), 818-27. ters in live ventricular myocytes. (2015) J
IF: 5.1350 BIOL CHEM, 290 (33), 20477-20487.
Herraiz-Martinez A., Alvarez-Garcia J., Llach IF: 4.2580
A., Molina C.E., Fernandes J., Ferrero-Gregori Revuelta-Lopez E., Cal R., Herraiz-Martinez
A., Rodriguez C., Vallmitjana A., Benitez R., A., de Gonzalo-Calvo D., Nasarre L., Roura S.,
Padro J.M., Martinez-Gonzalez J., Cinca J., Galvez-Monton C., Bayes-Genis A., Badimon

Lipids and Cardiovascular Pathology
Coordinator
Llorente Cortés,
Concepción Vicenta ICCC
cllorente@csic-iccc.org
Members
De Gonzalo Calvo, David IR
Revuelta Pérez, Elena ICCC
ff Molecular mechanisms involved in the ff Lipids and diabetic cardiomyopathy.

modulation of LRP1 by cardiovascular risk
factors.
ff Lipids and breast cancer.
ff Impact of LRP1 on vascular and myocar-

ff LRP1 and inflammation.
of Research
Main Lines
dial cholesterol accumulation. ff Circulating non-coding RNAs as biomark-

ff Impact of lipoproteins on LRP1-Intracellu- ers of cardiovascular disease.
lar signal pathways under normoxic and ff Role of non-coding RNAs in vascular lipid
hypoxic conditions. accumulation.
ff Alterations in LRP1 expression and ff Role of non-coding RNAs in myocardial
LRP1-intracellular signal pathways in hy- lipid accumulation.
poxia/ischaemia in in vitro and in vivo
models.
ff Develop transgenic mice with tissue-specific ff Maintain and strengthen international col-
Challenges
LRP1 modulation to proceed to in-depth laborations to set up future applications for

analysis of LRP1-dependent mechanisms. European funding.
ff Maintain and amplify relationship with IIB ff Establish collaborations with companies
Sant Pau groups regarding translation in this with the aim of developing new products
research area. useful for prognosis, diagnosis and treat-
ment.
ff Circulating microRNAs as emerging cardiac ff David de Gonzalo-Calvo. Young investiga-

biomarkers: response to acute exercise in tor fellowship 2015, European Society of
Awards
healthy subjects and implications for health Atheroclerosis.

and performance. Third place in XVII Na-
tional Sports Medicine Research Award,
Spain.
ff David de Gonzalo Calvo. Contractes “Sara tact Initiative Grant from the ESC Council on
Borrell” 2014. CD14/00109. Instituto de Basic Cardiovascular Science.
Grants
Salud Carlos III. Duration: 2015-2017.

Active

€89,598. indirect costs.
ff David de Gonzalo-Calvo. Grant of the Euro-
pean Society of Cardiology (ESC). First Con-
Theses
ff Elena Revuelta-López. Implicación del receptor LRP1 en el remodelado vascular y cardiaco.

Universitat de Barcelona. Director: Vicenta Llorente Cortés.

Collaborations with other IIB Sant Pau Groups International Collaborations

ff Cardiovascular Biochemistry (PI: Jordi Ordóñez) ff Colette Lacabanne & Valerie Samouillan. Group Physique des
Polymères, Institut Carnot, CIRIMAT, Université Paul Sabatier. Tou-
ff Regulation of Cardiac Rhythm and Contraction (PI: Leif Hove- louse, France.
Madsen)
ff Max Bown. Vascular Surgery group. Department of Cardiovascular
ff Molecular Pathology and Therapeutic of Ischaemic and Athero- Sciences University of Leicester, New England.
thrombotic Diseases (PI: Lina Badimon)
ff Fulvia Ortolani. Department of Experimental Clinical Medicine.
ff Clinical and Translational Cardiology (PI: Juan Cinca) Università degli Studi di Udine. Italy.
ff Metabolic Bases of Cardiovascular Risk (PI: Francisco Blanco) ff Gustavo Alberto Chiabrando. CIBICI-CONICET/FCQ-Universidad
ff Molecular Bases of Disease (PI: Pablo Fuentes) Nacional de Córdoba, Argentina.
ff Clinical Oncology (PI: Agustí Barnadas) ff Claudia Huesca Gómez. Departamento de Biomedina Cardiovas-
cular. Instituto Nacional de Cardiología “Ignacio Chávez”. México
Collaborations
ff Oncogenesis and Antitumour Drug (PI: Ramon Mangues) D.F.

ff Enrique Lerma (researcher of Molecular Pathology of Gineaco-
logic Cancer) Other Collaborations
ff Lluís Guirado (researcher at Fundació Puigvert) ff InnoPharma BioFarma-USEF Research Group. University of San-
tiago de Compostela.
National Collaborations ff Teresa Tarragó. Iproteos. Parc Científic. Barcelona. Spain.
ff Dr. Bayés-Genís. Grupo ICREC (Insuficiencia Cardiaca y Regener-
ación Cardiaca). Hospital Germans Trias i Pujol. Badalona.
ff Marta Casado Pinna. Unidad de Patología Médica Experimental.
Consejo Superior de Investigaciones Científicas. Valencia.
ff Francisco Tinahones. Endocrinology Department, Biomedical Re-
search Laboratory. Hospital Virgen de la Victoria, Málaga.
ff Eduardo Iglesias Gutiérrez. Grupo ITS (Intervenciones Traslaciona-
les para la Salud). Universidad de Oviedo.
ff Rocío Toro. Departamento de Medicina. Facultad de Medicina,
Universidad de Cádiz.
*TIF: 23.9440 **MIF: 3.9907

Costales P., Fuentes-Prior P., Castellano J., blor P., Casas-Agustench P., Rabadan M., Di- ticulum calcium ATPase 2 (SERCA2) down-
Revuelta-Lopez E., Corral-Rodriguez M.A., az-Martinez A.E., Ubeda N., Iglesias-Gutierrez regulation depends on low-density
Nasarre L., Badimon L., Llorente-Cortes V., K E., Circulating inflammatory miRNA signa- lipoprotein receptor-related protein 1
domain CR9 of low density lipoprotein (LDL) ture in response to different doses of aerobic (LRP1)-signalling in cardiomyocytes. (2015) J
receptor-related protein 1 (LRP1) is critical exercise. (2015) J APPL PHYSIOL, 119 (2), MOL CELL CARDIOL, 85, 25-36.
for aggregated LDL-induced foam cell for- 124-134. IF: 4.8740
mation from human vascular smooth mus- IF: 3.0040
Revuelta-Lopez E., Cal R., Julve J., Rull A.,

cle cells. (2015) J BIOL CHEM, 290 (24), De Gonzalo-Calvo D., Cenarro A., Mar- Martinez-Bujidos M., Perez-Cuellar M., Or-
14852-14865. tinez-Bujidos M., Badimon L., Bayes-Genis A., donez-Llanos J., Badimon L., Sanchez-Que-
IF: 4.2580 Ordonez-Llanos J., Civeira F., Llorente-Cortes sada J.L., Llorente-Cortes V., Hypoxia wors-
de Gonzalo-Calvo D., Lopez-Vilaro L., Nasarre V., Circulating soluble low-density lipopro- ens the impact of intracellular triglyceride
L., Perez-Olabarria M., Vazquez T., Escuin D., tein receptor-related protein 1 (sLRP1) con- accumulation promoted by electronegative
Badimon L., Barnadas A., Lerma E., Llorente- centration is associated with hypercholes- low-density lipoprotein in cardiomyocytes
Cortes V., Intratumor cholesteryl ester accu- terolemia: A new potential biomarker for by impairing perilipin 5 upregulation. (2015)
mulation is associated with human breast atherosclerosis. (2015) INT J CARDIOL, 201, INT J BIOCHEM CELL B, 65, 257-267.
cancer proliferation and aggressive poten- 20-29. IF: 3.9050
tial: A molecular and clinicopathological IF: 4.6380
study. (2015) BMC CANCER, 15 (1). Revuelta-Lopez E., Cal R., Herraiz-Martinez
IF: 3.2650 A., de Gonzalo-Calvo D., Nasarre L., Roura S.,
De Gonzalo-Calvo D., Davalos A., Montero A., Galvez-Monton C., Bayes-Genis A., Badimon
Garcia-Gonzalez A., Tyshkovska I., Gonza- L., Hove-Madsen L., Llorente-Cortes V., Hy-
lez-Medina A., Soares S.M.A., Martinez-Cam- poxia-driven sarcoplasmic/endoplasmic re-

AREA 2
Genetic, Metabolic
Inflammatory Disea
80 Genetic Diseases
82 Metabolic Bases of Cardiovascular Risk
84 Inflammatory Diseases
86 Endocrinology, Diabetes and Nutrition
92 Pituitary Gland Disorders
94 Digestive Diseases

c and
ases
98 Microbiology and Infectious Diseases
104 Multi-organ Damage
108 Chronic Respiratory Diseases
112 Research Group in HIV and AIDS

80 AREA 2 · Genetic, Metabolic and Inflammatory Diseases
Genetic Diseases
Coordinator
Baiget Bastus, Montserrat FGS
mbaiget@santpau.cat
Members
Albelo Manuel, Lissette FGS
Alias Andreu, Laura CIBERER
Baena Gimeno, Manel IR
Barceló Rubira,
Maria Jesús FGS
Benítez Amaro, Aleyda CIBERER
Cornet Ciurana, Mònica FGS
Del Rio Conde, Elisabeth FGS
Domènech Maria,
Montserrat
ff Study of the clinical heterogeneity of ge- 3. Analysis of free circulating tumor DNA
netic autosomal recessive transmission of (cfDNA) as a predictor of response to the
Gallano Petit, Maria Pia FGS
waist dystrophy and autosomal dominant treatment of breast cancer.
González Quereda, transmission.
Lidia CIBERER ff Pharmacogenetics: adverse reactions to
Iturbe Ferreiro,
ff Spinal atrophy and SMN genes: medications.
Ana Isabel FGS 1. Studies of molecular pathology, disease ff Congenital coagulopathies: molecularpa-
Lasa Laborde, mechanisms and SMN gene expression. thology of haemophilias.
Adriana Maria FGS 2. Identification of modifying genes. Duchenne and Becker muscular dystro-
of Research
ff
Main Lines
Moron López, Sara FGS phy: molecular pathology of DMD gene.

3. Study of biomarkers for validation pro-
Riera Armengol, Pau FGS cessing in spinal muscular atrophy.
Rodríguez Fernández,
4. Study of the neuromuscular junction in
María José FGS
human development.
Salazar Blanco, Juliana CIBERER
Sebio García, Ana IR ff Hereditary breast cancer and BRCA muta-
Sullivan, Ivana Gabriela IR tions:
Vencesla Garcia, Adoración IR 1. Identification of mutations and genetic
variants.
2. Molecular characterization of Circulat-
ing tumor cells (CTCSS) through expres-
sion profiles in patients with breast cancer.
Pharmacogenetics Hereditary Breast/Ovarian Cancer

ff Colorectal and lung cancer treatments. ff DNA studies to classify DNA variants
found in the BRCAs genes as pathogenic
ff Chronic inflammatory disease treatment. or neutral.
ff HIV infection treatment. ff CTCs as prognostic markers in patients
with locally advanced and disseminated
Muscular Dystrophies breast cancer.
Challenges
ff Post-transcriptional regulation of the dys-

ff Workflow development for the analysis
trophin gene using nonsense-mediated of BRCA1 and BRCA2 genes by NGS tech-
decay analysis in DNA from patients with niques.
Duchenne muscular dystrophy.
Hereditary Motor Neurone Diseases
ff Genes associated with new phenotypic
forms of limb girdle muscular dystrophy. ff Development of neuromuscular junction
ff Workflow development for the analysis of studies in health and disease.
DMD gene by NGS techniques. ff Broadening of the spectrum of motor neu-
ron diseases to include bulbar and spinal
muscular atrophy, distal muscular atro-
phies and amyotrophic lateral sclerosis.

AREA 2 · Genetic, Metabolic and Inflammatory Diseases 81
ff Ana Sebio García. Young Investigator Award. Gastrointestinal

Awards
Group of the European Organisation for Research and Treate-

ment of Cancer.
ff Maria Pia Gallano Petit. Elaboración de paneles de diagnóstico ff David Paez López-Bravo. Estudio farmacogenético fase II ran-
molecular en patología monogénica hereditaria mediante el sis- domizado para evaluar eficacia y seguridad del esquema FOL-
Active Grants
tema de nanofluidos y secuenciación masiva. PI11/02586. Insti- FIRI con altas dosis de irinotecán (FOLFIRIAD) en pacientes con
tuto de Salud Carlos III. Duration: 2012-2016. €78,250. cáncer colorrectal metastásico de acuerdo con el genotipo
UGT1A 1. EC11-336. Ministerio de Sanidad y Política Social. Dura-
ff Montserrat Baiget Bastus. Servei de Genètica. 2014 SGR 403. tion: 2015-2016. 13,965.97 €.
Agència de Gestió d’Ajuts Universitaris i de Recerca. Duration:
2014-2016. Note: Total amount granted to PI. It does not include indirect costs.
ff Ana Sebio García. Contratos Juan Rodés 2014. JR14/00006. Insti-

tuto de Salud Carlos III. Duration: 2015-2018. €135,000.
ff Lidia González Quereda. Implementación de la secuenciación masiva en el estudio de las Miopatías Congénitas y los Síndromes Mi-
Awarded
asténicos congénitos: un modelo de investigación traslacional en enfermedades raras. FMM 2015. Fundación Mutua Madrileña. Dura-
in 2015
Grants
tion: 2015-2017. €74,200.

*TIF: 43.8040 **MIF: 3.9822

Boza-Moran M.G., Martinez-Hernandez R., Juan-Mateu J., Gonzalez-Quereda L., Rodri- repair genes: Genomic predictors of com-
Bernal S., Wanisch K., Also-Rallo E., Le Heron guez M.J., Baena M., Verdura E., Nascimento plete response after capecitabine-based
A., Alias L., Denis C., Girard M., Yee J.-K., Tiz- A., Ortez C., Baiget M., Gallano P., DMD muta- chemoradiotherapy in locally advanced rec-
zano E.F., Yanez-Munoz R.J., Decay in survival tions in 576 dystrophinopathy families: A tal cancer. (2015) PHARMACOGENOMICS J,
motor neuron and plastin 3 levels during step forward in genotype-phenotype cor- 15 (1), 77-83.
differentiation of iPSC-derived human mo- relations. (2015) PLOS ONE, 10 (8). IF: 3.7840
tor neurons. (2015) SCI REP-UK, 5. IF: 3.0570 Stintzing S., Zhang W., Heinemann V., Neure-
IF: 5.2280 Loureiro Amigo J., Gallardo Vigo E., Gallano iter D., Kemmerling R., Kirchner T., Jung A.,
Gaya J.M., Palou J., Rosales A., Maroto P., P., Grau-Junyent J.M., Dysferlinopathy mas- Folwaczny M., Yang D., Ning Y., Sebio A.,
Sullivan I., Villavicencio H., Is there a limit for querading as a refractory polymyositis. Stremitzer S., Sunakawa Y., Matsusaka S.,
the laparoscopic approach of a retroperito- (2015) MED CLIN-BARCELONA. Yamauchi S., Loupakis F., Cremolini C., Fal-
neal residual mass postchemotherapy?. IF: 1.2670 cone A., Lenz H.-J., Polymorphisms in genes
(2015) ACTAS UROL ESP. Martin-Blanco A., Ferrer M., Soler J., Arranz involved in EGFR turnover are predictive for
IF: 0.9640 M.J., Vega D., Bauza J., Calvo N., Elices M., cetuximab efficacy in colorectal cancer.
Gaya J.M., Palou J., Pena J.A., Rosales A., Ma- Sanchez-Mora C., Garcia-Martinez I., Salazar (2015) MOL CANCER THER, 14 (10), 2374-
roto P., Sullivan I., Villavicencio H., Is there a J., Ribases M., Carmona C., Prat M., Pascual 2381.
limit for the laparoscopic approach of a J.C., An exploratory association study of the IF: 5.5790
retroperitoneal residual masspostchemo- influence of noradrenergic genes and child- Vieitez I., Gallano P., Gonzalez-Quereda L.,
therapy?. (2015) ACTAS UROL ESP, 39 (4), hood trauma in Borderline Personality Disor- Borrego S., Marcos I., Millan J.M., Jairo T., Prior
264-267. der. (2015) PSYCHIAT RES, 229 (1-2), 589-592. C., Molano J., Trujillo-Tiebas M.J., Gallego-
IF: 0.9640 IF: 2.4660 Merlo J., Garcia-Barcina M., Fenollar M., Na-
Geva R., Vecchione L., Kalogeras K.T., Jensen Pare-Brunet L., Sebio A., Salazar J., Berengu- varro C., Mutational spectrum of Duchenne
muscular dystrophy in Spain: Study of 284
B.V., Lenz H.-J., Yoshino T., Paez D., Montagut er-Llergo A., Rio E., Barnadas A., Baiget M.,
C., Souglakos J., Cappuzzo F., Cervantes A., Paez D., Genetic variations in the VEGF path- cases. (2015) NEUROLOGIA.
Frattini M., Fountzilas G., Johansen J.S., Hog- way as prognostic factors in metastatic col- IF: 1.7900
dall E.V., Zhang W., Yang D., Yamazaki K., orectal cancer patients treated with ox-
Nishina T., Papamichael D., Vincenzi B., Mac- aliplatin-based chemotherapy. (2015)
arulla T., Loupakis F., De Schutter J., Spindler PHARMACOGENOMICS J, 15 (5), 397-404.
K.L.G., Pfeiffer P., Ciardiello F., Piessevaux H., IF: 3.7840
Tejpar S., FCGR polymorphisms and cetuxi- Sebio A., Barnadas A., Salazar J., Paez D., Be-
mab efficacy in chemorefractory metastatic renguer-Llergo A., Del Rio E., Tobena M.,
colorectal cancer: An international consor- Martin-Richard M., Sullivan I., Targarona E.,
tium study. (2015) GUT, 64 (6), 921-928. Balart J., Baiget M., EGFR ligands and DNA
IF: 14.9210

Metabolic Bases of Cardiovascular Risk
Coordinator
Blanco Vaca, Francisco FGS
fblancova@santpau.cat
Members
Cedo Gine, Lidia CIBERDEM
Errico, Laura Teresa IR
Escolá Gil, Juan Carlos IR
Garcia Leon, Annabel IR
Julve Gil, Josep IR
Martín Campos, Jesús Maria IR
Martínez Figueroa,
Susana FGS
Méndez Lara,
Karen Alejandra IR
ff HDL and susceptibility to diabetes, arterio- ff Positive health effects of phytosterols.
sclerosis and breast cancer: this relation-
of Research
Pérez Pérez, Antonio FGS

Main Lines
ship is being analysed through the study

ff Development, validation and application
Quesada Vázquez, Helena IR of metabolic disorders, genetic modifica- of new clinical laboratory methods in
Roig Martínez, Rosa FGS tion, and dietary or drug intervention. the field of metabolic and cardiovascular
Ruiz Nogales, Sheila IR medicine.
ff Genetic determinants of metabolic factors
Santos Palacios, of cardiovascular risk: dyslipidaemia, type
David CIBERDEM 2 diabetes, hyperhomocysteinaemia.
ff Analyse the effects of diabetes mellitus ff Study anti-cancer mechanisms of HDL ge-
and hyperhomocysteinaemia in reverse netic modification and phytosterol con-
cholesterol transport in vivo. sumption.
Challenges
ff Determine the pathogenic relevance of ff Develop new molecular techniques to

alterations in cholesterol metabolism in diagnose metabolic inherited diseases to
diabetic retinopathy. be used in the clinical laboratory.
ff Compare the effects of niacine and feno-
fibrate in the HDL of patients with type 2
diabetes.
ff Juan Carlos Escolá Gil. Estrategias terapéu- ff Karen Alejandra Méndez Lara. Estratègies
ticas y nutricionales basadas en la mejora terapèutiques i nutricionals basades en la
de las funciones antioxidante y antiinflam- millora de les funcions antioxidant i antiin-
atoria de las HDL en la diabetes mellius flamatòria de les lipoproteïnes d’alta den-
tipo 2 y el cáncer de mama. PI12/00291. sitat (HDL) en la diabetis tipus 2 i el càncer
Instituto de Salud Carlos III. Duration: de mama. 2014 FI00171. Agència de
2013-2016. €164,000. Gestió d’Ajuts Universitaris i de Recerca.
Duration: 2014-2017. €39,306.
ff Laura Teresa Errico. Contrato FIS Pre-Doc
Active Grants
Formación. FI12/00226. Instituto de Salud ff Francisco Blanco Vaca. Avances en el

Carlos III. Duration: 2012-2016. €85,200. diagnóstico molecular de pacientes con
dislipemias hereditarias, con especial re-
ff Josep Julve Gil. Contratos Miguel Servet ferencia a la base poligénica de algunas
2013 - Tipo I. MS13/00070. Instituto de de ellas y a la hipercolesterolemia familiar.
Salud Carlos III. Duration: 2014-2019. PI14/01648. Instituto de Salud Carlos III.
€202,500. Duration: 2015-2017. €76,500.
ff Josep Julve Gil. Molecular studies of Note: Total amount granted to PI. It does not include
monogenic familial dyslipemias and con- indirect costs.
struction of a diagnostic/prognosis crite-
ria in mutation-negative patients with fa-
milial hypercholesterolemia. CP13/00070.
Instituto de Salud Carlos III. Duration:
2014-2016. €121,500.

ff Juan Carlos Escolá Gil. Evaluación de nuevos biomarcadores de

las funciones cardioprotectoras de las HDL en pacientes con
Awarded
in 2015
Grants
diabetes mellitus y en estudios de intervención farmacológica.

IR15-P5. Institut de Recerca de l’Hospital de la Santa Creu i Sant
Pau. Duration: 2015-2016. €33,000.
*TIF: 35.3700 **MIF: 3.2155

Cedo L., Cedo L., Escola-Gil J.C., Metso J., Spanish Interdisciplinary Committee for Car- Revuelta-Lopez E., Cal R., Julve J., Rull A.,
Santos D., Sanchez-Quesada J.L., Julve J., diovascular Disease Prevention and the Martinez-Bujidos M., Perez-Cuellar M., Or-
Garcia-Leon A., Mora-Brugues J., Jauhiainen Spanish Society of Cardiology position donez-Llanos J., Badimon L., Sanchez-Que-
M., Blanco-Vaca F., Consumption of polyun- statement on dyslipidemia management. sada J.L., Llorente-Cortes V., Hypoxia wors-
saturated fat improves the saturated fatty Differences between the European and ens the impact of intracellular triglyceride
acid-mediated impairment of HDL antioxi- American guidelines. (2015) REV ESP SALUD accumulation promoted by electronegative
dant potential. (2015) MOL NUTR FOOD RES, PUBLIC, 89 (1), 15-26. low-density lipoprotein in cardiomyocytes
59 (10), 1987-1996. IF: 0.6060 by impairing perilipin 5 upregulation. (2015)
IF: 4.5510 Masana L., Cabre A., Heras M., Amigo N., INT J BIOCHEM CELL B, 65, 257-267.
Chehaibi K., Blanco-Vaca F., Cedo L., Metso J., Correig X., Martinez-Hervas S., Real J.T., As- IF: 3.9050
Palomer X., Santos D., Quesada H., Naceur caso J.F., Quesada H., Julve J., Palomer X., Rull A., Martinez-Bujidos M., Perez-Cuellar
Slimane M., Wahli W., Julve J., Vazquez-Car- Vazquez-Carrera M., Girona J., Plana N., Blan- M., Perez A., Ordonez-Llanos J., San-
rera M., Jauhiainen M., Escola-Gil J.C., PPAR- co-Vaca F., Remarkable quantitative and chez-Quesada J.L., Increased concentration
β/δ activation promotes phospholipid qualitative differences in HDL after niacin or of clusterin/apolipoprotein J (apoJ) in hy-
transfer protein expression. (2015) BIOCHEM fenofibrate therapy in type 2 diabetic pa- perlipemic serum is paradoxically associated
PHARMACOL, 94 (2), 101-108. tients. (2015) ATHEROSCLEROSIS, 238 (2), with decreased apoJ content in lipoproteins.
IF: 5.0910 213-219. (2015) ATHEROSCLEROSIS, 241 (2), 463-470.
Chehaibi K., Escola-Gil J.C., Hrira M.Y., Tra- IF: 3.9420 IF: 3.9420
belsi I., Escola-Gil J.C., Slimane M.N., Gene Minambres I., Sanchez-Quesada J.L., Vinagre
Variant and Level of IL-1β in Ischemic Stroke I., Sanchez-Hernandez J., Urgell E., De Leiva
Patients With and Without Type 2 Diabetes A., Perez A., Hypovitaminosis D in type 2 di-
Mellitus. (2015) J MOL NEUROSCI, 57 (3), abetes: Relation with features of the meta-
404-409. bolic syndrome and glycemic control. (2015)
IF: 2.3520 ENDOCR RES, 40 (3), 160-165.
Kareinen I., Cedo L., Silvennoinen R., Laurila IF: 1.4760
P.-P., Jauhiainen M., Julve J., Blanco-Vaca F., Minambres I., Sanchez-Quesada J.L., Perez
Escola-Gil J.C., Kovanen P.T., Lee-Rueckert M., A., The association between hypovitamin-
Enhanced vascular permeability facilitates osis D and metabolic syndrome: Current
entry of plasma HDL and promotes macro- understanding. (2015) CLIN LIPIDOL, 10 (6),
phage-reverse cholesterol transport from 513-524.
skin in mice. (2015) J LIPID RES, 56 (2), 241- IF: 0.7690
253. Padro T., Vilahur G., Sanchez-Hernandez J.,
IF: 4.3680 Hernandez M., Antonijoan R.M., Perez A.,
Lobos Bejarano J.M., Brotons Cuixart C., Badimon L., Lipidomic changes of LDL in
Galve E., Royo-Bordonada M.A., Alegria Ez- overweight and moderately hypercholester-
querra E., Armario P., Camafort Babkowski olemic subjects taking phytosterol- and
M., Cordero Fort A., Maiques Galan A., Man- omega-3-supplemented milk. (2015) J LIPID
tilla Morato T., Perez Perez A., Pedro-Botet J., RES, 56 (5), 1043-1056.
Villar Alvarez F., Gonzalez-Juanatey J.R., IF: 4.3680

Inflammatory Diseases
Coordinator
Juarez Rubio, Cándido FGS
cjuarez@santpau.cat
Members
Agustí Martí, Manuela FGS
Baucells de la Peña, Andrés FGS
Canto Naves, Elisabeth IR
De La Calle Martín, Oscar FGS
Julia Agulló, German FGS
Mariscal Rodriguez, Anais FGS
Martínez Carretero,
María Ángeles FGS
Martínez Martínez, Laura FGS
Moga Naranjo, Maria Esther FGS
ff The role of the natural immune system ff Mechanisms involved in immunodefi-
in the development of autoimmune and ciency.
Nieto Sachica, Juan Camilo IR
inflammatory processes.
Ortiz de Juana, Maria Àngels IR ff Study of lymphocyte subpopulations
of Research
ff Immunological response and clinical involved in chronic graft rejection in car-

Main Lines
Rubiales Robles,
Maria Victòria FGS course in immunomodulator treatment. diac posttransplant patients.
Sanz Martínez, Maria Teresa IR ff The role of autoantibodies, components
Vidal Alcorisa, Silvia IR of the adaptive immunity system, in the
Zamora Atenza, Carlos IR pathogenesis of autoimmune processes
and their use as diagnostic and prognos-
tic markers in these diseases.
ff Role of cells and molecules of the innate ff Inflammation and rejection in heart trans-
immune response in the development plantation.
and control of inflammatory processes,
in the appearance of autoimmune phe-
ff Effects of immunobiological treatments
nomena, immunodeficiencies, infections, on immunological variables.
cardiovascular diseases and development ff Analysis of the evolution of immunologi-
of tumours. cal parameters and their correlation with
Challenges
ff Role of TLR and STAT signalling in inflam- clinical response to treatment with immu-
matory diseases. nomodulators.
ff Involvement of STAT family of transcrip-

ff Effects of rituximab, tocilizamab and adali-
tion factors in response to superantigens. mumab in immunological variables and
their correlation with the clinical response
ff Study of mechanisms involved in immu- in patients with inflammatory diseases.
nodeficiency caused by alterations of the
CD8a molecule.
ff Role of perivascular adipocytes and TLR
signalling pathways in the development
of atherosclerosis.
ff Cándido Juárez Rubio. Mecanismos impli- ff Silvia Vidal Alcorisa. Estudio de la inter-
cados en la acción del rtuximab en mias- acción entre el linfocito T y plaquetas: su
tenia gravis: efecto diferencial sobre los aplicación en el desarrollo de una terapia
Active Grants
autoanticuerpos anti-AchR y ANTI-MuSK. celular para regular la respuesta inmune

PI11/00927. Instituto de Salud Carlos III. en la artritis reumatoide. PI14/00741. In-
Duration: 2012-2016. €66,500. stituto de Salud Carlos III. Duration: 2015-
2017. €41,500.
ff Cándido Juárez Rubio. Grup d’Immuno-
logia. 2014 SGR 357. Agència de Gestió Note: Total amount granted to PI. It does not include
d’Ajuts Universitaris i de Recerca. Dura- indirect costs.
tion: 2014-2016.

ff Juan C. Nieto Sachica. Caracterización de la respuesta inmune ff Eder Fredy Mateus Medina. Papel de STAT1 y STAT3 en la tole-
innata a ligandos de TLR, infecciones bacterianas y tratamiento rancia inducida por Staphylococcal enterotoxin B. Universitat
Theses
con probióticos en la cirrosis. Universitat Autònoma de Barce- Autònoma de Barcelona. Director: Cándido Juárez Rubio. Date
lona. Director: Silvia Vidal Alcorisa. Date of defense: 2 Novem- of defense: 30 November 2015.
ber 2015.
*TIF: 29.6270 **MIF: 2.9627

Barnadas M.A., Rubiales M.V., Gich I., Gelpi C., of leukocytes from ascitic fluid of patients Selva-O’Callaghan A., Trallero-Araguas E.,
Usefulness of specific anti-desmoglein 1 and with spontaneous bacterial peritonitis. Martinez M.A., Labrador-Horrillo M., Pi-
3 enzyme-linked immunoassay and indirect (2015) J LEUKOCYTE BIOL, 98 (5), 819-825. nal-Fernandez I., Grau-Junyent J.M., Juarez
immunofluorescence in the evaluation of IF: 4.1650 C., Inflammatory myopathy: Diagnosis and
pemphigus activity. (2015) INT J DERMATOL, Ortiz M.A., Diaz-Torne C., Hernandez M.V., clinical course, specific clinical scenarios and
54 (11), 1261-1268. Reina D., de la Fuente D., Castellvi I., Moya P., new complementary tools. (2015) EXPERT
IF: 1.4150 Ruiz J.M., Corominas H., Zamora C., Canto E., REV CLIN IMMU, 11 (6), 737-747.
Bravo Garcia-Morato M., Padilla-Merlano B., Sanmarti R., Juarez C., Vidal S., IL-6 blockade IF: 2.5960
Nozal P., Espino M., Juarez C., Villar L.M., reverses the abnormal STAT activation of
Lopez-Trascasa M., Laboratory guidelines for peripheral blood leukocytes from rheuma-
the diagnosis and follow-up of patients with toid arthritis patients. (2015) CLIN IMMU-
monoclonal gammopathies. (2015) REV NOL, 158 (2), 174-182.
CLIN ESP. IF: 4.0340
IF: 0.7600 Roldan C., Mirabet S., Cecilia C., Brossa V.,
Cuesta-Mateos C., Colom-Fernandez B., Por- Roig E., Martin C., Gelpi C., CD4+C-
tero-Sainz I., Tejedor R., Garcia-Garcia C., D45RO+CD25-/lowCD127+: CD4+CD45RO+C-
Concha-Garzon M.J., De Las Heras-Alonso D25hiCD127-/low Ratio in Peripheral Blood: A
M.E., Martinez M.A., Juarez C., Munoz-Calleja Useful Biomarker to Detect Cardiac Allograft
C., Autoantibodies against TIF-1-γ and Vasculopathy in Heart Transplanted Patients.
CADM-140 in Spanish patients with clinically (2015) TRANSPLANTATION, 99 (7), 1521-
amyopathic dermatomyositis (CADM): Clini- 1528.
cal significance and diagnostic utility. (2015) IF: 3.6900
J EUR ACAD DERMATOL, 29 (3), 482-489. Sanchez E., Nieto J.C., Boullosa A., Vidal S.,
IF: 3.0290 Sancho F.J., Rossi G., Sancho-Bru P., Oms R.,
Martinez-Martinez L., Martinez-Saavedra Mirelis B., Juarez C., Guarner C., Soriano G.,
M.T., Fuentes-Prior P., Barnadas M., Rubiales VSL#3 probiotic treatment decreases bacte-
M.V., Noda J., Badell I., Rodriguez-Gallego C., rial translocation in rats with carbon tetra-
de la Calle-Martin O., A novel gain-of-func- chloride-induced cirrhosis. (2015) LIVER INT,
tion STAT1 mutation resulting in basal phos- 35 (3), 735-745.
phorylation of STAT1 and increased distal IF: 4.4700
IFN-γ-mediated responses in chronic mu- Sanchez E., Soriano G., Mirelis B., Gonzalez B.,
cocutaneous candidiasis. (2015) MOL IMMU- Nieto J.C., Vidal S., Guarner-Argente C.,
NOL, 68 (2), 597-605. Juarez C., Mones J., Guarner C., Effect of
IF: 3.3750 long-term acid gastric inhibition on bacte-
Nieto J.C., Sanchez E., Romero C., Roman E., rial translocation in cirrhotic rats. (2015) EUR
Poca M., Guarner C., Juarez C., Soriano G., J GASTROEN HEPAT, 27 (5), 570-576.
Vidal S., Impaired innate immune response IF: 2.0930

Endocrinology, Diabetes and Nutrition
Coordinator
De Leiva Hidalgo, Alberto FGS
aleiva@santpau.cat
Members
Alcántara Aragon, Valeria IR
Bell Ramirez,
Olga Lidia CIBERBBN
Castilla Manjón,
María José IR
Chico Ballesteros,
Ana Isabel FGS
Corcoy Pla, Rosa FGS
Cubero Marcos, José María FGS
González Blanco, Cintia FGS
ff Endocrine neoplasms: investigation of tumour dedifferentiation mechanisms through ge-
nomic, proteomic and bioinformatic procedures.
Juárez Muriel, Fabiola IR
Karseladze, Ekaterina ff Autoimmune diabetes mellitus (classic type 1 and LADA) and gestational diabetes.
of Research
Main Lines
María María, Miguel Ángel FGS ff Telemedicine and intelligent systems for therapeutic optimization of diabetes mellitus.
Maria Marina, Borja IR
Martínez Roldan,
ff Prediction, prevention and optimization of the treatment of obesity, hyperlipidaemia, met-
abolic syndrome and complications.
María José IR
Mato Matute, ff Diabetes and endocrine disorders in pregnancy.
Eugenia CIBERBBN ff History of insulin: old and new controversies about the discovery of insulin.
Mercader Farres, Laia IR
Navarro Cano, Gemma FGS
Pérez Pérez, Antonio FGS
Pujol Jiménez, Isabel IR
ff Cintia González Blanco. Intensificación y ff Alberto de Leiva Hidalgo. Grup de Recerca
Rabassa Francisco, Georgina IR
monitorización telemática personalizada en Endocrinologia, Diabetis i Metabo-
Rivas Urbina, Andrea Patricia IR de la modificación del estilo de vida en lisme. 2014 SGR 569. Agència de Gestió
el tratamiento de la obesidad y la pre- d’Ajuts Universitaris i de Recerca. Dura-
vención del riesgo cardiometabólico. tion: 2014-2016. €50.000.
Active Grants
PI12/00931. Instituto de Salud Carlos III.

Duration: 2013-2017. €68,000.
ff Rosa Corcoy Pla. Vitamin D and Life-
style Intervention for Gestational Di-
ff Valeria Alcántara Aragón. Intensificación y abetes Mellitus (GDM) Prevention.
monitorización telemática personalizada (DALI) 7th Framework Programme, EU.
de la modificación del estilo de vida en el HEALTH-F2-2009-242187. Duration: Mar
tratamiento de la obesidad y la prevención 2010-Dec 2015. €171,920.
del riesgo cardiometabólico (PREDIRCAM
2). 2014FI00149. Agència de Gestió d’Ajuts indirect costs.
Universitaris i de Recerca. Duration: 2014-
2017. €60,465.12.
Awarded in
ff Miñambres I. Apolipoproteina J (Cluste- Española de Diabetes. Duration: Apr 2015-

rina) en la diabetes tipo 2: distribución en Aug 2016. €20,000.
Grants
2015
las fracciones lipoproteicas, efectos sobre

su funcionalidad y relación con el grado indirect costs.
de control glucémico. Beca de la Sociedad
ff Gemma Carreras González. Terapia inten-

siva en la diabetes mellitus tipo 1 desde el
debut. Efecto sobre el control glucémico
Theses
y las complicaciones tardías a los 20 años

de evolución. Universitat Autònoma de
Barcelona. Directors: Antonio Pérez, Isabel
Badell. Date of defense: November 2015.

Endocrine Neoplasms Telemedicine and Intelligent Systems for Therapeutic

Optimization of Diabetes Mellitus
ff Molecular markers of the epithelial lineage: expression of the
ABCG2 gene/BCRP1 transporter. ff Development of a technological platform for the prediction,
ff Importance of thyroglobulin and antithyroglobulin antibodies prevention and treatment of obesity, DM, HTA, dyslipidemia and
as prognostic prediction markers in differentiated thyroid cancer cardiometabolic risk.
of epithelial lineage.
Optimization of the Treatment of Obesity, Hyperlipidaemia,
ff Transcriptomics and proteomics as prediction and prognosis in-
struments for epithelial thyroid cancer. Metabolic Syndrome and Complications
ff Intramural CELL-NANO-THYROID project: investigation of human ff Optimal treatment and prevention of cardiovascular risk asso-
mesenchymal cell capacity as an instrument for administering ciated with obesity, hyperlipidaemia, metabolic syndrome and
Challenges
anti-tumour cell drugs in the form of conjugated nanoparticles. diabetes mellitus 2.
Autoimmune Diabetes Mellitus and Gestational Diabetes History of Insulin: Old and New Controversies about the
Discovery of Insulin
ff Classic type 1 autoimmune diabetes mellitus: discovery of genes
that influence susceptibility to autoimmune diabetes (classic ff To demonstrate with documented evidence (heuristics) that
type 1). European research on the development of pancreatic extracts
ff LADA type diabetes: prevalence of metabolic syndrome among achieved beneficial results in the opotherapy of both experi-
patients with LADA compared to prevalence among patients mental and clinical diabetis.
with classic type 1 diabetes, type 2 diabetes and the general non- ff Research into impaired glucose tolerance in women suffering
-diabetic population in European countries. from polycystic ovary syndrome.
ff Diabetes and pregnancy: clinical research aimed at optimizing ff Acquisition of information to help assess the clinical and socio-
care for women with pre-gestational and gestational diabetes economic relevance of cardiometabolic risk.
at different pre-conception, pregnancy, birth and postpartum
stages.
Collaborations with other IIB Sant Pau Groups ff University of Toronto, Mount Sinai Hospital, Department Endo-
crinology & Metabolism. Toronto, Canada.
ff Oncogenesis and Antitumour Drugs (Ramon Mangues).
ff Dalhousie University, Staff Endocrinologist, Department of Med-
ff Ophthalmology (Fernando Rodríguez Álvarez). icine. Halifax, Canada.
ff Cardiovascular Biochemistry (Jorge Ordóñez, José Luis Quesada, ff University of British Columbia, BC Women’s Diabetes Pregnancy
Francisco Blanco). Service. Vancouver, Canada.
ff General and Digestive Surgery (Antonio Moral, Ignacio Pérez). ff McMaster University, Endocrinology/General Internal Medicine.
Hamilton, Canada.
ff Reproductive Health (Juan Adelantado).
ff University of Ottawa, The Ottawa Hospital, Division of Endocri-
ff Metabolic Bases of Cardiovascular Risk (Francisco Blanco).
nology and Metabolism. Ottawa, Canada.
ff Sunnybrook Health Sciences Centre, Department of Endocrinol-
Collaborations
ogy. Toronto, Canada.
CIBER-BBN ff University of Western Ontario, Department of Medicine: Endocri-
nology & Metabolism. London, Ontario, Canada.
ff Bioengineering and Telemedicine Group at the Universidad Poli-
técnica de Madrid, Spain (GBT-UPM). PI: Enrique J. Gómez Agu- ff Centre de Recherche du CHUL. Unité de recherche sur le diabète.
ilera. Québec, Canada.
ff Biomedical Engineering Research Group at the Universidad de ff McGill University, Department of Medicine, Division of Endo-
Sevilla, Spain (GIB-US). PI: Laura Roa Romero. crinology & Metabolism, Metabolic Day Centre and Antenatal
Clinic. Montréal, Canada.
CELL-NANO-THYROID
ff University of Calgary, Departments of Medicine and Obstetrics &
ff Molecular Oncology Group at HVH, PI: S. Schwartz, Jr. Gynaecology. Calgary, Canada.
ff Development of New Drugs Group at the Universidad del País ff Charles H. Best Diabetes Centre. Ajax, Canada.
Vasco, Spain. PI: JL Pedraz.
ff Yale University. Diabetes Clinic. New Haven, US.
CONCEPTT: Women with Type 1 Diabetes in Pregnancy Trial
ff Tel-Aviv University. Helen Schneider Hospital for Women; Rabin
ff Sansum Diabetes Research Institute (SDRI). Santa Barbara (Cali- Medical Center. Israel
fornia) USA.


ff Universitat Autònoma de Barcelona. Hospital de la Santa Creu ff Recherche en Santé Lawson S.A. (LAWSON), Switzerland.
i Sant Pau. Servei d’Endocrinologia i Nutrició. Barcelona, Spain.
ff Katholieke Universiteit Leuven (K.U. Leuven), Belgium.
ff Health and Social Secretariat. Assembly of First Nations. Ottawa,
Canada.
ff Copenhagen University Hospital (CUH), Denmark.
ff CIHR Institute of Aboriginal Peoples’ Health. Ottawa, Canada.

ff Akademia Medyczna im Karola Marcinkowskiego (PUM), Poland.
ff Community Programs Directorate First Nations and Inuit Health

ff BAP Health Outcomes Research (S.L. BAP), Spain.
Branch. Ottawa, Canada. ff Università degli studi di Padova (UNIPD), Italy.
ff University of Western Ontario. Department of Epidemiology and ff National University of Ireland (NUI), Ireland.
Biostatistics and the Division of Endocrinology. London, Ontario,
Canada. ff Vrije Universiteit Medisch Centrum (VU), Netherlands.
ff Royal University Hospital. Department of Medicine. Saskatoon, Action LADA European Consortium
Canada.
David Leslie, Co-Ordinator, St. Bartholomew’s Hospital, UK.
Collaborations
ff
ff Sunnybrook Health Sciences Centre. Centre for Mother, Infant,
and Child Research (CMICR). Toronto, Canada.
ff Rhys Williams and Mark Airey, Nuffield Institute for Health, UK.
ff Jaeb Center for Health Research. Tampa, US.

ff Henning Beck-Nielsen, Odense University Hospital, Denmark.
ff University of Waterloo. Office of Research. Waterloo, Canada.

ff David Hadden and Stephen Hunter, Royal Victoria Hospital, UK.
ff Juvenile Diabetes Research Foundation (JDRF). Canada.

ff Umberto Di Mario, University of Rome “La Sapienza”, Italy.
ff Juvenile Diabetes Research Foundation International (JDRF). US.

ff Werner Scherbaum and Jochen Seissler, University of Dusseldorf,
Germany.
ff JDRF Lay Review Committee Members (LRC).
ff Hubert Kolb, Germany, University of Dusseldorf, Germany.
ff JDRF Canadian Clinical Trial Network (CCTN).
ff Guntram Schernthaner, Rudolfstiftung Hospital, Austria.
Vitamin D and Lifestyle Intervention for Gestational Diabetes ff Jaakko Tuomilehto and Johan Eriksson, National Public Health
Mellitus (GDM) Prevention (DALI) Inst., Finland.
ff Medizinische Universität Graz (MUG), Austria. ff Alberto de Leiva, Hospital de Sant Pau, Spain.
ff Medical Research Council (MRC), United Kingdom. ff Charles Thivolet, Hospital Edouard Herriot, France.
ff Medical University Vienna (MUV), Austria. ff Type 1 Diabet Genetics European Network (ET1DGC), Asia-Pacif-
ff University Central Hospital (HUCH), Finland. ic, North America and United Kingdom.
*TIF: 117.6560 **MIF: 5.6027

Aulinas A., Ramirez M.-J., Barahona M.-J., Va- Mahmood T., Nizard J., Savona-Ventura C., pregnancy worries in European obese preg-
lassi E., Resmini E., Mato E., Santos A., Crespo Dunne F., A proposal for the use of uniform nant women: Results from the DALI study.
I., Bell O., Surralles J., Webb S.M., Dyslipi- diagnostic criteria for gestational diabetes in (2015) BMC PREGNANCY CHILDB, 15 (1).
demia and chronic inflammation markers Europe: an opinion paper by the European IF: 2.1800
are correlated with Telomere Length short- Board & College of Obstetrics and Gynaecol- Feig D.S., Corcoy R., Jensen D.M., Kaut-
ening in Cushing’s syndrome. (2015) PLOS ogy (EBCOG). (2015) DIABETOLOGIA, 58 (7), zky-Willer A., Nolan C.J., Oats J.J.N., Sacks
ONE, 10 (3). 1422-1429. D.A., Caimari F., Mcintyre H.D., Diabetes in
IF: 3.0570 IF: 6.2060 pregnancy outcomes: A systematic review

Aulinas A., Colom C., Garcia Patterson A., Cubedo J., Padro T., Garcia-Arguinzonis M., and proposed codification of definitions.
Ubeda J., Maria M.A., Orellana I., Adelantado Vilahur G., Minambres I., Pou J.M., Ybarra J., (2015) DIABETES-METAB RES, 31 (7), 680-
J.M., de Leiva A., Corcoy R., Smoking affects Badimon L., A novel truncated form of apoli- 690.
the oral glucose tolerance test profile and poprotein A-I transported by dense LDL is IF: 3.0640
the relationship between glucose and increased in diabetic patients. (2015) J LIPID Hernandez M., Mollo A., Marsal J.R., Esquerda
HbA1c in gestational diabetes mellitus. RES, 56 (9), 1762-1773. A., Capel I., Puig-Domingo M., Pozzilli P., de
(2015) DIABETIC MED. IF: 4.3680 Leiva A., Mauricio D., Insulin secretion in pa-
IF: 3.1520 de Wit L., Jelsma J.G.M., van Poppel M.N.M., tients with latent autoimmune diabetes
Balsells M., Garcia-Patterson A., Sola I., Roque Bogaerts A., Simmons D., Desoye G., Corcoy (LADA): Half way between type 1 and type 2
M., Gich I., Corcoy R., Glibenclamide, metfor- R., Kautzky-Willer A., Harreiter J., van Assche diabetes: Action LADA 9. (2015) BMC EN-
min, and insulin for the treatment of gesta- A., Devlieger R., Timmerman D., Hill D., DOCR DISORD, 15 (1), 1-6.
tional diabetes: A systematic review and Damm P., Mathiesen E.R., Wender-Oze- IF: 1.7390
meta-analysis. (2015) BMJ-BRIT MED J, 350. gowska E., Zawiejska A., Rebollo P., Lapolla Lobos Bejarano J.M., Brotons Cuixart C.,
IF: 19.6970 A., Dalfra M.G., Del Prato S., Bertolotto A., Galve E., Royo-Bordonada M.A., Alegria Ez-
Benhalima K., Mathieu C., Damm P., Van Ass- Dunne F., Jensen D.M., Andersen L., Snoek querra E., Armario P., Camafort Babkowski
che A., Devlieger R., Desoye G., Corcoy R., F.J., Physical activity, depressed mood and M., Cordero Fort A., Maiques Galan A., Man-

*TIF: 117.6560 **MIF: 5.6027

tilla Morato T., Perez Perez A., Pedro-Botet J., Minambres I., Sanchez-Quesada J.L., Perez donez-Llanos J., Badimon L., Sanchez-Que-
Villar Alvarez F., Gonzalez-Juanatey J.R., A., The association between hypovitamin- sada J.L., Llorente-Cortes V., Hypoxia wors-
Spanish Interdisciplinary Committee for Car- osis D and metabolic syndrome: Current ens the impact of intracellular triglyceride
diovascular Disease Prevention and the understanding. (2015) CLIN LIPIDOL, 10 (6), accumulation promoted by electronegative
Spanish Society of Cardiology position 513-524. low-density lipoprotein in cardiomyocytes
statement on dyslipidemia management. IF: 0.7690 by impairing perilipin 5 upregulation. (2015)
Differences between the European and Nazare J.A., Smith J., Borel A.L., Aschner P., INT J BIOCHEM CELL B, 65, 257-267.
American guidelines. (2015) REV ESP SALUD Barter P., Van Gaal L., Tan C.E., Wittchen H.U., IF: 3.9050
PUBLIC, 89 (1), 15-26. Matsuzawa Y., Kadowaki T., Ross R., Brul- Rull A., Martinez-Bujidos M., Perez-Cuellar
IF: 0.6060 le-Wohlhueter C., Alméras N., Haffner S.M., M., Perez A., Ordonez-Llanos J., San-
Martinez-Bujidos M., Rull A., Gonzalez-Cura Balkau B., Després J.P.; INSPIRE ME IAA Inves- chez-Quesada J.L., Increased concentration
B., Perez-Cuellar M., Montoliu-Gaya L., Ville- tigators (A. Pérez). Usefulness of Measuring of clusterin/apolipoprotein J (apoJ) in hy-
gas S., Ordonez-Llanos J., Sanchez-Quesada Both Body Mass Index and Waist Circumfer- perlipemic serum is paradoxically associated
J.L., Clusterin/apolipoprotein J binds to ag- ence for the Estimation of Visceral Adiposity with decreased apoJ content in lipoproteins.
gregated LDL in human plasma and plays a and Related Cardiometabolic Risk Profile (2015) ATHEROSCLEROSIS, 241 (2), 463-470.
protective role against LDL aggregation. (from the INSPIRE ME IAA Study). (2015) AM IF: 3.9420
(2015) FASEB J, 29 (5), 1688-1700. J CARDIOL, 115(3), 307-15. Simmons D., Jelsma J.G.M., Galjaard S.,
IF: 5.2990 IF: 3.2760 Devlieger R., Van Assche A., Jans G., Corcoy
Mato E., Barcelo-Batllori S., Orera I., Selva L., Onengut-Gumuscu S., Chen W.M., Burren O., R., Adelantado J.M., Dunne F., Desoye G.,
Corra M., Gonzalez C., Bell O., Lerma E., Moral Cooper N.J., Quinlan, A.R., Mychaleckyj J.C., Harreiter J., Kautzky-Willer A., Damm P., Ma-
A., Perez J.I., de Leiva A., The proteomic 2D- Farber E., Bonnie J.K., Szpak M., Schofield E., thiesen E.R., Jensen D.M., Andersen L.L., La-
DIGE approach reveals the protein volt- Achuthan P., Guo H., Fortune M.D., Stevens polla A., Dalfra M., Bertolotto A., Wender-O-
age-dependent anion channel 2 as a poten- H., Walker N.M., Ward L.D., Kundaje A., Kellis zegowska E., Zawiejska A., Hill D., Rebollo P.,
tial therapeutic target in epithelial thyroid M., Daly M.J., Barrett J.C., Cooper J.D., De- Snoek F.J., Van Poppel M.N.M., Results from a
tumours. (2015) MOL CELL ENDOCRINOL, loukas P., Todd J.A., Wallace C., Concannon P., European multicenter randomized trial of
404, 37-45. Rich S.S., Type 1 Diabet Genetics Consortium physical activity and/or healthy eating to
IF: 3.8590 (de Leiva, Alberto). Fine mapping of type 1 reduce the risk of gestational diabetes melli-
Mato E., Puras G., Bell O., Agirre M., Hernández diabetes susceptibility loci and evidence for tus: The DALI lifestyle pilot. (2015) DIABETES
R.M., Igartua M., Moreno R., Gonzalez G., de colocalization of causal variants with lym- CARE, 38 (9), 1650-1656.
Leiva A., Pedraz J.L. Selective Antitumoral Ef- phoid gene enhancers. (2015) NATURE GE- IF: 8.9340
fect of Sorafenib Loaded PLGA Nanoparticles NETICS. Volume 47; Issiue 4: 381-UI99. Vilchez J.A., Perez-Cuellar M., Marin F., Gal-
Conjugated with Cetuximab on Undifferenti- IF: 29.3520 lego P., Manzano-Fernandez S., Valdes M.,
ated/ Anaplastic Thyroid Carcinoma Cells. Padro T., Vilahur G., Sanchez-Hernandez J., Vicente V., Noguera-Velasco J.A., Lip G.Y.H.,
(2015) J NANOMED NANOTECHNOL, 6, 3. Hernandez M., Antonijoan R.M., Perez A., Ordonez-Llanos J., Roldan V., sST2 levels are
IF: 5.7200 Badimon L., Lipidomic changes of LDL in associated with all-cause mortality in antico-
Minambres I., Sanchez-Quesada J.L., Vinagre overweight and moderately hypercholester- agulated patients with atrial fibrillation.
I., Sanchez-Hernandez J., Urgell E., De Leiva olemic subjects taking phytosterol- and (2015) EUR J CLIN INVEST, 45 (9), 899-905.
A., Perez A., Hypovitaminosis D in type 2 di- omega-3-supplemented milk. (2015) J LIPID IF: 2.6870
abetes: Relation with features of the meta- RES, 56 (5), 1043-1056.
bolic syndrome and glycemic control. (2015) IF: 4.3680
ENDOCR RES, 40 (3), 160-165. Revuelta-Lopez E., Cal R., Julve J., Rull A.,
IF: 1.4760 Martinez-Bujidos M., Perez-Cuellar M., Or-


ff Alcantara-Aragon V., Gonzalez C., Corcoy R., Ubeda J., Chico A. Pérez A., Pedro-Botet J., Villar Álvarez F., González-Juanatey J.R.;
Carbohydrate-to-Insulin Ratio in a Mediterranean Population of Spanish Interdisciplinary Committee for Cardiovascular Disease
Type 1 Diabetic Patients on Continuous Subcutaneous Insulin Prevention and the Spanish Society of Cardiology. Spanish Inter-
Infusion Therapy. (2015) JOURNAL OF DIABETES SCIENCE AND disciplinary Committee for Cardiovascular Disease Prevention
TECHNOLOGY, 9 (3), 588-92. and the Spanish Society of Cardiology Position Statement on
Dyslipidemia Management. Differences Between the European
ff Colom C., Chico A., Carreras G., Aulinas A., Pujol I., Pérez A. Con- and American Guidelines. (2015) HIPERTENS RIESGO VASC, 32(2),
trol glucémico y complicaciones crónicas a 20 años del comienzo 83-91.
de la diabetes tipo 1. Resultados de una unidad especialitzada.
(2015) AV DIABETOL, 31, 113-9. ff Menéndez Torre E., Gaztambide S., Rica I., Castaño L., Salvador
F.J., Escalada F.J., Grupo de trabajo MIPDI-1 (Chico A.I., González
ff Grupo Español de Diabetes y Embarazo (GEDE). Sociedad C.). Proyecto manejos integral en la DM tipo 1. el manejo integral
Española de Diabetes (SED), España; Sociedad Española de del paciente con diabetes mellitus tipo 1. (2015) AV DIABETOL,
Ginecología y Obstetricia (SEGO), España (Chico A., Corcoy R.). 31(1), 13-23.
Asistencia a la gestante con diabetes. Guía de práctica clínica ac-
tualizada en 2014. (2015) AV DIABETOL, 31(2), 45-59. ff Pérez A. Statin-centered treatment of dyslipidemia. New evi-
dence-based paradigm, or only part of the evidence? (2015)
Lobos Bejarano J.M., Galve E., Royo-Bordonada M.A., Alegria
Other Publications
ff
ENDOCRINOL NUTR. Pii: S1575-0922(15)00225-9. Doi:10.1016/j.
Ezquerra E., Armario P., Brotons Cuixart C., Camafort Babkowski Endonu. 2015.08.005.
M., Cordero Fort A., Maiques Galán A., Mantilla Morató T., Pérez
Pérez A., Pedro-Botet J., Villar Álvarez F., González-Juanatey J.R.; ff Pérez A., Mezquita Raya P., Ramírez de Arellano A., Briones T.,
on behalf of Comité Español Interdisciplinario de Prevención Hunt B., Valentine W.J. Cost-Effectiveness Analysis of Incretin
Cardiovascular and Sociedad Española de Cardiología. Spanish Therapy for Type 2 Diabetes in Spain: 1.8mg Liraglutide Versus
Interdisciplinary Committee for Cardiovascular Disease Preven- Sitagliptin. (2015) DIABETES THER, 6, 61-74.
tion and the Spanish Society of Cardiology Position Statement
on Dyslipidemia management: differences between the Euro-
ff Salord N., Fortuna A.M., Monasterio C., Gasa M., Pérez A., Bon-
pean and American Guidelines. (2015) SEMERGEN; 41(3), 149-57. signore M.R., Vilarrasa N., Montserrat J.M., Mayos M. A Random-
ized Controlled Trial of CPAP on Glucose Tolerance in Obese
ff Lobos Bejarano J.M., Galve E., Royo-Bordonada M.A., Alegria Ez- Patients with Obstructive Sleep Apnea. (2015) SLEEP. Pii: sp-
querra E., Armario P., Brotons Cuixart C., Camafort Babkowski M., 00651-14. [Epub ahead of print].
Cordero Fort A., Maiques Galán A., Mantilla Morató T., Pérez Pérez
A., Pedro-Botet J., Villar Álvarez F., González-Juanatey J.R.; on be-
ff Vázquez F., Barrio R., Goñi M.J., Díaz-Soto G., Simón Muela I.,
half of Comité Español Interdisciplinario de Prevención Cardio- González Blanco C., on behalf of Grupo de Nuevas Tecnologías
vascular and Sociedad Española de Cardiología. Spanish Inter- de la Sociedad Españoola de Diabetes (SED). Documento de
disciplinary Committee for Cardiovascular Disease Prevention consenso sobre el tratamiento con infusión subcutánea conti-
and the Spanish Society of Cardiology Position Statement on nua de insulina en el medio hospitalario. (2015) AV DIABETOL,
Dyslipidemia management: differences between the European 31(3), 81-88.
and American Guidelines. (2015) CLIN INVESTIG ARTERIOSCLER. ff Zafón C., Puig-Domingo M., Biarnés J., Halperin I., Bella M.R.,
27(1):36-44. Castells I., González C., Megía A., Santos L., García-Pascual L., Re-
ff Lobos Bejarano J.M., Galve E., Royo-Bordonada M.A., Alegria verter J.L., Pizarro E., Mauricio D., on behalf of Consorcio para el
Ezquerra E., Armario P., Brotons Cuixart C., Camafort Babkowski Estudio del Cáncer de Tiroides (CECaT). Registro CECaT. (2015)
M., Cordero Fort A., Maiques Galán A., Mantilla Morató T., Pérez ENDOCRINOL NUTR, 62(6), 264-269.


Pituitary Gland Disorders
Coordinator
Webb Youdale, Susan FGS
swebb@santpau.cat
Members
Aulinas Maso, Anna IR
Crespo, Iris IR
Resmini, Eugenia CIBERER
Roig Garcia, Olga IR
Santos, Alicia IR
Valassi, Elena IR
ff Morbimortality, low-grade inflammation health-related quality of life (HRQoL) in

and cardiovascular risk in patients with ac- Cushing syndrome and acromegaly.
romegaly or Cushing syndrome.
ff Study of bone microarchitecture and re-
ff ERCUSYN: European Registry on Cushing sistance and their predictors in patients
of Research
Main Lines
syndrome. Initiated with funding from with Cushing’s syndrome and acromegaly
SANCO, EU Public Health Programme. in remission. A model to investigate the
interaction between bone and body fat.
ff Neuroradiological, neuropsychological
and clinical study of endogenous hy- ff Aetiology of cardiopathy in acromegaly
percortisolism: comparison of Cushing and its relation to body composition.
syndrome and chronic major depressive
disorder.
ff Role of telomeres in endocrine diseases.
ff Validation of psychological properties

of specific questionnaires to evaluate
ff Investigate the neuropsychological, neu- (ERCUSYN), which at the end of 2013 in-
roradiological and clinical correlation cluded over 1100 patients from 57 centres
of patients with endogenous hypercor- in 36 countries.
tisolism (due to Cushing syndrome or
chronic major depressive disorder) or ex-
ff Conduct in vitro molecular analysis of op-
ogenous exposure to low-dose glucocor- erated pituitary adenomas within the RE-
ticoids (due to treatment of adrenal insuf- MAH (Molecular Registry of Pituitary Ade-
ficiency or rheumatoid arthritis). Similar nomas) study, sponsored by the Spanish
studies for acromegaly. Endocrinology and Nutrition Society.
Challenges
ff Correlate neuropsychological status and

ff Investigate correlations of telomere
circadian rhythm of cortisol in patients length and different clinical and biochem-
with hypercortisolism (Cushing syndrome) ical parameters in patients with Cushing
and without hypercortisolism (non-func- syndrome.
tioning pituitary adenomas) compared to ff Evaluate long-term morbidity and mortal-
normal controls. ity in patients who have had Cushing syn-
ff Evaluate long-term morbidity and mortal- drome or acromegaly in the last 25 years.
ity in patients who have had Cushing syn-
drome or acromegaly in the last 25 years.
ff Analyse and update the European data-
base of patients with Cushing syndrome
ff Alícia Santos. Estudio neuropsicológico, ena of early ageing and specific morbidity.
neuroradiológico y clínico en el hipercor- Director: Dra. Susan Webb. Date of de-
Theses
tisolismo endógeno. Universitat de Barce- fense: 19 June 2015.

lona. Date of defense: 15 December 2015.
ff Anna Aulinas. Investigation of the telo-
mere maintenance system in Cushing’s
syndrome: A contribution to the phenom-

ff Elena Valassi. Subprograma Juan de la Cierva 2012. JLC-2012- Cushing o acromegalia en remisión. Modelo para investigar la
13447. Ministerio de Economía y Competitividad. Duration: interacción hueso- grasa corporal. PI14/00194. Instituto de Salud
Active Grants
2013-2016. €86,400. Carlos III. Duration: 2015-2017. €91,500.

ff Susana Webb Youdale. Grup de Recerca de Malalties de la ff Susan Webb Youdale. Etiopatogenia de la cardiopatía en la acro-
Hipòfisi i Grup CIBERER 747 (CIBER de Malalties Rares). 2014 SGR megalia y su relación con la composición corporal. Merck Serono
355. Agència de Gestió d’Ajuts Universitaris i de Recerca. Dura- 2012. Duration: 04/06/12-04/06/15. €16.667.
tion: 2014-2016.
ff Susana Webb Youdale. Estudio de microarquitectura y resisten-
cia óseas y de factores que las determinan en el síndrome de
*TIF: 51.7690 **MIF: 3.5412

Andela C.D., Van Haalen F.M., Ragnarsson O., Crespo I., Webb S.M., Santos A., Webb S.M., syndrome: A DTI study. (2015) AM J NEURO-
Papakokkinou E., Johannsson G., Santos A., Quality of life in patients with hypopituitar- RADIOL, 36 (6), 1043-1048.
Webb S.M., Biermasz N.R., Van Der Wee ism. (2015) CURR OPIN ENDOCRINOL, 22 (4), IF: 3.1240
N.J.A., Pereira A.M., Cushing’s syndrome 306-312. Santos A., Crespo I., Aulinas A., Resmini E.,
causes irreversible effects on the human IF: 3.1190 Valassi E., Webb S.M., Quality of life in Cush-
brain: A systematic review of structural and ing’s syndrome. (2015) PITUITARY, 18 (2),
functional magnetic resonance imaging Denes J., Swords F., Rattenberry E., Stals K.,
Owens M., Cranston T., Xekouki P., Moran L., 195-200.
studies. (2015) EUR J ENDOCRINOL, 173 (1), IF: 3.4070
R1-R14. Kumar A., Wassif C., Fersht N., Baldeweg S.E.,
IF: 3.8920 Morris D., Lightman S., Agha A., Rees A., Santos A., Resmini E., Gomez-Anson B., Cre-
Grieve J., Powell M., Boguszewski C.L., Dutta spo I., Granell E., Valassi E., Pires P., Vives-Gila-
Aulinas A., Ramirez M.-J., Barahona M.-J., Va- P., Thakker R.V., Srirangalingam U., Thomp- bert Y., Martinez-Momblan M.A., De Juan M.,
lassi E., Resmini E., Mato E., Santos A., Crespo son C.J., Druce M., Higham C., Davis J., Eeles Mataro M., Webb S.M., Cardiovascular risk
I., Bell O., Surralles J., Webb S.M., Dyslipi- R., Stevenson M., O’Sullivan B., Taniere P., and white matter lesions after endocrine
demia and chronic inflammation markers Skordilis K., Gabrovska P., Barlier A., Webb control of Cushing’s syndrome. (2015) EUR J
are correlated with Telomere Length short- S.M., Aulinas A., Drake W.M., Bevan J.S., Preda ENDOCRINOL, 173 (6), 765-775.
ening in Cushing’s syndrome. (2015) PLOS C., Dalantaeva N., Ribeiro-Oliveira A., Garcia IF: 3.8920
ONE, 10 (3). I.T., Yordanova G., Iotova V., Evanson J., Gross-
IF: 3.0570 Vila G., Akerblad A.-C., Mattsson A.F., Riedl
man A.B., Trouillas J., Ellard S., Stratakis C.A., M., Webb S.M., Hana V., Nielsen E.H., Biller
Aulinas A., Colom C., Garcia Patterson A., Maher E.R., Roncaroli F., Korbonits M., Het- B.M.K., Luger A., Pregnancy outcomes in
Ubeda J., Maria M.A., Orellana I., Adelantado erogeneous genetic background of the as- women with growth hormone deficiency.
J.M., de Leiva A., Corcoy R., Smoking affects sociation of pheochromocytoma/paragan- (2015) FERTIL STERIL, 104 (5), 1210-1217.e1.
the oral glucose tolerance test profile and glioma and pituitary adenoma: Results from IF: 4.4260
the relationship between glucose and a large patient cohort. (2015) J CLIN EN-
HbA1c in gestational diabetes mellitus. DOCR METAB, 100 (3), E531-E541. Yoshida K., Fukuoka H., Matsumoto R., Bando
(2015) DIABETIC MED. IF: 5.5310 H., Suda K., Nishizawa H., Iguchi G., Ogawa
IF: 3.1520 W., Webb S.M., Takahashi Y., The quality of life
Graupera I., Webb S., Villanueva C., Pavel O., in acromegalic patients with biochemical
Barahona M.-J., Resmini E., Vilades D., Fer- Hernandez-Gea V., Ardevol A., Webb S., Urg- remission by surgery alone is superior to
nandez-Real J.-M., Ricart W., Moreno-Navar- ell E., Colomo A., Llao J., Concepcion M., that in those with pharmaceutical therapy
rete J.-M., Pons-Llado G., Leta R., Webb S.M., Relative adrenal insufficiency in severe acute without radiotherapy, using the newly de-
Soluble TNFα-receptor 1 as a predictor of variceal and non-variceal bleeding: Influ- veloped Japanese version of the AcroQoL.
coronary calcifications in patients after long- ence on outcomes. (2015) LIVER INT, 35 (8), (2015) PITUITARY, 18 (6), 876-883.
term cure of Cushing’s syndrome. (2015) PI- 1964-1973. IF: 3.4070
TUITARY, 18 (1), 135-141. IF: 4.4700
IF: 3.4070 Minambres I., Sanchez-Quesada J.L., Vinagre
Crespo I., Santos A., Valassi E., Pires P., Webb I., Sanchez-Hernandez J., Urgell E., De Leiva
S.M., Resmini E., Impaired decision making A., Perez A., Hypovitaminosis D in type 2 di-
and delayed memory are related with anxi- abetes: Relation with features of the meta-
ety and depressive symptoms in acromeg- bolic syndrome and glycemic control. (2015)
aly. (2015) ENDOCRINE, 50 (3), 756-763. ENDOCR RES, 40 (3), 160-165.

IF: 3.2790 IF: 1.4760
Crespo I., Valassi E., Santos A., Webb S.M. Pires P., Santos A., Vives-Gilabert Y., Webb
Health-Related Quality of Life in Pituitary S.M., Sainz-Ruiz A., Resmini E., Crespo I., De
Diseases. (2015) ENDOCRINOL METAB CLIN Juan-Delago M., Gomez-Anson B., White
NORTH AM, 44, 1, 161-170. matter alterations in the brains of patients
IF: 2.1300 with active, remitted, and cured cushing

Digestive Diseases
Coordinator
Guarner Aguilar, Carlos FGS
cguarner@santpau.cat
Members
Alvarado Tapias,
Edilmar Auxiliadora IR
Ardevol Ribalta, Alba CIBEREHD
Colán-Hernández, Juan FGS
Escuredo Rodríguez,
Bibiana FGS
Gallego Moya, Adolfo FGS
García Planella, Esther FGS
Gely Vila, Cristina IR
Gómez Oliva, Cristina FGS Experimental research ff Physiopathology, diagnosis, treatment
and prevention of digestive haemorrhage
González Juan, Dolores FGS Experimental rat model of cirrhosis and
ff due to portal hypertension of non-vari-
Gordillo Ábalos, Jorge FGS ascites. cose origin.
Guarner Argente, Carlos FGS
ff Mechanisms and prevention of bacterial ff Diagnosis and treatment of chronic hepa-
Huelin Álvarez, Patricia FGS
translocation in rats with cirrhosis. titis B and C.
Llao Guardia, Jordina IR
Experimental model of spontaneous and Diagnosis and treatment of hepatocarci-
Main Lines of Research
ff ff
Lozano Martínez,
Gloria Andrea SOL·LICITUD induced bacterial peritonitis: physiopa- noma.
thology and treatment.
Marín Sánchez, Laura IR ff Physiopathology, diagnosis and treatment
Poca Sans, Maria FGS ff MiRNAs expression profile in inflamma- of intestinal inflammatory disease (inflam-
Román Abal, Eva María IR tory bowel disease after stimulation with matory bowel disease).
Sainz Saenz-Torre, Sergio FGS toll-like receptor ligands.
ff Diagnosis and treatment in advanced gas-
Sánchez Ardid, trointestinal endoscopy.
Elisabet CIBEREHD Clinical investigation
ff Diagnosis and treatment of acute pancre-
Soriano Pastor, Germán FGS atitis.
ff Physiopathology, diagnosis, treatment
Torras Colell, Javier FGS and prevention of bacterial infections,
Villanueva Sánchez, ff Prevention of acute post-ERCP pancreatitis.
ascites and hepatorenal syndrome in cir-
Càndid FGS rhosis. ff Chronic pancreatitis and pancreatic neo-
plasms: molecular studies, early detection
ff Diagnosis and treatment of hepatic en-
and treatment.
cephalopathy in cirrhosis.
ff Cognitive impairment, falls and quality of
life in patients with cirrhosis.
ff Consolidate the CIBEREHD research group ff Consolidate the inflammatory bowel dis-
by studying complications in cirrhosis. ease research line.
Challenges
ff Expand the hepatology research lab and ff Consolidate the polyps and colon cancer
develop new research. research line.
ff Consolidate the portal hypertension re- ff Develop a digestive endoscopy research
search group. line.
ff Consolidate the pancreatic illness re-
search line.
Collaborations
ff Carlos Guarner Argente. Beca per a la in-

tensificació de la recerca de la Societat
Catalana de Digestologia (2014-2015).

ff Eva María Román Abal. Estudio del síndrome de fragilidad en los tensión portal: Estudio multicéntrico a doble-ciego. PI13/02535.
pacientes con cirrosis hepática: relación con las caídas, la calidad Instituto de Salud Carlos III. Duration: 2014-2016. €218,750.
de vida y el pronóstico. PI12/00629. Instituto de Salud Carlos III.
Duration: 2013-2016. €31,500.
ff Carlos Guarner Argente. Ensayo clínico multicéntrico, aleatori-
Active Grants
zado y doble ciego sobre el uso de antibiótico profiláctico en la

ff Càndid Villanueva Sánchez. Estudio randomizado y controlado punción por ecoendoscopia de lesiones quísticas del páncreas.
para comparar el tratamiento con anticoagulación oral con an- PI13/00609. Instituto de Salud Carlos III. Duration: 2014-2016.
tagonistas de la vitamina K versus heparina de bajo peso molec- €33,750.
ular (bemiparina) en pacientes con criterios de anticoagulación.
Conveni Rovi. Laboratoris Farmacèutics Rovi. Duration: 2012-
ff Carlos Guarner Aguilar. Estudio de las alteraciones de la barrera
2016. €6,507.11. intestinal en la cirrosis hepática. PI14/00680. Instituto de Salud
Carlos III. Duration: 2015-2017. €81,500.
ff Càndid Villanueva Sánchez. Prevención de la descompensación
de la cirrosis a largo plazo mediante el tratamiento de la hiper-
ff Càndid Villanueva Sánchez. Convocatòria d’intensificació 2015.

Awarded
IR15-INT4. Institut de Recerca de l’Hospital de la Santa Creu i Sant

in 2015
Grants
Pau. Duration: 2015-2016. €30,000.

ff Elisabet Sánchez Ardid. Modelos experimentales de peritonitis

Theses
bacteriana inducida en ratas con cirrosis y nuevas estrategias

terapéuticas. Director: Carlos Guarner. Date of defense: October
2015.
*TIF: 128.5290 **MIF: 6.1204

Alonso A., Domenech E., Julia A., Panes J., Buti M., Franco A., Carmona I., Sanchez-Ru- M., Romero M., Salmeron J., Sanchez J.,
Garcia-Sanchez V., Mateu P.N., Gutierrez A., ano J.J., Sanso A., Berenguer M., Garcia-Buey Sanchez-Ruano J.J., Sanso A., Santamaria
Gomollon F., Mendoza J.L., Garcia-Planella E., L., Hernandez-Guerra M., Morillas R.M., Le- G., Serra M.A., Serrano T., Sola R., Torras J.,
Barreiro-De Acosta M., Munoz F., Vera M., desma F., Esteban R., Aguilera V., Alonso Turnes J., Urquijo J.J., Vergara M., Vilella A.,
Saro C., Esteve M., Andreu M., Chaparro M., M.J., Alonso S., Alonso-Burgal M., Andrade Vinolo C., Profiles and clinical management
Manye J., Cabre E., Lopez-Lasanta M., Tortosa R., Anton S., Aparcero R., Artaza T., Barcena of hepatitis C patients in Spain: DisHCovery
R., Gelpi J.L., Garcia-Montero A.C., Bertran- R., Barrera P., Berenguer M., Blas J.M., Buti study. (2015) REV ESP QUIM, 28 (3), 145-
petit J., Absher D., Myers R.M., Marsal S., Gis- M., Calleja J.L., Carmona I., Casas M., Casado 153.
bert J.P., Identification of risk loci for crohn’s M., Costan G., Cuaresma M., Cuenca F., Dal- IF: 1.0140
disease phenotypes using a genome-wide mau B., Daponte S., Vaquer P., Delgado M., Calleja J.L., Pascasio J.M., Ruiz-Antoran B.,
association study. (2015) GASTROENTEROL- De La Bandera M., De La Fuente E., De La Gea F., Barcena R., Larrubia J.R., Perez-Alvarez
OGY, 148 (4), 794-805. Mata M., Devesa M.J., Diago M., Erana L.F., R., Sousa J.M., Romero-Gomez M., Sola R., de
IF: 18.1870 Escudero M., Estevez M., Fernandez-Ber- la Revilla J., Crespo J., Navarro J.M., Arenas
Buti M., Morillas R.M., Perez J., Prieto M., Sola mejo M., Fernandez A., Fernandez-Cas- J.I., Delgado M., Fernandez-Rodriguez C.M.,
R., Palau A., Diago M., Bonet L., Gallego A., troagudin J., Fernandez I., Forns X., Fraga E., Planas R., Buti M., Forns X., Anton, Arenas,
Garcia-Samaniego J., Testillano M., Rodri- Gallego A., Gallego R., Garcia-Buey M.L., Barcena, Calleja, Castellote, Castillo, Cas-
guez M., Castellano G., Gutierrez M.L., Del- Garcia I., Garcia-Samaniego J., Gely C., Gila tro-Iglesias, Cuenca-Moron, Delgado, Er-
gado M., Mas A., Romero-Gomez M., Calleja A., Gonzalez L., Gomez-Alonso M., Go- dozain, Fernandez, Ferrer, Forns, Garcia-Ben-
J.L., Gonzalez-Guirado A., Arenas J.I., Gar- mez-Rubio M., Gonzalez M., Gonzalez M.L., goechea, Garcia-Hoz, Garcia-Samaniego,
cia-Buey L., Andrade R., Gila A., Almandoz E., Gutierrez M.L., Hernandez-Guerra M., Hom- Gea, Gomez-Garcia, Gonzalez, Crespo, Lade-
Alonso M., Burgal M.A., Esteban R., Fernan- brados M., Jimenez M., JorDan T., Jorquera ro-Quesada, Larrubia-Marfil, Lens, Manzano,
dez C., Gallego R., Vila C.G., Gimenez D., Go- F., Lens S., Linares P., Lopez G., Lopez-Cep- Martinez-Sierra, Martinez, Miguel, Molina,
mez M., Garcia A.G., Gonzalez-Dieguez M.L., ero J., Lopez C., Lorente S., Manzano M.L., Monge, Munoz, Narvaez, Navarro-Jarabo,
Madejon A., Manzano M.L., Herrera I.M., Maraver A., Mera J., Miquel M., Molina C., Nunez, Olveira, Pascasio, Planas, Portu, Perez-
Navascues C.A., Planas R., Cubero J.C.P., Fer- Molina E., Montero J.L., Montoliu S., Moreno -Alvarez, de la Revilla, Rodado, Romero,
nandez I.R., Salmeron J., Sanchez-Tapias J.M., J., Moreno I., Morillas R., Olcoz J.L., Olveira Ruiz-Antoran, Ryan, Salcedo I., San-
Sotelo R., Vinaixa C., Entecavir has high effi- A., Palau A., Pardo A., Pascasio J.M., Perez J., chez-Tapias, Serra, Sola, Sousa-Martin, Tor-
cacy and safety in white patients with Pelaez G., Perez-Moreno J., Perez-Tristancho ras, Vergara, Safety and efficacy of triple
chronic hepatitis B and comorbidities. (2015) M.R., Planas R., Pons J.A., Porcel A., Povato therapy with peginterferon, ribavirin and
EUR J GASTROEN HEPAT, 27 (1), 46-54. A., Primo J., Puertas-Montenegro, Quer J.C., boceprevir within an early access pro-
IF: 2.0930 Rincon D., Rivas L., Rodriguez M., Romero gramme in Spanish patients with hepatitis C

Digestive Diseases
*TIF: 128.5290 **MIF: 6.1204
genotype 1 with severe fibrosis: SVRw12 Guarner C., Soriano G., Alterations in cere- Margall N., March F., Espanol M., Torras X.,
analysis. (2015) LIVER INT, 35 (1), 90-100. bral white matter and neuropsychology in Gallego A., Coll P., Two unusual hepatitis C
IF: 4.4700 patients with cirrhosis and falls. (2015) PLOS virus subtypes, 2j and 2q, in Spain: Identifica-
Castaño-Milla C., Chaparro M., Saro C., Bar- ONE, 10 (3). tion by nested-PCR and sequencing of a
reiro-de Acosta M., García-Albert A.M., Bu- IF: 3.0570 NS5B region. (2015) J VIROL METHODS, 223,
janda L., Martín-Arranz M.D., Carpio D., Gomez-Rubio P., Zock J.-P., Rava M., Marquez 105-108.
Muñoz F., Manceñido N., García-Planella E., M., Sharp L., Hidalgo M., Carrato A., Ilzarbe L., IF: 1.5080
Piqueras M., Calvet X., Cabriada J.L., Botella Michalski C., Molero X., Farre A., Perea J., Masip M., Tuneu L., Pages N., Torras X., Gal-
B., Bermejo F., Gisbert J.P. Effectiveness of Greenhalf W., O’Rorke M., Tardon A., Gress T., lego A., Guardiola J.M., Faus M.J., Mangues
adalimumab in perianal fistulas in crohn’s Barbera V., Crnogorac-Jurcevic T., Domin- M.A., Prevalence and detection of neuropsy-
disease patients naive to anti-TNF therapy. guez-Munoz E., Munoz-Bellvis L., Alvarez-Ur- chiatric adverse effects during hepatitis C
(2015) J CLIN GASTROENTEROL, 49(1), 34-40. turi C., Balcells J., Barneo L., Costello E., Guil- treatment. (2015) INT J CLIN PHARM-NET, 37
IF: 7.680 len-Ponce C., Kleeff J., Kong B., Lawlor R., (6), 1143-1151.
Cerini F., Gonzalez J.M., Torres F., Puente A., Lohr M., Mora J., Murray L., O’Driscoll D., Pe- IF: 1.3390
Casas M., Vinaixa C., Berenguer M., Ardevol laez P., Poves I., Scarpa A., Real F.X., Malats N., Nieto J.C., Sanchez E., Romero C., Roman E.,
A., Augustin S., Llop E., Senosiain M., Vil- Reduced risk of pancreatic cancer associated Poca M., Guarner C., Juarez C., Soriano G.,
lanueva C., de la Pena J., Banares R., Genesca with asthma and nasal allergies. (2015) GUT. Vidal S., Impaired innate immune response
J., Sopena J., Albillos A., Bosch J., Hernandez- IF: 14.9210 of leukocytes from ascitic fluid of patients
Gea V., Garcia-Pagan J.C., Impact of antico- Gordillo J., Cabré E., Garcia-Planella E., Ricart with spontaneous bacterial peritonitis.
agulation on upper-gastrointestinal bleed- E., Ber-Nieto Y., Márquez L., Rodríguez-Mo- (2015) J LEUKOCYTE BIOL, 98 (5), 819-825.
ing in cirrhosis. A retrospective multicenter ranta F., Ponferrada A., Vera I., Gisbert J.P., IF: 4.1650
study. (2015) HEPATOLOGY, 62 (2), 575-583. Barrio J., Esteve M., Merino O., Muñoz F., Robles-Diaz M., Garcia-Cortes M., Medina-
IF: 11.7110 Domènech E.; ENEIDA Project of the Spanish Caliz I., Gonzalez-Jimenez A., Gonzalez-
Derikx M.H., Kovacs P., Scholz M., Masson E., Working Group in Crohn’s Disease and Ulcer- Grande R., Navarro J.M., Castiella A., Zapata
Chen J.-M., Ruffert C., Lichtner P., Te Morsche ative Colitis (GETECCU). Thiopurine Therapy E.M., Romero-Gomez M., Blanco S., Soriano
R.H.M., Cavestro G.M., Ferec C., Drenth J.P.H., Reduces the Incidence of Colorectal Neopla- G., Hidalgo R., Ortega-Torres M., Clavijo E.,
Witt H., Rosendahl J., Berg T., Bodeker H., sia in Patients with Ulcerative Colitis. Data Bermudez-Ruiz P.M., Lucena M.I., Andrade
Bluher M., Bruno M.J., Buch S., Bugert P., from the ENEIDA Registry. (2015) J CROHNS R.J., The value of serum aspartate
Cichoz-Lach H., Dabrowski A., Farre A., Frank COLITIS, 9(12), 1063-70. aminotransferase and gamma-glutamyl
J., Gasiorowska A., Geisz A., Goni E., Grothaus IF: 6.585 transpetidase as biomarkers in hepatotoxic-
J., Grutzmann R., Haas S., Hampe J., Heller- Graupera I., Webb S., Villanueva C., Pavel O., ity. (2015) LIVER INT, 35 (11), 2474-2482.
brand C., Hegyi P., Huster D., Ioana M., Ior- Hernandez-Gea V., Ardevol A., Webb S., Urg- IF: 4.4700
dache S., Jurkowska G., Keim V., Landt O., Di ell E., Colomo A., Llao J., Concepcion M., Sanchez E., Nieto J.C., Boullosa A., Vidal S.,
Leo M., Lerch M.M., Levy P., Lohr M.J., Macek Relative adrenal insufficiency in severe acute Sancho F.J., Rossi G., Sancho-Bru P., Oms R.,
M., Malats N., Malecka-Panas E., Mariani A., variceal and non-variceal bleeding: Influ- Mirelis B., Juarez C., Guarner C., Soriano G.,
Martorana D., Mayerle J., Mora J., Mossner J., ence on outcomes. (2015) LIVER INT, 35 (8), VSL#3 probiotic treatment decreases bacte-
Muller S., Ockenga J., Paderova J., Pedrazzoli 1964-1973. rial translocation in rats with carbon tetra-
S., Pereira S.P., Pfutzer R., Real F.X., Rebours V., IF: 4.4700 chloride-induced cirrhosis. (2015) LIVER INT,
Ridinger M., Rietschel M., Rohde K., Sack S., Gustot T., Fernandez J., Garcia E., Morando F., 35 (3), 735-745.
Saftoiu A., Schneider A., Schulz H.-U., Soyka Caraceni P., Alessandria C., Laleman W., Tre- IF: 4.4700
M., Simon P., Skipworth J., Stickel F., Stumvoll bicka J., Elkrief L., Hopf C., Solis-Munoz P.,
M., Testoni P.A., Tonjes A., Treiber M., Weiss Sanchez E., Soriano G., Mirelis B., Gonzalez B.,
Saliba F., Zeuzem S., Albillos A., Benten D., Nieto J.C., Vidal S., Guarner-Argente C.,
F.U., Werner J., Wodarz N., Polymorphisms at Montero-Alvarez J.L., Chivas M.T., Concep-
PRSS1-PRSS2 and CLDN2-MORC4 loci asso- Juarez C., Mones J., Guarner C., Effect of
cion M., Cordoba J., Mccormick A., Stauber long-term acid gastric inhibition on bacte-
ciate with alcoholic and non-alcoholic R., Vogel W., de Gottardi A., Welzel T.M.,
chronic pancreatitis in a European replica- rial translocation in cirrhotic rats. (2015) EUR
Domenicali M., Risso A., Wendon J., Deulofeu J GASTROEN HEPAT, 27 (5), 570-576.
tion study. (2015) GUT, 64 (9), 1426-1433. C., Angeli P., Durand F., Pavesi M., Gerbes A.,
IF: 14.9210 IF: 2.0930
Jalan R., Moreau R., Gines P., Bernardi M., Ar-
Fernandez J., Aracil C., Sola E., Soriano G., royo V., Clinical Course of acute-on-chronic Small A.J., Sutherland S.E., Hightower J.S.,
Cinta Cardona M., Coll S., Genesca J., Hom- liver failure syndrome and effects on prog- Guarner-Argente C., Furth E.E., Kochman
brados M., Morillas R., Martin-Llahi M., Pardo nosis. (2015) HEPATOLOGY, 62 (1), 243-252. M.L., Forde K.A., Bewtra M., Falk G.W., Gins-
A., Sanchez J., Vargas V., Xiol X., Gines P., IF: 11.7110 berg G.G., Comparative risk of recurrence of
Evaluation and treatment of the critically ill dysplasia and carcinoma after endoluminal
Lens S., Mensa L., Gambato M., Gonzalez P., eradication therapy of high-grade dysplasia
cirrhotic patient. (2015) GASTROENT HEPAT- Torras X., Soriano G., Costa J., Capon A., Lon-
BARC. versus intramucosal carcinoma in Barrett’s
dono M.-C., Marino Z., Navasa M., Perez- esophagus. (2015) GASTROINTEST ENDOSC,
IF: 0.8000 -del-Pulgar S., Forns X., HEV infection in two 81 (5), 1158-1166.e4.
Gomez-Anson B., Roman E., De Bobadilla referral centers in Spain; epidemiology and IF: 6.2170
R.F., Pires-Encuentra P., Diaz-Manera J., Nuez clinical outcomes. (2015) J CLIN VIROL, 63,
F., Martinez-Horta S., Vives-Gilabert Y., Pago- 76-80.
nabarraga J., Kulisevsky J., Cordoba J., IF: 2.6470

ff Villanueva C. Gastrointestinal bleeding: Blood transfusion for

Publications
acute upper gastrointestinal bleeding. Nat Rev Gastroenterol

Hepatol. 2015 Aug;12(8):432-4.
Other
ff Guarner-Argente C., Colán-Hernández J., Concepción-Martín M.,

Martínez-Guillén M., Soriano G., Sainz S., Guarner C. Replace-
ment of the same lumen-apposing metallic stent for multiple
necrosectomy sessions. (2015) ENDOSCOPY, 47 Suppl 1, E447-8.

Microbiology and Infectious Diseases
Coordinator
Coll Figa, Pere FGS
pcoll@santpau.cat
Members
Canal Girol, Cristina F. Puigvert
Cortes Palacios, Ana Pilar FGS
Cotura Vidal, María Ángeles FGS
De Benito Hernández,
María Natividad FGS
Domingo Pedrol, Pere FGS
Español Fran, Montserrat IR
Espinal Marín, Paula Andrea IR
Facundo Molas,
Carme F. Puigvert Clinical Microbiology ff Biomarkers for BKV in urine samples.
Fontanet Giralt, Àngels FGS ff Study of resistance mechanisms. ff Medical care projects.
Gálvez Deltoro, María Luz FGS
Gil Olivas, Eva IR ff Tuberculosis, epidemiology and antitu-
Infectious Pathologies
berculosis resistance mechanisms.
Gómez Martínez, Laura IR
Guirado Perich, Lluís F. Puigvert ff Molecular biology applications in infec- ff Restricted-use policies for antibiotic and
tious disease detection, taxonomy and antimicrobial agents and suitable use of
of Research
Gurgui Ferrer, Mercedes FGS

Main Lines
epidemiology. antimicrobial agents.

Lamarca Soria, Maria Karuna IR
López-Contreras ff Medical care projects. ff Study of infections associated with foreign
González, Joaquín FGS bodies (joint prostheses, catheters, car-
March Vallverdú, Francesca FGS diac prostheses and pacemakers).
Kidney Transplantation
Margall Coscojuela, Núria FGS ff Study of infections due to multiresistant
Martí Carrizosa, Mar IR ff Vaccines in patients at high risk of CMV in- microorganisms or requiring isolation.
Martín Andrés, Esther FGS fection post-transplantation.
ff Tuberculosis.
Mirelis Otero, Beatriz FGS ff Detection of patients IgG positive for CMV
Miró Cardona, Elisenda FGS but with posttransplantation risk of CMV
Muñoz Batet, Carmen FGS infection.
Mur Arizon, Isabel FGS
Navarro Risueño, Ferran FGS
Pomar Solchaga, Virginia FGS
Prim Bosch, Núria FGS Clinical Microbiology Resistance ff Molecular detection of resistance using a
Rabella García, Núria FGS molecular antibiogram.
Mechanisms
Rivera Martínez, María Alba FGS
ff Study of the epidemiology and spread of
Rubio Bueno, Marc IR ff Study of increased resistance as a result of resistant strains and assessment of the im-
Sánchez Reus, Fernando FGS gene carrier-vector spread. pact of immigration and the contribution
Serra Cabañas, Núria F. Puigvert ff Continuity of work in the context of the of new Mycobacterium tuberculosis fami-
Villarroya Terrade, Joan IR Spanish Network for Research into Infec- lies (Beijing, EAI, CAS).
tious Pathologies (REIPI), heading certain
projects (e.g., epidemiology of class C be- Molecular Biology Applications to
ta-lactamases in Spain) and cooperating
Infectious Disease Detection, Taxonomy
Challenges
with a project on the epidemiology of

resistance to amoxicillin-clavulanic acid and Epidemiology
among others.
ff Study of the usefulness of the 16S RNA
ff Advancement of other research lines, both gene for microbiological diagnosis and
in-house and in cooperation with other molecular identification.
centres, leading to two doctoral theses.
ff Genotype characterization of Cryptospo-
ridium spp. oocysts from stool samples
Tuberculosis, Epidemiology and collected by the HSCSP Microbiology Unit.
Resistance Mechanisms
Medical Care
ff Prospective monitoring of primary and
acquired Mycobacterium tuberculosis re- ff Government health department agree-
sistance to first-second-line drugs. ment (ongoing) regarding the develop-
ment of epidemiological surveillance sup-

port functions for nosocomial infections Infectious Pathologies Tuberculosis

and flaccid paralysis.
ff To cooperate with studies of resistance
ff Study of mycoses in depth, especially in- Restricted-use Antibiotic and and with new treatment regimes for tu-
vasive fusariosis and aspergillosis and re- berculosis.
Antimicrobial Policies
spiratory tract viral infections in patients
with onco-haematological diseases. ff To minimize resistance, reduce cost and Other Projects
ff Multicentre studies of HIV (ongoing). improve compliance with surgical pro-
phylaxis (at the time of administration) To continue with the government health
ff Monitoring of congenital infection in through suitable use of antimicrobial department agreement regarding the de-
prenant women with Chagas disease. agents. velopment of support functions as follows:
Kidney Surgery ff Epidemiological surveillance of nosoco-

Epidemic Cutbreaks and Infections
mial infections (VINCat).
ff Vaccine in patients with high risk of CMV
Caused by Multiresistant
ff Tuberculosis control: Barcelona-Dreta
infection posttransplantation: Phase 2 Microorganisms and Microorganisms
Tuberculosis Operations Committee (co-
randomized, double-blind, placebo-con- Requiring Isolation ordinator: Dr Sambeat).
trolled trial of MCMV5322A/MCMV3068A
for the prevention of cytomegalovirus ff To study epidemiology for our hospital. ff New influenza control: Barcelona-Dreta
Challenges
disease in high-risk kidney allograft re- Epidemiological Surveillance Operations

ff To reduce incidence. Committee (coordinator: Dr López-Con-
cipients, Clinical trial sponsored by Ge-
netech. ff To prevent/contain epidemic outbreaks treras).
and work with the Microbiology Unit in Database for monitoring CMV infections
ff Detection of patients IgG positive for ff
epidemiology and molecular studies. after renal transplantation.
CMV with high or low risk of CMV infec-
tion posttransplantation: Translational ff Database for monitoring BK virus infec-
study to assess the clinical utility of Infections Associated with Foreign
tions after renal transplantation.
determination pre-transplant of IFN-γ Bodies (Joint Prostheses, Catheters,
secreted by CD8 + T-cell-specific guide ff Observational and multicentre case-con-
for the prevention of CMV infection in
Cardiac Prostheses, Pacemakers)
trolled (1:2) study to compare the evolu-
patients of low risk of CMV infection. ff To reduce incidence. tion of renal transplantation in patients
Clinical trial sponsored by Consejería de with HIV infection (Dr Canal, Dr Facundo
Sanidad y Bienestar Social de Andalucía, ff To develop effective conservative treat- and Dr Serra), sponsored by the Andal-
Spain. ment regimes. usian Organ and Tissue Transplantation
Society.
ff Biomarkers for BKV in urine sample: De-
termination of a diagnostic and prog- Infections in Transplant Patients (Heart, ff Observational, epidemiological and ret-
nostic biomarker in urine by proteom- Haemopoietic Progenitors) rospective study of management of CMV
ics of nephropathy by BK virus in renal infection in a cohort of patients receiving
transplant receptors, sponsored by the ff To study current epidemiology. solid organ transplantation in Catalo-
Infectious Diseases Department, Vall nia (Dr Canal, Dr Facundo and Dr Serra),
d’Hebron University Hospital, Barcelona,
ff To assess the efficacy of prophylaxis and
sponsored by the Catalan Transplanta-
Spain. other preventive measures.
tion Society.
ff Laura García Arroyo. Epidemiologia de les infeccions respira- ff Mar Martí Carrizosa. Cándida Parapsilosis, C. Orthopsilosis y C.
Theses
tòries víriques a l’Hospital de la Santa Creu i Sant Pau: Estudi Metapsilosis: Epidemiología de las candidemias, patrones de
retrospectiu de 17 anys i avaluació de dos mètodes moleculars sensibilidad y mecanismos de resistencia a las equinocandidas.
pel diagnòstic virològic. Directors: Núria Rabella, Ferran Navarro. Director: Fernando Sánchez.


ff Pere Coll Figa. Conveni Departament de Salut - Dr. Coll (IR). De- ff Pere Coll Figa. Grup de Recerca en Patologia Infecciosa i Microbi-
senvolupar conjuntament funcions de vigilància epidemiològica ologia Clínica. 2014 SGR 333. Agència de Gestió d’Ajuts Universi-
de les infeccions nosocomials i la poliomielitis (Vigilància de les taris i de Recerca. Duration: 2014-2016.
paràlisis flàccides). Departament de Salut. Duration: 2011-2015.
€89,671.55.
Active Grants
ff Pere Coll Figa. Red Española de Investigación en Patología In-

fecciosa. RD12/0015/0017. Instituto de Salud Carlos III. Duration:
2013-2016. €212,100.41.
ff Pere Domingo Pedrol. Red de sida (RIS). RD12/0017/0014. Insti-
ff Ferran Navarro Risueño. Implicación de plásmidos y bacte-
riófagos en la difusión de las resistencias a antimicrobianos y
factores de virulencia bacterianos en humanos. PI13/00329. Ins-
tituto de Salud Carlos III. Duration: 2014-2016. €50,300.
*TIF: 259.4560 **MIF: 4.7174

Alonso N., Miro E., Pascual V., Rivera A., Simo Podzamczer D., Plana M., Clotet B., Gatell J.B., Blanquer J., Navarro D., Camarena J.J., Zara-
M., Garcia M.C., Xercavins M., Morera M.A., Miro J.M., Paredes R., Clinical value of ultra- goza R., Abril V., Gimeno C., Hernaez S., Ezpe-
Espejo E., Gurgui M., Perez J., Rodriguez-Car- deep HIV-1 genotyping and tropism testing leta G., Bereciartua E., Hernandez J.L.,
balleira M., Garau J., Calbo E., Navarro F., Mi- in late presenters with advanced disease. Montejo M., Rivas R.A., Ayarza R., Planes A.M,
relis B., Coll P., Molecular characterisation of (2015) AIDS, 29 (12), 1493-1504. Ruiz-Camps I., Almirante B., Mensa J., Almela
acquired and overproduced chromosomal IF: 4.4070 M., Gurgui M., Sanchez-Reus F., Martinez-
bla AmpC in Escherichia coli clinical isolates. Casadella M., van Ham P.M., Noguera-Julian Montauti J., Sierra M., Horcajada J.P., Sorli L.,
(2015) INT J ANTIMICROB AG. M., van Kessel A., et al., Primary resistance to Gomez J., Gene A., Urrea M., Cuervo G., Gar-
IF: 4.0970 integrase strand-transfer inhibitors in Eu- cia-Vidal C., Ayats J., Gudiol C., Carratala J.,
Arribas J.R., et al., Dual treatment with rope. (2015) J ANTIMICROB CHEMOTH, 70 Nucci M., Obed M., Manzur A., A simple pre-
lopinavir-ritonavir plus lamivudine versus (10), 2885-2888. diction score for estimating the risk of candi-
triple treatment with lopinavir-ritonavir plus IF: 4.9190 daemia caused by fluconazole non-suscep-
lamivudine or emtricitabine and a second tible strains. (2015) CLIN MICROBIOL INFEC,
Catala A., Puig L., Roe E., Dalmau J., Pomar V., 21 (7), 684.e1-684.e9.
nucleos(t)ide reverse transcriptase inhibitor Munoz C., Yelamos O., Anti-tumour necrosis
for maintenance of HIV-1 viral suppression IF: 4.5750
factor-induced visceral and cutaneous leish-
(OLE): A randomised, open-label, non-inferi- maniasis: Case report and review of the liter- Cuervo G., Camoez M., Shaw E., Dominguez
ority trial. (2015) LANCET INFECT DIS, 15 (7), ature. (2015) DERMATOLOGY, 230 (3), 204- M., Gasch O., Padilla B., Pintado V., Almirante
785-792. 207. B., Molina J., Lopez-Medrano F., Ruiz de

IF: 21.3720 IF: 1.4490 Gopegui E., Martinez J.A., Bereciartua E., Ro-
Benito N., Garcia-Vazquez E., Horcajada J.P., driguez-Lopez F., Fernandez-Mazarrasa C.,
Cereijo R., Gallego-Escuredo J.M., Moure R., Goenaga M., Benito N., Rodriguez-Bano J.,
Gonzalez J., Oppenheimer F., Cofan F., Ricart Villarroya J., Domingo J.C., Fontdevila J., Mar-
M.J., Rimola A., Navasa M., Rovira M., Roig E., Espejo E., Pujol M., Methicillin-resistant
tinez E., Del Mar Gutierrez M., Mateo M.G., Staphylococcus aureus (MRSA) catheter-re-
Perez-Villa F., Cervera C., Moreno A., Clinical Giralt M., Domingo P., Villarroya F., The mo-
features and outcomes of tuberculosis in lated bacteraemia in haemodialysis patients.
lecular signature of HIV-1-associated lipom- (2015) BMC INFECT DIS.
transplant recipients as compared with the atosis reveals differential involvement of
general population: A retrospective IF: 2.6900
brown and beige/brite adipocyte cell lin-
matched cohort study. (2015) CLIN MICRO- eages. (2015) PLOS ONE, 10 (8). Domingo P., Pomar V., Bacterial meningitis:
BIOL INFEC, 21 (7), 651-658. IF: 3.0570 The end of the beginning?. (2015) LANCET
IF: 4.5750 INFECT DIS.
Cuervo G., Puig-Asensio M., Garcia-Vidal C., IF: 21.3720
Cabrerizo M., Trallero G., Pena M.J., Cilla A., Fernandez-Ruiz M., Peman J., Nucci M.,
Megias G., Munoz-Almagro C., Del Amo E., Aguado J.M., Salavert M., Gonzalez-Romo F., Espinel-Ingroff A., Alvarez-Fernandez M.,
Roda D., Mensalvas A.I., Moreno-Docon A., Guinea J., Zaragoza O., Gudiol C., Carratala J., Canton E., Carver P.L., Chen S.C.-A., Eschen-
Garcia-Costa J., Rabella N., Omenaca M., Ro- Almirante B., Padilla B., Munoz P., Guinea J., auer G., Getsinger D.L., Gonzalez G.M., Gov-
mero M.P., Sanbonmatsu-Gamez S., Perez- Pano J.R., Garcia J., Garcia C., Fortun J., Martin ender N.P., Grancini A., Hanson K.E., Kidd S.E.,
-Ruiz M., Santos-Munoz M.J., Calvo C., Com- P., Gomez E., Ryan P., Campelo C., Santos Klinker K., Kubin C.J., Kus J.V., Lockhart S.R.,
parison of epidemiology and clinical I.D.L., Buendia B., Perez B., Alonso M., Sanz F., Meletiadis J., Morris A.J., Pelaez T., Quindos
characteristics of infections by human pare- Aguado J.M., Merino P., Gonzalez F., Gorgolas G., Rodriguez-Iglesias M., Sanchez-Reus F.,
chovirus vs. those by enterovirus during the M., Gadea I., Losa J.E., Delgado-Iribarren A., Shoham S., Wengenack N.L., Borrell Sole N.,
first month of life. (2015) EUR J PEDIATR, 174 Ramos A., Romero Y., Sanchez I., Zaragoza O., Echeverria J., Esperalba J., De La Pedrosa
(11), 1511-1516. Cuenca-Estrella M., Jesus Rodriguez-Bano, E.G.-G., Garcia Garcia I., Linares M.J., Marco F.,
IF: 1.7910 Suarez A.I., Loza A., Aller A.I., Martin-Mazue- Merino P., Peman J., Perez Del Molino L.,
Casadella M., Manzardo C., Noguera-Julian los E., Ruiz M., Garnacho-Montero J., Ortiz C., Rosello Mayans E., Rubio Calvo C., Ruiz Perez
M., Ferrer E., Domingo P., Perez-Alvarez S., Chavez M., Maroto F.L., Salavert M., Peman J., De Pipaon M., Yague G., Garcia-Effron G.,
Guinea J., Perlin D.S., Sanguinetti M., Shields

*TIF: 259.4560 **MIF: 4.7174

R., Turnidge J., Multicenter Study of Epidemi- Garin N., Velasco C., de Pourcq J.T., Lopez B., Beltran-Debon R., Alba V., Gatell J.M., Ven-
ological Cutoff Values and Detection of Re- del Mar Gutierrez M., Haro J.M., Feliu A., drell J., Vidal F., Chacon M.R., HIV-1/HAART-re-
sistance in Candida spp. to Anidulafungin, Mangues M.A., Trilla A., Recreational drug lated lipodystrophy syndrome (HALS) is as-
Caspofungin, and Micafungin Using the use among individuals living with HIV in sociated with decreased circulating stweak
Sensititre YeastOne Colorimetric Method. Europe: Review of the prevalence, compari- levels. (2015) PLOS ONE, 10 (12).
(2015) ANTIMICROB AGENTS CH, 59 (11), son with the general population and HIV IF: 3.0570
6725-6732. guidelines recommendations. (2015) FRONT Mansfeld M., et al, Major differences in orga-
IF: 4.4150 MICROBIOL, 6 (JUN). nization and availability of health care and
Fernandez-Martinez M., Miro E., Ortega A., IF: 4.1650 medicines for HIV/TB coinfected patients
Bou G., Gonzalez-Lopez J.J., Oliver A., Pascual Garriga C., Garcia de Olalla P., Miro J.M., across Europe. (2015) HIV MED, 16 (9), 544-
A., Cercenado E., Oteo J., Martinez-Martinez Ocana I., Knobel H., Barbera M.J., Humet V., 552.
L., Navarro F., Molecular identification of Domingo P., Gatell J.M., Ribera E., Gurgui M., IF: 3.3410
aminoglycoside-modifying enzymes in clin- Marco A., Cayla J.A., Gil S., Masdeu E., Simon Margall N., March F., Espanol M., Torras X.,
ical isolates of Escherichia coli resistant to P., Ros M., Clos R., Gorrindo P., Mateo M.G., Gallego A., Coll P., Two unusual hepatitis C
amoxicillin/clavulanic acid isolated in Spain. Gutierrez M.M., Falco V., Vall M., Armengol P., virus subtypes, 2j and 2q, in Spain: Identifica-
(2015) INT J ANTIMICROB AG, 46 (2), 157- Aranda M., Carbonell T., Manzardo C., Garcia tion by nested-PCR and sequencing of a
163. F., Blanco J.L., Martinez E., Mallolas J., Vitaloni NS5B region. (2015) J VIROL METHODS, 223,
IF: 4.0970 M., Mortality, causes of death and associated 105-108.
Fernandez-Ruiz M., Gurgui M., Puig-Asensio factors relate to a large HIV population-based IF: 1.5080
M., Guinea J., Almirante B., Padilla B., Almela cohort. (2015) PLOS ONE, 10 (12).
IF: 3.0570 Martinez E., Gonzalez-Cordon A., Ferrer E.,
M., Diaz-Martin A., Rodriguez-Bano J., Cuen- Domingo P., Negredo E., Gutierrez F., Portilla
ca-Estrella M., Aguado J.M., Munoz P., Pano Gonzalez V., Fernandez G., Dopico E., Margall J., Curran A., Podzamczer D., Ribera E., Muril-
Pardo J.R., Garcia-Rodriguez J., Cerrada C.G., N., Esperalba J., Munoz C., Castro E., Sulleiro las J., Bernardino J.I., Santos I., Carton J.A.,
Fortun J., Martin P., Gomez E., Ryan P., Cam- E., Matas L., Evaluation of the Vitros Syphilis Peraire J., Pich J., Deulofeu R., Perez I., Gatell
pelo C., Gil I.S., Buendia V., Gorricho B.P., TPA chemiluminescence immunoassay as a J.M., Arnaiz J.A., Beleta H., Garcia D., Peje-
Alonso M., Sanz F.S., Merino P., Romo F.G., first-line method for reverse syphilis screen- naute A., Ramos N., Arcaina P., Giner L., Moya
Gorgolas M., Gadea I., Losa J.E., Delgado-Iri- ing. (2015) J CLIN MICROBIOL, 53 (4), 1361-
S., Pampliega M., Portilla J., Barrera G., Pod-

barren A., Ramos A., Romero Y., Romero I.S., 1364. zamczer D., Rozas N., Saumoy M., Ferrer E.,
Zaragoza O., Rodriguez-Bano J., Suarez A.I., IF: 3.6310 Asensi V., Carton J.A., Gatell J.M., Gonzalez-
Loza A., Aller Garcia A.I., Martin-Mazuelos E., Grint D., Peters L., Rockstroh J.K., Rakmanova Cordon A., Perez I., Martinez E., Masia M.,
Perez de Pipaon M.R., Garnacho J., Ortiz C., A., et al, Liver-related death among HIV/ Padilla S., Ramos J.R., Robledano C., Gutier-
Chavez M., Maroto F.L., Salavert M., Peman J., hepatitis C virus-co-infected individuals: rez F., Puig J., Negredo E., Arribas J.R., Castro
Blanquer J., Navarro D., Camarena J.J., Zara- Implications for the era of directly acting J.M., Bernardino J.I., Sanz J., Santos I., Cairo
goza R., Abril V., Gimeno C., Hernaez S., Ezpe- antivirals. (2015) AIDS, 29 (10), 1205-1215. M., Velli P., Dalmau D., Lamas A., Marti-Belda
leta G., Bereciartua E., Hernandez Almaraz IF: 4.4070 P., Dronda F., Blanco J.R., Gutierrez M., Mateo
J.L., Montejo M., Rivas R.A., Ayarza R., Planes M.G., Domingo P., Losada E., Prieto A., Antela
A.M., Camps I.R., Mensa J., Gurgui M., San- Guembe M., et al, Nationwide study on the
use of intravascular catheters in internal A., Murillas J., Aguilar A., Peraire J., Vargas M.,
chez-Reus F., Martinez-Montauti J., Sierra M., Vilades C., Vidal F., Crespo M., Curran A., Rib-
Horcajada J.P., Sorli L., Gomez J., Gene A., medicine departments. (2015) J HOSP IN-
FECT, 90 (2), 135-141. era E., Arnaiz J.A., Beleta H., Garcia D., Peje-
Urrea M., Valerio M., Puchades F., Mularoni A., naute A., Ramos N., Pich J., Differential body
Candida tropicalis bloodstream infection: IF: 2.6550
composition effects of protease inhibitors
Incidence, risk factors and outcome in a Iribarren J.A., Rubio R., Aguirrebengoa K., recommended for initial treatment of HIV
population-based surveillance. (2015) J IN- Arribas J.R., Baraia-Etxaburu J., Gutierrez F., infection: A randomized clinical trial. (2015)
FECTION, 71 (3), 385-394. Lopez Bernaldo de Quiros J.C., Losa J.E., Miro CLIN INFECT DIS, 60 (5), 811-820.
IF: 4.3820 J.M., Moreno S., Perez Molina J., Podzamczer IF: 8.7360
Gallego-Escuredo J.M., Gomez-Ambrosi J., D., Pulido F., Riera M., Rivero A., Sanz Moreno
J., Amador C., Antela A., Arazo P., Arrizabal- Martinez-Castelao A., Cases A., Coll E., Bonal
Catalan V., Domingo P., Giralt M., Fruhbeck J., Galceran J.M., Fort J., Moreso F., Torregrosa
G., Villarroya F., Opposite alterations in aga J., Bachiller P., Barros C., Berenguer J.,
Cayla J., Domingo P., Estrada V., Knobel H., J.-V., Guirado L., Ruiz P., Torguet P., Lauzurica
FGF21 and FGF19 levels and disturbed ex- R., Garcia R., Llibre J., Fulladosa X., Canas L.,
pression of the receptor machinery for en- Locutura J., Lopez Aldeguer J., Llibre J.M.,
Lozano F., Mallolas J., Malmierca E., Miralles Bayes B., C.E.R.A. administered once monthly
docrine FGFs in obese patients. (2015) INT J corrects and maintains stable hemoglobin
C., Miralles P., Munoz A., Ocampo A., Olalla J.,
OBESITY, 39 (1), 121-129. levels in chronic kidney disease patients not

IF: 5.3370 Perez I., Perez Elias M.J., Perez Arellano J.L.,
Portilla J., Ribera E., Rodriguez F., Santin M., on dialysis: The observational study MICE-
Garcia-Cadenas I., Castillo N., Martino R., Sanz Sanz J., Tellez M.J., Torralba M., Valencia NAS II. (2015) NEFROLOGIA, 35 (1), 80-86.
Barba P., Esquirol A., Novelli S., Orti G., Gar- E., Von Wichmann M.A., Prevention and IF: 1.2070
rido A., Saavedra S., Moreno C., Granell M., treatment of opportunistic infections and Mico M., Navarro F., de Miniac D., Gonzalez Y.,
Briones J., Brunet S., Navarro F., Ruiz I., Ra- other coinfections in HIV-infected patients: Brell A., Lopez C., Sanchez-Reus F., Mirelis B.,
bella N., Valcarcel D., Sierra J., Impact of Ep- May 2015. (2015) ENFERM INFEC MICR CL. Coll P., Efficacy of the filmarray blood culture
stein Barr virus-related complications after IF: 1.5300 identification panel for direct molecular di-
high-risk allo-SCT in the era of pre-emptive agnosis of infectious diseases from samples
rituximab. (2015) BONE MARROW TRANSPL, Lopez-Dupla M., Maymo-Masip E., Martinez
E., Domingo P., Leal M., Peraire J., Vilades C., other than blood. (2015) J MED MICROBIOL,
50 (4), 579-584. 64 (12), 1481-1488.
IF: 3.6360 Veloso S., Arnedo M., Ferrando-Martinez S.,
IF: 2.2690


*TIF: 259.4560 **MIF: 4.7174
Monge S., et al. Use of cohort data to esti- Pedrol E., Caro-Murillo A.M., Castano M.A., demiology and outcome of candidaemia in
mate national prevalence of transmitted Riera M., Olalla J., Domingo P., Arazo P., Go- patients with oncological and haematologi-
drug resistance to antiretroviral drugs in mez-Sirvent J.L., Pulido F., Romero-Palacios cal malignancies: RESULTS from a popula-
Spain (2007-2012). (2015) CLIN MICROBIOL A., Aguirrebengoa K., Vera F., Ferrer P., Blanco tion-based surveillance in Spain. (2015) CLIN
INFEC, 21 (1), 105.e1-105.e5. Ramos J.R., Renal safety of coformulated MICROBIOL INFEC, 21 (5), 491.e1-491.e10.
IF: 4.5750 tenofovir/emtricitabine vs other nucleoside IF: 4.5750
Moren C., Bano M., Gonzalez-Casacuberta I., analogues in combination therapy in an- Rivero A., Domingo P., Safety profile of do-
Catalan-Garcia M., Guitart-Mampel M., To- tiretroviral-naive patients aged 50 years or lutegravir. (2015) ENFERM INFEC MICR CL, 33
bias E., Cardellach F., Pedrol E., Peraire J., older in Spain: The TRIP study. (2015) HIV (S1), 9-13.
Vidal F., Domingo P., Miro O., Gatell J.M., CLIN TRIALS, 16 (1), 43-48. IF: 1.5300
Martinez E., Garrabou G., Mitochondrial and IF: 1.9510
Rubio M., March F., Garrigo M., Moreno C.,
apoptotic in vitro modelling of differential Peraire J., Lopez-Dupla M., Alba V., Bel- Espanol M., Coll P., Inducible and acquired
HIV-1 progression and antiretroviral toxicity. tran-Debon R., Martinez E., Domingo P., clarithromycin resistance in the mycobacte-
(2015) J ANTIMICROB CHEMOTH, 70 (8), Asensi V., Leal M., Vilades C., Inza M.-I., Escote rium abscessus complex. (2015) PLOS ONE,
2330-2336. X., Arnedo M., Mateo G., Valle-Garay E., Fer- 10 (10).
IF: 4.9190 rando-Martinez S., Veloso S., Vendrell J., IF: 3.0570
Munoz P., et al, Current epidemiology and Gatell J., Vidal F., Aguilar A., Aguilar A., Ali-
balic A., Balana J., Ceausu A., Garcia M., Guil- Ruiz-Morales J., et al, Left-sided infective en-
outcome of infective endocarditis: A multi- docarditis in patients with liver cirrhosis.
center, prospective, cohort study. (2015) len G., Milian M., Munoz G., Vargas M., Font-
anet A., Gutierrez M., Munoz J., Sambeat (2015) J INFECTION, 71 (6), 627-641.
MEDICINE, 94 (43). IF: 4.3820
IF: 1.2060 M.A., Egana-Gorrono L., HIV/antiretroviral
therapy-related lipodystrophy syndrome Sanchez E., Nieto J.C., Boullosa A., Vidal S.,
Murray D.D., et al, Circulating microRNAs in (HALS) is associated with higher RBP4 and Sancho F.J., Rossi G., Sancho-Bru P., Oms R.,
sera correlate with soluble biomarkers of lower omentin in plasma. (2015) CLIN MI- Mirelis B., Juarez C., Guarner C., Soriano G.,
immune activation but do not predict mor- CROBIOL INFEC, 21 (7), 711.e1-711.e8. VSL#3 probiotic treatment decreases bacte-
tality in ART treated individuals with HIV-1 IF: 4.5750 rial translocation in rats with carbon tetra-
infection: A case control study. (2015) PLOS chloride-induced cirrhosis. (2015) LIVER INT,
ONE, 10 (10). Perez-Molina J.A., et al, Dual treatment with

atazanavir-ritonavir plus lamivudine versus 35 (3), 735-745.
IF: 3.0570 IF: 4.4700
triple treatment with atazanavir-ritonavir
Oteo J., Ortega A., Bartolome R., Bou G., plus two nucleos(t)ides in virologically sta- Sanchez E., Soriano G., Mirelis B., Gonzalez B.,
Conejo C., Fernandez-Martinez M., Gonza- ble patients with HIV-1 (SALT): 48 week re- Nieto J.C., Vidal S., Guarner-Argente C.,
lez-Lopez J.J., Martinez-Garcia L., Mar- sults from a randomised, open-label, non-in- Juarez C., Mones J., Guarner C., Effect of
tinez-Martinez L., Merino M., Miro E., Mora feriority trial. (2015) LANCET INFECT DIS, 15 long-term acid gastric inhibition on bacte-
M., Navarro F., Oliver A., Pascual A., Rodri- (7), 775-784. rial translocation in cirrhotic rats. (2015) EUR
guez-Bano J., Ruiz-Carrascoso G., Ruiz-Gar- IF: 21.3720 J GASTROEN HEPAT, 27 (5), 570-576.
bajosa P., Zamorano L., Bautista V., Perez-Vaz- IF: 2.0930
quez M., Campos J., Prospective multicenter Podlekareva D., et al, Changing utilization of
study of carbapenemase-producing En- Stavudine (d4T) in HIV-positive people in Sanchez-Infantes D., Gallego-Escuredo J.M.,
terobacteriaceae from 83 hospitals in Spain 2006-2013 in the EuroSIDA study. (2015) HIV Diaz M., Aragones G., Sebastiani G.,
reveals high in vitro susceptibility to colistin MED, 16 (9), 533-543. Lopez-Bermejo A., De Zegher F., Domingo P.,
and meropenem. (2015) ANTIMICROB IF: 3.3410 Villarroya F., Ibanez L., Circulating FGF19 and
AGENTS CH, 59 (6), 3406-3412. Puig-Asensio M., Ruiz-Camps I., Fernandez- FGF21 surge in early infancy from infra-to
IF: 4.4150 -Ruiz M., Aguado J.M., Munoz P., Valerio M., supra-adult concentrations. (2015) INT J
Delgado-Iribarren A., Merino P., Bereciartua OBESITY, 39 (5), 742-746.
Pascual V., Ortiz G., Simo M., Alonso N., Gar- IF: 5.3370
cia M.C., Xercavins M., Rivera A., Morera M.A., E., Fortun J., Cuenca-Estrella M., Almirante B.,
Miro E., Espejo E., Navarro F., Gurgui M., Perez Padilla B., Munoz P., Guinea J., Pano J.R., Gar- Schneider J.L., Villarroya J., Diaz-Carretero A.,
J., Rodriguez-Carballeira M., Garau J., Calbo cia J., Garcia C., Fortun J., Martin P., Gomez E., Patel B., Urbanska A.M., Thi M.M., Villarroya F.,
E., Epidemiology and risk factors for infec- Ryan P., Campelo C., Santos I.D.L., Buendia B., Santambrogio L., Cuervo A.M., Loss of he-
tions due to AmpC Β-lactamase-producing Perez B., Alonso M., Sanz F., Aguado J.M., patic chaperone-mediated autophagy ac-
Escherichia Coli. (2015) J ANTIMICROB CHE- Merino P., Gonzalez F., Gorgolas M., Gadea I., celerates proteostasis failure in aging. (2015)
MOTH, 70 (3), 899-904. Losa J.E., Delgado-Iribarren A., Ramos A., AGING CELL.
IF: 4.9190 Romero Y., Sanchez I., Zaragoza O., Cuen- IF: 5.7600
ca-Estrella M., Rodriguez-Bano J., Suarez A.I., Schneider J.L., Villarroya J., Diaz-Carretero A.,
Pea C., Cabot G., Gomez-Zorrilla S., Zamo- Loza A., Aller A.I., Martin-Mazuelos E., Ruiz
rano L., Ocampo-Sosa A., Murillas J., Almi- Patel B., Urbanska A.M., Thi M.M., Villarroya F.,
M., Garnacho-Montero J., Ortiz C., Chavez M., Santambrogio L., Cuervo A.M., Loss of he-
rante B., Pomar V., Aguilar M., Granados A., Maroto F.L., Salavert M., Peman J., Blanquer
Calbo E., Rodriguez-Bao J., Rodriguez-Lopez patic chaperone-mediated autophagy ac-
J., Navarro D., Camarena J.J., Zaragoza R., celerates proteostasis failure in aging. (2015)
F., Tubau F., Martinez-Martinez L., Oliver A., Abril V., Gimeno C., Hernaez S., Ezpeleta G.,
Influence of virulence genotype and resis- AGING CELL, 14 (2), 249-264.
Bereciartua E., Hernandez J.L., Montejo M., IF: 5.7600
tance profile in the mortality of pseu- Rivas R.A., Ayarza R., Planes A., Almirante B.,
domonas aeruginosa bloodstream infec- Segura R., Prim N., Montemayor M., Valls
Mensa J., Almela M., Gurgui M., Sanchez-Reus
tions. (2015) CLIN INFECT DIS, 60 (4), 539-548. M.E., Munoz C., Predominant virulent
F., Martinez-Montauti J., Sierra M., Horcajada
IF: 8.7360 IbA10G2 subtype of Cryptosporidium hom-
J.P., Sorli L., Gomez J., Gene A., Urrea M., Epi-

*TIF: 259.4560 **MIF: 4.7174

inis in human isolates in barcelona: A five- mycin plus fosfomycin versus daptomycin Villarroya J., Redondo-Angulo I., Iglesias R.,
year study. (2015) PLOS ONE, 10 (3). monotherapy in treating MRSA: Protocol of Giralt M., Villarroya F., Planavila A., Sirt1 me-
IF: 3.0570 a multicentre, randomised, phase III trial. diates the effects of a short-term high-fat
Shaw E., Benito N., Rodriguez-Bano J., Padilla (2015) BMJ OPEN, 5 (3). diet on the heart. (2015) J NUTR BIOCHEM,
B., Pintado V., Calbo E., Pallares M., Gozalo M., IF: 2.5620 26 (11), 1328-1337.
Ruiz-Garbajosa P., Horcajada J.P., Gomez J., Sibila O., Suarez-Cuartin G., Rodrigo-Troyano IF: 4.6680
Cercenado E., Bunshow E., Sanchez-Carrillo A., Fardon T.C., Finch S., Mateus E.F., Gar- Zamorano L., Miro E., Juan C., Gomez L., Bou
C., Xercavins M., Riera M.M., Mirelis B., Ga- cia-Bellmunt L., Castillo D., Vidal S., San- G., Gonzalez-Lopez J.J., Martinez-Martinez L.,
mallo R., Martinez L., Farinas M.C., de Cueto chez-Reus F., Restrepo M.I., Chalmers J.D., Aracil B., Conejo M.C., Oliver A., Navarro F.,
M., Pascual A., Risk factors for severe sepsis in Secreted mucins and airway bacterial colo- Mobile genetic elements related to the dif-
community-onset bacteraemic urinary tract nization in non-CF bronchiectasis. (2015) fusion of plasmid-mediated AmpC β-lact-
infection: Impact of antimicrobial resistance RESPIROLOGY, 20 (7), 1082-1088. amases or carbapenemases from enterobac-
in a large hospitalised cohort. (2015) J IN- IF: 3.0780 teriaceae: Findings from a multicenter study
FECTION, 70 (3), 247-254. Viciana-Fernandez P., Falco V., Castano M., De in Spain. (2015) ANTIMICROB AGENTS CH, 59
IF: 4.3820 Los Santos-Gil I., Olalla-Sierra J., Hernando (9), 5260-5266.
Shaw E., Miro J.M., Puig-Asensio M., Pigrau A., Deig E., Clotet B., Knobel H., Podzamczer IF: 4.4150
C., Barcenilla F., Murillas J., Garcia-Pardo G., D., Pedrol P.D., Barriers to ART initiation in
Espejo E., Padilla B., Garcia-Reyne A., Pas- HIV infected subjects and with treatment
quau J., Rodriguez-Bano J., Lopez-Contreras indication in Spain. Why don’t they start
J., Montero M., De La Calle C., Pintado V., their treatment? Bridgap Study. (2015) EN-
Calbo E., Gasch O., Montejo M., Salavert M., FERM INFEC MICR CL, 33 (6), 397-403.
Garcia-Pais M.J., Carratala J., Pujol M., Dapto- IF: 1.5300

Multi-organ Damage
Coordinator
Casademont Pou, Jordi FGS
jcasademont@santpau.cat
Members
Acosta Pereira, Asunción IR
Arroyo Díaz, Juan Antonio FGS
Ballart Roig, Judith IR
Barceló Trias, Montserrat FGS
Benet Gusta, Maria Teresa IR
Castella Rovira, Marta IR
De Llobet Zubiaga,
Josep Maria FGS
Díaz Torné, César IR
Filella Agulló, David FGS Bone Metabolism and Osteoporosis ff Pharmacokinetics of methotrexate.
Francia Santamaria, Esther FGS ff Analysis of genetic influence on osteopo- ff Evaluation of bariticinib in patients with
Geli Ferrer, Carme FGS rosis by means of aggregation studies in moderately to severely active rheumatoid
Herrera Bachs, Silvia IR families of three or more generations with arthritis who have had an inadequate re-
Izquierdo Caeiro, a minimum of 15 members. sponse to methotrexate or antiTNF ther-
apy.
Maria de los Ángeles IR ff Bone structure study with quantitative
Laiz Alonso, Ana María FGS CT of hip and spine, analysing the contri- ff Evaluation of tofacitinib in patients with
Magallares López, bution of trabecular and cortical compo- moderately to severely active rheumatoid
nents using HRCT. arthritis with inadequate response to bio-
Berta Paula IR
logic DMARD.
Malouf Sierra, Jorge IR ff Description of fat values and percentages in
Martín Marcuello, Jordi IR a normal population (in collaboration with ff Evaluation of the JAK-STAT pathway in
Mascaró Lamarca, Jordi FGS the HIV Unit and CETIR Medical Group). patients with rheumatoid arthritis treated
with tocilizumab.
Matas Pericas, Laia FGS ff Analysis of the influence of an interven-
Monmany Roca, Jaume FGS tion (physical exercise) on changes in the
Moya Alvarado, Patricia IR Systemic Sclerosis
muscle compartment of patients with cir-
Pares Oliva, Mireia IR rhosis measured by DXA and HRQCT (in ff Capillaroscopy patterns and correlation
Ponte, Paola collaboration with the Gastroenterology with auto-antibodies and pulmonary
Rius Llorens, María Carmen IR Department). function tests.

Rodríguez de la Serna, ff Description of bone structure in patients ff Evidence-based detection of pulmonary
Arturo FGS with a history of acromegaly assessed by arterial hypertension in systemic sclerosis:
Ruiz Hidalgo, Domingo FGS DXA and HRQCT. the DETECT study.
Torres Bonafonte,
Hypertension and Vascular Risk
ff Use of endothelin receptor antagonism to
Olga Herminia FGS
prevent pulmonary arterial hypertension
ff Hypertension and quality of life. (in collaboration with Vall d’Hebron Uni-
versity Hospital, Barcelona, Spain).
ff Refractory hypertension.
ff Genetic studies in systemic sclerosis and
ff Use of alirocumab in hypercholestero- collaboration with DUO Registry and
laemia. LAUDES study.
ff Study of capillaroscopy patterns in diffuse
Clinical Management, Internal Medicine connective tissue diseases: QuantiCAP
and Geriatrics study.
ff Health care quality indexes (mortality, re-

Gout
admissions, etc).
ff Perioperative medicine. ff Epidemiology of hyperuricaemia and
gout.
ff Potentially inappropriate prescribing to
older patients admitted to hospital.
Sjögren Syndrome
Rheumatology and Rheumatoid Arthritis ff Clinical and epidemiological findings in
Spanish patients with primary Sjögren
ff Immunomodulation due to anti-CD20 (rit- syndrome (in collaboration with Spanish
uximab) treatment and study of polymor- Society of Rheumatology).
phisms.

Challenges
ff To establish stable work relations between the HSCSP Bone Me- ff To strengthen ties between the HSCSP Rheumatology and Im-
tabolism and Genomics of Complex Diseases Groups and the munology departments regarding the study of immunological
Bone Metabolism Unit of Hospital del Mar Medical Research In- diseases.
stitute and the Faculty of Biology of the University of Barcelona.
Collaborations with other IIB Sant Pau Groups External Collaborations

ff Digestive Diseases (Dr Germán Soriano), Study by densitome- ff Dr Luis del Rio, Standardized measures of different tissues us-
try and ergospirometry of the effects of an exercise programme ing dual-energy X-ray absorptiometry, CETIR Medical Group,
in overweight patients with liver cirrhosis. Barcelona, Spain.
Collaborations
ff Orthopaedic Surgery and Traumatology Service (Dr José Car- ff Internal Medicine Pneumonia Study (ENEMI), coordinated by
los González Rodríguez), Randomized, double-blind, place- the Hospital General Universitario Gregorio Marañón, Madrid,
bo-controlled clinical trial of parallel groups assessing the Spain.
efficacy of subcutaneous denosumab for periprosthetic re-
sorption decrease in patients with total knee prosthesis, IIB-
ff Dr César Díaz Torné, panellist for the Guidelines to Clinical Prac-
SP-DEN-2012-24, Eudra No: 2012-001285-15. tice for Gout (GuipClinGot), Spanish Rheumatology Society.
ff Cardiovascular Risk Group (Dr Laiz Matas), Longitudinal ep-

idemiological study for the assessment of arterial stiffness in
patients with renal insufficiency and treatment with vitamin D3
and vitamin D analogues, IIBSP- VIT-2013-138.
ff Olga Herminia Torres Bonafonte. Estudio sobre la utilización ina- ff Jordi Casademont Pou. Estudio GAO: de los fenotipos intermedi-
propiada de medicamentos en pacientes de edad avanzada hos- arios al análisis global del genoma. PI14/01036. Instituto de Salud
Grants
Active
pitalizados en servicios de medicina interna de diferentes hospi- Carlos III. Duration: 2015-2017. €76,000.
tales españoles. EC10-077. Ministerio de Sanidad y Política Social.
Duration: 2011-2016. €22,790.88.
*TIF: 207.5840 **MIF: 9.0254

AlquezarArbe A., Rizzi M., Martin-Marcuello nists with established research careers. Diaz-Torne C., Perez-Herrero N., Perez-Ruiz F.,
J., de Diego-Bustillos E., Comments about (2015) REV CLIN ESP, 215 (7), 371-379. New medications in development for the
the status of oral anticoagulant treatment in IF: 0.7600 treatment of hyperuricemia of gout. (2015)
patients with nonvalvular atrial fibrillation in Castellvi I., Simeon-Aznar C.P., Sarmiento CURR OPIN RHEUMATOL, 27 (2), 164-169.
Spain. (2015) REV CLIN ESP. M., Fortuna A., Mayos M., Geli C., Diaz-Torne IF: 4.2270
IF: 0.7600 C., Moya P., De Llobet J.M., Casademont J., Elices M., Pascual J.C., Carmona C., Martin-
Blanco F.J., Moller I., Romera M., Rozadilla Association between nailfold capillaros- Blanco A., Feliu-Soler A., Ruiz E., Goma-i-
A., Sanchez-Lazaro J.A., Rodriguez A., copy findings and pulmonary function Freixanet M., Perez V., Soler J., Exploring the
Galvez J., Fores J., Monfort J., Ojeda S., Mor- tests in patients with with systemic sclero- relation between childhood trauma, tem-
agues C., Caracuel M.A., Clavaguera T., sis. (2015) J RHEUMATOL, 42 (2), 222-227. peramental traits and mindfulness in bor-
Valdes C., Soler J.M., Orellana C., Belmonte IF: 3.2360 derline personality disorder. (2015) BMC
M.A., Martin F., Gimenez S., Ucar E., Pous J., Correction Naghavi M., et al, Global, re- PSYCHIATRY, 15 (1).
Bartolome N., Artieda M., Szczypiorska M., gional, and national age-sex specific all- IF: 2.5760
Tejedor D., Martinez A., Montell E., Martinez cause and cause-specific mortality for 240 Formiga F., Chivite D., Ruiz D., Navarro M., Pe-
H., Herrero M., Verges J., Climent A., Fernan- causes of death, 1990-2013: A systematic rez Castejon J.M., Duaso E., Montero A., Lopez-
dez-Moreno M., Font P., Izquierdo M.A., Lo- analysis for the Global Burden of Disease Soto A., Corbella X., Clinical evidence of diabe-
zano L., Montanes F.J., Nunez M., Oreiro N., Study 2013. (2015) LANCET, 385 (9963), tes mellitus end-organ damage as risk factor
Saiz E., Soto-Hermida A., Tornero C., Im- 117-171. for falls complicated by hip fracture: A multi-
proved prediction of knee osteoarthritis IF: 44.0020 center study of 1225 patients. (2015) DIABE-
progression by genetic polymorphisms: TES RES CLIN PR, 109 (2), 233-237.
The Arthrotest Study. (2015) RHEUMATOL- Cuesta F., Formiga F., Lopez-Soto A., Masanes
F., Ruiz D., Artaza I., Salva A., Serra-Rexach IF: 3.0450
OGY, 54 (7), 1236-1243.
IF: 4.5240 J.A., I Luque X.R., Cruz-Jentoft A.J., Preva- Guembe M., et al, Nationwide study on the
lence of sarcopenia in patients attending use of intravascular catheters in internal
Burbano Santos P., Miro O., Martin-Sanchez outpatient geriatric clinics: The ELLI study. medicine departments. (2015) J HOSP IN-
F.J., Fernandez Perez C., Casademont J., Sci- (2015) AGE AGEING, 44 (5), 807-809. FECT, 90 (2), 135-141.
entific production and bibliometric impact IF: 4.2010 IF: 2.6550
of a representative group of Spanish inter-

Multi-organ Damage
*TIF: 207.5840 **MIF: 9.0254
Helena Ponte Marquez P., Jose Sole M., Ar- Montes A., Perez-Pampin E., Joven B., Car- sonality Disorder: A randomized controlled
royo J.A., Matas L., Benet M.T., Roca-Cusachs reira P., Fernandez-Nebro A., Del Carmen trial. (2015) BMC PSYCHIATRY.
A., Differences in the reduction of blood Ordonez M., Navarro-Sarabia F., Moreira V., IF: 2.5760
pressure according to drug administration Vasilopoulos Y., Sarafidou T., Caliz R., Ferrer Planavila A., Redondo-Angulo I., Ribas F.,
at activity hours or rest hours. (2015) MED M.A., Canete J.D., De La Serna A.R., Magal- Garrabou G., Casademont J., Giralt M., Villar-
CLIN-BARCELONA, 144 (2), 51-54. lares B., Narvaez J., Gomez-Reino J.J., Gonza- roya F., Fibroblast growth factor 21 protects
IF: 1.2670 lez A., FCGR polymorphisms in the treat- the heart from oxidative stress. (2015) CAR-
Julia A., Pinto J.A., Gratacos J., Queiro R., Fer- ment of rheumatoid arthritis with DIOVASC RES, 106 (1), 19-31.
randiz C., Fonseca E., Montilla C., Tor- Fc-containing TNF inhibitors. (2015) PHAR- IF: 5.4650
re-Alonso J.C., Puig L., Venegas J.J.P., Nebro MACOGENOMICS, 16 (4), 333-345.
IF: 2.7100 Rizzi M.A., Ruiz D., Torres Bonafonte O.H.,
A.F., Fernandez E., Munoz-Fernandez S., Alquezar A., Herrera Mateo S., Pinera P., Puig
Dauden E., Gonzalez C., Roig D., Carazo J.L.S., Murray C.J.L., et al, Global, regional, and na- M., Benito S., Prognostic Value and Risk Fac-
Zarco P., Erra A., Estebaranz J.L.L., Rodriguez tional disability-adjusted life years (DALYs) tors of Delirium in Emergency Patients With
J., Ramirez D.M., De La Cueva P., Vanaclocha for 306 diseases and injuries and healthy life Decompensated Heart Failure. (2015) J AM
F., Herrera E., Castaneda S., Rubio E., Salvador expectancy (HALE) for 188 countries, 1990- MED DIR ASSOC, 16 (9), 799.e1-799.e6.
G., Diaz-Torne C., Blanco R., Dominguez A.W., 2013: Quantifying the epidemiological tran-
IF: 6.6160
Mosquera J.A., Vela P., Tornero J., San- sition. (2015) LANCET, 386 (10009), 2145-
chez-Fernandez S., Corominas H., Ramirez J., 2191. Rizzi M.A., Alquezar A., Marcuello J.M., On-
Lopez-Lasanta M., Tortosa R., Palau N., IF: 44.0020 tiveros H.H., The Redin SCORE: Useful, but
Alonso A., Garcia-Montero A.C., Gelpi J.L., not for all. (2015) EUR J HEART FAIL.
Narvaez J., Diaz-Torne C., Magallares B., Her- IF: 5.1350
Codo L., Day K., Absher D., Myers R.M., Can- nandez M.V., Reina D., Corominas H., San-
ete J.D., Marsal S., A deletion at adamts9- marti R., De La Serna A.R., Llobet J.M., Nolla San-Jose A., Agusti A., Vidal X., Formiga F.,
magi1 locus is associated with psoriatic ar- J.M., Comparative effectiveness of tocili- Gomez-Hernandez M., Garcia J., Lopez-Soto
thritis risk. (2015) ANN RHEUM DIS, 74 (10), zumab with either methotrexate or lefluno- A., Ramirez-Duque N., Torres O.H., Barbe J.,
1875-1881. mide in the treatment of rheumatoid arthri- Inappropriate prescribing to the oldest old
IF: 12.3840 tis. (2015) PLOS ONE, 10 (4). patients admitted to hospital: Prevalence,
Montes A., Perez-Pampin E., Navarro-Sarabia IF: 3.0570 most frequently used medicines, and associ-
F., Moreira V., de la Serna A.R., Magallares B., ated factors. (2015) BMC GERIATR, 15 (1).
Ortiz M.A., Diaz-Torne C., Hernandez M.V., IF: 2.3710
Vasilopoulos Y., Sarafidou T., Fernandez-Ne- Reina D., de la Fuente D., Castellvi I., Moya P.,
bro A., Ordonez M.C., Narvaez J., Canete J.D., Ruiz J.M., Corominas H., Zamora C., Canto E., Vos T., et al, Global, regional, and national
Marquez A., Pascual-Salcedo D., Joven B., Sanmarti R., Juarez C., Vidal S., IL-6 blockade incidence, prevalence, and years lived with
Carreira P., Moreno-Ramos M.J., Caliz R., Fer- reverses the abnormal STAT activation of disability for 301 acute and chronic diseases
rer M.A., Garcia-Portales R., Blanco F.J., Magro peripheral blood leukocytes from rheuma- and injuries in 188 countries, 1990-2013: A
C., Raya E., Valor L., Alegre-Sancho J.J., Balsa toid arthritis patients. (2015) CLIN IMMU- systematic analysis for the Global Burden of
A., Martin J., Plant D., Isaacs J., Morgan A.W., NOL, 158 (2), 174-182. Disease Study 2013. (2015) LANCET, 386
Barton A., Wilson A.G., Gomez-Reino J.J., IF: 4.0340 (9995), 743-800.
Gonzalez A., Rheumatoid arthritis response IF: 44.0020
to treatment across IgG1 allotype - anti-TNF Pascual J.C., Palomares N., Ibanez A., Portella
incompatibility: A case-only study. (2015) M.J., Arza R., Reyes R., Feliu-Soler A., Di-
ARTHRITIS RES THER, 17 (1), 1-12. az-Marsa M., Saiz-Ruiz J., Soler J., Carrasco
IF: 3.9790 J.L., Efficacy of cognitive rehabilitation on
psychosocial functioning in Borderline Per-


Chronic Respiratory Diseases
Coordinator
Plaza Moral, Vicente FGS
vplaza@santpau.cat
Members
Anton Albisu,
Pedro Antonio FGS
Barril Farre, Silvia FGS
Bigorra Rodríguez, Teresa IR
Brienza, Sonia Nadia IR
Burgués Mauri, Carmen FGS
Calaf Sordo, Núria FGS
Castellano Villarreal, Abilio FGS
Castillo Villegas, Diego FGS
Cisneros Antó, Josep Lluís FGS Asthma COPD and Respiratory Failure
Feliu Ropero, Anna IR ff Asthma exacerbations. ff Non-invasive mechanical ventilation.
Fortuna Gutiérrez,
Ana María FGS ff Severe asthma. ff Respiratory rehabilitation.
Giménez Palleiro, ff Good clinical practice guidelines for ff Pathophysiology.
Ana María FGS asthma.
of Research
Exacerbation.
Main Lines
ff
Giner Donaire, Jordi FGS ff Bronchial inflammation.
Granel Tena, Carme FGS
ff Experimental asthma and pathogenic Obstructive Sleep Apnoea (OSA)
Guell Rous, Maria Rosa FGS
mechanisms.
Martín Arroyo, Iñigo FGS ff Physiology and clinical, diagnostic and
Mayos Pérez, Mercedes FGS ff Multicentre biobank specializing in bron- treatment consequences of sleep disor-
Miralda Galán, Rosa Maria FGS chial biopsies for research into asthma. ders.
Morante Velez, Fátima FGS ff Bronchial thermoplasty. ff Obesity-hypoventilation syndrome.
Muñoz Fernández,
ff Clinical trials. ff Analysis of airway inflammation in pa-
Ana Maria IR
tients with OSA.
Paz del Rio, Luis Daniel
Peiró Fabregas, Meritxell FGS
Peñacoba Toribio, Patricia IR
Puy Rion, Maria Carme FGS
Ramos Barbón, David FGS ff Consolidate a leading clinical trial unit in ff Support the development of multidis-
Rodrigo Troyano, respiratory diseases. ciplinary research networks such as the
Barcelona Respiratory Network and the
Challenges
Ana María FGS ff Capture pre-clinical development con- Programme for Integrated Research for
Rubio Gil, Julio FGS tracts from the pharmaceutical and bio- Asthma of the Spanish Society of Pneu-
Sánchez López, Ester IR tech industry, using the capabilities of mology and Thoracic Surgery (SEPAR), and
Sauret Valet, Jesús Maria FGS our basic research lab and experimental collaborate with or become involved in
Segura Medina, Macarena FGS animal models. existing networks such as CIBER-Respira-
Sibila Vidal, Oriol FGS ff Recruit research trainees seeking a doc- tory Disorders.
Solanes Garcia, Íngrid FGS toral degree.
Soto Retes,
Lorena Concepción FGS
Suárez Cuartin,
ff Oriol Sibila Vidal. Premio Investigador Joven, for his line of research “Infección bronquial en
Awards
Guillermo Rafael IR
pacientes con EPOC y agudizaciones frecuentes; papel de la inmunidad innata y utilidad de
Torredemer Palau, Anna IR una nariz electrónica para su diagnóstico”. Fundación Astra Zeneca.
Torrego Fernández, Alfonso FGS
Torrejón Lázaro, Montserrat FGS

Collaborations with other IIB Sant Pau Groups ff Dr. D. Ramos Barbón (PI), Multicentre Biobank of Bronchial Biop-
sies for Asthma Research, with collaborators as follows:
ff Ear, Nose and Throat Cancers (collaboration of Dr. V. Plaza in the -- Dr. Carlos Martínez Rivera from Hospital Universitari Germans
EPONA study). Trias i Pujol, Badalona, Spain.
ff Genetics and Vascular Surgery Departments (collaboration of Dr. -- Dr. Antolín López Viña from Hospital Universitario Puerta de
V. Plaza in the TAGA study). Hierro, Madrid, Spain.
-- Dr. Francisco Javier González Barcala from Complejo Hospita-
External Collaborations lario de Pontevedra, Spain.
Collaborations
-- Dr. Teresa Bazús González from Hospital Universitario Central

ff Dr. V. Plaza, Emergent Asthma Group, SEPAR. de Asturias, Oviedo, Spain.
ff Dr. V. Plaza, INASMA Group.
-- Dr. Luis Pérez de Llano from Hospital Lucus Augusti, Lugo,
Spain (pending approval).
ff Drs. V. Plaza and D. Ramos Barbón, Integrated Research Pro- -- Dr. Patrick Berger from Université Bordeaux 2, Bordeaux,
gramme (PII) for Asthma, SEPAR. France.
ff Drs. V. Plaza and D. Ramos Barbón, group associated with CI- -- Dr. James G Martin from McGill University, Montreal, Canada.
BER-Respiratory.
ff Dr. D. Castillo Villegas, National Institute for Rare Diseases, Insi-
tuto de Salud Carlos III, Madrid, Spain.
ff Dr. D. Castillo Villegas, International Working Group on Langer-
hans Cell Histiocytosis and EUROHISTIONET.
ff David Ramos Barbón. The interaction between immune regula- ff Mercedes Mayos Pérez. Proyecto PASHOS: Plataforma avanzada
tion and airway remodeling mechanisms in asthma: pathogenic para el estudio del síndrome de apnea hipopnea del sueño
outcomes versus therapeutic potencial. PI11/01001. Instituto de (SAHS): Estudio de validación de un modelo de criba del SAHS
Salud Carlos III. Duration: 2012-2016. €129,372. en Atención Primaria. PI14/01985. Instituto de Salud Carlos III.
Duration: 2015-2017. €19,400.
ff Íngrid Solanes Garcia. Conveni Fundació Catalana de Pneumolo-
gia (FUCAP). Astra Zeneca 2011 (FUCAP). Fundació Catalana de ff David Ramos Barbón. Mecanismos patogénicos versus terapéu-
Pneumologia. Duration: 2011-2016. €10.555,56. ticos de las células madre mesenquimales sobre la remodelación
bronquial en asma: prueba de concepto para subsiguiente de-
ff Diego Castillo Villegas. Caracterización genética y funcional de sarrollo farmacéutico. PI14/00257. Instituto de Salud Carlos III.
la histiocitosis pulmonar de células de langerhans: implicaciones Duration: 2015-2017. €121,500.
Active Grants
diagnósticas y terapéuticas. FMM 2013-2. Fundació Mutua Ma-

drileña. Duration: 2013-2016. €23,161. ff Mercedes Mayos Pérez. Proyecto PASHOS: Plataforma avanzada
para el estudio del síndrome de apnea hipopnea obstructiva del
ff Diego Castillo Villegas. Caracterización genética y funcional de sueño (SAHS). SOCAP 2013-2014. Societat Catalana de Pneumo-
la histiocitosis pulmonar de células de langerhans: Implicaciones logia. Duration: 2014-2016. €10,909.08.
diagnósticas y terapéuticas. EPID-FUTURO 2013. Sociedad Es-
pañola de Pneumología y Cirugía Torácica. Duration: 2013-2016. ff Oriol Sibila Vidal. Infección bronquial en pacientes con bronqui-
€2,180.90. ectasias NO-FQ; papel de los mecanismos de defensa pulmonar
y utilidad de una nariz electrónica para su diagnóstico. SEPAR
ff David Ramos Barbón. Grup de recerca en malalties respiratòries 2013-6. Sociedad Española de Pneumología y Cirugía Torácica.
cròniques. 2014 SGR 1294. Agència de Gestió d’Ajuts Universi- Duration: 2014-2016. €6,761.81.
taris i de Recerca. Duration: 2014-2016.
ff Astrid del Carmen Crespo Lessmann. Caracterización fenotípica
del asmático hipersecretor. Papel de las mucinas y de los recep-
tores Toll-Like. Beca VIFOR PHARMA / FUCAP 2014. Fundació Ca-
talana de Pneumologia. Duration: 2014-2016. €10,363.64.
Oriol Sibila Vidal. Infección bronquial en pacientes con EPOC y Oriol Sibila Vidal. Respiratory Microbiome and COPD exacerba-
Grants Awarded
ff ff
agudizaciones frecuentes; papel de la inmunidad innata y utili- tions. Ramón Pla Armengol 2015. Fundació Ramón Pla Armen-
dad de una nariz electrónica para su diagnóstico. ASTRAZENECA gol. Duration: 2015-2018. €63,636.36.
in 2015
2015-1. Fundació AstraZeneca. Duration: 2015-2016. €20,000.

ff Alfonso Torrego Fernández. Estudi dels mecanismes fisio-
patològics i resultats de l’aplicació de termoplàstia bronquial
en asma greu. BECA VIFOR - FUCAP 2015. Fundació Catalana de
Pneumologia. Duration: 2015-2018. €10,363.65.

Chronic Respiratory Diseases

ff Diego M. Castillo Villegas. Rendimiento de un programa de estu- rectors: Joaquín Sanchís Aldas, Vicente Plaza Moral. Universitat
dio de casos de EPOC en usuarios de alto riesgo de la farmacia Autònoma de Barcelona. Date of defense: 30 November 2015.
Theses
comunitaria. Universitat Autònoma de Barcelona. Directors: Pere

Casan Clara, Mercedes Mayos. Date of defense: October 2015.
ff Virginia Pajares Ruiz. Utilización de criosondas para la realización
de la biopsia pulmonar transbronquial. Universitat Autònoma de
ff Jordi Giner Donaire. Estàndards i qualitat en la determinació Barcelona. Directors: Joaquín Sanchis Aldás, Vicente Plaza Moral.
de la funció pulmonar (l’espirometria) a l’Atenció Primària. Di- Date of defense: 12 February 2015.
*TIF: 128.4550 **MIF: 5.3523

Agusti A., Anto J.M., Auffray C., Barbe F., Bar- Castillo D., Burgos F., Gascon M.P., The Role of Lessmann A.C., Giner J., Torrego A., Mateus
reiro E., Dorca J., Escarrabill J., Faner R., Fur- Community Pharmacies in Respiratory Dis- E., Torrejon M., Belda A., Plaza V., Usefulness
long L.I., Garcia-Aymerich J., Gea J., Lindmark ease Control. (2015) ARCH BRONCONEU- of the exhaled breath temperature plateau
B., Monso E., Plaza V., Puhan M.A., Roca J., MOL, 51 (9), 429-430. in asthma patients. (2015) RESPIRATION, 90
Ruiz-Manzano J., Sampietro-Colom L., Sanz IF: 1.7710 (2), 111-117.
F., Serrano L., Sharpe J., Sibila O., Silverman Escarrabill J., Torrente E., Esquinas C., Her- IF: 2.6510
E.K., Sterk P.J., Sznajder J.I., Personalized re- nandez C., Monso E., Freixas M., Almagro P., Martinez-Garcia M.A., Chiner E., Hernandez
spiratory medicine: Exploring the horizon, Tresserras R., Escarrabill J., Jimenez J., Llauger L., Cortes J.P., Catalan P., Ponce S., Diaz J.R.,
addressing the issues: Summary of a BR- M.A., Roger N., Rosas A., Salto E., Gilabert Pastor E., Vigil L., Carmona C., Montserrat
N-AJRCCM workshop held in Barcelona on C.S., Madrigal R.C., Delgado O., Casals N.R., J.M., Aizpuru F., Lloberes P., Mayos M., Selma
June 12, 2014. (2015) AM J RESP CRIT CARE, Batlles J.S., Lara B., Munoz M.R., Nieto C.S., M.J., Cifuentes J.F., Munoz A., Sancho J.N.,
191 (4), 391-401. Olive R.J., Vilaplana M.B., Moreno A., Seto L., Landete P., Ferre A., Masdeu M.J., Dalmases
IF: 13.1180 Ruiz V.P., Moral V.P., Sola J.R., Perez S.S., Sarga- M., Zamora L., Miranda-Serrano E., Obstruc-
Balcells E., Gimeno-Santos E., de Batlle J., tal J.D., Sanchez C.P., Mateos N.P., Abos J.E., tive sleep apnoea in the elderly: Role of
Ramon M.A., Rodriguez E., Benet M., Farrero Jimenez N.C., Queralto J.A.L., PalauBenavent continuous positive airway pressure treat-
E., Ferrer A., Guerra S., Ferrer J., Sauleda J., M., Camarasa J.T., Colon Y.G., San-chez E.B., ment. (2015) EUR RESPIR J, 46 (1), 142-151.
Barbera J.A., Agusti, Rodriguez-Roisin R., Gea Obradors L.L., Sancho-Munoz A., Pedreny R., IF: 8.3320
J., Anto J.M., Garcia-Aymerich J., Anto J.M., Gea J., Medrano Y.L., Flores E.R., Salinas M.T., Masa J.F., Duran-Cantolla J., Capote F.,
Serra I., Donaire-Gonzalez D., Gayete A., Barrio A., Bueno E., Rodriguez E., Molina S., Cabello M., Abad J., Garcia-Rio F., Ferrer A.,
Orozco-Levi M., Vollmer I., Barbera J.A., Go- Ramos C.C., Nunez C.A., Balana J.M.V., Casa- Fortuna A.M., Gonzalez-Mangado N., De La
mez F.P., Pare C., Roca J., Freixa X., Rodriguez novas A.L., Castiello C.V., Velasco J.A.M., Albo Pena M., Aizpuru F., Barbe F., Montserrat J.M.,
D.A., Portillo K., Andreu J., Pallissa E., Rodri- J.A., Milian E.S., Golpe E.S., Flix S.H., Bruguera Larrateguy L.D., De Castro J.R., Garcia-Le-
guez E., Casan P., Guell R., Gimenez A., Monso A.M.T., Mendez L.F.C., Diez S.S., Perez R.C., desma E., Corral J., Martin-Vicente M.J., Mar-
E., Marin A., Morera J., Escarrabill J., Agusti Garrigos O.R., Vinas C., Company V.B., Vila tinez-Null C., Egea C., Cancelo L., Garcia-Diaz
A.G., Togores B., Galdiz J.B., Lopez L., Belda J., J.C.T., Ysern E.C., Candelich C.J., del Pilar Or- E., Carmona-Bernal C., Sanchez-Armengol
Characterisation and prognosis of undiag- tega Castillo M., Iguacen M.J.C., Gomez E.T., A., Mayos M., Miralda R.M., Troncoso M.F.,
nosed chronic obstructive pulmonary dis- Marquilles E., Bernadich O., Capsada A., Mo- Gonzalez M., Martinez-Martinez M., Can-
ease patients at their first hospitalisation. lina A., Domingo R., Seijas N., Soler N., Clini- talejo O., Pierola J., Vigil L., Embid C., Del Mar
(2015) BMC PULM MED, 15 (1). cal audit of patients hospitalized due to Centelles M., Prieto T.R., Rojo B., Lores V., Effi-
IF: 2.3290 COPD exacerbation. MAG-1 Study. (2015) cacy of home single-channel nasal pressure
Casanova C., Marin J.M., Martinez-Gonzalez ARCH BRONCONEUMOL, 51 (10), 483-489. for recommending continuous positive air-
C., De Lucas-Ramos P., Mir-Viladrich I., Cosio IF: 1.7710 way pressure treatment in sleep apnea.
B., Peces-Barba G., Solanes-Garcia I., Aguero Gimenez S., Romero S., Alonso J.F., Mananas (2015) SLEEP, 38 (1), 13-21.
R., Feu-Collado N., Calle-Rubio M., Alfageme M.A., Pujol A., Baxarias P., Antonijoan R.M., IF: 4.7930
I., De Diego-Damia A., Irigaray R., Marin M., Monitoring sleep depth: analysis of bispec- Miravitlles M., Alcazar B., Alvarez F.J., Bazus T.,
Balcells E., Llunell A., Galdiz J.B., Golpe R., tral index (BIS) based on polysomnographic Calle M., Casanova C., Cisneros C., De-Torres
Lacarcel C., Cabrera C., Marin A., Soriano J.B., recordings and sleep deprivation. (2015) J J.P., Entrenas L.M., Esteban C., Garcia-Sidro P.,
Lopez-Campos J.L., Soler-Cataluna J.J., De- CLIN MONIT COMPUT, 1-8. Cosio B.G., Huerta A., Iriberri M., Izquierdo
Torres J.P., Differential effect of modified IF: 1.8190 J.L., Lopez-Vina A., Lopez-Campos J.L., Mar-
Medical Research Council Dyspnea, COPD Giner J., The American thoracic society/Euro- tinez-Moragon E., de Llano L.P., Perpina M.,
Assessment Test, and Clinical COPD Ques- pean respiratory society acceptability crite- Ros J.A., Serrano J., Soler-Cataluna J.J., Tor-
tionnaire for symptoms evaluation within
ria for spirometry: Asking too much or not rego A., Urrutia I., Plaza V., What pulmonolo-
the new GOLD staging and mortality in enough?. (2015) RESP CARE, 60 (5), e114-. gists think about the asthma–COPD overlap
COPD. (2015) CHEST, 148 (1), 159-168. IF: 1.9220 syndrome. (2015) INT J CHRONIC OBSTR, 10,
IF: 5.9400 1321-1330.
Hsu C.-H., Reyes L.F., Orihuela C.J., Buitrago
Castellvi I., Simeon-Aznar C.P., Sarmiento M., R., Anzueto A., Soni N.J., Levine S., Peters J., IF: 3.0460
Fortuna A., Mayos M., Geli C., Diaz-Torne C., Hinojosa C.A., Aliberti S., Sibila O., Rodriguez Pajares V., Castillo D., Torrego A., Reply.
Moya P., De Llobet J.M., Casademont J., Asso- A., Chalmers J.D., Martin-Loeches I., Bordon (2015) RESPIROLOGY.
ciation between nailfold capillaroscopy find- J., Blanquer J., Sanz F., Marcos P.J., Rello J., IF: 3.0780
ings and pulmonary function tests in pa- Sole-Violan J., Restrepo M.I., Chromogranin
tients with with systemic sclerosis. (2015) J Plaza V., Peiro M., Torrejon M., Fletcher M.,
A levels and mortality in patients with severe Lopez-Vina A., Ignacio J.M., Quintano J.A.,
RHEUMATOL, 42 (2), 222-227. sepsis. (2015) BIOMARKERS, 20 (3), 171-176.
IF: 3.2360 Bardagi S., Gich I., A repeated short educa-
IF: 2.0160

*TIF: 128.4550 **MIF: 5.3523

tional intervention improves asthma control Sibila O., Laserna E., Maselli D.J., Fernandez Agusti C., Effect of corticosteroids on treat-
and quality of life. (2015) EUR RESPIR J, 46 (5), J.F., Mortensen E.M., Anzueto A., Waterer G., ment failure among hospitalized patients
1298-1307. Restrepo M.I., Risk factors and antibiotic with severe community-acquired pneumo-
IF: 8.3320 therapy in P.aeruginosa community-ac- nia and high inflammatory response: A ran-
Plaza V., Crespo A., Giner J., Merino J.L., quired pneumonia. (2015) RESPIROLOGY. domized clinical trial. (2015) JAMA-J AM
Ramos-Barbon D., Mateus E.F., Torrego A., IF: 3.0780 MED ASSOC, 313 (7), 677-686.
Cosio B.G., Agusti A., Sibila O., Inflammatory Sibila O., Laserna E., Maselli D.J., Fernandez IF: 37.6840
asthma phenotype discrimination using an J.F., Mortensen E.M., Anzueto A., Waterer G.,
electronic nose breath analyzer. (2015) J IN- Restrepo M.I., Risk factors and antibiotic
VEST ALLERG CLIN, 25 (6), 431-437. therapy in P. aeruginosa community-ac-
IF: 2.1310 quired pneumonia. (2015) RESPIROLOGY, 20

Rodrigo G.J., Soler-Cataluna J.J., Solanes I., (4), 660-666.
Bolibar I., Llauger M.A., Plaza V., Assessment IF: 3.0780
of the internal structure of GOLD 2011 sys- Sibila O., Soto-Gomez N., Restrepo M.I., The
tem. (2015) PULM PHARMACOL THER, 30, risk and outcomes of pneumonia in patients
87-92. on inhaled corticosteroids. (2015) PULM
IF: 2.9300 PHARMACOL THER, 32, 130-136.
Serrano-Pariente J., Rodrigo G., Fiz J.A., Cre- IF: 2.9300
spo A., Plaza V., Identification and character- Sibila O., Suarez-Cuartin G., Rodrigo-Troyano
ization of near-fatal asthma phenotypes by A., Fardon T.C., Finch S., Mateus E.F., Gar-
cluster analysis. (2015) ALLERGY, 70 (9), cia-Bellmunt L., Castillo D., Vidal S., San-
1139-1147. chez-Reus F., Restrepo M.I., Chalmers J.D.,
IF: 6.3350 Secreted mucins and airway bacterial colo-
Shafiek H., Fiorentino F., Merino J.L., Lopez C., nization in non-CF bronchiectasis. (2015)
Oliver A., Segura J., De Paul I., Sibila O., Agusti RESPIROLOGY, 20 (7), 1082-1088.
A., Cosio B.G., Using the electronic nose to IF: 3.0780
identify airway infection during COPD exac- Torres A., Sibila O., Ferrer M., Polverino E.,
erbations. (2015) PLOS ONE, 10 (9). Menendez R., Mensa J., Gabarrus A., Sellares
IF: 3.0570 J., Restrepo M.I., Anzueto A., Niederman M.S.,

Research Group in HIV and AIDS
Coordinator
Domingo, Pere IR
Members
Cadafalch Arpa, Josep FGS
Gutiérrez Macia,
Maria del Mar IR
Lamarca Soria, Maria Karuna IR
Mateo García, Gracia Maria IR
Muñoz Rodríguez, Jessica IR
Ponte Márquez, Paola Helena IR
Sambeat Domènech,
Maria Antònia FGS
Villarroya Terrade, Joan IR
ff Medical care projects. ff Cardiovascular risk associated with an-
tiretroviral treatment.
ff Study of pathogenic mechanisms altering
of Research
Main Lines
body fat distribution. ff Comorbid conditions associated with HIV-

1 infection.
ff Study of metabolic disorders associated
with antiretroviral treatment. ff Pharmacogenetics (toxicokinetics).
ff Body composition changes. ff Bacterial meningitis.
ff New antiretroviral drugs.
Medical Care Projects ff Development of in vitro models (adipo-

cyte cultures) to study the adipose toxicity
ff Continuing with, expanding and, as ap- of antiretroviral drugs.
propriate, consolidating the care team
for HIV-1 infected patients, consisting ff Study of new manifestations of the lipo-
currently of 3 staff physicians, 4 grant- dystrophy syndrome.
aided research assistants (including a Río ff Development of measurements for an-
Hortega-funded research assistant) and 2 tiretroviral drug concentrations in adipose
nurses). tissue.
ff Continuing with participation in multicen- ff Exploration of the role of inflammation in
tre projects (especially the AIDS network, the pathogenesis of lipodystrophy asso-
Gesida, VACH, EuroSIDA and ART collabo- ciated with HIV-1 and antiretroviral treat-
ration). ment.
ff Exploration of possible participation in ff Metabolism of uridine and its role in the
clinical trials of new antiretroviral drugs. pathogenesis of lipodystrophy.
Challenges
ff Increasing the number of HIV-1 infected

patients attended to in our hospital (given Metabolic disorders associated with
current mortality rates, an estimated an- antiretroviral treatment
nual increase of 50 patients is required).
ff Continuing with current clinical research ff In vivo assessment of metabolic toxicity
and mixed basic reserch-clinical research associated with antiretroviral treatment.
lines. ff Development of in vitro models (adipo-
cyte cultures) to study the adipose toxicity
Pathogenic mechanisms altering body of antiretroviral drugs.
fat distribution ff Study of factors contributing to hepatic
steatosis in patients receiving antiretrovi-
ff Study of metabolism in pyrimidines and ral treatment.
derivatives in the genesis of lipodystrophy
associated with HIV-1 and antiretroviral ff Study of the pathogenic role of FGF21 in
treatment. insulin resistance in HIV-1- infected pa-
tients.
ff Development of an animal (mouse) model
of lipodystrophy. ff Study of role of FABP4 in metabolic disor-
ders associated with antiretroviral treat-
ment.

Body composition ff Evaluation of the neurocognitive function in patients with HIV-1

infection with and without antiretroviral treatment.
ff Definition of normal fat distribution in the general population.
ff Participation in multicentre cohort studies to determine the inci-
ff Establishment of abnormal fat distribution patterns. dence of specific comorbidities (cancer, HCV, cardiovascular dis-
ease, osteogenesis/osteoporosis): EuroSIDA, ART Collaboration,
ff Development of a definition of lipodystrophy associated with
Gesida, VACH, etc.
HIV-1 and antiretroviral treatment.
ff Treatment of HCV in patients with HIV-1 and its prognostic sig-
New antiretroviral drugs nificance.
ff Clinical trials of new antiretroviral drugs (phases 2 and 3). Pharmacogenetics (toxicogenetics)
ff Ritonavir and non-ritonavir pharmacokinetic potentiation of an- ff Role of enzyme polymorphism of the pyrimidine pathways in
tiretroviral drugs.
Challenges
the pathogenesis of lipodystrophy.
Cardiovascular risk associated with antiretroviral treatment

ff Role of enzyme polymorphism of the pyrimidine pathways in
the pathogenesis of clinical toxicity (neuropathy, pancreatitis).
ff Establishment of a multicentre cardiovascular risk cohort. ff Role of IL28B polymorphism in spontaneous HCV clearance in
ff Study of antiretroviral treatmentdependent and non-treatment- the response to antiviral treatment based on interferon and
dependent factors in multicentre cohorts. ribavirin.
ff Development of in vitro models (adipose cultures) to study adi-
pose toxicity for antiretroviral drugs. Bacterial meningitis
ff Identification of prognostic factors in adult bacterial meningitis.
Comorbid conditions associated with HIV-1 infection
ff Continuation with a cohort study of adult bacterial meningitis.
ff Study of ageing in different tissues associated with HIV-1 infec- ff Identification of host-intrinsic factors in the in the pathogenesis
tion and antiretroviral treatment. and prognosis of adult bacterial meningitis and meningococcal
ff Study of fragility in patients with HIV-1 infection and the role of disease.
HAART.
Collaborations
Collaborations with other IIB Sant Pau Groups

ff Microbiology and Infectious Diseases (Dr. Pere Coll)
ff Pere Domingo Pedrol. El sistema FGF23/alpha-Klotho como medi-

ador de las comorbilidades no directamente relacionadas con la
Grants
Active
infección por VIH en el eje cardio-osteo-renal. PI14/00700. Institu-

to de Salud Carlos III. Duration: 2015-2017. €116,500.
ff Pere Domingo Pedrol. Convocatòria d’intensificació 2015. IR15-

Awarded
INT1. Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau.

in 2015
Grants
Duration: 2015-2016. €30,000.


Research Group in HIV and AIDS

*TIF: 158.3990 **MIF: 5.8666
Arribas J.R., et al, Dual treatment with lopina- factors relate to a large HIV population-based J.M., Bernardino J.I., Sanz J., Santos I., Cairo
vir-ritonavir plus lamivudine versus triple cohort. (2015) PLOS ONE, 10 (12). M., Velli P., Dalmau D., Lamas A., Marti-Belda
treatment with lopinavir-ritonavir plus lami- IF: 3.0570 P., Dronda F., Blanco J.R., Gutierrez M., Mateo
vudine or emtricitabine and a second nucle- Grint D., et al, Liver-related death among M.G., Domingo P., Losada E., Prieto A., Antela
os(t)ide reverse transcriptase inhibitor for HIV/hepatitis C virus-co-infected individuals: A., Murillas J., Aguilar A., Peraire J., Vargas M.,
maintenance of HIV-1 viral suppression Implications for the era of directly acting Vilades C., Vidal F., Crespo M., Curran A., Rib-
(OLE): A randomised, open-label, non-inferi- antivirals. (2015) AIDS, 29 (10), 1205-1215. era E., Arnaiz J.A., Beleta H., Garcia D., Peje-
ority trial. (2015) LANCET INFECT DIS, 15 (7), IF: 4.4070 naute A., Ramos N., Pich J., Differential body
785-792. composition effects of protease inhibitors
IF: 21.3720 Helena Ponte Marquez P., Jose Sole M., Ar- recommended for initial treatment of HIV
royo J.A., Matas L., Benet M.T., Roca-Cusachs infection: A randomized clinical trial. (2015)
Casadella M., Manzardo C., Noguera-Julian A., Differences in the reduction of blood
M., Ferrer E., Domingo P., Perez-Alvarez S., CLIN INFECT DIS, 60 (5), 811-820.
pressure according to drug administration IF: 8.7360
Podzamczer D., Plana M., Clotet B., Gatell J.B., at activity hours or rest hours. (2015) MED
Miro J.M., Paredes R., Clinical value of ultra- CLIN-BARCELONA, 144 (2), 51-54. Monge S., Diez M., Alvarez M., Guillot V., Iri-
deep HIV-1 genotyping and tropism testing IF: 1.2670 barren J.A., et al, Use of cohort data to esti-
in late presenters with advanced disease. mate national prevalence of transmitted
(2015) AIDS, 29 (12), 1493-1504. Iribarren J.A., Rubio R., Aguirrebengoa K., drug resistance to antiretroviral drugs in
IF: 4.4070 Arribas J.R., Baraia-Etxaburu J., Gutierrez F., Spain (2007-2012). (2015) CLIN MICROBIOL
Lopez Bernaldo de Quiros J.C., Losa J.E., Miro INFEC, 21 (1), 105.e1-105.e5.
Casadella M., et al, Primary resistance to inte- J.M., Moreno S., Perez Molina J., Podzamczer
grase strand-transfer inhibitors in Europe. IF: 4.5750
D., Pulido F., Riera M., Rivero A., Sanz Moreno
(2015) J ANTIMICROB CHEMOTH, 70 (10), J., Amador C., Antela A., Arazo P., Arrizabal- Moren C., Bano M., Gonzalez-Casacuberta I.,
2885-2888. aga J., Bachiller P., Barros C., Berenguer J., Catalan-Garcia M., Guitart-Mampel M., To-
IF: 4.9190 Cayla J., Domingo P., Estrada V., Knobel H., bias E., Cardellach F., Pedrol E., Peraire J.,
Cereijo R., Gallego-Escuredo J.M., Moure R., Locutura J., Lopez Aldeguer J., Llibre J.M., Vidal F., Domingo P., Miro O., Gatell J.M.,
Villarroya J., Domingo J.C., Fontdevila J., Mar- Lozano F., Mallolas J., Malmierca E., Miralles Martinez E., Garrabou G., Mitochondrial and
tinez E., Del Mar Gutierrez M., Mateo M.G., C., Miralles P., Munoz A., Ocampo A., Olalla J., apoptotic in vitro modelling of differential
HIV-1 progression and antiretroviral toxicity.
Giralt M., Domingo P., Villarroya F., The mo- Perez I., Perez Elias M.J., Perez Arellano J.L.,
lecular signature of HIV-1-associated lipom- Portilla J., Ribera E., Rodriguez F., Santin M., (2015) J ANTIMICROB CHEMOTH, 70 (8),
atosis reveals differential involvement of Sanz Sanz J., Tellez M.J., Torralba M., Valencia 2330-2336.
brown and beige/brite adipocyte cell lin- E., Von Wichmann M.A., Prevention and IF: 4.9190
eages. (2015) PLOS ONE, 10 (8). treatment of opportunistic infections and Murray D.D., et al, Circulating microRNAs in
IF: 3.0570 other coinfections in HIV-infected patients: sera correlate with soluble biomarkers of
Domingo P., Pomar V., Bacterial meningitis: May 2015. (2015) ENFERM INFEC MICR CL. immune activation but do not predict mor-
The end of the beginning?. (2015) LANCET IF: 1.5300 tality in ART treated individuals with HIV-1
INFECT DIS. Lopez-Dupla M., Maymo-Masip E., Martinez infection: A case control study. (2015) PLOS
IF: 21.3720 E., Domingo P., Leal M., Peraire J., Vilades C., ONE, 10 (10).
Veloso S., Arnedo M., Ferrando-Martinez S., IF: 3.0570
Gallego-Escuredo J.M., Gomez-Ambrosi J.,
Catalan V., Domingo P., Giralt M., Fruhbeck Beltran-Debon R., Alba V., Gatell J.M., Ven- Pedrol E., Caro-Murillo A.M., Castano M.A.,
G., Villarroya F., Opposite alterations in drell J., Vidal F., Chacon M.R., HIV-1/HAART-re- Riera M., Olalla J., Domingo P., Arazo P., Go-
FGF21 and FGF19 levels and disturbed ex- lated lipodystrophy syndrome (HALS) is as- mez-Sirvent J.L., Pulido F., Romero-Palacios
pression of the receptor machinery for en- sociated with decreased circulating stweak A., Aguirrebengoa K., Vera F., Ferrer P., Blanco
docrine FGFs in obese patients. (2015) INT J levels. (2015) PLOS ONE, 10 (12). Ramos J.R., Renal safety of coformulated
OBESITY, 39 (1), 121-129. IF: 3.0570 tenofovir/emtricitabine vs other nucleoside
IF: 5.3370 Mansfeld M., et al, Major differences in orga- analogues in combination therapy in an-
nization and availability of health care and tiretroviral-naive patients aged 50 years or
Garin N., Velasco C., de Pourcq J.T., Lopez B., older in Spain: The TRIP study. (2015) HIV
del Mar Gutierrez M., Haro J.M., Feliu A., medicines for HIV/TB coinfected patients
across Europe. (2015) HIV MED, 16 (9), 544- CLIN TRIALS, 16 (1), 43-48.
Mangues M.A., Trilla A., Recreational drug IF: 1.9510
use among individuals living with HIV in 552.
Europe: Review of the prevalence, compari- IF: 3.3410 Peraire J., Lopez-Dupla M., Alba V., Bel-
son with the general population and HIV Martinez E., Gonzalez-Cordon A., Ferrer E., tran-Debon R., Martinez E., Domingo P.,
Asensi V., Leal M., Vilades C., Inza M.-I., Escote
guidelines recommendations. (2015) FRONT Domingo P., Negredo E., Gutierrez F., Portilla
MICROBIOL, 6 (JUN). J., Curran A., Podzamczer D., Ribera E., Muril- X., Arnedo M., Mateo G., Valle-Garay E., Fer-
IF: 4.1650 las J., Bernardino J.I., Santos I., Carton J.A., rando-Martinez S., Veloso S., Vendrell J.,
Peraire J., Pich J., Deulofeu R., Perez I., Gatell Gatell J., Vidal F., Aguilar A., Aguilar A., Ali-
Garriga C., Garcia de Olalla P., Miro J.M., balic A., Balana J., Ceausu A., Garcia M., Guil-
Ocana I., Knobel H., Barbera M.J., Humet V., J.M., Arnaiz J.A., Beleta H., Garcia D., Peje-
naute A., Ramos N., Arcaina P., Giner L., Moya len G., Milian M., Munoz G., Vargas M., Font-
Domingo P., Gatell J.M., Ribera E., Gurgui M., anet A., Gutierrez M., Munoz J., Sambeat
Marco A., Cayla J.A., Gil S., Masdeu E., Simon S., Pampliega M., Portilla J., Barrera G., Pod-
zamczer D., Rozas N., Saumoy M., Ferrer E., M.A., Egana-Gorrono L., HIV/antiretroviral
P., Ros M., Clos R., Gorrindo P., Mateo M.G., therapy-related lipodystrophy syndrome
Gutierrez M.M., Falco V., Vall M., Armengol P., Asensi V., Carton J.A., Gatell J.M., Gonzalez-
Cordon A., Perez I., Martinez E., Masia M., (HALS) is associated with higher RBP4 and
Aranda M., Carbonell T., Manzardo C., Garcia lower omentin in plasma. (2015) CLIN MI-
F., Blanco J.L., Martinez E., Mallolas J., Vitaloni Padilla S., Ramos J.R., Robledano C., Gutier-
rez F., Puig J., Negredo E., Arribas J.R., Castro CROBIOL INFEC, 21 (7), 711.e1-711.e8.
M., Mortality, causes of death and associated IF: 4.5750

*TIF: 158.3990 **MIF: 5.8666

Perez-Molina J.A., et al, Dual treatment with Schneider J.L., Villarroya J., Diaz-Carretero A., Villarroya J., Redondo-Angulo I., Iglesias R.,
atazanavir-ritonavir plus lamivudine versus Patel B., Urbanska A.M., Thi M.M., Villarroya F., Giralt M., Villarroya F., Planavila A., Sirt1 me-
triple treatment with atazanavir-ritonavir Santambrogio L., Cuervo A.M., Loss of he- diates the effects of a short-term high-fat
plus two nucleos(t)ides in virologically sta- patic chaperone-mediated autophagy ac- diet on the heart. (2015) J NUTR BIOCHEM,
ble patients with HIV-1 (SALT): 48 week re- celerates proteostasis failure in aging. (2015) 26 (11), 1328-1337.
sults from a randomised, open-label, non-in- AGING CELL. IF: 4.6680
feriority trial. (2015) LANCET INFECT DIS, 15 IF: 5.7600
(7), 775-784. Schneider J.L., Villarroya J., Diaz-Carretero A.,
IF: 21.3720 Patel B., Urbanska A.M., Thi M.M., Villarroya F.,
Podlekareva D., et al, Changing utilization of Santambrogio L., Cuervo A.M., Loss of he-
Stavudine (d4T) in HIV-positive people in patic chaperone-mediated autophagy ac-
2006-2013 in the EuroSIDA study. (2015) HIV celerates proteostasis failure in aging. (2015)
MED, 16 (9), 533-543. AGING CELL, 14 (2), 249-264.
IF: 3.3410 IF: 5.7600
Rivero A., Domingo P., Safety profile of do- Viciana-Fernandez P., Falco V., Castano M., De
lutegravir. (2015) ENFERM INFEC MICR CL, 33 Los Santos-Gil I., Olalla-Sierra J., Hernando
(S1), 9-13. A., Deig E., Clotet B., Knobel H., Podzamczer
IF: 1.5300 D., Pedrol P.D., Barriers to ART initiation in
Sanchez-Infantes D., Gallego-Escuredo J.M., HIV infected subjects and with treatment
Diaz M., Aragones G., Sebastiani G., indication in Spain. Why don’t they start
Lopez-Bermejo A., De Zegher F., Domingo P., their treatment? Bridgap Study. (2015) EN-
Villarroya F., Ibanez L., Circulating FGF19 and FERM INFEC MICR CL, 33 (6), 397-403.
FGF21 surge in early infancy from infra-to IF: 1.5300
supra-adult concentrations. (2015) INT J
OBESITY, 39 (5), 742-746.
IF: 5.3370

AREA 3
Haematological
and Oncological Di
118 Clinical Oncology
122 Oncogenesis and Antitumour Drugs
126 Haematological Diagnosis
130 Molecular Pathology of Gynaecologic Cancer
132 Ear, Nose and Throat Cancers
134 Oncology/Haematology and Transplantation

iseases

118 AREA 3 · Haematological and Oncological Diseases
Clinical Oncology
Coordinator
Barnadas Molins, Agustí FGS
abarnadasm@santpau.cat
Members
Albor Parada, Cecilia Verónica IR
Alfonso Ruiz, Rosa IR
Anguera Palacios, Georgia IR
Arroyo Solera, Irene IR
Calvo Vergés, Núria FGS
Castells Tello, Diana IR
Escuín Borràs, Daniel IR
Fisas Masferrer, David IR
Gallego Rubio,
Óscar Salvador FGS Clinical Translational
of Research
Main Lines
García Serrano, Sara IR ff Development of new therapeutic strate- ff Personalized anticancer therapy.
Lavèrnia Rosell, Laia IR gies.
Lladó Jordan, Gina IR ff Studies of predictive and prognostic mo-
ff Studies to improve tumour staging. lecular markers.
Llobet Busquets, Mireia IR
López Pousa, Antonio FGS ff Studies to detect residual disease.
Majem Tarruella, Margarita FGS
Maroto Rey, José Pablo FGS
Martín Lorente, Cristina FGS
Challenges
Martín Richard, Marta FGS

ff Consolidate clinical research into cancer. ff Consolidate the bank of tumours, DNA
and serum for patients with cancer diag-
Menéndez Cuervo, ff Foster translational research into cancer in nosed and treated in our hospital.
Dulce María IR cooperation with other internal and exter-
Merino Merino, Eva IR nal research groups. ff Develop new early-stage drugs (phase 0/1
Millet López, Maria Pilar IR studies).
Murata Yonamine,
Eleonor Paola IR
Paez López-Bravo, David FGS
Collaborations with other IIB Sant Pau ff Breast Cancer (Dr. E Lerma).
Pallarès Curto, Maria Cinta FGS
Groups
Collaborations
Pérez Olabarria, Maitane IR

Pich Martínez, Olga IR ff Oncogenesis and Antitumour Drugs (Dr.
Quintana Aparicio, Maria IR Ramon Mangues). ff Tumoural progression modelling group at
Ramon y Cajal Asensio, the Biomedical Research Institute (IRB) (Dr.
ff Molecular Pathology of Gynaecologic Can-
Teresa FGS cer (Dr. Jaime Prat). A. Nebreda).
Ribas Carbonell, Romina IR ff Methylation and resistance to chemothera-
Sanz Cobos, Patricia IR
ff Genetic Diseases (Dr. Montserrat Baiget).
py in ovarian cancer (Dr. M. Esteller).
Sebio Garcia, Ana IR
Sullivan, Ivana Gabriela IR
Tibau i Martorell, Ariadna FGS
Tobeña Puyal, Maria FGS ff Irene Arroyo Solera. Desenvolupament caciones en los mecanismos de invasión
d’una signatura genètica per predir la res- y su valor como marcadores metastásicos.
Active Grants
posta al tractament de quimioradioteràpia PI13/00110. Instituto de Salud Carlos III.

en pacients amb carcinoma escatós de Duration: 2014-2016. €76,000.
cap i coll localment avançat. 2013FI00188.
Agència de Gestió d’Ajuts Universitaris i de
ff Ivana Gabriela Sullivan. Contratos Río Hor-
Recerca. Duration: 2013-2016. €62,103.38. tega 2013. CM13/00117. Instituto de Salud
ff Daniel Escuín Borras. Perfil de expresión
de miRNAs en tumor primario de mama indirect costs.
y sus ganglios linfáticos centinela: impli-
ff Ivana Sullivan. Identification of molecular abnormalities in Pulmonary Neuroendocrine

Awards
Tumors through whole-exome, RNA sequencing and DNA methylation. Georges Mathé
Translational Research Fellowship. European Society for Medical Oncology (ESMO).

AREA 3 · Haematological and Oncological Diseases 119
Theses
ff Bárbara Garcia-Valdecasas Vilanova. Cáncer de mama: estudio de focos neoplásicos invasores y no invasores de la expresión de Ki67 y
su relación con la supervivencia. Universitat Autònoma de Barcelona. Director: Agustí Barnadas. Date of defense: 21 December 2015.
*TIF: 331.7160 **MIF: 8.5055

Alamo P., Gallardo A., Di Nicolantonio F., Llorente-Cortes V., Intratumor cholesteryl Gaya J.M., Palou J., Pena J.A., Rosales A., Ma-
Pavon M.A., Casanova I., Trias M., Mangues ester accumulation is associated with hu- roto P., Sullivan I., Villavicencio H., Is there a
M.A., Lopez-Pousa A., Villaverde A., Vazquez man breast cancer proliferation and aggres- limit for the laparoscopic approach of a
E., Bardelli A., Cespedes M.V., Mangues R., sive potential: A molecular and clinico- retroperitoneal residual masspostchemo-
Higher metastatic efficiency of KRas G12V pathological study. (2015) BMC CANCER, 15 therapy?. (2015) ACTAS UROL ESP, 39 (4),
than KRas G13D in a colorectal cancer (1). 264-267.
model. (2015) FASEB J, 29 (2), 464-476. IF: 3.2650 IF: 0.9640
IF: 5.2990 De Quintana-Schmidt C., Alvarez-Holzapfel Geva R., Vecchione L., Kalogeras K.T., Jensen
Ales-Martinez J.E., Ruiz A., Chacon J.I., Lluch M.J., Nomdedeu-Guinot J., Bague-Rosell S., B.V., Lenz H.-J., Yoshino T., Paez D., Montagut
Hernandez A., Ramos M., Cordoba O., Gallego-Rubio O., Leidinger A., Sal- C., Souglakos J., Cappuzzo F., Cervantes A.,
Aguirre E., Barnadas A., Jara C., Gonzalez S., gado-Lopez L., Molet-Teixido J., Isocitrate Frattini M., Fountzilas G., Johansen J.S., Hog-
Plazaola A., Florian J., Andres R., Sanchez dehydrogenase type i mutation as a prog- dall E.V., Zhang W., Yang D., Yamazaki K.,
Rovira P., Frau A., Preventive treatments for nostic factor in glioblastoma and a literature Nishina T., Papamichael D., Vincenzi B., Mac-
breast cancer: recent developments. (2015) review. (2015) NEUROCIRUGIA, 26 (6), 276- arulla T., Loupakis F., De Schutter J., Spindler
CLIN TRANSL ONCOL, 17 (4), 257-263. 283. K.L.G., Pfeiffer P., Ciardiello F., Piessevaux H.,
IF: 2.0750 IF: 0.4100 Tejpar S., FCGR polymorphisms and cetuxi-
Aulinas A., Ramirez M.-J., Barahona M.-J., Va- Esteban E., Majem M., Martinez Aguillo M., mab efficacy in chemorefractory metastatic
lassi E., Resmini E., Mato E., Santos A., Crespo Martinez Banaclocha N., Domine M., Gomez colorectal cancer: An international consor-
I., Bell O., Surralles J., Webb S.M., Dyslipi- Aldaravi L., Juan O., Cajal R., Gonzalez Arenas tium study. (2015) GUT, 64 (6), 921-928.
demia and chronic inflammation markers M.C., Provencio M., Prevalence of EGFR mu- IF: 14.9210
are correlated with Telomere Length short- tations in newly diagnosed locally advanced Gil-Gil M.J., Bellet M., Morales S., Ojeda B.,
ening in Cushing’s syndrome. (2015) PLOS or metastatic non-small cell lung cancer Manso L., Mesia C., Garcia-Martinez E., Mar-
ONE, 10 (3). Spanish patients and its association with tinez-Janez N., Mele M., Llombart A., Pernas
IF: 3.0570 histological subtypes and clinical features: S., Villagrasa P., Blasco C., Baselga J., Pegy-
Blanco I., et al, Assessing associations be- The Spanish REASON study. (2015) CANCER lated liposomal doxorubicin plus cyclophos-
tween the AURKAHMMR-TPX2-TUBG1 func- EPIDEMIOL, 39 (3), 291-297. phamide followed by paclitaxel as primary
tional module and breast cancer risk in IF: 2.6440 chemotherapy in elderly or cardiotoxicity-
BRCA1/2 mutation carriers. (2015) PLOS Fernandez-Martos C., Garcia-Albeniz X., Per- -prone patients with high-risk breast cancer:
ONE, 10 (4). icay C., Maurel J., Aparicio J., Montagut C., results of the phase II CAPRICE study. (2015)
IF: 3.0570 Safont M.J., Salud A., Vera R., Massuti B., Es- BREAST CANCER RES TR, 151 (3), 597-606.
cudero P., Alonso V., Bosch C., Martin M., IF: 4.0850
Blay J.-Y., Papai Z., Tolcher A.W., Italiano A.,
Cupissol D., Lopez-Pousa A., Chawla S.P., Minsky B.D., Chemoradiation, surgery and Gras-Cabrerizo J.R., Leon-Vintro X., Tarruella
Bompas E., Babovic N., Penel N., Isambert N., adjuvant chemotherapy versus induction M.M., Sarria G.P., Gonzalez C.B., Montser-
Staddon A.P., Saada-Bouzid E., Santoro A., chemotherapy followed by chemoradiation rat-Gili J.R., Kolanczak K., Massegur-Solench
Franke F.A., Cohen P., Le-Guennec S., De- and surgery: Long-term results of the Span- H., Management of sinonasal mucosal mela-
metri G.D., Ombrabulin plus cisplatin versus ish GCR-3 phase II randomized trial. (2015) nomas and comparison of classification
placebo plus cisplatin in patients with ad- ANN ONCOL, 26 (8), 1722-1728. staging systems. (2015) AM J RHINOL AL-
vanced soft-tissue sarcomas after failure of IF: 9.2690 LERGY, 29 (1), e37-e40.
anthracycline and ifosfamide chemother- Fuentes-Raspall M.J., Caragol I., Alonso C., IF: 1.9600
apy: A randomised, double-blind, placebo- Ramon Y Cajal T., Fisas D., Seoane A., Carvajal Guillem V., Climent M.A., Cassinello J., Este-
controlled, phase 3 trial. (2015) LANCET ON- N., Bonache S., Diez O., Gutierrez-Enriquez S., ban E., Castellano D., Gonzalez-Larriba J.L.,
COL, 16 (5), 531-540. Apoptosis for prediction of radiotherapy late Maroto P., Camps C., Controversies in the
IF: 26.5090 toxicity: Lymphocyte subset sensitivity and treatment of invasive urothelial carcinoma:
Choueiri T.K., Escudier B., Powles T., Mainwar- potential effect of TP53 Arg72Pro polymor- A case report and review of the literature.
ing P.N., Rini B.I., Donskov F., Hammers H., phism. (2015) APOPTOSIS, 20 (3), 371-382. (2015) BMC UROL, 1-6.
Hutson T.E., Lee J.-L., Peltola K., Roth B.J., IF: 3.5920 IF: 1.6060
Bjarnason G.A., Geczi L., Keam B., Maroto P., Gallego O., Nonsurgical treatment of recur- Guillem V., Climent M.A., Cassinello J., Esteban
Heng D.Y.C., Schmidinger M., Kantoff P.W., rent glioblastoma. (2015) CURR ONCOL, 22 E., Castellano D., Gonzalez-Larriba J.L., Maroto
Borgman-Hagey A., Hessel C., Scheffold C., (4), e273-e281. P., Camps C., Controversies in the treatment of
Schwab G.M., Tannir N.M., Motzer R.J., IF: 1.8290 invasive urothelial carcinoma: A case report
Cabozantinib versus everolimus in advanced Gaya J.M., Palou J., Rosales A., Maroto P., and review of the literature Urological oncol-
renal-cell carcinoma. (2015) NEW ENGL J Sullivan I., Villavicencio H., Is there a limit for ogy. (2015) BMC UROL, 15 (1).
MED, 373 (19), 1814-1823. the laparoscopic approach of a retroperito- IF: 1.6060
IF: 59.5580 neal residual mass postchemotherapy?. Karachaliou N., Codony-Servat J., Teixido C.,
De Gonzalo-Calvo D., Lopez-Vilaro L., Na- (2015) ACTAS UROL ESP. Pilotto S., Drozdowskyj A., Codony-Servat C.,
sarre L., Perez-Olabarria M., Vazquez T., Es- IF: 0.9640 Gimenez-Capitan A., Molina-Vila M.A., Ber-
cuin D., Badimon L., Barnadas A., Lerma E., tran-Alamillo J., Gervais R., Massuti B., Moran

Clinical Oncology
*TIF: 331.7160 **MIF: 8.5055
T., Majem M., Felip E., Carcereny E., Garcia- A., Perez J.I., de Leiva A., The proteomic 2D- Rebbeck T.R., et al, Association of type and
Campelo R., Viteri S., Gonzalez-Cao M., Mo- DIGE approach reveals the protein volt- location of BRCA1 and BRCA2 mutations
rales-Espinosa D., Verlicchi A., Crisetti E., age-dependent anion channel 2 as a poten- with risk of breast and ovarian cancer. (2015)
Chaib I., Santarpia M., Luis Ramirez J., tial therapeutic target in epithelial thyroid JAMA-J AM MED ASSOC, 313 (13), 1347-
Bosch-Barrera J., Felipe Cardona A., De Ma- tumours. (2015) MOL CELL ENDOCRINOL, 1361.
rinis F., Lopez-Vivanco G., Miguel Sanchez J., 404, 37-45. IF: 37.6840
Vergnenegre A., Sanchez Hernandez J.J., IF: 3.8590 Rubio-Casadevall J., Martinez-Trufero J., Gar-
Sperduti I., Bria E., Rosell R., BIM and mTOR Motzer R.J., Hutson T.E., Glen H., Michaelson cia-Albeniz X., Calabuig S., Lopez-Pousa A.,
expression levels predict outcome to erlo- M.D., Molina A., Eisen T., Jassem J., Zolnierek del Muro J.G., Fra J., Redondo A., Lainez N.,
tinib in EGFR-mutant non-small-cell lung J., Maroto J.P., Mellado B., Melichar B., Tom- Poveda A., Valverde C., De Juan A., Sevilla I.,
cancer. (2015) SCI REP-UK, 5. asek J., Kremer A., Kim H.-J., Wood K., Dutcus Casado A., Andres R., Cruz J., Martin-Broto J.,
IF: 5.2280 C., Larkin J., Lenvatinib, everolimus, and the Maurel J., Role of Surgery in Patients with
Leon X., Aguero A., Lopez M., Garcia J., Farre combination in patients with metastatic re- Recurrent, Metastatic, or Unresectable Lo-
N., Lopez-Pousa A., Quer M., Salvage surgery nal cell carcinoma: A randomised, phase 2, cally Advanced Gastrointestinal Stromal Tu-
after local recurrence in patients with head open-label, multicentre trial. (2015) LANCET mors Sensitive to Imatinib: A Retrospective
and neck carcinoma treated with chemora- ONCOL, 16 (15), 1473-1482. Analysis of the Spanish Group for Research
diotherapy or bioradiotherapy. (2015) AURIS IF: 26.5090 on Sarcoma (GEIS). (2015) ANN SURG ON-
NASUS LARYNX, 42 (2), 145-149. Palassini E., Ferrari S., Verderio P., Paoli A.D., COL, 22 (9), 2948-2957.
IF: 1.0380 Broto J.M., Quagliuolo V., Comandone A., IF: 3.6550
Lopez-Pousa A., Broto J.M., Garrido T., Vaz- Sangalli C., Palmerini E., Lopez-Pousa A., Sebio A., Barnadas A., Salazar J., Paez D., Be-
quez J., Giant cell tumour of bone: new treat- Sanctis R.D., Bottelli S., Libertini M., Picci P., renguer-Llergo A., Del Rio E., Tobena M.,
ments in development. (2015) CLIN TRANSL Casali P.G., Gronchi A., Feasibility of preoper- Martin-Richard M., Sullivan I., Targarona E.,
ONCOL, 17 (6), 419-430. ative chemotherapy with or without radia- Balart J., Baiget M., EGFR ligands and DNA
IF: 2.0750 tion therapy in localized soft tissue sarcomas repair genes: Genomic predictors of com-
Marquez-Rodas I., Gonzalez M.M., Nagore E., of limbs and superficial trunk in the Italian plete response after capecitabine-based
Gomez-Fernandez C., Aviles-Izquierdo J.A., sarcoma group/grupo español de investiga- chemoradiotherapy in locally advanced rec-
Maldonado-Seral C., Soriano V., Majem-Tar- ción en sarcomas randomized clinical trial: tal cancer. (2015) PHARMACOGENOMICS J,
ruella M., Palomar V., Maseda R., Martin-Car- Three versus five cycles of full-dose epiru- 15 (1), 77-83.
nicero A., Puertolas T., Godoy E., Cerezuela P., bicin plus ifosfamide. (2015) J CLIN ONCOL, IF: 3.7840
De Olza M.O., Campos B., Perez-Ruiz E., Soria 33 (31), 3628-3634. Sepulveda J.M., Belda-Iniesta C., Gil-Gil M.,
A., Gil-Arnaiz I., Gonzalez-Cao M., Galvez E., IF: 20.9820 Perez-Segura P., Berrocal A., Reynes G., Gal-
Arance A., Belon J., De La Cruz-Merino L., Pare-Brunet L., Sebio A., Salazar J., Berengu- lego O., Capellades J., Ordonez J.M., La Or-
Martin-Algarra S., Frequency and character- er-Llergo A., Rio E., Barnadas A., Baiget M., den B., Balana C., A phase II study of feasibil-
istics of familial melanoma in Spain: The Paez D., Genetic variations in the VEGF ity and toxicity of bevacizumab in
FAM-GEM-1 study. (2015) PLOS ONE, 10 (4). pathway as prognostic factors in metastatic combination with temozolomide in patients
IF: 3.0570 colorectal cancer patients treated with ox- with recurrent glioblastoma. (2015) CLIN
Martin M., Simon A.R., Borrego M.R., Ribelles aliplatin-based chemotherapy. (2015) TRANSL ONCOL, 17 (9), 743-750.
N., Rodriguez-Lescure A., Munoz-Mateu M., PHARMACOGENOMICS J, 15 (5), 397-404. IF: 2.0750
Gonzalez S., Vila M.M., Barnadas A., Ramos M., IF: 3.7840 Sonnenblick A., Francis P.A., Azim H.A., De
Del Barco Berron S., Jara C., Calvo L., Martinez- Pavon M.A., Arroyo-Solera I., Tellez-Gabriel Azambuja E., Nordenskjold B., Gutierez J.,
Janez N., Fernandez C.M., Rodriguez C.A., De M., Leon X., Viros D., Lopez M., Gallardo A., Quinaux E., Mastropasqua M.G., Ameye L.,
Duenas E.M., Andres R., Plazaola A., De La Cespedes M.V., Casanova I., Lopez-Pousa A., Anderson M., Lluch A., Gnant M., Gold-
Haba-Rodriguez J., Lopez-Vega J.M., Adrover Mangues M.A., Quer M., Barnadas A., hirsch A., Di Leo A., Barnadas A., Cortes-
E., Ballesteros A.I., Santaballa A., Sanchez-Ro- Mangues R., Enhanced cell migration and Funes H., Piccart M., Crown J., Final 10-year
vira P., Baena-Canada J.M., Casas M., Del Car- apoptosis resistance may underlie the asso- results of the Breast International Group
men Camara M., Carrasco E.M., Lluch A., Epiru- ciation between high SERPINE1 expression 2-98 phase III trial and the role of Ki67 in
bicin plus cyclophosphamide followed by and poor outcome in head and neck carci- predicting benefit of adjuvant docetaxel in
docetaxel versus epirubicin plus docetaxel noma patients. (2015) ONCOTARGET, 6 (30), patients with oestrogen receptor positive
followed by capecitabine as adjuvant therapy 29016-29033. breast cancer. (2015) EUR J CANCER, 51
for node-positive early breast cancer: Results IF: 5.0080 (12), 1481-1489.
from the GEICAM/2003-10 study. (2015) J Ramon y Cajal T., Chirivella I., Miranda J., IF: 6.1630
CLIN ONCOL, 33 (32), 3788-3795. Teule A., Izquierdo, Balmana J., San- Stintzing S., Zhang W., Heinemann V., Neure-
IF: 20.9820 chez-Heras A.B., Llort G., Fisas D., Lope V., iter D., Kemmerling R., Kirchner T., Jung A.,
Martin-Richard M., Custodio A., Garcia-Giron Hernandez-Agudo E., Juan-Fita M.J., Tena I., Folwaczny M., Yang D., Ning Y., Sebio A.,
C., Gravalos C., Gomez C., Jimenez-Fonseca Robles L., Guillen-Ponce C., Perez-Segura P., Stremitzer S., Sunakawa Y., Matsusaka S.,
P., Manzano J.L., Pericay C., Rivera F., Carrato Luque-Molina M.S., Hernando-Polo S., Sali- Yamauchi S., Loupakis F., Cremolini C., Fal-
A., Seom guidelines for the treatment of nas M., Brunet J., Salas-Trejo M.D., Barnadas cone A., Lenz H.-J., Polymorphisms in genes
gastric cancer 2015. (2015) CLIN TRANSL A., Pollan M., Mammographic density and involved in EGFR turnover are predictive for
ONCOL, 17 (12), 996-1004. breast cancer in women from high risk fam- cetuximab efficacy in colorectal cancer.
IF: 2.0750 ilies. (2015) BREAST CANCER RES, 17 (1). (2015) MOL CANCER THER, 14 (10), 2374-
Mato E., Barcelo-Batllori S., Orera I., Selva L., IF: 5.2110 2381.
Corra M., Gonzalez C., Bell O., Lerma E., Moral IF: 5.5790

*TIF: 331.7160 **MIF: 8.5055

Suarez C., Puente J., Gallardo E., Mendez- Tibau A., Bedard P.L., Srikanthan A., Ethier J.-
-Vidal M.J., Climent M.A., Leon L., Olmos D., L., Vera-Badillo F.E., Templeton A.J., Ocana A.,
Garcia del Muro X., Gonzalez-Billalabeitia E., Seruga B., Barnadas A., Amir E., Author finan-
Production
Scientific
Grande E., Bellmunt J., Mellado B., Maroto P., cial conflicts of interest, industry funding,
Gonzalez del Alba A., New advances in gen- and clinical practice guidelines for antican-
itourinary cancer: evidence gathered in cer drugs. (2015) J CLIN ONCOL, 33 (1), 100-
2014. (2015) CANCER METAST REV, 34 (3), 106.
443-464. IF: 20.9820
IF: 5.3160

Oncogenesis and Antitumour Drugs
Coordinator
Mangues Bafalluy, Ramon IR
rmangues@santpau.cat
Members
Boullosa Goberna,
Ana María CIBERBBN
Cabrera Rodríguez,
Maria del Carmen CIBERBBN
Casanova Rigat,
Isolda CIBERBBN
Céspedes Navarro,
Virtudes CIBERBBN
Navas Jiménez, Luis Carlos IR
Sala Faig, Rita IR
ff Development of novel animal models of ff Identification of prognostic biomarkers in
of Research
Main Lines
disseminated disease in solid tumours and head and neck squamous cell carcinoma
Suárez Vasallo, Cristina IR
haematological neoplasms for the mecha- and their functional validation in vivo.
Turrado Rodríguez, Víctor FGS nistic study of metastases and preclinical
Unzueta Elorza, Ugutz IR drug development.
ff Development of nanoconjugates for tar-
geted delivery of antitumour drugs or tox-
ins to metastasis stem cells.
ff Obtain funding to ensure stable employ- ff Achieve antimetastatic effects by target-

Challenges
ment of senior researchers, attract post- ing antitumour drugs to metastasis stem
doctoral fellows and reinforce current col- cells in solid tumors and haematological
laborations with clinicians. neoplasies.
ff Develop molecular markers for therapeu- ff Enhance international collaboration and
tic decision-making in head and neck car- participation in EU networks and indus-
cinomas. trial projects.
ff Ramon Mangues Bafalluy. Modelos de ciadoras de metástasis en cáncer colo-

cáncer de colon metastásico para el estu- rectal. EUIN2013-50829. Ministerio de
dio de la recidiva tumoral. PI12/01861. Ins- Economía y Competitividad. Duration:
tituto de Salud Carlos III. Duration: 2013- 2014-2016. €22,000.
2016. €181,500.
ff Ugutz Unzueta Elorza. Contratos “Sara Bor-
Active Grants
ff Ramon Mangues Bafalluy. Genotoxic rell” 2014. CD14/00055. Instituto de Salud

nanoparticles targeting colorectal cancer Carlos III. Duration: 2015-2018. €86,598.
stem cells. 20132030. Fundació La Marató
de TV3. Duration: 2014-2017. €142,000.
ff Ramon Mangues Bafalluy. Terapia diri-
gida de Auristatina E o Ara-C a células de
ff Ramon Mangues Bafalluy. Grup d’on- leucemia mieloide aguda que expresan
cogènesi i antitumorals (GOA). 2014 SGR CXCR4, receptor implicado en adhesión al
1041. Agència de Gestió d’Ajuts Univer- estroma y quimiorresistencia. PI14/00450.
sitaris i de Recerca. Duration: 2014-2016. Instituto de Salud Carlos III. Duration:
€30,000. 2015-2017. €172,000.
ff Ramon Mangues Bafalluy. Terapia de Note: Total amount granted to PI. It does not include
nanoconjugados dirigida a células ini- indirect costs.
ff Laia Estalella Mercadé. Estudio de factores

clínico-patológicos y valor pronóstico de
la expresión subcelular de E-cadherina en
Theses
metástasis hepáticas de cáncer colorectal.

Directors: María Virtudes Céspedes, Vicenç
Artigas, Manuel Trias. Date of defense: 15
May 2015.

ff Ramon Mangues Bafalluy. Desenvolupament d’un nanoconju- 2015. PIE15/00028. Instituto de Salud Carlos III. Duration: 2016-
gat antimetastàtic dirigit a cèl·lules mare metastàtiques CXCR4+. 2018. €660,000.
2014 PROD 00055. Agència de Gestió d’Ajuts Universitaris i de
Recerca. Duration: 2015-2017. €89,500.
ff Ramon Mangues Bafalluy Nanoconjugados inteligentes para
Awarded
la terapia dirigida del cáncer colorectal (CCR) metastático.

in 2015
Grants
ff Ramon Mangues Bafalluy. Estrategias para aumentar la eficien- PI15/00378. Instituto de Salud Carlos III. Duration: 2016-2018.
cia metastática de los modelos animales de cáncer colorrectal. €208,000.
IR15-P4. Institut de Recerca de l’Hospital de la Santa Creu i Sant
Pau. Duration: 2015-2016. €33,000.
ff Ramon Mangues Bafalluy. Targeted nanocongugates for the se-
lective elimination of stem cells in disseminated cancer. MINECO
Collaborations with other IIB Sant Pau Groups International Collaborations

ff Irene Arroyo Solera (GOA). Beca AGAUR. Desenvolupament de ff Achilea Bittencourt. Visiting Researcher, International Coopera-
models metastàtics de carcinoma de cap i coll i paper de Serpina1 tion with Brasil, MCT/CNPq 046/2010.
en diseminació. AGAUR, Generalitat de Catalunya. FI DGR-2013.
ff Paolo Micheli, Institute for Cancer Resaerch and Treatment, Can-
diol, Turin (Italy).
National Collaborations ff Arne Östman, Cancer Center Karolinska, Karolinska Institutet,

Stockholm (Sweden).
ff Eduard Batlle, Biomedical Research Institute (IRB) and Barcelona ff Alberto Bardelli, University of Torino, Medical School, Turin (Italy).
Scientific Park (PCB).
ff COST Action CM1106. European Union. Chemical Approaches
ff Roger Gomis, Biomedical Research Institute (IRB) and Barcelona to Targeting Drug Resistance in Cancer Stem Cells. EU RTD
Collaborations
Scientific Park (PCB). Framework Programme. MC Member: Ramon Mangues. Man-

ff CB06/01/1031. Centro de Investigación Biomédica en Red de agement Committee Member & Biology and Pharmacology
Bioingenieria, Biomateriales y Nanomedicina (CIBER-BBN). Insti- Working Group Member, Duration: 28/03/12-27/03/16.
tuto de Salud Carlos III. 2010-2015. €80,000-117,000/year. ff ATMP-EATRIS, European Union. Member of the Working Group
ff ICTS 141007: NANBIOSIS. Recognition by MINECO as Infraes- on Advanced therapies and biologicals of ATMP (Advanced
tructura Científica y Técnica Singular (ICTS) en Ciencias de la Therapy Medicinal Products), EATRIS (European Insfrastructure
Salud y Biotecnología (Producción y Caracterización de Nano- for Translational Medicine) Network.
materiales, Biomateriales y Sistemas en Biomedicina), Unitat ff ETP Nanomedicine, European Union, Member of the European
de Natoxoicologia, Institut d’Investigacions Biomèdiques Sant Technology Platform on Nanomedicine.
Pau and CIBER-BBN. Coordinators: Centro de Investigación Bio-
médica en Red (CIBER-BBN) y Centro de Cirugía Mínima Invasiva ff TME-AACR member. Member of the Tumor Microenvironment
Jesus Usón (JUSMISC). Financing agency: MINECO. Grant date: Working Group, American Association for Cancer Research
8/10/14. (AACR).
ff OncoCat. Member of the Catalonian Cancer Research Network.
Xarxa ConnectEU, Biocat, Generalitat de Catalunya.
ff NanoBioMed. Member of the Catalonian Network on Nanobio-
technology, Xarxa Connect-EU. Biocat.

Oncogenesis and Antitumour Drugs

*TIF: 64.5510 **MIF: 7.1723
Alamo P., Gallardo A., Di Nicolantonio F., Pavon M.A., Arroyo-Solera I., Tellez-Gabriel analysis of the applicability of the specialty
Pavon M.A., Casanova I., Trias M., Mangues M., Leon X., Viros D., Lopez M., Gallardo A., program in General and Digestive Surgery.
M.A., Lopez-Pousa A., Villaverde A., Vazquez Cespedes M.V., Casanova I., Lopez-Pousa A., (2015) CIR ESPAN, 93 (3), 152-158.
E., Bardelli A., Cespedes M.V., Mangues R., Mangues M.A., Quer M., Barnadas A., IF: 1.0000
Higher metastatic efficiency of KRas G12V Mangues R., Enhanced cell migration and Unzueta U., Cespedes M.V., Vazquez E., Fer-
than KRas G13D in a colorectal cancer apoptosis resistance may underlie the asso- rer-Miralles N., Mangues R., Villaverde A., To-
model. (2015) FASEB J, 29 (2), 464-476. ciation between high SERPINE1 expression wards protein-based viral mimetics for can-
IF: 5.2990 and poor outcome in head and neck carci- cer therapies. (2015) TRENDS BIOTECHNOL,
noma patients. (2015) ONCOTARGET, 6 (30),
De la Torre C, Casanova I, Acosta G, Coll C, 33 (5), 253-258.

Moreno MJ, Albericio F, Aznar E, Mangues R, 29016-29033. IF: 12.0650
Royo M, Sancenón F, Martínez-Máñez R. IF: 5.0080
Xu Z., Cespedes M.V., Unzueta U., Alamo P.,
Gated Mesoporous Silica Nanoparticles Us- Rueda F., Cespedes M.V., Conchillo-Sole O., Pesarrodona M., Mangues R., Vazquez E.,
ing a Double-Role Circular Peptide for the Sanchez-Chardi A., Seras-Franzoso J., Cu- Villaverde A., Ferrer-Miralles N., Targeting
Controlled and Target-Preferential Release barsi R., Gallardo A., Pesarrodona M., Fer- low-density lipoprotein receptors with pro-
of Doxorubicin in CXCR4-expresing Lym- rer-Miralles N., Daura X., Vazquez E., Garcia- tein-only nanoparticles. (2015) J NANOPART
phoma cells. (2015) ADV FUNCT MATER, Fruitos E., Mangues R., Unzueta U., Villaverde RES, 17 (3).
25(5), 687-695. A., Bottom-Up Instructive Quality Control in IF: 2.1010
IF: 10.3000 the Biofabrication of Smart Protein Materi-
als. (2015) ADV MATER, 27 (47), 7816-7822. Xu Z., Unzueta U., Roldan M., Mangues R.,
Moreno M.J., Bosch R., Dieguez-Gonzalez R., Sanchez-Chardi A., Ferrer-Miralles N.,
Novelli S., Mozos A., Gallardo A., Pavon M.A., IF: 18.9600
Villaverde A., Vazquez E., Formulating tu-
Cespedes M.V., Granena A., Alcoceba M., Targarona Soler E.M., Jover Navalon J.M., mor-homing peptides as regular nanoparti-
Blanco O., Gonzalez-Diaz M., Sierra J., Gutierrez Saiz J., Turrado Rodriguez V., Par- cles enhances receptor-mediated cell pene-
Mangues R., Casanova I., CXCR4 expression rilla Paricio P., Targarona E.M., Torres A.J., trability. (2015) MATER LETT, 154, 140-143.
enhances diffuse large B cell lymphoma Gallego J.L, Pacheco D., Salvador-Sanchis IF: 2.4370
dissemination and decreases patient sur- J.L., Hernandez E., Lucena J.L., del Riego F.J.,
vival. (2015) J PATHOL, 235 (3), 445-455. Jover J.M., Pina J., Saavedra D., The surgical
IF: 7.3810 experience of general surgery residents: An


Haematological Diagnosis
Coordinator
Nomdedéu Guinot,
Josep Francesc FGS
jnomdedeu@santpau.cat
Members
Aventín Artisan, Ana María FGS
Ayats Aubert, Ramon FGS
Bussaglia Petrillo,
Elena Mart FGS
Carricondo Morcillo, Maite
Espadaler Pare, Montserrat FGS
Estivill Riezu, María Camino FGS
Fernández Rosales,
María Nieves FGS Malignant Haemopathologies Noncancerous Haemopathologies
Fuentes Hernández, Diagnostic activities: morphological, im- Diagnosis and characterization of throm-
ff ff
Francisca FGS munophenotyping, cytogenetic and mo- bocytopenias, thrombocytopathies and
Hernández Campos, lecular characterization (particularly of other platelet pathologies, especially
Carmen FGS acute leukaemias). complex pathologies (of genetic, mixed
Martínez Sánchez, or unknown origin) and including unusual
ff Biological characteristics responding to presentations of common diseases.
Elisabeth FGS therapy.
Martínez Valverde, ff In the framework of the GAIT-2 (genetic
ff New treatments using cell line models analysis of idiopathic thrombophilia,
Clara Maria FGS
aimed at molecular targets. phase 2) project, to seek new phenotypes
Ortín Quílez, Rosa FGS
Remacha Sevilla, ff Genomic (microarrays) and proteomic that favour the development of thrombo-
platforms for diagnosis. sis, specifically related to the structure and
Ángel Francisco FGS function of platelets and other blood cells.
Rubio Olmos, Miguel Ángel IR ff Murine models development.
Sardà Vidal, Maria Pilar FGS
Serra Ferrer, Marta FGS
Úbeda Rodenas, José FGS
ff Consolidate characterization of haemato- ff Consolidate cooperation with the GAIT-2
logical tumours and complex, rare and ge- project, especially regarding platelet and
netic noncancerous haematopathologies. other blood cell participation in thrombo-
sis generation.
ff Include the results of mass-analysis ge-
Challenges
nomic and proteomic platforms in diag- ff Promote interaction and stable links with
nostic algorithms and establish prognos- internal groups (clinical haematology, pa-
tic factors for haematological disorders, thology, gastrointestinal, haemostasis and
preferably complex or genetic neoplasms thrombosis, complex disease genomics
and noncancerous pathologies. areas) and with other groups in Spain and
abroad, especially those with complemen-
ff Develop functional cell culture and animal tary technologies.
(murine) models.
Collaborations with other IIB Sant Pau External Collaborations

Group
Collaborations
ff Dr. Anna Bigas, IMIM Hospital del Mar.

ff Oncology / Haematology and Transplan- ff Dr. Pablo Menéndez, Josep Carreras Foun-
tation (PI: Jordi Sierra). dation (Hospital Clínic).
ff Genetic Diseases (PI: Montserrat Baiget). ff Dr. Alberto Villanueva, IDIBELL-Bellvitge
ff Molecular Bases of Disease (PI: Pablo Biomedical Research Institute.
Fuentes Prior).

ff Josep Francesc Nomdedéu Guinot. Niveles de ARNm de WT1 en ff Josep Francesc Nomdedéu Guinot. Diagnostic Hematologic.
neoplasias mieloides. Aplicación de los métodos de PCR digital 2014 SGR 383. Agència de Gestió d’Ajuts Universitaris i de Re-
Grants
Active
en la estratificación pronóstica y en el manejo de las recaídas. cerca. Duration: 2014-2016. €30,000.

PI13/02729. Instituto de Salud Carlos III. Duration: 2014-2016.
€57,500.
*TIF: 68.0700 **MIF: 3.7817

Aulinas A., Colom C., Garcia Patterson A., deu M., Risueno R.M., Hoyos M., Sierra J., Munoz Gomez M., Bisbe Vives E., Basora
Ubeda J., Maria M.A., Orellana I., Adelantado Monzo M., Navarro A., Esteve J., The lincRNA Macaya M., Garcia Erce J.A., Gomez Luque A.,
J.M., de Leiva A., Corcoy R., Smoking affects HOTAIRM1, located in the HOXA genomic Leal-Noval S.R., Colomina M.J., Comin Colet
the oral glucose tolerance test profile and region, is expressed in acute myeloid leuke- J., Contreras Barbeta E., Cuenca Espierrez J.,
the relationship between glucose and mia, impacts prognosis in patients in the in- Garcia de Lorenzo y Mateos A., Gomollon
HbA1c in gestational diabetes mellitus. termediate-risk cytogenetic category, and is Garcia F., Izuel Rami M., Moral Garcia M.V.,
(2015) DIABETIC MED. associated with a distinctive microRNA sig- Montoro Ronsano J.B., Paramo Fernandez
IF: 3.1520 nature. (2015) ONCOTARGET, 6 (31), 31613- J.A., Pereira Saavedra A., Quintana Diaz M.,
Baeza-Richer C., Arroyo-Pardo E., Blan- 31627. Remacha Sevilla A., Salinas Argente R., San-
co-Rojo R., Toxqui L., Remacha A., Vaquero IF: 5.0080 chez Perez C., Tirado Angles G., Torrabadella
M.P., Lopez-Parra A.M., Genetic contribu- Garcia-Dabrio M.C., Hoyos M., Brunet S., de Reinoso P., Forum for debate: Safety of
tion to iron status: SNPs related to iron de- Tormo M., Ribera J.-M., Esteve J., Gallardo D., allogeneic blood transfusion alternatives in
ficiency anaemia and fine mapping of CAC- Duarte R.F., de Llano M.P., Bargay J., Marti- the surgical/critically ill patient. (2015) MED
NA2D3 calcium channel subunit. (2015) Tutusaus J.M., Heras I., Garcia A., Salamero O., INTENSIVA, 39 (9), 552-562.
BLOOD CELL MOL DIS, 55 (4), 273-280. Aventin A., Lecrevisse Q., Orfao A., Sierra J., IF: 1.1930
IF: 2.7310 Nomdedeu J.F., Complex measurements Oliveras V., Martin-Baranera M., Gracia M.,
Civaschi E., Pujol-Moix N., Klersy C., Melazzini may be required to establish the prognostic Del Val J.L., Plans M., Pujol-Moix N., The rele-
F., Pujol-Moix N., Santoro C., Cattaneo M., impact of immunophenotypic markers in vance of the ankle-arm index to the reclassi-
Lavenu-Bombled C., Bury L., Minuz P., Nur- AML. (2015) AM J CLIN PATHOL, 144 (3), 484- fication of cardiovascular risk in asymptom-
den P., Cid A.R., Cuker A., Latger-Cannard V., 492. atic hypertensive middle-aged males. (2015)
Favier R., Nichele I., Noris P., Analysis of 65 IF: 2.2780 MED CLIN-BARCELONA, 144 (10), 435-439.
pregnancies in 34 women with five different Gonzalez-Gascon y Marin I., Hernandez-San- IF: 1.2670
forms of inherited platelet function disor- chez M., Rodriguez-Vicente A.-E., Sanzo C., Pujol-Moix N., Vazquez-Santiago M., Morera
ders. (2015) BRIT J HAEMATOL, 170 (4), 559- Aventin A., Puiggros A., Collado R., Heras C., A., Ziyatdinov A., Remacha A., Nomdedeu
563. Munoz C., Delgado J., Ortega M., Gonzalez J.F., Fontcuberta J., Soria J.M., Souto J.C., Ge-
IF: 5.4010 M.-T., Marugan I., de la Fuente I., Recio I., netic determinants of Platelet Large-Cell
De Quintana-Schmidt C., Alvarez-Holzapfel Bosch F., Espinet B., Gonzalez M., Hernandez- Ratio, Immature Platelet Fraction, and other
M.J., Nomdedeu-Guinot J., Bague-Rosell S., -Rivas J.-M., Hernandez J.-A., A high propor- platelet-related phenotypes. (2015)
Gallego-Rubio O., Leidinger A., Sal- tion of cells carrying trisomy 12 is associated THROMB RES, 136 (2), 361-366.
gado-Lopez L., Molet-Teixido J., Isocitrate with a worse outcome in patients with IF: 2.3200
dehydrogenase type i mutation as a prog- chronic lymphocytic leukemia. (2015) HE- Remacha AF., Arrizabalaga B., Villegas A.,
nostic factor in glioblastoma and a literature MATOL ONCOL. Duran M.S., Hermosin L., de Paz R., Garcia M.,
review. (2015) NEUROCIRUGIA, 26 (6), 276- IF: 3.4940 Diez Campelo M., Sanz G., Evolution of iron
283. Larocca L.M., Heller P.G., Podda G., Pujo- overload in patients with low-risk myelodys-
IF: 0.4100 l-Moix N., Glembotsky A.C., Pecci A., Alberelli plastic syndrome: iron chelation therapy
Diaz-Beya M., Brunet S., Nomdedeu J., Cor- M.A., Balduini C.L., Landolfi R., Cattaneo M., and organ complications. (2015) ANN HE-
deiro A., Tormo M., Escoda L., Ribera J.M., De Candia E., Megakaryocytic emperipolesis MATOL, 94 (5), 779-787.
Arnan M., Heras I., Gallardo D., Bargay J., and platelet function abnormalities in five IF: 3.0220
Queipo De Llano M.P., Salamero O., Marti patients with gray platelet syndrome. (2015) Remacha A.F., Wright I., Fernandez-Jimenez
J.M., Sampol A., Pedro C., Hoyos M., Pratco- PLATELETS, 26 (8), 751-757. M.C., Toxqui L., Blanco-Rojo R., Moreno G.,
rona M., Castellano J.J., Nomdedeu M., Ri- IF: 3.2130 Vaquero M.P., Vitamin B12 and folate levels
sueno R.M., Sierra J., Monzo M., Navarro A., Menendez J.A., Benboudjema L., Vellon L., increase during treatment of iron deficiency
Esteve J., The expression level of BAALC-as- Rubio M.A., Espinoza I., Campisi J., Lupu R., anaemia in young adult woman. (2015) INT
sociated microRNA miR-3151 is an indepen- Heregulin, a new interactor of the te- J LAB HEMATOL, 37 (5), 641-648.
dent prognostic factor in younger patients losome/shelterin complex in human telo- IF: 2.4010
with cytogenetic intermediate-risk acute meres. (2015) ONCOTARGET, 6 (37), 39408- Ribera J., Morgades M., Zamora L., Montesi-
myeloid leukemia. (2015) BLOOD CANCER J, 39421. nos P., Gomez-Segui I., Pratcorona M., Sarra
5, e352-. IF: 5.0080 J., Guardia R., Nomdedeu J., Tormo M., Mar-
IF: 4.4110 Menendez J.A., Rubio M.A., Campisi J., Lupu tinez-Lopez J., Hernandez-Rivas J.-M., Gon-
Diaz-Beya M., Brunet S., Nomdedeu J., Prat- R., Heregulin, a new regulator of telomere zalez-Campos J., Barba P., Escoda L., Genesca
corona M., Cordeiro A., Gallardo D., Escoda L., length in human cells. (2015) ONCOTARGET, E., Sole F., Milla F., Feliu E., Ribera J.-M., Prog-
Tormo M., Heras I., Ribera J.M., Duarte R., de 6 (37), 39422-39436. nostic significance of copy number altera-
Llano M.P.Q., Bargay J., Sampol A., Nomde- IF: 5.0080 tions in adolescent and adult patients with

Haematological Diagnosis
*TIF: 68.0700 **MIF: 3.7817
precursor B acute lymphoblastic leukemia Dulucq S., Farrugia J., Fletcher L., Foroni L., Sacha T., Talmaci R., Touloumenidou T., Van
enrolled in PETHEMA protocols. (2015) CAN- Ganderton R., Gerrard G., Gineikiene E., Hay- Der Velden V.H.J., Waits P., Wang L., Wilkinson
CER-AM CANCER SOC, 121 (21), 3809-3817. ette S., El Housni H., Izzo B., Jansson M., Joh- E., Wilson G., Wren D., Zadro R., Ziermann J.,
Production
Scientific
IF: 5.6490 nels P., Jurcek T., Kairisto V., Kizilors A., Kim Zoi K., Muller M.C., Hochhaus A., Schimmel
White H., Deprez L., Corbisier P., Hall V., Lin F., D.-W., Lange T., Lion T., Polakova K.M., Mar- H., Cross N.C.P., Emons H., A certified plasmid
Mazoua S., Trapmann S., Aggerholm A., An- tinelli G., Mccarron S., Merle P.A., Milner B., reference material for the standardisation of
drikovics H., Akiki S., Barbany G., Boeckx N., Mitterbauer-Hohendanner G., Nagar M., BCR-ABL1 mRNA quantification by real-time
Bench A., Catherwood M., Cayuela J.-M., Nickless G., Nomdedeu J., Nymoen D.A., Lei- quantitative PCR. (2015) LEUKEMIA, 29 (2),
Chudleigh S., Clench T., Colomer D., Daraio F., bundgut E.O., Ozbek U., Pajic T., Pfeifer H., 369-376.
Preudhomme C., Raudsepp K., Romeo G., IF: 12.1040


Molecular Pathology of Gynaecologic Cancer
Coordinator
Prat Díaz de Losada, Jaime FGS
jprat@santpau.cat
Members
Bértolo Martín
de Rosales, Cristina IR
D’angelo, Emanuela FGS
Espinosa Mariscal, Íñigo FGS
García-Valdecasas
Vilanova, Bárbara FGS
González Vidal, Alan FGS
Lerma Puertas, Enrique FGS
Muñoz Beatove, Josefina FGS
Nagel Moyano, Maria Jesús IR
ff Pathogenic mechanisms of gynaecologi- ff Clinical application of tumour markers.
cal cancer (endometrial/ovarian cancer).
Pascual García, Mónica IR ff Molecular biology of uterine and ex-
of Research
Main Lines
Pau Colomer, Laia ff Molecular mechanisms of stromal re- tra-uterine sarcomas.

Pons Pérez, Cristina FGS sponse and immunosuppression in en-
Rodríguez Santas, dometrial cancer.
María del Valle FGS ff Clinical application of prognostic factors
Serrat Aymerich, in common cancers (endometrial, ovarian,
María Nieves IR etc).
Szafranska, Justyna FGS
Vásquez Gámez,
Celina Paola FGS
Vázquez del Olmo, Tania IR
Challenges
ff Progress as a productive translational gy- ff Cooperate with other groups at the na-
naecological cancer research group, capa- tional and international levels.
ble of competing with other highly visible
groups in Barcelona that publish regular
articles in reputable journals.
Collaborations with other IIB Sant Pau ff Dr. Jaume Reventós, Vall d’Hebron Hospital
Groups Research Institute (VHIR), Barcelona, Spain.
Collaborations
ff Dr. Xavier Matias-Guiu, Institute for Bio-

ff Experimental Immunology (Silvia Vidal). medical Research (IRB Lleida), Lleida, Spain.
ff Dr. Miguel Abal, Santiago de Compostela
University Hospital Complex (CHUS), Spain.
Molecular alterations related with progres- ff Dr. Gema Moreno, Fundación MD Ander-
sion in endometrial cancer (Spanish Associ- son Internacional, Madrid, Spain.
ation Against Cancer, AECC):
ff Jaime Prat Díaz de Losada. Altera- ff Jaime Prat Díaz de Losada. Red Temática
ciones moleculares relacionadas con de Investigación Cooperativa en Cáncer
la progresión tumoral en el cáncer de (RTICC). RD12/0036/0011. Instituto de
endometrio. AECC 2011. Asociación Salud Carlos III. Duration: 2013-2016.
Active Grants
Española contra el Cáncer. Duration: 2011- €160,000.

2016. €262,000.
ff Jaime Prat Díaz de Losada. Agreement indirect costs.
ICO. ICO 2011. Duration: 2008-2016.
€109,090.88.
ff Íñigo Espinosa Mariscal. La importancia de
la vía CSF1 en los leiomiosarcomas uteri-
nos. PI12/01645. Instituto de Salud Carlos
III. Duration: 2013-2016. €70,000.

ff Jaime Prat. Method to predict risk of recurrence in endometrial

Patents
carcinoma. Application number: PCT/EP2015/053387.
*TIF: 61.9990 **MIF: 3.6470

Alonso-Alconada L., Santacana M., Gar- mas of the breast and ovary: Utility of Pax-8, Odicino F., Pecorelli S., Prat J., Quinn M.,
cia-Sanz P., Muinelo-Romay L., Colas E., Mi- WT-1, and GATA3 for distinguishing inde- Seoud M.A.-F., Shrivastava S.K., Figo’s staging
rantes C., Monge M., Cueva J., Oliva E., Sos- pendent primary tumors from metastases. classification for cancer of the ovary, fallo-
low R.A., Lopez M.A., Palacios J., Prat J., Valls (2015) INT J GYNECOL PATHOL, 34 (3), 257- pian tube, and peritoneum: Abridged re-
J., Krakstad C., Salvesen H., Gil-Moreno A., 265. publication. (2015) J GYNECOL ONCOL, 26
Lopez-Lopez R., Dolcet X., Moreno-Bueno G., IF: 1.4370 (2), 87-89.
Reventos J., Matias-Guiu X., Abal M., Annex- Guo X., Jo V.Y., Mills A.M., Zhu S.X., Lee C.-H., IF: 2.5220
in-A2 as predictor biomarker of recurrent Espinosa I., Nucci M.R., Varma S., Forgo E., Prat J., Abridged republication of FIGO’s
disease in endometrial cancer. (2015) INT J Hastie T., Anderson S., Ganjoo K., Beck A.H., staging classification for cancer of the
CANCER, 136 (8), 1863-1873. West R.B., Fletcher C.D., Van De Rijn M., Clini- ovary, fallopian tube, and peritoneum.
IF: 5.5310 cally relevant molecular subtypes in leiomy- (2015) EUR J OBSTET GYN R B, 188, 133-135.
Auguste A, Bessière L, Todeschini AL, Cabu- osarcoma. (2015) CLIN CANCER RES, 21 (15), IF: 1.6620
ret S, Sarnacki S, Prat J, D’Angelo E, de la 3501-3511. Prat J., Belhadj H., Berek J., Bermudez A.,
Grange P, Ariste O, Lemoine F, Legois B, Sul- IF: 8.7380 Bhatla N., Cain J., Denny L., Fujiwara K.,
tan C, Zider A, Galmiche L, Kalfa N, Veitia RA. Mancikova V., Castelblanco E., Pineiro-Yanez Hacker N., Avall-Lundqvist E., Mutch D.,
Molecular analyses of juvenile granulosa cell E., Perales-Paton J., De Cubas A.A., Inglada- Odicino F., Pecorelli S., Prat J., Quinn M.,
tumors bearing AKT1 mutations provide in- Perez L., Matias-Guiu X., Capel I., Bella M., Seoud M.A.-F., Shrivastava S.K., Abridged re-
sights into tumor biology and therapeutic Lerma E., Riesco-Eizaguirre G., Santisteban P., publication of FIGO’s staging classification
leads. (2015) Hum Mol Genet, 24, 6687-6698. Maravall F., Mauricio D., Al-Shahrour F., Rob- for cancer of the ovary, fallopian tube, and
IF: 6.3930 ledo M., MicroRNA deep-sequencing reveals peritoneum. (2015) EUR J GYNAECOL ON-
Binder P.S., Prat J., Mutch D.G., Molecular master regulators of follicular and papillary COL, 36 (4), 367-369.
staging of gynecological cancer: What is the thyroid tumors. (2015) MODERN PATHOL, 28 IF: 0.5800
future?. (2015) BEST PRACT RES CL OB, 29 (6), (6), 748-757. Prat J., Ovarian, fallopian tube and perito-
776-789. IF: 5.4850 neal cancer staging: Rationale and explana-
IF: 2.2910 Mato E., Barcelo-Batllori S., Orera I., Selva L., tion of new FIGO staging 2013. (2015) BEST
Cortes-Vicente E., Delgado-Mederos R., Bell- Corra M., Gonzalez C., Bell O., Lerma E., Moral PRACT RES CL OB, 29 (6), 858-869.
munt S., Borras X.F., Gomez-Anson B., Bague A., Perez J.I., de Leiva A., The proteomic 2D- IF: 2.2910
S., Camps-Renom P., Marti-Fabregas J., DIGE approach reveals the protein volt- Sanchez E., Nieto J.C., Boullosa A., Vidal S.,
Stroke caused by a myxoma stenosing the age-dependent anion channel 2 as a poten- Sancho F.J., Rossi G., Sancho-Bru P., Oms R.,
common carotid artery. (2015) J STROKE tial therapeutic target in epithelial thyroid Mirelis B., Juarez C., Guarner C., Soriano G.,
CEREBROVASC, 24 (4), e87-e89. tumours. (2015) MOL CELL ENDOCRINOL, VSL#3 probiotic treatment decreases bacte-
IF: 1.5990 404, 37-45. rial translocation in rats with carbon tetra-
de Gonzalo-Calvo D., Lopez-Vilaro L., Na- IF: 3.8590 chloride-induced cirrhosis. (2015) LIVER INT,
sarre L., Perez-Olabarria M., Vazquez T., Es- Moreno M.J., Bosch R., Dieguez-Gonzalez 35 (3), 735-745.
cuin D., Badimon L., Barnadas A., Lerma E., R., Novelli S., Mozos A., Gallardo A., Pavon IF: 4.4700
Llorente-Cortes V., Intratumor cholesteryl M.A., Cespedes M.V., Granena A., Alcoceba
ester accumulation is associated with hu- M., Blanco O., Gonzalez-Diaz M., Sierra J.,
man breast cancer proliferation and ag- Mangues R., Casanova I., CXCR4 expression
gressive potential: A molecular and clinico- enhances diffuse large B cell lymphoma
pathological study. (2015) BMC CANCER, 15 dissemination and decreases patient sur-
(1). vival. (2015) J PATHOL, 235 (3), 445-455.
IF: 3.2650 IF: 7.3810
De Quintana-Schmidt C., Alvarez-Holzapfel Perez-Balaguer A., Ortiz-Martinez F., Gar-
M.J., Nomdedeu-Guinot J., Bague-Rosell S., cia-Martinez A., Pomares-Navarro C., Lerma
Gallego-Rubio O., Leidinger A., Sal- E., Peiro G., FOXA2 mRNA expression is asso-
gado-Lopez L., Molet-Teixido J., Isocitrate ciated with relapse in patients with
dehydrogenase type i mutation as a prog- Triple-Negative/Basal-like breast carcinoma.
nostic factor in glioblastoma and a literature (2015) BREAST CANCER RES TR, 153 (2), 465-
review. (2015) NEUROCIRUGIA, 26 (6), 276- 474.
283. IF: 4.0850
IF: 0.4100 Prat J., Belhadj H., Berek J., Bermudez A.,
Espinosa I., Gallardo A., D’Angelo E., Mozos Bhatla N., Cain J., Denny L., Fujiwara K.,
A., Lerma E., Prat J., Simultaneous carcino- Hacker N., Avall-Lundqvist E., Mutch D.,

Ear, Nose and Throat Cancers
Coordinator
Quer Agustí, Miquel FGS
mquer@santpau.cat
Members
Bothe González, Carolina FGS
De Juan Beltran, Julia FGS
García Lorenzo, Jacinto FGS
Gras Cabrerizo, Juan Ramon FGS
Kolanczak, Katarzyna Alicja FGS
Leon Vintro, Xavier FGS
Lop Gros, Joan FGS
López Vilas, Montserrat FGS
Massegur Solench, Humbert
Montserrat Gili,
ff Genetic and molecular predictors of re- ff Nasosinal endoscopic surgery: innova-
sponse to head and neck cancer (with tions in skull base techniques.
of Research
Joan Ramon FGS

Main Lines
the Oncogenesis and Antitumour Drugs

Orús Dotu, César FGS group).
ff Internal ear: aspects related to severe
Venegas Pizarro, deafness, cochlear implants and otoneu-
María del Prado FGS
ff Molecular mechanisms of inflammation in rological surgery of tumours.
head and neck cancer (with the Inflamma-
tion Laboratory).
Challenges
ff Promote clinical and translational research ff Study relevant clinical issues in depth (sec-
into head and neck cancer with a very ond-third neoplasms, staging concerns,
large database of head and neck cancers. prognostic factors, etc) and investigate
translational aspects such as genetic and
molecular predictors.

Groups
Catalan Institute of Oncology: Epidemiol-
Collaborations
ff
ff Angiology, Vascular Biology and Inflamma- ogy (Dr. X. Bosch).

tion (Dr. Lluís Vila). ff Catalan Institute of Oncology: Oncology
ff Oncogenesis and Antitumour Drugs (Dr . (Dr. Ricard Mesia).
Ramon Mangues). ff Hospital Joan XXIII: Head and Neck Cancer
ff Translational Molecular Oncology (Dr. (Dr. F.J. Avilés).
Matilde Parreño). ff Hospital Central de Asturias: Head and
Neck Cancer (Dr. C. Suárez).
ff Xavier Leon Vintró. Herramienta de predic-

ción de respuesta a la radioterapia basada
en la expresión de genes relacionados
con la transición epitelial-mesenquimal
Grants
Active
en cáncer de cabeza y cuello. PI14/01918.

Instituto de Salud Carlos III. Duration: 2015-
2017. €71,500.
indirect costs.

*TIF: 20.3950 **MIF: 4.0790

Camacho M., Pineiro Z., Alcolea S., Garcia J., Leon X., Bothe C., Garcia J., Parreno M., Al-
Balart J., Terra X., Aviles-Jurado F.-X., Soler M., colea S., Quer M., Vila L., Camacho M., Expres-
Quer M., Leon X., Vila L., Prostacyclin-syn- sion of IL-1α correlates with distant metasta-
thase expression in head and neck carci- sis in patients with head and neck squamous
noma patients and its prognostic value in cell carcinoma. (2015) ONCOTARGET, 6 (35),
the response to radiotherapy. (2015) J 37398-37409.
PATHOL, 235 (1), 125-135. IF: 5.0080
IF: 7.3810 Pavon M.A., Arroyo-Solera I., Tellez-Gabriel

Gras-Cabrerizo J.R., Leon-Vintro X., Tarruella M., Leon X., Viros D., Lopez M., Gallardo A.,
M.M., Sarria G.P., Gonzalez C.B., Montser- Cespedes M.V., Casanova I., Lopez-Pousa A.,
rat-Gili J.R., Kolanczak K., Massegur-Solench Mangues M.A., Quer M., Barnadas A.,
H., Management of sinonasal mucosal mela- Mangues R., Enhanced cell migration and
nomas and comparison of classification apoptosis resistance may underlie the asso-
staging systems. (2015) AM J RHINOL AL- ciation between high SERPINE1 expression
LERGY, 29 (1), e37-e40. and poor outcome in head and neck carci-
IF: 1.9600 noma patients. (2015) ONCOTARGET, 6 (30),
Leon X., Aguero A., Lopez M., Garcia J., Farre 29016-29033.
N., Lopez-Pousa A., Quer M., Salvage surgery IF: 5.0080
after local recurrence in patients with head
and neck carcinoma treated with chemora-
diotherapy or bioradiotherapy. (2015) AURIS
NASUS LARYNX, 42 (2), 145-149.
IF: 1.0380

Oncology/Haematology and Transplantation
Coordinator
Sierra Gil, Jordi FGS
jsierra@santpau.cat
Members
Álvarez Fernández, Carmen IR
Ballarín Laliena, Gemma FGS
Barata Badiella, Anna IR
Borrell Gallardo, Silvia IR
Bosch Godia, Rosa Maria IR
Briones Meijide, Javier FGS
Brunet Mauri, Maria Salut FGS
Caballero González,
Ana Carolina FGS
Canaleta Ros, Cristina FGS
ff Study of the molecular and cellular patho- ff Design of new modalities of haemato-
physiology of haematological cancers. poietic stem-cell transplantation and cell
Corriguelas Armillas, Helena IR
therapy.
of Research
Main Lines
Cortes Barba, Susana FGS ff Study of the prognostic value of clinical

De Rueda Gamboa, and biological parameters in haematolog- ff Psychological intervention and quality of
María Jéssica IR ical malignancies. life in patients with haematological malig-
nancies.
Escriba Garcia, Laura IR ff Design of new modalities of chemother-
Esquirol Sanfeliu, Albert IR apy, biotherapy and drug treatment tar-
García Cadenas, Irene FGS geting molecular mechanisms.
Garrido Díaz, Anna IR
Granell Gorrochategui,
Miguel FGS
Hoyos Colell, Montserrat IR ff Identify new prognostic parameters for ff Model leukaemia and lymphoma in ani-
Martino Bofarull, Rodrigo FGS risk and therapeutic stratification. mals to better understand cell physiopa-
Miqueleiz Álamos, Sara IR thology and test new drugs (with the On-
ff Evaluate targeted therapy in cell lines and cogenesis and Antitumour Drugs group).
Monter Rovira, Anna FGS animal models (with the Oncogenesis and
Mora Raya, Alba
Challenges
Antitumour Drugs group). ff Molecularly characterize and determine

Moreno Atanasio, Carolina FGS the prognostic significance of cell physio-
ff Reduce toxicity and increase availability of pathology and immunotherapy for lymp-
Novelli Canales,
allogeneic transplants. hoproliferative diseases and evaluate an-
Silvana Ana Rina FGS
Pallares López, Manuel Víctor IR ff Molecularly characterize acute myeloid titumour immunotherapy in animals and
leukaemia and determine the prognostic humans.
Rosal Muntadas-Prim,
value of known genes and other genes of
Maria Josefa IR
uncertain significance (with the Haema-
Rovira Brugués, Sandra IR tology Laboratory).
Saavedra Gerosa,
Silvana Daniela FGS
Sanz Cobos, Patricia IR
Vicente Pascual, Eva Puy IR
Vilalta Seto, Noelia FGS Collaborations with other IIB Sant Pau ff European Research Initiative on Chronic
Groups Lymphocytic Leukemia (ERIC): C. Moreno,
coordinator.
ff Oncogenesis and Antitumour Drugs (Dr. ff Spanish lymphoma transplantation groups
Ramon Mangues). (GELTAMO): J. Briones, S. Novelli
Collaborations
ff Haematological Diagnosis (Dr. Josep Nom- ff Spanish haematologic malignancies con-

dedéu). sortium (PETHEMA): J. Sierra, M. Granell, S.
ff Microbiology and Infectious Diseases (Dr. Brunet
Pere Coll). ff Spanish CETLAM acute myeloid leukaemia
and myelodysplasia group hospitals: coor-
External Collaborations dinator, S. Brunet.
ff Haematologic cancer programme groups,

ff European Leukaemia Network of Excel-
Carlos III Health Institute Cooperative Can- lence groups.
cer Research Network (RTICC): J. Sierra, co-
ordinator.

ff Maria Salut Brunet Mauri. Tratamiento de la leucemia mieloide ff Manuel Víctor Pallarés López. Contratos Sara Borrell 2013.
aguda de novo con la combinación de idarrubicina en dosis CD13/00074. Instituto de Salud Carlos III. Duration: 2014-2017.
creciente, citarabiana y sensibilización (“priming”) con GCSF. Es- €80,598.
tudio prospectivo en fase I/II de toxicidad y eficacia. EC11-364.
ff Jordi Sierra Gil. Terapia dirigida de Auristatina E o Ara-C a células
Active Grants
Ministerio de Sanidad y Política Social. Duration: 2012-2016.

€93,135. de leucemia mieloide aguda que expresan CXCR4, receptor im-
plicado en adhesión al estroma y quimiorresistencia. PI14/00450.
ff Jordi Sierra Gil. Red Temática de Investigación Cooperativa en Instituto de Salud Carlos III. Duration: 2015-2017. €19,500.
Cáncer (RTICC). RD12/0036/0071. Instituto de Salud Carlos III.
Duration: 2013-2016. €321,500.
ff Javier Briones Meijide. Memory stem T cells transduced with a
chimeric antigen receptor targeting CD30 for the tretment of
hodgkin lymphoma. 20130710. Fundació La Marató de TV3. Du-
ration: 2014-2017. €153,970.
ff Jordi Sierra Gil. Grup de diagnòstic i tractament de les neoplàsies ff Carolina Moreno Atanasio. Anàlisi de l’expressió i funció del
hematològiques. 2014 SGR 1281. Agència de Gestió d’Ajuts Uni- FcyRIIb en cèl·lules B normals i en leucèmia limfàtica crònica.
versitaris i de Recerca. Duration: 2015-2016. €18,000. Conveni CELLEX-2. Fundació CELLEX. Duration: 2015-2017.
Grants Awarded
€118,181.82.
ff Alba Mora Raya. Caracterització immunofenotípica i molecular
de la malaltia residual en leucèmia limfàtica crònica. 2015 FI_B ff Javier Briones Meijide. Inmunoterapia mediante células T
in 2015
00295. Agència de Gestió d’Ajuts Universitaris i de Recerca. Du- de memoria “stem” modificadas con receptores quiméricos
ration: 2015-2018. €37,805.88. antígeno-específicos (CARs) para tratamiento de pacientes con
neoplasias linfoides. Conveni CELLEX-3. Fundació CELLEX. Dura-
ff Javier Briones Meijide. Terapia génica 2.0: nueva generación de tion: 2015-2017. €190,000.
vectores virales episomales de alta bioseguridad y su desarrollo
pre-industrial. RTC-2015-3393-1. Ministerio de Economía y Com- Note: Total amount granted to PI. It does not include indirect costs.
petitividad. Duration: 2015-2018. €112,138.60.
*TIF: 184.5090 **MIF: 5.2717

Arai S., Arora M., Wang T., Spellman S.R., He plantation. (2015) BONE MARROW Blood and Marrow Transplantation. (2015) J
W., Couriel D.R., Urbano-Ispizua A., Cutler TRANSPL. HEMATOL ONCOL.
C.S., Bacigalupo A.A., Battiwalla M., Flowers IF: 3.6360 IF: 6.2630
M.E., Juckett M.B., Lee S.J., Loren A.W., Barba P., Martino R., Martinez-Cuadron D., Bernal T., Martinez-Camblor P., Sanchez-Gar-
Klumpp T.R., Prockup S.E., Ringden O.T.H., Olga G., Esquirol A., Gil-Cortes C., Gonzalez cia J., De Paz R., Luno E., Nomdedeu B., Ar-
Savani B.N., Socie G., Schultz K.R., Spitzer T., J., Fernandez-Aviles F., Valcarcel D., Guardia danaz M.T., Pedro C., Amigo M.L., Xicoy B.,
Teshima T., Bredeson C.N., Jacobsohn D.A., R., Duarte R.F., Hernandez-Rivas J.M., Abella Del Canizo C., Tormo M., Bargay J., Valcarcel
Hayashi R.J., Drobyski W.R., Frangoul H.A., E., Montesinos P., Ribera J.M., Impact of D., Brunet S., Benlloch L., Sanz G., Effective-
Akpek G., Ho V.T., Lewis V.A., Gale R.P., Ko- transplant eligibility and availability of a ness of azacitidine in unselected high-risk
reth J., Chao N.J., Aljurf M.D., Cooper B.W., human leukocyte antigen-identical myelodysplastic syndromes: Results from
Laughlin M.J., Hsu J.W., Hematti P., Verdonck matched related donor on outcome of the Spanish registry. (2015) LEUKEMIA, 29
L.F., Solh M.M., Norkin M., Reddy V., Martino older patients with acute lymphoblastic (9), 1875-1881.
R., Gadalla S., Goldberg J.D., McCarthy P.L., leukemia. (2015) LEUKEMIA LYMPHOMA, 56 IF: 12.1040
Perez-Simon J.A., Khera N., Lewis I.D., Atsuta (10), 2812-2818.
Y., Olsson R.F., Saber W., Waller E.K., Blaise D., Briones J., Heat-shock proteins: A c-Myc lym-
IF: 3.0930 phoma target?. (2015) BLOOD, 125 (11),
Pidala J.A., Martin P.J., Satwani P., Born-
hauser M., Inamoto Y., Weisdorf D.J., Horow- Baron F., Labopin M., Ruggeri A., Mohty M., 1685-1686.
itz M.M., Pavletic S.Z., Increasing Incidence Sanz G., Milpied N., Bacigalupo A., Ram- IF: 11.8410
of Chronic Graft-versus-Host Disease inAl- baldi A., Bonifazi F., Bosi A., Sierra J., Yak- Castillo N., Garcia-Cadenas I., Garcia O.,
logeneic Transplantation: A Report from oub-Agha I., Santasusana J.M.R., Gluckman Barba P., Diaz-Heredia C., Martino R., Az-
the Center for International Blood and Mar- E., Nagler A., Unrelated cord blood trans- queta C., Ferra C., Canals C., Elorza I., Olive T.,
row Transplant Research. (2015) BIOL plantation for adult patients with acute Badell I., Sierra J., Duarte R., Valcarcel D.,
BLOOD MARROW TR, 21 (2), 266-274. myeloid leukemia: Higher incidence of Querol S., Few and nonsevere adverse infu-
IF: 3.9800 acute graft-versus-host disease and lower sion events using an automated method for
survival in male patients transplanted with diluting and washing before unrelated sin-
Barba P., Martino R., Orti G., Esquirol A., Pe- female unrelated cord blood-a report from
rez-Hoyos S., Sierra J., Valcarcel D., Valida- gle cord blood transplantation. (2015) BIOL
Eurocord, the Acute Leukemia Working BLOOD MARROW TR, 21 (4), 682-687.
tion of a new integrated prognostic score Party, and the Cord Blood Committee of the
to predict non-relapse mortality in patients IF: 3.9800
Cellular Therapy and Immunobiology
undergoing reduced-intensity condition- Working Party of the European Group for Castillo N., Garcia-Cadenas I., Barba P., Mar-
ing allogeneic hematopoietic cell trans- tino R., Azqueta C., Ferra C., Canals C., Sierra

Oncology/Haematology and Transplantation

*TIF: 184.5090 **MIF: 5.2717
J., Valcarcel D., Querol S., Post-Thaw Viable Aventin A., Lecrevisse Q., Orfao A., Sierra J., Menendez J.A., Rubio M.A., Campisi J., Lupu
CD45+ Cells and Clonogenic Efficiency are Nomdedeu J.F., Complex measurements R., Heregulin, a new regulator of telomere
Associated with Better Engraftment and may be required to establish the prognostic length in human cells. (2015) ONCOTARGET,
Outcomes after Single Cord Blood Trans- impact of immunophenotypic markers in 6 (37), 39422-39436.
plantation in Adult Patients with Malignant AML. (2015) AM J CLIN PATHOL, 144 (3), 484- IF: 5.0080
Diseases. (2015) BIOL BLOOD MARROW TR, 492. Millon Cano J.A., Vilalta Seto N., Mateo Ar-
21 (12), 2167-2172. IF: 2.2780 ranz J., Souto Andres J.C., Importance of ap-
IF: 3.9800 Garcia-Sanz R., Oriol A., Moreno M.J., De La propiate clinical management of direct oral
Diaz-Beya M., Brunet S., Nomdedeu J., Cor- Rubia J., Payer A.R., Hernandez M.T., anticoagulants. (2015) MED CLIN-BARCE-
deiro A., Tormo M., Escoda L., Ribera J.M., Palomera L., Teruel A.I., Blanchard M.J., Giro- LONA.
Arnan M., Heras I., Gallardo D., Bargay J., nella M., Ribas P., Bargay J., Abella E., Granell IF: 1.2670
Queipo De Llano M.P., Salamero O., Marti M., Ocio E.M., Ribera J.M., San Miguel J.F., Moreno M.J., Bosch R., Dieguez-Gonzalez R.,
J.M., Sampol A., Pedro C., Hoyos M., Pratco- Mateos M.V., Zoledronic acid as compared Novelli S., Mozos A., Gallardo A., Pavon M.A.,
rona M., Castellano J.J., Nomdedeu M., Ri- with observation in multiple myeloma pa- Cespedes M.V., Granena A., Alcoceba M.,
sueno R.M., Sierra J., Monzo M., Navarro A., tients at biochemical relapse: Results of the Blanco O., Gonzalez-Diaz M., Sierra J.,
Esteve J., The expression level of BAALC-as- randomized AZABACHE Spanish trial. (2015) Mangues R., Casanova I., CXCR4 expression
sociated microRNA miR-3151 is an indepen- HAEMATOLOGICA, 100 (9), 1207-1213. enhances diffuse large B cell lymphoma
dent prognostic factor in younger patients IF: 6.6710 dissemination and decreases patient sur-
with cytogenetic intermediate-risk acute Halter J.P., Michael W., Schupbach M., Man- vival. (2015) J PATHOL, 235 (3), 445-455.
myeloid leukemia. (2015) BLOOD CANCER J, del H., Casali C., Orchard K., Collin M., Valcar- IF: 7.3810
5, e352-. cel D., Rovelli A., Filosto M., Dotti M.T., Ma-
IF: 4.4110 Moreno C., Montillo M., Panayiotidis P.,
rotta G., Pintos G., Barba P., Accarino A., Dimou M., Bloor A., Dupuis J., Schuh A.,
Diaz-Beya M., Brunet S., Nomdedeu J., Prat- Ferra C., Illa I., Beguin Y., Bakker J.A., Boelens Norin S., Geisler C., Hillmen P., Doubek M.,
corona M., Cordeiro A., Gallardo D., Escoda L., J.J., De Coo I.F.M., Fay K., Sue C.M., Nachbaur Trneny M., Obrtlikova P., Laurenti L., Stilgen-
Tormo M., Heras I., Ribera J.M., Duarte R., de D., Zoller H., Sobreira C., Pinto Simoes B., bauer S., Smolej L., Ghia P., Cymbalista F.,
Llano M.P.Q., Bargay J., Sampol A., Nomde- Hammans S.R., Savage D., Marti R., Chin- Jaeger U., Stamatopoulos K., Stavroyianni N.,
deu M., Risueno R.M., Hoyos M., Sierra J., nery P.F., Elhasid R., Gratwohl A., Hirano M., Carrington P., Zouabi H., Leblond V., Go-
Monzo M., Navarro A., Esteve J., The lincRNA Barros Navarro G., Benoist J.F., Bierau J., mez-Garcia J.C., Rubio M., Marasca R., Mu-
HOTAIRM1, located in the HOXA genomic Bucalossi A., Carluccio M.A., Coll-Canti J., suraca G., Rigacci L., Farina L., Paolini R., Pos-
region, is expressed in acute myeloid leuke- Cotelli M.S., Diesch T., Di Fabio R., Donati pisilova S., Kimby E., Bradley C., Montserrat
mia, impacts prognosis in patients in the in- M.A., Garvin J.H., Hill K., Kappeler L., Ku Hne E., Ofatumumab in poor-prognosis chronic
termediate-risk cytogenetic category, and is T., Lara M.C., Lenoci M., Lucchini G., Mar- lymphocytic leukemia: A phase IV, non-in-
associated with a distinctive microRNA sig- ques W., Mattle H.P., Meyer A., Parini R., terventional, observational study from the
nature. (2015) ONCOTARGET, 6 (31), 31613- Passweg J.R., Pieroni F., Rodriguez-Palmero European research initiative on chronic lym-
31627. A., Santus F., Scarpelli M., Schlesser P., Si- phocytic leukemia. (2015) HAEMATOLOG-
IF: 5.0080 curelli F., Stern M., Stracieri A.B., Tonin P., ICA, 100 (4), 511-516.
Falantes J., Delgado R.G., Calderon-Cabrera Torres-Torronteras J., Voltarelli J.C., Zaidman IF: 6.6710
C., Marquez-Malaver F.J., Valcarcel D., de Mi- I., Allogeneic haematopoietic stem cell
transplantation for mitochondrial neuro- Moreno C., Chronic lymphocytic leukemia
guel D., Bailen A., Bargay J., Bernal T., Gonza- and the Warburg effect. (2015) BLOOD, 125
lez-Porras J.R., Tormo M., Ramos F., Andreu R., gastrointestinal encephalomyopathy.
(2015) BRAIN, 138 (10), 2847-2858. (22), 3368-3369.
Xicoy B., Nomdedeu B., Brunet S., Sanchez J., IF: 11.8410
Jurado A.F., Bonanad S., Perez-Simon J.A., IF: 10.1030
Sanz G., Multivariable time-dependent anal- Martino R., Bautista G., Parody R., Garcia I., Noriega V., Martinez-Laperche C., Buces E.,
ysis of the impact of azacitidine in patients Esquirol A., Rovira M., Cabrera J.R., Regidor Pion M., Sanchez-Hernandez N., Martin-An-
with lower-risk myelodysplastic syndrome C., Fores R., Garcia-Marco J.A., Serrano D., tonio B., Guillem V., Bosch-Vizcaya A., Bento
and unfavorable specific lower-risk score. Barba P., Heras I., Marquez-Malaver F.J., San- L., Gonzalez-Rivera M., Balsalobre P., Kwon
(2015) LEUKEMIA RES, 39 (1), 52-57. chez-Ortega I., Duarte R., Saavedra S., Sierra M., Serrano D., Gayoso J., De La Camara R.,
IF: 2.6060 J., Vazquez L., Severe infections after single Brunet S., Rojas-Contreras R., Nieto J.B., Mar-
umbilical cord blood transplantation in tinez C., Gonzalez M., Espigado I., Vallejo J.C.,
Garcia-Cadenas I., Castillo N., Martino R., Sampol A., Jimenez-Velasco A., Urbano-Ispi-
Barba P., Esquirol A., Novelli S., Orti G., Gar- adults with or without the co-infusion of
CD34+ cells from a third-party donor: Re- zua A., Solano C., Gallardo D., Diez-Martin
rido A., Saavedra S., Moreno C., Granell M., J.L., Buno I., The genotype of the donor for
Briones J., Brunet S., Navarro F., Ruiz I., Ra- sults of a multicenter study from the Grupo
Español de Trasplante Hematopoyético the (GT)n polymorphism in the promoter/
bella N., Valcarcel D., Sierra J., Impact of Ep- enhancer of FOXP3 Is associated with the
stein Barr virus-related complications after (GETH). (2015) TRANSPL INFECT DIS, 17 (2),
221-233. development of severe acute GVHD but
high-risk allo-SCT in the era of pre-emptive does not affect the GVL effect after myeloab-
rituximab. (2015) BONE MARROW TRANSPL, IF: 1.4590
lative HLA-Identical allogeneic stem cell
50 (4), 579-584. Menendez J.A., Benboudjema L., Vellon L., transplantation. (2015) PLOS ONE, 10 (10).
IF: 3.6360 Rubio M.A., Espinoza I., Campisi J., Lupu R., IF: 3.0570
Garcia-Dabrio M.C., Hoyos M., Brunet S., Heregulin, a new interactor of the telosome/
shelterin complex in human telomeres. Novelli S., Sierra J., Briones J., New therapies
Tormo M., Ribera J.-M., Esteve J., Gallardo D., in non-Hodgkin lymphoma. (2015) EXPERT
Duarte R.F., de Llano M.P., Bargay J., Marti- (2015) ONCOTARGET, 6 (37), 39408-39421.
IF: 5.0080 REV ANTICANC, 15 (3), 349-359.
Tutusaus J.M., Heras I., Garcia A., Salamero O., IF: 2.0940

*TIF: 184.5090 **MIF: 5.2717

Novelli S., Briones J., Flotats A., Sierra J., PET/ Ramos F., Thepot S., Pleyer L., Maurillo L., Sanchez-Ortega I., Querol S., Encuentra M.,
CT assessment of follicular lymphoma and Itzykson R., Bargay J., Stauder R., Venditti A., Ortega S., Serra A., Sanchez-Villegas J.M.,
high grade B cell lymphoma - Good correla- Seegers V., Martinez-Robles V., Burgstaller S., Grifols J.R., Pujol-Balaguer M.M., Pujol-Bosch
tion with clinical and histological features at Recher C., Deben G., Gaidano G., Gardin C., M., Marti J.M., Garcia-Cerecedo T., Barba P.,
diagnosis. (2015) ADV CLIN EXP MED, 24 (2), Musto P., Greil R., Sanchez-Guijo F., Fenaux P., Sancho J.M., Esquirol A., Sierra J., Duarte R.F.,
325-330. Thepot S., Recher C., Raffoux E., Quesnel B., Plerixafor in patients with lymphoma and
IF: 1.1270 Delaunay J., Cluzeau T., Koka A.M., Stama- multiple myeloma: Effectiveness in cases
Ocio E.M., Herrera P., Olave M.-T., Castro N., toullas A., Chaury M.-P., Gyan E., Cheze S., with very low circulating CD34+ cell levels
Perez-Simon J.A., Brunet S., Oriol A., Mateo Banos A., Morel P., Plantier I., Taksin A.-L., and preemptive intervention vs remobiliza-
M., Sanz M.-A., Lopez J., Montesinos P., Shanti A., Sanhes L., De Botton S., Marolleau tion. (2015) BONE MARROW TRANSPL, 50 (1),
Chillon M.-C., Prieto-Conde M.-I., Diez-Cam- J.P., Pautas C., Wattel E., Isnard F., Guerci A., 34-39.
pelo M., Gonzalez M., Vidriales M.-B., Mateos Vey N., Dreyfus F., Ifrah N., Ades L., Mar- IF: 3.6360
M.-V., San Miguel J.F., Panobinostat as part of tinez-Robles V., Deben G., Garrido A., Casano Urbano-Ispizua A., Pavletic S.Z., Flowers M.E.,
induction and maintenance for elderly pa- J., Salamero O., Bergua J.M., Colado E., Garcia Klein J.P., Zhang M.-J., Carreras J., Montoto S.,
tients with newly diagnosed acute myeloid R., Pedro C., Redondo S., Tormo M., Bonanad Perales M.-A., Aljurf M.D., Akpek G., Bredeson
leukemia: Phase Ib/II panobidara study. S., Diez-Campelo M., Perez-Encinas M., de la C.N., Costa L.J., Dandoy C., Freytes C.O., Fung
(2015) HAEMATOLOGICA, 100 (10), 1294- Fuente A., Xicoy B., Falantes J.F., Font P., Gon- H.C., Gale R.P., Gibson J., Hamadani M.,
1300. zalez-Lopez T.J., Martin-Nunez G., Montesi- Hayashi R.J., Inamoto Y., Inwards D.J., Lazarus
IF: 6.6710 nos P., Sanchez-Guijo F., Pleyer L., Burgstaller H.M., Maloney D.G., Martino R., Munker R.,
S., Schreder M., Tinchon C., Pfeilstoecker M., Nishihori T., Olsson R.F., Rizzieri D.A., Reshef
Orti G., Sanz J., Bermudez A., Caballero D., Steinkirchner S., Melchardt T., Mitrovic M.,
Martinez C., Sierra J., Cabrera Marin J.R., Espi- R., Saad A., Savani B.N., Schouten H.C., Smith
Girschikofsky M., Lang A., Krippl P., Sliwa T., S.M., Socie G., Wirk B., Yu L.C., Saber W., The
gado I., Solano C., Ferra C., Garcia-Noblejas Egle A., Linkesch W., Voskova D., Angermann
A., Jimenez S., Sampol A., Yanez L., Gar- Impact of Graft-versus-Host Disease on the
H., Spagnoli A., Lunghi M., Pietrantuono G., Relapse Rate in Patients with Lymphoma
cia-Gutierrez V., Pascual M.J., Jurado M., Mo-
Villani O., Azacitidine frontline therapy for Depends on the Histological Subtype and
raleda J.M., Valcarcel D., Sanz M.A., Carreras unfit acute myeloid leukemia patients: Clini-
E., Duarte R.F., Outcome of Second Alloge- the Intensity of the Conditioning Regimen.
cal use and outcome prediction. (2015) LEU- (2015) BIOL BLOOD MARROW TR, 21 (10),
neic Hematopoietic Cell Transplantation af- KEMIA RES, 39 (3), 296-306.
ter Relapse of Myeloid Malignancies follow- 1746-1753.
IF: 2.6060 IF: 3.9800
ing Allogeneic Hematopoietic Cell
Transplantation: A Retrospective Cohort on Rossi D., Terzi-Di-Bergamo L., De Paoli L., Xicoy B., Germing U., Jimenez M.-J., Garcia O.,
Behalf of the Grupo Español de Trasplante Cerri M., Ghilardi G., Chiarenza A., Bulian P., Garcia R., Schemenau J., Pedro C., Luno E.,
Hematopoyetico. (2015) BIOL BLOOD MAR- Visco C., Mauro F.R., Morabito F., Cortelezzi Bernal T., Gonzalez B., Strupp C., Ardanaz M.,
ROW TR. A., Zaja F., Forconi F., Laurenti L., Del Giudice Kuendgen A., Cedena M.-T., Neukirchen J.,
IF: 3.9800 I., Gentile M., Vincelli I., Motta M., Coscia M., Calabuig M., Brunet S., Medina A., Amigo
Rigolin G.M., Tedeschi A., Neri A., Marasca R., M.-L., Ramos F., Callejas M., Diez-Campelo
Parody R., Lopez-Corral L., Godino O.L., Cad- Perbellini O., Moreno C., Del Poeta G., Mas-
enas I.G., Martinez A.P., Vazquez L., Martino M., Bailen A., Collado R., Vicente A., Arnan M.,
saia M., Zinzani P.L., Montillo M., Cuneo A., Valcarcel D., Arilla M.J., Zamora L., Benlloch
R., Martinez C., Solano C., Barba P., Valcarcel Gattei V., Foa R., Gaidano G., Molecular pre-
D., Caballero-Velazquez T., Marquez-Malaver L., Sanz G., Response to erythropoietic-stim-
diction of durable remission after first-line ulating agents in patients with chronic mye-
F.J., Sierra J., Caballero D., Perez-Simon J.A., fludarabinecyclophosphamide-rituximab in
GVHD prophylaxis with sirolimus-tacrolimus lomonocytic leukemia. (2015) EUR J HAEMA-
chronic lymphocytic leukemia. (2015) TOL.
may overcome the deleterious effect on BLOOD, 126 (16), 1921-1924.
survival of HLA mismatch after reduced-in- IF: 2.5440
IF: 11.8410
tensity conditioning allo-SCT. (2015) BONE
MARROW TRANSPL, 50 (1), 121-126. Ruggeri A., Labopin M., Sanz G., Piemontese
IF: 3.6360 S., Arcese W., Bacigalupo A., Blaise D., Bosi A.,
Huang H., Karakasis D., Koc Y., Michallet M.,
Pavon M.A., Arroyo-Solera I., Tellez-Gabriel Picardi A., Sanz J., Santarone S., Sengelov H.,
M., Leon X., Viros D., Lopez M., Gallardo A., Sierra J., Vincent L., Volt F., Nagler A., Gluck-
Cespedes M.V., Casanova I., Lopez-Pousa A., man E., Ciceri F., Rocha V., Mohty M., Compar-
Mangues M.A., Quer M., Barnadas A., ison of outcomes after unrelated cord blood
Mangues R., Enhanced cell migration and and unmanipulated haploidentical stem cell
apoptosis resistance may underlie the asso- transplantation in adults with acute leuke-
ciation between high SERPINE1 expression mia. (2015) LEUKEMIA, 29 (9), 1891-1900.
and poor outcome in head and neck carci- IF: 12.1040
noma patients. (2015) ONCOTARGET, 6 (30),
29016-29033.
IF: 5.0080

AREA 4
Neurological, Ment
and Ageing
140 Cerebrovascular Diseases
142 Neuromuscular Diseases
146 Parkinson Disease and Movement Disorders
150 Molecular Neuropharmacology
152 Pharmacological Research in Humans
154 Clinical Psychiatry
158 Genetics in Neurodegenerative Diseases

tal Disorders
162 Human Neuropsychopharmacology
164 Neurobiology of Dementia
168 Neuroradiology
170 Ageing Institute
172 Addictive Behaviours
174 Molecular Physiology of the Synapse

140 AREA 4 · Neurological, Mental Disorders and Ageing
Cerebrovascular Diseases
Coordinator
Martí Fàbregas, Joan FGS
jmarti@santpau.cat
Members
Camps Renom, Pol FGS
Delgado Mederos, Raquel FGS
Jiménez-Xarrie, Elena
Marín Bueno, Rebeca IR
Martínez-Domeño, Alejandro
Prats Sánchez, Luis Antonio IR
ff Brain neurorepair after stroke. ff Benefits and risks of intravenous throm-

bolysis.
ff Role of statins in ischemic and haemor-
rhagic stroke. ff Sonothrombolysis.
of Research
Main Lines
ff Prevention of cerebral haemorrhage with ff Non-invasive monitoring of cerebral flow

anticoagulants. with applied optic methods.
ff Endothelial progenitor cells in stroke. ff Participation in clinical trials.
ff Aetiological classification of brain haem- ff Cancer and stroke, Vulnerability of the
orrhage. atherosclerotic plaque, predictors of atrial
fibrillation.
ff Pathophysiology of hematoma growth in
acute cerebral haemorrhage.
ff Enhance cooperation with other groups in Clínic de Barcelona, Dr. Turgut Durduran at
the framework of Spanish stroke research. ICFO). To obtain funding from FIS, regional
authorities and private companies.
Challenges
ff Network (RETICS/INVICTUS) and also

intrahospital cooperation (the Catalan ff Increase the number of contracted and
Institute of Cardiovascular Sciences and grant-aided researchers and profession-
the Haemostasis-Thrombosis group) and ally develop existing researchers.
extra-hospital cooperation (with groups
managed by Dr. García-Verdugo in Valen-
cia, Dr. Arús at the Autonomous University
of Barcelona, Dr. Anna Planas at Hospital
ff Joan Martí Fàbregas. INVICTUS. ff Joan Martí Fàbregas. REgenerative Stem

Active Grants
RD12/0014/0002. Instituto de Salud Carlos cell therapy for STroke in Europe-RESS-

III. Duration: 2013-2016. €165,220.40. TORE. PHC-15-2015. European Union. Du-
ration: 2015-2020. €389.58.
ff Joan Martí Fàbregas. Malalties Vascu-
lars Cerebrals. 2014 SGR 703. Agència de Note: Total amount granted to PI. It does not include
Gestió d’Ajuts Universitaris i de Recerca. indirect costs.
ff Joan Martí Fàbregas. Estudio de la progresión y la vulnerabilidad de la aterosclero-

Awarded
sis carotídea: influencia del recuento de células progenitoras y del control de factores
in 2015
Grants
de riesgo vascular. Proyectos de Investigación en Salud 2015. PI15/00884. Duration:

01/01/2016-31/12/2018. € 45,000.

AREA 4 · Neurological, Mental Disorders and Ageing 141
Collaborations with other IIB Sant Pau Groups ff Dr. Antonio Dávalos, Hospital Germans Trias i Pujol, Badalona,
Spain.
ff Neuroradiology.
ff Dr. Francesc Purroy, Hospital Arnau de Vilanova, Lleida, Spain.
ff Thrombosis and Haemostasis.
ff RETICS (cooperative health research network) / INVICTUS (ictus
ff Cardiovascular Biochemistry. research)
ff Neurobiology of Dementia. ff Clinical trials:
ff Molecular Pathology and Therapeutic of Ischaemic and Athero- -- IMPACT-24b: Implant in the sphenopalatine ganglion to in-
thrombotic Diseases. crease cerebral blood flow 24 hours after stroke onset.
-- IMPACT-24Bt: Implant in the sphenopalatine ganglion to in-
crease cerebral blood flow 24 hours after stroke onset (rt-PA
Collaborations
External Collaborations port).

ff Dr. García-Verdugo, Universidad de Valencia, Spain. -- CLEAR III: Evaluation of thrombolytic therapy in intraventricu-
lar haemorrhage.
ff Dr. Carles Arús, Facultat de Ciències, Universitat Autònoma de -- LIFE: Multicentre, randomized, double-blind, parallel group,
Barcelona, Spain. placebo-controlled study of the effect of treatment with
ff Dr. Turgut Durduran, Instituto de Ciencias Fotónicas, Castellde- F2695 (75 mg OD) in 3 months to improve functional capacity
in patients with ischaemic stroke.
fels, Barcelona, Spain.
ff Dr. Tomás Sobrino, Hospital General Universitario, Santiago de ff Dra. Jennifer Linn (SUSPECT study), University of Rochester, New
Compostela, Spain. York
ff Dr. Israel Fernández, Dr. Joan Montaner, Hospital Vall d’Hebron, ff Dr. David Werring (HERO study), National Hospital for Neurology
Barcelona, Spain. and Neurosurgery, London.
ff Dr. Blanca Fuentes, Hospital La Paz, Madrid, Spain. ff Dr. Peter Kelly (BIOVASC study), Mater University Hospital, Dub-
lin.
ff Dr. Patricia Martínez, Hospital La Paz, Madrid, Spain.
ff Dr. Antonio Gil. Hospital Gregorio Marañón, Madrid, Spain.
ff Dr. Ángel Chamorro, Hospital Clínico de Barcelona, Spain.
*TIF: 27.6160 **MIF: 2.7616

Aracil-Bolanos I., Prats-Sanchez L., Go- Jimenez-Xarrie E., Davila M., Gil-Perotin S., J., Cerebral amyloid angiopathy-related
mez-Anson B., Querol-Gutierrez L., Jurado-Rodriguez A., Candiota A.P., Del- atraumatic convexal subarachnoid hemor-
Nunez-Marin F., Marti-Fabregas J., Balo con- gado-Mederos R., Lope-Piedrafita S., Gar- rhage: An ARIA before the tsunami. (2015) J
centric sclerosis: A presentation mimicking cia-Verdugo J.M., Arus C., Marti-Fabregas J., CEREBR BLOOD F MET, 35 (5), 710-717.
ischaemic stroke. (2015) NEUROLOGIA. In vivo and ex vivo magnetic resonance IF: 4.9290
IF: 1.7900 spectroscopy of the infarct and the subven- Urra X., Abilleira S., Dorado L., Ribó M., Car-
Camps-Renom P., Delgado-Mederos R., Mar- tricular zone in experimental stroke. (2015) J dona P., Millán M., Chamorro A., Cobo E.,
tinez-Domeno A., Prats-Sanchez L., CEREBR BLOOD F MET, 35 (5), 828-834. Dávalos A., Jovin T.G., Gallofré M.; Catalan
Cortes-Vicente E., Simon-Talero M., Arboix A., IF: 4.9290 Stroke Code and Reperfusion Consortium.
Ois A., Purroy F., Marti-Fabregas J., Clinical Kase C.S., Mohr J.P., Marti-Fabregas J., José Mechanical Thrombectomy in and Outside
characteristics and outcome of the capsular Luis Martí Vilalta (1946-2014). (2015) CERE- the REVASCAT Trial: Insights From a Concur-
warning syndrome: A multicenter study. BROVASC DIS, 99-. rent Population-Based Stroke Registry.
(2015) INT J STROKE, 10 (4), 571-575. IF: 3.3590 (2015) STROKE, 46(12), 3437-42.
IF: 3.0440 Marti-Fabregas J., Delgado-Mederos R., Cre- IF: 1.4200
Cortes-Vicente E., Delgado-Mederos R., Bell- spo J., Pena E., Marin R., Jimenez-Xarrie E., Zapata-Wainberg G., Ximénez-Carrillo Rico
munt S., Borras X.F., Gomez-Anson B., Bague Fernandez-Arcos A., Perez-Perez J., Mar- Á., Benavente Fernández L., Masjuan Vallejo
S., Camps-Renom P., Marti-Fabregas J., tinez-Domeno A., Camps-Renom P., Prats- J., Gállego Culleré J., Freijó Guerrero M.M.,
Stroke caused by a myxoma stenosing the Sanchez L., Casoni F., Badimon L., Circulating Egido J., Gómez Sánchez J.C., Martínez
common carotid artery. (2015) J STROKE endothelial progenitor cells and the risk of Domeño A., Purroy García F., Vives Pastor B.,
CEREBROVASC, 24 (4), e87-e89. vascular events after ischemic stroke. (2015) Blanco González M., Vivancos J.; represent-
IF: 1.5990 PLOS ONE, 10 (4). ing the research team of the TAC Registry
Flores A., Tomasello A., Cardona P., De Miquel IF: 3.0570 study. Epidemiology of Intracranial Haemor-
M.A., Gomis M., Bermejo P.G., Obach V., Urra Martinez-Lizana E., Carmona-Iragui M., Al- rhages Associated with Vitamin K Antago-
X., Marti-Fabregas J., Canovas D., Roquer J., colea D., Gomez-Choco M., Vilaplana E., San- nist Oral Anticoagulants in Spain: TAC Regis-
Abilleira S., Ribo M., Endovascular treatment chez-Saudinos M.B., Clarimon J., Hernandez- try. (2015) INTERV NEUROL, 4(1-2), 52-8.
for M2 occlusions in the era of stentrievers: A -Guillamon M., Munuera J., Gelpi E., IF: 0.5300
descriptive multicenter experience. (2015) J Gomez-Anson B., De Juan-Delago M., Del-
NEUROINTERV SURG, 7 (4), 234-237. gado-Mederos R., Montaner J., Ois A., Amaro
IF: 2.9590 S., Blesa R., Marti-Fabregas J., Lleo A., Fortea

Neuromuscular Diseases
Coordinator
Illa Sendra, Maria Isabel FGS
iilla@santpau.cat
Members
Araque Palacios, Josefa CIBERER
Arribas Ibar, Elisabet IR
Belmonte, Izaskun FGS
De Luna Salva, Noemí CIBERER
Díaz Manera,
Jorge Alberto FGS
Gallardo Vigo, Eduard IR
Llauger Rosselló, Jaume FGS
Lleixa Rodríguez,
Maria Cinta IR Autoimmune neuromuscular diseases Muscular dystrophy, dysferlinopathy and
Ortiz Losada, Esther IR distal myopathies
ff Characterization of new target antigens in
Pedrosa Hernández, Irene FGS Myasthenia Gravis, and immune neuropa- ff Muscle MRI analysis as a biomarker of dif-
Piñol Jurado, Patricia IR thies (CIDP, GBS, MMN). Their use as diag- ferent muscular dystrophies.
Querol Gutiérrez, nostic and therapeutic biomarkers.
Luis Antonio FGS
ff Study of miRNA profiles and muscle secre-
ff Pathogenesis of newly recognized paran- tome in muscular dystrophies.

Rojas García, Ricardo FGS odal antigens in CIDP.
Segovia Simon, Sonia IR ff Role of PDGF in muscular dystrophies fi-
ff Analysis of the innate immunity in inflam- brosis.
Siles Gómez, Ana María IR
matory myopathies.
Suárez Calvet, Xavier IR ff Natural history of Dysferlinopathies. The
ff Analysis of the impact of new immuno- international COS-study Jain Foundation.
modulating therapies on IgG4 mediated
Neuromuscular Diseases (NMD). ff To evaluate the frequency of carriers of
mutations in the dyferlin gene in normal
ff Functional aspects of immune system population.
cells (response to ligands, production of
antibodies, etc).
Amyotrophic lateral sclerosis
ff IGOS data base for Guillain Barre syn-
drome. ff Epidemiology of ALS in Catalonia.
ff NMD-ES Spanish registry for neuromuscu- ff Gene profile of ALS patients in Spain.
lar diseases.
ff Biomarkers profile in different phenotypes
of ALS.
ff Advance in the knowledge of the immu- phies resulting from dysferlinopathy and
nological mechanisms involved in the other myopathies research (biomarkers
pathogenesis of autoimmune neuromus- (miRNA, secretome), MRI, etc).
cular diseases (MG, CIDP, MMN).
ff Advance in the knowledge of the patho-
Challenges
ff Advance in the knowledge of the patho- genetic mechanisms involved in muscular

genetic mechanisms of inflammatory my- dystrophy resulting from dysferlin defi-
opathies (DM, PM, IBM). ciency and other muscular dystrophies.
ff Search for new antigens and develop di- ff Cleanroom access to manipulate cells for
agnostic tests with new biomarkers in use in humans.
immune-mediated neuropathies and My-
asthenia Gravis.
ff Use of the NMD.ES registry to perform re-
search in different NMD.
ff Implement new diagnostic and disease
follow-up methods for muscular dystro-

Collaborations
ff Jerome Devaux, Marseilles, France.

ff Silvere van der Maarel, Leiden, The Netherlands.
ff Xavier Navarro, Departament de Medicina, Universitat Autònoma
de Barcelona, Spain.
ff R. Martí, Hospital Vall d’Hebron, Barcelona, Spain.
ff Eugenia Martínez. Extraordinary award for the thesis ff Xavier Suárez. Nous aspectes fisiopatogènics en la
Biomarcadores en el diagnóstico y tratamiento de la dermatomiositis. Universitat Autònoma de Barcelona
Awards
Theses
miastenia. Universitat Autònoma de Barcelona.
ff Jordi Díaz. Extraordinary award for the thesis Dysfer-
lin myopathy: new insights in diagnosis and therapy.
Universitat Autònoma de Barcelona .
ff Maria Isabel Illa Sendra. Nuevas reactividades antigénicas y es- ff Xavier Suárez Calvet. New therapeutic targets in dermatomyo-
tudios de inmunidad innata en enfermedades neuromusculares sitis. Research Grant Application 2014. The Myositis Association.
autoinmunes. PI13/00937. Instituto de Salud Carlos III. Duration: Duration: 2015-2017. €63,136.98.
2014-2016. €160,250.
ff Maria Isabel Illa Sendra. Paranodal autoimmunity in CIDP: diag-
Active Grants
ff Luis Antonio Querol Gutiérrez. Contratos Juan Rodés 2013. nostic and therapeutic value rationale and objective. GBS/CIDP
JR13/00014. Instituto de Salud Carlos III. Duration: 2014-2016. 2014. Foundation International Guillain-Barré syndrome chronic
€135,000. inflammatory demyelinating polyradiculopathy. Duration: 2014-
2016. €39,720.
ff Eduard Gallardo Vigo. Recerca en Malalties Neuromusculars.
2014 SGR 272. Agència de Gestió d’Ajuts Universitaris i de Re- Note: Total amount granted to PI. It does not include indirect costs.
cerca. Duration: 2014-2016. €30,000.
ff Ricardo Rojas García. Biomarkers profile in different phenotypes
of Motor Neuron Disease. MARATÓ 20143710. Fundació La Mar-
ató de TV3. Duration: 2015-2018. €120,500.
ff Maria Isabel Illa Sendra. Danger signals promoting innate immunity in dermatomyositis. AFM TELETHON 18476. The French Muscular
Awarded
Dystrophy Association (AFM-Téléthon). Duration: 2015-2016. €34,166.

in 2015
Grants
ff Eduard Gallardo Vigo. Influencia de factores inmunológicos y no inmunológicos en la patogenia de las miopatías inflamatorias. Proyec-
tos de Investigación en Salud. PI15/01597. Duration: 01/01/2016-31/12/2018. €30,000.

Neuromuscular Diseases
*TIF: 77.6120 **MIF: 3.2338
Aracil-Bolanos I., Prats-Sanchez L., Go- L.H., van Doorn P.A., Cornblath D.R.,Hahn Guidelines for monitoring late-onset Pompe
mez-Anson B., Querol-Gutierrez L., A.F., Faber C.G., Merkies I.S., PeriNomS study disease. (2015) REV NEUROLOGIA, 60 (7),
Nunez-Marin F., Marti-Fabregas J., Balo con- group (Barreira A.A., Bennett D., Hadden 321-328.
centric sclerosis: A presentation mimicking R.D., Hughes R.A., Lunn M.P., Reilly M.M., van IF: 0.6840
ischaemic stroke. (2015) NEUROLOGIA. den Berg L.H., van Doorn P.A., Faber C.G., van Halter J.P., Michael W., Schupbach M., Man-
IF: 1.7900 der Kooi A.J., Merkies I.S., Notermans N.C., del H., Casali C., Orchard K., Collin M., Valcar-
Balasa M., Gelpi E., Martin I., Antonell A., Rey Raaphorts J., van Schaik I.N., de Visser M., cel D., Rovelli A., Filosto M., Dotti M.T., Ma-
M.J., Grau-Rivera O., Molinuevo J.L., Sanchez- Cats E.A., Van den Bergh P.Y., Bombelli F., rotta G., Pintos G., Barba P., Accarino A., Ferra
Valle R., Llado A., Boada Hernandez M., Costa R., Franques J., Léger J.M., Pouget J., C., Illa I., Beguin Y., Bakker J.A., Boelens J.J., De
Mauleon A., Rosende M., Aguilar M., Rene R., Bril V., Hahn A.F., Katzberg H., Campanella A., Coo I.F.M., Fay K., Sue C.M., Nachbaur D.,
Povedano M., Valldeoriola F., Sanz P., Lleo A., Devigili G., Gallia F., Lauria G., Nobile-Orazio Zoller H., Sobreira C., Pinto Simoes B., Ham-
Blesa R., Rojas-Garcia R., Pena- Casanova J., E., Padua L., Cornblath D.R., Gorson K.C., mans S.R., Savage D., Marti R., Chinnery P.F.,
Alvarez-Sabin J., Pujadas F., Roy P., Lopez- Lewis R.A., Illa I., Querol L., van Nes S.I.). Grip Elhasid R., Gratwohl A., Hirano M., Barros
Pousa S., Turon A., Huerta M., Martinez-Yela- strength comparison in immune-mediated Navarro G., Benoist J.F., Bierau J., Bucalossi A.,
mos A., Aspiazu P., Almenar C., Lopez-Ville- neuropathies: Vigorimeter vs. Jamar. (2015) J Carluccio M.A., Coll-Canti J., Cotelli M.S.,
gas D., Abellan T., Otermin P., Pericot I., PERIPHER NERV SYST, 20(3), 269-76. Diesch T., Di Fabio R., Donati M.A., Garvin
Pinol-Ripoll G., Robles B., Escrig A., Latorre P., IF: 2.7580 J.H., Hill K., Kappeler L., Ku Hne T., Lara M.C.,
Escabia F., Mira M.L., Ananos G., Collado I., Draak T.H., Vanhoutte E.K., van Nes S.I., Gor- Lenoci M., Lucchini G., Marques W., Mattle
Diagnostic accuracy of behavioral variant son K.C., Van der Pol W.L., Notermans N.C., H.P., Meyer A., Parini R., Passweg J.R., Pieroni
frontotemporal dementia consortium crite- Nobile-Orazio E., Lewis R.A., Léger J.M., Van F., Rodriguez-Palmero A., Santus F., Scarpelli
ria (FTDC) in a clinicopathological cohort. den Bergh P.Y., Lauria G., Bril V., Katzberg H., M., Schlesser P., Sicurelli F., Stern M., Stracieri
(2015) NEUROPATH APPL NEURO, 41 (7), Lunn M.P., Pouget J., van der Kooi A.J., Hahn A.B., Tonin P., Torres-Torronteras J., Voltarelli
882-892. A.F., van den Berg L.H., van Doorn P.A., Corn- J.C., Zaidman I., Allogeneic haematopoietic
IF: 4.4830 blath D.R., Faber C.G., Merkies I.S., PeriNomS stem cell transplantation for mitochondrial
Bladen C.L., Salgado D., Monges S., Foncu- Study Group (Barreira A.A., Bennett D., Had- neurogastrointestinal encephalomyopathy.
berta M.E., Kekou K., Kosma K., Dawkins H., den R.D., Hughes R.A., Lunn M.P., Reilly M.M., (2015) BRAIN, 138 (10), 2847-2858.
van den Berg L.H., van Doorn P.A., Faber C.G., IF: 10.1030
Lamont L., Roy A.J., Chamova T., Guerguel-

tcheva V., Chan S., Korngut L., Campbell C., van der Kooi A.J., Merkies I.S., Notermans Horga A., Cottenie E., Tomaselli P.J., Rojas-
Dai Y., Wang J., Barisic N., Brabec P., Lahdetie N.C., Raaphorts J., van Schaik I.N., de Visser -Garcia R., Salvado M., Villarreal-Perez L.,
J., Walter M.C., Schreiber-Katz O., Karcagi V., M., Cats E.A., Van den Bergh P.Y., Bombelli F., Gamez J., Marquez-Infante C., Houlden H.,
Garami M., Viswanathan V., Bayat F., Buc- Costa R., Franques J., Léger J.M., Pouget J., Reilly M.M., Absence of HINT1 mutations in a
cella F., Kimura E., Koeks Z., van den Bergen Bril V., Hahn A.F., Katzberg H., Campanella A., UK and Spanish cohort of patients with in-
J.C., Rodrigues M., Roxburgh R., Lusakowska Devigili G., Gallia F., Lauria G., Nobile-Orazio herited neuropathies. (2015) J NEUROL.
A., Kostera-Pruszczyk A., Zimowski J., San- E., Padua L., Cornblath D.R., Gorson K.C., IF: 3.4080
tos R., Neagu E., Artemieva S., Rasic V.M., Lewis R.A., Illa I., Querol L., van Nes S.I.). Com-
paring the NIS vs. MRC and INCAT sensory Huijbers M.G., Querol L.A., Niks E.H., Plomp
Vojinovic D., Posada M., Bloetzer C., Jeannet J.J., van der Maarel S.M., Graus F., Dalmau J.,
P.-Y., Joncourt F., Diaz-Manera J., Gallardo E., scale through Rasch analyses. (2015) J PE-
RIPHER NERV SYST, 20(3), 277-88. Illa I., Verschuuren J.J., The expanding field of
Karaduman A.A., Topaloglu H., El Sherif R., IgG4-mediated neurological autoimmune
Stringer A., Shatillo A.V., Martin A.S., Peay IF: 2.7580
disorders. (2015) EUR J NEUROL, 22 (8), 1151-
H.L., Bellgard M.I., Kirschner J., Flanigan Gomez-Anson B., Roman E., De Bobadilla 1161.
K.M., Straub V., Bushby K., Verschuuren J., R.F., Pires-Encuentra P., Diaz-Manera J., Nuez IF: 3.9560
Aartsma-Rus A., Beroud C., Lochmuller H., F., Martinez-Horta S., Vives-Gilabert Y., Pago-
The TREAT-NMD DMD global database: nabarraga J., Kulisevsky J., Cordoba J., Lopez-Gongora M., Querol L., Escartin A., A
Analysis of more than 7,000 duchenne Guarner C., Soriano G., Alterations in cere- one-year follow-up study of the Symbol
muscular dystrophy mutations. (2015) bral white matter and neuropsychology in Digit Modalities Test (SDMT) and the Paced
HUM MUTAT, 36 (4), 395-402. patients with cirrhosis and falls. (2015) PLOS Auditory Serial Addition Test (PASAT) in re-
IF: 5.0890 ONE, 10 (3). lapsing-remitting multiple sclerosis: An ap-
IF: 3.0570 praisal of comparative longitudinal sensitiv-
Dillingham B.C., Benny Klimek M.E., Ger- ity. (2015) BMC NEUROL, 15 (1).
napudi R., Rayavarapu S., Gallardo E., Van Der Gutierrez-Rivas E., Bautista J., Vilchez J.J., IF: 1.9610
Meulen J.H., Jordan S., Ampong B., Gord- Muelas N., Diaz-Manera J., Illa I., Martinez-Ar-
ish-Dressman H., Spurney C.F., Nagaraju K., royo A., Olive M., Sanz I., Arpa J., Fernandez- Lopez-Gongora M., Escartin A., Mar-
tinez-Horta S., Fernandez-Bobadilla R.,
Inhibition of inflammation with celastrol -Torron R., Lopez de Munain A., Jimenez L.,
fails to improve muscle function in dysfer- Solera J., Lukacs Z., Targeted screening for Querol L., Romero S., Mananas M.A., Riba J.,
lin-deficient A/J mice. (2015) J NEUROL SCI, the detection of Pompe disease in patients Neurophysiological evidence of compensa-
356 (1-2), 157-162. with unclassified limb-girdle muscular dys- tory brain mechanisms in early-stage multi-
IF: 2.1260 trophy or asymptomatic hyperCKemia using ple sclerosis. (2015) PLOS ONE, 10 (8).
dried blood: A Spanish cohort. (2015) NEU- IF: 3.0570
Draak T.H., Pruppers M.H., van Nes S.I., Van-
houtte E.K., Bakkers M., Gorson K.C., Van der ROMUSCULAR DISORD, 25 (7), 548-553. Nogales-Gadea G., Santalla A., Brull A., de
Pol W.L., Lewis R.A., Notermans N.C., No- IF: 3.1070 Luna N., Lucia A., Pinos T., The pathogenom-
bile-Orazio E., Léger J.M., Van den Bergh P.Y., Gutierrez-Rivas E., Illa I., Pascual-Pascual S.I., ics of McArdle disease—genes, enzymes,
Lauria G., Bril V., Katzberg H., Lunn M.P., Perez-Lopez J., Vilchez-Padilla J.J., Bau- models, and therapeutic implications. (2015)
Pouget J., van der Kooi A.J., van den Berg tista-Lorite J., Barrot E., de Munain A.L., J INHERIT METAB DIS, 38 (2), 221-230.
IF: 3.5410

*TIF: 77.6120 **MIF: 3.2338

Osuna M.T., Querol L., Olivas-Chacon C.I., Ramos-Fransi A., Rojas-Garcia R., Segovia S., Notermans N.C., Lewis R.A., Nobile-Orazio E.,
Lejarreta-Andres S., Robert J., Ailouti-Cabal- Marquez-Infante C., Pardo J., Coll-Canti J., Léger J.M., Van den Bergh P.Y., Lauria G., Bril
lero N., Ramos-Duran L., Diaz-Manera J., Bel- Jerico I., Illa I., Alberti Aguilo M.A., Bataller V., Katzberg H., Lunn M.P., Pouget J., van der
vis R., Toxic demyelinating neuropathy and Alberola L., Berciano Blanco J., Casasnovas Kooi A.J., Hahn A.F., van Doorn P.A., Corn-
leukoencephalopathy in patients who take Pons C., Diaz-Manera J., Fernandez Torron blath D.R., van den Berg L.H., Faber C.G.,
the slimming products Thermatrim ® and M.R., Garcia Sobrino T., Gomez Caravaca M.T., Merkies I.S., PeriNomS Study Group (Barreira
Pura Alegría ®. (2015) REV NEUROLOGIA, 61 Guerrero Sola A., Gutierrez Gutierrez G., A.A., Bennett D., Hadden R.D., Hughes R.A.,
(11), 527-528. Lopez de Munain Arregui A, Martinez Pi- Lunn M.P., Reilly M.M., van den Berg L.H., van
IF: 0.6840 neiro A., Mendoza Grimon M.D., Munoz Doorn P.A., Faber C.G., van der Kooi A.J.,
Paco S., Casserras T., Rodriguez M.A., Jou C., Blanco J.L., Pelayo Negro A.L., Querol L., Merkies I.S., Notermans N.C., Raaphorts J.,
Puigdelloses M., Ortez C.I., Diaz-Manera J., Sevilla Mantecon T., Myasthenia gravis: De- van Schaik I.N., de Visser M., Cats E.A., Van
Gallardo E., Colomer J., Nascimento A., Kalko scriptive analysis of life-threatening events den Bergh P.Y., Bombelli F., Costa R., Fran-
S.G., Jimenez-Mallebrera C., Transcriptome in a recent nationwide registry. (2015) EUR J ques J., Léger J.M., Pouget J., Bril V., Hahn A.F.,
analysis of ullrich congenital muscular dys- NEUROL, 22 (7), 1056-1061. Katzberg H., Campanella A., Devigili G., Gal-
trophy fibroblasts reveals a disease extracel- IF: 3.9560 lia F., Lauria G., Nobile-Orazio E., Padua L.,
lular matrix signature and key molecular Suarez-Calvet X., Gallardo E., Illa I., Comment Cornblath D.R., Gorson K.C., Lewis R.A., Illa I.,
regulators. (2015) PLOS ONE, 10 (12). to “Role of Toll-like receptors and retinoic Querol L., van Nes S.I.). Impairment mea-
IF: 3.0570 acid inducible gene I in endogenous pro- sures versus inflammatory RODS in GBS and
duction of type I interferon in dermatomyo- CIDP: a responsiveness comparison. (2015) J
Pruppers M.H., Draak T.H., Vanhoutte E.K., PERIPHER NERV SYST, 20(3), 289-95.
Van der Pol W.L., Gorson K.C., Léger J.M., sitis”. (2015) J NEUROIMMUNOL.
IF: 2.5360 IF: 2.7580
Nobile-Orazio E., Lewis R.A., van den Berg
L.H., Faber C.G., Merkies I.S., PeriNomS study Vanhoutte E.K., Faber C.G., van Nes S.I., Cats Vanhoutte E.K., Hermans M.C., Faber C.G.,
group (Barreira A.A., Bennett D., Hadden E.A., Van der Pol W.L., Gorson K.C., van Doorn Gorson K.C., Merkies I.S., Thonnard J.L.; Peri-
R.D., Hughes R.A., Lunn M.P., Reilly M.M., van P.A., Cornblath D.R., van den Berg L.H., Merk- NomS Study Group (Barreira A.A., Bennett
den Berg L.H., van Doorn P.A., Faber C.G., van ies I.S., PeriNomS Study Group (Barreira A.A., D., Hadden R.D., Hughes R.A., Lunn M.P.,
der Kooi A.J., Merkies I.S., Notermans N.C., Bennett D., Hadden R.D., Hughes R.A., Lunn Reilly M.M., van den Berg L.H., van Doorn
Raaphorts J., van Schaik I.N., de Visser M., M.P., Reilly M.M., van den Berg L.H., van P.A., Faber C.G., van der Kooi A.J., Merkies I.S.,
Cats E.A., Van den Bergh P.Y., Bombelli F., Doorn P.A., Faber C.G., van der Kooi A.J., Notermans N.C., Raaphorts J., van Schaik I.N.,
Costa R., Franques J., Léger J.M., Pouget J., Merkies I.S., Notermans N.C., Raaphorts J., de Visser M., Cats E.A., Van den Bergh P.Y.,
Bril V., Hahn A.F., Katzberg H., Campanella A., van Schaik I.N., de Visser M., Cats E.A., Van Bombelli F., Costa R., Franques J., Léger J.M.,
Devigili G., Gallia F., Lauria G., Nobile-Orazio den Bergh P.Y., Bombelli F., Costa R., Fran- Pouget J., Bril V., Hahn A.F., Katzberg H., Cam-
E., Padua L., Cornblath D.R., Gorson K.C., ques J., Léger J.M., Pouget J., Bril V., Hahn A.F., panella A., Devigili G., Gallia F., Lauria G.,
Lewis R.A., Illa I., Querol L., van Nes S.I.). Out- Katzberg H., Campanella A., Devigili G., Gal- Nobile-Orazio E., Padua L., Cornblath D.R.,
come measures in MMN revisited: further lia F., Lauria G., Nobile-Orazio E., Padua L., Gorson K.C., Lewis R.A., Illa I., Querol L., van
improvement needed. (2015) J PERIPHER Cornblath D.R., Gorson K.C., Lewis R.A., Illa I., Nes S.I.) Rasch-ionale for neurologists. (2015)
NERV SYST, 20(3): 306-18. Querol L., van Nes S.I.). Rasch-built Overall J PERIPHER NERV SYST, 20(3), 260-8.
IF: 2.7580 Disability Scale for Multifocal motor neurop- IF: 2.7580
Querol L., Illa I., Paranodal and other autoan- athy (MMN-RODS©). (2015) J PERIPHER
tibodies in chronic inflammatory neuropa- NERV SYST, 20(3), 296-305.
thies. (2015) CURR OPIN NEUROL, 28 (5), IF: 2.7580
474-479. Vanhoutte E.K., Draak T.H., Gorson K.C., van
IF: 4.4690 Nes S.I., Hoeijmakers J.G., Van der Pol W.L.,

Parkinson Disease and Movement Disorders
Coordinator
Kulisevsky Bojarski, Jaime FGS
jkulisevsky@santpau.cat
Members
Arenas Ríos, Fabián Octavio IR
Belmonte Calderón, Sara IR
Campolongo Perillo, Antonia IR
Carceller Sindreu,
Maria del Mar IR
Castillejos Gallego, Laura IR
Fernández de Bobadilla
Martínez, José Ramón IR
García Sánchez, Carmen FGS
Gironell Carrero, Alexandre FGS Cognitive Impairment and Behavioural Translational Research - Parkinsonian
Horta Barba, Andrea IR Dysfunctions in Parkinson Disease Animal Models
Marín Lahoz, Juan IR ff Knowledge and detection of the neural ff Assessment of behavioural and cognitive
Martínez Horta, Saul Indra IR correlates of cognitive performance in Par- modulations exerted by distinct antipar-
Pagonabarraga Mora, kinson disease using neurophysiological kinsonian drugs in murine models of Par-
Javier FGS techniques (event-related brain cognitive kinson disease with lesions in particular
Parenti, Riccardo IR potentials) and structural and functional neurotransmitter systems (dopaminergic
Pascual Sedano, neuroimaging (voxel-based morphome- and noradrenergic lesions).
try, cortical thickness and spectroscopy).
Berta Marta FGS ff Assessment of behavioural and cognitive
Pérez Pérez, Jesús IR ff Development of more sensitive tools traits of murine models of HD.
Sosti Sosa, for cognitive and functional assessment
Maria Victòria CIBERNED in Parkinson disease to detect subtle
Translational Research - Cell Models
changes in cognitive performance and
Yarritu Corrales, Ion IR
treatment response. ff Assessment of cell cultures of neurons de-
ff Prospective follow-up analysis of cogni- rived of induced pluripotent cells (iPSCs)
tion and mood in patients with deep-brain obtained from skin fibroblast as in vitro
stimulation of the subthalamic nucleus. model for the modulation of key factors as-
sociated to both cognitive and neurotrans-
ff Physiological correlates and pharmaco- mitter disturbances in Parkinson disease.

logical approach to apathy in Parkinson
disease and other movement disorders.
Huntington Disease
ff Neurophysiological and cognitive cor-
relates of impulse control disorders in ff Study of the metabolic correlates (18-
Parkinson disease and other movement FDG PET) of disease progression from the
disorders. Behavioral and pharmacologi- pre-manifested to early-stages.
cal treatment. ff Study of the metabolic correlates (18-
ff Surgery and treatments of continuous in- FDG PET) of apathy and depression in
fusion in Parkinson disease. pre-manifested gene carriers.
ff Follow-up and etiologic study of weight ff Functional magnetic resonance imaging
loss in patients treated with continuous study of reward sensitivity in pre-mani-
infusion of intraduodenal levodopa. fested an early-stage Huntington’s disease.
ff Follow-up and etiologic study of weight ff Determination of the prevalence and clin-
loss in patients treated with continuous ical significance of neuropsychiatric fea-
infusion of intraduodenal levodopa. tures in Huntington’s disease.
ff Development of new instruments for cog-
Essential Tremor and Other Movement nitive and functional assessment in Hun-
Disorders tington’s disease.
ff Prospective observational study of Hun-
ff Molecular neuroimaging in essential
tington’s disease in a European cohort
tremor.
(Registry Study).
ff Clinical, neurophysiological and neuroim- ff Molecular, clinical, behavioural and cog-
aging assessment of patients with FXTAS
nitive characterisation of the BACHD rat
(fragile X-associated tremor/ataxia syn-
model of Huntington’s disease.
drome).
ff Collaboration in multicentre and Spanish

coordinated projects: Progresive Supranuclear Palsy

-- Relationship between intermediate alleles and clinical mani-
festations (PI: Esther Cubo, Burgos). ff Develompent of a cognitive rating scale.
of Research
Main Lines
-- Validation of the Spanish version of the Problem Behaviour ff Development of a standarized eye movement evaluation.
Assessment Scale (PBA-S; PI: Jesús Ruiz, Barcelona).
-- Study of dietary intake in Huntington’s disease (PI: Esther
Cubo, Burgos).
-- A multimodal neuroimaging approach to delineate emo-
tional, motor and cognitive cortico-striatal pathways. IDIBELL
(PI: Ruth de Diego-Balaguer, Barcelona).
Cognitive and Behavioural Dysfunctions in Parkinson Disease Essential Tremor and Other Movement Disorders
ff Study and understanding of the neural substrates of cognitive ff Genetic studies and genotype-phenotype correlations in essen-
impairment in Parkinson disease so as to improve diagnostic tial tremor.
and therapeutic approaches.
ff Development of new therapeutic interventions in essential
ff Development of specific tools to assess and track cognitive tremor.
changes in Parkinson disease.
Challenges
ff Neurochemical and structural neuroimaging studies on the pa-

thophysiological bases of essential tremor.
Huntington’s Disease
ff Study of the dynamics of mutant Htt protein aggregation and Translational Research - Animal Models of Parkinsonism
related neural and cognitive correlates along disease stages in
Huntington’s disease.
ff Behavioural, physiological and pharmacological characteriza-
tion of animal models of parkinsonism with combined dopa-
ff Validation of new instruments to assess and track subtle cog- minergic and noradrenergic lesions.
nitive changes in pre-manifested and early-stage Huntington’s
disease population.
ff Physiopathology of motor, cognitive and behavioural compli-
cations linked to antiparkinsonian drugs in animal models of
parkinsonism.
Collaborations with other IIB Sant Pau Groups ff International Movement Disorders Society (MDS). Task Force for
Developing Rating Scales in Parkinson’s Disease (Subcomitee
ff Active collaboration with the Reserach groups of Neuroradiol- for Cognitive Evaluation).
ogy and Nuclear Medicine (Huntington’s disease).
Collaborations
ff MDS Task Force for Mild Cognitive Impairment in Parkinson’s

Disease.
ff MDS Task Force for Evidence Based Medicine in Huntington’s
ff Active collaboration with the Cognition and Brain Plasticity Disease.
Group at the Bellvitge Health Science Campus at the University ff Spanish Coordinator of the European Huntington Disease Net-
of Barcelona adscribed to the Department of Basic Psychology,
work and the ENROLL Study (Cure for Huntington’s Disease In-
Faculty of Psychology - University of Barcelona and the IDIBELL
ternational - CHDI).
(Institut d’Investigació Biomèdica de Bellvitge).
ff Centro de Investigación Biomédica en Red de Enfermedades
neurodegenerativas (CIBERNED), Instituto de Salud Carlos III.
ff Eva Ruzafa Valiente. Comportamiento de la escala Parkinson’s

Disease – Cognitive Rating Scale (PD-CRS) en patologías dife-
rentes a la enfermedad de Parkinson. Universitat Autònoma de
Theses
Barcelona. Directors: Jaime Kulisevsky, Carmen García Sánchez.

Date of defense: 17 December 2015. Development of specific
tools to assess and track cognitive changes in Parkinson disease.

Parkinson Disease and Movement Disorders

ff Jaime Kulisevsky Bojarski. Conveni amb Preparados Alimenti- ff Jaime Kulisevsky Bojarski. Prediction of apathy and impulse con-
cios, SA-CENIT (Gallina Blanca). Henufood. Duration: 2010-2016. trol disorders in Parkinson’s disease based on Feedback related
€312,500. negativity. MARATÓ 20142410. Fundació La Marató de TV3. Du-
ration: 2015-2018. €159,686.
ff Jaime Kulisevsky Bojarski. Desarrollo, validación y estudio de la
sensibilidad al cambio de una versión alternativa de la Parkin- ff Javier Pagonabarraga Mora. Blood-based and neurophysiologi-
Active Grants
son’s Disease-Cognitive Rating Scale. PI12/03005. Instituto de cal markers of cognitive deterioration and dementia in Parkin-
Salud Carlos III. Duration: 2013-2016. €23,500. son’s disease. MARATÓ 20142910. Fundació La Marató de TV3.
Duration: 2015-2018. €159,589.
ff Jaime Kulisevsky Bojarski. Huntington’s Disease Network. EHDN.
Duration: 2010-2021. ff Javier Pagonabarraga Mora. Marcadores en sangre y neurofisi-
ológicos de la progresión del deterioro cognitivo en la enferme-
ff Jesús Pérez Pérez. Contratos Río Hortega 2013. CM13/00284. In- dad de Parkinson. PI14/02058. Instituto de Salud Carlos III. Dura-
stituto de Salud Carlos III. Duration: 2014-2016. €53,732. tion: 2015-2017. €54,500.
ff Jaime Kulisevsky Bojarski. Grup de Trastornos del Moviment de Note: Total amount granted to PI. It does not include indirect costs.
l’Hospital de la Santa Creu i Sant Pau. 2014 SGR 1203. Agència
de Gestió d’Ajuts Universitaris i de Recerca. Duration: 2014-2016.
€21,000.
Awarded in
ff Jaime Kulisevsky Bojarski. Correlatos anatómico-funcionales de

los trastornos del control de impulsos y apatía en la enfermedad
Grants
2015
de Parkinson. PI15/00962. Instituto de Salud Carlos III. Duration:

01/01/2016- 31/12/2018. €61,500.
*TIF: 117.1620 **MIF: 6.1664

Buongiorno M., Antonelli F., Camara A., Hor H., Francescatto L., Bartesaghi L., Orte- tion of deep brain stimulation of subcallosal
Puente V., de Fabregues-Nebot O., Hernan- ga-Cubero S., Kousi M., Lorenzo-Betancor O., cingulate gyrus in treatment-resistant de-
dez-Vara J., Calopa M., Pascual-Sedano B., Jimenez-Jimenez F.J., Gironell A., Clarimon J., pression. (2015) J AFFECT DISORDERS, 173,
Campolongo A., Valldeoriola F., Tolosa E., Drechse O., Agundez J.A.G., Kenzelmann 159-162.
Kulisevsky J., Marti M.J., Long-term response Broz D., Chiquet-Ehrismann R., Lleo A., Coria IF: 3.5700
to continuous duodenal infusion of levo- F., Garcia-Martin E., Alonso-Navarro H., Marti Martinez-Horta S., Perez-Perez J., van Duijn
dopa/carbidopa gel in patients with ad- M.J., Kulisevsky J., Hor C.N., Ossowski S., E., Fernandez-Bobadilla R., Carceller M., Pag-
vanced Parkinson disease: The Barcelona Chrast R., Katsanis N., Pastor P., Estivill X., onabarraga J., Pascual-Sedano B., Campo-
registry. (2015) PARKINSONISM RELAT D, 21 Missense mutations in TENM4, a regulator of longo A., Ruiz-Idiago J., Sampedro F.,
(8), 871-876. axon guidance and central myelination, Landwehrmeyer G.B., Kulisevsky J., Neurop-
IF: 3.7940 cause essential tremor. (2015) HUM MOL sychiatric symptoms are very common in
Carceller-Sindreu M., de Diego-Adelino J., GENET, 24 (20), 5677-5686. premanifest and early stage HD. (2015) PAR-
Serra-Blasco M., Vives-Gilabert Y., Marti;n- IF: 5.9850 KINSONISM RELAT D.

Blanco A., Puigdemont D., Alvarez E., Perez Lopez-Gongora M., Escartin A., Mar- IF: 3.7940
V., Portella M.J., Volumetric MRI study of the tinez-Horta S., Fernandez-Bobadilla R., Matias-Guiu J.A., Fernandez de Bobadilla R.,
habenula in first episode, recurrent and Querol L., Romero S., Mananas M.A., Riba J., Escudero G., Perez-Perez J., Cortes A., More-
chronic major depression. (2015) EUR NEU- Neurophysiological evidence of compensa- nas-Rodriguez E., Valles-Salgado M., Moreno-
ROPSYCHOPHARM, 25 (11), 2015-2021. tory brain mechanisms in early-stage multi- Ramos T., Kulisevsky J., Matias-Guiu J., Valida-
IF: 4.4090 ple sclerosis. (2015) PLOS ONE, 10 (8). tion of the Spanish version of Addenbrooke’s
Cattaneo G., Calabria M., Marne P., Gironell A., IF: 3.0570 Cognitive Examination III for diagnosing
Abutalebi J., Costa A., The role of executive Marti-Fabregas J., Delgado-Mederos R., Cre- dementia. (2015) NEUROLOGIA, 30 (9), 545-
control in bilingual language production: A spo J., Pena E., Marin R., Jimenez-Xarrie E., 551.
study with Parkinson’s disease individuals. Fernandez-Arcos A., Perez-Perez J., Mar- IF: 1.7900
(2015) NEUROPSYCHOLOGIA, 66, 99-110. tinez-Domeno A., Camps-Renom P., Prats- Odin P., Ray Chaudhuri K., Slevin J.T., Volk-
IF: 2.9890 Sanchez L., Casoni F., Badimon L., Circulating mann J., Dietrichs E., Martinez-Martin P.,
Gomez-Anson B., Roman E., De Bobadilla endothelial progenitor cells and the risk of Krauss J.K., Henriksen T., Katzenschlager R.,
R.F., Pires-Encuentra P., Diaz-Manera J., Nuez vascular events after ischemic stroke. (2015) Antonini A., Rascol O., Poewe W., Brucke T.,
F., Martinez-Horta S., Vives-Gilabert Y., Pago- PLOS ONE, 10 (4). Pirker W., Ransmayr G., Schwingenschuh P.,
nabarraga J., Kulisevsky J., Cordoba J., IF: 3.0570 Tomantschger V., Volc D., Jespersen H., Ka-
Guarner C., Soriano G., Alterations in cere- Martin-Blanco A., Serra-Blasco M., Perez-E- mal A., Karlsborg M., Oppel L., Pedersen S.,
bral white matter and neuropsychology in gea R., De Diego-Adelino J., Carceller-Sin- Avikainen S., Kaasinen V., Pekkonen E., Ruot-
patients with cirrhosis and falls. (2015) PLOS dreu M., Puigdemont D., Molet J., Alvarez E., tinen H., Azulay J.-P., Corvol J.-C., Courbon
ONE, 10 (3). Perez V., Portella M.J., Immediate cerebral C.B., Defebvre L., Durif F., Houeto J.-L., Krack
IF: 3.0570 metabolic changes induced by discontinua- P., Tison F., Andrich J., Ehret R., Klostermann

*TIF: 117.1620 **MIF: 6.1664

F., Kruger R., Lingor P., Liszka R., Schwarz J., Pastor P., Moreno F., Clarimon J., Ruiz A., Perez V., A randomized double-blind cross-
Timmermann L., Warnecke T., Bostantjopou- Combarros O., Calero M., De Munain A.L., over trial of deep brain stimulation of the
lou S., Konitsiotis S., Papageorgiou S., Bullido M.J., De Pancorbo M.M., Carro E., subcallosal cingulate gyrus in patients with
Stathishens P., Stefanis L., Zikos P., Browne P., Antonell A., Coto E., Ortega-Cubero S., Her- treatment-resistant depression: A pilot
Healy D., Lynch T., O’Riordan S., O’Sullivan S., nandez I., Tarraga L., Boada M., Lleo A., study of relapse prevention. (2015) J PSYCHI-
Walsh R., Abbruzzese G., Lopiano L., Mod- Dols-Icardo O., Kulisevsky J., Vazquez-Higu- ATR NEUROSCI, 40 (4), 224-231.
ugno N., Tamma F., Holmberg B., Linder J., era J.L., Infante J., Rabano A., Fernandez- IF: 5.5700
Nyholm D., Palhagen S., Matias Arbelo J., -Blazquez M.A., Valenti M., Indakoetxea B., Riba J., Valle M., Sampedro F., Rodriguez-Pu-
Bana R.Y., Castrillo J.C.M., Castro A., e Garcia Barandiaran M., Gorostidi A., Frank-Garcia A., jadas A., Martinez-Horta S., Kulisevsky J.,
Ruiz Espiga P.J., Kulisevsky J., Lezcano E., Sastre I., Lorenzo E., Pastor M.A., Elcoroaris- Rodriguez-Fornells A., Telling true from false:
Luquin R., Mir P., Puente V., Valldeoriola F., tizabal X., Lennarz M., Maier W., Ramirez A., Cannabis users show increased susceptibil-
Burn D., Clarke C., Foltynie T., Grosset D., Serrano-Rios M., Lee S.E., Sanchez-Juan P., ity to false memories. (2015) MOL PSYCHI-
Hindle J., Leake A., Lees A., Morris H., Stewart MAPT H1 haplotype is associated with ATR, 20 (6), 772-777.
D., Walker R., Worth P., Collective physician late-onset Alzheimer’s disease risk in APOE ε IF: 13.3140
perspectives on non-oral medication ap- 4 noncarriers: Results from the dementia
Trenkwalder C., Chaudhuri K.R., Mar-
proaches for the management of clinically genetics Spanish consortium. (2015) J ALZ-
relevant unresolved issues in Parkinson’s HEIMERS DIS, 49 (2), 343-352. tinez-Martin P., Rascol O., Ehret R., Valis M.,
disease: Consensus from an international IF: 3.9200 Satori M., Krygowska-Wajs A., Marti M.J., Re-
survey and discussion program. (2015) PAR- imer K., Oksche A., Lomax M., DeCesare J.,
Perez-Perez J., Pagonabarraga J., Mar- Hopp M., Balaz M., Jech R., Kanovsky P.,
KINSONISM RELAT D, 21 (10), 1133-1144. tinez-Horta S., Fernandez-Bobadilla R., Sierra
IF: 3.7940 Pazdera L., Mach V., Roubcova D., Kuchar M.,
S., Pascual-Sedano B., Gironell A., Kulisevsky Classen J., Dressler D., Muhlack S., Polzer U.,
Ortega-Cubero S., Lorenzo-Betancor O., J., Head-to-Head Comparison of the Neuro- Schwarz J., Sommer M., Kassubek J., Kuhn A.,
Lorenzo E., Agundez J.A.G., Jimenez-Jimenez psychiatric Effect of Dopamine Agonists in Eggert K., Winkler C., Ceballos-Baumann A.,
F.J., Ross O.A., Wurster I., Mielke C., Lin J.-J., Parkinson’s Disease: A Prospective, Cross- Reichman H., Csanyi A., Folyovich A., Levai
Coria F., Clarimon J., Ezquerra M., Brighina L., Sectional Study in Non-demented Patients. N., Lajtos J., Zsolnai M., Vecsei L., Polrola P.,
Annesi G., Alonso-Navarro H., Garcia-Martin (2015) DRUG AGING, 32 (5), 401-407. Szczepanska-Szerej A., Honczarenko A., Ka-
E., Gironell A., Marti M.J., Yueh K.-C., Wszolek IF: 2.6100 minska A., Potemkowski A., Opala G., Klimek
Z.K., Sharma M., Berg D., Kruger R., Pastor Pagonabarraga J., Piñol G., Cardozo A., Sanz A., Rudzinska M., Albu V., Enache C., Fa-
M.A., Pastor P., TREM2 R47H variant and risk P., Puente V., Otermín P., Legarda I., Delgado lup-Pecurariu C., Mitu C., Roceanu A.,
of essential tremor: A cross-sectional inter- T., Serrano C., Balaguer E., Aguirregomoz- Balaguer E., Garcia Moreno J., Linazasoro G.,
national multicenter study. (2015) PARKIN- corta M., Álvarez R., Kulisevsky J.J. Transder- Marti Domenech M., Vivancos F., Kulisevsky
SONISM RELAT D, 21 (3), 306-309. mal Rotigotine Improves Sleep Fragmenta- J., Sesar A., Rodriguez M., Chaudhuri K., Ellis
IF: 3.7940 tion in Parkinson’s Disease: Results of the S., Molloy S., Raw J., Amar K., Boothman B.,
Pagonabarraga J., Kulisevsky J., Strafella A.P., Multicenter, Prospective SLEEP-FRAM Study. Prolonged-release oxycodone-naloxone for
Krack P., Apathy in Parkinson’s disease: Clini- (2015) PARKINSONS DIS, 1-7. treatment of severe pain in patients with
cal features, neural substrates, diagnosis, IF: 1.7220 Parkinson’s disease (PANDA): A double-blind,
and treatment. (2015) LANCET NEUROL, 14 Puigdemont D., Portella M.J., Perez-Egea R., randomised, placebo-controlled trial. (2015)
(5), 518-531. Molet J., Gironell A., de Diego-Adelino J., LANCET NEUROL, 14 (12), 1161-1170.
IF: 23.4680 Martin A., Rodriguez R., Alvarez E., Artigas F., IF: 23.4680
ff Pérez-Pérez J., Martínez-Horta S., Pagonabarraga J., Carceller ff Krack P., Pagonabarraga J., Strafella A.P., Kulisevsky J. Apathy:
M., Kulisevsky J. Rasagiline for the treatment of parkinsonism who cares? (2015) LANCET NEUROL,14(5), 465.
in Huntington’s disease. (2015) PARKINSONISM RELAT DISORD,
21(3), 340-2.
ff Mild cognitive impairment in Parkinson’s Disease. In: Neuropsy-
Other Publications
chiatric Symptoms of Movement Disorders (p. 29-52). Editorial

ff Cubo E., Rivadeneyra J., Armesto D., Mariscal N., Martinez A., Springer.
Camara R.J.; Spanish members of the European Huntington Dis-
ease Network.
ff Functional Studies of Parkinson’s Disease. In: Brain Mapping: An
Encyclopedic Reference, 3 (p. 713-720). Editorial Elsevier.
ff Relationship between Nutritional Status and the Severity of

Huntington’s Disease. A Spanish MulticenterDietary Intake
Study. (2015) J HUNTINGTONS DIS, 4(1), 78-85.
ff Pérez-Pérez J., Martínez-Horta S., Pagonabarraga J., Carceller
M., Kulisevsky J. Rasagiline for the treatment of parkinsonism
in Huntington’s disease. (2015) PARKINSONISM RELAT DISORD,
21(3), 340-2. Epub 2015 Jan 10.

Molecular Neuropharmacology
Coordinator
Pol Rigau, Olga IR
opol@santpau.cat
Members
Grayston, Alba UAB
Leánez Morilla, Sergi
Mac Donnell, Christina UAB
Chronic pain affects a high percentage of the adult population and is difficult to treat even with
the most potent analgesic compounds, which represents one of the main challenges in the
current research of pain. Our main objective is to investigate new strategies for the treatment
of chronic pain using pharmacological, molecular and genetic approaches.
ff Establish new strategies to improve the analgesic effects produced by opioids and cann-
of Research
Main Lines
abinoids in the treatment of chronic pain and avoiding the development of side effects.
ff Identify new targets for the treatment of inflammatory, arthritic, and neuropathic pain by
using different pharmacological approaches in several animal models of pain.
ff Identify new approaches for treating diabetic neuropathy and oxidative stress, two of the
main complications of diabetes, by evaluating the effects produced by several specific
drug combinations in type I and II diabetic mice.
ff Investigate the role played by nitric oxide-carbon monoxide systems in the modulation of
the nociceptive and emotional responses induced by chronic pain in transgenic animals.
ff Identify new pharmacological com- ff Develop new effective drug combinations

pounds that effectively abolish chronic for the treatment of neuropathic pain and
pain without side effects and which use oxidative stress associated with diabetes.
Challenges
can be transferred to clinical practice and/

or patentable.
ff Knowledge of the role played by gaseous
neurotransmitters in the modulation of
ff Advance knowledge of the molecular nociceptive and emotional responses in-
mechanisms involved in the enhanced duced by inflammatory pain.
antinociceptive actions produced by opi-
oids and cannabinoids combined with the
heme oxygenase 1 signaling pathway in-
ducer compounds.
Collaborations with other IIB Sant Pau ff Prof. Roberto Motterlini. INSERM U955,
Groups University Paris-Est. France.
ff Pedro José Otaegui Goya. Equipos de
Collaborations
ff Metabolic Bases of Cardiovascular Risk (PI: Monitarización conductual. UNAB13-

Francisco Blanco) 4E-1952. Ministerio de Economía y Com-
petitividad. Duration: 2013-2015.
ff Prof. Christie Leite-Panissi. University of
São Paulo. Brazil.
ff Prof. Luiz Guilherme de Siqueira Branco.
University of São Paulo. Brazil.

Olga Pol Rigau. Nuevas estrategias en el tratamiento de la neuropatía diabética. PI14/00927. Instituto de Salud Carlos III. Duration:
Active Grants
ff
2015-2017. €71,500.
ff Olga Pol Rigau. Possible interaction CO-NO in the emotional and nociception modulation: role of locus coeruleus. PVE 2014. Ciencia sin
Fronteras. Duration: 2015-2017.
ff Best UAB Neuroscience thesis of the year extraordinary award to

Awards
Arnau Hervera’s these, directed by Olga Pol, year 2012-13.

Pharmacological Research in Humans
Coordinator
Antonijoan Arbós,
Rosa Maria FGS
Members
Ballester Verneda,
Maria Rosa IR
Claramunt Giralt, Judit IR
Clos Batet, Susana IR
Coma Bolta, Sonia IR
Fernández Buján, Marta
Ferrero Cafiero, Juan Manuel IR
Funes Ungria, Maria Àngels IR
García Gea, Consuelo IR Clinical Trials with no Therapeutic Neuro-Physio-Pharmacology of Sleep/
Garrido Sánchez, Benefits to Volunteer Participants Wake States
Maria Teresa IR ff Phase I clinical trials (healthy volunteers) ff Investigate human brain activity in sleep
Gich Saladich, Ignasi Josep FGS whose main objectives include: first-time- and wakefulness, mechanisms involved in
Giménez Badia, Sandra IR in-humans, safety and tolerability (local, these states, problems derived from sleep
Gomis Pulgar, Ana María IR systemic/dermatological, ophthalmolog- disturbances and possible interventions.
González Cuadros, Mireia IR ical, vaginal), pharmacokinetics, bioavail-
ability and bioequivalence (generic
ff Approach the phenomenon as a contin-
Lillo Arsenal, Yolanda IR uum: appropriate interpretation of the
drugs), pharmacodynamics, interactions
Martínez Bonifacio, David IR impact of a certain intervention, whether
(drug-drug/drug-food), evaluation and
of Research
Main Lines
Martínez Colomer, Juan IR characterization of biomarkers, proofs pharmacological or not, should take into
Martínez Domínguez, Pura IR of concept, acceptability and preference account the complementarity of evalua-
Martínez Martínez, studies. tions performed during sleep and during
wakefulness.
Maria Isabel IR ff Follow-up studies in populations with the
Mercader Seguí, Esteve IR same or different characteristics (elderly,
ff Develop studies that consider the 24-hour
Mora Amargós, Sara IR obese, postmenopausal, with liver or kid- day/night cycle as the phenomenon un-
Puntes Rodríguez, ney failure). der study cannot be evaluated without
taking this interactivity into account.
Montserrat IR ff Collaboration with clinical services to con-
duct phase II/III studies.
ff Develop psychomotor performance tests,
subjective evaluation scales, neurophys-
iologic recordings (quantitative EEG,
evoked-sensorial potentials and polysom-
nography), psychophysiological tests and
pupillometric tests.
ff Consolidate and strengthen leadership in ff Promote dissemination of our activity

this field in Spain, conserve relationships with a dual objective: to return knowl-
with the pharmaceutical industry on a edge generated to society and demystify
national level and strengthen and extend research in humans, bringing it closer to
relations abroad with multinational enter- the community so as to foster participa-
prises and industries from other sectors. tion in clinical trials (particularly in specific
sectors of the populations, such as the el-
ff Broaden the range of questions to ad- derly).
Challenges
dress in research projects along the lines

of the neuro-physio-pharmacology of ff Set up educational activities related to
sleep/wake states, focusing on pharmaco- our two main research lines: the applica-
therapeutic objectives and also on phys- tion of good clinical practices in clinical
iopathologic objectives in related fields, research into sleep medicine and its med-
such as dreams. ical (pathology, and treatment) and social
(quality of life, prevention of accident risk)
ff Develop neurophysiologic recording per- consequences.
formance in ambulatory conditions, sim-
plifying participation of volunteers but
not lowering the quality of data obtained
(non-negotiable element of their applica-
tion as a research variable).

Collabo-
ff Rosa M. Antonijoan Arbós. Centre d’Investigació

rations
Grants
Active
de Medicaments. 2014 SGR 386. Agència de Gestió
ff Phase I clinical trials for national and international d’Ajuts Universitaris i de Recerca. Duration: 2014-2016.
pharmaceutical companies (12 in total).
Theses
ff Savion Gropper Achitoov. Absorption, safety and tolerability of a

Topical Quinolone. Universitat Autònoma de Barcelona. Director:
Rosa Antonijoan. Date of defense: 2 December 2015.
*TIF: 62.8600 **MIF: 3.9288

Alonso J.F., Romero S., Ballester M.R., Antoni- lysinate, quicker and less variable: Relative Calle C., Lohr S.J.Z., Lalremruata A., Gunasek-
joan R.M., Mananas M.A., Stress assessment bioavailability compared to ibuprofen base era A., James E.R., Billingsley P.F., Richman A.,
based on EEG univariate features and func- in a pediatric suspension dosage form. Chakravarty S., Legarda A., Munoz J., Antoni-
tional connectivity measures. (2015) PHYS- (2015) INT J CLIN PHARM TH, 53 (11), 972- joan R.M., Ballester M.R., Hoffman S.L.,
IOL MEAS, 36 (7). 979. Alonso P.L., Kremsner P.G., Direct venous in-
IF: 1.5760 IF: 1.1290 oculation of Plasmodium falciparum sporo-
Alonso-Coello P., Montori V.M., Diaz M.G., Gimenez S., Romero S., Alonso J.F., Mananas zoites for controlled human malaria infec-
Devereaux P.J., Mas G., Diez A.I., Sola I., Roura M.A., Pujol A., Baxarias P., Antonijoan R.M., tion: A dose-finding trial in two centres.
M., Souto J.C., Oliver S., Ruiz R., Coll-Vinent B., Monitoring sleep depth: analysis of bispec- (2015) MALARIA J, 14 (1).
Gich I., Schunemann H.J., Guyatt G., Values tral index (BIS) based on polysomnographic IF: 3.0790
and preferences for oral antithrombotic recordings and sleep deprivation. (2015) J Plaza V., Peiro M., Torrejon M., Fletcher M.,
therapy in patients with atrial fibrillation: CLIN MONIT COMPUT, 1-8. Lopez-Vina A., Ignacio J.M., Quintano J.A.,
Physician and patient perspectives. (2015) IF: 1.8190 Bardagi S., Gich I., A repeated short educa-
HEALTH EXPECT, 18 (6), 2318-2327. Gomez-Perez G.P., Legarda A., Munoz J., Sim tional intervention improves asthma control
IF: 3.2070 B.K.L., Ballester M.R., Dobano C., Moncunill and quality of life. (2015) EUR RESPIR J, 46 (5),
Ballester M.R., Roig E., Gich I., Puntes M., G., Campo J.J., Cistero P., Jimenez A., Barrios 1298-1307.
Delgadillo J., Santos B., Antonijoan R.M., D., Mordmuller B., Pardos J., Navarro M., Zita IF: 8.3320
Randomized, open-label, blinded-endpoint, C.J., Nhamuave C.A., Garcia-Basteiro A.L., Riba J., Mcilhenny E.H., Bouso J.C., Barker
crossover, single-dose study to compare the Sanz A., Aldea M., Manoj A., Gunasekera A., S.A., Metabolism and urinary disposition of
pharmacodynamics of torasemide-PR 10 Billingsley P.F., Aponte J.J., James E.R., Guino- N,N-dimethyltryptamine after oral and
mg, torasemide-IR 10 mg, and furosemi- vart C., Antonijoan R.M., Kremsner P.G., Hoff- smoked administration: A comparative
de-IR 40 mg, in patients with chronic heart man S.L., Alonso P.L., Controlled human ma- study. (2015) DRUG TEST ANAL, 7 (5), 401-
failure. (2015) DRUG DES DEV THER, 9, 4291- laria infection by intramuscular and direct 406.
4302. venous inoculation of cryopreserved Plas- IF: 2.8590
IF: 2.8810 modium falciparum sporozoites in malar- Robleda G., Roche-Campo F., Urrutia G., Na-
Balsells M., Garcia-Patterson A., Sola I., Roque ia-naïve volunteers: effect of injection vol- varro M., Sendra M.-A., Castillo A., Rodri-
M., Gich I., Corcoy R., Glibenclamide, metfor- ume and dose on infectivity rates. (2015) guez-Arias A., Juanes-Borrejo E., Gich I.,
min, and insulin for the treatment of gesta- MALARIA J, 14 (1). Mancebo J., Banos J.-E., A randomized con-
tional diabetes: A systematic review and IF: 3.0790 trolled trial of fentanyl in the pre-emptive
meta-analysis. (2015) BMJ-BRIT MED J, 350. Hernandez D., Palou J., Sancho G., Salas D., treatment of pain associated with turning in
IF: 19.6970 Gimenez D., Buitrago P., Esquena S., de la patients under mechanical ventilation: RE-
Barnadas M.A., Rubiales M.V., Gich I., Gelpi C., Torre P., Pernas J., Gich I., de Segura G.G., SEARCH protocol. (2015) J ADV NURS, 71 (2),
Usefulness of specific anti-desmoglein 1 and Craven-Bartle J., Pelvic MRI findings in re- 441-450.
3 enzyme-linked immunoassay and indirect lapsed prostate cancer after radical prosta- IF: 1.9170
immunofluorescence in the evaluation of tectomy. (2015) RADIAT ONCOL, 10 (1). Robleda G., Roche-Campo F., Sanchez V.,
pemphigus activity. (2015) INT J DERMATOL, IF: 2.4660 Gich I., Banos J.-E., Postoperative Discomfort
54 (11), 1261-1268. Maqueda A.E., Valle M., Addy P.H., Antoni- After Abdominal Surgery: An Observational
IF: 1.4150 joan R.M., Puntes M., Coimbra J., Ballester Study. (2015) J PERIANESTH NURS, 30 (4),
Bouso J.C., Palhano-Fontes F., Rodriguez- M.R., Garrido M., Gonzalez M., Claramunt J., 272-279.
Fornells A., Ribeiro S., Sanches R., Crippa Barker S., Johnson M.W., Griffiths R.R., Riba J., IF: 0.6620
J.A.S., Hallak J.E.C., de Araujo D.B., Riba J., Salvinorin-A induces intense dissociative ef-
Long-term use of psychedelic drugs is asso- fects, blocking external sensory perception
ciated with differences in brain structure and modulating interoception and sense of
and personality in humans. (2015) EUR NEU- body ownership in humans. (2015) INT J
ROPSYCHOPHARM, 25 (4), 483-492. NEUROPSYCHOPH, 18 (12), 1-14.
IF: 4.4090 IF: 4.3330
Ferrero-Cafiero J.M., Gich I., Puntes M., Marti- Mordmuller B., Supan C., Sim K.L., Gomez-
nez J., Ballester M.R., Coimbra J., Mathison Y., Perez G.P., Ospina Salazar C.L., Held J., Bolte
Tarre M., Font X., Antonijoan R.M., Ibuprofen S., Esen M., Tschan S., Joanny F., Lamsfus

Clinical Psychiatry
Coordinator
Portella Moll, Maria Jesús IR
mportella@santpau.cat
Members
Allende, Saiko CIBERSAM
Alonso, Anna IR
Álvarez, Enric FGS
Arranz, María Jesús IR
Carceller, Maria del Mar IR
Carmona Farrés, Cristina FGS
Corripio, Iluminada FGS
Díaz, Anna FGS
De Diego, Francisco Javier FGS
of Research
Psychotic disorders (first episodes and persistent hallucinations).

Main Lines
ff
Duran-Sindreu, Santiago FGS
Elices, Matilde IR ff Affective disorders (major depression and validation of scales).
Feliu, Albert IR ff Borderline personality disorder.
Figueras, Maria FGS
Grasa, Eva Maria CIBERSAM
Jubero, Miriam IR
Martín, Anna IR
Pascual, Juan Carlos FGS ff Foster research that reduces the health- Research into Affective Disorders
Pérez, Josefina FGS care, social and personal costs of mental
Puigdemont, Dolors FGS illness by exploring areas such as epidemi- ff Identification and evaluation of new ther-
Rabella, Mireia IR ology, etiopathogenesis, physiopathol- apeutic targets in depression.
Serra, Maria IR ogy, prevention and treatment. ff Neuroimaging studies in first psychotic
Soler, Joaquín FGS ff Foster research into mental health thera- episodes.
Soriano, José FGS pies. ff Biological and genetic markers in affective
Tiana, Thaís FGS ff Foster research to improve quality of life of disorders.
patients with mental disorders. ff Implementation of new therapeutic pro-
Challenges
grammes, depression evaluation and so-

Research into Psychotic Disorders cial aspects of depression.
ff Neuroimaging studies in first psychotic
episodes. Research into Personality Disorders
ff Study of environmental, biological and ff Clinical trials regarding the usefulness of
genetic factors in psychosis. mixed treatment in patients with border-
line personality disorder and validation of
ff Efficacy and effectiveness studies of anti- diagnostic instruments.
psychotic drugs.
ff Genetic-neuroimaging studies of border-
ff Efficacy and effectiveness study of psy- line personality disorder (BPD).
chotherapy for hallucinations.
ff Efficacy and effectiveness studies of psy-
ff Study of treatment resistance in schizo- chotherapy for treating borderline per-
phrenia. sonality disorder.
ff A. Fernández Vidal, E. Salagre, A. Ancochea, A. Feliu, D. Puigdemont, M.J. Portella, J. Tru-

jols, E. Álvarez, V. Pérez, J. de Diego-Adeliño. Remissió en depressió: la felicitat i salut men-
tal positiva del pacient hi tenen res a dir? Premi accèssit a la millor comunicació de la
Jornada de Cloenda de Psiquiatria 2014, Societat Catalana de Psiquiatria i Salut Mental.
5-6 June 2014.
Awards
ff Joana Bauzà, Sara Vieira, Alexandra Roldán, Conrad Molins, Eva Grasa, Santiago Durán-
Sindreu, Anna Díaz, María J. Portella, Enric Álvarez, Iluminada Corripio. Podríem preveure
el perfil de remissió dels pacients psicòtics a través del seu rendiment neuropsicològic?
Premi a la millor comunicació de la Jornada de Cloenda de Psiquiatria 2014, Societat
Catalana de Psiquiatria i Salut Mental. 5-6 June 2014.


ff Addictive Behaviours. ff Hospital Clínic de Barcelona, Psychiatry Department.
ff Neuroradiology. ff Hospital Parc Taulí, Sabadell, Psychiatry Department.
ff Neurosurgery. ff Universidad Complutense de Madrid, Medicine-Pharmacology
Collaborations
Department.
ff Hypophysis Diseases.
ff Hospital Universitario de la Princesa, Madrid, Psychiatry Depart-
ff CIM – Sant Pau. ment.
ff Pain Clinic Sant Pau. ff Universidad de Valencia, Medicine-Psychiatry Department.
ff Genetics. ff Leipzig University, Medicine-Psychiatry Department.
ff Internal Medicine. ff Universidad de Cádiz, Medicine-Pharmacology Department.
ff Hospital Benito Menni – FIDMAG, Barcelona, Psychiatry Depart-
ment.
ff University of Oxford, Medicine-Psychiatry Department.
ff Iluminada Corripio Collado. Determinantes clínicos y neurobi- tudio traslacional. PI13/01102-1 C. Instituto de Salud Carlos III.
ológicos de segundos episodios de esquizofrenia. Estudio lon- Duration: 2014-2016.
gitudinal de primeros episodios psicóticos. PI11/00260. Instituto
de Salud Carlos III. Duration: 2012-2016. €75,727.
ff Iluminada Corripio Collado. Mobile Therapeutic Attention for
Patients with Treatment Resistant Schizophrenia (m-RESIST).
ff Maria Jesús Portella Moll. Contracte SNS Miguel Servet 2010. PHC26-2014(2)-IR. European Union. Duration: 2015-2017.
MS10/00393. Instituto de Salud Carlos III. Duration: 2011-2017. €126,474.19.
€151,875.
ff Juan Carlos Pascual Mateos. Estudio Epigenómico en el Tras-
ff Enric Álvarez Martínez. Estimulación Cerebral Profunda en el torno Límite de la Personalidad: estudio del patrón de meti-
tratamiento de la esquizofrenia refractaria: estudio piloto alea- lación (EWAS-Epigenome-wide association study) y su relación
torizado, controlado y cruzado. PI12/00042. Instituto de Salud con antecedentes traumáticos. PI14/00214. Instituto de Salud
Carlos III. Duration: 2013-2017. €91,500. Carlos III. Duration: 2015-2017. €81,500.
Francisco Javier de Diego Adeliño. Recerca farmacogenètica de Maria del Mar Carceller Sindreu. Contractes predoctorals de for-
Active Grants
ff ff
la difusió sexual induïda per antidepressius. JPC 2013. Socie- mació en investigació en salut 2014. FI14/00201. Instituto de
tat Catalana de Psiquiatria i Salut Mental. Duration: 2013-2016. Salud Carlos III. Duration: 2015-2019. €82,400.
€2,700.
ff Francisco Javier de Diego Adeliño. Contratos Juan Rodés 2014.
ff Maria Jesús Portella Moll. Estudio longitudinal de cambios cere- JR14/00011. Instituto de Salud Carlos III. Duration: 2015-2018.
brales en pacientes con un primer episodio de depresión mayor. €135,000.
€56,300.
ff Eva Maria Grasa Bello. Eficacia del Entrenamiento Metacogni-
tivo Individualizado (EMC+) en personas con psicosis de breve
ff Joaquín Soler Ribaudi. Efectos del Mindfulness en la Activi- evolución. PI14/00044 C. Instituto de Salud Carlos III. Duration:
dad y Conectividad Funcional de la Default Mode Network en 2015-2017.
Pacientes con Trastorno Límite de la Personalidad. PI13/00134.
Instituto de Salud Carlos III. Duration: 2014-2016. €46,150.
ff Iluminada Corripio Collado. Mobile Therapeutic Attention for
Patients with Treatment Resistant Schizophrenia (m-RESIST).
ff Enric Álvarez Martínez. Grup de Recerca en Trastorns Psiquiàtrics PHC26-2014(2)-FGS. European Union. Duration: 2015-2017.
de Sant Pau. 2014 SGR 468. Agència de Gestió d’Ajuts Universi- €152,667.81.
taris i de Recerca. Duration: 2014-2016.
ff Francisco Javier de Diego Adeliño. Papel de la microbiota en el
origen y las consecuencias de la inflamación en depresión. Es-
ff Maria Jesús Portella Moll. Biomarkers of treatment resistance in ect H2020. IR15-INTH2020. Institut de Recerca de l’Hospital de la
Awarded
major depressive disorders. IR15-P3. Institut de Recerca de l’Hos- Santa Creu i Sant Pau. Duration: 2015-2016. €30,000.
in 2015
Grants
pital de la Santa Creu i Sant Pau. Duration: 2015-2016. €33,000.

ff Iluminada Corripio Collado, Mobile Therapeutic Attention for
Patients with Treatment Resistant Schizophrenia: m-RESIST Proj-

Clinical Psychiatry
*TIF: 64.3960 **MIF: 3.0665
Aguado J., Luciano J.V., Cebolla A., Serrano- derline personality disorder. (2015) BMC Pascual J.C., Palomares N., Ibanez A., Portella
Blanco A., Soler J., Garcia-Campayo J., Bifac- PSYCHIATRY, 15 (1). M.J., Arza R., Reyes R., Feliu-Soler A., Di-
tor analysis and construct validity of the five IF: 2.5760 az-Marsa M., Saiz-Ruiz J., Soler J., Carrasco
facet mindfulness questionnaire (FFMQ) in Forcada I., Mur M., Mora E., Vieta E., Bartres- J.L., Efficacy of cognitive rehabilitation on
non-clinical Spanish samples. (2015) FRONT Faz D., Portella M.J., The influence of cogni- psychosocial functioning in Borderline Per-
PSYCHOL, 6 (MAR). tive reserve on psychosocial and neuropsy- sonality Disorder: A randomized controlled
IF: 2.4630 chological functioning in bipolar disorder. trial. (2015) BMC PSYCHIATRY.
Alonso-Solis A., Vives-Gilabert Y., Grasa E., (2015) EUR NEUROPSYCHOPHARM, 25 (2), IF: 2.5760
Portella M.J., Rabella M., Sauras R.B., Roldan 214-222. Puigdemont D., Portella M.J., Perez-Egea R.,
A., Nunez-Marin F., Gomez-Anson B., Perez V., IF: 4.4090 Molet J., Gironell A., de Diego-Adelino J.,
Alvarez E., Corripio I., Resting-state func- Lascorz D., Lopez V., Pinedo C., Trujols J., Martin A., Rodriguez R., Alvarez E., Artigas F.,
tional connectivity alterations in the default Vegue J., Perez V., Psychometric study of the Perez V., A randomized double-blind cross-
network of schizophrenia patients with per- Required Care Levels for People with Severe over trial of deep brain stimulation of the
sistent auditory verbal hallucinations. (2015) Mental Disorder Assessment Scale (ENAR- subcallosal cingulate gyrus in patients with
SCHIZOPHR RES, 161 (2-3), 261-268. TMG). (2015) REV PSIQUIATR SALUD. treatment-resistant depression: A pilot
IF: 4.4530 IF: 1.6500 study of relapse prevention. (2015) J PSYCHI-
Arranz B., Safont G., Corripio I., Ramirez N., ATR NEUROSCI, 40 (4), 224-231.
Martin-Blanco A., Serra-Blasco M., Perez-E- IF: 5.5700
Duenas R.M., Perez V., Alvarez E., San L., Sub- gea R., De Diego-Adelino J., Carceller-Sin-
stance use in patients with first-episode dreu M., Puigdemont D., Molet J., Alvarez E., Ruiz M.A., Alvarez E., Carrasco J.L., Olivares
psychosis: Is gender relevant?. (2015) J DUAL Perez V., Portella M.J., Immediate cerebral J.M., Perez M., Rejas J., Modeling the longitu-
DIAGN, 11 (3-4), 153-160. metabolic changes induced by discontinua- dinal latent effect of pregabalin on self-re-
IF: 0.8390 tion of deep brain stimulation of subcallosal ported changes in sleep disturbances in
Atanes A.C.M., Andreoni S., Hirayama M.S., cingulate gyrus in treatment-resistant de- outpatients with generalized anxiety disor-
Montero-Marin J., Barros V.V., Ronzani T.M., pression. (2015) J AFFECT DISORDERS, 173, der managed in routine clinical practice.
Kozasa E.H., Soler J., Cebolla A., Garcia-Cam- 159-162. (2015) DRUG DES DEV THER, 9, 4329-4340.
payo J., Demarzo M.M.P., Mindfulness, per- IF: 3.5700 IF: 2.8810
ceived stress, and subjective well-being: A Martin-Blanco A., Ferrer M., Soler J., Arranz Serra-Blasco M., de Vita S., Rodriguez M.R., de
correlational study in primary care health M.J., Vega D., Bauza J., Calvo N., Elices M., Diego-Adelino J., Puigdemont D., Martin-
professionals. (2015) BMC COMPLEM AL- Sanchez-Mora C., Garcia-Martinez I., Salazar Blanco A., Perez-Egea R., Molet J., Alvarez E.,
TERN M, 15 (1). J., Ribases M., Carmona C., Prat M., Pascual Perez V., Portella M.J., Cognitive functioning
IF: 1.9870 J.C., An exploratory association study of the after deep brain stimulation in subcallosal
Carceller-Sindreu M., de Diego-Adelino J., influence of noradrenergic genes and child- cingulate gyrus for treatment-resistant de-
Serra-Blasco M., Vives-Gilabert Y., Marti;n- hood trauma in Borderline Personality Disor- pression: An exploratory study. (2015) PSY-
Blanco A., Puigdemont D., Alvarez E., Perez der. (2015) PSYCHIAT RES, 229 (1-2), 589-592. CHIAT RES, 225 (3), 341-346.
V., Portella M.J., Volumetric MRI study of the IF: 2.4660 IF: 2.4660
habenula in first episode, recurrent and Martinez-Horta S., Perez-Perez J., van Duijn Trujols J., Ballesteros J., Sola I., Portella M.J.,
chronic major depression. (2015) EUR NEU- E., Fernandez-Bobadilla R., Carceller M., Pag- Improving systematic reviews on psycho-
ROPSYCHOPHARM, 25 (11), 2015-2021. onabarraga J., Pascual-Sedano B., Campo- metric properties of measurement instru-
IF: 4.4090 longo A., Ruiz-Idiago J., Sampedro F., ments: A letter to the Editor commenting on
Cuesta M.J., Sanchez-Torres A.M., Cabrera Landwehrmeyer G.B., Kulisevsky J., Neurop- Reilly etal.’s. (2015) review of the psychomet-
B., Bioque M., Merchan-Naranjo J., Corripio sychiatric symptoms are very common in ric literature on QIDS. (2015) J PSYCHIATR
I., Gonzalez-Pinto A., Lobo A., Bombin I., de premanifest and early stage HD. (2015) PAR- RES.
la Serna E., Sanjuan J., Parellada M., Saiz- KINSONISM RELAT D. IF: 4.4650
Ruiz J., Bernardo M., Mezquida G., Penades IF: 3.7940 Trujols J., Iraurgi I., Batlle F., Duran-Sindreu S.,
R., Calvo A., Arango C., Alonso-Solis A., Mitjans M., Catalan R., Vazquez M., Gonza- Perez de los Cobos J., Towards a genuinely
Grasa E.M., de Azua S.R., Barbeito S., Gutier- lez-Rodriguez A., Penades R., Pons A., Mas- user-centred evaluation of harm reduction
rez-Galve L., Barconesi F., Aguilar E.J., Berge sana G., Munro J., Arranz M.J., Arias B., Hypo- and drug treatment programmes: A further
D., Cortizo R., Torrent C., Vieta E., Baeza I., thalamic-pituitary-adrenal system, proposal. (2015) INT J DRUG POLICY, 26 (12),
Castro-Fornieles J., Contreras F., Albacete neurotrophic factors and clozapine re- 1285-1287.
A., Al-Halabi S., Bobes J., Zabala A., Rodri- sponse: Association with FKBP5 and NTRK2 IF: 3.1190
guez-Jimenez R., Usall J., Sarro S., Ibanez A.,
genes. (2015) PHARMACOGENET GENOM, Villalta L., Arevalo R., Valdeperez A., Pascual
Moreno-Izco L., Balanza-Martinez V., Pre- 25 (5), 274-277. J.C., de los Cobos J.P., Parental Bonding in
morbid adjustment and clinical correlates IF: 2.8570 Subjects with Pathological Gambling Disor-
of cognitive impairment in first-episode der Compared with Healthy Controls. (2015)
psychosis: The PEPsCog Study. (2015) Olivares J.M., Alvarez E., Carrasco J.L., Paramo
M.P., Lopez-Gomez V., Pregabalin for the PSYCHIAT QUART, 86 (1), 61-67.
SCHIZOPHR RES, 164 (1-3), 65-73. IF: 0.9780
IF: 4.4530 treatment of patients with generalized anxi-
ety disorder with inadequate treatment re-
Elices M., Pascual J.C., Carmona C., Martin- sponse to antidepressants and severe de-
Blanco A., Feliu-Soler A., Ruiz E., Goma-i- pressive symptoms. (2015) INT CLIN
Freixanet M., Perez V., Soler J., Exploring the PSYCHOPHARM, 30 (5), 265-271.
relation between childhood trauma, tem- IF: 2.4150
peramental traits and mindfulness in bor-


Genetics in Neurodegenerative Diseases
Coordinator
Clarimon Echavarria, Jordi IR
jclarimon@santpau.cat
Members
Cervera Carles, Laura IR
Dols Icardo, Oriol CIBERNED
Helgueta Romero, Sergui IR
Muñoz Llahuna, Laia CIBERNED
ff Use of state-of the-art genomic strate- ff Study of the relationship between

gies to study the genetic architecture of biomarkers and endophenotypes at the
complex diseases caused by neurodegen- individual genetic background.
of Research
erative processes, including Alzheimer

Main Lines
disease and other dementias, Parkinson

ff Evaluation of the effect of novel genes
disease, and neuromuscular disorders. related to neurodegenerative disorders in
the Spanish population through multicen-
ff Cloning and evaluation of novel genes tre collaborative studies.
associated with neurodegenerative disor-
ders through genomic analyses on fami-
lies with Mendelian pattern of inheritance.
Challenges
ff Assemble a research team of excellence in ff Develop a comprehensive genomic da-

the international field of genetics of neu- tabase from well-characterized Spanish
rodegenerative disorders. patients of European origin suffering from
neurodegenerative disorders.
ff Increase our capacity of funding through
EU support.
Collaborations with other IIB Sant Pau Collaborations with international centres
Groups ff Dr. John Hardy, University College of Lon-
don, UK.
ff Neurobiology of Dementia (Alberto Lleó).
ff Dr. Andrew Singleton, National Institutes
ff Parkinson Disease and Movement Disor- of Health, USA.
ders (Jaime Kulisevsky).
ff Dr. Coro Paisán-Ruiz, Mount Sinai School
ff Neuromuscular Diseases (Isabel Illa). of Medicine, USA.
Dr. Ekaterina Rogaeva, University of To-
Collaborations
ff
ronto, Canada.
National and international consortiums ff Dr. Mikko Hiltunen, Kuopio University, Fin-
land.
ff European Early Onset Dementia Consor-
tium (EU-EOD). ff Dr. Martin Ingelsson, Uppsala University,
Sweden.
ff European Alzheimer Disease Initiative
(EADI). ff Dr. Liana Fidani, Aristotle University of
Thessaloniki, Greece.
ff International Genomics of Alzheimer Proj-
ect (IGAP). ff Dr. Philippe Amouyel, Institut Pasteur de
Lille, France.
ff Dementia Genetics Spanish Consortium
(DEGESCO). ff Dr. Christine Van Broekhoven, University
of Antwerp, Belgium.
ff CIBER-Neurodegenerative Diseases (CIBER-
NED).

ff Jordi Clarimon Echavarria. Contratos Miguel Servet 2013 (II). Española de Enfermedades Raras / Fundación Isabel Gemio /
MSII13/00005. Instituto de Salud Carlos III. Duration: 2014-2017. Federación Española de Enfermedades Neuromusculares. Dura-
€101,250. tion: 2015-2017. €90,748.
Active Grants
ff Jordi Clarimon Echavarria. Grup de Recerca en Demècies. 2014 ff Jordi Clarimón Echevarria. Variantes genéticas raras y su im-
SGR 235. Agència de Gestió d’Ajuts Universitaris i de Recerca. Du- plicación en la enfermedad de Alzheimer: uso de nuevas tec-
ration: 2014-2016. €18,000. nologías de ultrasecuenciación para el estudio de genes impli-
cados en la enfermedad de Alzheimer. PI12/01311. Instituto de
ff Jordi Clarimon Echavarria. A comprehensive genomic analyis Salud Carlos III. Duration: 2013-2016. €110,110.
of patients with motor neuron disease and frontotemporal de-
mentia to disentangle the missing genetic architecture of amyo- Note: Total amount granted to PI. It does not include indirect costs.
trophic lateral sclerosis. TODOS SOMOS RAROS 2014. Federación
ff Jordi Clarimon Echavarria. Paper del gen CHCHD10 en el contínuum demència frontotemporal – esclerosi lateral amiotròfica. IR15-P6,
Awarded
Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau. Duration: 2015-2016. €33,000.
in 2015
Grants
*TIF: 111.0870 **MIF: 7.4058

Alcolea D., Vilaplana E., Pegueroles J., Montal Llado A., Gelpi E., Almeida M.R., Santana I., Dols-Icardo O., Iborra O., Valdivia J., Pastor P.,
V., Sanchez-Juan P., Gonzalez-Suarez A., Po- Tsolaki M., Koutroumani M., Clarimon J., Lleo Ruiz A., de Munain A.L., Sanchez-Valle R., Al-
zueta A., Rodriguez-Rodriguez E., Bartres- A., Fortea J., de Mendonca A., Martins M., varez V., Sanchez-Juan P., Lleo A., Fortea J.,
Faz D., Vidal-Pineiro D., Gonzalez-Ortiz S., Borroni B., Padovani A., Matej R., Rohan Z., Blesa R., Cardona F., Baquero M., Alonso
Medrano S., Carmona-Iragui M., Sanchez- Vandenbulcke M., Vandenberghe R., De M.D., Ortega-Cubero S., Pastor M.A., Razquin
Saudinos M., Sala I., Anton-Aguirre S., Deyn P.P., Cras P., van der Zee J., Sleegers K., C., Boada M., Hernandez I., Gorostidi A.,
Sampedro F., Morenas-Rodriguez E., Clari- Van Broeckhoven C., Rare Variants in PLD3 Moreno F., Zulaika M., Llado A., Coto E., Com-
mon J., Blesa R., Lleo A., Fortea J., Relation- Do Not Affect Risk for Early-Onset Alzheimer barros O., Perez-Tur J., Clarimon J., Assessing
ship between cortical thickness and cere- Disease in a European Consortium Cohort. the role of TUBA4A gene in frontotemporal
brospinal fluid YKL-40 in predementia stages (2015) HUM MUTAT, 36 (12), 1226-1235. degeneration. (2015) NEUROBIOL AGING,
of Alzheimer’s disease. (2015) NEUROBIOL IF: 5.0890 38, 215.e13-215.e14.
AGING, 36 (6), 2018-2023. Carmona-Iragui M., Fernandez-Arcos A., Al- IF: 5.1530
IF: 5.1530 colea D., Piazza F., Morenas-Rodriguez E., Heilmann S., Drichel D., Clarimon J., Fernan-
Alcolea D., Martinez-Lage P., Sanchez-Juan Anton-Aguirre S., Sala I., Clarimon J., Dols-I- dez V., Lacour A., Wagner H., Thelen M.,
P., Olazaran J., Antunez C., Izagirre A., Ecay- cardo O., Camacho V., Sampedro F., Munuera Hernandez I., Fortea J., Alegret M., Blesa R.,
Torres M., Estanga A., Clerigue M., Guisasola J., Nunez-Marin F., Lleo A., Fortea J., Go- Mauleon A., Roca M.R., Kornhuber J., Peters
M.C., Sanchez Ruiz D., Marin Munoz J., Calero mez-Anson B., Blesa R., Cerebrospinal Fluid O., Heun R., Frolich L., Hull M., Heneka M.T.,
M., Blesa R., Clarimon J., Carmona-Iragui M., Anti-Amyloid-Beta; Autoantibodies and Ruther E., Riedel-Heller S., Scherer M., Wilt-
Morenas-Rodriguez E., Rodriguez-Rodri- Amyloid PET in Cerebral Amyloid Angio- fang J., Jessen F., Becker T., Tarraga L., Boada
guez E., Vazquez Higuera J.L., Fortea J., Lleo pathy-Related Inflammation. (2015) J ALZ- M., Maier W., Lleo A., Ruiz A., Nothen M.M.,
A., Amyloid precursor protein metabolism HEIMERS DIS, 50 (1), 1-7. Ramirez A., PLD3 in non-familial Alzhei-
and inflammation markers in preclinical IF: 3.9200 mer’s disease. (2015) NATURE, 520 (7545),
Alzheimer disease. (2015) NEUROLOGY, 85 Cuyvers E., van der Zee J., Bettens K., Engel- E3-E5.
(7), 626-633. borghs S., Vandenbulcke M., Robberecht C., IF: 38.1380
IF: 8.1660 Dillen L., Merlin C., Geerts N., Graff C., Thon- Hor H., Francescatto L., Bartesaghi L., Orte-
Bufill E., Roura-Poch P., Sala-Matavera I., An- berg H., Chiang H.-H., Pastor P., Orte- ga-Cubero S., Kousi M., Lorenzo-Betancor O.,
ton S., Lleo A., Sanchez-Saudinos B., Tomas- ga-Cubero S., Pastor M.A., Diehl-Schmid J., Jimenez-Jimenez F.J., Gironell A., Clarimon J.,
Abadal L., Puig T., Abos J., Bernades S., Clari- Alexopoulos P., Benussi L., Ghidoni R., Binetti Drechse O., Agundez J.A.G., Kenzelmann
mon J., Blesa R., Reelin signaling pathway G., Nacmias B., Sorbi S., Sanchez-Valle R., Broz D., Chiquet-Ehrismann R., Lleo A., Coria
genotypes and Alzheimer disease in a Span- Llado A., Gelpi E., Almeida M.R., Santana I., F., Garcia-Martin E., Alonso-Navarro H., Marti
ish population. (2015) ALZ DIS ASSOC DIS, Clarimon J., Lleo A., Fortea J., de Mendonca M.J., Kulisevsky J., Hor C.N., Ossowski S.,
29 (2), 169-172. A., Martins M., Borroni B., Padovani A., Matej Chrast R., Katsanis N., Pastor P., Estivill X.,
IF: 2.5300 R., Rohan Z., Ruiz A., Frisoni G.B., Fabrizi G.M., Missense mutations in TENM4, a regulator of
Cacace R., Van den Bossche T., Engelborghs Vandenberghe R., De Deyn P.P., Van Broeck- axon guidance and central myelination,
S., Geerts N., Laureys A., Dillen L., Graff C., hoven C., Sleegers K., Genetic variability in cause essential tremor. (2015) HUM MOL
Thonberg H., Chiang H.-H., Pastor P., Orte- SQSTM1 and risk of early-onset Alzheimer GENET, 24 (20), 5677-5686.
ga-Cubero S., Pastor M.A., Diehl-Schmid J., dementia: A European early-onset dementia IF: 5.9850
Alexopoulos P., Benussi L., Ghidoni R., Binetti consortium study. (2015) NEUROBIOL Jones L., et al, Convergent genetic and ex-
G., Nacmias B., Sorbi S., Sanchez-Valle R., AGING, 36 (5), 2005.e15-2005.e22. pression data implicate immunity in Alzhei-
IF: 5.1530

Genetics in Neurodegenerative Diseases

*TIF: 111.0870 **MIF: 7.4058
mer’s disease. (2015) ALZHEIMERS DEMENT, national multicenter study. (2015) PARKIN- Anton-Aguirre S., Morenas-Rodriguez E.,
11 (6), 658-671. SONISM RELAT D, 21 (3), 306-309. Camacho V., Falcon C., Pavia J., Ros D., Clari-
IF: 11.6190 IF: 3.7940 mon J., Blesa R., Lleo A., Fortea J., APOE-by-
Martinez-Lizana E., Carmona-Iragui M., Al- Pastor P., Moreno F., Clarimon J., Ruiz A., sex interactions on brain structure and me-
colea D., Gomez-Choco M., Vilaplana E., San- Combarros O., Calero M., De Munain A.L., tabolism in healthy elderly controls. (2015)
chez-Saudinos M.B., Clarimon J., Hernandez- Bullido M.J., De Pancorbo M.M., Carro E., ONCOTARGET, 6 (29), 26663-26674.
-Guillamon M., Munuera J., Gelpi E., Antonell A., Coto E., Ortega-Cubero S., Her- IF: 5.0080
Gomez-Anson B., De Juan-Delago M., Del- nandez I., Tarraga L., Boada M., Lleo A.,
gado-Mederos R., Montaner J., Ois A., Amaro Dols-Icardo O., Kulisevsky J., Vazquez-Higu- Suarez-Calvet M., Camacho V., Gomez-An-
S., Blesa R., Marti-Fabregas J., Lleo A., Fortea era J.L., Infante J., Rabano A., Fernandez- son B., Anton S., Vives-Gilabert Y., Dols-Icardo
J., Cerebral amyloid angiopathy-related -Blazquez M.A., Valenti M., Indakoetxea B., O., Clarimon J., Alcolea D., Blesa R., Fortea J.,
atraumatic convexal subarachnoid hemor- Barandiaran M., Gorostidi A., Frank-Garcia A., Lleo A., Early cerebellar hypometabolism in
rhage: An ARIA before the tsunami. (2015) J Sastre I., Lorenzo E., Pastor M.A., Elcoroaris- patients with frontotemporal dementia car-
CEREBR BLOOD F MET, 35 (5), 710-717. tizabal X., Lennarz M., Maier W., Ramirez A., rying the C9orf72 expansion. (2015) ALZ DIS
IF: 4.9290 Serrano-Rios M., Lee S.E., Sanchez-Juan P., ASSOC DIS, 29 (4), 353-356.
Ortega-Cubero S., Lorenzo-Betancor O., MAPT H1 haplotype is associated with IF: 2.5300
Lorenzo E., Agundez J.A.G., Jimenez-Jimenez late-onset Alzheimer’s disease risk in APOE ε
F.J., Ross O.A., Wurster I., Mielke C., Lin J.-J., 4 noncarriers: Results from the dementia
Coria F., Clarimon J., Ezquerra M., Brighina L., genetics Spanish consortium. (2015) J ALZ-
Annesi G., Alonso-Navarro H., Garcia-Martin HEIMERS DIS, 49 (2), 343-352.
E., Gironell A., Marti M.J., Yueh K.-C., Wszolek IF: 3.9200
Z.K., Sharma M., Berg D., Kruger R., Pastor Sampedro F., Vilaplana E., de Leon M.J., Al-
M.A., Pastor P., TREM2 R47H variant and risk colea D., Pegueroles J., Montal V., Carmona-I-
of essential tremor: A cross-sectional inter- ragui M., Sala I., Sanchez-Saudinos M.-B.,


Human Neuropsychopharmacology
Coordinator
Riba Serrano, Jordi IR
jriba@santpau.cat
Members
Roberto Herrero, Natalia IR
Yarritu, Ion IR
General Neuropsychopharmacology
ff Pharmacological modulation of the different neurotransmission systems to study the role
of these systems in advanced cognitive functions (executive control) and emotions.
of Research
Main Lines
Neuropsychopharmacology of Abused Substances

ff Effects on the central nervous system of psychodysleptic drugs such as ayahuasca, salvi-
norin A, dimethyltryptamine and THC.
ff Assessment of the impact of long-term drug use on brain function (fMRI) and structure
(VBM, DTI).
ff Consolidate and extend existing research ff Communicate activities.

lines through possible cooperation agree-
Challenges
ments with other groups and according to

ff Maintain existing external cooperation
internal growth. agreements.
ff Obtain emerging-group recognition.

ff Establish new cooperation agreements
within HSCSP RI.
ff Obtain stable funding and supporting
technical staff.
Collaborations with other IIB Sant Pau ff Biomedical Engineering Research Cen-
Groups tre, Universitat Politècnica de Catalunya
(UPC), Spain.
ff Pharmacokinetic/Pharmacodynamic ff Brain Institute, Federal University of Rio
Collaborations
Modelling and Simulation. Grande do Norte, Natal, Brazil.

ff Parkinson Disease and Movement Disor- ff Neuroscience and Behaviour Department,
ders. Ribeirão Preto Medical School, University
ff Clinical Psychiatry. of São Paulo, Brazil.
ff Psychiatry and Behavioral Sciences De-
External Collaborations partment, Johns Hopkins School of Medi-
cine, USA.
ff Cognition and Brain Plasticity Group (IDI-
BELL Bellvitge Biomedical Research Insti-
ff Department of Comparative Biomedical
tute), Spain. Sciences, Louisiana State University, USA.

Jordi Riba Serrano. Farmacología humana de la salvinorina-A:

Active Grants
ff
estudio farmacocinético, farmacodinámico y de mecanismo
de acción mediante bloqueo farmacológico de los efectos.
€66,500.
ff Jordi Riba Serrano. Estudio de prueba de concepto de la estimu-

lación adrenérgica en el tratamiento de los síntomas negativos y
Awarded
in 2015
Grants
déficits cognitivos en la esquizofrenia. IR15-P2. Institut de Recer-

ca de l’Hospital de la Santa Creu i Sant Pau. Duration: 2015-2016.
€33,000.
*TIF: 41.7450 **MIF: 4.1745

Alonso J.F., Romero S., Mananas M.A., Rojas Salvinorin-A induces intense dissociative ef- ity to false memories. (2015) MOL PSYCHI-
M., Riba J., Barbanoj M.J., Evaluation of mul- fects, blocking external sensory perception ATR, 20 (6), 772-777.
tiple comparison correction procedures in and modulating interoception and sense of IF: 13.3140
drug assessment studies using LORETA body ownership in humans. (2015) INT J Sanches R.F., de Lima Osorio F., dos Santos
maps. (2015) MED BIOL ENG COMPUT, 53 NEUROPSYCHOPH, 18 (12), 1-14. R.G., Macedo L.R.H., Maia-de-Oliveira J.P.,
(10), 1011-1023. IF: 4.3330 Wichert-Ana L., de Araujo D.B., Riba J., S.
IF: 1.7970 Osorio Fd.e L., Sanches R.F., Macedo L.R., Crippa J.A., Hallak J.E.C., Antidepressant Ef-
Bouso J.C., Palhano-Fontes F., Rodriguez-For- Santos R.G., Maia-de-Oliveira J.P., Wichert- fects of a Single Dose of Ayahuasca in Pa-
nells A., Ribeiro S., Sanches R., Crippa J.A.S., Ana L., Araujo D.B., Riba J., Crippa J.A., Hallak tients With Recurrent Depression: A SPECT
Hallak J.E.C., de Araujo D.B., Riba J., Long- J.E., Antidepressant effects of a single dose Study. (2015) J CLIN PSYCHOPHARM.
term use of psychedelic drugs is associated of ayahuasca in patients with recurrent de- IF: 3.0000
with differences in brain structure and per- pression: A preliminary report. (2015) REV
sonality in humans. (2015) EUR NEUROPSY- BRAS PSIQUIATR, 37 (1), 13-20.
CHOPHARM, 25 (4), 483-492. IF: 2.1810
IF: 4.4090 Pitol D.L., Siessere S., Dos Santos R.G., Rosa
Francesc Alonso J., Romero S., Angel M.L.N.M., Hallak J.E.C., Scalize P.H., Pereira
Mananas M., Riba J., Serotonergic psychedel- B.F., Iyomasa M.M., Semprini M., Riba J., Re-
ics temporarily modify information transfer galo S.C.H., Ayahuasca Alters Structural Pa-
in humans. (2015) INT J NEUROPSYCHOPH, rameters of the Rat Aorta. (2015) J CARDIO-
18 (8), 1-9. VASC PHARM, 66 (1), 58-62.
IF: 4.3330 IF: 2.4620
Lopez-Gongora M., Escartin A., Mar- Riba J., Mcilhenny E.H., Bouso J.C., Barker
tinez-Horta S., Fernandez-Bobadilla R., S.A., Metabolism and urinary disposition of
Querol L., Romero S., Mananas M.A., Riba J., N,N-dimethyltryptamine after oral and
Neurophysiological evidence of compensa- smoked administration: A comparative
tory brain mechanisms in early-stage multi- study. (2015) DRUG TEST ANAL, 7 (5), 401-
ple sclerosis. (2015) PLOS ONE, 10 (8). 406.
IF: 3.0570 IF: 2.8590
Maqueda A.E., Valle M., Addy P.H., Antoni- Riba J., Valle M., Sampedro F., Rodriguez-Pu-
joan R.M., Puntes M., Coimbra J., Ballester jadas A., Martinez-Horta S., Kulisevsky J., Ro-
M.R., Garrido M., Gonzalez M., Claramunt J., driguez-Fornells A., Telling true from false:
Barker S., Johnson M.W., Griffiths R.R., Riba J., Cannabis users show increased susceptibil-
ff McKenna D., Riba J. New world tryptamine hallucinogens and

Publications
the neuroscience of ayahuasca. In: Current Topics in Behavioral

Neurosciences. (2015) Springer. DOI: 10.1007/7854_2015_368.
Other
ff Bouso J.C., Riba J., Barbanoj M.J. Drogas de abuso y sueño In:
Tratado de Sueño (2015). Editorial Médica Panamericana. Chap-
ter 25, pages 276-281.

Neurobiology of Dementia
Coordinator
Lleó Bisa, Albert FGS
alleo@santpau.cat
Members
Alcolea Rodríguez,
Daniel Andrés IR
Anton Aguirre, Susana Sofía IR
Belbin, Olivia IR
Blesa González, Rafael FGS
Carmona Iragui, Maria IR
Colom Cadena, Martí IR
Dols Icardo, Oriol CIBERNED
Fortea Ormaechea, Juan FGS
Illan Gala, Ignacio FGS
ff Biomarkers in Alzheimer disease and -- Novel MRI markers in preclinical Alzhei-
of Research
Main Lines
other neurodegenerative dementias: mer disease.

Morenas Rodríguez, Estrella IR
Núñez Llaves, Raúl IR
-- CSF biomarkers in Alzheimer disease,
dementia with Lewy bodies and fronto-
ff Biomarkers of Alzheimer disease in Down
Sala Matavera, Isabel FGS temporal dementia. syndrome.
Sánchez Saudinos, -- Amyloid imaging in neurodegenerative ff Molecular basis of neurodegenerative dis-
María Belén IR dementias. eases.
Vilaplana Martinez, Eduard IR
ff Maintain and increase scientific produc- ff Establish new cooperation agreements to

Challenges
tion and funding in the next 5 years. increase number of applications for Euro-
pean and international projects.
ff Develop a training plan for researchers
entering the group while maintaining its ff Establish links with technological innova-
translational nature. tion groups and companies to foster pat-
ent applications and contracts.

Groups ff Ellen Gelpi, José L Molinuevo, Hospital
ff Genetics in Neurodegenerative Diseases Clínic-IDIBAPS, Barcelona, Spain.
(PI: Jordi Clarimon). ff Jordi Magrané, Cornell University, New
York, USA.
Collaborations
ff Molecular Physiology of the Synapse (PI:

Alex Bayés). ff Tiago Outeiro, University Medical Centre,
ff Cerebrovascular Diseases (PI: Joan Martí- Goettingen, Germany.

Fàbregas). ff Martin Ingelsson, MD, PhD, Uppsala Uni-
ff Neuromuscular Diseases (PI: Isabel Illa). versity, Sweden.

ff Parkinson Disease and Movement Disor- ff Tara Spires-Jones, University of Edinburgh,
ders (PI: Jaime Kulisevsky). UK.

ff Nuclear Medicine (PI: Ignasi Carrió). ff Kaj Blennow, Götebord, Sweden.
ff Pieter J Visser, Amsterdam University, The

Netherlands.
ff Daniel Andrés Alcolea Rodríguez. Cere-

brospinal fluid biomarkers for the study
of the pathophysiological pathways in
Theses
alzheimer’s disease. Universitat Autònoma

de Barcelona. Directors: Alberto Lleó Bisa,
Rafael Blesa González. Date of defense: 30
November 2015.

ff Juan Fortea Ormaechea. Estudios multimodales de líquido cefalor- ff Juan Fortea Ormaechea. Alzheimer’s disease in Down’s syndrome.
racuideo y resonancia magnética en la enfermedad de Alzheimer CSF, MRI, EEG and PET multimodal studies. MARATÓ 20141210. Fun-
preclínica. PI11/02425. Instituto de Salud Carlos III. Duration: 2012- dació La Marató de TV3. Duration: 2015-2018. €159,200.
2016. €93,009.
ff Juan Fortea Ormaechea. La estructura cerebral y el metabolismo en
ff Albert Lleó Bisa. Biomarkers for Alzheimer’s disease and Parkinson’s la enfermedad de Alzheimer preclínica. Interacciones entre “nuevos
disease (BIOMARKAPD). PI11/03035. Instituto de Salud Carlos III. Du- y viejos” biomarcadores. PI14/01126. Instituto de Salud Carlos III.
ration: 2012-2016. €97,000. Duration: 2015-2017. €101,500.
Active Grants
ff Rafael Blesa González. Enfermedad de Alzheimer y síndrome de ff Albert Lleó Bisa. Marcadores sinápticos en la enfermedad de Alzhei-
Down. Estudios multimodales de líquido cefalorraquídeo, resonan- mer. PI14/01561. Instituto de Salud Carlos III. Duration: 2015-2017.
cia magnética y PET de amiloide. PI13/01532. Instituto de Salud Car- €111,500.
los III. Duration: 2014-2016. €107,500.
ff Maria Carmona Iragui. Ajuts per a contractes de formació Río Hort-
ff Olivia Belbín. Contratos Miguel Servet 2013-Tipo I. MS13/00091. In- ega 2014. CM14/00029. Instituto de Salud Carlos III. Duration: 2015-
stituto de Salud Carlos III. Duration: 2014-2019. €202,500. 2017. €53,732.
ff Olivia Belbín. Search for synaptic biomarkers of Alzheimer’s dis- ff Estrella Morenas Rodríguez. Estudi multimodal de biomarcadors
ease. CP13/00091. Instituto de Salud Carlos III. Duration: 2014-2016. en pacients amb demència amb cossos de Lewy. 2015 FI_B 00336.
€121.500. Agència de Gestió d’Ajuts Universitaris i de Recerca. Duration: 2015-
2018. €37,805.88.
ff Albert Lleó Bisa. Synaptic markers in preclinical Alzheimer’s disease.
MARATÓ 20142610. Fundació La Marató de TV3. Duration: 2015- Note: Total amount granted to PI. It does not include indirect costs.
2018. €159,903.
ff Albert Lleó Bisa, Convocatòria d’intensificació 2015. IR15-INT2.

Awarded
in 2015
Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau. Du-

Grants
ration: 2015-2016. €30,000.

Awards
ff Fortea J. Premio Joven Investigador Clínico CIBERNED 2014 (bi-

anual award), for the publication Fortea J et al, Annals of Neurol-
ogy 2014.
*TIF: 184.8850 **MIF: 6.8476

Alcolea D., Vilaplana E., Pegueroles J., Montal Balasa M., Gelpi E., Martin I., Antonell A., Rey Bocchetta M., Galluzzi S., Kehoe P.G.,
V., Sanchez-Juan P., Gonzalez-Suarez A., Po- M.J., Grau-Rivera O., Molinuevo J.L., Sanchez- Aguera E., Bernabei R., Bullock R., Ceccaldi
zueta A., Rodriguez-Rodriguez E., Bartres- Valle R., Llado A., Boada Hernandez M., M., Dartigues J.-F., De Mendonca A., Didic
Faz D., Vidal-Pineiro D., Gonzalez-Ortiz S., Mauleon A., Rosende M., Aguilar M., Rene R., M., Eriksdotter M., Felician O., Frolich L.,
Medrano S., Carmona-Iragui M., Sanchez- Povedano M., Valldeoriola F., Sanz P., Lleo A., Gertz H.-J., Hallikainen M., Hasselbalch
Saudinos M., Sala I., Anton-Aguirre S., Blesa R., Rojas-Garcia R., Pena- Casanova J., S.G., Hausner L., Heuser I., Jessen F., Jones
Sampedro F., Morenas-Rodriguez E., Clari- Alvarez-Sabin J., Pujadas F., Roy P., Lopez- R.W., Kurz A., Lawlor B., Lleo A., Marti-
mon J., Blesa R., Lleo A., Fortea J., Relation- Pousa S., Turon A., Huerta M., Martinez-Yela- nez-Lage P., Mecocci P., Mehrabian S.,
ship between cortical thickness and cere- mos A., Aspiazu P., Almenar C., Lopez-Villegas Monsch A., Nobili F., Nordberg A., Rikkert
brospinal fluid YKL-40 in predementia stages D., Abellan T., Otermin P., Pericot I., Pinol-Ripoll M.O., Orgogozo J.-M., Pasquier F., Peters O.,
of Alzheimer’s disease. (2015) NEUROBIOL G., Robles B., Escrig A., Latorre P., Escabia F., Salmon E., Sanchez-Castellano C., Santana
AGING, 36 (6), 2018-2023. Mira M.L., Ananos G., Collado I., Diagnostic I., Sarazin M., Traykov L., Tsolaki M., Visser
IF: 5.1530 accuracy of behavioral variant frontotemporal P.J., Wallin A.K., Wilcock G., Wilkinson D.,
Alcolea D., Martinez-Lage P., Sanchez-Juan P., dementia consortium criteria (FTDC) in a clini- Wolf H., Yener G., Zekry D., Frisoni G.B., The
Olazaran J., Antunez C., Izagirre A., Ecay-Torres copathological cohort. (2015) NEUROPATH use of biomarkers for the etiologic diagno-
M., Estanga A., Clerigue M., Guisasola M.C., APPL NEURO, 41 (7), 882-892. sis of MCI in Europe: An EADC survey.
Sanchez Ruiz D., Marin Munoz J., Calero M., IF: 4.4830 (2015) ALZHEIMERS DEMENT, 11 (2), 195-
Blesa R., Clarimon J., Carmona-Iragui M., Benejam B., Fortea J., Molina-Lopez R., Videla 206.e1.
Morenas-Rodriguez E., Rodriguez-Rodriguez S., Patterns of performance on the modified IF: 11.6190
E., Vazquez Higuera J.L., Fortea J., Lleo A., Amy- Cued Recall Test in Spanish adults with Bufill E., Roura-Poch P., Sala-Matavera I., An-
loid precursor protein metabolism and in- down syndrome with and without demen- ton S., Lleo A., Sanchez-Saudinos B., Tomas-
flammation markers in preclinical Alzheimer tia. (2015) AJIDD-AM J INTELLECT, 120 (6), Abadal L., Puig T., Abos J., Bernades S., Clari-
disease. (2015) NEUROLOGY, 85 (7), 626-633. 481-489. mon J., Blesa R., Reelin signaling pathway
IF: 8.1660 IF: 1.8820 genotypes and Alzheimer disease in a Span-

Neurobiology of Dementia
*TIF: 184.8850 **MIF: 6.8476
ish population. (2015) ALZ DIS ASSOC DIS, Ortega-Cubero S., Pastor M.A., Razquin C., Alzheimer and Parkinson diseases. (2015)
29 (2), 169-172. Boada M., Hernandez I., Gorostidi A., Moreno NAT REV NEUROL, 11 (1), 41-55.
IF: 2.5300 F., Zulaika M., Llado A., Coto E., Combarros O., IF: 18.4180
Cacace R., Van den Bossche T., Engelborghs Perez-Tur J., Clarimon J., Assessing the role of Martinez-Lizana E., Carmona-Iragui M., Al-
S., Geerts N., Laureys A., Dillen L., Graff C., TUBA4A gene in frontotemporal degenera- colea D., Gomez-Choco M., Vilaplana E., San-
Thonberg H., Chiang H.-H., Pastor P., Orte- tion. (2015) NEUROBIOL AGING, 38, 215. chez-Saudinos M.B., Clarimon J., Hernandez-
ga-Cubero S., Pastor M.A., Diehl-Schmid J., e13-215.e14. -Guillamon M., Munuera J., Gelpi E.,
Alexopoulos P., Benussi L., Ghidoni R., Binet- IF: 5.1530 Gomez-Anson B., De Juan-Delago M., Del-
ti G., Nacmias B., Sorbi S., Sanchez-Valle R., Heilmann S., Drichel D., Clarimon J., Fernan- gado-Mederos R., Montaner J., Ois A., Amaro
Llado A., Gelpi E., Almeida M.R., Santana I., dez V., Lacour A., Wagner H., Thelen M., S., Blesa R., Marti-Fabregas J., Lleo A., Fortea
Tsolaki M., Koutroumani M., Clarimon J., Hernandez I., Fortea J., Alegret M., Blesa R., J., Cerebral amyloid angiopathy-related
Lleo A., Fortea J., de Mendonca A., Martins Mauleon A., Roca M.R., Kornhuber J., Peters atraumatic convexal subarachnoid hemor-
M., Borroni B., Padovani A., Matej R., Rohan O., Heun R., Frolich L., Hull M., Heneka M.T., rhage: An ARIA before the tsunami. (2015) J
Z., Vandenbulcke M., Vandenberghe R., De Ruther E., Riedel-Heller S., Scherer M., Wilt- CEREBR BLOOD F MET, 35 (5), 710-717.
Deyn P.P., Cras P., van der Zee J., Sleegers K., fang J., Jessen F., Becker T., Tarraga L., Boada IF: 4.9290
Van Broeckhoven C., Rare Variants in PLD3 M., Maier W., Lleo A., Ruiz A., Nothen M.M., Matias-Guiu J.A., Fernandez de Bobadilla R.,
Do Not Affect Risk for Early-Onset Alzhei- Ramirez A., PLD3 in non-familial Alzhei- Escudero G., Perez-Perez J., Cortes A., More-
mer Disease in a European Consortium mer’s disease. (2015) NATURE, 520 (7545), nas-Rodriguez E., Valles-Salgado M., Moreno-
Cohort. (2015) HUM MUTAT, 36 (12), 1226- E3-E5. Ramos T., Kulisevsky J., Matias-Guiu J., Valida-
1235. IF: 38.1380 tion of the Spanish version of Addenbrooke’s
IF: 5.0890 Hor H., Francescatto L., Bartesaghi L., Orte- Cognitive Examination III for diagnosing
Carmona-Iragui M., Fernandez-Arcos A., Al- ga-Cubero S., Kousi M., Lorenzo-Betancor dementia. (2015) NEUROLOGIA, 30 (9), 545-
colea D., Piazza F., Morenas-Rodriguez E., O., Jimenez-Jimenez F.J., Gironell A., Clari- 551.
Anton-Aguirre S., Sala I., Clarimon J., Dols-I- mon J., Drechse O., Agundez J.A.G., Kenzel- IF: 1.7900
cardo O., Camacho V., Sampedro F., Munuera mann Broz D., Chiquet-Ehrismann R., Lleo Olde Rikkert M.G.M., Verhey F.R., Blesa R., Von
J., Nunez-Marin F., Lleo A., Fortea J., Go- A., Coria F., Garcia-Martin E., Alonso-Navar- Arnim C.A.F., Bongers A., Harrison J., Sijben J.,
mez-Anson B., Blesa R., Cerebrospinal Fluid ro H., Marti M.J., Kulisevsky J., Hor C.N., Os- Scarpini E., Vandewoude M.F.J., Vellas B.,
Anti-Amyloid-Beta; Autoantibodies and sowski S., Chrast R., Katsanis N., Pastor P., Witkamp R., Kamphuis P.J.G.H., Scheltens P.,
Amyloid PET in Cerebral Amyloid Angio- Estivill X., Missense mutations in TENM4, a Tolerability and safety of souvenaid in pa-
pathy-Related Inflammation. (2015) J ALZ- regulator of axon guidance and central tients with mild Alzheimer’s disease: Results
HEIMERS DIS, 50 (1), 1-7. myelination, cause essential tremor. (2015) of multi-center, 24-week, open-label exten-
IF: 3.9200 HUM MOL GENET, 24 (20), 5677-5686. sion study. (2015) J ALZHEIMERS DIS, 44 (2),
Cuyvers E., van der Zee J., Bettens K., Engel- IF: 5.9850 471-480.
borghs S., Vandenbulcke M., Robberecht C., Jones L., et al, Convergent genetic and ex- IF: 3.9200
Dillen L., Merlin C., Geerts N., Graff C., Thon- pression data implicate immunity in Alzhei- Pastor P., Moreno F., Clarimon J., Ruiz A.,
berg H., Chiang H.-H., Pastor P., Ortega-Cu- mer’s disease. (2015) ALZHEIMERS DEMENT, Combarros O., Calero M., De Munain A.L.,
bero S., Pastor M.A., Diehl-Schmid J., Alexo- 11 (6), 658-671. Bullido M.J., De Pancorbo M.M., Carro E.,
poulos P., Benussi L., Ghidoni R., Binetti G., IF: 11.6190 Antonell A., Coto E., Ortega-Cubero S., Her-
Nacmias B., Sorbi S., Sanchez-Valle R., Llado Kruse N., Persson S., Alcolea D., Bahl J.M.C., nandez I., Tarraga L., Boada M., Lleo A.,
A., Gelpi E., Almeida M.R., Santana I., Clari- Baldeiras I., Capello E., Chiasserini D., Boc- Dols-Icardo O., Kulisevsky J., Vazquez-Higu-
mon J., Lleo A., Fortea J., de Mendonca A., chio Chiavetto L., Emersic A., Engelborghs era J.L., Infante J., Rabano A., Fernandez-
Martins M., Borroni B., Padovani A., Matej R., S., Eren E., Fladby T., Frisoni G., Garcia-Ayllon -Blazquez M.A., Valenti M., Indakoetxea B.,
Rohan Z., Ruiz A., Frisoni G.B., Fabrizi G.M., M.-S., Genc S., Gkatzima O., Heegaard Barandiaran M., Gorostidi A., Frank-Garcia A.,
Vandenberghe R., De Deyn P.P., Van Broeck- N.H.H., Janeiro A.M., Kovacech B., Kuiperij Sastre I., Lorenzo E., Pastor M.A., Elcoroaris-
hoven C., Sleegers K., Genetic variability in H.B., Leitao M.J., Lleo A., Martins M., Matos tizabal X., Lennarz M., Maier W., Ramirez A.,
SQSTM1 and risk of early-onset Alzheimer M., Mollergard H.M., Nobili F., Ohrfelt A., Serrano-Rios M., Lee S.E., Sanchez-Juan P.,
dementia: A European early-onset demen- Parnetti L., de Oliveira C.R., Rot U., Saez-Vale- MAPT H1 haplotype is associated with
tia consortium study. (2015) NEUROBIOL ro J., Struyfs H., Tanassi J.T., Taylor P., Tsolaki late-onset Alzheimer’s disease risk in APOE ε
AGING, 36 (5), 2005.e15-2005.e22. M., Vanmechelen E., Verbeek M.M., Zilka N., 4 noncarriers: Results from the dementia
IF: 5.1530 Blennow K., Zetterberg H., Mollenhauer B., genetics Spanish consortium. (2015) J ALZ-
Dekker A.D., Strydom A., Coppus A.M.W., Ni- Validation of a quantitative cerebrospinal HEIMERS DIS, 49 (2), 343-352.
zetic D., Vermeiren Y., Naude P.J.W., Van Dam fluid alpha-synuclein assay in a Europe- IF: 3.9200
D., Potier M.-C., Fortea J., De Deyn P.P., Be- an-wide interlaboratory study. (2015) NEU- Sala-Llonch R., Llado A., Fortea J., Bosch B.,
havioural and psychological symptoms of ROBIOL AGING, 36 (9), 2587-2596. Antonell A., Balasa M., Bargallo N., Bartres-
dementia in Down syndrome: Early indica- IF: 5.1530 Faz D., Molinuevo J.L., Sanchez-Valle R.,
tors of clinical Alzheimer’s disease? (2015) Lleo A., Cavedo E., Parnetti L., Vanderstichele Evolving brain structural changes in PSEN1
CORTEX, 73, 36-61. H., Herukka S.K., Andreasen N., Ghidoni R., mutation carriers. (2015) NEUROBIOL
IF: 4.3140 Lewczuk P., Jeromin A., Winblad B., Tsolaki AGING, 36 (3), 1261-1270.
Dols-Icardo O., Iborra O., Valdivia J., Pastor P., M., Mroczko B., Visser P.J., Santana I., Sven- IF: 5.1530
Ruiz A., de Munain A.L., Sanchez-Valle R., Al- ningsson P., Blennow K., Aarsland D., Mo- Sampedro F., Vilaplana E., de Leon M.J., Al-
varez V., Sanchez-Juan P., Lleo A., Fortea J., linuevo J.L., Zetterberg H., Mollenhauer B., colea D., Pegueroles J., Montal V., Carmona-I-
Blesa R., Cardona F., Baquero M., Alonso M.D., Cerebrospinal fluid biomarkers in trials for ragui M., Sala I., Sanchez-Saudinos M.-B.,

*TIF: 184.8850 **MIF: 6.8476

Anton-Aguirre S., Morenas-Rodriguez E., M.M., Sando S.B., Aasly J.O., Dickson D.W., Lleo A., Early cerebellar hypometabolism in
Camacho V., Falcon C., Pavia J., Ros D., Clari- Graff-Radford N.R., Petersen R.C., Deak F., patients with frontotemporal dementia car-
mon J., Blesa R., Lleo A., Fortea J., APOE-by- Belbin O., Erratum to: Genetically-controlled rying the C9orf72 expansion. (2015) ALZ DIS
sex interactions on brain structure and me- Vesicle-Associated Membrane Protein 1 ex- ASSOC DIS, 29 (4), 353-356.
tabolism in healthy elderly controls. (2015) pression may contribute to Alzheimer’s pa- IF: 2.5300
ONCOTARGET, 6 (29), 26663-26674. thophysiology and susceptibility. (2015) Valech N., Mollica M.A., Olives J., Tort A., For-
IF: 5.0080 MOL NEURODEGENER. tea J., Lleo A., Belen S.-S., Molinuevo J.L.,
Sevlever D., Zou F., Ma L., Carrasquillo S., IF: 6.5100 Rami L., Informant’s Perception of Subjective
Crump M.G., Culley O.J., Hunter T.A., Bisceg- Spiegel J., Pirraglia E., Osorio R.S., Glodzik L., Cognitive Decline Helps to Discriminate Pre-
lio G.D., Younkin L., Allen M., Carrasquillo Li Y., Tsui W., Saint Louis L.A., Randall C., But- clinical Alzheimer’s Disease from Normal
M.M., Sando S.B., Aasly J.O., Dickson D.W., ler T., Xu J., Zinkowski R.P., Zetterberg H., Aging. (2015) J ALZHEIMERS DIS, 48 (S1),
Graff-Radford N.R., Petersen R.C., Morgan K., Fortea J., Fossati S., Wisniewski T., Davies P., S87-S98.
Belbin O., Genetically-controlled Vesicle-As- Blennow K., De Leon M.J., Greater Specificity IF: 3.9200
sociated Membrane Protein 1 expression for Cerebrospinal Fluid P-tau231 over
may contribute to Alzheimer’s pathophysi- P-tau181 in the Differentiation of Healthy
ology and susceptibility. (2015) MOL NEU- Controls from Alzheimer’s Disease. (2015) J
RODEGENER, 10 (1). ALZHEIMERS DIS, 49 (1), 93-100.
IF: 6.5100 IF: 3.9200
Sevlever D., Zou F., Ma L., Carrasquillo S., Suarez-Calvet M., Camacho V., Gomez-An-
Crump M.G., Culley O.J., Hunter T.A., Bisceg- son B., Anton S., Vives-Gilabert Y., Dols-Icardo
lio G.D., Younkin L., Allen M., Carrasquillo O., Clarimon J., Alcolea D., Blesa R., Fortea J.,

Neuroradiology
Coordinator
Gómez Ansón,
Beatriz María FGS
bgomeza@santpau.cat
Members
Camacho Martí,
Maria del Valle FGS
De Juan Delago, Manel FGS
López Mora, Diego Alfonso FGS
Ours is a multidisciplinary research group, central nervous system, including neurode-

which has the added value of combining generative and neuropsychiatric conditions.
neuroimaging skills of the members of the
of Research
Main Lines
Neuroradiology clinical unit at Hospital de A secondary focus is the implementation of

la Santa Creu i Sant Pau with technologi- automatic procedures and software tools to
cal knowledge from PIC/IFAE investigators improve neuroradiological practice.
at the Universitat Autònoma de Barcelona
(Spain).
Our main focus is the search for neuroim-
aging biomarkers in diseases involving the
Challenges
ff Achieve visibility for our research group

and for neuroradiology –often considered
by clinicians more a technical tool rather
than a discipline in itself– as a defined field
of knowledge.

Groups
Collaborations
ff PIC (Information Science Port) / IFAE (Insti-

ff Pituitary Gland Disorders. tute for High Energy Physics), Universitat
Autònoma de Barcelona, Spain.
ff Clinical Psychiatry.
ff COST-Action in ASL (European project),
ff Digestive Diseases.
National Hospital for Neurology and Neu-
ff Parkinson Disease and Movement Disor- rosurgery, London, UK.
ders.
ff Cerebrovascular Diseases.
ff Beatriz María Gómez Ansón. Estada formativa d’un investigador clínic a l’estranger 2015.
Awarded
IR15-E2. Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau. Duration: 2015-2016.
in 2015
Grants
€3,500.

*TIF: 34.3020 **MIF: 3.4302

Alonso-Solis A., Vives-Gilabert Y., Grasa E., bral white matter and neuropsychology in and white matter lesions after endocrine
Portella M.J., Rabella M., Sauras R.B., Roldan patients with cirrhosis and falls. (2015) PLOS control of Cushing’s syndrome. (2015) EUR J
A., Nunez-Marin F., Gomez-Anson B., Perez V., ONE, 10 (3). ENDOCRINOL, 173 (6), 765-775.
Alvarez E., Corripio I., Resting-state func- IF: 3.0570 IF: 3.8920
tional connectivity alterations in the default Martinez-Lizana E., Carmona-Iragui M., Al- Suarez-Calvet M., Camacho V., Gomez-An-
network of schizophrenia patients with per- colea D., Gomez-Choco M., Vilaplana E., San- son B., Anton S., Vives-Gilabert Y., Dols-Icardo
sistent auditory verbal hallucinations. (2015) chez-Saudinos M.B., Clarimon J., Hernandez- O., Clarimon J., Alcolea D., Blesa R., Fortea J.,
SCHIZOPHR RES, 161 (2-3), 261-268. -Guillamon M., Munuera J., Gelpi E., Lleo A., Early cerebellar hypometabolism in
IF: 4.4530 Gomez-Anson B., De Juan-Delago M., Del- patients with frontotemporal dementia car-
Aracil-Bolanos I., Prats-Sanchez L., Go- gado-Mederos R., Montaner J., Ois A., Amaro rying the C9orf72 expansion. (2015) ALZ DIS
mez-Anson B., Querol-Gutierrez L., S., Blesa R., Marti-Fabregas J., Lleo A., Fortea ASSOC DIS, 29 (4), 353-356.
Nunez-Marin F., Marti-Fabregas J., Balo con- J., Cerebral amyloid angiopathy-related IF: 2.5300
centric sclerosis: A presentation mimicking atraumatic convexal subarachnoid hemor-
ischaemic stroke. (2015) NEUROLOGIA. rhage: An ARIA before the tsunami. (2015) J
IF: 1.7900 CEREBR BLOOD F MET, 35 (5), 710-717.

Carmona-Iragui M., Fernandez-Arcos A., Al- IF: 4.9290
colea D., Piazza F., Morenas-Rodriguez E., Pires P., Santos A., Vives-Gilabert Y., Webb
Anton-Aguirre S., Sala I., Clarimon J., Dols-I- S.M., Sainz-Ruiz A., Resmini E., Crespo I., De
cardo O., Camacho V., Sampedro F., Munuera Juan-Delago M., Gomez-Anson B., White
J., Nunez-Marin F., Lleo A., Fortea J., Go- matter alterations in the brains of patients
mez-Anson B., Blesa R., Cerebrospinal Fluid with active, remitted, and cured cushing
Anti-Amyloid-Beta; Autoantibodies and syndrome: A DTI study. (2015) AM J NEURO-
Amyloid PET in Cerebral Amyloid Angio- RADIOL, 36 (6), 1043-1048.
pathy-Related Inflammation. (2015) J ALZ- IF: 3.1240
HEIMERS DIS, 50 (1), 1-7. Sampedro F., Vilaplana E., de Leon M.J., Al-
IF: 3.9200 colea D., Pegueroles J., Montal V., Carmona-I-
Cortes-Vicente E., Delgado-Mederos R., Bell- ragui M., Sala I., Sanchez-Saudinos M.-B.,
munt S., Borras X.F., Gomez-Anson B., Bague Anton-Aguirre S., Morenas-Rodriguez E.,
S., Camps-Renom P., Marti-Fabregas J., Camacho V., Falcon C., Pavia J., Ros D., Clari-
Stroke caused by a myxoma stenosing the mon J., Blesa R., Lleo A., Fortea J., APOE-by-
common carotid artery. (2015) J STROKE sex interactions on brain structure and me-
CEREBROVASC, 24 (4), e87-e89. tabolism in healthy elderly controls. (2015)
IF: 1.5990 ONCOTARGET, 6 (29), 26663-26674.
Gomez-Anson B., Roman E., De Bobadilla IF: 5.0080
R.F., Pires-Encuentra P., Diaz-Manera J., Nuez Santos A., Resmini E., Gomez-Anson B., Cre-
F., Martinez-Horta S., Vives-Gilabert Y., Pago- spo I., Granell E., Valassi E., Pires P., Vives-Gila-
nabarraga J., Kulisevsky J., Cordoba J., bert Y., Martinez-Momblan M.A., De Juan M.,
Guarner C., Soriano G., Alterations in cere- Mataro M., Webb S.M., Cardiovascular risk

Ageing Institute
Coordinator
Salvà Casanovas,
Antoni FSiE-UAB
antoni.salva@uab.es
Members
Coll Planas, Laura FSiE-UAB
Del Valle Fernández,
Gabriela FSiE-UAB
Domènech Pou, Sara FSiE-UAB
Domingo Riau,
Alexandre FSiE-UAB
González Guerra, Jordi FSiE-UAB
Rivero Fernández,
Antonio FSiE-UAB
ff Health research into ageing: ff Health and social services research.
Rojano Luque, Xavier FSiE-UAB -- Healthy ageing: physical activity, nutri- ff Research into caregivers of older adults.
of Research
tion and cognition.

Main Lines
Roque Figuls,
Marta Cristina FSiE-UAB -- Frequent health problems in older ff Promotion of active ageing among older
adults: falls, frailty and sarcopenia, func- people.
tional loss, Alzheimer and other demen- ff ICT applications to health, social services
tias, malnutrition and other geriatric
syndromes. and active ageing.
-- Epidemiological studies.
Health Research Area -- Comprehensive needs assessment.

-- Care quality.
ff Area mainly focused on health promotion
and disability prevention to improve qual- -- Good caregiving practices.
ity of life among older people. -- Assessment of dependence.
ff Clinical and epidemiological research un-
-- Home care services.
dertaken includes both observational and -- Analysis of economic costs.
Challenges
intervention studies, with the main lines

of research referring to mobility, nutrition
Research into ICT Applications to Health,
and cognition.
Social Services and Active Ageing
Health and Social Services Research ff Interest in this area mainly focuses on the
following topics:
ff Social care and healthcare as key for the
maintenance of autonomy, with a focus
-- Social appropriation of ICTs.
on the following topics: -- e-Health development.
-- Models of social care and healthcare. ff Development of new technological prod-
-- The organization of health and social ucts to promote active ageing.
services.

Collaborations with other IIB Sant Pau Groups ff The Group belongs to the Global Research Network of the Inter-
national Association of Geriatrics and Gerontology.
ff FRAPEM: FIS Fragilitat. EAP Sardenya.
ff Participation in european groups. Currently:
Collaborations
ff FIS Memory Workshops. Public Health Agency of Barcelona and -- The group of nutrition and cognitive decline of the EUGMS
EAP Sardenya. (European Union Geriatric Medicine Society)
-- MOBEX group: about mobility and falls
ff The group participates usually in CE-funded projects. During
2015 there were two collaborative projects in progress:
-- Profound
-- SAAPHO
*TIF: 16.409 **MIF: 1.8232

Coll-Planas L., del Valle Gomez G., Bonilla P., randomized controlled trial. (2015) AGING Study protocol for a randomized controlled
Masat T., Puig T., Monteserin R., Promoting CLIN EXP RES, 27 (2), 125-130. trial Psychology, psychiatry and quality of
social capital to alleviate loneliness and im- IF: 1.2150 life. (2015) BMC GERIATR, 15 (1).
prove health among older people in Spain. Perez L.M., Inzitari M., Roque M., Duarte E., IF: 1.6760
(2015) HEALTH SOC CARE COMM. Valles E., Rodo M., Gallofre M., Change in Rojano i Luque X., Sanchez Ferrin P., Salva A.,
IF: 1.3690 cognitive performance is associated with Hospital complications in the elderly. (2015)
Cuesta F., Formiga F., Lopez-Soto A., Masanes functional recovery during post-acute MED CLIN-BARCELONA.
F., Ruiz D., Artaza I., Salva A., Serra-Rexach stroke rehabilitation: a multi-centric study IF: 1.4170
J.A., I Luque X.R., Cruz-Jentoft A.J., Preva- from intermediate care geriatric rehabilita- Salva A., Roque M., Valles E., Bustins M., Bul-
lence of sarcopenia in patients attending tion units of Catalonia. (2015) NEUROL SCI, lich I., Sanchez P., Prognostic factors of func-
outpatient geriatric clinics: The ELLI study. 36 (10), 1875-1880. tional status improvement in individuals
(2015) AGE AGEING, 44 (5), 807-809. IF: 1.4470 admitted to convalescence care units. (2015)
IF: 3.6420 Perez A., Roque M., Domenech S., Mon- EUR GERIATR MED, 6 (4), 341-347.
Grotz C, Letenneur L, Bonsang E, Amieva H, teserin R., Soriano N., Blancafort X., Bosom IF: 0.7330
Meillon C, Quertemont E, Salmon E, Adam S; M., Vidal C., Petit M., Hortal N., Gil C., Espelt
ICTUS/DSA group. Retirement age and the A., Lopez M.J., Efficacy of memory training in
age of onset of Alzheimer’s disease: results healthy community-dwelling older people:
from the ICTUS study. (2015) PLOS ONE, Study protocol for a randomized controlled
10(2). trial. (2015) BMC GERIATR, 15 (1).
IF. 3.2340 IF: 1.6760
Martinez N., Martorell C., Espinosa L., Mar- Perez A., Roque M., Domenech S., Mon-
asigan V., Domenech S., Inzitari M., Impact of teserin R., Soriano N., Blancafort X., Bosom
Qigong on quality of life, pain and depres- M., Vidal C., Petit M., Hortal N., Gil C., Espelt
sive symptoms in older adults admitted to A., Lopez M.J., Efficacy of memory training in
an intermediate care rehabilitation unit: a healthy community-dwelling older people:
ff Ribera-Casado JM, González Montalvo JI, Sánchez del Corral F,

Publications
Salvà A, Formiga F.[Half a century of Spanish journal of geriatrics

and gerontology]. REVISTA ESPAÑOLA DE GERIATRÍA Y GERON-
Other
TOLOGÍA. 2015 Jan-Feb;50(1):3-4.


Addictive Behaviours
Coordinator
Pérez de Los Cobos Peris,
José Carlos FGS
jperezc@santpau.cat
Members
Alcaraz Garcia, Saül FGS
Batlle Batlle, Francesca FGS
Costa Juste, Silvia María IR
Guàrdia Serecigni, Josep FGS
Pinet Ogué, Maria Cristina FGS
Ribalta Corona, Elisa FGS
Tejero Pociello, Antonio FGS
Trujols Albet, Joan FGS
Valdepérez Toledo, Ana FGS Alcohol hydrochloride for smoking cessation in
subjects with and without a history of psy-
ff Pharmaco-epidemiological, non-interver- chiatric disorders.
ventional, prospective, multicenter study
with Selincro® in alcohol dependence, to de- ff Non-treatment follow-up for cardiac as-
termine patterns of use and consumption of sessments following use of smoking ces-
alcohol in routine clinical practice in Spain. sation treatments in subjects with and
without a history of psychiatric disorders.
ff Prospective observational study for re-
of Research
Main Lines
ducing the negative consequences asso- Opiates

ciated with excessive alcohol use (RINCA)
through the treatment program to reduce ff Patient satisfaction concerning mainte-
alcohol consumption with nalmefene. nance treatment with opioid agonists
(methadone and buprenorphine/nalox-
Cocaine one).
ff Evaluation of cocaine craving during hos- ff Satisfaction of the heroin-dependent pa-

pitalization conditions. tient regarding methadone and metha-
done pharmacogenetics.
Smoking
ff Evaluation of the neuropsychiatric safety
and efficacy of varenicline and bupropion
ff Establish bidirectional links between clini- ff Integrate clinical research in routine

cal practice and investigation both to sug- medical practice to assess the effective-
Challenges
gest hypotheses and incorporate recent ness of procedures.

advances.
ff Evaluate the validity and reliability of
ff Participate in controlled clinical trials on frequently used clinical evaluation pro-
the treatment of addictive disorders. cedures.
ff Develop clinical research studies into the
perspective of patients with addictions.

Groups
ff DeustoPsych, R+D+I in Psychology and
Collaborations
ff linical Epidemiology and Healthcare Ser-

C Health, University of Deusto, Bilbao, Spain.
vices. ff Joan Trujols. Calidad de vida y satisfacción
ff Clinical Psychiatry. con el tratamiento en pacientes depen-
dientes de opioides en mantenimiento
ff Genetic Diseases. con metadona: Desarrollo y estudio piloto
de dos autoinformes centrados en la pers-
pectiva del paciente (13BICIBE08). Internal
call CIBERSAM. €4,050.

ff José Carlos Pérez de los Cobos Peris. Hacia la identificación de los niveles de satisfacción en función del medicamento y de la
Active Grants
los mecanismos que permiten inhibir el craving de cocaína: va- escala. 2013I060. Ministerio de Sanidad y Política Social. Dura-
loración de factores motivacionales y cognitivos potencialmente tion: 2014-2016. €15,630.
relacionados con la ausencia de craving. PI12/00105. Instituto de
Salud Carlos III. Duration: 2013-2016. €74,500.
ff Joan Trujols Albet. Satisfacción con el tratamiento de manteni-
miento con agonistas opioides: Revisión sistemática de instru-
mentos de medida y síntesis cuantitativa de las diferencias en
*TIF: 17.2780 **MIF: 2.1598

Blanco C., García-Anaya M., Wall M., Pérez de starting hepatitis C treatment: Prevalence Villalta L., Arevalo R., Valdeperez A., Pascual
Los Cobos J.C., Swierad E., Wang S., Petry and associated factors. (2015) PSYCHIAT RES, J.C., de los Cobos J.P., Parental Bonding in
NM., Should pathological gambling and 230 (3), 749-756. Subjects with Pathological Gambling Disor-
obesity be considered addictive disorders? IF: 2.4660 der Compared with Healthy Controls. (2015)
A factor analytic study in a nationally repre- Serecigni J.G., Opioid receptor antagonists PSYCHIAT QUART, 86 (1), 61-67.
sentative sample. (2015) DRUG ALCOHOL in the treatment of alcoholism. (2015) ADIC- IF: 0.9780
DEPEND, 150, 129-134. CIONES, 27 (3), 214-230.
IF: 3.4230 IF: 1.7800

Guardia-Serecigni J., The reduction of alco- Trujols J., Ballesteros J., Sola I., Portella M.J.,
hol consumption. A new treatment target Improving systematic reviews on psycho-
for low severity alcoholism. (2015) ADIC- metric properties of measurement instru-
CIONES, 27 (1), 3-7. ments: A letter to the Editor commenting on
IF: 1.7800 Reilly etal.’s. (2015) review of the psychomet-
Marco A., Anton J.J., Trujols J., Saiz de la Hoya ric literature on QIDS. (2015) J PSYCHIATR
P., de Juan J., Faraco I., Cayla J.A., Personality RES.
disorders do not affect treatment outcomes IF: 4.4650
for chronic HCV infection in Spanish prison- Trujols J., Iraurgi I., Batlle F., Duran-Sindreu S.,
ers: The Perseo study. (2015) BMC INFECT Perez de los Cobos J., Towards a genuinely
DIS, 15 (1). user-centred evaluation of harm reduction
IF: 2.6900 and drug treatment programmes: A further
Marco A., Anton J.J., Saiz de la Hoya P., de proposal. (2015) INT J DRUG POLICY, 26 (12),
Juan J., Faraco I., Cayla J.A., Trujols J., Person- 1285-1287.
ality disorders among Spanish prisoners IF: 3.1190
ff Trujols J., The brain disease model of addiction: challenging or

reinforcing stigma? (2015). LANCET PSYCHIATRY, 2(4), 292.
Publications
Other

Molecular Physiology of the Synapse
Coordinator
Bayés Puig, Alejandro IR
abayesp@santpau.cat
Members
Gou Alsina, Gemma IR
Reig Viader, Rita IR
ff Molecular and cellular analyses of the vertebrate synapse.

of Research
Main Lines
ff Molecular and cellular dysfunctions underlying intellectual disability and autism.

ff Research into animal models of mental and behavioural disorders.
ff Development of new biochemical methods to study the synapse.
ff Characterize the molecular roots of cogni- ff Identify drugs which might help treat
tion and behaviour. mental and behavioural disorders.
Challenges
ff Identify the synaptic molecules and mech- ff Study the reversibility after birth of neuro-
anisms involved in mental and behavioural developmental disorders affecting cogni-
disorders, mainly intellectual disabilities tion.
and autism spectrum disorders.
Collaborations with other IIB Sant Pau ff Dr. Gavin Rumbaugh. Scripps Research In-
Groups stitute, USA.
ff Dr. Richard Emes, University of Notting-
ff Neurobiology of Dementias ham, UK.
Collaborations
ff Molecular Physiology of Synapse. (Alejan- ff Dr. Nael Nadif-Kasri. Radboud University.

dro Bayés. AGAUR 2014. SGR 297. Dura- The Netherlands.
tion: 2014-2016. €19.200.)
ff Dr. Montserrat Milà. Hospital Clínic de Bar-
celona.
ff Dr. Àngels García-Cazorla. Hospital Sant
ff Prof. Seth GN Grant. University of Edin- Joan de Déu, Barcelona.
burgh, UK.
ff Dr. Mark Collins, University of Sheffiled,
ff Dr. Noboru Komiyama. University of Edin- UK.
burgh, UK.

ff Alejandro Bayés Puig. Molecular Analysis of Synaptic Dys- ff Gemma Gou Alsina. Contratos Predoctorales para la Formación
functions Underlying Human Intellectual Disabilities. PCIG10- de Doctores 2013. BES-2013-063720. Ministerio de Economía y
GA-2011-304111. European Union. Duration: 2012-2016. Competitividad. Duration: 2013-2017. €83,900.
€100,000.
ff Alejandro Bayés Puig. Grup de senyalització sinàptica. 2014 SGR
ff Alejandro Bayés Puig. Subvenciones del Programa Ramón y Ca- 297-1 C. Agència de Gestió d’Ajuts Universitaris i de Recerca. Du-
Grants
Active
jal. RYC-2011-08391. Ministerio de Economía y Competitividad. ration: 2014-2016.

Duration: 2012-2017. €168,600.
ff Alejandro Bayés Puig. Red para el estudio de la sinapsis en el
ff Alejandro Bayés Puig. Estudio de los mecanismos moleculares contexto de la disfunción cognitiva. SAF2014-52624-REDT. Mi-
de la sinapsis implicados en procesos cognitivos y en la dis- nisterio de Economía y Competitividad. Duration: 2014-2016.
capacidad cognitiva no sindrómica. BFU2012-34398. Ministerio €32,000.
de Economía y Competitividad. Duration: 2013-2016. €125,000.

AREA 5
Uronephrology
and Experimental S
178 General and Digestive Surgery
180 Neurosurgery
182 Nephrology

Surgery

178 AREA 5 · Uronephrology and Experimental Surgery
General and Digestive Surgery
Coordinator
Trias Folch, Manel FGS
mtrias@santpau.cat
Members
Allende Honorato,
Luis Horacio
Artigas Raventos, Vicens FGS
Balagué Ponz,
María Carmen FGS
Bollo Rodríguez,
Jesús Manuel FGS
Caballero Mestres, Ferran FGS
Cerdan Riart, Gemma FGS
Clos Enríquez, Montserrat FGS Gastrointestinal Surgery and likelihood of tumour recurrence after
resection.
Garay Sola, Meritxell FGS ff Application of laparoscopic surgery in dis-
González López, eases of the spleen. ff Introduction of the laparoscopic methodol-
José Antonio FGS ogy to biliary lithiasis.
ff Application of laparoscopic surgery in disor-
Hernández Casanovas, ff Surgery for sarcomas: participation in GIST
ders of the oesophagogastric junction.
María Pilar FGS research through the Spanish Sarcoma Re-
Martín Arnau, Ana Belén FGS ff Advanced application of colorectal laparos- search Group (GEIS) and other entities.
Martínez Sánchez, copy.
ff Surgery for sarcomas: participation in the
of Research
María del Carmen FGS New stratification and treatment options in

Main Lines
ff development and results of surgery for retro-

Medrano Caviedes, colorectal cancer. peritoneal tumours.
Rodrigo Gustavo FGS
Moral Duarte, Antonio FGS Oncological and Hepatobiliopancreatic Emergency Care
Pérez García, José Ignacio FGS Surgery ff Collaborative project on clinical safety for the
Rodríguez Blanco, Manuel FGS introduction of safe practices for polytrau-
Rofin Serra, Silvia FGS ff Surgery for liver metastasis in colorectal cancer.
matized patients.
Targarona Soler, ff Development of diagnostic and therapeutic
Eduardo María FGS techniques in the global context of treat-
ment for liver metastasis in colorectal carci-
noma.
ff Surgery for primary hepatic tumours: deter-
mination of efficient prognostic parameters
for surgical resection of hepatocarcinoma
Gastrointestinal Surgery ff Viability of surgical interventions consid-

ering the likelihood of disease recurrence.
ff Design, develop and manage a dry labora-
tory for endoscopic surgery, creating a mul-
Emergency Surgery
tifunctional research and teaching space to
conduct applied technological research in ff Consolidation of a multidisciplinary group
minimally invasive surgery. for polytraumatized patient care.
Challenges
Hepatobiliopancreatic Surgery Breast Surgery

ff Development of techniques to study liver ff Technological innovations in surgery.
volume and function.
ff Possible role of genetic studies in diagnosis
ff Development of experimental studies on the and follow-up.
function and healing of bilio-intestinal sutures.
ff Studies of the value of nutrition in patients Endocrinal and Cervical Surgery
undergoing aggressive surgery for highly
debilitating cancer. ff Technical innovations in surgery.
ff Suitable stratification of GIST tumours in
accordance with an anatomopathological
classification.

AREA 5 · Uronephrology and Experimental Surgery 179
*TIF: 21.9890 **MIF: 2.7486

Alamo P., Gallardo A., Di Nicolantonio F., Luppi C.R.-O., Balague C., Targarona E.M., Jover J.M., Pina J., Saavedra D., The surgical
Pavon M.A., Casanova I., Trias M., Mangues Mocanu S., Bollo J., Martinez C., Trias M., experience of general surgery residents: An
M.A., Lopez-Pousa A., Villaverde A., Vazquez Laparoscopic sleeve gastrectomy in patients analysis of the applicability of the specialty
E., Bardelli A., Cespedes M.V., Mangues R., over 60 years: Impact of age on weight loss program in General and Digestive Surgery
Higher metastatic efficiency of KRas G12V and co-morbidity improvement (2015) (2015) CIR ESPAN, 93 (3), 152-158.
than KRas G13D in a colorectal cancer model SURG OBES RELAT DIS, 11 (2), 296-302. IF: 1.0000
(2015) FASEB J, 29 (2), 464-476. IF: 3.5400 Villar-del-Moral J., Capela-Costa J.,
IF: 5.2990 Mato E., Barcelo-Batllori S., Orera I., Selva L., Jimenez-Garcia A., Sitges-Serra A., Casano-
Ciga Lozano M.T., Codina Cazador A., Ortiz Corra M., Gonzalez C., Bell O., Lerma E., Moral va-Rituerto D., Rocha J., Martos-Martinez
Hurtado H., Lujan J., Faccalvieri D., Biondo A., Perez J.I., de Leiva A., The proteomic 2D- J.M., de la Quintana-Basarrate A., Rosa-San-
S.Sebastiano, Angel Ciga M., Espi A., Codina DIGE approach reveals the protein volt- tos J., Guirao-Garriga X., Bravo-de-Lifante
A., Ruiz M.D., Espin E., Palasi R., Parajo A., age-dependent anion channel 2 as a poten- J.M., Vidal-Perez O., Moral-Duarte A., Polonia
Camps I., Pinol M., Viciano V., Alonso E., Pera tial therapeutic target in epithelial thyroid J., On Behalf Of The Iberpara Study Group,
M., Garcia T., Casal E., Garcia J., Rodriguez M., tumours (2015) MOL CELL ENDOCRINOL, Compliance with recommendations on sur-
Reina A., Roig J., Errasti J.Jose, Mugica J.A., 404, 37-45. gery for primary hyperparathyroidism—
Gomez J., Rada R., Orelogio M., Uribe N., de IF: 3.8590 from guidelines to real practice: results from
Dios Franco J., Sierra J.E., Hernandez P., Pare- Sebio A., Barnadas A., Salazar J., Paez D., Be- an Iberian survey (2015) LANGENBECK ARCH
des J., Martinez G., Garcia M., Carreno G., renguer-Llergo A., Del Rio E., Tobena M., SURG, 1-11.
Cifuentes J., Monzon J., Maseda O., Huerga Martin-Richard M., Sullivan I., Targarona E., IF: 2.1490
D., Flores L., Gris F., Segura I., Palma P., Diaz Balart J., Baiget M., EGFR ligands and DNA
J.G., Oncological results according to type of repair genes: Genomic predictors of com-
resection for rectal cancer (2015) CIR ESPAN, plete response after capecitabine-based
93 (4), 229-235. chemoradiotherapy in locally advanced rec-
IF: 1.0000 tal cancer (2015) PHARMACOGENOMICS J,
Lopez J., Rodriguez K., Targarona E.M., Guz- 15 (1), 77-83.
man H., Corral I., Gameros R., Reyes A., Sys- IF: 3.7840
tematic review of cyanoacrylate emboliza- Targarona Soler E.M., Jover Navalon J.M.,
tion for refractory gastrointestinal fistulae: A Gutierrez Saiz J., Turrado Rodriguez V., Par-
promising therapy (2015) SURG INNOV, 22 rilla Paricio P., Targarona E.M., Torres A.J.,
(1), 88-96. Gallego J.L, Pacheco D., Salvador-Sanchis
IF: 1.3580 J.L., Hernandez E., Lucena J.L., del Riego F.J.,
ff Garcia del Muro; Alava; Artigas; Bagué; Braña; Cubedo; Cruz; Mulet;
Other Publications
Navaez; Martinez; Valverde; Vilals; Martin. Clinical practice guide-

lines for the diagnostic and treatment of patients with solf tissue
sarcomas by spanish group for research in sarcomas (GEIS). CANCER
CEHMOTHER AND PHARMACOL. 12/11/2015. ISSN 0344-5704.
ff V. Artigas , JA. Gonzalez. Cirugía de los sarcomas retroperitoneales.
Ed. Nature Publishing grup. Madrid. In: J. Martin, J. Cruz, C. Valverde,
R. Cubedo. Sarcomas partes blandas. ISBN:978-84-940238-4-2.

Neurosurgery
Coordinator
Molet Teixidó, Joan FGS
jmolet@santpau.cat
Members
Álvarez Holzapfel,
Maria Jesús FGS
Asencio Cortés, Carlos FGS
Català Antúnez,
Ignasi Eudald
De Quintana Schmidt,
Cristian José FGS
Montes Graciano,
Guillermo FGS
Muñoz Hernández,
ff Biomaterials: comparative study of two ff Anatomy of the skull base.
different cranial bone fixations.
Fernando FGS ff Clinical evaluation of neurostimulation
of Research
Main Lines
Rodríguez Rodríguez, ff Tumour biology: gliomas (prognostic techniques in different neurological enti-
Rodrigo FGS value of different mutations in anaplastic ties (treatment-resistant depression and
Salgado López, Laura FGS astrocytoma and GBM), pituitary gland neuropathic pain).
adenomas.
Tresserras Ribo, Pere FGS
Vilana Goma, ff Biomarkers in anaplastic astrocytomas
Francesc Xavier IR and glioblastoma multiforme.
ff Monitor the clinical trial on treatment-re-

Challenges
sistant depression treated using deep

brain stimulation techniques (jointly with
psychiatry).
ff Evaluate neurostimulation for other disor-
ders: cluster headache.
ff Joan Molet. MOBI-KITS study. Prospec- ff Joan Molet, Rodrígo Rodríguez. Estimu-
tive multicentre worldwide study of the lación Cerebral Profunda en el tratamiento
relationship between cell phone use and de la esquizofrenia refractaria: Estudio pi-
brain tumour development in the youth loto aleatorizado, controlado y cruzado.
population, 7th Framework Programme Fondo de Investigaciones Sanitarias
ENV-2008-226873. Coordinators Spain: PI12/00042. Duration: 2013-2015. Princi-
Carlos Díaz Acedo and Sandra Plans, Coor- pal researcher: Enric Álvarez.
Collaborations
dinator Catalonia: CREAL.

ff Fernándo Muñoz, Carlos Asencio. Estudi
ff Fernando Muñoz, Ignasi Català. IMPACT-24 MISTIE III. Minimally Invasive Surgery
study. Effects of pterygopalatine ganglion Plus rt-PA for Intracerebral Hemorrhage
stimulation on cerebral perfusion in pa- Evacuation. Principal researcher: Joan
tients with stroke, Brainsgate. Principal MartíFàbregas.
researcher: Joan Martí (Neurology Group).
ff Fernando Muñoz, Cristian de Quintada,
Ignasi Català, Carles Asencio. CLEAR III.
Clot Lysis: Evaluating Accelerated Resolu-
tion of Intraventricular Hemorrhage Phase
III. Johns Hopkins Hospital. Principal re-
searcher: Joan Martí (Neurology Group).

*TIF: 30.2030 **MIF: 6.0406

Alonso A., Domenech E., Julia A., Panes J., Martin-Blanco A., Serra-Blasco M., Perez-E- Blanco A., Perez-Egea R., Molet J., Alvarez E.,
Garcia-Sanchez V., Mateu P.N., Gutierrez A., gea R., De Diego-Adelino J., Carceller-Sin- Perez V., Portella M.J., Cognitive functioning
Gomollon F., Mendoza J.L., Garcia-Planella E., dreu M., Puigdemont D., Molet J., Alvarez E., after deep brain stimulation in subcallosal
Barreiro-De Acosta M., Munoz F., Vera M., Perez V., Portella M.J., Immediate cerebral cingulate gyrus for treatment-resistant de-
Saro C., Esteve M., Andreu M., Chaparro M., metabolic changes induced by discontinua- pression: An exploratory study (2015) PSY-
Manye J., Cabre E., Lopez-Lasanta M., Tortosa tion of deep brain stimulation of subcallosal CHIAT RES, 225 (3), 341-346.
R., Gelpi J.L., Garcia-Montero A.C., Bertran- cingulate gyrus in treatment-resistant de- IF: 2.4660
petit J., Absher D., Myers R.M., Marsal S., Gis- pression (2015) J AFFECT DISORDERS, 173,
bert J.P., Identification of risk loci for crohn’s 159-162.
disease phenotypes using a genome-wide IF: 3.5700
association study (2015) GASTROENTEROL- Puigdemont D., Portella M.J., Perez-Egea R.,
OGY, 148 (4), 794-805. Molet J., Gironell A., de Diego-Adelino J.,
IF: 18.1870 Martin A., Rodriguez R., Alvarez E., Artigas F.,
De Quintana-Schmidt C., Alvarez-Holzapfel Perez V., A randomized double-blind cross-
M.J., Nomdedeu-Guinot J., Bague-Rosell S., over trial of deep brain stimulation of the
Gallego-Rubio O., Leidinger A., Sal- subcallosal cingulate gyrus in patients with
gado-Lopez L., Molet-Teixido J., Isocitrate treatment-resistant depression: A pilot study
dehydrogenase type i mutation as a prog- of relapse prevention (2015) J PSYCHIATR
nostic factor in glioblastoma and a literature NEUROSCI, 40 (4), 224-231.
review (2015) NEUROCIRUGIA, 26 (6), 276- IF: 5.5700
283. Serra-Blasco M., de Vita S., Rodriguez M.R., de
IF: 0.4100 Diego-Adelino J., Puigdemont D., Martin-

Nephrology
Coordinator
Ballarín Castán, José F. Puigvert
jballarin@fundaciopuigvert.es
Members
Ars Criach, Elisabeth F. Puigvert
Bardaji de Quixano,
Beatriz F. Puigvert
Bover Sanjuan, Jordi F. Puigvert
Bullich Vilanova, Gemma F. Puigvert
Coll Piera, Elisabet F. Puigvert
Da Silva Santos,
Iara Karlla F. Puigvert
Díaz Encarnación,
Maria Montserrat F. Puigvert Proteomics Applied to Nephrology and Kidney Transplantation
Díaz Gómez, Joan Manel F. Puigvert Hypertension
ff Protocol biopsies, chronic transplant ne-
Eugui Anta, phropathy, kidney transplant and associ-
ff Water and sodium renal transport analy-
Estefanía Irene F. Puigvert sed from urinary exosomes, urinary pro- ated cardiovascular risk factors, pharma-
Fernández de la Llama, teomic characterization in diabetic neph- cogenetic and genomic studies.
Patricia F. Puigvert ropathy: evaluation of renal-angiotensin
Guillén Gómez, Elena F. Puigvert blockade. Chronic Kidney Disease (CKD)
Sancho Morón, Olga F. Puigvert
ff Early diagnosis of CKD, epidemiological
of Research
Sanmiguel Amigo, Luz F. Puigvert Hereditary Kidney Diseases

Main Lines
and clinical studies in CKD-related compli-

Silva Torres, Irene F. Puigvert
ff Genetic and clinical studies in cystic and cations such as renal anaemia, CKD min-
Torra Balcells, Roser F. Puigvert eral and bone disorders (CKD-MBD) and
glomerular inherited kidney diseases such
as polycystic kidney disease, Alport, corti- associated cardiovascular risk; haemodi-
coid-resistant nephrotic syndrome, Fabry alysis techniques and studies of genetic
disease, tuberous sclerosis and familial ne- damage in patients with CKD.
phropathies of uncertain origin. ff Mechanisms of epithelial-mesenchymal
transition and renal fibrosis.
Glomerular Disorders
ff Molecular and clinical studies in disorders
such as membranous glomerulopathy
and vasculitis with renal involvement,
among others.
ff Maintain the level of national and interna- ff Maintain participation in national working
tional publication. groups and increase international cooper-
ation.
ff Continue with both clinical and basic re-
Challenges
search in all the previously described ar- ff Engage in new pharmaceutical clinical
eas. studies, including clinical trials.
ff Participate in the elaboration of clinical
nephrology guidelines.
ff Continue with active collection of re-
search samples from CKD and transplant
patients.
ff Lluís Guirado Perich, clinical head of Renal Ayasreh, Montserrat Díaz-Encarnación,

Transplant of the Department of Neph- José Ballarín. Tratamiento con rituximab
Awards
rology. Award for Professional Excellence. en el síndrome nefrótico idiopático cor-

Fundació Puigvert. 18 May 2015. ticodependiente. Best Oral Communica-
tion. XXXI Reunió Anual de la Societat Cat-
ff Iara DaSilva, Edisson Rudas, Jackeline alana de Nefrologia.
del Carpio, César Ruiz, Patricia Lescano,
Pamela Chang, Cyntia Mercado, Nadia

Collaborations with other IIB Sant Pau Groups International academic collaborations
ff Biochemistry and Microbiology Institute UACH (Chile): renal fi-
Active collaborations in basic and clinical research projects
brosis and diabetic nephropathy.
ff Inflammatory Diseases Group: renal fibrosis. ff Mayo Clinic (Rochester, USA): Autosomal Dominant Polycystic
ff Anaesthesiology Group (in collaboration with the Catalan ANES- Kidney Disease (ADPKD).
CARDIOCAT Group): risk of major adverse cardiovascular and ff Hospital Tenon (Paris, France): Nephrotic syndrome.
cerebrovascular events in non-cardiac surgery associated with
the preoperative estimated glomerular filtration rate. ff EURenOmics Plataform: membranous nephropathy and neph-
rotic syndrome.
ff Paediatrics Group: nephrotic syndrome evolution, Ig A nephrop-
athy and inherited kidney diseases. ff Toronto General Hospital (Canada): molecular genetics of idio-
pathic nephrotic syndrome.
ff Andrology Group: infertility.
ff University of Melbourne (Australia): Alport syndrome.
ff Urology Group: genetic predisposition to prostate cancer and
transplant. ff University Medicine Goettingen (Germany): Alport syndrome.
Platforms ff EDTA (multinational, Europe): inherited kidney diseases and
Collaborations
chronic kidney disease-mineral and bone disorders.

ff Biobank platform.
ff Addenbrooke’s Hospital, Cambridge University Hospitals NHS
(United Kingdom): vasculitis.
ff EUVAS Group (multinationational collaborative Group): vasculi-
Other national academic collaborations tis.
ff Department of Biochemistry and Molecular Biology, Universi- Private national and international collaborations
tat de Barcelona, Institute of Biomedicine and Oncology Pro-
gramme, National Biomedical Research Institute of Liver and ff Participation in clinical studies including clinical trials and post-
Gastrointestinal Diseases (CIBER EHD): renal fibrosis. authorisation studies promoted by national and international
pharmaceutical companies.
ff Laboratory of Proteomics CSIC/Universitat Autònoma de Barce-
lona: diabetic nephropathy. ff Research Joint-Venture with VU Medisch Centrum (Amsterdam,
The Netherlands); Medizinische Klinik I (Aachen, Germany) and
ff Mutagenesis Department of Universitat Autònoma de Barce- San Paolo Hospital (Milan, Italy) sponsored by Abbvie Co on ef-
lona: renal impairment in chronic kidney disease. fects of vitamina D derivatives in CKD-MBD.
ff Genomic Regulation Center (CRG): inherited kidney diseases. Other collaborations
ff Universidad de Salamanca: acute kidney injury. ff Patient organisations: inherited diseases (AIRG), lupus (ACLECA)
ff Universitat de Lleida: chronic kidney disease. and chronic kidney disease (ALCER).
ff National Scientific Societies (such as Sociedad Española de Ne-
frología) and investigators of other centres: basic and clinical
studies (including public grants, clinical trials, observational
studies...) promoted by them.
ff Elisabeth Ars Criach. Enfermedades renales hereditarias quísti- ff Torra R. Genomic study of familial nephropathies of uncertain
cas y glomerulares: secuenciación masiva de un panel de genes etiology. PI12/01523. Instituto de Salud Carlos III. Duration: Jan-
para mejorar su diagnóstico y del exoma para identificar nuevos uary 2013-December 2015. €109,505.
genes. PI13/01731. Instituto de Salud Carlos III. Duration: 2014-
2016. €68,000.
ff Diaz M. Involvement of nucleoside transporter ENT1 in the mod-
ulation of macrophage-mediated renal fibrosis. PI12/01524.
ff Roser Torra Balcells. Contractes per a la intensificació de l’activi- Instituto de Salud Carlos III. Duration: January 2013-December
tat investigadora en el SNS 2014. INT14/00214. Instituto de Salud 2015. €41,745.
ff Coll E. Prognostic biomarkers and strategies to decrease the
Grants
Active
ff José Ballarín Castán. Ajuts de suport als Grups de Recerca de morbimortality in chronic kidney disease patients. PI12/02559.
Catalunya. Grup de Recerca en Nefrologia. AGAUR 2014. SGR Instituto de Salud Carlos III. Duration: January 2013-December
1441. Duration: January 2014-December 2016. 2015. €126,445.
ff José Ballarín Castán. Kidney Research Network. Instituto de Note: Total amount granted to PI. It does not include indirect costs.
Salud Carlos III. Duration: January 2013-December 2016.
RD12/0021/0033. €92,250.
ff Fernández-Llama P. Diabetic nephropathy: characterisation of
urinary proteoma and evaluation of renin angiotensin blocker
treatment. PI10/01261. Instituto de Salud Carlos III. Duration:
January 2011-December 2015. €181,742.

Nephrology
ff Laia Sans Atxer. Estudio del perfil cardiovascular, sistema ren- Fernández-Llama, Julio Pascual. Date of defense: 10 September
Theses
ina-angiotensina-aldosterona, inflamación y disfunción en- 2015.

dotelial en pacientes normotensos con poliquistosis renal au-
tosómica dominante y sin insuficiencia renal. Directors: Patricia
*TIF: 71.0610 **MIF: 4.1800

Anguiano L., et al, Circulating angiotensin- Chapman A.B., Devuyst O., Eckardt K.-U., Gan- Martinez-Castelao A., Cases A., Coll E., Bonal
converting enzyme 2 activity in patients sevoort R.T., Harris T., Horie S., Kasiske B.L., J., Galceran J.M., Fort J., Moreso F., Torregrosa
with chronic kidney disease without previ- Odland D., Pei Y., Perrone R.D., Pirson Y., Schrier J.-V., Guirado L., Ruiz P., Torguet P., Lauzurica
ous history of cardiovascular disease (2015) R.W., Torra R., Torres V.E., Watnick T., Wheeler R., Garcia R., Llibre J., Fulladosa X., Canas L.,
NEPHROL DIAL TRANSPL, 30 (7), 1176-1185. D.C., Ahn C., Alam A., Aussilhou B., Bae K.T., Bayes B., C.E.R.A. administered once monthly
IF: 4.0850 Bennett W.M., Bergmann C., Bichet D.G., corrects and maintains stable hemoglobin
Arias-Rodriguez M., Fernandez-Fresnedo G., Budde K., Chauveau D., Cowley B., De Coninck levels in chronic kidney disease patients not
Campistol J.M., Marin R., Franco A., Gomez E., B., Dell K.M., Drenth J.P.H., Ecder T., Emma F., on dialysis: The observational study MICE-
Cabello V., Diaz J.M., Osorio J.M., Gallego R., Ferec C., Flamion B., Galletti F., Gitomer B., NAS II (2015) NEFROLOGIA, 35 (1), 80-86.
Prevalence and clinical characteristics of re- Grantham J.J., Harr N., Harris P.C., Higashihara IF: 1.2070
nal transplant patients with true resistant E., Hodouchi E., Hogan M.C., Jha V., Korst U., Martinez-Castelao A., Gorostidi M., Gorriz
hypertension (2015) J HYPERTENS, 33 (5), Lagrafeuil C., Martin R.S., Mei C., Mrug M., J.L., Olmo R.S., Bover J., Segura J., Reflections
1074-1081. Obrador G.T., Ong A.C.M., Onuchic L.F., Pavia on two consensus documents about chronic
IF: 5.0620 L.S., Rangan G.K., Sandford R., Serra A.L., Stein- kidney disease (2015) NEFROLOGIA, 35 (2),
man T.I., Strandgaard S., Walz G., Winearls C.G., 127-130.
Ariceta G., Camacho J.A., Fernandez-Obispo Winston K.Y., Autosomal-dominant polycystic
M., Fernandez-Polo A., Gamez J., Garcia-Vil- IF: 1.2070
kidney disease (ADPKD): Executive summary
loria J., Monteczuma E.L., Leyes P., Martin-Be- from a Kidney Disease: Improving Global Moe S.M., et al, Cinacalcet, fibroblast growth
gue N., Oppenheimer F., Perello M., Morell Outcomes (KDIGO) Controversies Conference factor-23, and cardiovascular disease in he-
G.P., Torra R., Santandreu A.V., Guell A., Cysti- (2015) KIDNEY INT, 88 (1), 17-27. modialysis: The evaluation of cinacalcet HCl
nosis in adult and adolescent patients: Rec- IF: 7.6830 therapy to lower cardiovascular events
ommendations for the comprehensive care (EVOLVE) trial (2015) CIRCULATION, 132 (1),
of cystinosis (2015) NEFROLOGIA, 35 (3), Collado S., Coll E., Nicolau C., Pons M., 27-39.
304-321. Cruzado J.M., Pascual J., Cases A., Carotid IF: 17.0470
IF: 1.2070 atherosclerotic disease predicts cardiovas-
cular events in hemodialysis patients: A pro- Parfrey P.S., et al, Evaluation of Cinacalcet
Bover J., Egido J., Fernandez-Giraldez E., spective study (2015) PLOS ONE, 10 (6). HCL Therapy to Lower Cardiovascular Events
Praga M., Solozabal-Campos C., Torregrosa IF: 3.0570 (EVOLVE) Trial Investigators, The effects of
J.V., Martinez-Castelao A., Vitamin D, vitamin cinacalcet in older and younger patients on
D receptor and the importance of its activa- Corredor Z., Stoyanova E., Rodriguez-Ribera hemodialysis: The evaluation of cinacalcet
tion in patients with chronic kidney disease L., Coll E., Silva I., Diaz J.M., Ballarin J., Marcos HCL therapy to lower cardiovascular events
(2015) NEFROLOGIA, 35 (1), 28-41. R., Pastor S., Genomic damage as a biomarker (EVOLVE) trial (2015) CLIN J AM SOC NE-
IF: 1.2070 of chronic kidney disease status (2015) ENVI- PHRO, 10 (5), 791-799.
RON MOL MUTAGEN, 56 (3), 301-312. IF: 4.6570
Bover J., Evenepoel P., Urena-Torres P., IF: 3.3260
Vervloet M.G., Brandenburg V., Mazzaferro Rodriguez-Ribera L., Corredor Z., Sandoval
S., Covic A., Goldsmith D., Massy Z.A., Cozzo- Fernandez-Ruiz M., Arias M., Campistol J.M., S.B., Coll E., Silva I., Diaz J.M., Ballarin J., Mar-
lino M., Pro: Cardiovascular calcifications are Navarro D., Gomez-Huertas E., Gomez-Mar- cos R., Pastor S., Radiosensitivity in patients
clinically relevant (2015) NEPHROL DIAL quez G., Diaz J.M., Hernandez D., Bernal- suffering from chronic kidney disease (2015)
TRANSPL, 30 (3), 345-351. Blanco G., Cofan F., Jimeno L., Franco-Esteve INT J RADIAT BIOL, 91 (2), 172-178.
IF: 4.0850 A., Gonzalez E., Moreso F.J., Gomez-Alamillo IF: 1.7790
C., Mendiluce A., Luna-Huerta E., Aguado
Bullich G., Trujillano D., Santin S., Ossowski S., J.M., Cytomegalovirus prevention strategies
Mendizabal S., Fraga G., Madrid A., Ariceta in seropositive kidney transplant recipients:
G., Ballarin J., Torra R., Estivill X., Ars E., Tar- An insight into current clinical practice
geted next-generation sequencing in ste- (2015) TRANSPL INT, 28 (9), 1042-1054.
roid-resistant nephrotic syndrome: Muta- IF: 2.8350
tions in multiple glomerular genes may

influence disease severity (2015) EUR J HUM Gomiz J.L., Molina P., Cerveron M.J., Vila R.,
GENET, 23 (9), 1192-1199. Bover J., Nieto J., Barril G., Martinez-Castelao
IF: 4.5800 A., Fernandez E., Escudero V., Pinera C., Adra-
gao T., Navarro-Gonzalez J.F., Molinero L.M.,
Cabrera-López C., Bullich G., Martí T., Català Castro-Alonso C., Pallardo L.M., Jamal S.A.,
V., Ballarín J., Bissler J.J., Harris P.C., Ars E., Vascular calcification in patients with Nondi-
Torra R. Insight into response to motor inhi- alysis CKD over 3 years (2015) CLIN J AM SOC
bition when pkd1 and tsc2 are mutated. NEPHRO, 10 (4), 654-666.
(2015) BMC MED GENET,16, 39. IF: 4.6570
IF: 3.3800

ff Pippias M., Stel V.S., Abad Diez J.M., Afentakis N., Herrero-Calvo ff Campistol J.M., Arias M., Ariceta G., Blasco M., Espinosa l., Espi-
J.A., Arias M., Tomilina N., Bouzas Caamaño E., Buturovic-Ponik- nosa M., Grinyo J.M., Macia M., Mendizabal S., Praga M., Roman
var J., Čala S., Caskey F.J., Castro de la Nuez P., Cernevskis H., Coll- E., Torra R., Valdes F., Vilalta R., Rodriguez de Cordoba, S. Actu-
art F., Alonso de la Torre R., García Bazaga M.L., De Meester J., Díaz alizacion en síndrome hemolítico urémico atípico: diagnostico
Other Publications
J.M., Djukanovic L., Ferrer Alamar M., Finne P., Garneata L., Golan y tratamiento. Documento de consenso. (2015) NEFROLOGIA,
E., González Fernández R., Gutiérrez Avila G., Heaf J., Hoitsma A., 35(5), 421-447.
Kantaria N., Kolesnyk M., Kramar R., Kramer A., Lassalle M., Leives-
tad T., Lopot F., Macário F., Magaz A., Martín-Escobar E., Metcalfe
ff Bover J., Evenepoel P., Ureña P., Vervloet M., Brandenburg V.M.,
W., Noordzij M., Palsson R., Pechter Ü., Prütz K.G., Ratkovic M., Mazzaferro S., Covic A., Goldsmith D., Massy Z.A., Cozzolino M.
Resić H., Rutkowski B., Santiuste de Pablos C., Spustová V., Süley- OPPONENT´S COMMENT (Article: Zoccali C, London G. Vascular
manlar G., Van Stralen K., Thereska N., Wanner C., Jager KJ. Renal calcification is a surrogate marker, but not the cause of ongo-
replacement therapy in Europe: a summary of the 2012 ERA- ing vascular disease, and it is not a treatment target in chronic
EDTA Registry Annual Report. (2015) CLIN KIDNEY J, 8(3), 248-61. kidney disease Nephrol. Dial. Transplant. (2015) 30 (3): 352-357 ).
(2015) NEPHROL DIAL TRANSPLANT, 30(3), 357.
ff Fernández Llama P., Calero F. Hiperuricemia y riesgo cardiovascu-
lar: mito o realidad. (2015) HIPERTENSION, 32(4), 131-132.

AREA T1
Epidemiology, Pub
Healthcare Service
188 Clinical Epidemiology and Healthcare Services
192 Evaluation of Public Health Policies and Programmes
194 Transport and Health: Injuries and Mobility
196 Transmissible Diseases
200 Health Inequalities
204 Epidemiology of Addictions
206 Primary Care Research

blic Health and
es

188 AREA T1 · Epidemiology, Public Health and Healthcare Services
Clinical Epidemiology and Healthcare Services
Coordinator
Bonfill Cosp, Xavier FGS
xbonfill@santpau.cat
Members
Acosta Isaac, Francisco René IR
Alonso Coello, Pablo Ignacio IR
Álvarez Bustins, Gerard ACCIB
Balasso, Valentina IR
Ballesteros Silva,
Mónica Patricia ACCIB
Bolíbar Ribas, Ignasi FGS
Cánovas Martínez,
Leonor Esther IR
Cervera Alepuz, Andrea ACCIB
ff Evidence-based medicine: systematic Areas of interest
reviews, clinical practice guidelines and
of Research
Gich Saladich, Ignasi Josep FGS

Main Lines
clinical trials. ff Evidence-based medicine.

Girós Boixadós, Meritxell IR ff Health service evaluations. ff Cancer.
Gorgues Sendra, Marta FGS ff Methodological research. ff Perioperative medicine.
Leo Rosas, María Victoria ACCIB
ff Cardiovascular medicine.
Martínez García, Laura IR
ff Public health.
Martínez Zapata,
ff Appropriateness.
María José ACCIB
Mas Dalmau, Gemma IR
Osorio Sánchez, Dimelza FGS
Pardo Hernández, ff Become a reference group in Spain and ff Become a reference group for indepen-
Héctor CIBERESP Latin America regarding the preparation dent applied clinical research that fosters
Pequeño Saco, Sandra ACCIB of systematic reviews on the effects of relevant and scientifically sound studies
healthcare interventions, enhancing the aimed at meeting the real needs of the
Popova, Ekaterina IR
group’s capacity to provide technical and national healthcare system, whether on
Posso Rivera, Margarita FGS methodological support and increasing the group’s own initiative or through net-
Puchol Sanchez, Cristina ACCIB
Challenges
its scientific production in the framework worked relationships with similar groups.
Puig Reixach, Maria Teresa FGS of the Iberoamerican Cochrane Network. ff The group is currently setting up clini-
Quintana Ruiz, Maria Jesús FGS ff Promote greater use of scientific evi- cal and epidemiological studies (phase
Requeijo Lorenzo, Carolina FGS dence and evidence-based medicine 3/4 trials with non-commercial interests,
Rigau Comas, David IR tools in clinical and healthcare decision research into healthcare services and re-
Roqué Fíguls, making by means of stable agreements sults and studies of research methodolo-
with governmental, academic and sci- gies) and applying for additional public
Marta Cristina FSiE-UAB/IR
entific entities and institutions, thereby funding for new projects aimed at con-
Salas Gama, Karla Rocio FGS ensuring the ongoing development and solidating these research lines.
Sanabria Uribe, dissemination of these tools and the im-
Andrea Juliana IR plementation of training in their use.
Selva Olid, Anna IR
Solà Arnau, Ivan FGS
Sola Roca, Judit ACCIB
Tzanova, Maroussia ACCIB Collaborations with other IIB Sant Pau ff Clinical and Translational Cardiology
Urrutia Cuchi, Gerard FGS Groups
Vernooij, Robin External Collaborations
Whilhelmus Maria ACCIB ff Locomotor System Research
ff Urology
ff Population Health Research Institute, Mc-
Collaborations
Master University (Canada).

ff Palliative Care ff Clinical Trial Service Unit and Epidemio-
ff Angiology, Vascular Biology and Inflamma- logical Studies Unit, University of Oxford
tion (United Kingdom).
ff Anaesthesiology ff European Respiratory Society.
ff Facultad de Ciencias de la Salud, Universi-
ff Public Health Agency of Barcelona
dad Tecnológica Equinoccial (Ecuador).
ff Blood and Tissue Bank ff GRADE Working Group
ff Ageing Institute ff Joint Research Centre - European Comis-
ff EAP Sardenya sion

AREA T1 · Epidemiology, Public Health and Healthcare Services 189
ff Pablo Ignacio Alonso Coello. Contracte SNS Miguel Servet 2009. ff M. José Martinez Zapata. Prevención del sangrado postoperatorio:
MS09/00137. Instituto de Salud Carlos III. Duration: 2010-2016. Ensayo clínico, multicéntrico, aleatorizado, controlado, paralelo, que
€151,875. evalua la eficacia del ácido tranexámico y la cola de fibrina fracturas
subcapitales de fémur. EC11-341. Ministerio de Sanidad y Servicios
ff Maria Teresa Puig Reixach. Retos en salud pública: transferencia del Sociales e Igualdad. Duration: 2012-2015. €57,010.
conocimiento en obesidad, enfermedades cardiovasculares y con-
sumo de alcohol. PI12/02257. Instituto de Salud Carlos III. Duration: ff Pablo Alonso Coello. Developing and Evaluating Communication
2013-2016. €51,500. strategies to support Informed Decisions and practice based on
Evidence. DECIDE. 258583 FP7-HEALTH-2010. Duration: 2011-2015
ff Xavier Bonfill Cosp. Análisis y mejora del grado de adecuación de la €215,649.16.
cirugía programada del aneurisma de aorta abdominal. PI12/02530.
Instituto de Salud Carlos III. Duration: 2013-2016. €48,500. ff Xavier Bonfill Cosp. Multicentric, controlled, randomized clinical trial
to assess the efficacy and cost-effectiveness of urany catheters with
ff Pablo Ignacio Alonso Coello. La toma de decisiones compartida en silver alloy coating versus conventional catheters in spinal cord in-
cáncer de pulmón. PROYECTOS SINGULARES 2013. Associació Es-
Active Grants
jured patients. 112210. Fundació La Marató de TV3. Duration: 2012-

panyola Contra el Càncer. Duration: 2014-2017. €54,000. 2015.
ff Gerard Urrutia Cuchi. Cohorte prospectiva internacional de evalu- Note: Total amount granted to PI. It does not include indirect costs.
ación de los eventos vasculares en pacientes sometidos a cirugía
cardiaca (estudio CardioVISION). PI13/00502. Instituto de Salud Car-
los III. Duration: 2014-2016. €20,600.
ff Xavier Bonfill Cosp. Grup de Recerca Clínica i Sanitària Aplicada.
2014 SGR 673. Agència de Gestió d’Ajuts Universitaris i de Recerca.
Duration: 2014-2016. €21,000.
ff Pablo Ignacio Alonso Coello. Retos metodológicos en la elabo-
ración de guías de práctica clínica (GPC) del Sistema Nacional de
Salud. PI14/02006. Instituto de Salud Carlos III. Duration: 2015-2017.
€36,500.
ff Xavier Bonfill Cosp. Mapeo de la evidencia para mejorar las deci-
siones terapéuticas en pacientes con sarcomas de partes blandas.
Jose M. Buesa 2014. Grupo Español de Investigación en Sarcomas.
Duration: 2015-2017. €14,000.
*TIF: 230.9110 **MIF: 4.1984

Agoritsas T., Heen A.F., Brandt L., Alonso-Co- ciated with missing participant data in sys- Physician and patient perspectives (2015)
ello P., Kristiansen A., Akl E.A., Neumann I., tematic reviews: A methodological survey HEALTH EXPECT, 18 (6), 2318-2327.
Tikkinen K.A.O., Van Der Weijden T., Elwyn G., (2015) BMJ OPEN, 5 (9). IF: 3.2070
Montori V.M., Guyatt G.H., Vandvik P.O., Deci- IF: 2.5620 Alvarez G., Cerritelli F., Urrutia G., Using the
sion aids that really promote shared deci- Akl E.A., Shawwa K., Kahale L.A., Agoritsas T., template for intervention description and
sion making: The pace quickens (2015) BM- Brignardello-Petersen R., Busse J.W., Carras- replication (TIDieR) as a tool for improving
J-BRIT MED J, 350. co-Labra A., Ebrahim S., Johnston B.C., Neu- the design and reporting of manual therapy
IF: 19.6970 mann I., Sola I., Sun X., Vandvik P., Zhang Y., interventions (2015) MANUAL THER, 24, 85-
Aguilera X., Martinez-Zapata M.J., Hinarejos Alonso-Coello P., Guyatt G.H., Reporting 89.
P., Jordan M., Leal J., Gonzalez J.C., Monllau missing participant data in randomised tri- IF: 1.8690
J.C., Celaya F., Rodriguez-Arias A., Fernandez als: Systematic survey of the methodological Alvarez-Garcia J., Ferrero-Gregori A., Puig T.,
J.A., Pelfort X., Puig-Verdie L., Topical and in- literature and a proposed guide (2015) BMJ Vazquez R., Delgado J., Pascual-Figal D.,
travenous tranexamic acid reduce blood OPEN, 5 (12). Alonso-Pulpon L., Gonzalez-Juanatey J.R.,
loss compared to routine hemostasis in total IF: 2.5620 Rivera M., Worner F., Bardaji A., Cinca J., Hov-
knee arthroplasty: a multicenter, random- Almirall J., Serra-Prat M., Bolibar I., Palomera e-Madsen L., A simple validated method for
ized, controlled trial (2015) ARCH ORTHOP E., Roig J., Boixeda R., Bartolome M., de la predicting the risk of hospitalization for
TRAUM SU, 135 (7), 1017-1025. Torre M., Parra O., Torres A., Professions and worsening of heart failure in ambulatory
IF: 1.4960 Working Conditions Associated With Com- patients: The Redin-SCORE (2015) EUR J
Akl E.A., Carrasco-Labra A., Brignardel- munity-Acquired Pneumonia (2015) ARCH HEART FAIL, 17 (8), 818-827.
lo-Petersen R., Neumann I., Johnston B.C., BRONCONEUMOL, 51 (12), 627-631. IF: 5.1350
Sun X., Briel M., Busse J.W., Ebrahim S., IF: 1.7710 Alvarez-Garcia J., Ferrero-Gregori A., Puig T.,
Granados C.E., Iorio A., Irfan A., Garcia L.M., Alonso-Coello P., Montori V.M., Diaz M.G., Cinca J., The Redin SCORE: useful, but not for
Mustafa R.A., Ramirez-Morera A., Selva A., Devereaux P.J., Mas G., Diez A.I., Sola I., Roura all: Reply (2015) EUR J HEART FAIL.
Sola I., Sanabria A.J., Tikkinen K.A.O., Vandvik M., Souto J.C., Oliver S., Ruiz R., Coll-Vinent B., IF: 5.1350
P.O., Vernooij R.W.M., Zazueta O.E., Zhou Q., Gich I., Schunemann H.J., Guyatt G., Values
Guyatt G.H., Alonso-Coello P., Reporting, Arevalo-Rodriguez I., Roque I Figuls M.,
and preferences for oral antithrombotic Smailagic N., Ciapponi A., Sanchez-Perez E.,
handling and assessing the risk of bias asso- therapy in patients with atrial fibrillation: Giannakou A., Pedraza O.L., Bonfill Cosp X.,

Clinical Epidemiolgy and Healthcare Services

*TIF: 230.9110 **MIF: 4.1984
Cullum S., Mini-Mental State Examination mancas-Racines D., Lopez L., Correa R., Rojas- for thromboprophylaxis during pregnancy:
(MMSE) for the detection of Alzheimer’s dis- -De-Arias A., Loza C., Gianneo O., Pardo H., A comparison of direct-choice and decision
ease and other dementias in people with Identification of biomedical journals in analysis using patient specific utilities (2015)
mild cognitive impairment (MCI) (2015) Spain and Latin America (2015) HEALTH THROMB RES, 136 (2), 341-347.
COCHRANE DB SYST REV, 3, CD010783. INFO LIBR J, 32 (4), 276-286. IF: 2.3200
IF: 6.0350 IF: 0.7120 Ferrero-Cafiero J.M., Gich I., Puntes M., Marti-
Ballester M.R., Roig E., Gich I., Puntes M., Bufill E., Roura-Poch P., Sala-Matavera I., An- nez J., Ballester M.R., Coimbra J., Mathison Y.,
Delgadillo J., Santos B., Antonijoan R.M., ton S., Lleo A., Sanchez-Saudinos B., Tomas- Tarre M., Font X., Antonijoan R.M., Ibuprofen
Randomized, open-label, blinded-endpoint, Abadal L., Puig T., Abos J., Bernades S., Clari- lysinate, quicker and less variable: Relative
crossover, single-dose study to compare the mon J., Blesa R., Reelin signaling pathway bioavailability compared to ibuprofen base
pharmacodynamics of torasemide-PR 10 genotypes and Alzheimer disease in a Span- in a pediatric suspension dosage form (2015)
mg, torasemide-IR 10 mg, and furosemi- ish population (2015) ALZ DIS ASSOC DIS, 29 INT J CLIN PHARM TH, 53 (11), 972-979.
de-IR 40 mg, in patients with chronic heart (2), 169-172. IF: 1.1290
failure (2015) DRUG DES DEV THER, 9, 4291- IF: 2.5300 Hernandez D., Palou J., Sancho G., Salas D.,
4302. Carles M., Brosa M., Souto J.C., Garcia-Ala- Gimenez D., Buitrago P., Esquena S., de la
IF: 2.8810 mino J.M., Guyatt G., Alonso-Coello P., Torre P., Pernas J., Gich I., de Segura G.G.,
Balsells M., Garcia-Patterson A., Sola I., Roque Cost-effectiveness analysis of dabigatran Craven-Bartle J., Pelvic MRI findings in re-
M., Gich I., Corcoy R., Glibenclamide, metfor- and anticoagulation monitoring strategies lapsed prostate cancer after radical prosta-
min, and insulin for the treatment of gesta- of vitamin K antagonist (2015) BMC HEALTH tectomy (2015) RADIAT ONCOL, 10 (1).
tional diabetes: A systematic review and SERV RES. IF: 2.4660
meta-analysis (2015) BMJ-BRIT MED J, 350. IF: 1.6060 Kang D., Han J., Neuberger M.M., Moy M.L.,
IF: 19.6970 Carles M., Brosa M., Souto J.C., Garcia-Ala- Wallace S.A., Alonso-Coello P., Dahm P.,
Barnadas M.A., Rubiales M.V., Gich I., Gelpi C., mino J.M., Guyatt G., Alonso-Coello P., Transurethral radiofrequency collagen de-
Usefulness of specific anti-desmoglein 1 and Cost-effectiveness analysis of dabigatran naturation for the treatment of women with
3 enzyme-linked immunoassay and indirect and anticoagulation monitoring strategies urinary incontinence (2015) COCHRANE DB
immunofluorescence in the evaluation of of Vitamin K antagonist Utilization, expendi- SYST REV, 3, CD010217.
pemphigus activity (2015) INT J DERMATOL, ture, economics and financing systems IF: 6.0350
54 (11), 1261-1268. (2015) BMC HEALTH SERV RES, 15 (1). Kristiansen A., Brandt L., Alonso-Coello P.,
IF: 1.4150 IF: 1.6060 Agoritsas T., Akl E.A., Conboy T., Elbarbary M.,
Bellmunt-Montoya S., Escribano J.M., Dilme Carrasco-Labra A., Brignardello-Petersen R., Ferwana M., Medani W., Murad M.H., Rigau
J., Martinez-Zapata M.J., CHIVA method for Santesso N., Neumann I., Mustafa R.A., D., Rosenbaum S., Spencer F.A., Treweek S.,
the treatment of chronic venous insuffi- Mbuagbaw L., Ikobaltzeta I.E., De Stio C., Guyatt G., Vandvik P.O., Development of a
ciency (2015) COCHRANE DB SYST REV, 6, McCullagh L.J., Alonso-Coello P., Meerpohl novel, multilayered presentation format for
CD009648-. J.J., Vandvik P.O., Brozek J.L., Akl E.A., Bossuyt clinical practice guidelines (2015) CHEST,
IF: 6.0350 P., Churchill R., Glenton C., Rosenbaum S., 147 (3), 754-763.
Bessissow A., Khan J., Devereaux P.J., Alva- Tugwell P., Welch V., Guyatt G., Schunemann IF: 5.9400
rez-Garcia J., Alonso-Coello P., Postoperative H., Comparison between the standard and a Lopez-Alcalde J., Mateos-Mazon M., Guevara
atrial fibrillation in non-cardiac and cardiac new alternative format of the Summa- M., Conterno L.O., Sola I., Cabir Nunes S.,
surgery: An overview (2015) J THROMB HAE- ry-of-Findings tables in Cochrane review Bonfill Cosp X., Gloves, gowns and masks for
MOST, 13 (S1), S304-S312. users: Study protocol for a randomized con- reducing the transmission of meticillin-resis-
IF: 5.5650 trolled trial (2015) TRIALS, 16 (1). tant Staphylococcus aureus (MRSA) in the
IF: 1.8590 hospital setting (2015) COCHRANE DB SYST
Boardman H.M., Bonfill Cosp X., Hartley L.,
Eisinga A., Main C., Roque i Figuls M., Bonfill Coll-Planas L., del Valle Gomez G., Bonilla P., REV, 7, CD007087.
Cosp X., Gabriel Sanchez R., Knight B., Hor- Masat T., Puig T., Monteserin R., Promoting IF: 6.0350
mone therapy for preventing cardiovascular social capital to alleviate loneliness and im- Marti-Carvajal A.J., Anand V., Sola I., Janus
disease in post-menopausal women (2015) prove health among older people in Spain kinase-1 and Janus kinase-2 inhibitors for
COCHRANE DB SYST REV, 3, CD002229. (2015) HEALTH SOC CARE COMM. treating myelofibrosis (2015) COCHRANE DB
IF: 6.0350 IF: 1.5570 SYST REV, 4, CD010298.
Bonfill X., Martinez-Zapata M.J., Vernooij Delgado-Noguera M.F., Calvache J.A., Bonfill IF: 6.0350
R.W., Sanchez M.J., Suarez-Varela M.M., De la Cosp X., Kotanidou E.P., Galli-Tsinopoulou A., Marti-Carvajal A.J., Sola I., Antifibrinolytic
Cruz J., Emparanza J.I., Ferrer M., Pijoan J.I., Supplementation with long chain polyun- amino acids for upper gastrointestinal
Ramos-Goni J.M., Palou J., Schmidt S., Abraira saturated fatty acids (LCPUFA) to breastfeed- bleeding in people with acute or chronic
V., Zamora J., Clinical intervals and diagnosing mothers for improving child growth and liver disease (2015) COCHRANE DB SYST REV,
tic characteristics in a cohort of prostate development (2015) COCHRANE DB SYST 6, CD006007.
cancer patients in Spain: A multicentre ob- REV, 7, CD007901. IF: 6.0350
servational study (2015) BMC UROL, 15 (1). IF: 6.0350
Marti-Carvajal A.J., Anand V., Sola I., Treat-
IF: 1.6060 Eckman M.H., Alonso-Coello P., Guyatt G.H., ment for disseminated intravascular coagu-
Bonfill X., Osorio D., Posso M., Sola I., Rada G., Ebrahim S., Tikkinen K.A.O., Lopes L.C., Neu- lation in patients with acute and chronic
Torres A., Garcia Dieguez M., Pina-Pozas M., mann I., McDonald S.D., Zhang Y., Zhou Q., leukemia (2015) COCHRANE DB SYST REV, 6,
Diaz-Garcia L., Tristan M., Gandarilla O., Rin- Akl E.A., Jacobsen A.F., Santamaria A., An- CD008562.
con-Valenzuela D.A., Marti A., Hidalgo R., Si- nichino-Bizzacchi J.M., Bitar W., Sandset P.M., IF: 6.0350
Bates S.M., Women’s values and preferences

*TIF: 230.9110 **MIF: 4.1984

Marti-Carvajal A.J., Sola I., Vitamin K for up- Rios Castellanos E., Bonfill Cosp X., Seron P., Seron P., Lanas F., Rios E., Bonfill X., Alonso-
per gastrointestinal bleeding in people with Gisbert J.P., Bonfill Cosp X., Endoscopic injec- Coello P., Evaluation of the quality of clinical
acute or chronic liver diseases (2015) tion of cyanoacrylate glue versus other en- guidelines for cardiac rehabilitation: A criti-
COCHRANE DB SYST REV, 6, CD004792-. doscopic procedures for acute bleeding cal review (2015) J CARDIOPULM REHABIL,
IF: 6.0350 gastric varices in people with portal hyper- 35 (1), 1-12.
Martinez Garcia L., Sanabria A.J., Araya I., tension (2015) COCHRANE DB SYST REV, 5, IF: 1.6320
Lawson J., Sola I., Vernooij R.W.M., Lopez D., CD010180-. Seron P., Pardo H., Lanas F., Cochrane cor-
Garcia Alvarez E., Trujillo-Martin M.M., Etxe- IF: 6.0350 ner:Exercise for people with high cardiovas-
andia-Ikobaltzeta I., Kotzeva A., Rigau D., Robleda G., Roche-Campo F., Urrutia G., Na- cular risk (2015) HEART, 101 (9), 663-664.
Louro-Gonzalez A., Barajas-Nava L., Diaz Del varro M., Sendra M.-A., Castillo A., Rodri- IF: 5.6930
Campo P., Estrada M.D., Gracia J., Salce- guez-Arias A., Juanes-Borrejo E., Gich I., Serra-Grima R., Donate M., Alvarez-Garcia J.,
do-Fernandez F., Haynes R.B., Alonso-Coello Mancebo J., Banos J.-E., A randomized con- Barradas-Pires A., Ferrero A., Carballeira L.,
P., Alvarez Ariza M., Argente Oliver J., Armario trolled trial of fentanyl in the pre-emptive Puig T., Rodriguez E., Cinca J., Long-term
Garcia P., Arrieta Anton E., Balaguer Santam- treatment of pain associated with turning in follow-up of early repolarization pattern in
aria A., Borque Fernando A., Bunuel Alvarez patients under mechanical ventilation: RE- elite athletes (2015) AM J MED, 128 (2), 192.
J.C., Cervera Alvarez A., De Las Heras Linero SEARCH protocol (2015) J ADV NURS, 71 (2), e1-192.e9.
M.E., Dopico L., Eddy Ives L.S., Esco Baron R., 441-450. IF: 5.6100
Ferreira Gonzalez I., Ferrer F., Gil Sanz M.J., IF: 1.9170
Lago Deibe F.I., Marti Canales J.C., Martinez Sitja-Rabert M., Martinez-Zapata M.J., Fort
Robleda G., Roche-Campo F., Sanchez V., Vanmeerhaeghe A., Rey Abella F., Ro-
Rubio A., Martos Moreno G.A., Mejuto Marti Gich I., Banos J.-E., Postoperative Discomfort
T., Morales Ortiz A., Rioja Sanz L.A., Rioja mero-Rodriguez D., Bonfill X., Effects of a
After Abdominal Surgery: An Observational Whole body vibration (WBV) exercise inter-
Zuazu J., Rodriguez Gonzalez A., Rodri- Study (2015) J PERIANESTH NURS, 30 (4),
guez-Arias Palomo J.L., Saenz Cusi A., Effi- vention for institutionalized older people: A
272-279. randomized, multicentre, parallel, clinical
ciency of pragmatic search strategies to up- IF: 0.6620
date clinical guidelines recommendations trial (2015) J AM MED DIR ASSOC, 16 (2), 125-
(2015) BMC MED RES METHODOL, 15 (1). Rodrigo G.J., Soler-Cataluna J.J., Solanes I., 131.
IF: 3.0590 Bolibar I., Llauger M.A., Plaza V., Assessment IF: 6.6160
of the internal structure of GOLD 2011 sys- Tew G.A., Posso M.C., Arundel C.E., McDaid
Mcalister F.A., Jacka M., Graham M., Young- tem (2015) PULM PHARMACOL THER, 30,
son E., Cembrowski G., Bagshaw S.M., Pannu C.M., Systematic review: Height-adjustable
87-92. workstations to reduce sedentary behaviour
N., Townsend D.R., Srinathan S., Alonso-Co- IF: 2.9300
ello P., Devereaux P.J., The prediction of post- in office-based workers (2015) OCCUP
operative stroke or death in patients with Rueda J.-R., Guillen V., Ballesteros J., Tejada MED-OXFORD, 65 (5), 357-366.
preoperative atrial fibrillation undergoing M.-I., Sola I., L-acetylcarnitine for treating IF: 1.1280
non-cardiac surgery: A VISION sub-study fragile X syndrome (2015) COCHRANE DB Trujols J., Ballesteros J., Sola I., Portella M.J.,
(2015) J THROMB HAEMOST, 13 (10), 1768- SYST REV, 5, CD010012-. Improving systematic reviews on psycho-
1775. IF: 6.0350 metric properties of measurement instru-
IF: 5.5650 Sala Farre M.R., Osorio Sanchez D., Arias Va- ments: A letter to the Editor commenting on
Meerpohl J.J., Schell L.K., Bassler D., Gallus S., rela C., Simo Sanahuja M., Recasens Re- Reilly etal.’s (2015) review of the psychomet-
Kleijnen J., Kulig M., Vecchia C.L., Marusic A., casens A., Perez Jove J., Campylobacter and ric literature on QIDS (2015) J PSYCHIATR
Ravaud P., Reis A., Schmucker C., Strech D., Salmonella acute gastroenteritis: Epidemiol- RES.
Urrutia G., Wager E., Antes G., Evidence-in- ogy and health care utilization (2015) MED IF: 4.4650
formed recommendations to reduce dis- CLIN-BARCELONA, 145 (7), 294-297. Turrillas M., Sitja-Rabert M., Pardo H., Vilaro
semination bias in clinical research: Conclu- IF: 1.2670 Casamitjana J., Fort-Vanmeerhaeghe A.,
sions from the OPEN (Overcome failure to Sanabria A.J., Rigau D., Rotaeche R., Selva A., Morral Fernandez A., Cebria i Iranzo M.A.,
Publish nEgative fiNdings) project based on Marzo-Castillejo M., Alonso-Coello P., Bonfill Cosp X., Identification and descrip-
an international consensus meeting (2015) GRADE: Methodology for formulating and tion of controlled clinical trials published in
BMJ OPEN, 5 (5). grading recommendations in clinical prac- Physiotherapy journals in Spain (2015) J
IF: 2.5620 tice (2015) ATEN PRIM, 47 (1), 48-55. EVAL CLIN PRACT.
Plaza V., Peiro M., Torrejon M., Fletcher M., IF: 1.0980 IF: 1.0530
Lopez-Vina A., Ignacio J.M., Quintano J.A., Schmidt S., Frances A., Lorente Garin J.A., Walitt B., Urrutia G., Nishishinya M.B., Cantrell
Bardagi S., Gich I., A repeated short educa- Juanpere N., Lloreta Trull J., Bonfill X., Mar- S.E., Hauser W., Selective serotonin reuptake
tional intervention improves asthma control tinez-Zapata M.J., Morales Suarez-Varela M., inhibitors for fibromyalgia syndrome (2015)
and quality of life (2015) EUR RESPIR J, 46 (5), de la Cruz J., Emparanza J.I., Sanchez M.-J., SAO PAULO MED J, 133 (5), 454.
1298-1307. Zamora J., Pijoan J.I., Alonso J., Ferrer M., IF: 0.9550
IF: 8.3320 Quality of life in patients with non-mus-
Reveiz L., Chapman E., Asial S., Munoz S., cle-invasive bladder cancer: One-year re-
Bonfill X., Alonso-Coello P., Risk of bias of sults of a multicentre prospective cohort
randomized trials over time (2015) J CLIN study (2015) UROL ONCOL-SEMIN ORI, 33
EPIDEMIOL, 68 (9), 1036-1045. (1), 19.e7-19.e15.
IF: 4.7030 IF: 2.9210

Evaluation of Public Health Policies

and Programmes
Coordinator
Ariza Cardenal, Carles ASPB
cariza@aspb.cat
Members
Centrich Escarpenter,
Francesc ASPB
Continente García, Xavier ASPB
García Altés, Anna ASPB
Leon Pujades, Gabriel ASPB
López Medina, María José ASPB
Muñoz Guzmán, Gloria ASPB
Pérez Giménez, Anna ASPB
Puigpinós Riera, Rosa ASPB
Sánchez Martínez, Evaluation of Public Health Policies and based prevention programmes for obe-
Programmes sity, smoking, alcohol and cannabis
Francesca ASPB
of Research
Main Lines
consumption, breast cancer screening

Serral Cano, Gemma ASPB programmes and memory training work-
ff Monitoring of behaviours and other
Villalbí Hereter, health risk factors such as environmental shops for elderly people).
Joan Ramon ASPB exposure. ff Evaluation of ICT innovation in public
ff Process and impact evaluation of public health.
health programmes and services (school- ff Evaluation of food contaminants.
ff Promote research into the evaluation of ff Develop a theoretical corpus of concepts,

policies and programmes. principles, methods and examples that
contribute to filling the gap in under-
Challenges
ff Support the debate on conceptual and and postgraduate teaching regarding the
methodological aspects of results evalua- design and evaluation of risk prevention
tion in prevention and health promotion. and health promotion interventions.
ff Consolidate the group’s research, foster-
ing less developed aspects such as finan-
cial assessment and evaluation of health
protection interventions.
ff Xavier Continente, Carles Ariza, Francesca ff POIBA, Projecte de Prevenció de l’Obesitat

Sánchez, Anna Pérez, M. José López, Olga Infantil en escolars a Barcelona. Premi Ra-
Juárez. Consumo de tabaco y cannabis mon de Teserach 2015 a l’actuació cívica
en adolescentes de Barcelona. Best oral d’entitats per a la promoció de la salut. 5
communication. VI Jornada de Prevenció i May 2015.
Control del Tabaquisme del CNPT. 22 April
Awards
2015.
ff M. José López. Impact of the Spanish
smoke-free legislation on adult, non-
ff Agència de Salut Pública de Barcelona. smoker exposure to secondhand smoke:
POIBA, Proyecto de Prevención de la Obe- cross-sectional surveys before (2004) and
sidad en Barcelona. Primer accèssit. VIII after (2012) legislation. XXII Premio de la
“Estrategia NAOS” Awards of the Agencia Sociedad Española de Epidemiología al
Española de Consumo, Seguridad Alimen- mejor artículo original en epidemiologia.
taria y Nutrición (AECOSAN). 28 April 2015. 3 September 2015.
ff Núria Obradors. Factors individuals i ff Olga Juárez. Programas de prevención del

contextuals associats al consum de risc embarazo, las infecciones de transmisión
Theses
d’alcohol en joves de la Catalunya Central. sexual, incluida la infección por el VIH/

Director: Carles Ariza. Date of defense: 3 SIDA entre jóvenes escolarizados de Bar-
December 2015. celona ciudad (1992-2014). Director: Car-
les Ariza. Date of defense: 16 December
2015.

Collaborations with other IIB Sant Pau Groups ff Foreign universities: Johns Hopkins University, USA.
ff Clinical Epidemiology and Healthcare Services (PI: Xavier Bonfill). ff Spanish universities: Universitat Pompeu Fabra, Universitat
Ramon Llull, Universitat de Vic, Universitat Internacional de
ff Transport and Health: Injuries and Mobility (PI: Catherine Pérez). Catalunya, Universitat Oberta de Catalunya, Universidad de San-
tiago de Compostela.
ff Health Inequalities (PI: Carme Borrell).
Collaborations
ff Primary care centres: Ciutat Meridiana, Roquetes, Sant Rafael

ff Epidemiology of Addictions (PI: M. Teresa Brugal).
and Sardenya (Barcelona).
ff Catalan Institute of Oncology (ICO).
ff Municipal bodies: Barcelona Sports Institute (IBE), Barcelona Mu-
ff CIBER-Epidemiology and Public Health (Group 18: Evaluation of nicipal Institute of Education (IME).
public health policies and programmes).
ff Regional bodies: Public Health Agency of Catalunya (Promoting
ff AGAUR Consolidated Research Group (Evaluation of public Health through Physical Activity and Healthy Eating Plan) and
health policies and programmes). Catalan Health Information and Quality Agency (AQUAS).
ff Tobacco Working Group of the Spanish Epidemiology Society. ff Other bodies: Catalan Recreation Foundation (FCE).
ff Social Determinants Group of the Spanish Epidemiology Society. ff Companies: Fontvella and Danone (Health Affairs Departments).
Grants
Active
ff Rosa Puigpinós Riera. Influencia de determinantes sociales, es- mujeres diagnosticadas. PI13/01977. Instituto de Salud Carlos III.
tilos de vida, bienestar emocional y uso de terapias no conven- Duration: 2014-2016. €64,470.Transport and Health: Injuries and
cionales en la evolución del cáncer de mama en una cohorte de Mobility (PI: Catherine Pérez).
*TIF: 37.8190 **MIF: 2.5213

Alvarez-Bruned L., Garcia-Continente X., cents in Barcelona (Spain). (2015) AN PEDI- tins: A QuEChERS approach to the analysis of
Gotsens M., Perez A., Perez G., Trends in In- ATR, 83 (1), 3-10. food samples. (2015) FOOD CHEM, 181, 57-
equalities in the Use of Condom by Urban IF: 0.7730 63.
Teenagers in Spain. (2015) J URBAN HEALTH, Guitart A.M., Espelt A., Castellano Y., Suelves IF: 4.0520
92 (6), 1065-1080. J.M., Villalbi J.R., Brugal M.T., Injury-Related Rubies A., Munoz E., Gibert D., Cortes-Fran-
IF: 2.0460 Mortality Over 12 Years in a Cohort of Patients cisco N., Granados M., Caixach J., Centrich F.,
Ariza C., Ortega-Rodriguez E., Sanchez-Marti- with Alcohol Use Disorders: Higher Mortality New method for the analysis of lipophilic
nez F., Valmayor S., Juarez O., Pasarin M.I., Among Young People and Women. (2015) marine biotoxins in fresh and canned bi-
Childhood obesity prevention from a com- ALCOHOL CLIN EXP RES, 39 (7), 1158-1165. valves by liquid chromatography coupled to
munity view (2015) ATEN PRIM, 47 (4), 246- IF: 2.8290 high resolution mass spectrometry: A quick,
255. Perez A., Roque M., Domenech S., Monteserin easy, cheap, efficient, rugged, safe approach.
IF: 1.0980 R., Soriano N., Blancafort X., Bosom M., Vidal (2015) J CHROMATOGR A, 1386, 62-73.
Bosque-Prous M., Espelt A., Borrell C., Bartroli C., Petit M., Hortal N., Gil C., Espelt A., Lopez IF: 3.9260
M., Guitart A.M., Villalbi J.R., Brugal M.T., Gen- M.J., Efficacy of memory training in healthy Rubies A., Sans G., Kumar P., Granados M.,
der differences in hazardous drinking among community-dwelling older people: Study Companyo R., Centrich F., High-throughput
middle-aged in Europe: The role of social protocol for a randomized controlled trial. method for the determination of nitroimi-
context and women’s empowerment. (2015) (2015) BMC GERIATR, 15 (1). dazoles in muscle samples by liquid chroma-
EUR J PUBLIC HEALTH, 25 (4), 698-705. IF: 2.3710 tography coupled to mass spectrometry.
IF: 2.7510 Perez A., Roque M., Domenech S., Monteserin (2015) ANAL BIOANAL CHEM, 407 (15), 4411-
Cequier A., Garcia-Altes A., Transparency and R., Soriano N., Blancafort X., Bosom M., Vidal 4421.
benchmarking for sustainability of the health C., Petit M., Hortal N., Gil C., Espelt A., Lopez IF: 3.1250
system. (2015) MED CLIN-BARCELONA, 144 M.J., Efficacy of memory training in healthy Sureda X., Fernandez E., Martinez-Sanchez
(10), 449-451. community-dwelling older people: Study J.M., Fu M., Lopez M.J., Martinez C., Salto E.,
IF: 1.2670 protocol for a randomized controlled trial Secondhand smoke in outdoor settings:
Garcia-Altes A., Pinilla J., Mari-Dell’Olmo M., Psychology, psychiatry and quality of life. Smokers’ consumption, non-smokers’ per-
Fernandez E., Lopez M.J., Economic impact of (2015) BMC GERIATR, 15 (1). ceptions, and attitudes towards smoke-free
smoke-free legislation: Did the Spanish to- IF: 2.3710 legislation in Spain. (2015) BMJ OPEN, 5 (4).
bacco control law affect the economic activ- Perez-Rios M., Fernandez E., Schiaffino A., IF: 2.5620
ity of bars and restaurants? (2015) NICOTINE Nebot M., Lopez M.J., Changes in the preva- Villalbi J.R., Bartroli M., Bosque-Prous M.,
TOB RES, 17 (11), 1397-1400. lence of tobacco consumption and the profile Guitart A.M., Serra-Batiste E., Casas C., Brugal
IF: 3.8110 of Spanish smokers after a comprehensive M.T., Enforcing regulations on alcohol sales
Garcia-Continente X., Allue N., Perez-Gimenez smoke-free policy. (2015) PLOS ONE, 10 (6). and use as universal environmental preven-
A., Ariza C., Sanchez-Martinez F., Lopez M.J., IF: 3.0570 tion (2015) ADICCIONES, 27 (4), 288-293.
Nebot M., Eating habits, sedentary behaviors Rubies A., Antkowiak S., Granados M., Compa- IF: 1.7800
and overweight and obesity among adoles- nyo R., Centrich F., Determination of avermec-

Transport and Health: Injuries and Mobility
Coordinator
Pérez González, Catherine ASPB
cperez@aspb.cat
Members
Novoa Pardo, Ana ASPB
Olabarria Saenz
De Viguera, Marta ASPB
Santamariña Rubio, Elena ASPB
ff Public health injury surveillance. Research Projects in the Planning and

ff Evaluation of road safety strategies at the Design Phase
urban level.
ff Record linkage of health and police reg-
ff Evaluation of road safety strategies in isters to study road traffic injury determi-
of Research
Main Lines
Spain. nants.
ff Indicators of mobility exposure and risk of ff Inter-sector policies in transport: impact
traffic injuries. on sustainable environment, health and
equity.
ff Determinants of walking as a mode of
transport.
ff Health impact assessment of active trans-
port (walking and cycling).
ff Study of the nature of injuries and their ff Calculation of risk indicators using mobil-
Challenges
severity according to the characteristics ity exposure.

of the collision and the vehicles involved,
particularly in urban settings.
ff Study motorized and non-motorized mo-
bility and its impact on health.
ff Evaluate road safety policies and interven-
tions.
Collaborations with other IIB Sant Pau Biomédica de Epidemiologia y Salud

Groups Pública).
ff The IP of the group is member of the Eu-
ff Health Inequalities (PI: Carme Borrell) ropean Committee of The Transport and
ff Safety indicators for cities IRTAD Cities Health Study Group (THSG) (UK).
(Joint Transport Research Centre of the ff Joint action on monitoring injuries in Eu-
Collaborations
OECD and the International Transport Fo- rope (JAMIE) (European Agency for Health
rum (JTRC)). and Consumers).
ff Partners of the SafetyCube (Safety
CaUsation, Benefits and Efficiency) (H2020
ff All members of the group are members of N.633485), a research project funded by
the Working Group for Health Impact Eval- the European Commission under the Hori-
uation of Injuries in Spain (Sociedad Es- zons 2020, the EU Framework Programme
pañola de Epidemiología), which is leaded for Research and Innovation, in the do-
by the IP of the group (Catherine Pérez). main of Road Safety.
ff All members of the group are members

of the group of Social Inequalities of
CIBERESP (Consorcio de Investigación

*TIF: 17.0830 **MIF: 2.8471

Basagana X., Escalera-Antezana J.P., Dad- Olabarria M., Perez K., Santamarina-Rubio E., Rocha K.B., Perez K., Rodriguez-Sanz M.,
vand P., Llatje O., Barrera-Gomez J., Cunillera Novoa A.M., Racioppi F., Effect of neighbour- Muntaner C., Alonso J., Borrell C. Inequalities
J., Medina-Ramon M., Perez K., High ambient hood motorization rates on walking levels. in mental health in the spanish autonomous
temperatures and risk of motor vehicle (2015) EUR J PUBLIC HEALTH, 25 (4), 740-747. communities: a multilevel study. SPAN J
crashes in Catalonia, Spain (2000–2011): A IF: 2.7510 PSYCHOL, 2015, 18, E27.
time-series analysis. (2015) ENVIRON Olabarria M., Santamarina-Rubio E., Mari- IF: 0.493
HEALTH PERSP, 123 (12), 1309-1316. Dell’Olmo M., Gotsens M., Novoa A.M., Bor-
IF: 8.4430 rell C., Perez K., Head-on crashes on two-way
Novoa A.M., Ward J., Malmusi D., Diaz F., interurban roads: A public health concern in
Darnell M., Trilla C., Bosch J., Borrell C., How road safety. (2015) GAC SANIT, 29, 16-23.
substandard dwellings and housing afford- IF: 1.5090
ability problems are associated with poor Perez K., Lardelli P., Ramirez R., Gonza-
health in a vulnerable population during the lez-Luque J.C., Road traffic injuries: An exam-
economic recession of the late 2000s. (2015) ple of public health. (2015) GAC SANIT, 29,
INT J EQUITY HEALTH, 14 (1). 2-3.
IF: 2.3780 IF: 1.5090

Transmissible Diseases
Coordinator
Caylà Buqueras,
Joan Arturo ASPB
jcayla@aspb.cat
Members
Casals Toquero, Martí ASPB
De Benito Langa, Javier ASPB
García de Olalla Rizo,
Patricia ASPB
Gil Simon, Sonia ASPB
Horna Campos, Olivia ASPB
Manzanares, Sandra ASPB
Martín Sánchez, Vicente ASPB
Martín Valle, Silvia ASPB Application of New Technologies to Community Health Worker’s and
Millet Vilanova, Joan Pau ASPB Tuberculosis Control Notifiable Disease Control
Monedero Recuero, ff International diffusion of the new tech- ff The experiment regarding the commu-
Ignacio ASPB nologies. Google Analytics offers a highly nity health worker’s role in the control of
Moreno Martínez, effective system for analysing website vis- notifiable diseases has been presented at
Antonio ASPB its that enables us to profile visitors (2007, tuberculosis and primary care conferences
Orcau Palau, Àngels ASPB 13,429 visitors, 21% from Latin America). and workshops and in journals (Emerging
Pañella Noguera, Helena ASPB Infectious Diseases; Ethnicity and Health).
ff Production of scientific knowledge of rele- Results of a comparative study have re-
Rius Gibert, Cristina ASPB vance on the control, diagnosis, treatment cently been presented as a thesis in ful-
Rodrigo Sanz, and prevention of tuberculosis (key role in filment of the master in public health of
María Teresa ASPB Spain and South America). Pompeu Fabra University and the Auton-
omous University of Barcelona (an article
Clinical Trials for Tuberculosis Prevention is undergoing final review before publica-
and Treatment tion).
ff The inclusion of community health work-
ff Our centre, which is the only such centre ers in tuberculosis programme teams has
in Europe, is part of a network of interna- led to the creation of new tuberculosis
tional centres (in Canada, Brazil, South Af- consensus protocols. Institute of Health
rica and Uganda) associated with the Tu- studies are under development with spon-
berculosis Trials Consortium of the CDCs, sorship from the authorities and we are
promoting international involvement in participating as instructors and students
laying the therapeutic and strategic bases in the first intercultural mediation course
for the treatment of tuberculosis and tu- in the healthcare arena. The concept of
bercular infection. Preliminary results have the community health worker has been
recently been presented at the ICAAC and included in the framework Tuberculosis
other important international conferences Prevention and Control Plan for Spain.
e.g., the American Thoracic Society (the ar- The short- to medium-term objective is
ticle with definitive study data is pending for community health workers to continue
publication). A major research line aims working with us and for these profession-
to fix the bases for shortening treatment als to be included in other public health
times for tubercular infection and, by ex- areas.
tension, ensure compliance and control
over the disease.
Challenges
ff Prevent sexually transmitted infections ff Improve detection and research into

and other transmissible diseases. causes of hepatitis C.
ff Evaluate HIV screening programmes in ff Improve detection and control measures
gay saunas. of outbreaks.

External Collaborations ff Jacques C., García de Olalla P., Diez E., Martins, Cayla
J.A. ¿Cómo se explican las prácticas sexuales de ries-
Collaborations
ff CDC. go? Estudio cualitativo en un grupo de hombres que

tienen sexo con hombres. XVII Congreso Nacional so-
Awards
ff CASCADE.
bre el Sida e Infecciones de Transmisión Sexual. Best
ff GEMES. oral communication. San Sebastián, 6-8 May 2015.
ff SANCO.
ff COHERE.
ff Joan Artur Caylà Buqueras. Cribado de las enfermedades transmisibles en población inmigrante de un barrio con bajo nivel socio-
Grants
Active
económico: comparación de dos estrategias. PI12/02573. Instituto de Salud Carlos III. Duration: 2013-2016. €43,500.
ff Joan Artur Caylà Buqueras. Convocatòria d’intensificació 2015.

Awarded
in 2015
IR15-INT3,.Institut de Recerca de l’Hospital de la Santa Creu i

Grants
Sant Pau. Duration: 2015-2016. €30,000.

*TIF: 59.2640 **MIF: 2.3706

Arias-de la Torre J., Artazcoz L., Molina A.J., study. (2015) SORT-STAT OPER RES T, 39 (2), Dominguez A., Godoy P., Toledo D., Sol-
Fernandez-Villa T., Martin V., Inequalities in 281-308. devila N., Garcia-Cenoz M., Farrus G., Crespo
mental health in the working population of IF: 0.4140 I., Cayla J.A., Sala M.R., Camps N., Barrabeig
Spain: A National Health Survey-based Crespo I., Broner S., Soldevila N., Martinez A., I., Alvarez J., Importance of enhanced sur-
study. (2015) GAC SANIT. Godoy P., Sala-Farre M.-R., Company M., Rius veillance for prevention of pertussis in chil-
IF: 1.5090 C., Dominguez A., Characteristics of pertus- dren. (2015) PEDIATR INFECT DIS J, 34 (7),
Besoain F., Perez-Navarro A., Cayla J.A., Avino sis outbreaks in Catalonia, Spain, 1997 to 729-733.
C.J., de Olalla P.G., Prevention of sexually 2010. (2015) HUM VACC IMMUNOTHER, 11 IF: 2.5870
transmitted infections using mobile devices (1), 231-235. Efsen A.M.W., Schultze A., Post F.A., Pan-
and ubiquitous computing. (2015) INT J IF: 2.1460 teleev A., Furrer H., Miller R.F., Losso M.H.,
HEALTH GEOGR, 14 (1). Crespo I., Toledo D., Soldevila N., Jordan I., Toibaro J., Skrahin A., Miro J.M., Cayla J.A.,
IF: 2.2700 Solano R., Castilla J., Cayla J.A., Godoy P., Girardi E., Bruyand M., Obel N., Podlekareva
Blanquer R., Rodrigo T., Casals M., Ruiz Man- Munoz-Almagro C., Dominguez A., Hozbor D.N., Lundgren J.D., Mocroft A., Kirk O., Major
zano J., Garcia-Garcia J.M., Calpe J.L., Valen- D.F., Characteristics of hospitalized cases of challenges in clinical management of TB/HIV
cia E., Pascual T., Mir I., Jimenez M.T., Canas F., pertussis in Catalonia and Navarra, two re- coinfected patients in Eastern Europe com-
Vidal R., Penas A., Cayla J.A., Resistance to gions in the North of Spain. (2015) PLOS pared with Western Europe and Latin Amer-
First-Line Antituberculosis Drugs in Spain, ONE, 10 (10). ica. (2015) PLOS ONE, 10 (12).
2010-2011. RETUBES Study. (2015) ARCH IF: 3.0570 IF: 3.0570
BRONCONEUMOL, 51 (1), 24-30. Culqui D.R., Garcia-De-Olalla-Rizo P., Al- Garriga C., Garcia de Olalla P., Miro J.M.,
IF: 1.7710 va-Chavez K.P., Lafuente S., Rius C., De Simon Ocana I., Knobel H., Barbera M.J., Humet V.,
Carnicer-Pont D., Barbera-Gracia M.J., Fer- M., Sabater S., Cayla J.A., Analysis of the epi- Domingo P., Gatell J.M., Ribera E., Gurgui M.,
nandez-Davila P., Garcia de Olalla P., Munoz demiological pattern of Shigellosis in Barce- Marco A., Cayla J.A., Gil S., Masdeu E., Simon
R., Jacques-Avino C., Saladie-Marti M.P., lona between 1988 and 2012: Is it an emerg- P., Ros M., Clos R., Gorrindo P., Mateo M.G.,
Gosch-Elcoso M., Arellano Munoz E., Casab- ing sexually transmitted infection?. (2015) Gutierrez M.M., Falco V., Vall M., Armengol P.,
ona J., Use of new technologies to notify ENFERM INFEC MICR CL, 33 (6), 379-384. Aranda M., Carbonell T., Manzardo C., Garcia
possible contagion of sexually-transmitted IF: 1.5300 F., Blanco J.L., Martinez E., Mallolas J., Vitaloni
infections among men. (2015) GAC SANIT, M., Mortality, causes of death and associated
De Olalla P.G., Molas E., Barbera M.J., Martin factors relate to a large HIV population-based
29 (3), 190-197. S., Arellano E., Gosch M., Saladie P., Carbonell
IF: 1.5090 cohort. (2015) PLOS ONE, 10 (12).
T., Knobel H., Diez E., Cayla J.A., Effectiveness IF: 3.0570
Casals M., Langohr K., Carrasco J.L., Ronneg- of a pilot partner notification program for
ard L., Parameter estimation of poisson gen- new HIV cases in Barcelona, Spain. (2015) Godoy P., Broner S., Manzanares-Laya S.,
eralized linear mixed models based on three PLOS ONE, 10 (4). Martinez A., Parron I., Planas C., Sala-Farre
different statistical principles: A simulation IF: 3.0570 M.-R., Minguell S., de Olalla P.G., Jane M.,
Dominguez A., Outbreaks of hepatitis A as-

Transmissible Diseases
*TIF: 59.2640 **MIF: 2.3706
sociated with immigrants travelling to visit C., Karpov I., Vassilenko A., Skrahina E., Sk- Somoza M., Mila C., Penas A., Hidalgo C., Ca-
friends and relatives. (2015) J INFECTION. rahin A., Zalutskya A., Kondratenko O., Mit- sals M., Cayla J.A., alvarez F., Barron M., Ber-
IF: 4.3820 sura V., Bondarenko V., Suetnov O., Paduto mudez P., Bustamante A., Casals M., Casas F.,
Jacques Avino C., Garcia de Olalla P., Diez E., D., Dewit S., Payen M.C., Noscoi C., Kabeya K., Casas X., Cayla J.A., Delgado A.E., Garcia-
Martin S., Cayla J.A., Explanation of risky M.Wolff, Cortes C., Obel N., Kronborg G., Kirk Clemente M.M., Garcia-Garcia J.M., Garros
sexual behaviors in men who have sex with O., Iljna V., Kummik T., Bryand M., Dabis F., F.J., Gullon J.A., Hidalgo C., Jimenez G., Marin
men. (2015) GAC SANIT, 29 (4), 252-257. Bolokadze N., Lanchava N., Bablishvili N., M., Mila C., Morales-Garcia C., Moreno V.,
IF: 1.5090 Goginashvili L., Mikiashvili L., Mshvidobadze Munoz A., Penas A., Rodriguez J., Rodrigo T.,
K., Girardi E., Di Biagio A., Matteelli A., Apos- Somoza M., Valencia M.E., Villanueva M.A.,
Jarrin I., Pantazis N., Dalmau J., Phillips A.N., toli A., Barzoni S., Lapadula G., Purgatorio M., Factors associated with unreported tubercu-
Olson A., Mussini C., Boufassa F., Costagliola Carbonara S., Rozentale B., Zeltina I., Janush- losis cases in Spanish hospitals. (2015) BMC
D., Porter K., Blanco J., Del Amo J., Mar- kevich I., Caplinskas S., Kancauskienne Z., INFECT DIS, 15 (1).
tinez-Picado J., Chene G., Sabin C., Walker S., Caplinskienne I., Crabtree B., Pina A., Madero IF: 2.6900
Fisher M., Kelleher T., Cooper D., Finlayson R., J.S., Mosqueda J., Villanueva J.A., Grzeszczuk
Bloch M., Ramacciotti T., Gelgor L., Smith D., Moreno A., Manzanares-Laya S., Razquin E.,
A., Bura M., Garlicki A., Inglot M., Knysz B., Guix S., Dominguez A., De Simon M., Norovi-
Zangerle R., Gill J., Lutsar I., Dabis F., Thiebaut Kozlowska J., Loster J., Mularska E., Podlasin
R., Guiguet M., Vanhems P., Chaix M.-L., rus outbreaks in geriatric centers: Impor-
R., Thompson M., Wiercinska-Drapalo A., tance of an early detection. (2015) MED
Ghosn J., Meyer L., Hamouda O., Kucherer C., Duiculescu D., Tetradov S., Rakhmanova A.,
Bartmeyer B., Antoniadou A., Chrysos G., CLIN-BARCELONA, 144 (5), 204-206.
Yakovlev A., Panteleev A., Turkalova A., IF: 1.2670
Daikos G.L., Touloumi G., Katsarou O., Rezza Vlasova Y., Trotimora T., Borodulina E., Chu-
G., Dorrucci M., Monforte A.D., De Luca A., manova L., Mashkova Y., Miro J.M., Cayla J.A., Moreno-Martinez A., Casals M., Orcau A.,
Prins M., Geskus R., Van Der Helm J., Schuite- Moreno A., Millet J.P., Orcau A., Fina L., del Gorrindo P., Masdeu E., Cayla J.A., Factors
maker H., Sannes M., Brubakk O., Kran A.- associated with diabetes mellitus among
Bano L., Roldan L.L., Romero A., Martinez J.A.,

M.B., Rosinska M., Muga R., Tor J., De Olalla Manzardo C., Gonzalez J., Tudo G., Knobel H., adults with tuberculosis in a large European
P.G., Cayla J., Moreno S., Monge S., Del Ro- Sanchez F., Salvado M., Curran A., Tortola city, 2000-2013. (2015) INT J TUBERC LUNG
mero J., Perez-Hoyos S., Sonnerborg A., M.T., Pozamczer D., Saumoy M., Alcaide F., D, 19 (12), 1507-1512.
Bucher H.C., Gunthard H., Rickenbach M., Martinez-Lacasa X., Cuchi E., Sambeat M.A., IF: 2.1480
Malyuta R., Murphy G., Johnson A., Babiker Pomar V., Coll P., Miralles P., Moreno S., Iribar- Mozalevskis A., Manzanares-Laya S., Garcia
A., Pillay D., Morrison C., Salata R., Mugerwa ren J.A., Ibarguren M., Aldamiz T., Furrer H., De Olalla P., Moreno A., Jacques-Avino C.,
R., Chipato T., Amornkul P.N., Gilmour J., Ka- Rickenbach M., Sagette M., Post F.A., Miller Cayla J.A., Can we rely on the antiretroviral
mali A., Karita E., Burns F., Giaquinto C., R.F., Chapman A., Dockrell D., Wilkins E., treatment as the only means for human im-
Grarup J., Kirk O., Bailey H., Anne A.V., Pan- Cooke G., Ainsworth J., Macallen D., Dhar J., munodeficiency virus prevention? A Public
teleev A., Thorne C., Aboulker J.-P., Albert J., Vora N., Mullaney S., Kegg S., Kyselyova G., Health perspective. (2015) ENFERM INFEC
Asandi S., De Wit S., Reiss P., Gatell J., Karpov Major differences in organization and avail- MICR CL, 33 (9), e63-e68.
I., Ledergerber B., Lundgren J., Moller C., Ra- ability of health care and medicines for HIV/ IF: 1.5300
khmanova A., Rockstroh J., Sandhu M., TB coinfected patients across Europe. (2015)
Dedes N., Fenton K., Pizzuti D., Vitoria M., Reyes-Uruena J.M., Garcia De Olalla P., Vall-
HIV MED, 16 (9), 544-552. Mayans M., Arando M., Caballero E., Cayla
Faggion S., Fradette L., Frost R., Cartier A., IF: 3.3410
Raben D., Schwimmer C., Scott M., Does J.A., Lymphogranuloma venereum in Barce-
rapid HIV disease progression prior to com- Marco A., Anton J.J., Trujols J., Saiz de la Hoya lona, 2007-2012: The role of seroadaptation
bination antiretroviral therapy hinder opti- P., de Juan J., Faraco I., Cayla J.A., Personality in men who have sex with men. (2015) EPI-
mal CD4 + T-cell recovery once HIV-1 sup- disorders do not affect treatment outcomes DEMIOL INFECT, 143 (1), 184-188.
pression is achieved?. (2015) AIDS, 29 (17), for chronic HCV infection in Spanish prison- IF: 2.5150
2323-2333. ers: The Perseo study. (2015) BMC INFECT Reyes-Uruena J., Brugal M.T., Majo X., Do-
IF: 4.4070 DIS, 15 (1). mingo-Salvany A., Cayla J.A., Cross sectional
IF: 2.6900 study of factors associated to self-reported
Mansfeld M., Skrahina A., Shepherd L., Schul-
tze A., Panteleev A., Miller R., Miro J., Zeltina Marco A., Anton J.J., Saiz de la Hoya P., de blood-borne infections among drug users.
I., Tetradov S., Furrer H., Kirk O., Grzeszczuk Juan J., Faraco I., Cayla J.A., Trujols J., Person- (2015) BMC PUBLIC HEALTH.
A., Bolokadze N., Matteelli A., Post F., Lund- ality disorders among Spanish prisoners IF: 2.2090
gren J., Mocroft A., Efsen A., Podlekareva D., starting hepatitis C treatment: Prevalence Torner N., Solano R., Rius C., Dominguez A.,
Losso M.H., Toibaro J.J., Palmero D., Bartoletti and associated factors. (2015) PSYCHIAT RES, Implication of health care personnel in mea-
B.J., E.Warley, Gear O., Messina O.G., Michans 230 (3), 749-756. sles transmission. (2015) HUM VACC IMMU-
IF: 2.4660
M., Laplume H., David D., Marson C., Sca- NOTHER, 11 (1), 288-292.
pelatto F.P., Dalessandro D., Lupo S., Costilla Morales-Garcia C., Rodrigo T., Garcia-Clem- IF: 2.1460
Campero G., Herbst M., Remondegui C., Elias ente M.M., Munoz A., Bermudez P., Casas F.,


Health Inequalities
Coordinator
Borrell Thió, Carme ASPB
cborrell@aspb.cat
Members
Altimira Ávalos, Patricia ASPB
Artazcoz Lazcano, Lucía ASPB
Bartoll Roca, Xavier ASPB
Cortés Franch,
Immaculada ASPB
Díez David, Elia ASPB
Gotsens Miquel, Mercè ASPB
Mari Dell’Olmo, Marc ASPB
Palència Fernández, Laia ASPB
Pasarín Rua, Maria Isabel ASPB
ff In-depth health inequalities according to Social and Political Determinants of
social class in Spain and worldwide. Health and Their Impact on Policy
Pérez Albarracin, Glòria ASPB
Rodríguez Sanz, Maica ASPB ff Exploitation of information at the census Building and Interventions
Salvador Peral, Joaquín ASPB section level as the maximum disaggrega-
tion unit and at higher geographic aggre- ff Evidence of the macroeconomic deter-
of Research
Main Lines
gation levels such as the neighbourhood, minants of health inequalities between

town and region. countries.
ff The impact of the political context on the
Gender Inequalities in Health health of the population and the conclu-
sion that countries with better developed
ff Sexual division between productive and welfare states have better levels of health.
reproductive work (gender roles) and dif-
ferences in male and female identities as
the 2 main structural factors that generate
gender inequalities in health.
Health-Inequalities According to Social and Political Determinants of

Different Inequality Axes Health and Their Impact on Policy
Building and Interventions
ff Study of social determinants of health in
terms of social class and gender, with the ff Study the influence of policies on the
purpose of integrating these 2 axes and health of populations and on social in-
analysing inequalities among immigrants. equalities in health.
Challenges
ff Research into the impact of area of resi-

dence, especially smaller urbanized areas, Sex and Reproductive Inequalities in
on the health of the population. Health
Gender Inequalities in Health ff Establish a line of research to investigate

different aspects of sexual and reproduc-
ff Further explore the theoretical framework tive health (sexuality, contraception, preg-
and explanatory charts developed to nancy, birth, miscarriage, abortion, birth
guide comprehension of the gender de- rates, etc).
terminants that affect health.

ff Carme Borrell Thió. Evaluating the impact of structural policies on ff Carme Borrell Thió. Efectos de la crisis en la salud de la población y
health inequalities and their social determinants and fostering sus determinantes en España. PI13/00897. Instituto de Salud Car-
change. SOPHIE. Agència de Salut Pública de Barcelona. Duration: los III. Duration: 2014-2016. €58,564.
Grants
Active
2013-2016. €27,200.
ff Carme Borrell Thió. Evaluación de efectos en salud del programa
ff Gloria Pérez Albarracín. El efecto de la crisis económica en la salud “Treball als Barris”. RecerCaixa. Duration: 2015-2017. €78,359.69.
sexual y reproductiva y en las desigualdades sociales y económi-
cas en España y sus Comunidades Autónomas. PI13/02292. Insti-
*TIF: 98.5500 **MIF: 2.5269

Alvarez-Bruned L., Garcia-Continente X., social context and women’s empowerment. healthy immigrant effect in times of eco-
Gotsens M., Perez A., Perez G., Trends in In- (2015) EUR J PUBLIC HEALTH, 25 (4), 698-705. nomic crisis. (2015) EUR J PUBLIC HEALTH, 25
equalities in the Use of Condom by Urban IF: 2.7510 (6), 923-929.
Teenagers in Spain. (2015) J URBAN HEALTH, Cayuela A., Malmusi D., Lopez-Jacob M.J., IF: 2.7510
92 (6), 1065-1080. Gotsens M., Ronda E., The Impact of Educa- Hollmann M., Borrell C., Garin O., Fernandez
IF: 2.0460 tion and Socioeconomic and Occupational E., Alonso J., Factors influencing publication
Arias-de la Torre J., Artazcoz L., Molina A.J., Conditions on Self-Perceived and Mental of scientific articles derived from masters
Fernandez-Villa T., Martin V., Inequalities in Health Inequalities Among Immigrants and theses in public health. (2015) INT J PUBLIC
mental health in the working population of Native Workers in Spain. (2015) J IMMIGR HEALTH, 60 (4), 495-504.
Spain: A National Health Survey-based MINOR HEALT, 17 (6), 1906-1910. IF: 2.7540
study. (2015) GAC SANIT. IF: 1.5790 Ikram U.Z., Malmusi D., Juel K., Rey G., Kunst
IF: 1.5090 Cornejo-Ovalle M., Paraje G., Vasquez-Lavin A.E., Association between integration poli-
Ariza C., Ortega-Rodriguez E., Sanchez-Mar- F., Perez G., Palencia L., Borrell C., Changes in cies and immigrants’ mortality: An explo-
tinez F., Valmayor S., Juarez O., Pasarin M.I., socioeconomic inequalities in the use of rative study across three european coun-
Childhood obesity prevention from a com- dental care following major healthcare re- tries. (2015) PLOS ONE, 10 (6).
munity view. (2015) ATEN PRIM, 47 (4), 246- form in Chile, 2004–2009. (2015) INT J ENV IF: 3.0570
255. RES PUB HE, 12 (3), 2823-2836. Jacques Avino C., Garcia de Olalla P., Diez E.,
IF: 1.0980 IF: 2.0350 Martin S., Cayla J.A., Explanation of risky
Bartoll X., Toffolutti V., Malmusi D., Palencia De Moortel D., Palencia L., Artazcoz L., Borrell sexual behaviors in men who have sex with
L., Borrell C., Suhrcke M., Health and health C., Vanroelen C., Neo-Marxian social class men. (2015) GAC SANIT, 29 (4), 252-257.
behaviours before and during the Great Re- inequalities in the mental well-being of em- IF: 1.5090
cession, overall and by socioeconomic sta- ployed men and women: The role of Euro- Larrea S., Palencia L., Perez G., Medical abor-
tus, using data from four repeated cross-sec- pean welfare regimes. (2015) SOC SCI MED, tion provided by telemedicine to women in
tional health surveys in Spain (2001-2012). 128, 188-200. Latin America: Complications and their
(2015) BMC PUBLIC HEALTH, 15 (1). IF: 2.8140 treatment. (2015) GAC SANIT, 29 (3), 198-
IF: 2.2090 Espelt A., Domingo-Salvany A., San- 204.
Borrell C., Dominguez-Berjon M.F., Alva- chez-Niubo A., Mari-Dell’Olmo M., Brugal IF: 1.5090
rez-Dardet C., Bermudez-Tamayo C., Godoy M.T., Estimating trends in the prevalence of Lopez-Ruiz M., Artazcoz L., Martinez J.M.,
P., Lopez M.J., Negrin M.T., Perez G., Perez- problematic cocaine use (1999-2008). (2015) Rojas M., Benavides F.G., Informal employ-
Farinos N., Ruano A., Cases C.V., Garcia A.M., GAC SANIT, 29 (5), 353-357. ment and health status in Central America
Gaceta Sanitaria in 2014. (2015) GAC SANIT, IF: 1.5090 Health behavior, health promotion and soci-
29 (2), 84-87. Garcia-Altes A., Pinilla J., Mari-Dell’Olmo M., ety. (2015) BMC PUBLIC HEALTH, 15 (1).
IF: 1.5090 Fernandez E., Lopez M.J., Economic impact IF: 2.2090
Borrell C., Vives-Cases C., Dominguez-Berjon of smoke-free legislation: Did the Spanish Mackenbach J.P., Kulhanova I., Bopp M., De-
M.F., Alvarez-Dardet C., Gender inequalities tobacco control law affect the economic boosere P., Eikemo T.A., Hoffmann R., Kulik
in science: Gaceta Sanitaria takes a step for- activity of bars and restaurants?. (2015) NIC- M.C., Leinsalu M., Martikainen P., Menvielle
ward. (2015) GAC SANIT, 29 (3), 161-163. OTINE TOB RES, 17 (11), 1397-1400. G., Regidor E., Wojtyniak B., Ostergren O.,
IF: 1.5090 IF: 3.8110 Lundberg O., Biggeri A., Borrell C., Brown L.,
Borrell C., Palencia L., Bartoll X., Ikram U., Garcia-Calvente M.M., Ruiz-Cantero M.T., del Costa, Esnaola S., Klotz J., Kovacs K., Lange A.,
Malmusi D., Perceived discrimination and Rio-Lozano M., Borrell C., Lopez-Sancho M.P., Rodriguez-Sanz M., Strand B.H., White C.,
health among immigrants in europe accord- Gender inequalities in research in public Variations in the relation between education
ing to national integration policies. (2015) health and epidemiology in Spain (2007- and cause-specific mortality in 19 European
INT J ENV RES PUB HE, 12 (9), 10687-10699. 2014). (2015) GAC SANIT, 29 (6), 404-411. populations: A test of the “fundamental
IF: 2.0350 IF: 1.5090 causes” theory of social inequalities in
Bosque-Prous M., Espelt A., Borrell C., Bartroli Gotsens M., Malmusi D., Villarroel N., Vives- health. (2015) SOC SCI MED, 127, 51-62.
M., Guitart A.M., Villalbi J.R., Brugal M.T., Gen- Cases C., Garcia-Subirats I., Hernando C., IF: 2.8140
der differences in hazardous drinking Borrell C., Health inequality between immi- Mackenbach J.P., Kulhanova I., Menvielle G.,
among middle-aged in Europe: The role of grants and natives in Spain: The loss of the Bopp M., Borrell C., Costa G., Deboosere P.,

Health Inequalities
*TIF: 98.5500 **MIF: 2.5269
Esnaola S., Kalediene R., Kovacs K., Leinsalu Mehdipanah R., Manzano A., Borrell C., Mal- INT J EQUITY HEALTH, 14 (1).
M., Martikainen P., Regidor E., Rodri- musi D., Rodriguez-Sanz M., Greenhalgh J., IF: 2.3780
guez-Sanz M., Strand B.H., Hoffmann R., Muntaner C., Pawson R., Exploring complex Olabarria M., Santamarina-Rubio E., Mari-
Eikemo T.A., Ostergren O., Lundberg O., causal pathways between urban renewal, Dell’Olmo M., Gotsens M., Novoa A.M., Bor-
White C., Brown L., Andersen O., Lange A., health and health inequality using a theory- rell C., Perez K., Head-on crashes on two-way
Trends in inequalities in premature mortal- driven realist approach. (2015) SOC SCI MED, interurban roads: A public health concern in
ity: A study of 3.2 million deaths in 13 Euro- 124, 266-274. road safety. (2015) GAC SANIT, 29, 16-23.
pean countries. (2015) J EPIDEMIOL COM- IF: 2.8140 IF: 1.5090
MUN H, 69 (3), 207-217. Merino-Salazar P., Artazcoz L., Campos-Serna
IF: 3.8650 Perez G., Marti-Pastor M., Gotsens M., Bartoll
J., Gimeno D., Benavides F.G., National work- X., Diez E., Borrell C., Health and health-re-
Mackenbach J.P., Kulhanova I., Bopp M., Bor- ing conditions surveys in Latin America: lated behaviors according to sexual attrac-
rell C., Deboosere P., Kovacs K., Looman Comparison of methodological characteris- tion and behavior. (2015) GAC SANIT, 29 (2),
C.W.N., Leinsalu M., Makela P., Martikainen P., tics. (2015) INT J OCCUP ENV HEAL, 21 (3), 135-138.
Menvielle G., Rodriguez-Sanz M., Rych- 266-274. IF: 1.5090
tarikova J., de Gelder R., Inequalities in Alco- IF: 1.5540
hol-Related Mortality in 17 European Coun- Perez G., Potential risks of the use of big data
Monge S., Ronda E., Pons-Vigues M., Vives in research in public health and epidemiol-
tries: A Retrospective Analysis of Mortality Cases C., Malmusi D., Gil-Gonzalez D., Meth-
Registers. (2015) PLOS MED, 12 (12). ogy. (2015) GAC SANIT.
odological limitations and recommenda- IF: 1.5090
IF: 13.5850
tions in publications on migrant population

Malmusi D., Immigrants’ health and health health in Spain. (2015) GAC SANIT, 29 (6), Ruano-Ravina A., Alvarez-Dardet C., Domin-
inequality by type of integration policies in 461-463. guez-Berjon M.F., Fernandez E., Garcia A.M.,
European countries. (2015) EUR J PUBLIC IF: 1.5090 Borrell C., Externalities and article citations:
HEALTH, 25 (2), 293-299. Experience of a national public health jour-
Morrison J., Pons-Vigues M., Diez E., Pasarin nal (Gaceta Sanitaria). (2015) ANN EPI-
IF: 2.7510 M.I., Salas-Nicas S., Borrell C., Perceptions DEMIOL.
Malmusi D., Vives A., Benach J., Borrell C., and beliefs of public policymakers in a IF: 2.3350
Gender inequalities in health: Exploring the Southern European city. (2015) INT J EQUITY
contribution of living conditions in the inter- HEALTH, 14 (1). Santana P., Costa C., Mari-Dell’Olmo M.,
section of social class. (2015) GLOBAL IF: 2.3780 Gotsens M., Borrell C., Mortality, material
HEALTH ACTION, 8 (1). deprivation and urbanization: Exploring the
Nolasco A., Moncho J., Quesada J.A., social patterns of a metropolitan area. (2015)
IF: 1.8960 Melchor I., Pereyra-Zamora P., Tamayo-Fon- INT J EQUITY HEALTH, 14 (1).
Mari-Dell’Olmo M., Gotsens M., Palencia L., seca N., Martinez-Beneito M.A., Zurriaga O., IF: 2.3780
Burstrom B., Corman D., Costa G., Deboosere Ballesta M., Daponte A., Gandarillas A.,
P., Diez E., Dominguez-Berjon F., Dzurova D., Dominguez-Berjon M.F., Mari-Dell’Olmo M., Vandenheede H., Deboosere P., Espelt A.,
Gandarillas A., Hoffmann R., Kovacs K., Mar- Gotsens M., Izco N., Moreno M.C., Saez M., Bopp M., Borrell C., Costa G., Eikemo T.A.,
tikainen P., Demaria M., Pikhart H., Rodri- Martos C., Sanchez-Villegas P., Borrell C., Gnavi R., Hoffmann R., Kulhanova I., Kulik M.,
guez-Sanz M., Saez M., Santana P., Schwierz Trends in socioeconomic inequalities in Leinsalu M., Martikainen P., Menvielle G.,
C., Tarkiainen L., Borrell C., Socioeconomic preventable mortality in urban areas of 33 Rodriguez-Sanz M., Rychtarikova J., Macken-
inequalities in cause-specific mortality in 15 Spanish cities, 1996-2007 (MEDEA project). bach J.P., Educational inequalities in diabe-
European cities. (2015) J EPIDEMIOL COM- (2015) INT J EQUITY HEALTH, 14 (1). tes mortality across Europe in the 2000s: the
MUN H, 69 (5), 432-441. IF: 2.3780 interaction with gender. (2015) INT J PUBLIC
IF: 3.8650 HEALTH, 60 (4), 401-410.
Novoa A.M., Ward J., Malmusi D., Diaz F., IF: 2.7540
Mari-Dell’Olmo M., Martinez-Beneito M.A., A Darnell M., Trilla C., Bosch J., Borrell C., How
multilevel regression model for geographi- substandard dwellings and housing afford-
cal studies in sets of non-adjacent cities. ability problems are associated with poor
(2015) PLOS ONE, 10 (8). health in a vulnerable population during the
IF: 3.0570 economic recession of the late 2000s. (2015)


Epidemiology of Addictions
Coordinator
Brugal Puig, Maria Teresa ASPB
tbrugal@aspb.cat
Members
Bartroli Checa, Montse ASPB
Bosque Prous, Marina ASPB
Bruguera Guitart,
Anna Maria ASPB
Espelt Fernández, Albert ASPB
Guitart García, Anna ASPB
Jiménez Dueñas, Miriam ASPB
Moreno España, José ASPB
Pérez Guitart, Aina ASPB
Sanz Asín, Pedro ASPB Epidemiology of Drug Consumption and ff Mortality and its determinants in cohorts
Patterns of Use with substance abuse disorders (alcohol,
Serrano Jordan, Jaime ASPB
heroin and cocaine).
Vázquez Vázquez, ff Estimating cocaine use incidence and
José María ASPB consumption patterns. ff Factors associated with acute health prob-
lems developing after cocaine and heroin
ff Estimating heroin incidence and con- use.
sumption patterns.
ff Social and health discrepancies between
ff Estimating the prevalence of problematic immigrants and native drug users.
cocaine, heroin and alcohol users.
Health Policies
Health Problems Associated with Drug Use
ff Social inequalities in the evaluation of re-
ff Quality of life and psychiatric comorbidity sults and adherence to treatment.
in cocaine users.
ff Infectious diseases related to drug use.
ff Service use in cocaine and alcohol users.
ff Brief motivational intervention programs
ff Factors associated with cocaine addict as a treatment alternative for teenage us-
and alcoholic retention in treatment pro- ers of psychoactive substances.
grammes.
ff Role of the workplace in drug consump-
ff Violent behaviour and aggressive atti- tion.
tudes in young cocaine consumers.
Epidemiology of Drug Consumption and ff Assess mortality and its determinants in

Patterns of Use cohorts of alcohol and cocaine-dependent
subjects.
ff Determine incidence and patterns of co-
caine use. ff Analyse factors associated with acute health
problems following cocaine use.
ff Determine incidence and patterns of her-
oin use. ff Analyse differential social and health deter-
minants among immigrant users of illegal
ff Determine prevalence of cocaine, heroin and drugs.
Challenges
alcohol use.
Health Policies
Health Problems Associated with Drug Use
ff Evaluate supervised drug consumption
ff Analyse aggressive and violent attitudes and rooms and other policies to reduce harm.
behaviour in young cocaine users.
ff Study social inequalities in evaluating results
ff Assess quality of life in users with psychiatric and adherence to treatment.
comorbidity.
ff Evaluate brief motivational intervention
ff Determine use of services among young her- programmes as an alternative to disciplinary
oin, cocaine and alcohol users. measures in teenage users of psychoactive
substances.
ff Analyse factors associated with retention in
treatment programmes for cocaine and alco-
hol addiction.


Collaborations
ff Evaluation of Public Health Policies and Programmes (PI: Carlos ff Several CIBERSAM and CIBERESP groups.
Ariza)
ff Health Inequalities (PI: Carme Borrell)
*TIF: 33.6290 **MIF: 2.2419

Bosque-Prous M., Espelt A., Borrell C., Bartroli overdose in a community cohort of young Screening for Voice Disorders in Older
M., Guitart A.M., Villalbi J.R., Brugal M.T., Gen- heroin users. (2015) EUR ADDICT RES, 21 (6), Adults(Rastreamento de Alterações Vocais
der differences in hazardous drinking 300-306. emIdosos-RAVI)-Part I: Validity Evidence
among middle-aged in Europe: The role of IF: 2.3670 BasedonTest Content and Response Pro-
social context and women’s empowerment. Espelt A., Domingo-Salvany A., San- cesses. (2015) J VOICE.
(2015) EUR J PUBLIC HEALTH, 25 (4), 698-705. chez-Niubo A., Mari-Dell’Olmo M., Brugal IF: 1.1130
IF: 2.7510 M.T., Estimating trends in the prevalence of Reyes-Uruena J., Brugal M.T., Majo X., Do-
Bosque-Prous M., Espelt A., Sordo L., Guitart problematic cocaine use (1999-2008). (2015) mingo-Salvany A., Cayla J.A., Cross sectional
A.M., Brugal M.T., Bravo M.J., Job loss, unem- GAC SANIT, 29 (5), 353-357. study of factors associated to self-reported
ployment and the incidence of hazardous IF: 1.5090 blood-borne infections among drug users.
drinking during the late 2000s recession in Guitart A.M., Espelt A., Castellano Y., Suelves (2015) BMC PUBLIC HEALTH.
Europe among adults aged 50-64 years. J.M., Villalbi J.R., Brugal M.T., Injury-Related IF: 2.2090
(2015) PLOS ONE, 10 (10). Mortality Over 12 Years in a Cohort of Pa- Sarasa-Renedo A., Sordo L., Pulido J., Guitart
IF: 3.0570 tients with Alcohol Use Disorders: Higher A., Gonzalez-Gonzalez R., Hoyos J., Bravo
Chahua M., Sanchez-Niubo A., Torrens M., Mortality Among Young People and Women. M.J., Barrio G., Effect of immigration back-
Sordo L., Bravo M.J., Brugal M.T., Domin- (2015) ALCOHOL CLIN EXP RES, 39 (7), 1158- ground and country-of-origin contextual
go-Salvany A., Quality of life in a community 1165. factors on adolescent substance use in
sample of young cocaine and/or heroin us- IF: 2.8290 Spain. (2015) DRUG ALCOHOL DEPEN, 153,
ers: the role of mental disorders. (2015) Perez A., Roque M., Domenech S., Mon- 124-134.
QUAL LIFE RES, 24 (9), 2129-2137. teserin R., Soriano N., Blancafort X., Bosom IF: 3.3490
IF: 2.4290 M., Vidal C., Petit M., Hortal N., Gil C., Espelt Vandenheede H., Deboosere P., Espelt A.,
de Araujo Pernambuco L., Espelt A., Balata A., Lopez M.J., Efficacy of memory training in Bopp M., Borrell C., Costa G., Eikemo T.A.,
P.M.M., de Lima K.C., Prevalence of voice healthy community-dwelling older people: Gnavi R., Hoffmann R., Kulhanova I., Kulik M.,
disorders in the elderly: a systematic review Study protocol for a randomized controlled Leinsalu M., Martikainen P., Menvielle G.,
of population-based studies. (2015) EUR trial. (2015) BMC GERIATR, 15 (1). Rodriguez-Sanz M., Rychtarikova J., Macken-
ARCH OTO-RHINO-L, 272 (10), 2601-2609. IF: 2.3710 bach J.P., Educational inequalities in diabe-
IF: 1.6270 Perez A., Roque M., Domenech S., Mon- tes mortality across Europe in the 2000s: the
teserin R., Soriano N., Blancafort X., Bosom interaction with gender. (2015) INT J PUBLIC
De Araujo Pernambuco L., Espelt A., Morais HEALTH, 60 (4), 401-410.
Costa E.B.D., de Lima K.C., Screening for M., Vidal C., Petit M., Hortal N., Gil C., Espelt
A., Lopez M.J., Efficacy of memory training in IF: 2.7540
Voice Disorders in Older Adults (Rastrea-
mento de Alterações Vocais em Idoso- healthy community-dwelling older people: Villalbi J.R., Bartroli M., Bosque-Prous M.,
s-RAVI)-Part II: Validity Evidence and Reliabil- Study protocol for a randomized controlled Guitart A.M., Serra-Batiste E., Casas C., Brugal
ity. (2015) J VOICE. trial Psychology, psychiatry and quality of M.T., Enforcing regulations on alcohol sales
IF: 1.1130 life. (2015) BMC GERIATR, 15 (1). and use as universal environmental preven-
IF: 2.3710 tion. (2015) ADICCIONES, 27 (4), 288-293.
Espelt A., Barrio G., Alamo-Junquera D., IF: 1.7800
Bravo M.J., Sarasa-Renedo A., Vallejo F., Pernambuco L.D.A., Espelt A., Magalhaes
Molist G., Brugal M.T., Lethality of opioid Junior H.V., Cavalcanti R.V.A., Lima K.C.D.,

Primary Care Research
Coordinator
Brotons Cuixart,
Carles EAP Sardenya
cbrotons@eapsardenya.cat
Members
Aguado Jódar,
Maria Alba EAP Sardenya
Agustí Roca, Berta EAP Sardenya
Balagué Galito,
Enriqueta EAP Sardenya
Blasi Codinach, Anna EAP Sardenya
Casasa Plana, Albert EAP Sardenya
Coderch Aris, Marta EAP Sardenya
Cardiovascular prevention in primary care Diabetes.
of Research
ff ff
Main Lines
Cuixart Costa, Lluís EAP Sardenya

settings. ff Paediatric immunization.
De la Figuera Von
ff Health promotion in primary care settings.
Wichmann, Mariano EAP Sardenya
ff Ageing.
Delgado Álvarez,
Beatriz EAP Sardenya ff Hypertension.
Galán Díez,
María Luisa EAP Sardenya
Gallego Francisco, ff Enlarge the research team by linking up with and health promotion in primary care set-
Rut EAP Sardenya
Challenges
other primary care centres associated with tings.

Gil Calvo, Joan Josep EAP Sardenya the ACEBA Family Medicine Teaching Unit. ff Encourage research into medical ethics in
Ichazo Tobella, ff Cooperate with other research teams in IIB family medicine training.
Begoña EAP Sardenya Sant Pau.
Martí Braso, Agnès EAP Sardenya ff Cooperate with other European institutions
Martínez Gil, Mireia EAP Sardenya in implementing projects on risk prevention
Monteserín Nadal,
Rosa EAP Sardenya
Moral Peláez, Irene EAP Sardenya
Muñoz Pena, Aser EAP Sardenya
Groups
Palasí Bargalló, ff FATE project (fall detection in the elderly):
Carme EAP Sardenya ff Clinical Epidemiology and Health Care Universitat Politècnica de Catalunya, Siste-
Collaborations
Pedro Pijoan, Services ma d’Emergències Mèdiques, TicSalut.

Anna Maria EAP Sardenya Project number: 297178, European Com-
ff Evaluation of Public Health Policies and mission, ICT-PSP. Duration: 2011-2015.
Peix Sambola, Programmes
Maria Amor EAP Sardenya ff Carles Brotons. Calibratge i discriminació
Puig Palma, Mireia EAP Sardenya
ff Ageing Institute del model SCORE (Systematic Coronary
Rayo Martínez, Risk Evaluation) per a països de baix risc i
de la nova equació de risc de la US Ameri-
Elisabet EAP Sardenya can College of Cardiology (ACC)/American
Reyes Reyes, Carles EAP Sardenya Heart Association. Fundació La Marató de
Sellarès Sallas, TV3.
Jaume EAP Sardenya
Serrano Pons,
Helena EAP Sardenya
Soteras Prat, Anna EAP Sardenya ff Carles Brotons Cuixart. Desarrollo de una ecuación de riesgo cardiovascular de por vida en
Grants
Active
Verdú Arnal, población laboral. PI14/01177. Instituto de Salud Carlos III. Duration: 2015-2017. €45,500.
Montserrat EAP Sardenya Note: Total amount granted to PI. It does not include indirect costs.
Vila Garcia, Judit EAP Sardenya
Zamora Mestre,
Silvia EAP Sardenya
ff Carles Brotons Cuixart, Avaluació del risc cardiovascular en la gen gran. Premi Mutuam
Awarded
Conviure 2015. Fundació Mutuam Conviure. Duration: 2015-2016. €6,000.

in 2015
Grants

ff Carles Brotons Cuixart, Irene Moral Peláez, Lluís Cuixart Costa, ff Albert Casasa Plana. Award for professional excellence . Col·legi
Awards
Mireia Puig Palma. Avaluació del risc cardiovascular en la gen Oficial de Metges de Barcelona.
gran. Premis de Recerca de la Fundació Mutuam Conviure 2015.
*TIF: 39.0710 **MIF: 3.0055

Benitez-Camps M., Vinyoles-Bargallo E., Re- Lobos Bejarano J.M., Brotons Cuixart C., knee osteoarthritis: A region-wide ecologi-
bagliato-Nadal O., Morros-Pedros R., Galve E., Royo-Bordonada M.A., Alegria Ez- cal study. (2015) OSTEOARTHR CARTILAGE,
Pera-Pujadas H., Dalfo-Baque A., Lopez- querra E., Armario P., Camafort Babkowski 23 (8), 1323-1329.
Pavon I., Roca-Sanchez C., Coma-Carbo R.M., M., Cordero Fort A., Maiques Galan A., Man- IF: 4.5350
De La Figuera Von Wichmann M., Men- tilla Morato T., Perez Perez A., Pedro-Botet J., Rizzi M.A., Ruiz D., Torres Bonafonte O.H.,
gual-Martinez L., Yuste-Marco C., Teixido-Co- Villar Alvarez F., Gonzalez-Juanatey J.R., Alquezar A., Herrera Mateo S., Pinera P., Puig
let M., Pepio i Vilaubi J.M., Ciurana-Tost R., Spanish Interdisciplinary Committee for Car- M., Benito S., Prognostic Value and Risk Fac-
Pou-Vila R., Vila-Coll M.A., Bordas-Julve J.M., diovascular Disease Prevention and the tors of Delirium in Emergency Patients With
Aragones-Fores R., Pelegrina-Rodriguez F.J., Spanish Society of Cardiology position Decompensated Heart Failure. (2015) J AM
Agudo-Ugena J., Blanco-Mata C., de la Igle- statement on dyslipidemia management. MED DIR ASSOC, 16 (9), 799.e1-799.e6.
sia Berrojalbiz J., Burgos-Alonso N., Go- Differences between the European and IF: 6.6160
mez-Fernandez M.C., Evaluation of the rela- American guidelines. (2015) REV ESP SALUD
tionship between effervescent paracetamol PUBLIC, 89 (1), 15-26. Roffi M., Patrono C., Collet J.-P., Mueller C.,
and blood pressure: Clinical trial. (2015) BMC IF: 0.6060 Valgimigli M., Andreotti F., Bax J.J., Borger
CARDIOVASC DISOR, 15 (1). M.A., Brotons C., Chew D.P., Gencer B., Hasen-
Perez A., Roque M., Domenech S., Mon- fuss G., Kjeldsen K., Lancellotti P., Land-
IF: 1.9160 teserin R., Soriano N., Blancafort X., Bosom messer U., Mehilli J., Mukherjee D., Storey
Brotons C., Benamouzig R., Filipiak K.J., Lim- M., Vidal C., Petit M., Hortal N., Gil C., Espelt R.F., Windecker S., Baumgartner H., Gaem-
mroth V., Borghi C., A Systematic Review of A., Lopez M.J., Efficacy of memory training in perli O., Achenbach S., Agewall S., Badimon
Aspirin in Primary Prevention: Is It Time for a healthy community-dwelling older people: L., Baigent C., Bueno H., Bugiardini R., Carerj
New Approach?. (2015) AM J CARDIOVASC Study protocol for a randomized controlled S., Casselman F., Cuisset T., Erol C., Fitzsimons
DRUG, 15 (2), 113-133. trial. (2015) BMC GERIATR, 15 (1). D., Halle M., Hamm C., Hildick-Smith D.,
IF: 2.2330 IF: 2.3710 Huber K., Iliodromitis E., James S., Lewis B.S.,
Carratala-Munuera C., Gil-Guillen V.F., Oroz- Perez A., Roque M., Domenech S., Mon- Lip G.Y.H., Piepoli M.F., Richter D., Rosemann
co-Beltran D., Maiques-Galan A., Lago-Deibe teserin R., Soriano N., Blancafort X., Bosom T., Sechtem U., Steg P.G., Vrints C., Zamorano
F., Lobos-Bejarano J.M., Brotons-Cuixart C., M., Vidal C., Petit M., Hortal N., Gil C., Espelt J.L., Guía ESC 2015 sobre el tratamiento de
Martin-Rioboo E., Alvarez-Guisasola F., A., Lopez M.J., Efficacy of memory training in los síndromes coronarios agudos en
Lopez-Pineda A., Barriers to improved dys- healthy community-dwelling older people: pacientes sin elevación persistente del seg-
lipidemia control: Delphi survey of a multi- Study protocol for a randomized controlled mento ST: Grupo de Trabajo de la Sociedad
disciplinary panel. (2015) FAM PRACT, 32 (6), trial Psychology, psychiatry and quality of Europea de Cardiología (ESC) para el tratam-
672-680. life. (2015) BMC GERIATR, 15 (1). iento de los síndromes coronarios agudos
IF: 2.0220 IF: 2.3710 en pacientes sin elevación persistente del
Coll-Planas L., del Valle Gomez G., Bonilla P., Reyes C., Garcia-Gil M., Elorza J.M., Fina-Aviles segmento ST. (2015) REV ESP CARDIOL, 68
Masat T., Puig T., Monteserin R., Promoting F., Mendez-Boo L., Hermosilla E., Coma E., (12), 1125e1-1125e64.
social capital to alleviate loneliness and im- Carbonell C., Medina-Peralta M., Ramos R., IF: 4.5960
prove health among older people in Spain. Bolibar B., Diez-Perez A., Prieto-Alhambra D., Vinyoles E., Soldevila N., Torras J., Olona N.,
(2015) HEALTH SOC CARE COMM. Socioeconomic status and its association de la Figuera M., Prognostic value of non-
IF: 1.5570 with the risk of developing hip fractures: A -specific ST-T changes and left ventricular
Gabriel R., Brotons C., Tormo M.J., Segura A., region-wide ecological study. (2015) BONE, hypertrophy electrocardiographic criteria in
Rigo F., Elosua R., Carbayo J.A., Gavrila D., 73, 127-131. hypertensive patients: 16-year follow-up re-
Moral I., Tuomilehto J., Muniz J., The ERICe- IF: 3.7360 sults from the MINACOR cohort. (2015) BMC
score: The new native cardiovascular score Reyes C., Garcia-Gil M., Elorza J.M., Mendez- CARDIOVASC DISOR.
for the low-risk and aged Mediterranean Boo L., Hermosilla E., Javaid M.K., Cooper C., IF: 1.9160
population of Spain. (2015) REV ESP CAR- Diez-Perez A., Arden N.K., Bolibar B., Ramos
DIOL, 68 (3), 205-215. R., Prieto-Alhambra D., Socio-economic sta-
IF: 4.5960 tus and the risk of developing hand, hip or

AREA T2
Molecular, Genomi
Kinetic-Dynamic Ba
and their Treatmen
210 Genomics of Complex Diseases
212 Molecular Bases of Disease
214 Pharmacokinetic/Pharmacodynamic Modelling and Simulation
216 Generation of Advanced Therapy Medicines

ic, Cellular and
ases for Diseases
nt

AREA T2 · Molecular, Genomic, Cellular and Kinetic-Dynamic
210
Bases for Diseases and their Treatment
Genomics of Complex Diseases
Coordinator
Soria Fernández, José Manuel IR
jsoria@santpau.cat
Members
Brunel, Helena IR
Cárdenas Yebra, Antonio IR
Gavidia Bovadilla,
Giovana Elisabeth IR
López Moreno, Sonia IR
Martín Fernández, Laura IR
Martínez Perez, Ángel IR
Pérez Calleja, Raquel IR
Ziyatdinov, Andrey IR
Genetic Epidemiology and ff Modelling Individuals Risk of Thrombosis
Bioinformatics in Oncology (MIRTO, ONCOTHROMB).
ff Algorithms to risk assessment.

Epigenomics
of Research
Main Lines
Genomics of Complex Diseases ff miRNAs as a novel biomarkers in throm-

boembolic diseases.
ff Genetic analysis of idiopathic throm-
bophilia (GAIT).
Pharmacogenomics
ff Genetic analysis of osteoporosis (GAO).
ff Markers of genetic susceptibility and phar-
ff Genetics of chronic venous insufficiency. macogenomics of cardiovascular diseases.
ff Genetics of abdominal aortic aneurysms
(TAGA).
ff Consolidate the epigenomic, genetic ep- ff Coordinate an international cardiovascu-

Challenges
idemiology and bioinformatics research lar genomic project.

lines.
ff Continue the current agreements with
ff Increase human and material resources to biopharmaceutical companies and get
achieve the goals defined for the different new ones.
projects in which we are involved.

Groups
ff Clinical Oncology Department, Hospital
ff Thrombosis and Haemostasis: Projects: Gregorio Marañón, Madrid. Project Onco-
GAIT, MIRTO, RETROVE. thomb.
ff Multiorgan Damage – Internal Medicine: ff Centre de Recerca en Enginyeria Biomèdi-
Project GAO. ca, Universitat Politècnica de Catalunya,
Collaborations
Barcelona. Project SUMMIT.

ff Angiology, Vascular Biology and Inflam-
mation: Projects TAGA and GAIT. ff Laboratory Haematolgy, Hospital Timone
Marseille, France. Project GAIT.
ff Inflammation and Vascular Remodelling:
Project TAGA. ff Department of Genetic, University of Ge-
nève, Switzerland. Project GAIT.
ff Metabolic Bases of Cardiovascular Risk:
Project GAIT. ff Department of Cardiology, Karolinska In-
stitut, Sweden. Project GAIT.
ff Haematological Diagnosis: Project GAIT.
ff INSERN UMRS 937, Université Pierre et Ma-
rie Curie, Paris. Project GAIT.
ff Haematology Department, Karolinska
Hospital, Sweden. Project VEREMA.

211
ff Laura Martín Fernández. Contracte FIS Pre-Doc Formació. Tromboembólica Venosa. PI14/00582. Instituto de Salud Carlos III.
FI12/00322. Instituto de Salud Carlos III. Duration: 2012-2016. Duration: 2015-2017. €111,500.
Grants
Active
€85,200. Note: Total amount granted to PI. It does not include indirect costs.
ff José Manuel Soria Fernández. Identificación de Mecanismos de
Regulación de la Expresión Génica (microRNAs) en la Enfermedad
ff José Manuel Soria Fernández. Proyecto Oncothromb Estimación del Riesgo Individual de Enfermedad Tromboembólica en Pacientes
Awarded
con Cáncer. IR15-P1. Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau. Duration: 2015-2016. €33,000.
in 2015
Grants
ff José Manuel Soria Fernández. Modeling the Individual Risk of Thrombosis in Oncology (MIRTO). ESC Medical Research 2015. €268,253.
*TIF: 63.2430 **MIF: 6.6243

Arribas J.R., et al., Dual treatment with tance to HIV-1 infection. (2015) GENES IM- Perez-Molina J.A., et al., Dual treatment with
lopinavir-ritonavir plus lamivudine versus MUN, 16 (2), 134-141. atazanavir-ritonavir plus lamivudine versus
triple treatment with lopinavir-ritonavir plus IF: 2.4720 triple treatment with atazanavir-ritonavir
lamivudine or emtricitabine and a second Olson N.C., Butenas S., Lange L.A., Lange plus two nucleos(t)ides in virologically sta-
nucleos(t)ide reverse transcriptase inhibitor E.M., Cushman M., Jenny N.S., Walston J., ble patients with HIV-1 (SALT): 48 week re-
for maintenance of HIV-1 viral suppression Souto J.C., Soria J.M., Chauhan G., Debette S., sults from a randomised, open-label, non-in-
(OLE): A randomised, open-label, non-inferi- Longstreth W.T., Seshadri S., Reiner A.P., Tracy feriority trial. (2015) LANCET INFECT DIS, 15
ority trial. (2015) LANCET INFECT DIS, 15 (7), R.P., Coagulation factor XII genetic variation, (7), 775-784.
785-792. ex vivo thrombin generation, and stroke risk IF: 21.3720
IF: 21.3720 in the elderly: Results from the Cardiovascu- Pujol-Moix N., Vazquez-Santiago M., Morera
Frånberg M., Gertow K., Hamsten A.; PRO- lar Health Study. (2015) J THROMB HAE- A., Ziyatdinov A., Remacha A., Nomdedeu
CARDIS consortium, Lagergren J., Sennblad MOST, 13 (10), 1867-1877. J.F., Fontcuberta J., Soria J.M., Souto J.C., Ge-
B. Discovering Genetic Interactions in IF: 5.5650 netic determinants of Platelet Large-Cell

Large-Scale Association Studies by Stage- Pedrol E., Llibre J.M., Tasias M., Curran A., Ratio, Immature Platelet Fraction, and other
wise Likelihood RatioTests. (2015) PLOS Guardiola J.M., Deig E., Guelar A., Mar- platelet-related phenotypes. (2015)
GENET, 24, 11(9). tinez-Madrid O., Tikhomirova L., Ramirez R., THROMB RES, 136 (2), 361-366.
IF: 3.2340 Pedrol E., Tasias M., Ramirez R., Tikhomirova IF: 2.3200
Garcia-Dabrio M.C., Hoyos M., Brunet S., L., Ruiz S., Delegido A., Clotet B., Llibre J.M., Soler G., Bernal-Vicente A., Anton A.I., Torre-
Tormo M., Ribera J.-M., Esteve J., Gallardo D., Curran A., Guardiola J.M., Deig E., Guelar A., grosa J.M., Caparros-Perez E., Sanchez-Ser-
Duarte R.F., de Llano M.P., Bargay J., Marti- Montero M.M., Garcia I., Cortes C., Javaloyas rano I., Martinez-Perez A., Sanchez-Vega B.,
Tutusaus J.M., Heras I., Garcia A., Salamero O., M., Force L., Barrufet P., Valero S., Massabeu Vicente V., Ferrer-Marin F., The JAK2 46/1
Aventin A., Lecrevisse Q., Orfao A., Sierra J., A., Chamarro E., Escrich C., Orti A., Gomez- haplotype does not predispose to CALR-mu-
Nomdedeu J.F., Complex measurements Sirvent J., Ocampo A., Rodriguez Arrondo F., tated myeloproliferative neoplasms. (2015)
may be required to establish the prognostic Martinez Madrid O., Marino A., Reparaz J., ANN HEMATOL, 94 (5), 789-794.
impact of immunophenotypic markers in Amiguet J.A., Crusells M.J., Orihuela F., Lopez IF: 3.0220
AML. (2015) AM J CLIN PATHOL, 144 (3), 484- Ruz M.A., Pasquau J., Marco A., Lopez S., Soria J.M., Lopez S., The genetics of throm-
492. Castro A., Santos J., Cuadrado J.M., Aguirre- bosis in cancer. (2015) MED CLIN-BARCE-
IF: 2.2780 bengoa K., Antela A., Oteo J.A., Blanco J.R., LONA, 144 (S1), 26-30.
Herrero R., Real L.M., Rivero-Juarez A., Pineda Gil D., Arazo P., Flores J., Outcome of neurop- IF: 1.2670
J.A., Camacho A., Macias J., Laplana M., Ko- sychiatric symptoms related to an antiretro-
nieczny P., Marquez F.J., Souto J.C., Soria J.M., viral drug following its substitution by nevi-
Saulle I., Lo Caputo S., Biasin M., Rivero A., rapine: The RELAX study. (2015) HIV MED, 16
Fibla J., Caruz A., Association of complement (10), 628-634.
receptor 2 polymorphisms with innate resis- IF: 3.3410

212
Molecular Bases of Disease
Coordinator
Fuentes Prior, Pablo IR
pfuentes@santpau.cat
Members
Anton López, Rosa IR
Dorca Arévalo, Jonatan IR
Nadal Rovira, Marta IR
Vencesla Garcia, Adoración IR
Thrombosis and Haemostasis Cancer and Innate Immune Responses

ff Structural and functional investigations of ff Structural and functional analysis of in-
blood coagulation factors, with emphasis nate immune responses mediated by toll-
on thrombin generation by the prothrom- like receptors (TLRs) and, in particular, the
binase complex and on thrombin interac- role of the major adaptor MyD88.
tions with both physiological substrates
(factor V, factor VIII and protease-activated
ff Analysis of mutations and SNPs that affect
receptors) and with exogenous inhibitors the TET2 gene and implications for acute
myeloid leukaemia.
from haematophagous animals (e.g. ano-

phelin from Anopheles mosquitoes). ff Structural and functional analysis of the
microsomal prostaglandin E synthase
Lipid Metabolism and Dyslipidemias (mPGES-1) as a target for the generation
of novel anti-inflammatory drugs with
ff Structural and functional analysis of mu- fewer side effects.
tant apoA-V proteins identified in individ-
uals with hypertriglyceridaemia.
Neurodegenerative Diseases
ff Analysis of mutations that affect the SMN
genes, whose deficiency results in spinal
muscular atrophy.
ff Structural and functional investigations of
proteins associated with inherited forms
of Parkinson disease (PINK1, DJ-1 and Par-
kin).
ff Consolidate and extend research within the HSCSP Research Institute and the rest of the
Challenges
IIB Sant Pau in a context of limited access to financial support. To this end, the group needs
to participate in at least one financed structure-and-function project in each of three ma-
jor research areas (cardiovascular diseases, neurodegenerative diseases and cancer and
innate immune responses).

213

Collaborations
ff Metabolic Bases of Cardiovascular Risk ff Dr. Pereira. Institute of Molecular and Cellular Biology, Porto, Por-
tugal.
ff Parkinson Disease and Movement Disorders
ff Dr. Paul E. Bock. Vanderbilt University, Nashville, Tennessee, USA.
ff Haematological Diagnosis
ff Dr. Ricardo Gutiérrez-Gallego. IMIM-UPF, Barcelona, Spain.
ff Genetic Diseases
ff Angiology, Vascular Biology and Inflammation
ff Pablo Fuentes Prior. Bases Estructurals de Processos Fisio- Spinal Muscular Atrophy. SMA Europe. Spinal Muscular Atrophy
patològics Fonamentals. 2014 SGR 1214. Agència de Gestió (SMA Europe). Duration: 2014-2016. €117,500.
Grants
Active
d’Ajuts Universitaris i de Recerca. Duration: 2014-2016. Note: Total amount granted to PI. It does not include indirect costs.
ff Pablo Fuentes Prior. Modulating SMN2 splicing with dual inhibi-
tors of Sam68 and hnRNP A1: A novel therapeutic approach for
ff Pablo Fuentes Prior. Estudio de las interacciones de la trombina con sustratos e inhibidores y su aplicación al diseño de nuevos pro- y
Awarded
anticoagulantes. SAF2014-57994-R. Ministerio de Economía y Competitividad. Duration: 2015-2017. €100,000.

in 2015
Grants
*TIF: 7.6330 **MIF: 3.8165

Costales P., Fuentes-Prior P., Castellano J., cle cells. (2015) J BIOL CHEM, 290 (24), de la Calle-Martin O., A novel gain-of-func-
Production
Revuelta-Lopez E., Corral-Rodriguez M.A., 14852-14865. tion STAT1 mutation resulting in basal phos-
Scientific
Nasarre L., Badimon L., Llorente-Cortes V., K IF: 4.2580 phorylation of STAT1 and increased distal
domain CR9 of low density lipoprotein (LDL) Martinez-Martinez L., Martinez-Saavedra IFN-γ-mediated responses in chronic mu-
receptor-related protein 1 (LRP1) is critical M.T., Fuentes-Prior P., Barnadas M., Rubiales cocutaneous candidiasis. (2015) MOL IMMU-
for aggregated LDL-induced foam cell for- M.V., Noda J., Badell I., Rodriguez-Gallego C., NOL, 68 (2), 597-605.
mation from human vascular smooth mus- IF: 3.3750

214
Pharmacokinetic/Pharmacodynamic
Modelling and Simulation
Coordinator
Valle Cano, Marta IR
mvallec@santpau.cat
Members
Estévez Gómez,
Javier Alejandro IR
ff Population pharmacokinetic analysis clinical practice, such as categorical re-

aimed at establishing the pharmacoki- sponses, survival, frequency and censored
netic characteristics of drugs and at dif- responses.
ferentiating and quantifying the degree of
intra- and inter- variability.
ff Simulation of clinical trials and therapeu-
of Research
Main Lines
tic dosage selection aimed at assisting

ff Pharmacokinetic/pharmacodynamic anal- with the design of clinical trials to help the
ysis of continuous response aimed at the development of new drugs (for pharma-
analysis of effects (in the presence or ab- ceutical companies) and at improving the
sence of drugs) where the variable being design of clinical trials (basic research and
evaluated changes values gradually. non-profit clinical studies) and to help in
applications of daily clinical practice.
ff Pharmacokinetic/pharmacodynamic
analysis of non-continuous response for
responses most frequently observed in
ff Obtain recognition as an emerging group. ff Generate sufficient financial resources to

Challenges
maintain and expand group staffing.

ff Maintain existing external cooperation
agreements. ff Communicate the group’s activities.
ff Establish new cooperation agreements
within the HSCSP RI.
Collaborations with other IIB Sant Pau -- Ensayo clínico para evaluar la eficacia,
Groups la seguridad y el impacto económico
de la reducción de la dosis de darunavir
ff Human Neuropsychopharmacology. en pacientes infectados por el VIH en
tratamiento con darunavir/ritonavir
ff Pharmacological Research in Humans. una vez al día. Hospital Germans Trias i
Pujol.
ff Pharmacy.
Collaborations
ff HIV and AIDS.

ff Pharmacy Service, Hospital Quiron, Mal-
lorca, Spain.
ff Epidemiology and Traumatology Services.
ff Department of Pharmacology, Liverpool
University, UK.
ff Anaesthesiology Service, Hospital del Mar,
ff Lluita Contra la SIDA Foundation, Germans Barcelona, Spain.
Trias i Pujol Hospital, Badalona, Spain.
-- Eficacia y seguridad de la vacuna HIV-
consv más romidepsina en la reducción
del reservorio y el control viral tras la
interrupción del cART. Análisis PK/PD
poblacional y estudio de predictores,
Hospital Germans Trias i Pujol.

215
ff Marta Valle Cano. Grup d’Investigació en Farmaco- ff Ramon Mangues Bafalluy. Targeted nanocongu-
Awarded in
logia Humana. 2014 SGR 828. Agència de Gestió gates for the selective elimination of stem cells
Grants
Grants
d’Ajuts Universitaris i de Recerca. Duration: 2014- in disseminated cancer. PIE15/00028. Instituto de
Active
2015
2016. Salud Carlos III. Duration: 01/01/2016-31/12/2018.
€600,000.
*TIF: 17.6470 **MIF: 8.8235

Maqueda A.E., Valle M., Addy P.H., Antoni- Riba J., Valle M., Sampedro F., Rodriguez-Pu-
joan R.M., Puntes M., Coimbra J., Ballester jadas A., Martinez-Horta S., Kulisevsky J., Ro-
M.R., Garrido M., Gonzalez M., Claramunt J., driguez-Fornells A., Telling true from false:
Production
Scientific
Barker S., Johnson M.W., Griffiths R.R., Riba J., Cannabis users show increased susceptibil-
Salvinorin-A induces intense dissociative ef- ity to false memories. (2015) MOL PSYCHI-
fects, blocking external sensory perception ATR, 20 (6), 772-777.
and modulating interoception and sense of IF: 13.3140
body ownership in humans. (2015) INT J
NEUROPSYCHOPH, 18 (12), 1-14.
IF: 4.3330

216
Generation of Advanced Therapy Medicines
Coordinator
Garcia López, Joan BST
joangarcia@bst.cat
Members
Bartolome Torcal, Davinia BST
Blanco García, Margarita BST
Caminal Bobet, Marta BST
Codinach Creus, Margarita BST
Coll Bonet, Ruth BST
Medina Marrero, Laura BST
Oliver Vila, Irene BST
Pla Calvet, Arnau BST
Pujals Fonts, Noèlia BST
Querol Giner, Sergio Luis BST
ff Bioprocessing for cell and tissue production.
of Research
Reyes Moreno, Blanca BST

Main Lines
ff Regeneration of locomotor systems.

Rodríguez Gómez, Luciano BST ff Stem cell therapy for the lymphohaematopoietic system.
Vives Armengol, Joaquim BST
ff Stem cell therapy for multiple sclerosis.
ff Create a section within the Blood and

Challenges
Tissue Bank (BST) with the structure of

a pharmaceutical enterprise, capable of
developing, trialling, registering and com-
mercializing advanced therapeutic drugs.
ff Màrius Aguirre Canyadell (PI, Hospital Vall

Collaborations
d’Hebron), Arnau Pla Calvet (BST). Tract-

ament de l’osteonecrosi del cap femoral
amb teràpia cel·lular avançada i biomate-
rials en un model experimental oví. Fun-
dació La Marató de TV3. 61/C/2012. Dura-
tion: 2013-2015.
*TIF: 2.6670 **MIF: 2.6670

Production
Milian E., Prats E., Cairo J.J., Godia F., Vives J.,
Scientific
BHRF1 exerts an antiapoptotic effect and cell

cycle arrest via Bcl-2 in murine hybridomas.
(2015) J BIOTECHNOL, 209, 58-67.
IF: 2.6670


Associated Groups
220 Emerging Processes in Prevalent Diseases
222 Radiophysics and Radioprotection
224 Paediatrics
226 Ophthalmology
228 Nuclear Medicine
230 Intensive Medicine
232 Pharmacy
234 Dermatology
238 Anaesthesiology
240 Plastic Surgery
242 Palliative Care

s
244 Andrology
246 Urology
250 Radiation Oncology
252 Locomotor System Research
254 Multiple Sclerosis and Epilepsy Research
256 Pain and Neurosciences
258 Nursing Care Research
260 Reproductive Health
262 Translational Molecular Oncology
264 Cardiac Surgery

220 ASSOCIATED GROUPS
Emerging Processes in Prevalent Diseases
Coordinator
Benito Vales, Salvador FGS
sbenito@santpau.cat
Members
Agra Montava, Iván FGS
Alquézar Arbe, Aitor FGS
Álvarez Albarran,
Maria Teresa FGS
Barcons Pujol, Miquel FGS
Blázquez Andion, Marta FGS
Caballero Flores, Francisco FGS
Ceresuela Lobera, Andrés FGS
Díaz Rodríguez, Iván FGS
Díez Díez, Verónica FGS Emerging Processes in Prevalent Cardiovascular System (Miquel Santaló)
Guardiola Tey, José María FGS Diseases
ff Acute coronary syndrome PI: Ivan Díaz.
Hernández Ontiveros, ff Study and analysis of processes frequently ff Acute coronary syndrome in women. PI:
Héctor FGS observed in emergency departments so Marta Blázquez.
Herrera Mateo, as to transfer the results to clinical practice
Sergio Antonio FGS and provide better care to patients. ff Ultrasensitive markers in acute coronary
Higa Sansone, syndrome. PI: Aitor Alquézar.
Jorge Leopoldo FGS Clinical Organization and Management ff Cardiac failure. Pl: Miguel Rizzi.
Lozano Polo, Laura (Mireia Puig and Josep Ris) ff Supraventricular arrhythmias. PI: Olga
Mateo Roca, Miriam FGS
Trejo.
Mauri Plana, Albert FGS ff Patient safety and emergency service
Montiel Dacosta, quality. PI: Maite Álvarez.

Community Disorders
Josep Antoni FGS ff Nosocomial infection. PI: Albert Mauri.
Moreno Pinillos, Rosa FGS ff Diabetes care in emergency departments.
ff Short-stay unit. PI: J.M. Guargiola.
Puig Campmany, Mireia FGS PI: Iván Agra.
Ris Romeu, Josep FGS ff Undergraduate teaching. PI: J.A. Montiel.
ff Infection in emergency departments. PI:
Santaló Bel, Miguel FGS J.M.Guardiola.
Serradell Arranz, Sonia FGS Organ Donation and Coordination
Trejo Gutiérrez, Olga Maria FGS
ff Sepsis syndrome. Pl: Ivan Díaz.
(Francisco Caballero and Jesús Leal)
Turbau Valls, Miquel FGS ff Elderly patients. Pl: Leopoldo Higa.
Respiratory System Disorders (Salvador ff Sexes transmitted disease. Pl: Montse
Benito) Seres.
ff Haematology disease. Pl: Marta Blázquez.
ff Acute Respiratory Failure. PI: A. Moliné.
ff Ventilatory pattern analysis in heart fail-
ure. PI: Sergio Herrera.
ff Pneumonia in the emergency depart-
ment. PI: Míriam Mateo.
ff Noninvasive ventilation. PI: Miquel Turbau.
ff Pulmonary embolism. PI: Laura Lozano.
ff Programa ACCORD (Achieving Compre-

hensive Coordination on Organ Donation
Collaborations
throughout the European Union). Prácti-

cas clínicas al final de la vida en pacientes
fallecidos con daño cerebral catastrófico
y donación de órganos – Accord España.
Organización Nacional de Trasplantes and
Comisión de Trasplantes del Consejo In-
terterritorial de Salud.

ASSOCIATED GROUPS 221
*TIF: 46.6280 **MIF: 2.5904

Aldamiz-Echevarria T., Gonzalez-Garcia J., Azzalini L., Sole E., Sans J., Vila M., Duran A., ment care for acute heart failure: The CALP-
Von Wichmann M.A., Crespo M., Lopez-Alde- Gil-Alonso D., Santalo M., Garcia-Moll X., ERICA study. (2015) EMERGENCIAS, 27 (3),
guer J., Quereda C., Tellez M.J., Galindo M.J., Sionis A., Feasibility and safety of an early 161-168.
Sanz J., Santos I., Guardiola J.M., Bellon J.M., discharge strategy after low-risk acute myo- IF: 2.9170
Montes M., Berenguer J., Association of cardial infarction treated with primary per- Miro O., A. Rizzi M., Herrero P., Jacob J., Mar-
baseline CD4+ cell count and HIV-RNA on cutaneous coronary intervention: The ED- tin-Sanchez F.J., Gil V., Alquezar A., Escoda R.,
sustained virologic response to interfer- AMI pilot trial. (2015) CARDIOLOGY, 130 (2), Llorens P., OBESICA study: relationship be-
on-ribavirin in HIV/HCV coinfected patients. 120-129. tween BMI and acute heart failure outcome.
(2015) ANN HEPATOL, 14 (4), 464-469. IF: 1.9940 (2015) EUR J EMERG MED.
IF: 1.8110 Dieterich D., Nelson M., Soriano V., Arasteh IF: 2.0260
Alquezar Arbe A., Mateo Roca M., de Diego K., Guardiola J.M., Rockstroh J.K., Bhagani S., Pedrol E., Llibre J.M., Tasias M., Curran A.,
Bustillos E., Agra Montava I., Bullet points of Laguno M., Tural C., Ingiliz P., Jain M.K., Stern Guardiola J.M., Deig E., Guelar A., Mar-
emergency attendances for cocaine-users in J.O., Manero M., Vinisko R., Kort J., tinez-Madrid O., Tikhomirova L., Ramirez R.,
Spain. (2015) MED CLIN-BARCELONA. STARTVerso4: faldaprevir and pegylated in- Pedrol E., Tasias M., Ramirez R., Tikhomirova
IF: 1.2670 terferon α-2a/ribavirin in individuals co-in- L., Ruiz S., Delegido A., Clotet B., Llibre J.M.,
Alquezar Arbe A., Trejo Gutierrez O., Turbau fected with hepatitis C virus genotype-1 and Curran A., Guardiola J.M., Deig E., Guelar A.,
Valls M., Barcons Pujol M., Comments on HIV. (2015) AIDS. Montero M.M., Garcia I., Cortes C., Javaloyas
predictors of the use of the early invasive IF: 4.4070 M., Force L., Barrufet P., Valero S., Massabeu
strategy in women with non-ST-elevation Dieterich D., Nelson M., Soriano V., Arasteh A., Chamarro E., Escrich C., Orti A., Gomez-
acute coronary syndrome. (2015) MED IN- K., Guardiola J.M., Rockstroh J.K., Bhagani S., Sirvent J., Ocampo A., Rodriguez Arrondo F.,
TENSIVA. Laguno M., Tural C., Ingiliz P., Jain M.K., Stern Martinez Madrid O., Marino A., Reparaz J.,
IF: 1.1930 J.O., Manero M., Vinisko R., Kort J., Faldaprevir Amiguet J.A., Crusells M.J., Orihuela F., Lopez
Alquezar Arbe A., Santalo Bel M., Sionis A., and pegylated interferon α-2a/ribavirin in Ruz M.A., Pasquau J., Marco A., Lopez S.,
Clinical interpretation of high sensitivity individuals co-infected with hepatitis C virus Castro A., Santos J., Cuadrado J.M., Aguirre-
troponin T. (2015) MED CLIN-BARCELONA, genotype-1 and HIV. (2015) AIDS, 29 (5), 571- bengoa K., Antela A., Oteo J.A., Blanco J.R.,
145 (6), 258-263. 581. Gil D., Arazo P., Flores J., Outcome of neurop-
IF: 1.2670 IF: 4.4070 sychiatric symptoms related to an antiretro-
Jacob J., Miro O., Herrero P., Martin-Sanchez viral drug following its substitution by nevi-
Alquezar Arbe A., Seres Roig M., Sansone L., rapine: The RELAX study. (2015) HIV MED, 16
Blazquez Andion M., Dificultades para la co- F.J., Gil V., Tost J., Aguirre A., Escoda R.,
Alquezar A., Andueza J.A., Llorens P., Predict- (10), 628-634.
laboración en investigación entre IF: 3.3410
cardiólogos y médicos de urgencies. (2015) ing short-term mortality in patients with
AN SIST SANIT NAVAR, 38 (1), 139-140. acute exacerbation of chronic heart failure: Rizzi M.A., Ruiz D., Torres Bonafonte O.H.,
IF: 0.7830 The EAHFE-3D scale. (2015) MED INTENSIVA. Alquezar A., Herrera Mateo S., Pinera P., Puig
IF: 1.1930 M., Benito S., Prognostic Value and Risk Fac-
AlquezarArbe A., Rizzi M., Martin-Marcuello tors of Delirium in Emergency Patients With
J., de Diego-Bustillos E., Comments about Masip M., Tuneu L., Pages N., Torras X., Gal-
lego A., Guardiola J.M., Faus M.J., Mangues Decompensated Heart Failure. (2015) J AM
the status of oral anticoagulant treatment in MED DIR ASSOC, 16 (9), 799.e1-799.e6.
patients with nonvalvular atrial fibrillation in M.A., Prevalence and detection of neuropsy-
chiatric adverse effects during hepatitis C IF: 6.6160
Spain. (2015) REV CLIN ESP.
IF: 0.7600 treatment. (2015) INT J CLIN PHARM-NET, 37 Rizzi M.A., Alquezar A., Marcuello J.M., On-
(6), 1143-1151. tiveros H.H., The Redin SCORE: Useful, but
Alquezar-Arbe A., Ordonez-Llanos J., Quo IF: 1.3390 not for all. (2015) EUR J HEART FAIL.
vadis, troponin. (2015) REV ESP CARDIOL, 68 IF: 5.1350
(6), 457-459. Miro O., Escoda R., Martin-Sanchez F.J., Her-
IF: 4.5960 rero P., Jacob J., Alquezar A., Aguirre A., Gil V.,
Andueza J.A., Llorens P., Aguirre A., Pedrag-
Arcentales A., Caminal P., Diaz I., Benito S., osa M.A., Alonso M.I., Sancho H., Ruiz F.,
Giraldo B.F., Classification of patients under- Gimenez A., Franco J.M., Pardo S., Mecina
going weaning from mechanical ventilation A.B., Tost J., Fabregat J., Epelde F., Sanchez S.,
using the coherence between heart rate Pinera P., Garate R.T., Alquezar A., Rizzi M.A.,
variability and respiratory flow signal. (2015) Cabello I., Richard F., Lucas J., Patients’ per-
PHYSIOL MEAS, 36 (7), 1439-1452. ception of quality of emergency depart-
IF: 1.5760
ff Puig M., Ris J., Benito S. Nuevas herramientas frente a la satu-

Publications
ración en los servicios de urgencias hospitalarios: gestión de la

estancia, toma de decisiones y flexibilidad operativa. New Tools
Other
for coping with hospital emergency department overcrowding:

managing throughput, decision making, and operational flexi-
bility. Emergencias 2015;27:425-426.

Radiophysics and Radioprotection
Coordinator
Ribas Morales, Montserrat FGS
mribas@santpau.cat
Members
Eudaldo Puell, Teresa FGS
Jordi Ollero, Olivia FGS
Jornet Sala, Nuria FGS
Latorre Musoll, Arthur FGS
Lizondo Gisbert, Maria FGS
Pallerol Pinzano, Rosa M. FGS
Ruiz Martínez, Agustín FGS
External beam radiotherapy Computed tomography dosimetry

ff Characterization of various in vivo dose ff Index dose assessment for multislice CT.
measurement detectors for radiation ther-
apy treatments with intensity modulation
of Research
Main Lines
(IMRT).
ff Validation of dose calculation algorithms
for external beam radiotherapy planning
systems.
ff Optimization of QA procedures for IMRT,
stereotactic body radiation therapy (SBRT)
and gating respiratory treatments.
ff Skin dose in IMRT and SBRT techniques.
External Collaborations dosimetry for external beam radiotherapy

use. Application of the Monte Carlo sim-
Grup d’estudis citogenètics i moleculars ulation method for radiation transport in
Collaborations
ff
dels efectes de les radiacions ionitzants i a clinical environment and especially for
del càncer. 2014 SGR 534. Montserrat Ribas, testing and improving treatment plan-
Pablo Carrasco, Teresa Eudaldo, Núria Jor- ning systems algorithms used in external
net, Artur Latorre, Agustín Ruiz. 2014-2016. beam radiation therapy.
ff Institut de Tècniques Energètiques de
Catalunya (INTE), UPC. Ongoing research
and knowledge transfer projects: devel-
opment of thermoluminiscence in vivo
ff Montserrat Ribas Morales. Estudis Citogenètics i Moleculars dels efectes de les radiacions
ionitzants i del càncer. 2014 SGR 534-2 C. Agència de Gestió d’Ajuts Universitaris i de Re-
cerca. Duration: 2014-2016.
Grants
Active
ff Monsterrat Ribas Morales. Impacto dosimétrico del movimiento respiratorio durante la

administración del tratamiento de IMRT dinámica. FIS Project 2012. PI12/00521. Duration:
01/01/13-31/12/15. €16,500.
ff Pablo Carrasco de Fez. Dosimetría en piel en técnicas de IMRT y SBRT. Proyectos Singulares
Awarded
2015, Asociación Española contra el Cáncer. Duration: 2015-2017. €25,500.

in 2015
Grants

*TIF: 14.6260 **MIF: 3.6565

Carrasco P., Jornet N., Jordi O., Lizondo M., Hernandez V., Abella R., Calvo J.F., Jura- Muren L.P., Jornet N., Georg D., Garcia R.,
Latorre-Musoll A., Eudaldo T., Ruiz A., Ribas do-Bruggemann D., Sancho I., Carrasco P., Thwaites D.I., Improving radiotherapy
M., Characterization of the Exradin W1 scin- Determination of the optimal tolerance for through medical physics developments.
Production
tillator for use in radiotherapy. (2015) MED MLC positioning in sliding window and (2015) RADIOTHER ONCOL, 117 (3), 403-406.
Scientific
PHYS, 42 (1), 297-304. VMAT techniques. (2015) MED PHYS, 42 (4), IF: 4.8170
IF: 2.4960 1911-1916.
Fiorino C., Muren L.P., Clark C.H., van Elmpt IF: 2.4960
W., Jornet N., Expanding the scientific role of
medical physics in radiotherapy: Time to act.
(2015) RADIOTHER ONCOL.
IF: 4.8170
Publications
ff P. Carrasco, N. Jornet, O. Jordi, M. Lizondo, A. Latorre-Musoll, T. Eu-

daldo, A. Ruiz, and M. Ribas. “Response to “Comment on ‘Charac-
Other
terization of the Exradin W1 scintillator for use in radiotherapy’ ”.

Med Phys 2015; 47, 4417-9.

Paediatrics
Coordinator
Carreras González, Eduard FGS
ecarrerasg@santpau.cat
Members
Álvarez Pérez, Roser FGS
Amat Giménez,
Maria Isabel FGS
Badell Serra, Isabel FGS
Betancourt Castellanos,
Jocelyn Cristina FGS
Carreras González, Gemma FGS
Coca Fernández, Elisabet FGS
Curbelo, Madai FGS
Febles González, Patricia FGS
ff Erythropoietin as an alternative to transfu- ff Creation of a Catalan diagnostic and clini-
sion in paediatrics. cal monitoring network for rare anaemias
Fraga Rodríguez,
due to major haemoglobinopathies.
of Research
Main Lines
Gloria Maria FGS ff Clinical application of peritoneal drainage

García Borau, María José FGS in the treatment of enterocolitis in infants. ff Minimal residual disease in risk assess-
Ginovart Galiana, Gemma FGS ment in the treatment of children with
ff Chronic functional constipation: treat- acute lymphoblastic leukaemia in the
López Bernal, Ester FGS ment with PEG. SHOP protocol (in collaboration with the
Moliner Calderón, HSCSP Haematology Department).
Elisenda FGS
Pardo Garcia, Núria FGS
Sisinni, Luisa FGS
Tirado, Mireia FGS
Torrent Español, ff Transplant haematopoietic progenitor ff Apply adaptive cell immunotherapy to
Montserrat FGS cells from alternative donors. tumours.
Valle, Josep M. FGS
ff Make pre-implant genetic diagnoses. ff Intervention in postasphyxia neuronal
Turon Viñas, Eulalia FGS damage in infants with asphyxia by apply-
Verd Vallespir, Sergi FGS ff Transplant haematopoietic progenitor
Challenges
ing therapeutic hypothermia (in the con-

cells in congenital immunodeficiencies. text of a Catalan network).
ff Transplant haematopoietic progenitor ff Polytraumatized patient care programme.
cells in congenital metabolic pathologies. PPT implementation code in HSCSP and in
ff Research congenital immunodeficiencies. CatSalut central register.
ff Research Fanconi anaemia (group recog- ff Implement a multidisciplinary institu-
nized by the UAB, Barcelona). tional massive transfusion protocol in the
HSCSP.
ff Clinical research group linked to Centro Actualización. Asociación Española de

de Investigación Biomédica en la Red de Nefrología Pediátrica. 2014.
Enfermedades Raras (CIBERER).
ff Project “Compromiso por la Calidad de
ff G. Fraga (collaborator). Estudio multicén- las Sociedades Médicas” (coordinated by
trico europeo (París, Roma, Barcelona): es- Ministerio de Sanidad, Servicios Sociales e
Collaborations
tudio de Asociación de Genoma Completo Igualdad, Sociedad Española de Medicina

(GWAS) para la identificación de factores Interna and GuíaSalud).
genéticos de riesgo en pacientes con sín-
drome nefrótico córtico-sensible (SNCS)/
ff E. Carreras, S. Brió, E. Moliner. Programa
síndrome nefrótico por lesiones mínimas VINCat. Resultats de la vigilància estan-
(SNLM). darditzada de la incidència de bacterièmia
relacionada amb catèter venós central
ff Workgroup of the Guía de Práctica Clíni- (BRCVC) a les Unitats de Cures Intensives
ca sobre Manejo del Paciente con Reflujo Pediàtriques (UCIP) i Neonatals (UCIN) dels
Vesicoureteral primario o esencial. Guía de Hospitals de Catalunya.
Práctica Clínica. Manejo del Paciente con
Reflujo Vesicoureteral primario o esencial.

*TIF: 29.1700 **MIF: 3.2411

Armangue T., Moris G., Cantarin-Extremera Bullich G., Trujillano D., Santin S., Ossowski S., Martinez-Martinez L., Martinez-Saavedra
V., Conde C.E., Rostasy K., Erro M.E., Portilla- Mendizabal S., Fraga G., Madrid A., Ariceta M.T., Fuentes-Prior P., Barnadas M., Rubiales
Cuenca J.C., Turon-Vinas E., Malaga I., Mu- G., Ballarin J., Torra R., Estivill X., Ars E., Tar- M.V., Noda J., Badell I., Rodriguez-Gallego C.,
noz-Cabello B., Torres-Torres C., Llufriu S., geted next-generation sequencing in ste- de la Calle-Martin O., A novel gain-of-func-
Gonzalez-Gutierrez-Solana L., Gonzalez G., roid-resistant nephrotic syndrome: Muta- tion STAT1 mutation resulting in basal phos-
Casado-Naranjo I., Rosenfeld M., Graus F., tions in multiple glomerular genes may phorylation of STAT1 and increased distal
Dalmau J., Autoimmune post-herpes sim- influence disease severity. (2015) EUR J HUM IFN-γ-mediated responses in chronic mu-
plex encephalitis of adults and teenagers. GENET, 23 (9), 1192-1199. cocutaneous candidiasis. (2015) MOL IMMU-
(2015) NEUROLOGY, 85 (20), 1736-1743. IF: 4.5800 NOL, 68 (2), 597-605.
IF: 8.1660 Castillo N., Garcia-Cadenas I., Garcia O., IF: 3.3750
Avila-Alvarez A., Carbajal R., Courtois E., Per- Barba P., Diaz-Heredia C., Martino R., Az- Tucunduva L., Volt F., Cunha R., Locatelli F.,
tega-Diaz S., Muniz-Garcia J., Anand K.J.S., queta C., Ferra C., Canals C., Elorza I., Olive T., Zecca M., Yesilipek A., Caniglia M., Gungor T.,
Viana H., Lopez Ortego P., Saenz Gonzalez P., Badell I., Sierra J., Duarte R., Valcarcel D., Aksoylar S., Fagioli F., Bertrand Y., Addari
Escrig R., Bargallo Ailagas E., Carles C., San Querol S., Few and nonsevere adverse infu- M.C., de la Fuente J., Winiarski J., Biondi A.,
Feliciano L., Belen Mateo A., Esteban Diez I., sion events using an automated method for Sengeloev H., Badell I., Mellgren K., de Here-
Gonzalez Crespo R., Gonzalez Carrasco E., De diluting and washing before unrelated sin- dia C.D., Sedlacek P., Vora A., Rocha V., Rug-
La Nogal Tagarro I., Elorza Fernandez M.D., gle cord blood transplantation. (2015) BIOL geri A., Gluckman E., Combined cord blood
Benito Guerra N., Luna Lagares S., Jimenez BLOOD MARROW TR, 21 (4), 682-687. and bone marrow transplantation from the
Parrilla P., Botet F., Ciurana A., Tarjuelo R., IF: 3.9800 same human leucocyte antigen-identical
Garcia Borau M.J., Ibanez N., Dianez Vega G., Flores-Gonzalez J.C., Jordan-Garcia O., sibling donor for children with malignant
Arriaga Redondo M., Herranz G., De La Fu- Turon-Vinas E., Montero-Valladares C., and non-malignant diseases. (2015) BRIT J
ente Iglesias V., Perez Ocon A., Santiago Tellez-Gonzalez C., Fernandez-Carrion F., HAEMATOL, 169 (1), 103-110.
Aguinaga S., Martin Parra B., Valero Cardona Garcia-Iniguez J.P., Onate-Vergara E., Rodri- IF: 5.4010
A., Sanchez-Redondo M.D., Arroyos Plana A., guez-Nunez A., Etiology, clinical presenta- Verd S., Porta R., Botet F., Gutierrez A., Ginov-
Galve Pradel Z., Clavero Montanes N., Ri- tion and outcome of severe viral acute child- art G., Barbero A.H., Ciurana A., Plata I.I.,
palda Crespo M.J., Nogales Juarez R., Euba hood encephalitis (ECOVE study). (2015) REV Hospital outcomes of extremely low birth
Lopez A., Fernandez De Retana S., Vergeli NEUROLOGIA, 61 (1), 7-13. weight infants after introduction of donor
M.R., Vidal R., Fernandez-Trisac J.L., Taboada IF: 0.6840 milk to supplement mother’s milk. (2015)
M., Montoro Exposito A., Camba Longueira BREASTFEED MED, 10 (3), 150-155.
F., Solis Sanchez G., Ventura Faci M.P., Mallen Hladun R., Badell I., Gonzalez M., Martinez
A.M., Sanchez De Toledo J., Olive M.T., Gon- IF: 1.4380
M., Crespo Suarez P., De Sola E., Tapia Colla-
dos C., De Las Cuevas I., Martin B., Couce Pico zalez M.E., Elorza I., Diaz De Heredia C., Sur-
M.L., Perez Munuzuri A., Quintans S., Melgar vival analysis of hematopoietic stem cell
Bonis A., Bodas E., Concheiro Guisan A., Pe- transplantation in children with primary im-
rez Costas B., Sedation and analgesia prac- munodeficiency in Spain. (2015) AN PEDI-
tices among Spanish neonatal intensive care ATR, 82 (2), 62-67.
units. (2015) AN PEDIATR, 83 (2), 75-84. IF: 0.7730
IF: 0.7730

Ophthalmology
Coordinator
Buil Calvo, José Antonio FGS
jbuil@santpau.cat
Members
Bassaganyas Vilarrasa,
María Francisca IR
Bruix Tudó, Anna Maria FGS
Cancino, Reinaldo FGS
Conte Visus, Maria Àngels FGS
Crespi Vilimelis, Jaume FGS
Del Campo Carrasco,
Zoraida FGS
Díaz Cascajosa, Jesús FGS
García Parés, Eva FGS
ff Optimization of the functional rehabili- ff Comparison of the effectiveness and safe-
tation of patients after cataract surgery ty of intravitreal injection of ranibizumab
Gil Arnal, Miguel Ángel FGS
using multifocal intraocular lens, and eval- vs laser photocoagulation in patients with
Luna Marine, María Sabina FGS
of Research
uation of vision quality in terms of param- visual alteration due to diabetic macular
Main Lines
Marieges Jubany, eters such as visual acuity, sensitivity to edema.

Maria Teresa FGS contrast and aberrometry.
Mingorance Moya, Ester IR ff Ocular repercussions of allogeneic med-
Rodríguez Álvarez, ullary transplants and evaluation of the
Fernando FGS different clinical manifestations and re-
Sánchez Espallargas, sponse to treatment in graft-versus-host
Fernando FGS disease.
Sánchez Jayussi, Saskia FGS
Solans Barri, Teresa FGS
Téllez Vázquez, Jesús Maria FGS
ff José Ignacio Vela Segarra. Estudio de las ff Jaume Crespi Vilimelis. New gens en-
Vela Segarra, José Ignacio FGS
lesiones paravasculares en el paciente alto volved in rare diseases in Ophthalmology.
Theses
miope mediante OCT de dominio espec- Directors: José Antonio Buil Calvo, José
tral. Directors: José Antonio Buil Calvo, García-Arumí. Date of defense: 4 Decem-
José García-Arumí. Date of defense: 19 ber 2015.
November 2015.
*TIF: 3.4270 **MIF: 3.4270

Vega F., Alba-Bueno F., Millan M.S., Varon C., Gil
Production
M.A., Buil J.A., Halo and through-focus perfor-

Scientific
mance of four diffractive multifocal intraocu-

lar lenses. (2015) INVEST OPHTH VIS SCI, 56 (6),
3967-3975.
IF: 3.4270


Nuclear Medicine
Coordinator
Carrió Gasset, Ignasi FGS
icarrio@santpau.cat
Members
Achury Murcia, Carlos FGS
Domènech Vilardell, Anna FGS
Duch Renom, Joan FGS
Estorch Cabrera,
Montserrat FGS
Fernández León,
Alejandro FGS
Flotats Giralt, Albert FGS
Jaller Vanegas,
Rafael Enrique FGS Oncology ff Cardiovascular functional studies.
Jiménez Kockar, ff New diagnostic methods based on the ff New methods for assessing cardiac inner-
Marcelo Fabián FGS identification and visualization of molec- vation.
Montes Graciano, Alberto FGS ular targets employing metabolic mech-
Moustafa, Abdel Hakim FGS anisms, receptor systems, hypoxia, angio- Functional Neuroimaging
of Research
Main Lines
genesis and apoptosis.

ff Development of new functional imaging
ff New applications for sentinel node detec- methods for evaluating neurodegenera-
tion and radioguided surgery models. tive diseases (Parkinson, Parkinson-Plus,
Alzheimer, MCI).
Cardiovascular Research ff Dopaminergic system studies using IBZM
ff New methods for non-invasive assess- and Datscan.
ment of ischaemic heart disease and heart
failure.
ff Introduce new technologies to clinical re- building on pre-clinical and clinical mo-
search (given that imaging techniques are lecular imaging models developed using
evolving very rapidly towards multimodal SPECT and conventional nuclear medicine
systems that integrate biological, molecu- technologies.
lar, anatomical and functional information
Challenges
in a single examination) and include these

PET Imaging Biomarkers
technologies, mainly PET/CT and PET/MR,
in the group and hospital’s research activ- ff Develop new PET radioactive tracers to be
ities. used as biomarkers in new imaging tec-
nologies building on our experience with
New Molecular Imaging Techniques radioactive tracers to view in vivo diag-
nostic and therapeutic targets.
ff Develop new hybrid molecular imaging
technologies, mainly PET/CT and PET/MR,
Collaborations with other IIB Sant Pau ff Cerebrovascular Diseases (Dr. Carrió,
Groups member).
Collaborations
ff Neuroradiology: research into neurologi- External Collaborations

cal and mental disorders and ageing (Dr.
Camacho, member). ff Zhejiang University, Hangzhou, China.
ff Oncology, Gynaecology, Surgery, Radiol- Molecular imaging (Prof. Hong Zhang,
ogy, Radiotherapy, Nuclear Medicine and Prof. Mei Tian).
Pathology: evaluation of the usefulness
of PET CT with 18F-FDG in the staging of
locally advanced breast carcinoma (Dr.
Duch, PI).

ff Ignasi Carrió Gasset. Desarrollo e implementación de nuevas tecnologías de imagen para valorar los tumores neuroendocrinos y las
Grants
Active
enfermedades neurodegenerativas (IMANEDS). BARNATRON (IMANEDS). Duration: 2013-2016. €41,666.67.

*TIF: 25.7900 **MIF: 2.5790

Arbizu J., Garcia-Ribas G., Carrio I., Garrasta- M.A., Canete J.D., De La Serna A.R., Magal- phoma. (2015) NUCL MED COMMUN, 36 (4),
chu P., Martinez-Lage P., Molinuevo J.L., Rec- lares B., Narvaez J., Gomez-Reino J.J., Gonza- 328-333.
ommendations for the use of PET imaging lez A., FCGR polymorphisms in the treat- IF: 1.4530
biomarkers in the diagnosis of neurodegen- ment of rheumatoid arthritis with Verberne H.J., Acampa W., Anagnostopoulos
erative conditions associated with demen- Fc-containing TNF inhibitors. (2015) PHAR- C., Ballinger J., Bengel F., De Bondt P., Bue-
tia: SEMNIM and SEN consensus. (2015) REV MACOGENOMICS, 16 (4), 333-345. chel R.R., Cuocolo A., van Eck-Smit B.L.F.,
ESP MED NUCL IMA, 34 (5), 303-313. IF: 2.7100 Flotats A., Hacker M., Hindorf C., Kaufmann
IF: 0.9830 Novelli S., Briones J., Flotats A., Sierra J., PET/ P.A., Lindner O., Ljungberg M., Lonsdale M.,
Carrio I., Chiti A., Why New Journals? The CT assessment of follicular lymphoma and Manrique A., Minarik D., Scholte A.J.H.A., Sl-
Growth of the EJNMMI Family. (2015) EUR J high grade B cell lymphoma - Good correla- art R.H.J.A., Tragardh E., de Wit T.C., Hesse B.,
NUCL MED MOL I, 42 (11), 1625-1626. tion with clinical and histological features at EANM procedural guidelines for radionu-
IF: 5.5370 diagnosis. (2015) ADV CLIN EXP MED, 24 (2), clide myocardial perfusion imaging with
Montes A., Perez-Pampin E., Navarro-Sarabia 325-330. SPECT and SPECT/CT: 2015 revision. (2015)
F., Moreira V., de la Serna A.R., Magallares B., IF: 1.1270 EUR J NUCL MED MOL I, 42 (12), 1929-1940.
Vasilopoulos Y., Sarafidou T., Fernandez-Ne- Sampedro F., Escalera S., Domenech A., Car- IF: 5.5370
bro A., Ordonez M.C., Narvaez J., Canete J.D., rio I., Automatic tumor volume segmenta- Zhang H., Tian M., Carrio I., Civelek A.C.,
Marquez A., Pascual-Salcedo D., Joven B., tion in whole-body PET/CT scans: A super- Fujibayashi Y., Molecular image-guided ther-
Carreira P., Moreno-Ramos M.J., Caliz R., Fer- vised learning approach. (2015) J MED IMAG anostic and personalized medicine 2014.
rer M.A., Garcia-Portales R., Blanco F.J., Magro HEALTH IN, 5 (2), 192-201. (2015) BIOMED RES INT, 2015.
C., Raya E., Valor L., Alegre-Sancho J.J., Balsa IF: 0.8770 IF: 2.1340
A., Martin J., Plant D., Isaacs J., Morgan A.W., Sampedro F., Domenech A., Escalera S., Car-
Barton A., Wilson A.G., Gomez-Reino J.J., rio I., Deriving global quantitative tumor re-
Gonzalez A., Rheumatoid arthritis response sponse parameters from 18F-FDG PET-CT
to treatment across IgG1 allotype - anti-TNF scans in patients with non-Hodgkin’s lym-
incompatibility: A case-only study. (2015) phoma. (2015) NUCL MED COMMUN.
ARTHRITIS RES THER, 17 (1), 1-12. IF: 1.4530
IF: 3.9790
Sampedro F., Domenech A., Escalera S., Car-
Montes A., Perez-Pampin E., Joven B., Car- rio I., Deriving global quantitative tumor re-
reira P., Fernandez-Nebro A., Del Carmen sponse parameters from 18F-FDG PET-CT
Ordonez M., Navarro-Sarabia F., Moreira V., scans in patients with non-Hodgkin’s lym-
Vasilopoulos Y., Sarafidou T., Caliz R., Ferrer

Intensive Medicine
Coordinator
Mancebo Cortés, Jordi FGS
jmancebo@santpau.cat
Members
Aguirre Bermeo,
Hernán Marcelo FGS
Betbesé Roig, Antoni Jordi FGS
Marruecos Sant, Luis FGS
Moran Chorro, Indalecio FGS
Quintana Tort-Martorell,
Elisabet FGS
Roche Campo, Ferran FGS
Roglan Piqueras, Antoni FGS
Sánchez Segura, Juan FGS Acute Respiratory Failure and Artificial Study of the Usefulness of New
Santos Rodríguez, Ventilation Biomarkers in Critically Ill Patients
José Alberto FGS ff Non-invasive ventilation. ff BNP in weaning from mechanical ventila-
Vera Artazcoz, Paula FGS tion.
Zapata Fenor, Luis FGS ff New ventilation modes: proportional-as-
sist ventilation and NAVA. ff Use of the NGAL protein in the renal prog-
nosis of critically ill patients.
ff Prone decubitus in acute respiratory dys-
function syndrome (ARDS). ff Strict control of blood glucose in critically
ill patients.
of Research
Main Lines
ff Artificial ventilation withdrawal.

ff Prophylaxis of acute gastric mucosal in-
ff Expert ventilation systems. jury in critically ill patients.
ff Sleep and artificial ventilation. ff Study of the haemodynamic effects of
ff Early and active mobilization of the critical different antipyretic drugs in critically ill
patient. patients.
ff Extracorporeal CO2 removal in ARDS pa- ff Influence of position change to supine
tients. decubitus position in intra-abdominal
pressure.
ff High-flow oxygen administration by nasal
cannula in postextubation phase.
ff Prevalence of drug interactions in critical
care unit.
Challenges
ff Consolidate clinical and physiological re- ff Create a stable and well-trained group of
search into ventilation in critically ill pa- researchers in this discipline.
tients through multicentre and multina-
tional networking.
Collaboration with other IIB Sant Pau

Collaborations
Groups
ff Pharmacological Research in Humans.

ff Gemma Robleda Font. Relevancia clínica del dolor asociado con ff Mercedes García. Neutrophil gelatinase-associated lipocalin
los procedimientos en el paciente crítico. Universitat de Barce- (NGAL) como marcador predictivo de fracaso renal agudo en pa-
Theses
lona. Directors: Josep Eladi Baños Díez, Jordi Mancebo Cortés. cientes postoperados de cirugía cardíaca. Universitat Autònoma
Date of defense: 21 December 2015. de Barcelona. Directors: Antoni-Jordi Betbesé Roig, Jorge Or-
dóñez Llanos, Alfonso Martínez López. Date of defense: 23 Sep-
tember 2015.
ff Beduneau G., Pham T., Schortgen F., Piquilloud L., Zogheib E., Jonas M., Grelon F., Runge I., Terzi N., Grange S., Barberet G., Guitard P.G.,
Awards
Frat J.P., Mancebo J., Mercat A., Ricard J.C.M., Brochard L. Nouvelle classification du sevrage de la ventilation mécanique : résultat de
l’étude multicentrique WIND (Weaning accordIng New Definition). Best communication. 43th International Congress of the SRLF 2015.
*TIF: 40.6590 **MIF: 4.5177

Aguirre-Bermeo H., Tomasa T., Navas A., G A., B T., M E., B M., M A., B O., C M., C D., J S., Mancebo J., Banos J.-E., A randomized con-
Xirgu J., Catalan-Ibars R.M., Morillas J., Cuar- R S., S M., H G., B C., Richecoeur J., G M., G R., trolled trial of fentanyl in the pre-emptive
tero M., Mancino J.M., Roglan A., Renal re- A L., M J., Early Hepatic Dysfunction Is Asso- treatment of pain associated with turning in
placement therapy in Intensive Care Units in ciated with a Worse Outcome in Patients patients under mechanical ventilation: RE-
Catalonia (Spain). (2015) MED INTENSIVA, 39 Presenting with Acute Respiratory Distress SEARCH protocol. (2015) J ADV NURS, 71 (2),
(5), 272-278. Syndrome: A Post-Hoc Analysis of the 441-450.
IF: 1.1930 ACURASYS and PROSEVA Studies. (2015) IF: 1.9170
Ballus J., Lopez-Delgado J.C., Sabater-Riera PLOS ONE, 10 (12). Robleda G., Roche-Campo F., Sanchez V.,
J., Perez-Fernandez X.L., Betbese A.J., Roncal IF: 3.0570 Gich I., Banos J.-E., Postoperative Discomfort
J.A., Surgical site infection in critically ill pa- Guerin C., Mancebo J., Prone positioning After Abdominal Surgery: An Observational
tients with secondary and tertiary perito- and neuromuscular blocking agents are part Study. (2015) J PERIANESTH NURS, 30 (4),
nitis: Epidemiology, microbiology and influ- of standard care in severe ARDS patients: 272-279.
ence in outcomes. (2015) BMC INFECT DIS, yes. (2015) INTENS CARE MED. IF: 0.6620
15 (1). IF: 10.1250
IF: 2.6900 Guerin C., Mancebo J., Prone positioning
Beitler J.R., Guerin C., Ayzac L., Mancebo J., and neuromuscular blocking agents are part
Bates D.M., Malhotra A., Talmor D., PEEP titra- of standard care in severe ARDS patients:
tion during prone positioning for acute reyes. (2015) INTENS CARE MED, 41 (12), 2195-
spiratory distress syndrome. (2015) CRIT 2197.
CARE, 19 (1). IF: 10.1250
IF: 4.9500 Rittayamai N., Katsios C.M., Beloncle F., Frie-
Dizier S., Forel J.-M., Ayzac L., Richard J.-C., drich J.O., Mancebo J., Brochard L., Pressure-
Hraiech S., Lehingue S., Loundou A., Roch A., controlled vs volume-controlled ventilation
Guerin C., Papazian L., Gainnier M., Guervilly in acute respiratory failure: A physiolo-
C., Albanese J., Leone M., P G., Michelet P., S gy-based narrative and systematic review.
J., Azoulay E., P D., Capellier G., C J.M., C P., (2015) CHEST, 148 (2), 340-355.
Baudot J., A J.M., Durand-Gasselin J., Beuret IF: 5.9400
P., G A., L J.Y., Arich C., Richard J.C., Hilbert G., Robleda G., Roche-Campo F., Urrutia G., Na-
J S., B G., L’Her E., Leroy C., Pereira C., Scwebel varro M., Sendra M.-A., Castillo A., Rodri-
C., Zeni F., B F., B G., L V., B L., Reignier J., B P., guez-Arias A., Juanes-Borrejo E., Gich I.,

Pharmacy
Coordinator
Mangues Bafalluy,
Maria Antònia FGS
mmangues@santpau.cat
Members
Berga Garrote, Núria IR
Cardenete Ornaque, Juana FGS
Cardona Pera, Daniel FGS
Casanovas Navarro,
Maria Rosa IR
Castro Cels, Maria Isabel FGS
De Pourcq, Jan Thomas FGS
Fernández de Gamarra
Martínez, Edurne FGS
ff Pharmaceutical care.
of Research
Main Lines
Gallardo Alcañiz, ff Artificial nutrition.

Alberto ff Oncohaematology.
Garín Escrivà, Noé FGS
Gomis Pastor, Mar FGS ff Independent clinical trials.
Juanes Borrego, Ana María FGS
Masip Torné, Montserrat
Moreno Martínez,
María Estela FGS
Pagès Puigdemont, Neus IR
ff Evaluate the impact on effectiveness ff Study the stability of cytostatics in differ-
and safety of pharmacological treat- ent conditions of use.
Riera Armengol, Pau FGS ments in different pharmaceutical care
Challenges
Rodríguez-Arias Pal, Ainhoa IR programmes: clinical pharmacokinetics,

ff Predict response to anti-tumour treat-
Ruano Romero, Pilar IR health education for outpatients, medi- ment in a number of tumoural processes.
Sala Esteban, María Luisa FGS cine reconciliation and identification and ff Develop focal adhesion inhibitors, e.g., an-
Tuneu Valls, Laura FGS prevention of medication-related prob- titumour agents.
lems.
ff Actively cooperate in independent clinical
ff Evaluate the impact of artificial nutrition trials performed in the HSCSP.
on the clinical evolution of patients.
Collaboration with other IIB Sant Pau ff Edurne Fernández de Gamarra (PI), Drug in-
Groups teractions in patients in an intensive medical
service of a university hospital, HSCSP Inten-
ff Oncogenesis and Antitumour Drugs. sive Care Group, started 2013 (non-funded).
Collaborations
ff Spanish Hospital Pharmacy Society (SEFH).

ff Intensive Medicine.
ff Delgado O., Genúa M.I., Ibarra O., Morillo R.
ff Clinical Haematology. Madrid (coordinators), Montse Masip (col-
ff Dermatology. laborator), SEFH model for the selection and
pharmaceutical care of chronic patients,
ff Orthopaedics and Traumatology. Spanish Hospital Pharmacy Society (SEFH),
ff Digestive Diseases. started 2013.
ff Anna Feliu Ribera. Impacte assistencial de la incorporació de la Salud Mòbil (mHealth) en

Awarded
la pràctica clínica del pacient trasplantat cardíac. Beques Col·legials 2015, Col·legi de Far-
in 2015
Grants
macèutics de Barcelona. Duration: 2015-2016. €8,181.81.


ff Noé Garin Escrivà. Distribution of multiple chronic conditions and

Theses
their impact on the Spanish population. Universitat de Barcelona.

Director: M. Antònia Mangues. Date of defense: 17 April 2015..
*TIF: 27.6810 **MIF: 2.7681

Aguilera X., Martinez-Zapata M.J., Hinarejos Sainio P., Galas A., Haro J.M., The association Haro J.M., Diabetes mellitus and its associa-
P., Jordan M., Leal J., Gonzalez J.C., Monllau between obesity and severe disability tion with central obesity and disability
J.C., Celaya F., Rodriguez-Arias A., Fernandez among adults aged 50 or over in nine among older adults: A global perspective.
J.A., Pelfort X., Puig-Verdie L., Topical and in- high-income, middle-income and low-in- (2015) EXP GERONTOL, 64, 70-77.
travenous tranexamic acid reduce blood come countries: A cross-sectional study. IF: 3.3500
loss compared to routine hemostasis in total (2015) BMJ OPEN, 5 (4). Wanden-Berghe C., Hernandez J.A., Pelaez
knee arthroplasty: a multicenter, random- IF: 2.5620 R.B., Compes C.C., Martin P.M., Perez L.M.L.,
ized, controlled trial. (2015) ARCH ORTHOP Masip M., Tuneu L., Pages N., Torras X., Gal- Candela C.G., De La Cruz A.P., Fernandez A.C.,
TRAUM SU, 135 (7), 1017-1025. lego A., Guardiola J.M., Faus M.J., Mangues Olmos M.A.M., Gonzalez L.L., Martin C.C.,
IF: 1.4960 M.A., Prevalence and detection of neuropsy- Garcia P.L., Rocamora J.A.I., Llanos J.P.S., Pera
Alamo P., Gallardo A., Di Nicolantonio F., chiatric adverse effects during hepatitis C D.C., Marin M.G., Lazaro M.A.P., Sancez C.B.,
Pavon M.A., Casanova I., Trias M., Mangues treatment. (2015) INT J CLIN PHARM-NET, 37 Soler A.R., Orbaiz C.G., Gaillemin B.C., Villares
M.A., Lopez-Pousa A., Villaverde A., Vazquez (6), 1143-1151. J.M.M., Del Olmo Garcia M.D., Perez F.C., Iri-
E., Bardelli A., Cespedes M.V., Mangues R., IF: 1.3390 goyen C.A., Mauri S., Burdiel O.S.-V., Casas
Higher metastatic efficiency of KRas G12V Pavon M.A., Arroyo-Solera I., Tellez-Gabriel N.V., Aranda N.M., Celaya A.A., Soto M.A.P.,
than KRas G13D in a colorectal cancer M., Leon X., Viros D., Lopez M., Gallardo A., Gonzalez M.A.P., A home enteral nutrition
model. (2015) FASEB J, 29 (2), 464-476. Cespedes M.V., Casanova I., Lopez-Pousa A., (HEN); Spanish registry of NADYA-SENPE
IF: 5.2990 Mangues M.A., Quer M., Barnadas A., group; for the year 2013. (2015) NUTR HOSP,
Baena Parejo M.I., Borrego A.M.J., Ruiz J.A., Mangues R., Enhanced cell migration and 31 (6), 2518-2522.
Monjo M.C., Garcia-Pelaez M., Hernanz B.C., apoptosis resistance may underlie the asso- IF: 1.4970
Hernandez M.A.C., Fernandez M.I.C., Riera ciation between high SERPINE1 expression
M.P., Sanchez R.G., Sanchez L.G., Lopez C.V., and poor outcome in head and neck carci-
Echeverria M.D.M., Serrano P.M., Medication noma patients. (2015) ONCOTARGET, 6 (30),
list assessment in Spanish hospital emer- 29016-29033.
gency departments. (2015) J EMERG MED, IF: 5.0080
48 (4), 416-423. Robleda G., Roche-Campo F., Urrutia G., Na-
IF: 1.0480 varro M., Sendra M.-A., Castillo A., Rodri-
Garin N., Velasco C., de Pourcq J.T., Lopez B., guez-Arias A., Juanes-Borrejo E., Gich I.,
del Mar Gutierrez M., Haro J.M., Feliu A., Mancebo J., Banos J.-E., A randomized con-
Mangues M.A., Trilla A., Recreational drug trolled trial of fentanyl in the pre-emptive
use among individuals living with HIV in treatment of pain associated with turning in
Europe: Review of the prevalence, compari- patients under mechanical ventilation: RE-
son with the general population and HIV SEARCH protocol. (2015) J ADV NURS, 71 (2),
guidelines recommendations. (2015) FRONT 441-450.
MICROBIOL, 6 (JUN). IF: 1.9170
IF: 4.1650 Tyrovolas S., Koyanagi A., Garin N., Olaya B.,
Koyanagi A., Moneta M.V., Garin N., Olaya B., Ayuso-Mateos J.L., Miret M., Chatterji S., To-
Ayuso-Mateos J.L., Chatterji S., Leonardi M., biasz-Adamczyk B., Koskinen S., Leonardi M.,

Dermatology
Coordinator
Puig Sanz, Luis FGS
lpuig@santpau.cat
Members
Alegre Fernández, Marta FGS
Barnadas Andiñach,
Maria Assumpció FGS
Baselga Torres, Eulàlia FGS
Dalmau Arias, Joan FGS
Díaz-Salazar Monreal, Maria IR
Fuentes Finkelstein,
Paulina Andrea FGS
Garcés Gatnau,
Joan Ramon FGS
ff Biologic therapy in dermatology. ff Psychopathological studies of patients
of Research
Main Lines
with chronic dermatological disorders.

García Muret, Maria Pilar FGS ff Genome-wide association studies in pso-
López Ferrer, Anna riasis. ff Innate and acquired immunologically-me-
Margarit de Miguel, Esther IR diated dermatological.
ff Medical and physical treatment options
Mir Bonafe, Juan Francisco FGS for vascular tumours.
Morales Munera,
Caridad Elena IR
Roe Crespo, Esther FGS
Ros Abarca, Sandra IR
Challenges
Ruiz Salas, Verònica FGS

ff Ensure a stable clinical research infrastruc-
ture and staff.
Salvador Figuerola, Laura IR
Serra Baldrich, Esther FGS ff Foster interdepartmental collaborative
Spertino, Jorge Luis IR research.
Vilarrasa Rull, Eva FGS
Collaborations with other IIB Sant Pau Groups

Collaborations
ff Parkinson Disease and Movement Disorders.

*TIF: 216.5080 **MIF: 6.9841

Arriola E., Reguart N., Artal A., Cobo M., Gar- Stahle M., Van De Kerkhof P.C.M., Allez M., in Patients with Active Psoriatic Arthritis:
cia-Campelo R., Esteban E., Rodriguez M.C., Emery P., Paul C., Early intervention in psori- Results from a Randomized, Placebo-Con-
Garcia-Muret M.P., Management of the ad- asis and immune-mediated inflammatory trolled Phase III Trial. (2015) ARTHRIT CARE
verse events of afatinib: A consensus of the diseases: A hypothesis paper. (2015) J DER- RES, 67 (12), 1739-1749.
recommendations of the Spanish expert MATOL TREAT, 26 (2), 103-112. IF: 3.2290
panel. (2015) FUTURE ONCOL, 11 (2), 267- IF: 1.8570 Leaute-Labreze C., Hoeger P., Mazer-
277. Gyulai R., Bagot M., Griffiths C.E.M., Luger T., eeuw-Hautier J., Guibaud L., Baselga E., Posi-
IF: 2.1290 Naldi L., Paul C., Puig L., Kemeny L., Current unas G., Phillips R.J., Caceres H., Lopez
Barnadas M.A., Rubiales M.V., Gich I., Gelpi C., practice of methotrexate use for psoriasis: Gutierrez J.C., Ballona R., Friedlander S.F.,
Usefulness of specific anti-desmoglein 1 and Results of a worldwide survey among der- Powell J., Perek D., Metz B., Barbarot S., Maru-
3 enzyme-linked immunoassay and indirect matologists. (2015) J EUR ACAD DERMATOL, ani A., Szalai Z.Z., Krol A., Boccara O., Foel-
immunofluorescence in the evaluation of 29 (2), 224-231. ster-Holst R., Febrer Bosch M.I., Su J., Buckova
pemphigus activity. (2015) INT J DERMATOL, IF: 3.0290 H., Torrelo A., Cambazard F., Grantzow R.,
54 (11), 1261-1268. Hoeger P.H., Harper J.I., Baselga E., Bonnet D., Wargon O., Wyrzykowski D., Roessler J., Bern-
IF: 1.4150 Boon L.M., Atti M.C.D., El Hachem M., Oranje abeu-Wittel J., Valencia A.M., Przewratil P.,
Baselga Torres E., Bernabeu Wittel J., van A.P., Rubin A.T., Weibel L., Leaute-Labreze C., Glick S., Pope E., Birchall N., Benjamin L.,
Esso Arbolave D.L., Febrer Bosch M.I., Car- Treatment of infantile haemangiomas: rec- Mancini A.J., Vabres P., Souteyrand P., Frieden
rasco Sanz A., de Lucas Laguna R., del Pozo ommendations of a European expert group. I.J., Berul C.I., Mehta C.R., Prey S., Boralevi F.,
Losada J., Hernandez Martin A., Jimenez (2015) EUR J PEDIATR, 174 (7), 855-865. Morgan C.C., Heritier S., Delarue A., Voisard
Montanes L., Lopez Gutierrez J.C., Mar- IF: 1.7910 J.-J., A randomized, controlled trial of oral
tin-Santiago A., Redondo Bellon P., Ruiz- propranolol in infantile hemangioma. (2015)
Huijbers M.G., Querol L.A., Niks E.H., Plomp NEW ENGL J MED, 372 (8), 735-746.
Canela Caceres J., Torrelo Fernandez A., Vera J.J., van der Maarel S.M., Graus F., Dalmau J.,
Casano A., Vicente Villa M.A., Spanish con- IF: 59.5580
Illa I., Verschuuren J.J., The expanding field of
sensus on infantile haemangioma. (2015) IgG4-mediated neurological autoimmune Lebwohl M., Strober B., Menter A., Gordon K.,
AN PEDIATR. disorders. (2015) EUR J NEUROL, 22 (8), 1151- Weglowska J., Puig L., Papp K., Spelman L.,
IF: 0.7730 1161. Toth D., Kerdel F., Armstrong A.W., Stingl G.,
Belinchon I., Vanaclocha F., De La Cueva-Do- IF: 3.9560 Kimball A.B., Bachelez H., Wu J.J., Crowley J.,
bao P., Coto-Segura P., Labandeira J., Herranz Langley R.G., Blicharski T., Paul C., Lacour J.-P.,
Julia A., Ferrandiz C., Dauden E., Fonseca E., Tyring S., Kircik L., Chimenti S., Duffin K.C.,
P., Taberner R., Julia B., Cea-Calvo L., Puig L., Fernandez-Lopez E., Sanchez-Carazo J.L.,
Metabolic syndrome in Spanish patients with Bagel J., Koo J., Aras G., Li J., Song W., Mil-
Vanaclocha F., Puig L., Moreno-Ramirez D., mont C.E., Shi Y., Erondu N., Klekotka P., Kot-
psoriasis needing systemic therapy: Preva- Lopez-Estebaranz J.L., Herrera E., De La
lence and association with cardiovascular zin B., Nirula A., Phase 3 studies comparing
Cueva P., Avila G., Alonso A., Tortosa R., brodalumab with ustekinumab in psoriasis.
disease in PSO-RISK, a cross-sectional study. Lopez-Lasanta M., Marsal S., Association of
(2015) J DERMATOL TREAT, 26 (4), 318-325. (2015) NEW ENGL J MED, 373 (14), 1318-
the PDE3A-SLCO1C1 locus with the re- 1328.
IF: 1.8570 sponse to anti-TNF agents in psoriasis. IF: 59.5580
Catala A., Puig L., Roe E., Dalmau J., Pomar (2015) PHARMACOGENOMICS J, 15 (4), 322-
V., Munoz C., Yelamos O., Anti-tumour ne- 325. Lopez-Ferrer A., Vilarrasa E., Puig L.,
crosis factor-induced visceral and cutane- IF: 3.7840 Secukinumab (AIN457) for the treatment of
ous leishmaniasis: Case report and review psoriasis. (2015) EXPERT REV CLIN IMMU, 11
Julia A., Pinto J.A., Gratacos J., Queiro R., Fer- (11), 1177-1188.
of the literature. (2015) DERMATOLOGY, 230 randiz C., Fonseca E., Montilla C., Tor-
(3), 204-207. IF: 2.5960
re-Alonso J.C., Puig L., Venegas J.J.P., Nebro
IF: 1.4490 A.F., Fernandez E., Munoz-Fernandez S., Marques L., Nunez-Cordoba J.M., Aguado L.,
Chamlin S.L., Mancini A.J., Lai J.-S., Beaumont Dauden E., Gonzalez C., Roig D., Carazo J.L.S., Pretel M., Boixeda P., Nagore E., Baselga E.,
J.L., Cella D., Adams D., Drolet B., Baselga E., Zarco P., Erra A., Estebaranz J.L.L., Rodriguez Redondo P., Topical rapamycin combined
Frieden I.J., Garzon M., Holland K., Horii K.A., J., Ramirez D.M., De La Cueva P., Vanaclocha with pulsed dye laser in the treatment of
Lucky A.W., McCuaig C., Metry D., Morel K.D., F., Herrera E., Castaneda S., Rubio E., Salvador capillary vascular malformations in Sturge-
Newell B.D., Nopper A.J., Powell J., Siegel D., G., Diaz-Torne C., Blanco R., Dominguez A.W., Weber syndrome: Phase II, randomized,
Haggstrom A.N., Development and valida- Mosquera J.A., Vela P., Tornero J., San- double-blind, intraindividual placebo-con-
tion of a quality-of-life instrument for infan- chez-Fernandez S., Corominas H., Ramirez J., trolled clinical trial. (2015) J AM ACAD DER-
tile hemangiomas. (2015) J INVEST DERMA- Lopez-Lasanta M., Tortosa R., Palau N., MATOL, 72 (1), 151-158.e1.
TOL, 135 (6), 1533-1539. Alonso A., Garcia-Montero A.C., Gelpi J.L., IF: 5.6210
IF: 6.9150 Codo L., Day K., Absher D., Myers R.M., Can- Martinez-Martinez L., Martinez-Saavedra
Fernandez-Figueras M.T., Carrato C., Saenz ete J.D., Marsal S., A deletion at adamts9- M.T., Fuentes-Prior P., Barnadas M., Rubiales
X., Puig L., Musulen E., Ferrandiz C., Ariza A., magi1 locus is associated with psoriatic ar- M.V., Noda J., Badell I., Rodriguez-Gallego C.,
Actinic keratosis with atypical basal cells (AK thritis risk. (2015) ANN RHEUM DIS, 74 (10), de la Calle-Martin O., A novel gain-of-func-
I) is the most common lesion associated 1875-1881. tion STAT1 mutation resulting in basal phos-
with invasive squamous cell carcinoma of IF: 12.3840 phorylation of STAT1 and increased distal
the skin. (2015) J EUR ACAD DERMATOL, 29 Kavanaugh A., Puig L., Gottlieb A.B., Ritchlin IFN-γ-mediated responses in chronic mu-
(5), 991-997. C., Li S., Wang Y., Mendelsohn A.M., Song M., cocutaneous candidiasis. (2015) MOL IMMU-
IF: 3.0290 Zhu Y., Rahman P., McInnes I.B., Maintenance NOL, 68 (2), 597-605.
of Clinical Efficacy and Radiographic Benefit IF: 3.3750
Girolomoni G., Griffiths C.E.M., Krueger J.,
Nestle F.O., Nicolas J.-F., Prinz J.C., Puig L., Through Two Years of Ustekinumab Therapy

Dermatology
*TIF: 216.5080 **MIF: 6.9841
Puig L., Ruiz-Salas V., Long-term efficacy, moderate-to-severe psoriasis. Results of a Dugas M., European EADV network on as-
safety and drug survival of ustekinumab in a multicentric observational study in Spain. sessment of severity and burden of Pruritus
spanish cohort of patients with moderate to (2015) EUR J DERMATOL, 25 (5), 410-417. (PruNet): First meeting on outcome tools.
severe plaque psoriasis. (2015) DERMATOL- IF: 2.0690 (2015) J EUR ACAD DERMATOL.
OGY, 230 (1), 46-54. Reich K., Zschocke I., Bachelez H., De Jong IF: 3.0290
IF: 1.4490 E.M.G.J., Gisondi P., Puig L., Warren R.B., Van De Kerkhof P.C.M., Reich K., Kavanaugh
Puig L., Strohal R., Husni M.E., Tsai T.-F., Nop- Mrowietz U., Efficacy of a fixed combination A., Bachelez H., Barker J., Girolomoni G., Lan-
pakun N., Szumski A., Yang S., Robertson D., of calcipotriol/betamethasone dipropionate gley R.G., Paul C.F., Puig L., Lebwohl M.G.,
Boggs R., Koenig A.S., Cardiometabolic pro- topical gel in adult patients with mild to Physician perspectives in the management
file, clinical features, quality of life and treat- moderate psoriasis: Blinded interim analysis of psoriasis and psoriatic arthritis: Results
ment outcomes in patients with moder- of a phase IV, multicenter, randomized, con- from the population-based Multinational
ate-to-severe psoriasis and psoriatic arthritis. trolled, prospective study. (2015) J EUR Assessment of Psoriasis and Psoriatic Arthri-
(2015) J DERMATOL TREAT, 26 (1), 7-15. ACAD DERMATOL, 29 (6), 1156-1163. tis survey. (2015) J EUR ACAD DERMATOL, 29
IF: 1.8570 IF: 3.0290 (10), 2002-2010.

Puig S., Marcoval J., Paradelo C., Azon A., Sandoval J., Diaz-Lagares A., Salgado R., Ser- IF: 3.0290
Bartralot R., Bel S., Bigata X., Boada A., Cam- vitje O., Climent F., Ortiz-Romero P.L., Perez- Wassef M., Blei F., Adams D., Alomari A.,
poy A., Carrera C., Curco N., Dalmau J., Fer- Ferriols A., Garcia-Muret M.P., Estrach T., Gar- Baselga E., Berenstein A., Burrows P., Frieden
randiz C., Ferreres J.R., Formigon M., Gallardo cia M., Nonell L., Esteller M., Pujol R.M., I.J., Garzon M.C., Lopez-Gutierrez J.-C., Lord
F., Gonzalez A., Just M., Llistosella E., Marti Espinet B., Gallardo F., MicroRNA Expression D.J.E., Mitchel S., Powell J., Prendiville J., Vik-
R.M., Nogues M.E., Pedragosa R., Pujol J.A., Profiling and DNA Methylation Signature for kula M., Vascular anomalies classification:
Roldan-Marin R., Sabat M., Salleras M., Sman- Deregulated MicroRNA in Cutaneous T-Cell Recommendations from the international
dia J.A., Zaballos P., Plana E., Malvehy J., Mel- Lymphoma. (2015) J INVEST DERMATOL, 135 society for the study of vascular anomalies.
anoma incidence increases in the elderly of (4), 1128-1137. (2015) PEDIATRICS, 136 (1), e203-e214.
Catalonia but not in the younger popula- IF: 6.9150 IF: 5.1960
tion: Effect of prevention or consequence of Spence-Shishido A.A., Good W.V., Baselga E., Yelamos O., Puig L., Systemic methotrexate
immigration. (2015) ACTA DERM-VENEREOL, Frieden I.J., Hemangiomas and the eye. for the treatment of psoriasis. (2015) EXPERT
95 (4), 422-426. (2015) CLIN DERMATOL, 33 (2), 170-182. REV CLIN IMMU, 11 (5), 553-563.
IF: 3.6380 IF: 2.3670 IF: 2.5960
Puig L., PASI90 response: The new standard Stander S., Zeidler C., Riepe C., Steinke S.,
in therapeutic efficacy for psoriasis. (2015) J Fritz F., Bruland P., Soto-Rey I., Storck M., Ag-
EUR ACAD DERMATOL, 29 (4), 645-648. ner T., Augustin M., Blome C., Dalgard F., Ev-
IF: 3.0290 ers A.W.M., Garcovich S., Goncalo M., Lam-
Puig L., Camacho F., Garcia-Patos V., Fernan- bert J., Legat F.J., Leslie T., Misery L., Raap U.,
dez-Diaz M.L., Marquina A., Garcia-Calvo C., Reich A., Savk E., Streit M., Serra-Baldrich E.,
Long-term (1 year) efficacy of etanercept in Szepietowski J., Wallengren J., Weisshaar E.,


Anaesthesiology
Coordinator
Moral García, María Victoria FGS
vmoralg@santpau.cat
Members
Argilaga, Marta
Azparren, Gonzalo
Baños, Victoria
Bastitta, Micaela
Batalla, Astrid
Bausili Ribera, Marc FGS
Bolaños, Jorge Javier
Bueno, Ana
Campos Suárez, Juan Manuel FGS
Cartrillo, Agustín Peláez Vaamonde, Xavier FGS Santacana, Esther Unzueta Merino,
Casas Vila, Joan Ignasi FGS Perona, Judith Santaeularia Verges, María Carmen FGS
Castrillón Restrepo, Sebastian FGS Piñol Sapena, Santiago FGS Maria Teresa FGS Vila Bou, Jordi FGS
Cegarra, Virginia Revuelta Rizo, Miren Eli FGS Serra Segui, Rafael Villamor Vázquez,
Cueva, Luisa Rivilla Lizano, Maria Teresa FGS Solans, José Ramón José María FGS
Díaz, Rubén Rodríguez Prieto, Mireia FGS Villanueva, José Antonio
Espinosa López Davalillo,
Nieves FGS
Felipe Correoso, Mar
Fernández Nuñez, Critical analysis of new clinical ff Identification and recovery from preoper-
technologies ative anaemia.
José Antonio FGS
Ferrándiz Mach, Marta FGS ff Study of the Prevalence of perioperative
ff Anaconda-inhaled sedation in patients transfusions.
Font Gual, Adrià FGS undergoing postoperative mechanical
Galán Serrano, Josefa FGS ventilation. ff Monitoring of perioperative fluid therapy.
García Álvarez,
ff New monitoring systems for anaesthesia
María Mercedes FGS New health service delivery systems
depth and cerebral oxygen status.
García Muret, Albert
Genové Cortada, ff Professional team preoperative evalua-
Perioperative medicine tions.
Maria Mercè FGS
of Research
Main Lines
Gil de Bernabé Sala, ff Epidemiological study of perioperative ff Zero preoperative stay.

Maria Àngels FGS morbidity and mortality in collaboration
Gil Sánchez, Josep M. with the epidemiology department of the
Physiology, pharmacology and
Giné, Marta HSCSP (Iberoamerican Cochrane Centre)
and the European Society of Anesthesiol- anaesthetic techniques
Gómez Caro, Ana M.
ogy.
González Carrasco, ff Intraoperative respiratory physiology.
Francisco Javier FGS
Rationalization of perioperative fluid ff Peripheral nerve blocking for postopera-
González Rodríguez, Raúl FGS tive analgesia in CMA.
Gonzalez Turmo, Anna M. therapy and blood products
Hoffmann, Rolf Dieter FGS
ff Lipid Rescue due systemic complications
ff Institutional protocolization of massive after ALR.
Illa, Susana transfusions.
India Aldana, Inmaculada FGS
ff Monitoring of critical perioperative coag-
Italiano, Stefano
ulopathy.
Koller, Tobías Bernhard FGS
Maestre Hittinger, María Luz FGS
Martín Huerta, María Beatriz FGS
Melo Cruz, Martha Cristina FGS
Merten, Alfredo R. FGS ff Critical analysis of new clinical technolo- ff Clinical and preclinical research into phys-
gies. iology, pharmacology and anaesthetic/
Miralles, Jordi
Challenges
analgesic techniques.
Moreno Bueno, Marisa FGS ff Patient blood management.
Muñoz, Rolando ff Perioperative medicine.
Pablo, Rosa
Paniagua Iglesias, Pilar FGS ff Development of new health service sys-
tems.
Parera, Ana


Collaborations
ff MANAGE (Management of myocardial injury alter non cardiac ff POPULAR (Postanesthesia PULmonary complications After use
surgery): Randomized clinical trial. Centro Cochrane. ClinicalTri- of muscle Relaxants in Europe), multicentre observational study.
als.gov: NCT01661101. European Society of Anaesthesiology (ESA).
ff Analysis of the Hemostatic Potential of Coagulation Factor Con-
centrates in an In Vitro Model of Extreme Hemodilution. Beca
Heimburger.
ff Maria Carmen Unzueta Merino. Reducción de las complicaciones izado y controlado. PI14/00829 C. Instituto de Salud Carlos III.
Grants
Active
postoperatorias y de la estancia hospitalaria con una estrategia Duration: 2015-2017.

perioperatoria individualizada de ventilación de protección pul-
monar. Estudio comparativo, prospectivo, multicéntrico, aleator-
ff M. L. Maestre Hittinger. Valoración de los factores de riesgo aso- ff Rodríguez Prieto, Mireia. Eficacia del bloqueo ecoguiado de
ciados a la transfusión en pacientes de criugía cardíaca mediante nervios periféricos en el control del dolor postoperatorio en
análisis de partición recursiva. Universitat Autònoma de Barce- cirugía ambulatoria de rizartrosis. Universitat Autònoma de Bar-
lona. Directors: Xavier Rius Cornadó, Xavier Borràs Pérez, Josep celona. Directors: Xavier Rius Cornadó, Claudia Lamas Gómez,
Theses
M. Padró Fernández. Date of defense: 6 November 2015. Albert García Muret. Date of defense: 30 April 2015.
ff Pilar Paniagua Iglesias. Lesión miocárdica tras la cirugía no ff Mercedes García Álvarez. NGAL como biomarcador de disfunción
cardíaca: Análisis de la cohorte española del estudio VISION. Uni- renal aguda en pacientes postoperados de Cirugía Cardíaca. Uni-
versitat Autònoma de Barcelona. Directors: Xavier León Vintró, versitat Autònoma de Barcelona. Directors: Antoni Jordi Betbesé
Pablo Alonso Coello. Date of defense: 14 Decembre 2015. Roig, Alfonso Martínez López, Jordi Ordóñez. Date of defense:
10 July 2015.
*TIF: 9.5090 **MIF: 2.3773

Ferrando C., et al., Rationale and study de- Garcia de Lorenzo y Mateos A., Gomollon Ranieri M., Scavonetto F., Schilling T., Schmid
sign for an individualized perioperative Garcia F., Izuel Rami M., Moral Garcia M.V., W., Selmo G., Severgnini P., Sprung J., Sundar
open lung ventilatory strategy (iPROVE): Montoro Ronsano J.B., Paramo Fernandez S., Talmor D., Treschan T., Unzueta C., Wein-
Study protocol for a randomized controlled J.A., Pereira Saavedra A., Quintana Diaz M., garten T.N., Wolthuis E.K., Wrigge H., Gama
trial. (2015) TRIALS, 16 (1). Remacha Sevilla A., Salinas Argente R., San- De Abreu M., Pelosi P., Schultz M.J., Protec-
IF: 1.8590 chez Perez C., Tirado Angles G., Torrabadella tive versus Conventional Ventilation for Sur-
Llau J.V., Acosta F.J., Escolar G., Fernandez- de Reinoso P., Forum for debate: Safety of gery: A Systematic Review and Individual
Mondejar E., Guasch E., Marco P., Paniagua P., allogeneic blood transfusion alternatives in Patient Data Meta-analysis. (2015) ANESTHE-
Paramo J.A., Quintana M., Torrabadella P., the surgical/critically ill patient. (2015) MED SIOLOGY, 123 (1), 66-78.
Multidisciplinary consensus document on INTENSIVA, 39 (9), 552-562. IF: 5.2640
the management of massive haemorrhage IF: 1.1930
(HEMOMAS document). (2015) MED INTEN- Serpa Neto A., Hemmes S.N.T., Barbas C.S.V.,
SIVA, 39 (8), 483-504. Beiderlinden M., Biehl M., Binnekade J.M.,
IF: 1.1930 Canet J., Fernandez-Bustamante A., Futier E.,
Munoz Gomez M., Bisbe Vives E., Basora Gajic O., Hedenstierna G., Hollmann M.W.,
Macaya M., Garcia Erce J.A., Gomez Luque A., Jaber S., Kozian A., Licker M., Lin W.-Q.,
Leal-Noval S.R., Colomina M.J., Comin Colet Maslow A.D., Memtsoudis S.G., Reis Miranda
J., Contreras Barbeta E., Cuenca Espierrez J., D., Moine P., Ng T., Paparella D., Putensen C.,

Plastic Surgery
Coordinator
Masià Ayala, Josep Jaume FGS
jmasia@santpau.cat
Members
Bernárdez, Débora FGS
Fernández Garrido, Manuel FGS
Liuzza, Claudia FGS
López Fernández, Susana FGS
Olivares, Leyre FGS
Pons Playá, Gemma FGS
Rodríguez Bauza,
Elena María FGS
Sánchez-Porro, Lidia FGS
Vega García,
ff Application of imaging techniques to in- ff Research by indocyanine green angiog-
traoperative studies of perforators with raphy of the relationship between the
Maria del Carmen FGS
the aim to improve the design of flaps, different anatomical patterns of lymphatic
evaluate the suitable and viability of per- vessels in the upper extremity and its
fusion avoiding secondary postoperative readiness to develop lymphedema in the
complications and vascular complications. affected breast cancer patients.
of Research
ff Anatomical studies of the variability of ff Feasibility of the research in animal mod-

Main Lines
perforators in the following regions: in- els of major surgical and nonsurgical tech-
ternal mammary artery, inferior epigastric niques existing today to treat secondary
system and internal superficial circumflex lymphatic insufficiency: fat transplant
system. autologous stem cells, stem cell transplan-
tation autologous bone marrow, lymphat-
ff Study of the perioperative and postoper- ic-venous anastomosys flap free vascu-
ative factors that influence on the viability larised autologous lymph node.
of the microsurgical free flaps.
ff Research by indocyanine green angiogra-
phy of the concept of post-vascular bal-
ance post diseccional of perforator flap.
ff Consolidate and optimize preoperative node and/or axillaries lymph node dis-
management techniques for locating per- sections using new techniques of surgi-
forating vessels suitable for each micro- cal treatment for this disease (lymphatic
surgical flap. venous anastomosys, transfer of vascula-
Challenges
rised nodes).
ff Minimize intra- and postoperative com-
plications in perforator flaps using new ff Identification by indocyanine green angi-
imaging techniques to visualize intraop- ography for those patients affected with
eratively patterns of vascularisation of the breast cancer with a major risk of develop-
flaps and vascular dominance. ing secondary lymphedema.
ff Lymphedema prevention in those pa-
tients with mastectomy in which we per-
form searching procedures of sentinel
ff Josep Jaume Masià Ayala. Modelo experimental comparativo entre trasplante de células
madre de tejido adiposo/médula ósea, anastomosis linfáticovenosas, trasplante de gan-
Grants
Active
glios vascularizados en el linfedema. PI13/02793. Instituto de Salud Carlos III. Duration:

2014-2016. €29,000.
Theses
ff Gemma Pons Playá. Planificación preoperatoria de anastomosis linfático-venosas mediante

ICG y linfoRMN. Universitat Autònoma de Barcelona. Directors: Jaume Masiá, Xavier Rius, Xavier
León. Date of defense: November 2015.

*TIF: 9.6770 **MIF: 1.9354

Masia J., Bordoni D., Pons G., Liuzza C., Cast- Syndrome Using 2 Abdominal Perforator Masia J., SurgicalTreatment for Lymphedema:
agnetti F., Falco G., Oncological safety of Free Flaps. (2015) ANN PLAS SURG, 74 (5), State of the Art. (2015) J RECONSTR MICRO-
breast cancer patients undergoing free-flap 580-583. SURG.
Production
Scientific
reconstruction and lipofilling. (2015) EJ- IF: 1.5350 IF: 1.7340

SO-EUR J SURG ONC, 41 (5), 612-616. Masia J., Pons G., Nardulli M.L., Combined Masia J., SurgicalTreatment for Lymphedema:
IF: 2.9400 Surgical Treatment in Breast Cancer-Related State of the Art. (2015) J RECONSTR MICRO-
Masia J., Pons G., Loschi P., Sanchez Porro-Gil Lymphedema. (2015) J RECONSTR MICRO- SURG, 32 (1), 1.
L., Nardulli M.L., Olivares L., Autologous Re- SURG, 32 (1), 16-27. IF: 1.7340
construction of a Complex Form of Poland IF: 1.7340

Palliative Care
Coordinator
Pascual López, Antonio FGS
apascual@santpau.cat
Members
Collette, Nadia IR
Fariñas Balaguer, Óscar FGS
Güell Pérez, Ernest FGS
Ramos Fernández,
Adelaida FGS
ff Symptom evaluation and control: pain, ff Training in palliative care: training needs,
dyspnoea, cognitive failure, complex sit- outcomes.
uations.
of Research
Main Lines
ff Art therapy.
ff End-of-life ethical issues: sedation, expres-
sion of a desire for death, euthanasia.
ff Psychosocial care for patients and families:
adaptation to the terminal situation, grief,
spiritual needs.
Challenges
ff Psychosocial care for patients and families. ff Integrated care: analysis and care of end-
of-life emotional, social and spiritual di-
ff Counselling and hospital sensitization. mensions and adequate ethical reflection
ff Quality evaluation and control. in decision making.
ff Symptom evaluation and control.
*TIF: 8.0050 **MIF: 2.6683

Guell E., Ramos A., Zertuche T., Pascual A., Study of Ambulatory andHospitalized Cancer
Verbalized desire for death or euthanasia in Patients. (2015) J PALLIAT MED, 18(11), 923-32.
advanced cancer patients receiving palliative IF: 3.685

care. (2015) PALLIAT SUPPORT CARE, 13 (2), Sanso N., Galiana L., Oliver A., Pascual A., Sin-
295-303. clair S., Benito E., Palliative care professionals’
IF: 1.2110 inner life: Exploring the relationships among
Porta-Sales J., Nabal-Vicuna M., Vallano A., Es- awareness, self-care, and compassion satis-
pinosa J., Planas-Domingo J., Verger-Fransoy faction and fatigue, burnout, and coping with
E., Julià-Torras J., Serna J., Pascual-López A., death. (2015) J PAIN SYMPTOM MANAG, 50
Rodríguez D., Grimau I., Morlans G., Sala-Ro- (2), 200-207.
vira C., Calsina-Berna A., Borras-Andrés J.M., IF: 2.6490
Gomez-Batiste X. Have We Improved Pain
Control in Cancer Patients? A Multicenter


Andrology
Coordinator
Ruiz Castañe, Eduard F. Puigvert
eruiz@fundacio-puigvert.es
Members
Bassas Arnau, Lluís F. Puigvert
Chianese, Chiara F. Puigvert
Krausz, Csilla
Gabriella F. Puigvert
Lo Giacco, Deborah
Grazia F. Puigvert
Martínez Pasarell,
Olga F. Puigvert
Rajmil Marqueson,
Osvaldo F. Puigvert
ff Genetics applied to male infertility. to andrological diseases and conditions
of Research
Main Lines
(male sexual dysfunction, hypogonadism,

ff Optimisation of preimplantation genetics Peyronie disease, premature ejaculation,
diagnosis and in vitro fertilization tech- sexually transmitted diseases).
niques.
ff Clinical research into new surgical proce-
dures, drugs and medical devices applied
Our multidisciplinary team of professionals tional publications, train professionals and

Challenges
develops translational research in the field of enhance collaboration with hospital and uni-
diagnosis and treatment of andrological dis- versity groups inside and outside the IIB Sant
orders. To improve our knowledge and there- Pau.
by improve healthcare for patients, we seek to
continue active projects, develop new lines of
investigation, increase the number of interna-
Collaborations with other IIB Sant Pau International

Groups ff Mario Serio Experimental and Clinical Bio-
medical Sciences Unit, University of Flo-
ff Nephrology. rence: genetics applied to male infertility.
ff Reproductive Genomics Laboratory, Hu-
man Genetics Centre (KU Leuven): genet-
Collaborations
ics applied to male infertility.

National
ff New England Research Institutes: hypo-
ff Medical and Molecular Genetics Centre gondadism.
(RI)-IDIBELL: genetics applied to infertility.
ff European Academy of Andrology: radiol-
ff Cellular Biology and Medical Genetics ogy examinations of the male genital
Unit-UAB: preimplantation genetic diag- tract.
nosis techniques.
Private
ff Participation in clinical studies including
clinical trials and postauthorization stud-
ies sponsored by national and interna-
tional pharmaceutical companies.

ff Csilla Gabriella Krausz . Estudio genético y genómico de subtipos específicos de azoospermia secretora: desarrollo de nuevas herram-
Grants
Active
ientas diagnósticas y pronósticas. PI14/01250. Instituto de Salud Carlos III. Duration: 2015-2017. €86,500.
ff O. López, A. Mata, A. García, O. Martínez, R. Gustá, J. Sánchez, ff O. López, A. Mata, A. García, O. Martínez, R. Gustá, J. Sánchez,
MJ. Saiz, C. Chianese, D. Lo Giacco, O. Bogle, C. Attardo, R. Olivia, MJ. Saiz, C. Chianese, D. Lo Giaco, O. Bogle, C. Attardo, R. Oliva,
Awards
Ll. Bassas. Caracterización funcional de patrones específicos de Ll. Bassas. Caracterización funcional de patrones específicos de
teratozoospermia severa. Best communication. 17 Congreso Na- teratozoospermia severa. Best poster. XVII Congreso Nacional de
cional de Andrología, Medicina Sexual y Reproductiva. La Pineda Andrología, Medicina Sexual y Reproductiva. Gran Canaria, 14-
(Vila-Seca, Tarragona), 8-10 May 2015. 16 May 2015.
ff Chiara Chianese. Genetic and Epigenetic Aspects of Male Infer-

Theses
tility. Università degli studi di Firenze. Director: C. Krausz. Date of

defense: 27 March 2015.
*TIF: 26.0510 **MIF: 3.2564

Chianese C., Fino M.G., Riera Escamilla A., Gimenez C., Sarasa J., Arjona C., Vilamajo E., tation from three males carrying balanced
Lopez Rodrigo O., Vinci S., Guarducci E., Da- Martinez-Pasarell O., Wheeler K., Valls G., chromosome rearrangements. (2015) FER-
guin F., Muratori M., Tamburrino L., Lo Giacco Garcia-Guixe E., Wells D., Karyomapping al- TIL STERIL, 104 (3), 681-687.e2.
D., Ars E., Bassas L., Costa M., Pisatauro V., lows preimplantation genetic diagnosis of a IF: 4.4260
Noci I., Coccia E., Provenzano A., Ruiz-Cas- de-novo deletion undetectable using con- Urdinguio R.G., Bayón G.F., Dmitrijeva M.,
tane E., Giglio S., Piomboni P., Krausz C., Com- ventional PGD technology. (2015) REPROD Toraño E.G., Bravo C., Fraga M.F., Bassas L.,
prehensive investigation in patients affected BIOMED ONLINE, 31 (6), 770-775. Larriba S., Fernández A.F. Aberrant DNA
by sperm macrocephaly and globozoo- IF: 2.7960 methylation patterns of spermatozoa in

spermia. (2015) ANDROLOGY-US, 3 (2), 203- Krausz C., Escamilla A.R., Chianese C., Genet- men with unexplained infertility. (2015)
212. ics of male infertility: From research to clinic. HUM REPROD, 30(5), 1014-28.
IF: 2.5150 (2015) REPRODUCTION, 150 (5), R159-R174. IF: 4.621
Cosentino M., Sarquella J., Ruiz-Castane E., IF: 3.1840
Priapism secondary to tamsulosin: A case Munoz X., Mata A., Bassas L., Larriba S., Al-
report. (2015) REV INT ANDROL, 13 (1), 37- tered miRNA Signature of Developing Germ-
39. cells in Infertile Patients Relates to the Sever-
IF: 0.2380 ity of Spermatogenic Failure and Persists in
Daina G., Ramos L., Obradors A., Rius M., del Spermatozoa. (2015) SCI REP-UK, 5.
Rey J., Martinez-Pasarell O., Pujol A., Benet J., IF: 5.2280
Navarro Ferrete J., Double-factor preimplan- Ramos L., Daina G., Del Rey J., Ribas-Maynou
tation genetic diagnosis: Monogenic and J., Fernandez-Encinas A., Martinez-Passarell
cytogenetic diagnoses analyzing a single O., Boada M., Benet J., Navarro J., Compre-
blastomere. (2015) PRENATAL DIAG, 35 (13), hensive preimplantation genetic screening
1301-1307. and sperm deoxyribonucleic acid fragmen-
IF: 3.0430

Urology
Coordinator
Villavicencio Maverich,
Humberto F. Puigvert
hvillavicencio@fundaciopuigvert.es
Members
Algaba Arrea, Fernando F. Puigvert
Arce Terroba, Yolanda F. Puigvert
Breda, Alberto F. Puigvert
Bujons Tur, Ana F. Puigvert
Caffaratti Sfulcini, Jorge F. Puigvert
Millán Rodríguez, Fèlix F. Puigvert
Palou Redorta, Juan F. Puigvert
Rodríguez Faba, Óscar F. Puigvert
ff Tissue engineering applied to urological ff Clinical research of new surgical proce-
oncology and congenital urogenital mal- dures, drugs and medical device products
of Research
Main Lines
formations. applied to urological oncology, kidney

transplantation and benign urogenital pa-
ff Genetic and immunohistochemistry anal- thology (e.g. incontinence, benign hyper-
yses applied to urological cancers (diag- plasia of the prostate, lithiasis).
nostic and prognostic biomarkers in urine,
blood and tissues).
Translational research in the field of diagnosis

and treatment of urological disorders. We
seek to continue active projects, develop new
Challenges
lines of investigation, increase the number of

international publications, train professionals
and increase collaboration with hospital and
university groups to improve our knowledge
about kidney disorders and thereby improve
healthcare for patients.
Collaborations with other IIB Sant Pau International academic

Groups ff Aarhus University Molecular Genetics De-
partment: bladder cancer.
ff Nephrology: genetic predisposition to
prostate cancer. ff International Robotic Cystectomy Consor-
tium: robotic cystectomy.
ff Clinical Epidemiology and Healthcare: epi-
demiological studies of urological cancers. ff International Renal Cell Carcinoma-Ve-
nous Thrombus Consortium: renal-cava
ff Clinical Oncology: detection of prognosis
Collaborations
thrombus in kidney cancer.

biomarkers for drug response in kidney
cancer. Private national and international
collaborations
External Collaborations ff Clinical trials and postauthorization stud-
ies promoted by national and internation-
National academic al pharmaceutical companies.
ff IDIBELL Molecular Genetics Laboratory:
cystine lithiasis.
ff CNIO: biomarkers in bladder cancer.
ff National scientific societies (Spanish Urol-
ogy Association, etc): clinical studies.

ff Humberto Villavicencio. EAU Frans Debruyne Life Time Achieve- ff Humberto Villavicencio. Medalla Shlomo Raz. Confederación
ment Award. 30th Annual Congress of the European Association Americana de Urología (CAU). XXXIV Congreso CAU. LXVI Con-
of Urology. Madrid, 20-24 March 2015. greso Nacional de Urología. XX Congreso SIUP. Cancún (México),
10-14 November 2015.
ff Department of Pediatric Urology. Quality of life in bladder ex-
strophy-epispadias in female patients. Best poster. 30th Annual ff Lluís Gausa, Alberto Breda. First complete kidney transplant with
Congress of the European Association of Urology. Madrid, 20-24 robotic surgery in Europe. Premi Diario Médico a Las Mejores
March 2015. Ideas. 16 November 2015.
Awards
ff A. Bujons, C. Centeno, et al. Calidad de vida en varones con ex- ff C. Gutiérrez, C. Errando-Smet, J.M. López-Martínez, C. Isalt-Lem-
trofia vesical. Seguimiento a largo plazo. Best communication. III onche, P. Arañó Bertrán, H. Villavicencio-Mavric. Efficacy and
Congrés Català d’Urologia. Meloneras (Gran Canaria), 14-16 May safety of botulinum toxin a bladder injection in the treatment
2015. of painful bladder syndrome/ic. Best Poster. III Annual Meeting
MIPS. Ljubljana (Slovenia), 10-12 December 2015.
ff Department of Pediatric Urology. Calidad de vida en pacientes
varones con extrofia vesical. Best communication. XXVI Reunión
Nacional del Grupo de Uropediatría. Salamanca, 12 June 2015.
ff Humberto Villavicencio. Creation of the Premio al Mérito
Urológico Dr. Humberto Villavicencio of the Sociedad Boliviana
de Urología. Cochabamba (Bolivia), 12 September 2015.
ff Carlos Errando. Valoración funcional y de la calidad de vida tras implante de cabestrillo reajustable tipo remeex® en incontinencia de
Theses
orina femenina recidivada o insuficiencia esfinteriana intrínseca. Directors: A. Gelabert, F. Millán, J. Palou. Date of defense: 30 November
2015.
*TIF: 178.9570 **MIF: 4.9710

Abrate A., Lazzeri M., Lughezzani G., Buffi N., Algaba F., Value of frozen sections in uropa- Bach T., Muschter R., Herrmann T.R., Knoll
Bini V., Haese A., De La Taille A., McNicholas thology. (2015) ANAL QUANT CYTOPATHO, T., Scoffone C., Laguna P., Skolarikos A.,
T., Redorta J.P., Gadda G.M., Lista G., Kinzi- 37 (1), 23-28. Rischmann P., Janetschek G., De la Ros-
keeva E., Fossati N., Larcher A., Dell’Oglio P., IF: 0.9180 sette J., Nagele U., Malavaud B., Breda A.,
Mistretta F., Freschi M., Guazzoni G., Clinical Amin M.B., Smith S.C., Reuter V.E., Epstein J.I., Palou J., Bachmann A., Frede T., Geavlete P.,
performance of the Prostate Health Index Grignon D.J., Hansel D.E., Lin O., Mckenney Liatsikos E., Stenz l., Brausi M., Rassweiler
(PHI) for the prediction of prostate cancer in J.K., Montironi R., Paner G.P., Al-Ahmadie J.J. Technical solutions to improve the
obese men: Data from the PROMEtheuS H.A., Algaba F., Ali S., Alvarado-Cabrero I., management of non muscle invasive tran-
project, a multicentre European prospective Bubendorf L., Cheng L., Cheville J.C., Kristian- sitional cell carcinoma: summary of a eu-
study. (2015) BJU INT, 115 (4), 537-545. sen G., Cote R.J., Delahunt B., Eble J.N., ropean assopciation of urology section for
IF: 4.3870 Genega E.M., Gulmann C., Hartmann A., uro-technology(esut) and section for
Ahmed K., Khan R., Mottrie A., Lovegrove C., Langner C., Lopez-Beltran A., Magi-Galluzzi uro-oncology(esou) expert meeting and
Abaza R., Barret E., Cathelineau X., Challa- C., Merce J., Netto G.J., Oliva E., Rao P., Ro J.Y., current and future perspectivas. (2015)
combe B., Khan M.S., Montorsi F., Palou J., Srigley J.R., Tickoo S.K., Tsuzuki T., Umar S.A., BJU INT, 115(1), 14-23.
Van Poppel H., Sanchez-Salas, R., Stolzen- Van Der Kwast T., Young R.H., Soloway M.S., IF: 4.387
burg J.U., Volpe A., Wagner C., Wiklund P., Update for the practicing pathologist: The Berney D.M., Algaba F., Amin M., Delahunt
Wilson T., Wirth M.P., Witt J., Dasgupta P. De- International Consultation On Urologic Dis- B., Comperat E., Epstein J.I., Humphrey P.,
velopment of a standardised training curric- ease-European association of urology con- Idrees M., Lopez-Beltran A., Magi-Galluzzi
ulum for robotic surgery: a consensus state- sultation on bladder cancer. (2015) MODERN C., Mikuz G., Montironi R., Oliva E., Srigley J.,
ment from an international multidisciplinary PATHOL, 28 (5), 612-630. Reuter V.E., Trpkov K., Ulbright T.M., Varma
group of experts. (2015) BJU INT, 116(1), 93- IF: 5.4850 M., Verrill C., Young R.H., Zhou M., Egevad L.,
101. Avila M., Becerra V., Guedea F., Suarez J.F., Handling and reporting of orchidectomy
IF: : 4.387 specimens with testicular cancer: Areas of
Fernandez P., Macias V., Marino A., Hervas A.,

Albers P., Albrecht, W., Algaba F., Bokemeyer Herruzo I., Ortiz M.J., De Leon J.P., Sancho G., consensus and variation among 25 experts
C., Cohn-Cedermark G., Fizazi K., Horwich A., Cunillera O., Pardo Y., Cots F., Ferrer M., and 225 European pathologists. (2015) HIS-
Laguna P., Nicolai N., Oldenburg J. Guide- Alonso J., Garin O., Pont A., Boladeras A., TOPATHOLOGY, 67 (3), 313-324.
lines on testicular cancer: 2015 update. Ferrer F., Martinez E., Pera J., Ventura M., IF: 3.4250
(2015) EUR UROL, 68(6), 1054-1068. Aguilo F., Castells M., Villavicencio H., Cra- Bonfill X., Martinez-Zapata M.J., Vernooij
IF: 14.976 ven-Bratle J., De Paula B., Guix B., Hernandez R.W., Sanchez M.J., Suarez-Varela M.M., De
Algaba F., Trias I., Mimickers of prostate can- H., Munoz V., Ramos A., Prada P.J., Estimating la Cruz J., Emparanza J.I., Ferrer M., Pijoan
cer in needle biopsies. (2015) ANAL QUANT preferences for treatments in patients with J.I., Ramos-Goni J.M., Palou J., Schmidt S.,
CYTOPATHO, 37 (1), 57-64. localized prostate cancer. (2015) INT J RA- Abraira V., Zamora J., Clinical intervals and
IF: 0.9180 DIAT ONCOL, 91 (2), 277-287. diagnostic characteristics in a cohort of
IF: 4.4950 prostate cancer patients in Spain: A multi-

Urology
*TIF: 178.9570 **MIF: 4.9710
centre observational study. (2015) BMC Freschi M., Lughezzani G., Abrate A., Bini V., Millan-Rodriguez F., Gavrilov P., Gracia-Gar-
UROL, 15 (1). Redorta J.P., Graefen M., Guazzoni G., Lazzeri cia S., Angerri-Feu O., Sanchez-Martin F.M.,
IF: 1.6060 M., Preoperative prostate-specific antigen Villavicencio-Mavrich H., Implications of vi-
Breda A., Lucarelli G., Rodriguez-Faba O., isoform p2PSA and its derivatives, %p2PSA tamin D deficiency in lithiasic patient and in
Guirado LL., Facundo C., Bettocchi C., Gesu- and prostate health index, predict patho- general population. (2015) ACTAS UROL ESP,
aldo L., Castellano G., Grandaliano, G., Batt- logic outcomes in patients undergoing radi- 39 (4), 245-252.
aglia M., Palou J., Ditonno P., Villavicencio H. cal prostatectomy for prostate cancer: Re- IF: 0.9640
Clinical and pathological outcomes of renal sults from a multicentric european Nguyen H.G., Tilki D., Dall’Era M.A., Durbin-
cell carcinoma(rcc) in native kidneys of pa- prospective study. (2015) EUR UROL, 68 (1), Johnson B., Carballido J.A., Chandrasekar T.,
tients with end-stage renal disease: a long- 132-138. Chromecki T., Ciancio G., Daneshmand S.,
term comparative retrospective study with IF: 14.9760 Gontero P., Gonzalez J., Haferkamp A., Ho-
rcc diagnosed in the general population. Gaya J.M., Palou J., Rosales A., Maroto P., henfellner M., Huang W.C., Espinos E.L., Man-
(2015) WORLD J UROL, 33(1), 1-7. Sullivan I., Villavicencio H., Is there a limit for del P., Martinez-Salamanca J.I., Master V.A.,
IF: 2.3970 the laparoscopic approach of a retroperito- McKiernan J.M., Montorsi F., Novara G., Pa-
Breda A., Schwartzmann I., Emiliani E., Rodri- neal residual mass postchemotherapy. hernik S., Palou J., Pruthi R.S., Rodriguez-
guez-Faba O., Gausa L., Caffaratti J., de Leon (2015) ACTAS UROL ESP. Faba O., Russo P., Scherr D.S., Shariat S.F.,
X.P., Villavicencio H., Mini-laparoscopic live IF: 0.9640 Spahn M., Terrone C., Vergho D., Wallen E.M.,
donor nephrectomy with the use of 3-mm Gaya J.M., Lopez-Martinez J.M., Karni- Xylinas E., Zigeuner R., Libertino J.A., Evans
instruments and laparoscope. (2015) Schmidt O., Bonal D.M., Algaba F., Palou J., C.P., Cardiopulmonary Bypass has No Signifi-
WORLD J UROL, 33 (5), 707-712. Villavicencio H., Benson M.C., Cordon-Cardo cant Impact on Survival in Patients Undergo-
IF: 2.3970 C., Castillo-Martin M., Δnp63 expression is a ing Nephrectomy and Level III-IV Inferior
protective factor of progression in clinical Vena Cava Thrombectomy: Multi-Institu-
Bujons A., Saldana L., Caffaratti J., Garat J.M., tional Analysis. (2015) J UROLOGY.
Angerri O., Villavicencio H., Can endoscopic high grade T1 bladder cancer. (2015) J UROL-
OGY, 193 (4), 1144-1150. IF: 4.7000
balloon dilation for primary obstructive me-
gaureter be effective in a long-term fol- IF: 4.7000 Palou J., Rodriguez O., Gaya J.M., Urothelial
low-up. (2015) J PEDIATR UROL, 11 (1), 37. Gaya J.M., Palou J., Pena J.A., Rosales A., Ma- Carcinoma In Situ: Concerns About Daily
e1-37.e6. roto P., Sullivan I., Villavicencio H., Is there a Practice. (2015) EUR UROL.
IF: 1.1700 limit for the laparoscopic approach of a IF: 14.9760
Cozar J.M., Minana B., Palou-Redorta J., Me- retroperitoneal residual masspostchemo- Palou J., Rodriguez O., Gaya J.M., Urothelial
dina R.A., De La Rosa-Kehrmann F., Lo- therapy. (2015) ACTAS UROL ESP, 39 (4), 264- carcinoma in situ: Concerns about daily
zano-Palacio F., Ribal-Caparros M.J., Hernan- 267. practice. (2015) EUR UROL, 67 (5), 889-890.
dez-Fernandez C., Castineiras-Fernandez J.J., IF: 0.9640 IF: 14.9760
Requena M.J., Moreno-Sierra J., Carbal- Gaya J.M., Palou J., Palazzetti A., Novoa R., Palou J., Hernandez C., Solsona E., Abascal R.,
lido-Rodriguez J., Baena-Gonzalez V., Análisis Fernandez M., Gausa L., Pena J.A., Villavicen- Burgues J.P., Rioja C., Cabrera J.A., Gutierrez
comparativo de la incidencia de cáncer de cio H., Endoscopic bladder neck incision as C., Rodriguez O., Iborra I., Herranz F., Abascal
vejiga en las comunidades de Andalucía, first step in radical prostatectomy: An aid for J.M., Conde G., Oliva J., Effectiveness of hex-
Cataluña y Comunidad de Madrid en el año patients previously treated for bladder out- aminolevulinate fluorescence cystoscopy
2011. (2015) ACTAS UROL ESP, 39 (7), 420-428. let obstruction. (2015) ARCH ESP UROL, 68 for the diagnosis of non-muscle-invasive
IF: 0.9640 (7), 587-594. bladder cancer in daily clinical practice: A
Emiliani E., Herrmann T.R.W., Breda A., Thu- IF: 0.3070 Spanish multicentre observational study.
lium laser for the treatment of upper urinary Hernandez D., Palou J., Sancho G., Salas D., (2015) BJU INT, 116 (1), 37-43.
tract carcinoma (UTUC)? Are we there, yet. Gimenez D., Buitrago P., Esquena S., de la IF: 4.3870
(2015) WORLD J UROL. Torre P., Pernas J., Gich I., de Segura G.G., Palou-Redorta J., Solsona E., Angulo J., Fer-
IF: 2.3970 Craven-Bartle J., Pelvic MRI findings in re- nandez J.M., Madero R., Unda M., Mar-
Emiliani E., Breda A., Laser endoureterotomy lapsed prostate cancer after radical prosta- tinez-Pineiro J.A., Portillo J., Chantada V.,
and endopyelotomy: an update. (2015) tectomy. (2015) RADIAT ONCOL, 10 (1). Moyano J.L., Retrospective study of various
WORLD J UROL, 33 (4), 583-587. IF: 2.4660 conservative treatment options with bacille
IF: 2.3970 Martinez-Piñeiro L., Portillo J.A., Fernandez Calmette-Guérin in bladder urothelial carci-
J.M., Zabala J.A., Cadierno I., Moyano J.L., noma T1G3: Maintenance therapy. (2015)
Fossati N., Lazzeri M., Haese A., McNicholas ACTAS UROL ESP.
T., De La Taille A., Buffi N.M., Lughezzani G., Solsona E., Unda M., Beardo P., Rodri-
IF: 0.9640
Gadda G.M., Lista G., Larcher A., Abrate A., guez-Molina J., Chantada V., Palou J., Mun-
Mistretta F., Bini V., Redorta J.P., Graefen M., tañola P., Alonso J.M., Perez-Garcia F.J., Silva Rodriguez Faba O., Breda A., Gausa L., Palou
Guazzoni G., Clinical performance of serum J.M., Chesa N., Montesinos M., Ojea A., Ma- J., Villavicencio H., De novo urologic tumors
isoform [-2]proPSA (p2PSA), and its deriva- dero R., Martínez-Piñeiro J.A. Maintenance in kidney transplant patients. (2015) ACTAS
tives %p2PSA and the Prostate Health Index, therapy with 3-monthly bacillus calmette- UROL ESP, 39 (2), 122-127.
in men aged <60 years: Results from a mul- guerin for 3 years is not superior to satan- IF: 0.9640
ticentric European study. (2015) BJU INT, 115 dard induction therapy in high-risk non- Rodriguez Faba O., Comment to “residency
(6), 913-920. -muscle-invasive urothelial bladder in urology and training in Kidney transplan-
IF: 4.3870 carcinoma: final results of randomised cueto tion. Result of a national survey”. (2015) AC-
study 98013. (2015) EUR UROL, 68(2), 256- TAS UROL ESP, 39 (5), 310-.
Fossati N., Buffi N.M., Haese A., Stephan C., 262.
Larcher A., McNicholas T., De La Taille A., IF: 0.9640
IF: 14.976

*TIF: 178.9570 **MIF: 4.9710

Rodriguez-Faba O., Palou J., Rosales A., De La ares E., Lorentz C.A., Mandel P., Martinez-Sal-
Torre P., Marti J., Palazzetti A., Villavicencio H., amanca J.I., Master V.A., Matloob R.,
Prospective study of ultrasound-guided per- McKiernan J.M., Mlynarczyk C.M., Montorsi
cutaneous renal cryotherapy: Case selection F., Novara G., Pahernik S., Palou J., Pruthi R.S.,
as an optimization factor for a technique. Ramaswamy K., Rodriguez Faba O., Russo P.,
(2015) ACTAS UROL ESP, 39 (1), 8-12. Shariat S.F., Spahn M., Terrone C., Thieu W.,
IF: 0.9640 Vergho D., Wallen E.M., Xylinas E., Zigeuner
Roupret M., Babjuk M., Comperat E., Zi- R., Libertino J.A., Evans C.P., Impact of syn-
geuner R., Sylvester R.J., Burger M., Cowan chronous metastasis distribution on cancer
N.C., Bohle A., Van Rhijn B.W.G., Kaasinen E., specific survival in renal cell carcinoma after
Palou J., Shariat S.F., European association of radical nephrectomy with tumor thrombec-
urology guidelines on upper urinary tract tomy. (2015) J UROLOGY, 193 (2), 436-442.
urothelial cell carcinoma: 2015 update. IF: 4.7000
(2015) EUR UROL, 68 (5), 868-879. Yuh B., Wilson T., Bochner B.H., Chan K., Palou
IF: 14.9760 J., Stenz L., Montorsi F., Thalmann G., Guru
Sanchez-Martin F.M., Millan Rodriguez F., In K.A., Catto J., Wiklund P., Novara G. System-
reference to paper «Prevalence of renal atic review and cumulative analysisi of onco-
stones in andalusian population: Results of logic and functional outcomes after ro-
PreLiRenA study». (2015) ACTAS UROL ESP. bot-assisted radical cystectomy. (2015) EUR
IF: 0.9640 UROL, 67(3), 402-422.
IF: 14.976
Tilki D., Hu B., Nguyen H.G., Dall’Era M.A.,
Bertini R., Carballido J.A., Chandrasekar T.,
Chromecki T., Ciancio G., Daneshmand S.,
Gontero P., Gonzalez J., Haferkamp A., Ho-
henfellner M., Huang W.C., Koppie T.M., Lin-
ff Fernandez Ibieta M., Bujons A., Caffaratti J., Ayuso l., Villavicencio Catto J. Best practices in robot-assisted radical cystectomy and
H. La larga marcha de los traumatismos uretrales. (2015) AN PE- urinary reconstruction: recommendations of the pasadena con-
DIATR (BARC), 82(3), 192-193. sensus panel. (2015) EUR UROL, 67(3), 363-375.
ff Ricciardulli S., Ding Q., Zhang X., Li H., Tang Y., Yang G., Wang ff Orsola A., Palou J., Solsona E. High-risk nonmuscle invasive blad-
X.M.A., Breda A., Celia A. Evaluation of laparoscopic vs robotic der cancer. (2015) HEMATOL ONCOL CLIN NORTH AM, 29(2), 227-
Other Publications
partial nephrectomy using the margin, ischemia and complica- 236.

tions score system: a retrospective single center analysis. (2015)
ARCH ITAL UROL ANDROL, 87(1), 49-55.
ff Palou J. Chemo -and radiotherapy- induced urinary side effects:
the role ofglycosaminoglycans. (2015) UROLOGIA , 82(S3), S1.
ff Fernandez Ibieta M., Bujons A., Caffaratti J., Alberola J., Bonnin D.,
Jimenez R., Villavicencio H. Litotricia extracorpórea en pacientes
ff Ricciardulli S., Ding Q., Xu Z., Xin M, Hongzhao L., del Biondo
pediátricos. (2015) CIR PEDIATR, 28(2), 59-66. D., Zeccolini G., Breda A., Celia A. Use of UCSF-CAPRA score as a
predictor of positive surgical margins after robotassisted radical
ff Mostafid H., Palou J., Sylvester R., Witjes A. Therapeutic options prostatectomy. (2015) UROLOGIA, 82(3), 168-173.
in high-risk non-muscle-invasive bladder cancer during the cur-
rent worldwide shortage of bacille calmette-guerin. (2015) EUR
UROL, 67(3), 359-360.
ff Wilson T, Guru K.A., Rosen R.C., Wiklund P., Annerstedt M., Boch-
ner B.H., Chan K., Montorsi F., Mottrie A., Murphy D., Novara G.,
Peabody J., Palou J., Skinner E.C., Thalmann G., Stenz l., Yuh B.,

Radiation Oncology
Coordinator
Craven-Bartle Lamote
de Grignon, Jordi FGS
jcraven@santapu.cat
Members
Balart Serra, Josep FGS
Benítez Rodríguez,
José Fernando FGS
Research is partially conducted on the prem- Radiation Therapy Based on PET/CT

ises of the Translational Research Laboratory of Functional Imaging of Tumours
the Catalan Oncology Institute (ICO)-Bellvitge
Biomedical Research Institute (IDIBELL) under ff Implementation of planning techniques
a framework agreement between the HSCSP for radiotherapy treatment with PET/CT for
and the ICO. chest locations and head and neck tumours
squamous cell tumours.
Modulation of Radiosensitivity ff Image-guided radiotherapy and respira-
of Research
Main Lines
ff Modulation of radiosensitivity by SRC protein tory movement control.

inhibitors in combination with anti-EGFR. ff Salvage brachytherapy for local recurrence after
ff Modulation of radiosensitivity by HMG-CoA external beam radiotherapy in prostate cancer.
reductase inhibitors in combination with an- ff Hypofractionated intensity-modulated GRT
ti-EGFR. in prostate cancer.
SBRT for Patients with Lung Cancer and

with Oligometastases
ff Stereotactic body radiotherapy techniques in
radical treatment of patients with early-stage
non-surgical lung cancer and selected pa-
tients with non-surgical oligometastases.
ff Establish relatively radioresistant cell lines ff Evaluate the effect on carcinomas of SRC and
Challenges
compared with the parental cells from which HMG-CoA reductase inhibitors in combina-
they derive (by clonal selection). tion with anti-EGFR.
ff Determine the resistant phenotype in cul- ff Explore signal transduction changes in the
tures and xenografts. EGFR-MAPK pathway and SRC-EGFR/SRC-
STAT3 cooperation induced by SRC and
ff Determine molecular radioresistance. HMG-CoA reductase inhibitors.

*TIF: 22.1550**MIF: 3.6925

Avila M., Becerra V., Guedea F., Suarez J.F., Fernandez-Gonzalo P., De-Paula-Carranza B., Hernandez D., Palou J., Sancho G., Salas D.,
Fernandez P., Macias V., Marino A., Hervas A., Ferrer M., Guedea F., Sancho-Pardo G., Cra- Gimenez D., Buitrago P., Esquena S., de la
Herruzo I., Ortiz M.J., De Leon J.P., Sancho G., ven-Bartle J., Ortiz-Gordillo M.J., Cabre- Torre P., Pernas J., Gich I., de Segura G.G.,
Cunillera O., Pardo Y., Cots F., Ferrer M., ra-Roldan P., Rodriguez-Melcon J.I., Herre- Craven-Bartle J., Pelvic MRI findings in re-
Alonso J., Garin O., Pont A., Boladeras A., ra-Ramos E., Rodriguez-Gallego C., Lara P.C., lapsed prostate cancer after radical prosta-
Ferrer F., Martinez E., Pera J., Ventura M., Genetic variations in genes involved in tes- tectomy. (2015) RADIAT ONCOL, 10 (1).
Aguilo F., Castells M., Villavicencio H., Cra- tosterone metabolism are associated with IF: 2.4660
ven-Bratle J., De Paula B., Guix B., Hernandez prostate cancer progression: A Spanish mul- Sebio A., Barnadas A., Salazar J., Paez D., Be-
H., Munoz V., Ramos A., Prada P.J., Estimating ticenter study. (2015) UROL ONCOL-SEMIN renguer-Llergo A., Del Rio E., Tobena M.,
preferences for treatments in patients with ORI, 33 (7), 331.e1-331.e7. Martin-Richard M., Sullivan I., Targarona E.,
Production
localized prostate cancer. (2015) INT J RA- IF: 2.9210

Scientific
Balart J., Baiget M., EGFR ligands and DNA

DIAT ONCOL, 91 (2), 277-287. Henriquez-Hernandez L.A., Valenciano A., repair genes: Genomic predictors of com-
IF: 4.4950 Foro-Arnalot P., Alvarez-Cubero M.J., Cozar plete response after capecitabine-based
Camacho M., Pineiro Z., Alcolea S., Garcia J., J.M., Suarez-Novo J.F., Castells-Esteve M., chemoradiotherapy in locally advanced rec-
Balart J., Terra X., Aviles-Jurado F.-X., Soler M., Fernandez-Gonzalo P., De-Paula-Carranza B., tal cancer. (2015) PHARMACOGENOMICS J,
Quer M., Leon X., Vila L., Prostacyclin-syn- Ferrer M., Guedea F., Sancho-Pardo G., Cra- 15 (1), 77-83.
thase expression in head and neck carci- ven-Bartle J., Ortiz-Gordillo M.J., Cabre- IF: 3.7840
noma patients and its prognostic value in ra-Roldan P., Herrera-Ramos E., Rodri-
the response to radiotherapy. (2015) J guez-Gallego C., Lara P.C., Intraethnic
PATHOL, 235 (1), 125-135. variation in steroid-5-alpha-reductase poly-
IF: 7.3810 morphisms in prostate cancer patients: a
Henriquez-Hernandez L.A., Valenciano A., potential factor implicated in 5-alpha-reduc-
Foro-Arnalot P., Alvarez-Cubero M.J., Cozar tase inhibitor treatment. (2015) J GENET, 94
J.M., Suarez-Novo J.F., Castells-Esteve M., (2), 335-341.
IF: 1.1080

Locomotor System Research

Antiresorptives in Orthopedic and ff In vitro experimental study of the feasibil-
Coordinator ity of a polyurethane replacement menis-
Crusi Sererols, Xavier FGS
Trauma Surgery
cus pre-seeded with stem cells.
xcrusi@santpau.cat ff Effect of zoledronic acid (Aclasta) on ff Evolution of allogeneic meniscal trans-
periprosthetic bone mineral density in pa- plants and relationship with extrusion.
Members tients undergoing total knee arthroplasty.
Study approved by the HSCSP ethics com-
Aguilera Roig, Xavier FGS Hip
mittee and authorized by the Spanish
Bascuñana Ambrós, Helena FGS Medicines and Health Products Agency
Calvo Oyon, Rafael FGS
ff Coxarthrosis in young adults: etiological
(AEMPS) for the out-of-context indication
study of biomechanical factors.
Celaya Ibáñez, Fernando FGS of Aclasta.
De Caso Rodríguez, Julio FGS ff Biomechanics of coxarthrosis in young
Gelber Ghertner, Knee adults: finite element study.
Pablo Eduardo FGS ff Influence of hip anatomy in early develop-
González Lucena, Haemostasis ment of coxarthrosis: controlled, prospec-
Gemma Maria FGS ff Blood loss control using tranexamic acid tive radiographic study.
González Rodríguez, in primary prosthetic and knee revision
José Carlos FGS surgery. Upper Limb
of Research
Main Lines
Gracía Alegria, Isidre FGS ff Retrospective study of revision knee ar-
Ibáñez Aparicio, throplasty to compare the effects of in- ff Anatomical study of stabilizing ligaments
travenous tranexamic acid and normal in the trapeziometacarpal joint: the
Natàlia Maria FGS
haemostasis. role played by dorsoradial and anterior
Lamas Gómez, oblique ligaments in Bennett and Rolando
ff Clinical trial comparing outcomes for in-
Clàudia Maria FGS fractures.
travenous tranexamic acid with fibrin glue
Monllau Garcia, (Tissucol) and normal haemostasis in pri- ff Surgical treatment of middle-third clavicle
Joan Carles FGS mary knee prosthetic surgery. fractures in high-energy trauma in young
Nadal Castells, ff Observational study of blood loss in redon patients.
Maria Josefa FGS drainage over time in pertrochanteric hip ff Retrospective study of the use of vascular-
Peiró Ibáñez, Ana FGS fractures. ized bone graft using the 1,2-ICSR artery
Proubasta Renart, Ignacio FGS in the revascularization of proximal pole
Cartilage
Soria Villegas, Laura FGS necrosis in scaphoid pseudarthrosis.
Torrades Solé, Maria Teresa FGS ff Regeneration of cartilage defects using
Valera Pertegas, Màrius FGS tissue engineering and a matrix seeded
with characterized allogeneic chondro-
Velázquez Fragoso, cytes.
Juan José FGS
Meniscus
ff Effect of normal and growth-factor-en-
riched cell cultures on the meniscal col-
lagen network and glycosaminoglycan
expression.
ff Mireia Rodríguez Prieto. Eficacia del bloqueo de riesgo. Director: Claudia Mariana Lamas
ecoguiado de nervios periféricos en el con- Gómez. Date of defense: 13 July 2015.
trol del dolor postoperatorio en cirugía am-
bulatoria de rizartrosis. Director: Xavier Rius
ff Francisco Javier Aguilera Roig. Ácido tranex-
Theses
Cornadó, Claudia Mariana Lamas Gómez, ámico en cirugía protésica de rodilla. Univer-
Albert Garcia Muret. Date of defense: 30 April sitat Autònoma de Barcelona. Director: Clau-
2015. dia Mariana Lamas Gómez. Date of defense:
12 November 2015.
ff Jordi Álvarez San Nicolás. Cirugía de salva-
mento de extremidad en sarcoma de Ewing:
supervivencia, complicaciones y factores

*TIF: 13.4990 **MIF: 2.2498

Aguilera X., Martinez-Zapata M.J., Hinarejos Gelber P.E., Petrica A.M., Isart A., Mari-Molina don autograft. (2015) KNEE SURG SPORT TR
P., Jordan M., Leal J., Gonzalez J.C., Monllau R., Monllau J.C., The magnetic resonance as- A, 1-7.
J.C., Celaya F., Rodriguez-Arias A., Fernandez pect of a polyurethane meniscal scaffold is IF: 3.0970
J.A., Pelfort X., Puig-Verdie L., Topical and in- worse in advanced cartilage defects without Perez-Prieto D., Capurro B., Gelber P.E., Gino-
travenous tranexamic acid reduce blood deterioration of clinical outcomes after a vart G., Reina F., Sanchis-Alfonso V., Monllau
loss compared to routine hemostasis in total minimum two-year follow-up. (2015) KNEE, J.C., The anatomy and isometry of a qua-
knee arthroplasty: a multicenter, random- 22 (5), 389-394. si-anatomical reconstruction of the medial
Production
Scientific
ized, controlled trial. (2015) ARCH ORTHOP IF: 1.4460 patellofemoral ligament. (2015) KNEE SURG
TRAUM SU, 135 (7), 1017-1025. Gomez C.L., Renart I.P., Perez M.L., Relation- SPORT TR A, 1-4.
IF: 1.4960 ship between wrist motion and capitolunate IF: 3.0970
Castellvi I., Simeon-Aznar C.P., Sarmiento M., reduction in four-corner arthrodesis. (2015)
Fortuna A., Mayos M., Geli C., Diaz-Torne C., ORTHOPEDICS, 38 (11), e1040-e1045.
Moya P., De Llobet J.M., Casademont J., Asso- IF: 1.1270
ciation between nailfold capillaroscopy find- Monllau J.C., Masferrer-Pino A., Ginovart G.,
ings and pulmonary function tests in pa- Perez-Prieto D., Gelber P.E., Sanchis-Alfonso
tients with with systemic sclerosis. (2015) J V., Clinical and radiological outcomes after a
RHEUMATOL, 42 (2), 222-227. quasi-anatomical reconstruction of medial
IF: 3.2360 patellofemoral ligament with gracilis ten-

Multiple Sclerosis and Epilepsy Research
Coordinator
Escartín Siquier,
Antonio Eduardo FGS
aescartin@santpau.cat
Members
Figueroa Bonaparte,
Sebastian Ariel IR
López Góngora, Mariana IR
Navas Madroñal, Miquel IR
Querol Gutiérrez,
Luis Antonio FGS
Simon-Talero Horga, Manuel IR
Vidal Fernández, Maria Núria IR
ff Neuropsychological impairment in patients with multiple sclerosis.
of Research
Main Lines
ff Pharmacogenetics in epilepsy.
ff Neuropsychological impairment in juvenile myoclonic epilepsy.
ff Basic research line.
ff Study cognitive evoked potentials in early ff Determine pharmacogenetic variations

detection of cognitive impairment in involving different responses to antiepi-
patients with radiologically isolated syn- leptic treatment.
Challenges
drome, clinically isolated syndrome and

newly diagnosed multiple sclerosis.
ff Study neuropsychological alterations in
patients diagnosed with juvenile myoclo-
ff Study the effects of immunomodulatory nic epilepsy.
and immunosuppressive treatments on
the cognitive functions of patients with
multiple sclerosis.

*TIF: 32.0030 **MIF: 2.9094

Aracil-Bolanos I., Prats-Sanchez L., Go- Auditory Serial Addition Test (PASAT) in re- Ramos-Fransi A., Rojas-Garcia R., Segovia S.,
mez-Anson B., Querol-Gutierrez L., lapsing-remitting multiple sclerosis: An ap- Marquez-Infante C., Pardo J., Coll-Canti J.,
Nunez-Marin F., Marti-Fabregas J., Balo con- praisal of comparative longitudinal sensitiv- Jerico I., Illa I., Alberti Aguilo M.A., Bataller
centric sclerosis: A presentation mimicking ity. (2015) BMC NEUROL, 15 (1). Alberola L., Berciano Blanco J., Casasnovas
ischaemic stroke. (2015) NEUROLOGIA. IF: 1.9610 Pons C., Diaz-Manera J., Fernandez Torron
IF: 1.7900 Lopez-Gongora M., Escartin A., Mar- M.R., Garcia Sobrino T., Gomez Caravaca M.T.,
Camps-Renom P., Delgado-Mederos R., Mar- tinez-Horta S., Fernandez-Bobadilla R., Guerrero Sola A., Gutierrez Gutierrez G.,
tinez-Domeno A., Prats-Sanchez L., Querol L., Romero S., Mananas M.A., Riba J., Lopez de Munain Arregui A, Martinez Pi-
Cortes-Vicente E., Simon-Talero M., Arboix A., Neurophysiological evidence of compensa- neiro A., Mendoza Grimon M.D., Munoz
Ois A., Purroy F., Marti-Fabregas J., Clinical tory brain mechanisms in early-stage multi- Blanco J.L., Pelayo Negro A.L., Querol L.,
characteristics and outcome of the capsular ple sclerosis. (2015) PLOS ONE, 10 (8). Sevilla Mantecon T., Myasthenia gravis: De-
warning syndrome: A multicenter study. IF: 3.0570 scriptive analysis of life-threatening events
(2015) INT J STROKE, 10 (4), 571-575. in a recent nationwide registry. (2015) EUR J
Marti-Fabregas J., Delgado-Mederos R., Cre- NEUROL, 22 (7), 1056-1061.
IF: 3.0440 spo J., Pena E., Marin R., Jimenez-Xarrie E., IF: 3.9560
Carmona-Iragui M., Fernandez-Arcos A., Al- Fernandez-Arcos A., Perez-Perez J., Mar-
Production
colea D., Piazza F., Morenas-Rodriguez E., tinez-Domeno A., Camps-Renom P., Prats- Zadeh W.W., Escartin A., Byrnes W., Tennig-
Scientific
Anton-Aguirre S., Sala I., Clarimon J., Dols-I- Sanchez L., Casoni F., Badimon L., Circulating keit F., Borghs S., Li T., Dedeken P., De Backer
cardo O., Camacho V., Sampedro F., Munuera endothelial progenitor cells and the risk of M., Efficacy and safety of lacosamide as first
J., Nunez-Marin F., Lleo A., Fortea J., Go- vascular events after ischemic stroke. (2015) add-on or later adjunctive treatment for
mez-Anson B., Blesa R., Cerebrospinal Fluid PLOS ONE, 10 (4). uncontrolled partial-onset seizures: A multi-
Anti-Amyloid-Beta; Autoantibodies and IF: 3.0570 centre open-label trial. (2015) SEIZURE-EUR J
Amyloid PET in Cerebral Amyloid Angio- EPILEP, 31, 72-79.
Osuna M.T., Querol L., Olivas-Chacon C.I., IF: 2.1090
pathy-Related Inflammation. (2015) J ALZ- Lejarreta-Andres S., Robert J., Ailouti-Cabal-
HEIMERS DIS, 50 (1), 1-7. lero N., Ramos-Duran L., Diaz-Manera J., Bel-
IF: 3.9200 vis R., Toxic demyelinating neuropathy and
Huijbers M.G., Querol L.A., Niks E.H., Plomp leukoencephalopathy in patients who take
J.J., van der Maarel S.M., Graus F., Dalmau J., the slimming products Thermatrim ® and
Illa I., Verschuuren J.J., The expanding field of Pura Alegría ®. (2015) REV NEUROLOGIA, 61
IgG4-mediated neurological autoimmune (11), 527-528.
disorders. (2015) EUR J NEUROL, 22 (8), 1151- IF: 0.6840
1161. Querol L., Illa I., Paranodal and other autoan-
IF: 3.9560 tibodies in chronic inflammatory neuropa-
Lopez-Gongora M., Querol L., Escartin A., A thies. (2015) CURR OPIN NEUROL, 28 (5),
one-year follow-up study of the Symbol 474-479.
Digit Modalities Test (SDMT) and the Paced IF: 4.4690

Pain and Neurosciences
Coordinator
Català Puigbò, Elena FGS
ecatala@santpau.cat
Members
Castillo Pérez, Carmen
Díaz Jover, Rubén
Ferrándiz Mach, Marta
Genové Cortada, Mercè
Melo Cruz, Martha
Moral Garcia, M. Victoria
Parera Ruiz, Ana
Revuelta Rizo, Miren
Rius Llorens, Carme
Santeularia Vergès, M. Teresa
ff Involvement of brain areas and release of ff Profile in terms of demographics, comor-
substances in acute and chronic neuro- bidities, kind of pain, physical and mental-
Serrano Alienza, Isabel
pathic pain. status and diability of patient.
of Research
Main Lines
ff Sleep disturbance on initiating systemic ff Look for a local and non pharmacological
opioid treatment in patients with severe treatment for olderly patients with pain.
chronic pain and altered sleep patterns.
ff Influence epidural corticosteroids treat-
ment by diferent approach on the effec-
tiveness of the radicular pain due to her-
niated lumbar disc.
ff Establish the possible differences in brain chopathology, essentially anxiety, depres-

area involvement between acute and sion and catastrophizing.
chronic pain.
ff Determine the profile of patients who
Challenges
ff Determine the extent of chronic pain ac- would benefit from treatment with major
cording to the involvement of different systemic opioids in relation to night rest
brain areas and if these alterations can im- and establish the recommendable opioid.
prove with the relive of pain.
ff Establish the recomended opioid dose
ff Determine whether the intensity of to start a treatment and how to remove
chronic neuropathic pain assessed by the them.
patient is correlated with the patient’s psy-
Collaborations with other IIB Sant Pau

Groups
Collaborations
ff Psyquiatry
ff Anesthesiology
ff Neurosurgery
ff Neuroradiology
ff M. Mercè Genové Cortada. Impacte de les ff Miren Revuelta Rizo. Efectividad de la

alteracions cerebrals en la percepció del respuesta al tratamiento intervencionista
Theses
dolor per herpes zòster i neuràlgia posth- en la Unidad del Dolor sobre la radiculalgia
erpètica. Universitat Autònoma de Barce- secundaria a hernia discal . Directors: Xavier
lona. Directors: Xavier Rius Cornadó, Elena León Vintró, Elena Català Puigbò. Date of
Català Puigbò, Maria J. Portella Moll. Date defense: December 2015.
of defense: 8 October 2015.

*TIF: 3.827 **MIF: 3.827

Montes A, Roca G, Sabate S, Lao JI, Navarro
A, Cantillo J, Canet J; GENDOLCAT Study
Production
Scientific
Group. Genetic and Clinical Factors Associ-

ated with Chronic Postsurgical Pain after
Hernia Repair, Hysterectomy, and Thoracot-
omy: A Two-year Multicenter Cohort Study.
(2015) ANESTHESIOLOGY, 122, 1123-41.
IF: 3.827
ff Melo M.C., Revuelta M.E., Santeularia T., Genové M., Català E. Management of transient radicular pain after receiving an epidural blood
Publications
patch for headaches due to spontaneous intracranial hypotension. (2015) REV ESP ANESTESIOL REANIM, 62, 533-5.
Other
ff Català E., Ferrándiz M., Genové M, Revuelta M., Santeularia T., Parera A., Melo M., Diaz R., Rius C. Manual de Tratamiento del dolor. Tercera
edición. Editorial Permanyer. 2015.

Nursing Care Research
Coordinator
López Ortega, Laura FGS
llopez@santpau.cat
Members
Berga Congost, Gemma FGS
Cebrià Morales,
Maria Queralt FGS
Jover Sancho, Carmen FGS
Ricart Basagaña,
Maria Teresa FGS
Robleda Font, Gemma FGS
Sillero Sillero, Amàlia FGS
ff Fall prevention and analysis of fall-related tive methods, text analysis and discourse
factors. analysis.
of Research
Main Lines
ff Translation and validation of care evalua- ff Patient satisfaction with nursing care.
tion questionnaires.
ff Attention to the family.
ff Constipation and ageing.
ff Pain.
ff Quality of life related to nursing care.
ff Development and application of health
science methods: qualitative and qualita-
ff Strengthen implemented research lines ff Improve the development and under-

and disseminate the results of active proj- standing of qualitative research in the
Challenges
ects. context of the health sciences and dis-

seminate qualitative methods and analy-
ff Explore the impact of nursing care for ses of text and discourse as tools in health
patients, strategies for care improvement science research.
and the application of results in cure mod-
els. ff Create the synergies necessary to consoli-
date the group’s activities.
Collaborations
ff Gemma Robleda. Estudio multicéntrico de

validez y fiabilidad de la Escala de Conduc-
tas Indicadoras de Dolor (ESCID) para medir
el dolor en pacientes críticos, no comunica-
tivos y sometidos a ventilación mecánica.
Instituto de Investigación Clínica, Hospital
Universitario Puerta de Hierro Majadahon-
da. Madrid. PI11-00766. Duration: 2012-15.
ff Gemma Robleda Font. Evaluación del dolor en personas adultas sin capacidad de comu-
Awarded
nicación, un análisis bioético en las unidades de hospitalización de pacientes críticos. GRI-

in 2015
Grants
FOLS 2015, Fundació Víctor Grífols i Lucas. Duration: 2015-2016. €4,545.46.


ff Gemma Robleda Font, Josep Eladi Baños Díez. Premio de Inves-

Awards
tigación Fundación Grifols. 2014-2016.
ff M. Teresa Ricart Basagaña. Proceso de alta de una unidad de cui- ff Gemma Robleda Font. Relevancia clínica del dolor asociado con
Theses
dados intensivos: medición de la ansiedad y factores relaciona- los procedimientos del paciente crítico. Universitat de Barce-
dos. Universitat Rovira i Virgili. Director: Mar Lleixà Fortuño. Date lona. Directors: Josep Eladi Baños Díez, Jordi Mancebo Cortés.
of defense: November 2015. Date of defense: December 2015.
*TIF: 2.5790 **MIF: 1.2895

Robleda G., Roche-Campo F., Urrutia G., Na- Robleda G., Roche-Campo F., Sanchez V.,
varro M., Sendra M.-A., Castillo A., Rodri- Gich I., Banos J.-E., Postoperative Discomfort
guez-Arias A., Juanes-Borrejo E., Gich I., After Abdominal Surgery: An Observational
Production
Scientific
Mancebo J., Banos J.-E., A randomized con- Study. (2015) J PERIANESTH NURS, 30 (4),
trolled trial of fentanyl in the pre-emptive 272-279.
treatment of pain associated with turning in IF: 0.6620
patients under mechanical ventilation: RE-
SEARCH protocol. (2015) J ADV NURS, 71 (2),
441-450.
IF: 1.9170

Reproductive Health
Coordinator
Calaf Alsina, Joaquim FGS
jcalaf@santpau.cat
Members
Adelantado Pérez,
Juan María FGS
Alejos Abad, Obdulia FGS
Armengol Santacreu, Josep FGS
Bordas Serrat,
Josep Ramon F. Puigvert
Espinós Gómez, Juan José FGS
Estadella Tarriel,
Josep Ramon FGS
Guinot Gasull, Misericordia FGS
ff Qualitative study of foetal motility by ff Cutoff point for foetal pyelectasis as a ne-
means of 2D ultrasound in foetuses with phrourologic pathology discriminator.
Medina Mallen,
spinal muscular atrophy.
Maria del Carmen FGS ff Value of ultrasound in the control of foetal
of Research
Main Lines
Pares Baulenas, Pere F. Puigvert ff Value of foetal nuchal translucency as a anaemia.

Parra Roca, Juan FGS marker of neuromuscular diseases and
other monogenic diseases.
Polo Ramos,
Ana María F. Puigvert ff Usefulness of Doppler ultrasound of the
Porta Roda, Josep Oriol FGS umbilical artery during the second trimes-
ter as a discriminator of pregnancies at
Rams Llop, Noelia FGS
high risk of poor perinatal outcomes.
Rovira Negre, Ramon FGS
Saiz Eslava,
Maria Jesús F. Puigvert
Senosiain Echarte, Raquel FGS
ff Consolidate a line of work with the HSCSP tial usefulness of the markers used either
Simó González, Marta FGS
genetics department concerning possible alone or in combination as indicators of
Trilla Sola, Cristina FGS early clinical manifestations detectable populations at risk of placental insuffi-
Challenges
using 2D and 4D ultrasound in foetuses ciency.

affected by genetic diseases, particularly
neuromuscular disorders, given that the
ff Investigate the usefulness of new technol-
HSCSP is a referral centre for a particular ogies such as 3D power Doppler angiog-
group of rare diseases. raphy of the placenta in the diagnosis and
control of certain foetal diseases.
ff Screen for chromosomal abnormalities
from the ultrasound and biochemistry
points of view, investigating the poten-
Collaborations with other IIB Sant Pau

Collaborations
Groups
ff Genetic Diseases.
ff Juan José Espinós Gómez. Impacto de la dieta hipocalórica y ejercicio en mujeres con obesidad
que se sometan a un ciclo de FIV. PI11/02816. Instituto de Salud Carlos III. Duration: 2012-2016.
Grants
Active
€42,909.

ff Ramon Rovira. Dispositivo para simular una operación en-

Patents
doscópica vía orificio natural. Application number: P201531796.
*TIF: 13.5210**MIF: 4.5070

Aulinas A., Colom C., Garcia Patterson A., Simmons D., Jelsma J.G.M., Galjaard S.,
Ubeda J., Maria M.A., Orellana I., Adelantado Devlieger R., Van Assche A., Jans G., Corcoy
J.M., de Leiva A., Corcoy R., Smoking affects R., Adelantado J.M., Dunne F., Desoye G.,
the oral glucose tolerance test profile and Harreiter J., Kautzky-Willer A., Damm P., Ma-
the relationship between glucose and thiesen E.R., Jensen D.M., Andersen L.L., La-
HbA1c in gestational diabetes mellitus. polla A., Dalfra M., Bertolotto A., Wender-O-
(2015) DIABETIC MED. zegowska E., Zawiejska A., Hill D., Rebollo P.,
IF: 3.1520 Snoek F.J., Van Poppel M.N.M., Results from a
Bitzer J., Heikinheimo O., Nelson A.L., Calaf- European multicenter randomized trial of
Alsina J., Fraser I.S., Medical management of physical activity and/or healthy eating to
heavy menstrual bleeding: A comprehen- reduce the risk of gestational diabetes melli-
sive review of the literature. (2015) OBSTET tus: The DALI lifestyle pilot. (2015) DIABETES
GYNECOL SURV, 70 (2), 115-130. CARE, 38 (9), 1650-1656.
IF: 1.4350 IF: 8.9340

Translational Molecular Oncology
Coordinator
Parreño Gómez, Matilde IR
mparreno@santpau.cat
Members
Blanco, Maria Laura FGS
of Research
In vitro and in vivo studies by genetic manipulation of putative biomarkers of prognosis in

Main Lines
ff
squamous cell carcinoma (SCC) in tumour progression and as potential therapeutic targets.
ff Preclinical cancer models to study alternative strategy of treatments in leukemia.
ff Evaluate survival pathways and epitheli- ff Reinforce and encourage translational

Challenges
al-mesenchymal transition involving the research in tumour progression through

studied genes. collaboration with internal and external
research groups.
ff Improve a mouse model of cancer, based
on implantation of human primary tu-
mour.
Collaborations with other IIB Sant Pau ff Angiology, Vascular Biology and Inflam-
Groups mation (Luis Vila, Mercedes Camacho):
studies of HNSCC.
ff Haematological Diagnosis (Josep Nom-
Collaborations
dedéu): External Collaborations

-- Establishment of “in vivo” model of leu-
komogenesis. ff Translational Research Laboratory, Institut
-- Ajuts de suport als Grups de Recerca Català d’Oncologia (ICO) - IDIBELL (Alberto
de Catalunya. Grup de Diagnòstic He- Villanueva): studies of orthotopic tumor
matològic. AGAUR 2014. 2014-SGR-383. models.
Duration: 2014- 2016. €30,000. ff Cell signalling and checkpoints, Faculty of
ff Ear, Nose and Throat Cancers (Xavier Medicine, IDIBAPS (Neus Agell and Mont-
Leon): studies of HNSCC. serrat Jaumot).
*TIF: 5.0080 **MIF: 5.0080

Leon X., Bothe C., Garcia J., Parreno M., Alcolea
S., Quer M., Vila L., Camacho M., Expression of
IL-1α correlates with distant metastasis in pa-
Production
Scientific
tients with head and neck squamous cell car-

cinoma. (2015) ONCOTARGET, 6 (35), 37398-
37409.
IF: 5.0080


Cardiac Surgery
ff ff-pump coronary artery by-pass graft-
O ff Follow-up of surgical check-list implemen-
Coordinator ing surgery. tation.
Padro Fernández,
ff Mitral repair surgery. ff Use of erythropoietin before cardiac sur-
of Research
Josep Maria FGS
Main Lines
gery.
jpadro@santpau.cat ff Ascending aorta pathology.
ff articipation in VISION study (Vascular
P
ff athogenesis of atrial fibrillation after car-
P events In Surgery patients cOhort evalua-
Members diac surgery: electrophisiologic and mito-
Cuevas Herreros, tioN)-Cardiac Surgery.
chondrial analysis.
Óscar Andrés FGS
ff Follow-up of sutureless aortic valve pros-
Julia, Ignasi FGS
thesis: Perceval S.
Montiel Serrano, José FGS
Muñoz Guijosa, Christian FGS
Roselló Díez, Elena FGS
ff Consolidation as a research group in dif- ff Collaboration with different national and
ferent cardiac surgery-related fields, spe- international research teams involved in
Challenges
cific utureless valve prosthesis-perioper- our lines of study.

ative myocardial infarction.
ff Participation in the assessment and vali-
dation of new products employed in car-
diac surgery: haemostatics, sutures, sys-
tems for sternal closure…
Collaborations with other IIB Sant Pau ff Elisabeth Berastegui. Department of Car-
Groups diac Surgery. Hospital Germans Trias i Pu-
jol, Badalona, Spain.
Collaborations
ff Leif Hove-Madsen, ICCC-CSIC. ff Mercé Cladellas Capdevila. Department of

ff M. Luz Maestre Hittinger. Department of Cardiology. Hospital del Mar, Barcelona,
Anaesthesiology. Spain.
ff E lena Roselló Díez. Follow-up of sutureless
External Collaborations aortic valve prosthesis Perceval S. Palex
Medical, June 2014-September 2015.
ff Elena Domínguez Garrido. Unit of Molec-
ular Diagnosis. Fundación Rioja Salud, La
Rioja, Spain.
*TIF: 10.0610 **MIF: 5.0305

Herraiz-Martinez A., Alvarez-Garcia J., Llach A.,
Molina C.E., Fernandes J., Ferrero-Gregori A.,
Rodriguez C., Vallmitjana A., Benitez R., Padro
J.M., Martinez-Gonzalez J., Cinca J., Hov-
e-Madsen L., Ageing is associated with deteri-
oration of calcium homeostasis in isolated
Production
human right atrial myocytes. (2015) CARDIO-

Scientific
VASC RES, 106 (1), 76-86.

IF: 5.4650
Vilades Medel D., Munoz Guijosa C., Carreras
Costa F., Padro Fernandez J.M., Pons Llado G.,
Leta Petracca R., Assessment of Radial Artery
Graft Patency Through 256-slice Cardiac Com-
puted Tomography, and the Mid-term Prog-
nostic Impact of Graft Occlusion. (2015) REV
ESP CARDIOL.
IF: 4.5960


Sant Pau
Biomedical Research Institute
Sant Antoni Maria Claret, 167

08025 Barcelona
iib@santpau.cat
Institut de Recerca
Institut Català de
Ciències Cardiovasculars
© Sant Pau Biomedical Research Institute (IIB Sant Pau), 2016

Sant Antoni Maria Claret, 167
08025 Barcelona
Spain
Design
Santi Porta
Coordination and Edition

Corporate Communications and Public Relations Department
Photography
Hospital de la Santa Creu i Sant Pau Image bank
Alfonso García
David Cuní
iStockphoto

2015 Scientific Report IIB Sant Pau

Diunggah oleh

Informasi Dokumen

Hak Cipta

Format Tersedia

Bagikan dokumen Ini

Bagikan atau Tanam Dokumen

Opsi Berbagi

Apakah menurut Anda dokumen ini bermanfaat?

Apakah konten ini tidak pantas?

Hak Cipta:

Format Tersedia

2015 Scientific Report IIB Sant Pau

Diunggah oleh

Hak Cipta:

Format Tersedia

2015

Sant Pau Biomedical Research Institute

Managing Director, Jordi Bachs i Ferrer

Designated by the Hospital de la Santa Creu Lluís Tort i Bardolet

Designated by the Generalitat de Catalunya Helena Isábal Roca

Designated by the Board of the Research Institute Jaume Sellarès Sallas

Jaume Kulisevsky Bojarski

Sant Pau Biomedical Research Institute

Scientific Report 2015

Sant Pau Biomedical Research Institute

Scientific Report 2015

Sant Pau Biomedical Research Institute

IIB Sant Pau Scientific

The vertical line has five main areas:

The transversal line consists of two areas:

Activities in the transversal line complement and support research in

Scientific Report 2015

Sant Pau Biomedical Research Institute

Scientific Report 2015

IIB Sant Pau Entities

Hospital de la Santa Creu i Sant Pau Research Institute

Hospital de la Santa Creu i Sant Pau Private Foundation

Autonomous University of Barcelona (UAB) - Ageing Institute

The Ageing Institute, attached to this university, is a non-profit foundation governed by

Sant Pau Biomedical Research Institute

Catalan Institute of Cardiovascular Sciences (ICCC)

Iberoamerican Cochrane Centre

Barcelona-Sardenya Primary Care Centre

Public Health Agency of Barcelona

Blood and Tissue Bank

Scientific Report 2015

Genetic, Metabolic and Inflammatory Diseases

Haematological and Oncological Diseases

Neurological, Mental Disorders and Ageing

Uronephrology and Experimental Surgery

Sant Pau Biomedical Research Institute

Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and

Scientific Report 2015

IIB Sant Pau Management

HSCSP Research Institute Management Director Research Areas

Steering Committee Executive Committee

Sant Pau Biomedical Research Institute

Internal Scientific External Scientific

Dr. Carlos Brotons Dr. Alberto Lleó Dr. José Palacios

Scientific Report 2015

Sant Pau Biomedical Research Institute

Income Statement year ending 31 December 2015

Income from activities 14,030,821

OPERATIONAL PROFIT/LOSS -104,787

Financial income 245,811

FINANCIAL PROFIT/LOSS 65,602

OVERALL PROFIT/LOSS -39,185

Scientific Report 2015

Sant Pau Biomedical Research Institute

Scientific Report 2015

Sant Pau Biomedical Research Institute

Mean IF 5.062 5.389 6.346 4.806 3.916 3.444 6.382 4.096

Scientific Report 2015

Sant Pau Biomedical Research Institute

2014 2015 2014 2015

AGAUR (Agència de Gestió d'Ajuts Universitats i Recerca) 3 5 2 2

Source: Hospital de la Santa Creu i Sant Pau Research Institute

Scientific Report 2015

Sant Pau Biomedical Research Institute